<SEC-DOCUMENT>0000950170-24-027984.txt : 20240307
<SEC-HEADER>0000950170-24-027984.hdr.sgml : 20240307
<ACCEPTANCE-DATETIME>20240307162032
ACCESSION NUMBER:		0000950170-24-027984
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240307
DATE AS OF CHANGE:		20240307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oncternal Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001260990
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				621715807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50549
		FILM NUMBER:		24730422

	BUSINESS ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 230
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 434-1113

	MAIL ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 230
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GTX INC /DE/
		DATE OF NAME CHANGE:	20030822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>onct-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:onct="http://www.oncternal.com/20231231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_646342b7-ae99-43b7-a311-6b6c2f42d92f" name="dei:DocumentFiscalPeriodFocus" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47">FY</ix:nonNumeric><ix:nonNumeric id="F_172e3ea9-bc50-4cd3-913c-fef462d45e07" name="dei:EntityCentralIndexKey" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47">0001260990</ix:nonNumeric><ix:nonNumeric id="F_a711c1cd-0219-4139-9d92-02c1d6d4ffd3" name="dei:AmendmentFlag" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47">false</ix:nonNumeric><ix:nonFraction id="F_c51b8fcc-6943-4e4a-ba2d-2e171034ab9b" name="us-gaap:CommitmentsAndContingencies" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6a5f452d-b332-4939-a1c1-8e54f1e5256f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ee1e1737-1e34-4355-a0d8-679b3a702be0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="C_eaf7c44c-5611-4b86-8805-7a0f392d4123" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_0942af95-94b2-4cac-8c0c-f1444938ea88" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d">http://fasb.org/us-gaap/2023#Assets</ix:nonNumeric><ix:nonNumeric id="F_cdb93c50-11db-48e2-b68f-a8c32248923f" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58">http://fasb.org/us-gaap/2023#Assets</ix:nonNumeric><ix:nonNumeric id="F_cb4bed05-8324-4d04-8ccd-d2135d259695" name="us-gaap:LeaseExpirationDate1" contextRef="C_25540dfb-13c9-4cf9-b450-dba094402df1" format="ixt:date-monthname-day-year-en">July 31 2023</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="onct-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_8ae3137a-dca4-44e8-9e74-9a641eabeef4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a9ea6d5-a2b4-44b7-a30b-0362d9e0d9d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onct:RepricedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9b3636c-d8fd-4fc6-949c-e35056896198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7fcd6fe-26a1-4370-be58-59d9b95517db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b521705-9521-4715-a360-b03c0afb492c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec9bb144-86a5-4e9b-906e-419e8387d5a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_390cdc10-d67e-4245-b090-a0003a2a440e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac63083b-0e54-4d72-845f-1395615d3acc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaf7c44c-5611-4b86-8805-7a0f392d4123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ed66ec3-01b3-42a3-840a-a1a07973fcfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_befd2887-568e-464a-9888-a3946d8ca800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22537a93-b320-44dd-a549-708fcd3422dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fc5f62a-291e-46d8-9a20-5a29e0475095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66241dba-1f12-43c0-83cc-7d8e203311cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_239353fd-6f89-4cb6-b125-6d9371f0edeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_721f94da-46a0-4238-a04c-81022ac3098d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8ac1f25-733f-4759-8f62-55c4db818235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22cf68f2-c77f-4eed-9ca5-da8ef5c46854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be17b684-ca82-4e8f-9152-2a66d621a493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3b5002b-9469-4aba-b020-3e3c596b6535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10b44321-be1f-47e8-a18e-447594cad864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7969de4f-8469-45fc-82de-c6f6103bd889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7417c2f-59d7-47f2-b82f-869b45d68de1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6b88d8c-42b2-44bd-afc8-e948c76c63df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18a29548-1851-4d54-88f2-fd40d4620a4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54d18d54-d3a4-492f-b13b-e21ffaa85ccf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25540dfb-13c9-4cf9-b450-dba094402df1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdc3f0e1-0d49-4984-a42d-fbfadb17116b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f9b6b80-f252-4916-a2f7-309b047bf50e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c0da6fd-d05b-4a5b-92ed-45a0294999a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9b0328c-d0e2-4383-b5a2-733916d1b3cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4a3a9c0-78f1-4226-a01b-c86a4a08a0b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf19402d-8314-4a7e-802d-f56c3da68afb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f23d092f-edc0-4d76-893a-ca1ffe860492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_098930be-5884-474e-975f-9a2650ccb706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20da3ab-11b5-4858-a9c2-a02c8c66bf0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08168037-6b24-4204-95ca-d790554ec7eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97f0b34a-98a0-4cbd-85a6-33dc53e598fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfcce48d-55f4-42fa-bc8b-242ea98fde12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f14623dc-d310-4e54-b789-c60026ee8444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a46d83e-f6dd-44d4-909e-9d8f3ea263ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_008b4d81-ffe3-4ba2-bbc8-a66325c8241c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fb8e0da-acaa-47c5-a6c1-2e4c104b6914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd81aada-e08c-4c52-98c2-314c93335b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30d36d96-6cac-47d1-9709-bc013ca4bfac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d80acc3e-af09-4afd-b5cf-5196b734c37c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b0d5398-0c7c-48f9-837d-be8269901856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ee21224-3ff5-40c8-8d3b-f3bc87c0f528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b28e1922-05f1-4509-a2c3-99e3ae9adb2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64618a52-3613-4a92-9d8a-011deabe6e3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f73bd1b2-ebe8-43b0-9837-980ac35e9116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_885b6bbf-2f96-47f6-8d8a-193adfbcc27b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4cb10c4-5548-41a5-bded-833419a5f7c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39371a89-6f01-47df-bc36-a1e47990e15b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88e26592-4d13-462a-9b53-e67a374ae51e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onct:RepricedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_467dc9e5-7495-40f7-ab23-9880e9cfc171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3f1feeb-4862-4bb4-888b-eed88eeb8df2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b56bb628-693a-44de-82e4-d1feaf30ec85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f9e4329-2631-4545-b375-e1684aab746d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf9fff34-6f4a-4470-8d7d-50c7f427439f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76233f9f-1322-4238-beea-ec554143cbd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef53d5cd-37dc-49c8-870b-ecc190d62e21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83e4c228-480e-409e-8176-6d50e59820db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46c60dff-cac9-4018-8575-385d2a411a84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ec0d6a2-b31e-4889-b743-4923e7241cd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb81806a-0e46-4915-b3ab-4166af11612d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f742e918-e6dc-4348-81a6-2801923bd3ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bd0a19a-3bcb-4dee-819e-826450508497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd4a10dd-2b20-4eb7-a455-5be36a531fe8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fbc6ca3-a3dc-4149-94d7-cb8b93ecb98d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff6125a7-fb79-405a-8961-0ede053bee4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80c0e7a1-8307-44d0-921c-0a9be8697b02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_caa34144-abe4-4bd3-99a2-59f166c310aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f27580a4-262d-49d1-b2c6-fb20b05f065f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf6a6ea3-bfb5-4119-956f-554febc07729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94005552-abb1-417c-87b6-43d4fedeb7de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3649747f-9c0d-4482-8bdd-75153c2821e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62fa3949-0347-4273-b069-49f2fd0e5194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_060e4155-636b-4f25-aae8-2486660150ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2eeadccf-0f17-4175-823b-dbcd8f8dac1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_406903e5-8180-4559-aaf2-4760656464dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_441dc867-c190-4ac7-8f43-7108e23f4032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84d1bde4-f42c-44ac-a1d9-1e1ecae3e8c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88c0a536-1858-45ff-bae1-c4b868dccb47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4d11d3c-bc06-418b-a44d-1f7e43dc53ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_188444b1-f178-47d3-9b2d-59943870aebd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e7e0a37-b10a-43a8-b067-4e1f34e10da0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c896d669-13f7-473c-89c3-89994dcf773a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaaac3ff-7e7c-4e08-9dcf-37c2593ea85b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26ab1cc2-d243-44c9-9db3-5cbed36397d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4d53eba-2e84-48f2-b931-0b43041273df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d3b13ce-5124-4fca-9299-dd3bdf5074c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07c0adf7-ec21-415e-8412-b371f3a6a24a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a773db65-a5e7-4e4b-84c4-30dbe6ad792f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a6930d4-f451-44ee-affa-37ae8d65ee2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4bde5a8-ae87-4557-801d-ca9157cf9106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23c75ad6-c16c-4b5c-a758-b8db79ffc925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fddd24a2-50cf-4852-b216-6ce6bed4bb65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed194973-5fdd-4e52-855b-ebf609d37cc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86f3153e-89c6-4d7e-ae5d-a42564364970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_199ad02d-9d2d-4836-8616-89dc61afce31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d7bbaa5-7054-4572-8d82-9320f96f8511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfadbdac-a035-479c-8d33-fb8090124ed6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_494fe420-acc3-40f1-a076-42280b1684de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc68c081-7397-41f0-9a80-0bb2d48bf304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56a6188c-3033-46da-a539-5db40eb23bba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adabef98-d9b7-4120-a5c5-cb803bd266ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed1bd376-c8fc-43e3-8746-8f969b50e374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_534fa586-63e2-4243-8afa-2b2e6ad52e2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97e3e97f-b9c5-4887-aa84-bb0855f10787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d9980d5-e3a0-4b27-8681-b22f63c165b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4b57fdc-9184-48da-aa31-8dfde603a140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_075d13c8-bda5-4ad2-bc71-30df6eefa0e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa85d7fe-bbad-46f8-a7b1-37cddaed1e71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_806fe93c-57b0-45eb-9528-ffd11fc44374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_559906c9-0c59-49e6-96f8-3366e04dca58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e681e21e-1bbb-4c53-855b-c79b986ff160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f873de6c-929f-4ec4-8634-115ea3443d28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_124609d2-2d46-4cef-af3e-ff9ad6a610d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7403617-2bd9-4378-8e28-1026eb094276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d67c732-6cc2-4ca8-b0fb-1ec761145cf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24db6605-9fb8-4748-a200-1daa7520b56f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a954e431-fdf8-4bae-8667-e303c67e3782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb2712dc-866f-414f-a8f2-3c9dde12d934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3d6b78d-a32d-49a2-80f4-722dd0cb10ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd959724-6c14-44e2-acc1-de40c1c6b60a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57f4bb0b-624b-482c-99f5-8c8960913a1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_612bfa44-754f-486e-bf9e-c145316436ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebd6887c-a70a-4f63-862c-61c7842c1226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c46c1db-0184-4718-8ed6-39821e77c4c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1324e5fb-9834-45ea-8fde-84ef2eed74cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ee2b049-c3a9-4492-adeb-159a901587f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbe31993-74d8-4712-92b5-682ceee9fb09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_945c64cc-8fd5-4390-8555-ead6c7c1f64a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d70503fc-4a1c-4d6b-9214-610f9b23fc86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42761111-9f62-4a8d-88a7-53d404e3f90e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bff7594-8784-4e75-992e-1abf18d3a26a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b99fc277-6a5f-4381-b86d-98c34d084f57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e420a3e6-0b0a-450b-a468-f2a3164e557e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>onct:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:14pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41b9a9ec-b88f-44c3-9fb3-b65751c279ca" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.08%;"/>
    <td style="width:95.92%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a393c71b-c780-466b-aa22-562f4be83d8b" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc4ce151-87df-4fb1-8858-4537721a6d38" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d06894c1-eab9-415e-a806-568145c4a049" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30a34b15-c21d-4ca5-bc4d-d9676116b495" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.42%;"/>
    <td style="width:95.58%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_f031e6e7-6520-4998-8801-cf16536fd134" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f672d56-b489-4549-9bce-e024e498264c" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">000-50549</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0178f3c6-b85b-49a9-b733-98138601d7a0" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.2%;"/>
    <td style="width:1%;"/>
    <td style="width:48.8%;"/>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_3286542e-2b27-471d-b23e-dcb5c731bbf4" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_42c15c9d-8bd9-4933-b649-e25905c13390" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">62-1715807</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:17.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">(State or </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">other jurisdiction</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">&#160;of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1aa9dd67-7fc6-4c4c-b45c-73890e917d0b" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12230 El Camino Real</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa08278a-926f-4260-a5f2-4195e96545fd" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 230</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7441fb1b-fbf5-4e99-86cc-f9df3c927415" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_193288df-47bc-45bf-a3b4-109deacdba9d" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58426588-ff28-49e2-8280-ad35c451db40" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92130</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4c3fe6c-bf41-40d2-835e-a771e47da62c" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c8239ae-d7f9-4145-95ef-a04c58950923" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">434-1113</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.9%;"/>
    <td style="width:1.28%;"/>
    <td style="width:25.64%;"/>
    <td style="width:1.28%;"/>
    <td style="width:35.9%;"/>
   </tr>
   <tr style="height:8.65pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of Each Class</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol (s)</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #ffffff;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of Each Exchange on Which Registered</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_0a1a6fbe-3439-491c-819a-fe4df2b88a84" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2c6bfe5c-e8bf-4915-9f50-aaf83b82b8f4" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ONCT</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">The </span><span style="font-size:8pt;"><ix:nonNumeric id="F_b53479a9-2899-40ef-adcc-e3278c8abfab" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b30a8ac3-9874-4923-8f56-1a582819b48e" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbbe51e5-fc2c-408a-857c-fe6ba9d88464" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18adb29f-0f52-4378-bd01-b98bbaaed017" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f10f27e-21e0-4c63-be95-43148893c541" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28%;"/>
    <td style="width:3%;"/>
    <td style="width:38%;"/>
    <td style="width:28%;"/>
    <td style="width:3%;"/>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4a1f0d5d-7651-49d4-aa6c-3598c7f6e7ec" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9cf32ad8-056e-4f89-b4bf-e9add4f7ff87" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_1eb2da4f-21ac-4be1-adca-b1cc0b1fa836" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_026aeb9c-ce78-4dff-8243-8da34868e158" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b5830e9a-435a-4a66-afe5-047f1f116441" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b of the Exchange Act).      Yes </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_1d01cd12-d7f5-4053-b5e3-dbe465f00606" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76cc460a-4806-4117-9578-96782853fda8" contextRef="C_97e3e97f-b9c5-4887-aa84-bb0855f10787" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Capital Market on June 30, 2023 of $7.00 per share.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The number of outstanding shares of the registrant&#8217;s common stock as of March 1, 2024 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78d85ebe-6040-4608-adb2-39114b968b12" contextRef="C_66241dba-1f12-43c0-83cc-7d8e203311cb" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,959,645</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_ef92521e-a655-4801-bb68-c3e1533d7552" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#8217;s 2024 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM 10-K &#8212; ANNUAL REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the Fiscal Year Ended December 31, 2023</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.18%;"/>
    <td style="width:1%;"/>
    <td style="width:83.76%;"/>
    <td style="width:6.06%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i_1"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1_business_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedingsfrom_q3_form_10q"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statement_or_supplement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> I</span></p>
  <p style="font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K, or this Annual Report, including the sections entitled &#8220;Summary,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; contains forward-looking statements. We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected timing for achieving key milestones, including commencing, completing and announcing preclinical or clinical trial results of our product candidates, including ONCT-534, our dual-action androgen receptor inhibitor, or DAARI, candidate and ONCT-808, our ROR1-targeted CAR T cell therapy candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify and advance into the clinic new product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing or likelihood of regulatory filings for marketing authorization and approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the estimated size of the patient population and anticipated market potential for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of products that compete with our product candidates that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain favorable regulatory designations for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing upon the intellectual property rights of others;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization and marketing strategies and reliance on third-party manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the plans and objectives of management for future operations and future results of our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing through collaborations or other means. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We qualify all of the forward-looking statements in this Annual Report by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investing in our common stock is subject to numerous risks and uncertainties, including those described in Part I, Item 1A, &#8220;Risk Factors&#8221; of this Annual Report. The principal risks and uncertainties affecting our business include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a relatively limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, as of December 31, 2023, and our independent registered public accounting firm, in their report on our financial statements as of and for the fiscal year ended December 31, 2023, have concluded that there is substantial doubt as to our ability to continue as a going concern. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend heavily on the success of our product candidates, which are in clinical or preclinical development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials as planned. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties for the manufacture of our product candidates for preclinical and clinical development activities and expect to continue to do so for the foreseeable future.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to maintain orphan drug designations for some of our product candidates, and may be unable to leverage the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast Track designation by the U.S. Food and Drug Administration, or FDA, for our product candidates may not actually lead to a faster development or regulatory review or approval process.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third-party to conduct the clinical trials according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, or ICH, Guidelines, national requirements, and other requirements in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our trademarks, trade names, and service marks referenced in this Annual Report include Oncternal</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is protected under intellectual property laws and is our property. All other trademarks, trade names and service marks are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report appear without the </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;&#65039;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">sm</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> symbols, but such references should not be construed as any indication that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Use or display by us of other parties&#8217; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1_business_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">usiness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on prostate cancer and hematological malignancies. We expect partnerships and collaborations to be essential for implementing our broader development strategy. The following table summarizes our current development programs:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img205696091_0.jpg" alt="img205696091_0.jpg" style="width:720px;height:263px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ONCT-534 Dual-Action Androgen Receptor Inhibitor, or DAARI</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ONCT-534 is an investigational dual-action androgen receptor inhibitor, or DAARI, product candidate with a novel mechanism of action that includes inhibition of androgen receptor, or AR, function and degradation of the AR protein mediated by interaction with both the ligand binding domain, or LBD, and N-terminal domain, or NTD, of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated AR, and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR LBD, and splice variants with loss of the AR LBD. ONCT-534 is a potential monotherapy treatment for patients with advanced prostate cancer and other AR-driven diseases, including relapsed or refractory metastatic castration-resistant prostate cancer, or mCRPC, an area of high unmet need. We have dosed and continue to enroll patients with mCRPC under Study ONCT-534-101 (NCT05917470).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ONCT-808 ROR1 Cell Therapy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ONCT-808, our cell therapy product candidate, is an investigational autologous chimeric antigen receptor T cell, or CAR T, therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, or ROR1, using sequences from the binding domain of zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a closed, robust and automated cell manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. We have dosed patients under Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zilovertamab</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zilovertamab is an investigational, humanized, potentially first-in-class, monoclonal antibody designed to inhibit the function of ROR1. Zilovertamab has been evaluated in a Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib, a Bruton&#8217;s Tyrosine Kinase, or BTK, inhibitor, for the treatment of patients with chronic lymphocytic leukemia, or CLL, mantle cell lymphoma, or MCL, and marginal zone lymphoma, or MZL, which resulted in 100% progression free survival, or PFS, through 48 months in CLL patients expressing a p53 mutation/del(17p), a population underserved by current treatment options. Zilovertamab is being evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC. In April 2023, we reprioritized the development of zilovertamab and closed the Phase 3 ZILO-301 Study for the potential treatment of patients with relapsed or refractory MCL, prior to enrolling any patients, and closed enrollment for the Phase 1/2 Study CIRM-0001.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ONCT-216</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our program activities previously included ONCT-216, an investigational small molecule designed to inhibit the ETS, or E26 Transformation Specific, family of oncoproteins, which was shown in preclinical studies of Ewing sarcoma and other tumor types to alter gene transcription and RNA processing that led to decreased cell proliferation and invasion. In April 2022, we deprioritized the development of ONCT-216 and closed the Phase 1/2 clinical trial in patients with relapsed or refractory Ewing sarcoma in May 2022. We continue to study its mechanism of action and formulation under nondilutive grant support.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our team</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have assembled a management team, board of directors and scientific founders who have significant experience in successfully developing and commercializing therapeutics in oncology and orphan diseases, having worked or served on the Board of companies such as Amgen, Inc., Bavarian Nordic, Inc. (lead cancer asset acquired by Bristol Meyers Squibb Company), Baxalta Incorporated (acquired by Shire PLC), Bristol Meyers Squibb, Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc), Checkmate Pharmaceuticals (acquired by Regeneron), Dynavax Technologies Corporation, Elan Corporation (acquired by Perrigo), Eli Lilly and Company, Gilead Sciences, Inc., Immunomedics (acquired by Gilead), Innocrin Pharmaceuticals, Inc., Johnson &amp; Johnson, Merck &amp; Co., or Merck, Micromet, Inc. (acquired by Amgen, Inc.), Pfizer, Inc., Precision Therapeutics, Inc., Roche Holding AG, Sorrento Therapeutics, Inc., Teva Pharmaceutical Industries Ltd, Tracon Pharmaceuticals, Inc., VelosBio, Inc. (acquired by Merck) and Zavante Therapeutics, Inc. (acquired by Nabriva Therapeutics plc).</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs. We believe our investigational agents target novel cancer pathways and have unique or first in class mechanisms of action. Our current pipeline is derived from our ability to identify therapeutic candidates that have generated promising, late-stage preclinical results or clinical data, and in-license them for further development. We are particularly focused on therapeutic approaches for which there is a genetic or protein biomarker that can be used to identify populations of patients most likely to respond. We prioritize targets that we believe have the potential to transform the treatment paradigm of difficult-to-treat cancers with either single agent or combination therapy. As is the case for many oncology products, we believe that potential efficacy in one indication suggests the potential for application in other indications that carry the same target. Our focus is on prostate cancer and hematological malignancies as we believe our product pipeline can have the greatest impact in addressing unmet needs of patients diagnosed with these diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key elements of our strategy are as follows:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance ONCT-534, our lead DAARI product candidate, through clinical development with an initial focus for the treatment of patients with advanced prostate cancer;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance ONCT-808, our ROR1-targeting autologous CAR T cell therapy candidate, through a Phase 1/2 clinical trial for the treatment of patients with aggressive B cell Non-Hodgkin&#8217;s Lymphoma, including those who have failed previous CD19 CAR T treatment; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">secure a partnership to advance zilovertamab through clinical development initially in TP53-altered CLL, and potentially other indications; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluate our product pipeline in preclinical studies in additional tumors with a focus on prostate cancer and hematological malignancies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect partnerships and collaborations to be essential for implementing our strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DAARI Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ONCT-534, our lead DAARI product candidate, is a novel investigational, potentially first-in-class, orally bioavailable, AR inhibitor, for the treatment of patients with advanced prostate cancer and other AR-driven diseases. Based on preclinical studies, we believe ONCT-534 has the potential to be a novel treatment option for patients with advanced prostate cancer, with potential in earlier stages of the disease. We license ONCT-534 and certain other DAARI program rights from the University of Tennessee Research Foundation, or UTRF, under an exclusive, worldwide license agreement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 1. Schematic Representation of Clinically Relevant Domains of the Androgen Receptor</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img205696091_1.jpg" alt="img205696091_1.jpg" style="width:660px;height:181px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ONCT-534 has demonstrated activity in preclinical models of AR overexpression, numerous AR LBD mutations, as well as AR splice variants, which are all common mechanisms of resistance to current standard of care agents in advanced prostate cancer. ONCT-534 is also active against unmutated AR, promoting similar AR antagonistic effects compared to other treatments. ONCT-534 has a potentially novel and unique mechanism of action through the inhibition of AR function by interacting with both the ligand-binding domain, or LBD, and N-terminal domain, or NTD, of the AR, as well as induction of AR degradation. We believe that NTD binding is critical to the activity of ONCT-534 against tumors expressing AR splice variants that do not contain an LBD. Current standard of care treatment options, such as enzalutamide or apalutamide, bind only to the LBD of the AR, which may explain their reduced efficacy in patients with tumors expressing AR splice variants, as these AR variants lack the LBD. We believe that the differentiated dual-action pharmacology and the activity against unmutated AR of ONCT-534 has the potential to translate into improved clinical outcomes over current standard of care agents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prostate cancer overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to The Surveillance, Epidemiology, and End Results (SEER) Program database, there were 288,300 new cases of prostate cancer in the U.S. in 2023 and it is the second-leading cause of cancer death in American men. Approximately one-third of all prostate cancer patients who have been treated for local disease with curative intent will subsequently have rising serum levels of prostate-specific antigen, or PSA, which is an indication of recurrent disease with or without development of distant metastasis. Patients with recurrent disease as indicated by rising PSA usually undergo androgen deprivation therapy, or ADT. While most of these patients initially respond to ADT, many experience a recurrence in tumor growth despite the reduction of testosterone to castrate levels, and at that point are considered to have castrate resistant prostate cancer, or CRPC. Following diagnosis of CRPC, patients are usually treated with an AR pathway inhibitor, or ARPI, which include AR inhibitors that act through the AR LBD (e.g. darolutamide, enzalutamide, apalutamide or bicalutamide), or agents that inhibit synthesis of androgens (e.g. abiraterone). More recently, significant improvements in PFS and overall survival, or OS, have been achieved by utilizing this latest generation of ARPIs in combination with ADT and/or chemotherapy earlier in the course of disease, such as hormone-sensitive prostate cancer, or HSPC, and non-metastatic CRPC, or nmCRPC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The growth of prostate tumors is initially mediated by an activated AR pathway. Generally, there are three means of activating the AR. First, androgens, such as dihydrotestosterone, can activate the AR by binding to its LBD and interacting with the activation domain on the AR. Second, CRPC can be driven by variants of AR that lack an LBD, are constitutively activated, and consequently do not require androgens for activation. Generally, current ARPI drugs for the treatment of prostate cancer are inhibiting activation of the AR pathway by: (i) interfering with the production of androgens, (ii) preventing androgen from binding to the LBD, or (iii) inducing a negative signal through the AR LBD. Over time, these approaches will eventually fail due to mechanisms of resistance, which involve the LBD end of the receptor, whether at the DNA level via AR amplification or LBD mutations, or at the RNA level via the emergence of AR splice variants. Lastly, in patients who have been treated for years with various antiandrogen therapies, genomic changes may lead to additional, non-AR-related oncogenic drivers, and become variably insensitive to inhibition of the AR pathway.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mechanism of action</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a DAARI, ONCT-534 has a potentially novel and unique mechanism of action: it interacts with both the NTD and the LBD of the AR (Figure 1 above), inhibiting AR function and leading to AR protein degradation. We believe that this NTD binding is relevant to the activity of ONCT-534 against tumors expressing AR splice variants by preventing constitutive AR activation. In this respect, ONCT-534 is designed to differ mechanistically from ARPIs that interfere with androgen synthesis, such as abiraterone, and agents such as darolutamide, enzalutamide, or apalutamide, that bind only to the LBD of the AR, which may explain their reduced efficacy in patients with AR-SV-expressing tumors, as these AR variants may lack parts of the LBD. An essential difference between ONCT-534 and certain other novel agents in development is that ONCT-534 is active against a broad spectrum of AR mutations, but is also active against unmutated or native AR. We believe that the potentially differentiated dual-action pharmacology of ONCT-534 has the potential to translate into significantly improved clinical outcomes over current standard of care agents.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we are focusing on prostate cancer, we believe our novel mechanism of action offers potential for DAARI therapeutic development in other AR-driven diseases, such as luminal AR-positive triple-negative breast cancer, which can be driven by AR splice variants, as well as non-oncology indications, such as Spinal Bulbar Muscular Atrophy, also known as Kennedy&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ONCT-534 development in prostate cancer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are initially evaluating ONCT-534 as a potential therapy for patients with advanced mCRPC who have relapsed or were refractory to prior ARPI therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In preclinical studies, ONCT-534 demonstrated antagonism and degradation of full-length native AR, mutant LBD AR, and AR splice variants. ONCT-534 is active in animal models with castrate androgen levels and in uncastrated animals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess the ability of ONCT-534 to treat enzalutamide-resistant prostate cancers, we conducted in vivo studies in an enzalutamide-resistant MDVR VCaP xenograft model. This treatment resistance can be seen below for both castrated and intact animals (Figure 2), as tumors in rats dosed with enzalutamide grew at nearly the same rate as tumors in rats dosed only with the placebo drug vehicle. Orally delivered ONCT-534 substantially inhibited tumor growth, described as tumor growth inhibition, or TGI, in these enzalutamide-resistant MDVR tumors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 2. ONCT-534 Exhibited AR-specific Anti-tumor Activity in ENZA-resistant MDVR CRPC Preclinical Model</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img205696091_2.jpg" alt="img205696091_2.jpg" style="width:655px;height:224px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a mouse xenograft model of human prostate cancer in intact animals, treatment with ONCT 534 significantly inhibited tumor growth of LnCAP human prostate cancer cells that overexpress AR (LnCAP-AR), as shown in the figure below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 3. ONCT-534 Exhibited AR-specific Anti-tumor Activity in AR-overexpressing Preclinical Model</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img205696091_3.jpg" alt="img205696091_3.jpg" style="width:407px;height:189px;"/>&#160;</p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AR-V7 is a splice variant of AR that lacks the LBD and hinge region and is expressed in 22Rv1 cells, which are human prostate carcinoma epithelial cells derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent xenograft. As shown in Figure 4 below, enzalutamide is not efficacious in an animal model of human prostate containing both AR dependent elements, driven by the AR-V7 splice variant that lacks the LBD, and AR independent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">elements against these tumors that lack the LBD. Treatment with ONCT-534 however, resulted in tumor growth inhibition, even in this model with mixed AR-dependent and independent tumors, as well as significant reduction in PSA in this model, demonstrating activity at the NTD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 4. ONCT-534 Exhibited Anti-tumor Activity in AR Splice Variant Preclinical Model</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img205696091_4.jpg" alt="img205696091_4.jpg" style="width:627px;height:206px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DAARI Study ONCT-534-101</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the broad activity of ONCT-534 against multiple forms of prostate cancer driven by AR mutations, in 2023, we commenced Study ONCT-534-101, a Phase 1/2, single-arm, open-label, multi-center study to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of ONCT-534 in patients with mCRPC who have relapsed or are refractory to approved ARPIs including enzalutamide, abiraterone, apalutamide and darolutamide. The Phase 1 portion of the study utilizes an adaptive Bayesian Optimal Interval (BOIN) design with five ONCT-534 dosing cohorts ranging from 40 mg to 600 mg per day. After the safety and tolerability and preliminary antitumor activity of ONCT-534 have been assessed in the Phase 1 portion of this study, Phase 2 will commence to further evaluate the safety and preliminary antitumor activity of ONCT-534 to support selecting an optimal dose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we announced the first and second cohorts treated one patient each at 40 mg ONCT-534 per day and 80 mg ONCT-534 per day, respectively. The decision in late 2023 to proceed to dose level 3 of 160 mg was confirmed by the study&#8217;s Safety Review Committee (SRC). Additional patients have enrolled into the third dosing cohort of 160 mg ONCT-534 per day.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROR1 CAR T Cell Therapy Program</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ROR1 scientific background: inhibition of ROR1 as a therapeutic strategy in cancer</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROR1 is an onco-embryonic protein essential for normal fetal development whose expression is suppressed at birth unless reactivated as a survival factor by many different cancers. The switching-on of ROR1 is consistent with the general process of de-differentiation in cancer, in which normal cells lose their highly differentiated functions and return to a more primitive state, where they exhibit a greatly increased capacity for invasion, metastasis and resistance to treatment. This de-differentiation is associated with expression of a number of genes normally restricted to fetal development, one of which is ROR1. Cancer cells with the highest potential for self-renewal are sometimes referred to as tumor-initiating cells or cancer stem cells and are capable of invading other tissues or metastasizing to form tumors in distant sites in the body. These tumor-initiating cells are also the cells that have been found to be the most resistant to standard cancer therapies including chemotherapy and radiation therapy. Cancer cells that overexpress ROR1 have been shown to have increased survival, migration and resistance to chemotherapy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Histological staining of over 350 human tumor samples identified that a majority expressed ROR1, including 90% or more of lymphomas and CLL, as well as prostate and uterine cancers, as shown below:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.105%;"/>
    <td style="width:24.105%;"/>
    <td style="width:3.581%;"/>
    <td style="width:24.105%;"/>
    <td style="width:24.105%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cancer Type</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ROR1 Expressed</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cancer Type</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ROR1 Expressed</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uterus</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96%</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adrenal</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MCL</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95%</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lung</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CLL</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95%</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Breast</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lymphoma</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90%</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Testicular</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prostate</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90%</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Colon</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Skin</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89%</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ovarian</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pancreas</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83%</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bladder</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">High ROR1 expression on patients&#8217; tumor cells in a variety of cancers is associated with the development of metastases, early relapse after therapy, and a poorer prognosis. ROR1 expression levels on patients&#8217; tumor cells is higher in cancers that are more advanced or poorly differentiated. For example, whereas Grade 1 or 2 ovarian tumors were found to be 21% positive for ROR1, Grade 3 or 4 tumors were found to be 62% positive for ROR1. High expression of ROR1 has been associated with more aggressive disease and shorter patient survival in multiple tumor types, including CLL, breast cancer, ovarian cancer and multiple myeloma.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inhibition of ROR1 signaling or silencing of ROR1 expression in multiple preclinical cancer models including lymphoma, CLL, breast cancer, ovarian cancer and glioblastoma, was associated with suppressing the expression of genes characteristic of tumor-initiating cells, and with repression of cancer migration and metastasis. Preclinical models also demonstrated that inhibition of ROR1, or blocking of Wnt5a-induced ROR1 signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells &#8211; resulting in fewer metastases and improved survival.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inhibition of ROR1 has been demonstrated in preclinical models to be additive to, or synergistic with, chemotherapy agents such as paclitaxel, and with targeted therapy agents such as ibrutinib and venetoclax. In addition, inhibition of ROR1 has been shown to enhance sensitivity of cancer cells to targeted therapy with agents such as erlotinib and may increase apoptosis and decrease proliferation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In summary, in addition to our Study ONCT-808-101 (NCT05588440) and Study CIRM-0001 Phase 1/2 initial clinical trial results described below, we believe ROR1 is an attractive therapeutic target in oncology for multiple reasons:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROR1 is widely expressed on many cancers, including hematologic malignancies and solid tumors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expression of high levels of ROR1 on patients&#8217; tumors is associated with more rapid disease progression, resistance to therapy and shorter patient survival, and therefore may represent an especially high unmet medical need;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Blocking of ROR1 activity in preclinical models inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inhibition of ROR1 has been observed in preclinical models to be synergistic with certain chemotherapies and targeted therapies, potentially allowing for safer and more efficacious combination therapies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical data presented for zilovertamab vedotin (MK-2140), a ROR1-targeting antibody-drug conjugate, or ADC, included a safety profile similar to other ADCs of the class, with no apparent on-target, off-tumor organ toxicity. Zilovertamab is the ROR1 antibody used in Merck&#8217;s MK-2140 product candidate. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Two notable acquisitions in 2020 involved companies developing product candidates targeting ROR1: Merck acquired VelosBio, Inc. and its ROR1-targeting ADC (which was initially developed at Oncternal), and Boehringer-Ingelheim acquired NBE Therapeutics and its ROR1-targeting ADC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ROR1 CAR T cell therapy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing our CAR T cell therapy candidate based on the ROR1 binding domain of zilovertamab, our monoclonal antibody described below, to treat patients with hematological malignancies or solid tumors. We believe that the selective expression of ROR1 on many tumor cells and its absence on most normal cells make it an attractive target for a CAR T cell therapy approach. In addition, we believe that ROR1-negative relapses might be less likely to develop after ROR1 CAR T cell therapy, because the survival</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">benefit imparted on cancer cells by ROR1 expression may limit the development of ROR1-negative mutant tumor cells, given that tumor cells that lose or mutate ROR1 to escape CAR T cell treatment may be less aggressive than the parental cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ONCT-808 is an autologous cell therapy consisting of CD4 and CD8 T cells that are genetically modified by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transduction with a lentivirus vector to express a chimeric antigen receptor, or CAR, that contains a ROR1 directed single chain variable fragment (scFv) region derived from zilovertamab and also includes 4-1BB and CD3&#950; signaling domains.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In late 2022, we received a Study May Proceed letter from the FDA for a Phase 1/2 dose escalation clinical study of ONCT-808 in patients with aggressive B cell Non-Hodgkin&#8217;s Lymphoma, including those who have failed previous CD19 CAR T treatment. We are pursuing a two-pronged development strategy for our ROR1 CAR T cell therapy program. The first part of the strategy is to evaluate evidence of safety and clinical activity of our ROR1 CAR T cell therapy in humans while using an established autologous CAR T approach and targeting hematological indications that are known to be susceptible to CAR T cell therapy. The second part of the strategy will evaluate autologous therapies for advancement on a stand-alone basis as well as to develop next-generation cell therapies targeting ROR1 by introducing more advanced cell therapy technologies, which could include combination therapy with agents that target the immunosuppressive solid tumor milieu, CAR T cells bearing additional features to overcome the solid tumor microenvironment, or &#8220;off-the-shelf&#8221; or allogeneic CAR T cell or chimeric antigen receptor NK cell, or CAR-NK, therapies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect partnerships and collaborations to be essential for implementing our next-generation strategy. In January 2021, we announced a research and development collaboration with Karolinska Institutet to investigate novel optimized ROR1-targeting cell therapies focused on CAR T cells and CAR-NK. In April 2022, we established a clinical manufacturing agreement with the Dana-Farber Cancer Institute to conduct cGMP cell preparation and manufacturing activities for use in our Phase 1/2 study.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Scientific background: CAR T cell therapy overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immuno-oncology approaches to treating cancer involve redirecting one of the pillars of the immune system, the adaptive immune system, so that it specifically and efficaciously recognizes cancerous cells that might previously have escaped immune recognition. A key element in the adaptive immune response is the T cell that can recognize and kill infected and abnormal cells. T cells also act to signal other immune cells to respond to threats. T cells recognize their targets because they are selected in a way that allows them to specifically recognize foreign antigens on the surface of other cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T cells are well suited for immuno-oncology applications based on several characteristics. They have evolved to be specific and avid killers. One T cell can eliminate numerous target cells. T cells are highly specific, able to recognize a cancer cell and kill it, while ignoring an almost identical healthy cell. T cells are thought to be vigilant all the time, eliminating cancer cells from the body before they can form tumors. However, tumor cells sometimes evolve to escape T cell killing by activating a number of pathways that suppress T cell function. Adoptive T cell therapies, and specifically CAR T cells, are being developed to provide methods to generate large quantities of T cells capable of specifically recognizing and killing tumor cells despite tumor suppressive mechanisms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T cells have potent cell killing activity that is directed to target cells that are recognized by specific T cell receptors, or TCRs, that are expressed on the surface of these T cells. While some T cells have TCRs that can recognize cancer cells leading to their killing, potent T cells do not develop against all tumor targets. In some cases, the potential cancer cell target is also a protein that has an essential role in other tissues or at other stages of development, and TCRs that recognize these targets are eliminated during normal T cell development. CAR T cell therapy has emerged as a way to engineer T cells to recognize specific targets, such as those that are selectively expressed on cancer cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAR T cell therapies are typically produced from a patient&#8217;s own T cells, which are isolated by leukapheresis. These cells are then genetically modified with a chimeric antigen gene construct which can be delivered by various mechanisms, such as lentiviral gene delivery vectors, which contain a gene encoding a chimeric protein incorporating a single antigen-binding domain derived from the sequence of an antibody that specifically recognizes the target, with one or more T cell costimulatory domains and a portion of the T cell receptor. Transduced cells are then expanded and undergo quality testing before being reintroduced into the same patient. This approach is also known as autologous CAR T cell therapy.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 5. CAR T Production and Patient Treatment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img205696091_5.jpg" alt="img205696091_5.jpg" style="width:320px;height:212px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1/2 Study of ONCT-808-101</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, we commenced Study ONCT-808-101, a Phase 1/2, single-arm, open-label, multi-center study to evaluate the safety and tolerability, pharmacokinetics, and anti-tumor activity of ONCT-808 in subjects with aggressive B cell lymphoma, including large B-cell lymphoma, or LBCL, and MCL. After the safety and tolerability of ONCT-808 have been assessed to select the RP2D in Phase 1, Phase 2 will commence to further validate the dose and evaluate the safety and efficacy of ONCT-808. In Phase 2, subjects with LBCL or MCL will be enrolled into 2 separate dose expansion cohorts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, we announced a study status update. At the initial dose of 1x10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAR T cells per kg, two of the three patients achieved complete metabolic response, or CMR, and the third achieved a partial response, or PR, by fluorodeoxyglucose positron emission tomography/computed tomography, or FDG PET-CT. Common adverse events in this dosing cohort included decreased blood counts, pneumonia and Grade 1-2 cytokine release syndrome, or CRS, as of a December 4, 2023 data cutoff date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first patient treated at the second dose level of 3x10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAR T cells per kg, an 80-year-old with bulky disease who had received four previous lines of therapy and was refractory to CD19 CAR T, experienced a Grade 5 (fatal) serious adverse event consistent with CRS and immune effector cell-associated neurotoxicity syndrome, or ICANS. No evidence of his lymphoma was found histologically based on the patient&#8217;s autopsy report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After communicating with the FDA, we modified our eligibility criteria and are testing lower doses of ONCT-808 for future patients in the study including at 0.3x10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAR T cells per kg and at 0.6x10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAR T cells per kg.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional potential clinical opportunities for ONCT-808 in other indications</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chronic Lymphocytic Leukemia. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROR1 is expressed on CLL cells in over 90% of patients, and its expression has been correlated to leukemia development in rodents and disease progression in humans, with higher expression linked to more aggressive disease manifestations and shorter OS. The ROR1 expression has also been implicated in the development of disease resistance to other therapies, including BTK inhibitors and venetoclax. As such, relapsed or refractory CLL after treatment with BTK inhibitors remains a significant unmet need, particularly in patients with high ROR1 expression. In preclinical studies in MEC1-ROR1 CLL rodent models with second generation ROR1+ CAR T cells, employing the same scFv region as ONCT-808, significant potency and clearance of leukemic cells was observed. The administered CAR T cells were persistent in the rodent models for greater than three months and remained highly active following administration, without evidence of T cell exhaustion. Complete tumor regression, as measured by luminescence, was observed in CLL rodent models, after treatment with the CAR-T therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Multiple Myeloma. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global multiple myeloma market is estimated to reach $31 billion  by 2026. It is the second most prevalent hematological cancer. Among the potential clinical antigens for treatment of myeloma, ROR1 is a very attractive tumor-selective target. ROR1 is frequently expressed on myeloma cells, particularly from patients with relapsed or refractory disease. ROR1 expression in myeloma patients having undergone and failed various lines of previous therapy was shown to increase after each treatment, making ROR1 an attractive and abundant target for relapsed or refractory patients with myeloma.  In a preclinical study with ROR1 high expressing RPMI-8226 models of human multiple myeloma/plasmacytoma in NSG mice, tumors were eliminated with the highest dose of ONCT-808, with significant tumor reduction in mice receiving the highest dose, relative to vehicle and controls. ROR1+ CAR-T cells were detected 28 days after administration, suggesting the in vivo persistence of the ONCT-808 CAR-T cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lung cancer. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROR1 is expressed by approximately 77% to 93% of lung cancers. In adenocarcinoma of the lung, higher levels of ROR1 expression were correlated with advanced stages of disease and with positive lymph node metastases. In addition, high ROR1 expression was associated with worse OS in patients with lung adenocarcinoma. ROR1 expression in lung cancer has been shown to be correlated with the presence of other negative prognostic factors such as phosphorylated AKT, or p-AKT, or phosphorylated CREB, or p-CREB. Inhibition of ROR1 in lung cancer cell lines induced apoptosis and cell cycle arrest and led to a reduction in levels of p-CREB and p-AKT. A recent preclinical study has shown that downregulating ROR1 expression re-sensitizes osimertinib-resistant lung cancer cells to an EGFR inhibitor drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ovarian cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ROR1 is expressed by approximately 54% of ovarian cancers, which is the most lethal gynecologic malignancy among women worldwide. Analysis of ROR1 expression on ovarian cancer patient samples revealed that disease-free survival and OS rate in patients with high ROR1 expression were significantly lower than in patients with low or no ROR1 expression. In a preclinical study, it was shown that a ROR1 antibody inhibited growth of ovarian cancer cell lines in vitro and slowed tumor growth in a mouse model. Zilovertamab also demonstrated an anti-proliferative effect on certain ovarian and endometrial cancer cell lines in vitro.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zilovertamab - monoclonal antibody targeting ROR1</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zilovertamab development in CLL and MCL</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CLL is the most common form of leukemia in adults, accounting for 25-30% of all leukemias in the U.S. BTK inhibitor therapy has emerged as a standard of care for CLL and is recommended by the National Comprehensive Cancer Network (NCCN) guidelines as first-line therapy. Patients with CLL can experience a substantial period of disease control, but the disease eventually recurs in most patients, and is more likely to do so for patients with previous CLL therapy. Adverse events have been shown in a real-world analysis to limit ibrutinib treatment duration for almost half of all patients. An acceptable safety profile may be particularly important for patients with CLL who are older and may have multiple co-morbidities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MCL is an aggressive form of non-Hodgkin&#8217;s lymphoma. There are approximately 4,200 new cases of MCL each year in the U.S., with the average age at diagnosis in the mid-60s. MCL is an aggressive lymphoma and carries a poor prognosis, with a median survival of about two to five years. The 10-year survival rate is about 5-10%. While there are several therapeutic options available to treat patients with relapsed or refractory MCL, we believe none of these options offer curative benefit, with most patients relapsing in less than 20 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROR1 is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen, which is a protein typically expressed during embryogenesis that may confer a survival and fitness advantage when reactivated and expressed by tumor cells. ROR1 is over-expressed in many different cancers, including CLL, MCL, breast cancer and prostate cancer, and has been reported to be associated with more aggressive disease, resistance to therapy and shorter PFS or OS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies have shown that when zilovertamab bound to ROR1, it blocked growth factor Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of CLL tumor cells. Preclinical studies with zilovertamab also showed that treating CLL or MCL patient&#8217;s tumor cells with a combination of zilovertamab and ibrutinib led to reduced proliferation that was at least additive. Additional in vitro studies showed that the combination of zilovertamab plus a BTK inhibitor was active in MCL cells that had become insensitive to BTK inhibitor alone. In vivo studies have shown that the combination of ibrutinib and zilovertamab reduced tumor engraftment in a mouse model of human CLL.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a Phase 1 dose escalation clinical trial of zilovertamab in patients with relapsed or refractory CLL, zilovertamab was well tolerated when given intravenously every two weeks at doses from 0.015 to 20 mg/kg/dose. There were no dose-limiting toxicities, no serious adverse events, and no discontinuations related to adverse events. Treatment was too short (4 doses total) to see objective responses, but 17 of 22 evaluable patients had stable disease, and median time to next treatment was 262 days. The plasma half-life of zilovertamab was over 28 days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal and UC San Diego, with funding from CIRM, and a donation of ibrutinib product from Pharmacyclics LLC, conducted Study CIRM-0001, a Phase 1/2 clinical trial of zilovertamab in combination with ibrutinib in patients with relapsed or refractory CLL, MCL or MZL. This clinical trial was designed to evaluate the safety, pharmacokinetics, or PK, pharmacodynamics, immunogenicity, and antitumor activity of zilovertamab in combination with ibrutinib in adult patients with adequate performance status and organ function.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A recommended dose regimen, or RDR, of 600 mg of zilovertamab administered intravenously every two weeks for three doses, followed by dosing every four weeks until disease progression or intolerance was selected after the dose escalation portion of the study. Zilovertamab was given in combination with 420 mg of ibrutinib administered once daily for patients with CLL, or 560 mg of ibrutinib once daily for patients with MCL, which was at that time the FDA-approved doses of ibrutinib in these indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the 50 patients with CLL that were evaluable for efficacy, 20 patients were treatment na&#239;ve and 30 patients had relapsed or refractory CLL. Ten of the evaluable patients had CLL with 17p deletions and/or TP53 mutations, including five patients with treatment-na&#239;ve CLL and five patients with relapsed or refractory CLL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Landmark PFS was 100% at 48 months and 44 months in both treatment-na&#239;ve and relapsed/refractory TP53/del(17p) patients with CLL, respectively, that received the combination of zilovertamab and ibrutinib. Landmark OS was 100% at 42 months and 49 months in treatment-na&#239;ve and relapsed/refractory TP53/del(17p) patients, respectively, that received the combination of zilovertamab and ibrutinib. Landmark OS was 67% at 43 through 48 months in treatment-na&#239;ve TP53/del(17p) patients that received the combination of zilovertamab and ibrutinib. The most recent data update from the Phase 3 ALPINE study comparing zanubrutinib monotherapy to ibrutinib monotherapy in patients with relapsed or refractory CLL showed a landmark PFS of 60.1% for zanubrutinib and 43.6% for ibrutinib in TP53/del(17p) patients at 36 months. TP53 mutations are among the most commonly acquired mutations in cancer, including hematological malignancies, and are associated with decreased survival and predict inadequate therapeutic response. Inhibition of these pathways may complement inhibition of B-cell receptor signaling by ibrutinib, particularly in TP53-aberrant disease.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Landmark PFS was 95% at 24 months in all patients with relapsed/refractory CLL treated with the combination of zilovertamab plus ibrutinib in Parts 1 and 2 of Study CIRM-0001. The most recent data update from the ALPINE study showed a landmark PFS of 65.8% for zanubrutinib and 54.3% for ibrutinib in patients with relapsed or refractory CLL at 36 months.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data from Part 3 of Study CIRM-0001, comparing ibrutinib plus zilovertamab to ibrutinib alone in 28 patients with CLL, continue to mature, and median PFS for both arms had not been reached as of the July 2023 cut-off date after a median follow up of 44 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PFS and OS curves for evaluable patients with CLL are presented in the following figure.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 6. Study CIRM-0001, patients with CLL, PFS and OS, by prior treatment status (A and B) and by TP53 aberration status (C and D)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img205696091_6.jpg" alt="img205696091_6.jpg" style="width:720px;height:405px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the 28 evaluable patients with relapsed or refractory MCL in Study CIRM-0001 treated with zilovertamab plus ibrutinib, 25 (89%) achieved an overall response (CR or PR) rate, or ORR, and 12 (43%) achieved a CR. The total clinical benefit rate (CR, PR, SD) was 93% as of the data cut-off date. The combination of zilovertamab and ibrutinib demonstrated rapid achievement of response with ORR of 78.6% (17.9% CR and PR 60.7%) of study patients at 3 months, and ORR increased to 89.3% (39.3% CR and 50% PR) at 12 months with 43% CR at 26 months (see Figure 7 below). A merged analysis of three studies of single agent ibrutinib in patients with MCL showed CR rates of 5.9% at 4 months, 18.4% at 12 months and 20.0% at 25 months (Rule 2017). The ORR and median duration of response were encouraging in patients with high-risk features associated with difficult to treat disease. High Ki-67 (&#8805;30%) patients had an ORR of 86% and the median duration of response was not reached after 46 months (95% confidence interval (CI) 3.0 months &#8211; not evaluable, or NE). Five patients had received prior treatment with ibrutinib, with three achieving CRs and two achieving</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PRs for an ORR of 100%. The PFS results for MCL TP53 mutations (see Figure 7 below) enhanced our belief that zilovertamab works in TP53 mutations regardless of the tumor type.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PFS for TP53 mutations and CR efficacy results for the evaluable population of patients with MCL are presented in the following figures, along with relevant literature results for single-agent ibrutinib.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 7. Study CIRM-0001, patients with MCL, objective response rate (left) and progression free survival by TP53 aberration status (right)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img205696091_7.jpg" alt="img205696091_7.jpg" style="width:720px;height:249px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zilovertamab development in prostate cancer</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prostate cancer is the second most frequently diagnosed cancer among men in the U.S., according to the American Cancer Society. ROR1 is expressed by approximately 90% of prostate cancers, and the Wnt5a signaling pathway is activated in patients with advanced prostate cancer that is progressing while on treatment with an AR inhibitor. Treatment of prostate cancer cell lines with an AR inhibitor was found to increase the expression of Wnt5a, and the addition of Wnt5a attenuated the antiproliferative effect of AR inhibition. The expression of Wnt5a in the tumors of patients with mCRPC has been associated with poor OS. ROR1 expression has also been shown on certain prostate cancer cell lines that had lost dependence on the AR signaling pathway, an important mechanism of resistance development in advanced prostate cancer. We are collaborating with academic investigators to investigate the potential effects of zilovertamab on this disease.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An investigator-sponsored prospective, open-label, non-randomized, one-arm Phase 1b study to evaluate the safety and efficacy of, and to determine the recommended Phase 2 dose, or RP2D, of, docetaxel combined with zilovertamab in patients with mCRPC is recruiting patients at UC San Diego. During the treatment period, zilovertamab and docetaxel will be administered by IV infusion on an outpatient basis. Initially, zilovertamab will be given as a series of loading doses with biweekly IV infusions on days 1, 15 and 29 of cycle 1. Following this, zilovertamab will be given concurrently with docetaxel (cycles 2 up to 6 depending on tolerance to docetaxel) and each cycle will be 21 days in length. Patients will be treated for a maximum of six cycles with combination therapy. Following completion or discontinuation of docetaxel, cycle length will be 28 days and zilovertamab will be administered day one of every 28-day cycle starting at cycle eight (or earlier depending on tolerance). Zilovertamab will be administered IV on day one of the cycle.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are intensely competitive and characterized by rapid technology evolution. Our potential competitors include large pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as government, academic and other research institutions. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to our programs. Our commercial opportunities may be reduced or eliminated if our competitors develop and commercialize similar products that are safer, more effective, have fewer side effects or are less expensive than any products that we or our collaborators may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, we compete with other companies that are developing and commercializing treatments for patients with cancer. Competing therapies include chemotherapies, targeted therapies and immunotherapies and may represent various therapeutic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">modalities including small molecules, antibodies, cell therapies, gene therapies, and cancer vaccines. These companies may compete with us for clinical trial sites and eligible patient populations, scientific and management talent, outsourced manufacturing capacity and healthcare budgets for commercial-stage products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ONCT-534</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While there are currently no approved drugs with similar mechanism of action as our DAARI program, ONCT-534, the competition in the advanced prostate cancer market is very high. Several therapies have already been approved and many more are currently in development. Second-generation antiandrogens including Xtandi (Astellas and Pfizer), Zytiga/Erleada (Johnson &amp; Johnson), and Nubeqa (Bayer) have become the preferred regimens for first line therapy in this indication. Other therapeutic modalities, such as checkpoint inhibitors are being evaluated in combination with either antiandrogen or chemotherapies. Bispecific antibodies and CAR T therapies targeted towards prostate-specific member antigen are also in early development. Other approaches to interfering with AR signaling include strategies to: (i) blocking AR activation via NTD binding as being pursued by ESSA Pharma, Inc., and (ii) degrading the AR protein such as that being pursued by Arvinas, Inc.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ROR1 CAR T</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While there are currently no approved cell therapy products targeting the ROR1 receptor, we are aware of an autologous CAR T cell therapy clinical program targeting ROR1 sponsored by Lyell Immunopharma, Inc. for patients with solid tumors. Precigen, Inc. announced plans to initiate a Phase 1/1b clinical trial of PRGN-3007, an autologous CAR T cell therapy targeting ROR1, in patients with hematological malignancies and solid tumors. Caribou Biosciences, Inc. announced plans to develop an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR1 CAR-NK cell therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are numerous companies developing or marketing cell therapy treatments for the same oncology indications that we may target with our ROR1 CAR T program including AbbVie, Adicet, Allogene Therapeutics, Atara Biotherapeutics, Inc., Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Therapeutics, Fate Therapeutics, Gilead Sciences, Inc., Johnson &amp; Johnson, Legend Biotech, Merck, NantKwest, Nkarta Therapeutics, Novartis Pharmaceuticals Corporation, Poseida Therapeutics, Roche Holding AG, and others. Six CAR T cell therapies have been approved by the FDA, Yescarta and Tecartus are marketed by Gilead Sciences, Inc., Kymriah is marketed by Novartis Pharmaceuticals Corporation, Abcema and Breyanzi are marketed by Bristol-Myers Squibb Company, and Carvykti, marketed by Johnson and Johnson. Yescarta, Tecartus, Kymriah and Breyanzi target the CD19 protein, a protein expressed on the surface of the majority of B cells, including B cell tumorigenic cells.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Licenses and Collaborative Relationships</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2015, and as amended and restated in March 2022 and August 2022, we entered into a license agreement with UTRF (the &#8220;DAARI License Agreement&#8221;) pursuant to which we were granted exclusive worldwide rights in all existing DAARI technologies owned or controlled by UTRF, including all improvements thereto. Under the DAARI License Agreement we are obligated to employ active, diligent efforts to conduct preclinical research and development activities for the DAARI program to advance one or more lead compounds into clinical development. We are obligated to pay UTRF annual license maintenance fees in the mid five digits and low single-digit royalties on aggregate net sales of licensed products. We are also obligated to pay UTRF tiered royalties ranging from a low single digit to low double-digit percentage of consideration received by our sublicensees, excluding royalties, such percentage dependent on the stage of development of a clinical product candidate at the time it is sublicensed. Our obligation to pay UTRF royalties expires on a country-by-country and licensed product-by-licensed product basis on the last-to-expire valid patent claim of a licensed patent covering such licensed product in such country. As of December 31, 2023, we believe we have met our obligations under the DAARI License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless terminated earlier, the term of the DAARI License Agreement will continue, on a country-by-country basis, until the expiration of the last-to-expire valid claim of any licensed patent covering a licensed product in such country. Either party may terminate the DAARI License Agreement for the other party&#8217;s uncured material breach, subject to certain notice and cure periods. UTRF may terminate the DAARI License Agreement for our bankruptcy or insolvency. We may terminate the Amended and Restated UTRF Agreement with advance written notice to UTRF, provided we have satisfied our payment obligations to UTRF prior to such termination.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">UC San Diego</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2016, we entered into a license agreement with the Regents of the University of California, or the Regents, represented by UC San Diego, which was amended and restated in August 2018, and amended thereafter through January 2024 (the &#8220;Regents License Agreement&#8221;), for the development, manufacturing and distribution rights to naked antibodies, including zilovertamab and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">genetically engineered cellular therapy products, including CAR T products that are covered by licensed patents for all human therapeutic, diagnostic and preventive applications in all indications. The Regents License Agreement requires us to pay certain development and regulatory milestones aggregating from $20.1 million to $24.5 million, on a per product basis, certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, low single-digit royalties including potential future minimum annual royalties on net sales of each product, certain annual patent costs, and annual license maintenance fees. Unless terminated earlier, the Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15th anniversary of the first commercial sale of a licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UC San Diego may terminate the Regents License Agreement if a material breach by us is not cured within a reasonable time, we file a claim asserting the licensed patent rights are invalid or unenforceable, or we file for bankruptcy. We may terminate the agreement at any time upon at least 60 days&#8217; written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, we entered into a research agreement with the Regents for research on the ROR1 therapeutic development program. Under this five-year agreement that expired in June 2021, UC San Diego was paid an aggregate of $3.6 million. Effective January 1, 2022, we entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on the ROR1 therapeutic development program. Under this four-year agreement that expires on December 31, 2025, the Regents will receive payments aggregating $1.6 million, with quarterly payments of $125,000 in 2022, $131,250 in 2023, and $137,813 in 2024 and 2025. Such costs are includable as part of our annual diligence obligations under the Regents License Agreement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CIRM</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2017, and as amended and restated in December 2020, the California Institute for Regenerative Medicine, or CIRM, awarded an $18.3 million grant to researchers at UC San Diego to advance the Study CIRM-0001. We: (i) conducted this study in collaboration with UC San Diego, (ii) received $14.5 million in development milestones under research subaward agreements during the award project period from October 1, 2017 through March 31, 2022, (iii) were committed to certain co-funding requirements, and (iv) were required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. As of December 31, 2023, we believe we have met and completed our obligations under the CIRM award and UC San Diego subawards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2018, and as amended in August 2020, we entered into a license agreement with SPH USA, or the SPH USA License Agreement, under which we granted exclusive rights to SPH USA to manufacture, develop, market, distribute and sell in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan ("Greater China"), our product candidates under the Georgetown License Agreement and the UC San Diego License Agreement. Under the License and Development Agreement, or LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying us a low single digit royalty on net sales in the territory. The SPH USA License Agreement will expire on a licensed product-by-licensed product and country/region-by-country/region basis on the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country/region.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SPH USA License Agreement may be terminated by SPH USA, on a country/region-by-country/region or product-by-product basis with 180 days written notice following the first anniversary of the effective date of the agreement or at any time on a product-by-product basis for a safety concern with respect to such product. Either party may terminate the SPH USA License Agreement in its entirety or on a licensed product-by-licensed product basis upon material breach that is not cured within 90 days, or in its entirety the event the other party becomes insolvent or enters into bankruptcy proceedings. We may terminate the agreement with 60 days written notice if SPH USA or its affiliates or sublicensees commence an action challenging the validity or enforceability of any licensed patent, or with 10 days written notice if SPH USA fails to own at least 20% of the voting securities of any assignee of the SPH USA License Agreement. Upon termination of the agreement for any reason all rights and licenses granted to SPH USA under the agreement will terminate, and in the event of termination for reasons other than our material breach, SPH USA would grant us non-exclusive, royalty-free, worldwide license to any intellectual property rights controlled by SPH USA or its affiliates to exploit the terminated program in Greater China.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a manufacturing strategy of contracting with third parties to manufacture API, drug substance and drug product in accordance with current Good Manufacturing Practices, or cGMPs, and additional manufacturers are used to label, package and distribute investigational drug products. This strategy allows us to maintain a more flexible infrastructure while focusing our expertise on the development of our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to rely on third parties for the production, characterization, and release testing of clinical and commercial quantities of all product candidates and associated reagents. We have developed a fully closed, robust and automated manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. For example, we work with Lentigen on lentivirus manufacturing, Miltenyi on cell processing, and the Dana-Farber Cancer Institute on cGMP cell preparation and manufacturing activities for use in first-in-human studies of our ROR1-targeting CAR T cell therapy candidate ONCT-808. There are no unusually complicated biochemistries or equipment required in the manufacturing process for ONCT-534, ONCT-808 or zilovertamab, which we believe allows for potential manufacturing flexibility and cost and vein to vein time efficiencies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established a quality control and quality assurance program, which includes a set of standard operating procedures and specifications designed to ensure that our products are manufactured in accordance with cGMPs, and other applicable domestic and foreign regulations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or acquired or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the U.S and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology, continuing innovation, and acquisition and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of cancer therapeutics.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success may depend in part on our ability to: (i) obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements, (ii) preserve the confidentiality of our trade secrets, (iii) defend and enforce our proprietary rights, including our patents, and (iv) operate without infringing the valid and enforceable patents and other proprietary rights of third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed, licensed and acquired numerous patents and patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of healthcare products and services. As of February 4, 2024, our owned and in-licensed patent portfolio consisted of approximately 50 issued U.S. patents and 19 pending U.S. patent applications related to certain of our proprietary technology, inventions, and improvements, and 113 issued patents and 116 pending patent applications in jurisdictions outside of the U.S.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DAARI Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have exclusive worldwide rights to a portfolio of patents and patent applications related to Dual-Action Androgen Receptor Inhibitor, or DAARI, compounds for use in therapeutics. We hold a portfolio of patents and patent applications related to DAARIs and jointly owned with UTRF, which as of February 8, 2024 included 14 issued U.S. patents directed to DAARI ligands and methods of use thereof: U.S. Pat. No. 9,814,698, U.S. Pat. No. 10,017,471, U.S. Pat. No. 10,035,763, U.S. Pat. No. 10,441,570, U.S. Pat. No. 10,865,184, U.S. Pat. No. 9,815,776, U.S. Pat. No. 9,834,507, U.S. Pat. No. 10,093,613, U.S. Pat. No. 10,597,354, U.S. Pat. No. 10,806,720, U.S. Pat. No. 11,273,147, U.S. Pat. No. 11,648,234, U.S. Pat. No. 11,873,282, and U.S. Pat. No. 11,591,290, as well as approximately ten issued patents in Australia, Japan, Canada, China, Europe (validated in Great Britain, France and Germany), India, and Russia, and one pending U.S. patent application and two pending patent applications outside of the U.S., each with a patent term not due to expire before April 2036. We also have a portfolio of patents and patent applications licensed from UTRF which as of February 8, 2024 included five issued U.S. patent directed to DAARI ligands and methods of use thereof: U.S. Pat. No. 10,314,797, U.S. Pat. No. 10,654,809, U.S. Pat. No. 10,806,719, U.S. Pat. No. 11,230,523, and U.S. Pat. No. 11,230,531, approximately nine issued patents in Australia, India, Japan, Israel, Korea, Mexico, and Russia, two pending U.S. patent applications and nine patent applications outside of the U.S., each with a potential patent term not due to expire before June 2037. As of February 8, 2024, a third portfolio for the DAARI program included approximately 51 patent applications licensed from UTRF including approximately six pending patent applications in the U.S. and approximately 45 pending patent applications outside of the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">filed in the U.S. are effective for 20 years from the earliest effective and non-provisional filing date. The patent term may be adjusted to compensate for delayed patent issuance when such delays are caused by the patent office or successful appeals against patent office actions. There is no limit on this patent term adjustment. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The extended restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following the date of FDA approval of the applicable drug product. The duration of patents outside of the U.S. varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective non-provisional filing date. Our issued patents are due to expire on dates ranging from 2036-2037. If patents are issued on our pending patent applications, the resulting patents would be due to expire on dates ranging from 2036-2044. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. Most countries require a patent owner to pay maintenance fees or annuities in order to extend the patent to the full length of its term. If these fees and annuities are not paid timely, our patents will expire prior to the expiration date.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ROR1 Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have an exclusive, commercial, worldwide, transferrable license to a portfolio of patents and patent applications directed to ROR1 antibodies and CAR T therapies for all therapeutic indications. This portfolio is licensed from the Regents of the University of California. We have know-how and trade secrets related to compositions of matter for treating cancers, methods for treating cancer, and methods of screening for additional compositions of matter used for treating cancer, as well as to additional antibodies and molecules that modulate ROR1 signaling. We have also developed certain patents and patent applications directed to ROR1 based therapies, which are owned by Oncternal.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 4, 2024, our licensed patent portfolio included patents related to our zilovertamab clinical candidate currently in Phase 1/2 and Phase 3 clinical trials. Zilovertamab is a humanized monoclonal antibody that specifically binds to the ROR1 receptor. We have two issued U.S. patents directed to the zilovertamab composition of matter: U.S. Pat. No. 9,217,040, with a patent term not due to expire before 2032; and U.S. Patent No. 9,758,591, with a patent term not due to expire before March 2033. We have one patent issued in the U.S. directed to methods of using zilovertamab to treat cancer, U.S. Pat, No. 10,344,096, with a patent term not due to expire before March 2033. We have one issued patent in the U.S. related to single chain variable region fragments derived from zilovertamab with a patent term not due to expire before March 2033. We also have patents issued in Australia, China, Europe, Israel, Japan, Korea, Macao, Canada, Brazil, India, Philippines, Malaysia and Mexico directed to zilovertamab compositions of matter. In Europe patents directed to zilovertamab compositions of matter have been validated in jurisdictions including France, Germany, Italy, UK, Spain, Turkey, Belgium, Poland, Netherlands, Greece, Switzerland, Sweden, Austria, Denmark, and Ireland. We have applications pending in foreign jurisdictions related to zilovertamab compositions of matter and methods of use in treating cancer, including Australia, Europe, Japan, and Thailand. Patents, if issued from these pending foreign applications, would not be due to expire before 2033.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 4, 2024, we have approximately 30 licensed patent applications pending in the U.S. and in jurisdictions outside the U.S. related to methods of treating cancer using a combination of zilovertamab and small-molecule chemotherapeutics. We have two issued patents, U.S. Patent No. 10,688,181, and U.S. Patent No. 11,654,193, directed to methods of treating cancer with the combination of zilovertamab and a BTK inhibitor. We have one issued patent, U.S. Patent No. 11,883,492, directed to methods of treating cancer with the combination of zilovertamab and paclitaxel or docetaxel. Patents, if issued from these pending non-provisional applications, would not be due to expire before dates ranging from 2037 to 2041.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 4, 2024, we have licensed patents and patent applications related to additional ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-zilovertamab ROR1 binding antibodies, polypeptides, and chimeric antigen receptors. We have eight issued U.S. patents directed to non-zilovertamab ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-zilovertamab ROR1 binding antibodies, polypeptides, and chimeric antigen receptors: U.S. Pat. No. 8,212,009, with a patent term not due to expire before November 2026; U.S. Patent No. 9,242,014, with a patent term not due to expire before June 2031; U.S. Patent No. 9,938,350, with a patent term not due to expire before June 2031; U.S. Patent No. 9,217,040, with a patent term not due to expire before January 2032; U.S. Patent No. 10,627,409 with a patent term not due to expire before January 2032; U.S. Patent No. 10,900,973 with a patent term not due to expire before January 2032; U.S. Patent No. 11,548,953 with a patent term not due to expire before June 2031; U.S. Patent No. 11,536,727 with a patent term not due to expire before January 2032. We have two patent applications pending in the U.S. related to additional non-zilovertamab ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-zilovertamab ROR1 binding antibodies, polypeptides and chimeric antigen receptors, which, if issued, would have a patent term not due to expire before dates ranging from 2031 to 2032. We also have patents issued in Europe and Canada directed to additional ROR1 binding antibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 4, 2024, we have licensed patents and patent applications related to methods of screening for antibodies that specifically bind to ROR1. We have two issued U.S. patents, U.S. Pat. Nos. 9,523,695, and 9,933,434, with patent terms not due to expire before January 2032, directed to methods of screening for antibodies that specifically bind to ROR1. We additionally have one issued U.S. patent and patent applications issued in Japan, Australia, Canada, and Europe directed to methods of screening for modulators of ROR1 signaling; additionally, we have applications pending in the U.S., China, and Hong Kong directed to methods of screening for modulators of ROR1 signaling.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 4, 2024, we also own two patent applications filed under the Patent Cooperation Treaty directed to methods of treating cancer using a combination of zilovertamab and small molecule cancer chemotherapeutics or checkpoint inhibitors, which, if issued, would have a patent term not due to expire before 2043.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 4, 2024, we also own one patent application filed under the Patent Cooperation Treaty directed to pharmaceutical zilovertamab formulations which, if issued, would have a patent term not due to expire before 2043.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ONCT-216 Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have exclusive worldwide rights to a portfolio of patents and patent applications related to small molecules, including ONCT-216, targeting EWS-FLI1 for use in therapeutics and companion diagnostics. We hold a portfolio of patents and patent applications, the Oncternal Portfolio, related to ONCT-216, analogs thereof, and uses thereof, as well as the Georgetown Licensed Portfolio, which is licensed from Georgetown University.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#201f1e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 8, 2024, the Oncternal Portfolio directed to the new chemical entity ONCT-216 contained approximately nine U.S. issued patents and two pending applications in the U.S., as well as approximately 35 patents and approximately nine pending patent applications in jurisdictions outside of the U.S. As of February 8, 2024, we had two U.S. patents directed to ONCT-216: U.S. Pat. No. 9,604,927, with a patent term not due to expire before October 2035, and U.S. Pat. No. 9,987,251, with a patent term not due to expire before October 2035. We also had a U.S. patent with claims directed to methods of inhibiting proliferation of a cell that overexpresses an ETS gene or comprises an ETS fusion gene, or inhibiting growth of or killing neoplastic cells: U.S. Pat. No. 9,895,352, with a patent term not due to expire before October 2035. We had approximately one pending U.S. application and approximately 20 patents or pending applications in jurisdictions outside the U.S., including Australia, Canada, China, Eurasia, Europe, Hong Kong, India, Israel, Japan, Korea, Macao, Mexico, New Zealand, and Taiwan. These patents have a patent term not due to expire before October 2035, and patents, if issued from these applications, would not be due to expire before October 2035. We also had a patent with claims covering compositions of ONCT-216 in combination with venetoclax and associated methods of inducing apoptosis in cells in AML and DLBCL: U.S. Pat. No. 10,159,660, with a patent term not due to expire before July 2037, a patent covering ONCT-216 in combination with lenalidomide and associated methods for inducing apoptosis in a lymphocyte produced in mantle cell lymphoma: U.S. Pat. No. 10,646,470, with a patent term not due to expire before July 2037, and a patent covering ONCT-216 in combination with bortezomib, idelalisib, vincristine, bendamustine, lidelalisib, PQR309, or Selinexor and associated methods for inducing apoptosis in a myeloblast produced in acute myeloid leukemia or a lymphocyte produced in diffuse large B cell lymphoma: U.S. Pat. No. 11,285,132, with a patent term not due to expire before July 2037. We had approximately one pending U.S. application and approximately 15 pending applications filed in jurisdictions outside the U.S., including Canada, China, Europe, Hong Kong, Japan, Korea, Mexico, Singapore, and Taiwan directed to ONCT-216 combination therapies. Patents, if issued from these applications, would not be due to expire before July 2037. The Oncternal Portfolio further contained additional patents and pending applications related to indoline derivative compounds, which are analogs of ONCT-216. We had two issued U.S. patents directed to compounds and methods of inhibiting proliferation of a cell expressing an ETS gene or comprising an ETS fusion gene: U.S. Pat. No. 9,822,122, with a patent term not due to expire before March 2037, and U.S. Pat. No. 10,351,569, with a patent term not due to expire before March 2037. We also had an issued U.S. patent with claims directed to killing or inhibiting the growth of a neoplastic cell and methods of treating specific cancers by administering an analogue of ONCT-216: U.S. Pat. No. 10,711,008, with a patent term not due to expire before March 2037. There were also approximately nine patents or applications pending outside the U.S. in China, Europe (including a European patent validated in Austria, Belgium, Denmark, France, Germany, Great Britain, Ireland, Italy, Spain, Sweden, and Switzerland), Japan, Korea, and Taiwan. Patents, if issued from these applications, would not be due to expire before March 2037.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 8, 2024, the Georgetown Licensed Portfolio contained patents directed to other EWS-FLI1 inhibitor compounds. We had three U.S. patents directed to compounds and methods for treating Ewing sarcoma or pancreatic cancer: U.S. Pat. No. 8,232,310, with a patent term not due to expire before November 2028, U.S. Pat. No. 9,045,415, with a patent term not due to expire before August 2028, and U.S. Pat. No. 9,758,481, with a patent term not due to expire before December 2027. We had four issued patents in jurisdictions outside the U.S., including Australia, Canada, Europe (validated in Germany, France and Great Britain), and Hong Kong. These patents are not due to expire before December 2027. We had two issued U.S. patents directed to compounds and methods for treating pancreatic cancer or Ewing sarcoma: U.S. Pat. No. 9,290,449, with a patent term not due to expire before April 2033, and U.S. Pat. No. 9,714,222, with a patent term not due to expire before April 2033. There are approximately 17 patents outside</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the U.S. in Australia, Canada, China, Europe (validated in Great Britain, France and Germany), Hong Kong, India, Israel, Japan, Korea, Macao, Mexico, and New Zealand. These patents have a patent term not due to expire before April 2033. The Georgetown Licensed Portfolio contained additional patents related to methods of treating cancers. We had one issued U.S. patent directed to methods of treating lung cancer or glioblastoma multiforme: U.S. Pat. No. 9,511,050, with a patent term not due to expire before October 2034. There were approximately two patents issued outside the U.S. in China and Japan. These patents have a patent term not due to expire before October 2034.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the U.S., at the federal, state and local levels, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process and a new biologic must be approved by the FDA through the BLA process before it may be legally marketed in the U.S. There are similar processes required for marketing authorization in other countries. For all European Union (EU) countries, marketing authorization for biologics and any product to treat patients with cancer is evaluated and granted on a pan-EU basis.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">United States Drug Development Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and in the case of biologics, also under the Public Health Service Act, or PHSA, and their implementing regulations. We, along with third-party contractors, are required to navigate the various nonclinical, clinical, manufacturing and commercial approval requirements and guidance. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following steps are usually required by the FDA before a drug or biologic may be marketed in the U.S.:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with GLP requirements and other applicable regulations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an Investigational New Drug Application, or IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent Institutional Review Board, or IRB, or Ethics Committee associated with each clinical site before patients can be enrolled into each trial at that particular clinical site;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practices, or GCP, requirements to establish the safety and efficacy of the proposed drug, or safety, purity and potency of the proposed biologic, for its intended use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an NDA or BLA after completion of pivotal clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA or BLA whether to file the application for review;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential review of the product application by an FDA advisory committee, where appropriate and if applicable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality and purity, and potential audits of selected clinical trial sites to ensure compliance with GCP; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the NDA or BLA.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies usually include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. Prior to beginning the first clinical trial with a product candidate in the U.S., a Sponsor must submit an IND to the FDA, which is a request for allowance from the FDA to administer an investigational drug product to humans. The IND submission contains the general investigational plan, the clinical protocol, protocols and results from preclinical studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls, or CMC, information, and any available human data or literature to support the use of the investigational product. The FDA will review the IND, and if the information is adequate, the IND goes into effect and human clinical trials may begin. The IND automatically goes into effect 30 days after receipt by the FDA, unless the FDA requires additional information, which may result in a clinical hold if the data are insufficient. In such a case, the IND Sponsor and the FDA must resolve any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">outstanding concerns before the clinical study can begin. The FDA may also impose clinical holds on any drug or biological product candidate at any time before or during clinical trials due to safety concerns about ongoing or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the submission of an IND to the FDA, supervision of certain human gene transfer trials may also require evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such assessment may result in some delay before initiation of a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of a product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study Sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing procedures, patient selection and exclusion criteria, and the parameters to be used to monitor patient safety, including stopping rules that assure a clinical study will be stopped if certain adverse events should occur. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations including GCP requirements, including the requirement that all research patients provide informed consent. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, each clinical study must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical study will be conducted. The FDA, the IRBs, or the Sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or if a trial is unlikely to meet its stated objectives. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the Sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The product candidate is initially administered to healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine the appropriate dosage for further clinical trials.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The product candidate is administered to an expanded patient population at geographically dispersed clinical study sites. These clinical trials are intended to establish the safety and efficacy of the product and the overall risk benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Postmarketing requirements and commitments refer to studies and clinical trials that a Sponsor conducts after FDA approval to gather additional information about a product&#8217;s safety, efficacy, or optimal use. Some of the studies and clinical trials, sometimes referred to as Phase 4 studies, may be required under one or more statutes and regulations; others may be studies or clinical trials a Sponsor has committed to conduct. Postmarketing commitments are studies or clinical trials that a Sponsor has agreed to conduct, but that are not required by a statute or regulation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the development of a drug or biologic, Sponsors are given opportunities to meet with the FDA at certain points. These meetings may be prior to submission of an IND, at the end of Phase 1 or 2, and before an NDA or BLA is submitted, or at other times important in product candidate development. These meetings can provide an opportunity for the Sponsor to share information about the clinical, preclinical or CMC data gathered to date, for the FDA to provide advice, and for the Sponsor and the FDA to reach agreement on the next phase of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, Sponsors usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">United States Review and Approval Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of product development, including results from preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s CMC and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from several alternative sources, including studies initiated and sponsored by investigators. The submission of an NDA or BLA is subject to the payment of user fees. A waiver of such fees may be obtained under certain limited circumstances, such as an application seeking an indication with orphan drug designation or a small business submitting its first application.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and BLAs and certain supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is deemed safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews all NDAs and BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the NDA or BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once the submission is accepted for filing, the FDA will determine the type of review (standard or priority) and the FDA begins an in depth substantive review. The FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended for three months by the FDA to review  additional information deemed a major amendment to the application. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. The FDA reviews a BLA to determine, among other things whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may refer the NDA or BLA to an FDA advisory committee so that independent advice can be provided to contribute to the FDA&#8217;s decision-making and lends credibility to the review process. The FDA is not bound by the recommendation of an FDA advisory committee, but it generally follows such recommendations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities follow cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical sites to assure compliance with GCP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the FDA evaluates an NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, it will issue an Approval Letter or a Complete Response Letter, or CRL. An Approval Letter authorizes commercial marketing of the drug and is accompanied with the approved U.S. Prescribing Information, or USPI. A CRL indicates that the review cycle of the NDA or BLA is complete and the application will not be approved in its current form. A CRL usually describes the specific deficiencies in the NDA or BLA identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a CRL is issued, the Sponsor must resubmit the NDA or BLA, addressing all of the deficiencies identified in the CRL. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product receives FDA approval, the approval may be significantly limited to a specific disease subset, dosages, or use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to require post-marketing information including additional information from certain trials, perform Phase 4 clinical trials designed to further assess a products safety and effectiveness after NDA or BLA approval, may require testing and surveillance programs to monitor the safety of approved products. The FDA may also place other conditions on approval including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the Sponsor of the NDA or BLA must submit a proposed REMS program. The FDA will not approve the NDA without an approved REMS program, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan Drug Designation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S. or, if it affects more than 200,000 individuals in the U.S., there is no reasonable expectation that the cost of developing and making a drug or biologic product available in the U.S. for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug or biologic also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user&#8209;fee waivers. However, competitors, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA offers several expedited development and review programs for qualifying product candidates. For example, the FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs or biologics are eligible for Fast Track designation if they are intended for the treatment of a serious or life-threatening disease or condition and which demonstrate the potential to address an unmet medical need for the disease or condition. An unmet medical need is a condition whose treatment or diagnosis is not addressed adequately by available therapy. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied The Sponsor of a Fast Track product candidate has opportunities for more frequent meetings with the FDA review team during product development and, once an NDA or BLA is submitted, the application may be eligible for priority review. With regard to a Fast Track product candidate, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the Sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the Sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation, or BTD to expedite its development and review. A product candidate can receive BTD if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate submitted to the FDA for approval, including a product with a Fast Track designation or Breakthrough Therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review. A BLA or NDA for a product candidate is eligible for priority review if the product candidate has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. A serious disease or condition is a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning. Short-lived and self-limiting morbidity will usually not be sufficient, but the morbidity need not be irreversible if it is persistent or recurrent. The FDA will attempt to direct additional resources to the evaluation of a BLA or NDA designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of original BLAs and new molecular entity NDAs under its standard review goals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, depending on the design of the applicable clinical trials, a product candidate may be eligible for Accelerated Approval. Drugs and biologics intended to treat serious or life-threatening diseases or conditions may be eligible for Accelerated Approval upon a determination that the product candidate has an effect on a surrogate endpoint, is a marker such as a laboratory measurement, radiographic image, physical sign, or other measure, that is thought to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a Sponsor of a drug receiving Accelerated Approval perform adequate and well-controlled confirmatory clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other predicted clinical benefit, and may require that such confirmatory trials be underway before granting any accelerated approval. Products approval using the Accelerated Approval pathway may be subject to expedited withdrawal procedures if the Sponsor fails to conduct the required post-marketing studies in a timely manner or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for Accelerated Approval preapproval of promotional materials, which could adversely impact the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2017, the FDA established the regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug or biologic. Regenerative medicine therapies to treat, modify, reverse, or cure serious conditions are eligible for FDA&#8217;s expedited programs, including fast track designation, breakthrough therapy designation, RMAT designation, Accelerated Approval, and priority review designation, if they meet the following criteria: (i) the drug or biologic qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) the drug or biologic is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the drug or biologic has the potential to address unmet medical needs for such a disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast Track designation, Breakthrough Therapy designation, RMAT designation, priority review and Accelerated Approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time for FDA review or approval will not be shortened.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#201f1e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rare Pediatric Disease Priority Review Voucher Program</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#201f1e;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#201f1e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the U.S. Congress authorized the FDA to award priority review vouchers to Sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product. The Sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the Sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#201f1e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (b) rare diseases or conditions within the meaning of the Orphan Drug Act. On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the Sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any Rare Pediatric Disease Priority Review Voucher.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post&#8209;approval requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an approval of marketing authorization is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug and biologics manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any drug products manufactured or distributed pursuant to FDA approvals remain be subject to continuing regulation by the FDA, including, among other things, recordkeeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug and biologics manufacturers, such as those related to direct to consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry sponsored scientific and educational activities, and promotional activities involving the internet. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and consistent with the provisions of the approved label. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications about off-label use of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications or supplements to approved applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug Product Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example, the FDCA provides a five-year period of non-patent data exclusivity within the U.S. to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDCA alternatively provides three years of non-patent exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of marketing exclusivity available in the U.S. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of regulatory exclusivity or patent term if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the Sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biosimilars and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being addressed by the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the Sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A biological product can also obtain pediatric market exclusivity in the U.S. as described above, if the BLA sponsor voluntarily completes a pediatric study that fairly response to a &#8220;written request&#8221; from the FDA to conduct such study.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA Regulation of Companion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may require use of an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> diagnostic to identify appropriate patient populations. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the U.S., the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA, approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If use of companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August 6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In Vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Companion Diagnostic Devices.&#8221; According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the Sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> companion diagnostic devices on issues related to co-development of these products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> companion diagnostics in conjunction with the review of therapeutic candidates such as those we are developing involves coordination of review by the FDA&#8217;s Center for Drug Evaluation and Research and by the FDA&#8217;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are also subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains several conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained, or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Approval Process Outside of the United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, marketing authorization, post-marketing requirements and any commercial sales and distribution of our product candidates. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. In addition, ethical, social, and legal concerns about gene-editing technology, gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may want to use.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product candidates in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulations Governing Marketing Authorization of Medicinal Products in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical studies and clinical trials</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly to the U.S., the various phases of preclinical and clinical research in the European Union, or EU, are subject to significant regulatory controls.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Preclinical studies must be conducted in compliance with the principles of GLP as set forth in EU Directive 2004/10/EC. In particular, preclinical studies, both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for preclinical studies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose Clinical Trial Application, or CTA, was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, Sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the Clinical Trials Directive required a separate CTA to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier, or IMPD, containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the Sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketing Authorization</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, to obtain regulatory approval of an investigational chemical or biological product under EU regulatory systems, a marketing authorization application, or MAA, must be submitted. Medicinal product candidates can only be placed on the market after obtaining a marketing authorization, or MA. The process for doing this depends, among other things, on the nature of the medicinal product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medical Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the EU. The centralized procedure is compulsory for certain types of medicinal medicines, such as: (i) medicinal products derived from biotechnology processes, such as genetic engineering, (ii) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) designated orphan medicines, and (iv) Advanced Therapy Medicinal Products, or ATMPs, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. It is very likely that the centralized procedure would apply to the products we are developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Committee for Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT&#8217;s opinion is then taken into account by the CHMP when giving its</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion, if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs; the manufacturing and control information that should be submitted in a marketing authorization application; and post-approval measures required to monitor patients and evaluate the long-term efficacy and potential adverse reactions of ATMPs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure and in exceptional cases, the CHMP might perform an accelerated review of a MA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. In March 2016, the EMA launched an initiative, the Priority Medicines, or PRIME, scheme, a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment, but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;standard&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data and Marketing Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU also provides opportunities for market exclusivity. Upon receiving MA, reference medicinal products generally qualify for eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. During the additional two&#8209;year period of market exclusivity, a generic/biosimilar MA can be submitted, and the innovator&#8217;s data may be referenced, but no generic/biosimilar product can be marketed until 10 years have elapsed from the initial authorization of the reference product in the EU. The overall ten-year market exclusivity period may be extended to a maximum of 11 years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Medicinal Products</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the U.S. A medicinal product may be designated as orphan if its Sponsor can establish that: (1) the product is intended for the diagnosis, prevention or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">treatment of a life-threatening or chronically debilitating condition, (2) either: (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment, and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The application for orphan drug designation must be submitted before the application for MA. Orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and access to the centralized procedure. Once authorized, orphan medicinal products are entitled to ten years of market exclusivity for the approved therapeutic indication. During the ten-year market exclusivity period, the competent authorities cannot accept a MAA, or grant a MA, or accept an application to extend a MA, for the same indication, in respect of a similar medicinal product. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MAA is submitted. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan, or PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 10&#8209;year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold. In addition, MA may be granted to a similar product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (2) the applicant consents to a second orphan medicinal product application; or (3) the applicant cannot supply enough quantities of the orphan medicinal product. A company may voluntarily remove a product from the orphan register.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.56%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulation of Companion Diagnostics in the EU</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> diagnostic medical devices are regulated by Directive 98/79/EC, or IVDD, which regulates the placing on the market, the CE marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufactures and devices as well as the vigilance procedure. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> diagnostic medical devices must comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulation of companion diagnostics is subject to further requirements since the in-vitro diagnostic medical devices Regulation No 2017/746, or IVDR, became effective on May 26, 2022. The IVDR will fully apply on May 26, 2022, but there will be a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IVDR introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a MAA for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA.</span></p>
  <p style="margin-left:0.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:0.56%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United Kingdom, or UK, left the EU on January 31, 2020, following which existing EU medicinal product legislation continued to apply in the UK during the transition period under the terms of the EU-UK Withdrawal Agreement. The transition period, which ended on December 31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the EU on behalf of its members. The transition period provided time for the UK and EU to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement, or TCA, and became effective on the January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. However, new legislation such as the EU CTR will not be applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#8216;appropriate authority&#8217; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland, together, Great Britain, or GB; broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in GB and in Northern Ireland following the expiry of the Brexit transition period on December 31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the UK. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019, or the Exit Regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA holder chooses to opt-out. In order to use the centralized procedure to obtain a MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, after Brexit, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a GB authorization; or use the MHRA&#8217;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in GB.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Foreign Regulations Governing Marketing Authorization of Medicinal Products</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the U.S. federal and state governments and by authorities in the foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. Violation of these laws or other governmental regulations may result in penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the U.S., and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that may require companies to provide scientific and clinical support for the use of a product to each payor separately. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. Lastly, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic (or biosimilar) products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity, and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. and some foreign jurisdictions are considering or have enacted several reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2010, the Affordable Care Act, or ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the U.S., and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular importance to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers, which was temporarily suspended from May 1, 2020, through March 31, 2022, and reduced payments to several types of Medicare providers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the way manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most significantly, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations.  HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is likely that federal and state legislatures within the U.S. and foreign governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy and Security Laws</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous state, federal and foreign laws, regulations, and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information and could apply now or in the future to our operations or the operations of our partners. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. For example, the European Union General Data Protection Regulation, or GDPR, imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant undertaking, whichever is greater. Further, from January 1, 2021, companies have had to comply with the GDPR and the United Kingdom GDPR, or UK GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in United Kingdom, or UK, national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 1, 2024, we had 27 full-time employees, three part-time employees, and several consultants, most of whom are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our management team and our clinical, scientific, and other employees and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and motivate personnel through the granting of stock-based and cash-based compensation awards, to align our interests and the interests of our stockholders with those of our employees and consultants.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facilities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are in San Diego, California, where we lease 3,748 square feet of office space available for corporate, research, development, clinical, regulatory, manufacturing and quality functions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information and Merger</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated under the name Genotherapeutics, Inc. in Tennessee in September 1997. We changed our name to GTx, Inc. in 2001 and reincorporated in Delaware in 2003. On March 6, 2019, we, then operating as GTx, Inc., or GTx, entered into an Agreement and Plan of Merger and Reorganization, as amended, or the Merger Agreement, with privately-held Oncternal Therapeutics, Inc., or Private Oncternal, and Grizzly Merger Sub, Inc., our wholly-owned subsidiary, or Merger Sub. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as our wholly-owned subsidiary (the &#8220;Merger&#8221;). On June 7, 2019, the Merger was completed.  GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as our wholly-owned subsidiary, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive offices are located at 12230 El Camino Real, Suite 230, San Diego, CA 92130, and our telephone number is (858) 434-1113. Our website address </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is www.oncternal.com.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. We make available on our website at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.oncternal.com</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of that website is </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.sec.gov</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing. Further, our references to the URLs for these websites are intended to be inactive textual references only.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 1A. Risk Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should consider carefully the following risk factors, together with the other information contained in this Annual Report, including our financial statements and the related notes and &#8220;Management Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business operations or financial condition.</span></p>
  <div style="font-size:0;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a relatively limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical&#8209;stage biopharmaceutical company with a relatively limited operating history upon which you can evaluate our business and prospects. To date, we have focused primarily on staffing our company, business planning, raising capital, identifying, acquiring, and in&#8209;licensing our product candidates and conducting preclinical studies and clinical trials. ONCT-534, our DAARI candidate, and ONCT&#8209;808, our ROR1 CAR T cell therapy candidate, are in clinical development. We have not yet demonstrated an ability to successfully obtain marketing authorization approvals, manufacture a commercial scale product, or finalize plans for a third&#8209;party to do so on our behalf, or embark on sales and marketing activities necessary for successful post marketing authorization product commercialization, and have not developed, if necessary, any companion diagnostic test for our product candidates. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since our inception. If our product candidates are not successfully developed and approved, we may never generate any revenue. Our net losses were $39.5 million and $44.2 million for the years ended December 31, 2023, and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $197.8 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and anticipate these losses will increase substantially as we continue to develop, seek regulatory approval for and potentially commercialize any of our product candidates, and seek to identify, assess, acquire, in&#8209;license or develop additional product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our product candidates, obtaining marketing authorization approval for these product candidates and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. We are only in the early stages in a number of these commercialization activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in our company&#8217;s value could also cause stockholders to lose all or part of their investment.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development of biopharmaceutical product candidates is capital intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of ONCT-534 and ONCT 808 and seek regulatory approval for our current product candidates and any future product candidates we may develop. In addition, as our product candidates progress through development and toward commercialization, we will need to make milestone payments to the licensors and other third parties from whom we have in licensed or acquired our product candidates, including ONCT 534, ONCT 808, and zilovertamab. If we obtain regulatory approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution and we will need to make royalty payments to the licensors and other third parties from whom we have in licensed or acquired our product candidates, including our DAARI, ROR1 CAR T and zilovertamab programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have based our estimates of our funding requirements on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through a combination of equity financings, debt financings, government funding or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day&#8209;to&#8209;day activities, which may adversely affect our ability to develop our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the type, number, scope, progress, expansions, results, costs and timing of our clinical trials of our DAARI and ROR1 CAR T programs or additional indications of our current product candidates as well as other product candidates that we may choose to pursue in the future;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of manufacturing our product candidates, including commercial manufacturing if any product candidate is approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and capacity for CAR T development and lentivirus manufacturing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with hiring additional personnel, contract research organizations, or CROs and consultants as our clinical and other development activities increase;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and amount of the milestone or other payments we must make to the licensors and other third parties from whom we have in&#8209;licensed or acquired our product candidates or technology;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of establishing or securing sales and marketing capabilities if any of our product candidates are approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third&#8209;party payors and adequate market share and revenue for any approved products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs associated with any products or technologies that we may in&#8209;license or acquire.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conducting clinical trials and preclinical studies is a time consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2021, our Form S 3 shelf registration statement became effective. Future sales under a Form S 3, if any, will depend on a variety of factors including, but not limited to, the effectiveness of a Form S 3, prevailing market conditions, the trading price of our common stock, our public float and our capital needs. In December 2021, we entered into an Open Market Sales AgreementSM, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million pursuant to the Form S 3 registration statement. There can be no assurance that the Sales Agent will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate. In addition, under current SEC regulations, as of the filing of this annual report on Form 10 K, our public float is less than $75 million, and under SEC regulations for so long as our public float remains less than $75 million, the amount we can raise through primary public offerings of securities in any twelve month period using shelf registration statements is limited to an aggregate of one third of our public float, which is referred to as the baby shelf rules. As of March 1, 2024, our public float was approximately $27.0 million, based on 2,689,233 shares of outstanding common stock held by non-affiliates and at a price of $10.03 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on March 1, 2024. As a result of our public float being below $75 million, we will be limited by the baby shelf rules until such time as our public float exceeds $75 million, which means we only have the capacity to sell shares up to one-third of our public float under shelf registration statements in any twelve-month period. As of March 1, 2024, we had the capacity to issue up to approximately $38.8 million of additional shares of common stock pursuant to the Sales Agreement. We will remain constrained by the baby shelf rules under our Form S 3 shelf registration statement until such time as our public float exceeds $75 million, at which time, the number of securities we may sell under a Form S 3 registration statement will no longer be limited by the baby shelf rules.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our management, as of December 31, 2023, and our independent registered public accounting firm, in their report on our financial statements as of and for the fiscal year ended December 31, 2023, have concluded that there is substantial doubt as to our ability to continue as a going concern.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audited financial statements for the year ended December 31, 2023 were prepared assuming that we will continue as a going concern. The going concern basis of presentation assumes that we will continue in operation for the foreseeable future and will be able to realize our assets and satisfy our liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from our inability to continue as a going concern. As of December 31, 2023, our management concluded that, based on expected operating losses and negative cash flows, there is substantial doubt about our ability to continue as a going concern for the twelve months after the date the financial statements were issued. Our ability to continue as a going concern is subject to our ability to raise additional capital through equity offerings or debt financings, including through potential future sales of common stock pursuant to the Sales Agreement. However, we may not be able to secure additional financing in a timely manner or on favorable terms, if at all. If we cannot continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that our stockholders may lose some or all of their investment in us. If we seek</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, government funding or other capital sources, including potentially collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect stockholders&#8217; rights as a common stockholder. Debt financing and preferred equity financing, if available, may have collateral requirements or may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Development and Regulatory Approval of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend heavily on the success of our product candidates, which are in clinical or preclinical development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ONCT-534</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is an investigational dual-action androgen receptor inhibitor (DAARI) with preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR aberration. It is a potential treatment for patients with mCRPC with unmet medical need because of resistance to androgen receptor inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. Oncternal has initiated Study ONCT-534-101 which is open and enrolling patients for treatment with mCRPC. </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ONCT-808</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. Oncternal has dosed patients under Study ONCT-808-101 with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on various factors, including the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful initiation and completion of preclinical and clinical studies with favorable results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of INDs, by the FDA, or under similar regulatory applications by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed designs for future clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">demonstrating safety, purity, potency and/or efficacy of our product candidates to the satisfaction of applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receiving marketing approvals from applicable regulatory authorities, including BLAs or NDAs from the FDA, and maintaining such approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">making arrangements with our third&#8209;party manufacturers for commercial manufacturing capabilities and manufacturing process optimization for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP or similar foreign requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demonstration of an acceptable safety profile of our products following approval, if any; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing, in&#8209;licensing or acquiring companion diagnostics to our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining and growing an organization for people who can develop our product candidates and technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in April 2023 we announced a strategic reprioritization of the development of zilovertamab and our decision to close the Phase 3 ZILO&#8209;301 and the Phase 1/2 CIRM&#8209;0001 clinical studies, based on the rapidly changing commercial landscape for Bruton&#8217;s tyrosine kinase inhibitors. We cannot provide any assurance that our reprioritization decision will reap the expected benefits, and our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercializing our product candidates. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials or preclinical studies will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, we cannot assure you that we will be able to successfully progress our preclinical programs from candidate identification to Phase 1 clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union, or EU, recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the EU Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is currently unclear to what extent the United Kingdom, or UK, will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency, or MHRA, launched an eight-week consultation on reframing the UK legislation for clinical trials with specific aims to streamline clinical trials approvals,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The MHRA published its consultation outcome on March 21, 2023 in which it confirmed that it would update the existing legislation. The resulting legislative changes, which are yet to be published, will ultimately determine the extent to which the UK regulations align with the (EU) CTR. A decision by the UK not to closely align its regulations with the new approach adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are slow or are unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue, and adversely affect our commercial prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans, or with respect to our product candidates regulated as biologics in the U.S., that such candidates are safe, pure and potent for their intended uses. We will have to follow the same procedure for our other preclinical product candidates that we plan to advance to clinical development, and would also be required to submit regulatory filings to foreign regulatory authorities if we decide to initiate clinical trials outside of the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not know whether our planned trials or studies will begin on time or be completed on schedule, if at all. The commencement, data readouts and completion of clinical trials and preclinical studies can be delayed for a number of reasons, including delays related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties in obtaining regulatory authorizations or allowances to commence a trial or reaching a consensus with regulatory authorities on trial design;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties in recruiting clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining approval from one or more institutional review boards, or IRBs, or ethics committees;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional patients, or withdrawing their approval of the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to clinical trial protocols;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites deviating from trial protocols or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges in manufacturing sufficient quantities of product candidates or obtaining sufficient quantities of combination therapies for use in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients failing to enroll or remain in our trial at the rate we expect, or failing to return for post&#8209;treatment follow&#8209;up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients experiencing severe or unexpected drug&#8209;related adverse effects;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events in clinical trials of the same class of agents conducted by other companies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or infections or cross&#8209;contaminations of product candidates in the manufacturing process;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any changes to our manufacturing process that may be necessary or desired;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third&#8209;party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials in a timely manner or consistent with applicable clinical trial protocols, GCP, or other regulatory requirements; third&#8209;party contractors not performing data collection or analysis in a timely or accurate manner; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third&#8209;party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could also encounter delays if our clinical trials are suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial, or by the FDA or comparable foreign regulatory authorities. Regulatory authorities may suspend or terminate clinical trials due to a number of factors, including failure to conduct clinical trials in accordance with regulatory requirements or the applicable clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if we decide to conduct clinical trials of our product candidates in foreign countries additional risks may arise that may delay completion of those clinical trials. These risks include the failure of enrolled patients in other countries to adhere to clinical protocol as a result of differences in healthcare practices or cultural customs, managing additional administrative burdens associated with the regulatory schemes of other countries, as well as political and economic risks relevant to other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under our license and development agreement with SPH USA, SPH USA has the right to manufacture, develop, market, distribute and sell our zilovertamab, ROR1 CAR T, and ONCT-216 product candidates in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan, or Greater China, and the obligation to perform all preclinical and clinical development activities required to obtain regulatory approvals for such product candidates in Greater China. In the event that SPH USA&#8217;s preclinical studies or clinical trials of our product candidates raise new safety or efficacy concerns, the prospects for obtaining regulatory approval of our product candidates in the U.S. and other countries, and our business, could be adversely impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in the completion of, or termination of, clinical trials of our product candidates, the commercial prospects of such product candidates may be harmed, and our ability to generate product revenues from such product candidates may be delayed. Moreover, delays in completing our clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, many of the factors that cause, or lead to, the termination, suspension or delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. If we make formulation or manufacturing changes to our product candidates or revise the route of administration or dosing regimen for our product candidates, we may be required to conduct additional preclinical or clinical studies to bridge our modified product candidates to earlier versions or to bridge the new dosing regimens to dosing regimens used in our clinical trials. The need to conduct additional preclinical or clinical studies could result in delays in the approval or commercialization of our product candidates, which could shorten any period during which we may have the exclusive right to commercialize our product candidates and enable our competitors to bring products to market before we do. In such an event, the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the U.S. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the availability of competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for our planned clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing patients may prove costly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The timing of our clinical trials depends, in part, on the speed at which we can establish investigative clinical trial sites and recruit patients to participate in our trials, as well as completion of required follow&#8209;up periods. For certain of our product candidates, the conditions which we currently plan to evaluate are orphan or rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. If patients are unwilling to participate in our clinical trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of approved therapies, or if we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we rely on CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and preclinical studies and, while we have entered into agreements governing their services, we have limited influence over their actual performance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure stockholders that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of the label for an approved product candidate, or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with oncology drugs generally, it is likely that there may be side effects and adverse events associated with the use of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence, or unexpected characteristics of side effects. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials, result in a more restrictive label for the product candidate, or delay or cause the denial of regulatory approval of the product candidate by the FDA or comparable foreign regulatory authorities. The drug&#8209;related side effects could also affect patient recruitment for our clinical trials, or the ability of enrolled patients to complete the trials, or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk&#8209;benefit perspective, which may limit the commercial prospects for the product candidate if approved. We may also be required to modify our plans for future studies based on findings in our ongoing clinical trials. Many compounds that initially showed promise in early&#8209;stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as the use of our product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw, suspend or limit approvals of such product;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients or similar risk management measures;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way a product is distributed or administered, conduct additional clinical trials or change the labeling of a product or be required to conduct additional post&#8209;marketing studies or surveillance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of the product may decrease significantly or the product could become less competitive; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation could suffer.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to maintain orphan drug designations for certain of our product candidates, and may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the U.S. and EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population of greater than 200,000 individuals in the U.S., but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the EU, orphan designation is granted by the European Commission based on a scientific opinion of the European Medicines Agency&#8217;s, or EMA, Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its sponsor can establish that (i) the product is intended for the diagnosis, prevention or treatment of a life&#8209;threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. The application for orphan designation must be submitted before the application for marketing authorization. There can be no assurance that the FDA or the European Commission will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., orphan designation entitles a party to financial incentives such as opportunities for grant funding for clinical trial costs, tax advantages and user&#8209;fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a NDA or BLA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in the EU, but such exclusivity period can be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan designation, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same disease or condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same disease or condition if such regulatory authority concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory landscape that will apply to development of gene therapy or cell&#8209;based therapeutic product candidates by us or by our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory requirements governing products involving gene therapy treatment have changed frequently and will likely continue to change in the future. Approvals by one regulatory agency may not be indicative of what any other regulatory agency may require for approval, and there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of gene therapy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">products, cell therapy products and other products created with genome editing technology. For example, in addition to the submission of an IND to the FDA, before initiation of a clinical trial in the U.S., certain human clinical trials for cell therapy products and gene therapy are subject to the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules, or NIH Guidelines. The NIH Guidelines call for the supervision of human gene transfer trials including an evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. We will therefore be subject to significant regulatory oversight by the FDA, and in addition to the government regulators, the applicable IBC and IRB of each institution at which we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, would need to review and approve the proposed clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar requirements apply in the EU. The EMA has a Committee for Advanced Therapies, or CAT, that is responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products, or ATMPs. ATMPs include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for ATMP candidate that is submitted to the EMA. In the EU, the development and evaluation of an ATMP must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Similarly complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. As a result, the procedures and standards applied to ATMPs may be applied to any of our gene therapy product candidates such as CAR T, but that remains uncertain at this point.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to evaluate the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for product candidates involving gene therapy can be more lengthy, rigorous and expensive than the process for other better known or more extensively studied product candidates and technologies. Since we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or comparable regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. This may be a particularly significant risk for many of the genetically defined diseases for which we may develop product candidates alone or with collaborators due to small patient populations for those diseases, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene therapy in a timely manner or under technically or commercially feasible conditions. Even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene therapy, either of which could materially harm our business. Furthermore, regulatory action or private litigation could result in increased expenses, delays or other impediments to our research programs or the development or commercialization of current or future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development, manufacturing, labeling, storage, record&#8209;keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">guaranteed. We are not permitted to market any of our product candidates in the U.S. until we receive approval of a BLA or an NDA from the FDA. Similar risks exist in foreign jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we must demonstrate with substantial evidence from adequate and well&#8209;controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses, and in the case of biological products, that such product candidates are safe, pure and potent. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post&#8209;approval, or may object to elements of our clinical development program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree with the design or execution of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected drug&#8209;related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of their own country;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree with us regarding the formulation, labeling and/or the product specifications of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval may be granted only for indications that are significantly more limited than those sought by us, and/or may include significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes or facilities of the third&#8209;party manufacturers with which we contract for clinical and commercial supplies; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failure to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we eventually complete clinical trials and receive approval of a BLA, NDA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS or similar risk management measures, which may be required because the FDA or the comparable foreign regulatory authority believes it is necessary to ensure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe use of the drug after approval. The FDA or the comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there are a greater likelihood of success.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have relatively limited financial and managerial resources, we are focused on specific product candidates, indications and development programs. As a result, we may forgo or delay the pursuit of opportunities with other indications or other product candidates that could have greater commercial potential. For example, in April 2023 we announced a strategic reprioritization of the development of zilovertamab and our decision to close the Phase 3 ZILO&#8209;301 and the Phase 1/2 CIRM&#8209;0001 clinical studies, in favor of the advancement ONCT-534 and of ONCT-808.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we could relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements, when it might be more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A Fast Track Designation from the FDA, even if granted, for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 23, 2023 the FDA granted Fast Track Designation to ONCT&#8209;534 for the treatment of adult subjects with relapsed or refractory mCRPC resistant to ARPIs, and we may seek additional Fast Track designations for our other programs. The Fast Track program is intended to expedite or facilitate the process for reviewing new product candidates that meet certain criteria. Specifically, biologics are eligible for Fast Track Designation if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life&#8209;threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track Designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the application may be eligible for priority review. A BLA submitted for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the Sponsor pays any required user fees upon submission of the first section of the BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Although we have received Fast Track Designation for ONCT 534 for the treatment of adult subjects with relapsed or refractory mCRPC resistant to ARPIs, and even if we receive additional Fast Track Designations for our product candidates, such product candidates may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Furthermore, such a designation does not increase the likelihood that ONCT 534 or any other product candidate that may be granted Fast Track designation will receive marketing approval in the U.S. Many product candidates that have received Fast Track Designation have ultimately failed to obtain approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek PRIME designation by EMA or other designations, schemes or tools in the EU, including the conditional marketing authorization or marketing authorization under exceptional circumstances, for one or more of our product candidates, which we may not receive. Such designations may not lead to a faster development or regulatory review or approval process and do not increase the likelihood that our product candidates will receive marketing authorization.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek EMA PRIME (Priority Medicines) designation or other designations, schemes or tools for one or more of our product candidates. In the EU, innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the Breakthrough Therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reach patients earlier. The benefits of a PRIME designation include the appointment of a rapporteur before submission of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we believe one of our product candidates is eligible for PRIME, the EMA may disagree and instead determine not to make such designation. The EMA PRIME scheme or other schemes, designations, or tools, even if obtained or used for any of our product candidates may not lead to a faster development, regulatory review or approval process compared to therapies considered for approval under conventional procedures and do not assure ultimate approval. In addition, even if one or more of our product candidates is eligible to the PRIME scheme, the EMA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for review or approval will not be shortened.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product developers that benefit from PRIME designation may be eligible for accelerated assessment (in 150 days instead of 210 days), which may be granted for medicinal products of major interest from a public health perspective or that target an unmet medical need, but this is not guaranteed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, in the EU, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed. Furthermore, marketing authorizations may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to the introduction of specific procedures. This may arise when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This type of marketing authorization is close to a conditional marketing authorization as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a marketing authorization. However, unlike a conditional marketing authorization, the applicant does not have to provide the missing data and will never have to. Although a marketing authorization &#8220;under exceptional circumstances&#8221; is granted definitively, the risk&#8209;benefit balance of the medicinal product is reviewed annually and the marketing authorization may be withdrawn where the risk&#8209;benefit ratio is no longer favorable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The competent regulatory authorities in the EU have broad discretion whether to grant such an accelerated assessment, conditional marketing authorization or marketing authorization under exceptional circumstances, and, even if such assessment or authorization is granted, we may not experience a faster development process, review or authorization compared to conventional procedures. Moreover, the removal or threat of removal of such designation or marketing authorizations may create uncertainty or delay in the clinical development of our product candidates and threaten the commercialization prospects of our product candidates, if approved. Such an occurrence could materially impact our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may conduct certain of or portions of our clinical trials for our product candidates outside of the U.S. and the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future choose to conduct one or more of our clinical trials or a portion of our clinical trials for our product candidates outside the U.S. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on&#8209;site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on&#8209;site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well&#8209;designed and well&#8209;conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time&#8209;consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, topline and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our clinical studies and preclinical studies, which are based on preliminary analyses of then&#8209;available data. Such preliminary or topline results and related findings and conclusions are subject to change following more comprehensive reviews of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data or topline data we previously published. As a result, preliminary or topline data should be viewed with caution until the final data are available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may also disclose interim data from our clinical studies. Interim data from this clinical trial and future clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available. Adverse differences between topline, preliminary or interim data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses of data from preclinical studies or clinical trials of its product candidates, or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or prospects for commercialization of the product candidate, or our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Information that we decide not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the interim, topline or preliminary data that we disclose differ from actual results, or if others, including regulatory authorities, disagree with the conclusions we reach based on our analyses of such data, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third&#8209;party to conduct the clinical trials according to GLPs, GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on third parties to conduct our clinical trials and preclinical studies, including our ongoing clinical trials for our DAARI and ROR1 cell therapy programs. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and applicable regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third&#8209;party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of its clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards and obligations, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations or similar foreign requirements outside the U.S. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities conclude that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any BLA or NDA we submit to the FDA. Similar risks may exist in foreign jurisdictions where we decide to conduct clinical trials. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties for the manufacture of our product candidates for clinical and preclinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and related raw materials for clinical and preclinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. The facilities used by third&#8209;party manufacturers to manufacture our product candidates must be approved by the FDA or other regulatory agencies pursuant to inspections that will be conducted after we submit a BLA or an NDA to the FDA or their equivalent to other regulatory agencies. We do not control the manufacturing process of, and are completely dependent on, third&#8209;party manufacturers for compliance with cGMP or similar foreign requirements for manufacture of our drug products. If these third&#8209;party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the manufacturing of high potency and pure compounds or other products, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of third&#8209;party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, or if regulatory authorities withdraw any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third&#8209;party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our or a third&#8209;party&#8217;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms, or to comply with cGMP or similar foreign requirements could adversely affect our business in a number of ways, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an inability to initiate or continue clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjecting third&#8209;party manufacturing facilities to additional inspections by regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to cease development or to recall batches of our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we do not have any long&#8209;term commitments or supply agreements with any third&#8209;party manufacturers. We may be unable to establish any long&#8209;term supply agreements with third&#8209;party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third&#8209;party manufacturers, reliance on third&#8209;party manufacturers entails additional risks, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of third&#8209;party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">breach of the manufacturing agreement by the third&#8209;party;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to manufacture our product according to our specifications;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to manufacture our product according to our schedule, or at all;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">misappropriation of our proprietary information, including our trade secrets and know&#8209;how; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">termination or nonrenewal of the agreement by the third&#8209;party at a time that is costly or inconvenient for us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP or foreign regulations and that might be capable of manufacturing for us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time&#8209;consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our current third&#8209;party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we currently rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees, consultants and contractors prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know&#8209;how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have entered into and may seek to enter into additional collaborations, licenses and other similar arrangements, and we may not be successful in doing so, and we may not realize the benefits of such relationships.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints, in addition to our collaboration with Shanghai Pharmaceutical Holding Co., Ltd. We may not be successful in our efforts to establish such collaborations for our product candidates because our research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time&#8209;consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we would. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Commercialization of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following potential approval of any of our product candidates, the FDA or comparable foreign regulatory authorities may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time&#8209;consuming post&#8209;approval studies, post&#8209;market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA or comparable foreign regulatory authorities may also require a REMS or similar risk management measures or as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post&#8209;marketing information and reports, registration, as well as continued compliance with cGMPs or similar foreign requirements and GCP requirements for any clinical trials that we conduct post&#8209;approval. Later discovery of previously unknown problems with our products, including adverse events of unanticipated type, severity or frequency, or with our third&#8209;party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on product distribution or use, or requirements to conduct post&#8209;marketing studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications we filed or suspension or revocation of approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our products; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA and comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s and comparable foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s and comparable foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and comparable foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA, following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs and biologics, or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">demonstration of clinical efficacy and safety compared to other more&#8209;established products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the indications for which our product candidates are approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA or foreign regulatory authority-approved labeling;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing and cost&#8209;effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain sufficient third&#8209;party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third&#8209;party payors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay all, or a portion of, out&#8209;of&#8209;pocket costs associated with our products in the absence of sufficient third&#8209;party coverage and adequate reimbursement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential product liability claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of our products as well as competitive drugs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our or any of our potential future collaborators&#8217; sales and marketing strategies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable publicity relating to the product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third&#8209;party payors regarding the benefits of our products may require significant resources and may never be successful.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be limited to patients who are ineligible for or have failed prior treatments and may be small or different from our estimates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, including targeted therapy, immunotherapy, chemotherapy, hormone therapy, surgery or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. In markets with approved therapies, there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive later stage therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. In addition, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first&#8209;line or second&#8209;line therapy.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA&#8209;licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12&#8209;year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the Sponsor&#8217;s own preclinical data and data from adequate and well&#8209;controlled clinical trials to demonstrate the safety, purity and potency of its product. Similar risks may exist in foreign jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that any of our future product candidates approved as a biological product under a BLA should qualify for the 12&#8209;year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non&#8209;biological products will depend on a number of marketplace and regulatory factors that are still developing.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off&#8209;label uses. If we are found or alleged to have improperly promoted off&#8209;label uses, we may become subject to significant liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as our product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted such off&#8209;label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off&#8209;label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion and avoid off&#8209;label promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third&#8209;party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third&#8209;party payors will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third&#8209;party payor, the resulting reimbursement payment rates may not be adequate or may require co&#8209;payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the U.S., the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third&#8209;party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third&#8209;party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third&#8209;party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to third&#8209;party payor coverage and reimbursement of newly approved products. In the U.S., third&#8209;party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third&#8209;party payors may require pre&#8209;approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third&#8209;party payors will decide with respect to the coverage and reimbursement for our products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third&#8209;party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates as we are targeting certain defined populations for our treatments. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement sought for our product candidates, once approved. While we, or our collaborators, have not yet developed any companion diagnostic test for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain approval, coverage and adequate reimbursement for the same reasons applicable to our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost&#8209;containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the U.S, the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, increasing efforts by governmental and third&#8209;party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do, or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the fields of immunology, inflammation and oncology. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying and in&#8209;licensing new product candidates. Smaller or early&#8209;stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved in oncology indications, they will compete with small molecule therapies, biologics, cell&#8209;based therapies and vaccines, either approved or under development, that are intended to treat the same cancers that we are targeting, including through approaches that may prove to be more effective, have fewer side effects, be less costly to manufacture, be more convenient to administer or have other advantages over any product candidates we develop. In addition to competing with other therapies targeting similar indications, there are numerous other companies and academic institutions focused on similar targets as our product candidates and/or different scientific approaches to treating the same indications. We face competition from such companies in seeking any future potential collaborations to partner our product candidates, as well as potentially competing commercially for any approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of products we may develop, if approved, could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, the number who have the specific indicated stage or treatment history we believe will be the approved indication, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the indication approved by regulatory agencies and the diagnostic criteria included in the final label for each of our product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the U.S. and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in most other countries, we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, manufacturing, pricing and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distribution of our product candidates. If we receive regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different regulatory requirements for approval of drugs in foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the existence of additional third&#8209;party patent rights of potential relevance to our business;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, public health emergencies, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, public health emergencies, such as the outbreak of a novel strain of coronavirus affecting the People&#8217;s Republic of China and elsewhere or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business Operations and Industry</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our product candidates, which may change from time to time;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and any manufacturing issues or challenges requiring additional manufacturing activities, and the terms of our agreements with third&#8209;party manufacturers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters such as earthquakes, typhoons, floods and fires or public health emergencies or pandemics;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and amount of any milestone or other payments we must make to the licensors and other third parties from whom we have in&#8209;licensed or acquired our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of demand for any approved products, which may vary significantly;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period&#8209;to&#8209;period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on the services of our management and if we are not able to retain these individuals or recruit additional management or other key personnel, our business will suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our Chief Executive Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned operations, planned clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 1, 2024, we had 27 full-time employees and three part-time employees. As we continue research and development activities and pursue the potential commercialization of our product candidates, as well as function as a public company, we will need to expand our financial, research, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for the company. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to various foreign, federal, and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third&#8209;party payors and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti&#8209;Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti&#8209;Kickback Statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may assert that a claim including items or services resulting from a violation of the federal Anti&#8209;Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, or collectively HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti&#8209;Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services, CMS, information related to payments and other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non&#8209;physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous U.S. state and foreign laws and regulations, such as state anti&#8209;kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non&#8209;governmental third&#8209;party payors, including private insurers, or by the patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our consulting arrangements with physicians and other healthcare providers, some of whom received stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non&#8209;compliance with these laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S. and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost&#8209;containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, referred to collectively as the ACA, was enacted in the U.S. Among the provisions of the ACA of importance to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our potential product candidates, the ACA: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expands eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the Public Health program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; created a new Medicare Part D coverage gap discount program; establishes a new Patient&#8209;Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through August 15, 2021. The executive order instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, there has been heightened governmental scrutiny in the U.S. of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price, or AMP. Most recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third&#8209;party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that the ACA, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In foreign jurisdictions, including the EU, similar developments may affect our ability to profitably commercialize our product candidates, if approved. For instance, in December 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 12, 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive health-related or other personal information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, or CCPA, went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that has increased the likelihood of, and risks associated with, data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or CPRA, generally went into effect on January 1, 2023, and significantly amends the CCPA. It imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency specifically tasked to issue substantive regulations and enforce the CCPA and CPRA, which has increased regulatory scrutiny of covered businesses in the areas of data protection and security. Additional compliance investment and potential business process changes may also be required. Similar laws have passed in other states, and continue to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the U.S. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, the EU General Data Protection Regulation, or GDPR, went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA, or in the context of our activities within the EEA. In addition, some of the personal data we process in respect of clinical trial participants is special category or sensitive personal data under the GDPR, and subject to additional compliance obligations and to local law derogations. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease/ change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/ or civil claims (including class actions). Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the EEA and the U.S. remains uncertain. Case law from the Court of Justice of the EU, or the CJEU, states that reliance on the standard contractual clauses</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On October 7, 2022 President Biden signed an Executive Order on &#8216;Enhancing Safeguards for United States Signals Intelligence Activities&#8217; which introduced new redress mechanisms and binding safeguards to address the concerns raised by the CJEU in relation to data transfers from the EEA to the U.S. and which formed the basis of the new EU-US Data Privacy Framework, or DPF, as released on December 13, 2022. The European Commission adopted its Adequacy Decision in relation to the DPF on July 10, 2023, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. The DPF also introduced a new redress mechanism for EU citizens which addresses a key concern in the previous CJEU judgments and may mean transfers under standard contractual clauses are less likely to be challenged in future. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the U.S. and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. To the extent we are unable to transfer personal data between and among regions in which we operate or intend to operate as a result of regulatory authorities issuing further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, it could affect the manner in which we operate and could adversely affect our financial results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, since January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law, or collectively, the UK GDPR. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a UK GDPR data transfer mechanism to U.S. entities self-certified under the UK Extension to the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. If we or our third-party CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Further, the use of social media by our, and our third-party service providers&#8217;, employees and contractors could give rise to liability with respect to intentional or inadvertent data privacy and security breaches involving our data or result in other incidents that could cause reputational damage.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our historical operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#8217;s time and our resources;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant negative financial impact; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decline in our stock price.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently hold $10.0 million in product liability insurance coverage in the aggregate. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we and any of our potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer cyberattacks or other security breaches, which could have a material adverse effect on our business, results of operation, and financial condition, and result in a material disruption of our product development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. Further, U.S. federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of health-related and other personal information, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personal or other confidential information, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals, governmental authorities, supervisory bodies, the media and other parties of security breaches involving particular personal information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. Further, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could be subject to regulatory scrutiny, incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures, our information technology systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to attack, interruption, and damage from computer viruses and malware (e.g. ransomware), malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Our corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any business disruptions from natural disasters could seriously harm our operations and financial condition and increase our costs and expenses. In addition, attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who continue to work remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, including cGMP and similar foreign requirements, (3) federal, state and foreign data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad or (4) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non&#8209;compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti&#8209;corruption laws and anti&#8209;money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, and anti&#8209;corruption and anti&#8209;money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti&#8209;bribery and anti&#8209;money laundering laws in the countries in which we conduct activities. Anti&#8209;corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the U.S., to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government&#8209;affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out&#8209;licensing or in&#8209;licensing of intellectual property, products or technologies, similar to our approach in in&#8209;licensing and acquiring our current product candidates. Any future transactions could increase our near and long&#8209;term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in&#8209;process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a variety of business arrangements, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">spin&#8209;offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by licensing or filing patent applications in the U.S. and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our or our licensors&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our or our licensors&#8217; patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available, and such protection may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we hold and license issued patents in the U.S. and foreign countries, we cannot be certain that the claims in our or our licensors&#8217; other U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the U.S. Patent and Trademark Office, or USPTO, courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our or our licensors&#8217; issued patents will be found valid or enforceable if challenged.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we, our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensors to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, although we enter into non&#8209;disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third&#8209;party manufacturers, consultants, advisors, licensees, collaboration partners, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, including with respect to ONCT-534, ONCT 808, and zilovertamab, or otherwise experience disruptions in our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to several license agreements under which we are granted rights to important intellectual property and we may enter into additional license agreements in the future. For example, we license intellectual property rights to develop and commercialize product candidates in our DAARI program, including ONCT&#8209;534, from the University of Tennessee Research Foundation. We also license intellectual property rights to develop and commercialize genetically engineered cellular therapy products, including ONCT&#8209;808, and zilovertamab from the Regents of the University of California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our license agreements impose, and we expect that any future license agreements where we in license intellectual property will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third party patents do not exist that might be enforced against our product candidates in the absence of such a license. We may not be able to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation&#8209;related issues;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patents and other rights to third parties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to transfer or assign the license; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ownership of inventions and know&#8209;how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensors&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our or our licensors&#8217; patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our and our licensors&#8217; patents may not cover our product candidates or may be challenged in the courts or patent offices in the U.S. and abroad. Our and our licensors&#8217; patents may be subject to a third party pre issuance submission of prior art to the USPTO or foreign patent offices, or become involved in opposition, derivation, revocation, reexamination, post grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our or our licensors&#8217; patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our predecessors or our licensor and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which we, our predecessors or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, but that may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our or our licensors&#8217; patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of patent rights or loss of exclusivity, or our or our licensors&#8217; patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our or our licensors&#8217; patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The patent protection and patent prosecution for some of our product candidates may be dependent on third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we or our licensors may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our or our licensors&#8217; patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments or extensions. If there are material defects as to form, preparation, prosecution, or enforcement of our or our licensors&#8217; patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. If we or our licensors, whether current or future, fail to establish, maintain or protect our patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents directed to any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to our assuming control over patent prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in&#8209;licensed technology, we may be unable to successfully develop, out&#8209;license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out&#8209;license or market and sell our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march&#8209;in&#8221; rights, certain reporting requirements and a preference for U.S.&#8209;based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non&#8209;U.S. manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work on ONCT&#8209;534, ONCT-808 and certain other programs was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our product candidates pursuant to the Bayh&#8209;Dole Act of 1980, or Bayh&#8209;Dole Act. These U.S. government rights include a non&#8209;exclusive, non&#8209;transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non&#8209;exclusive licenses to any of these inventions to a third&#8209;party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs, or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march&#8209;in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the U.S. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non&#8209;U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. With respect to state funding, specifically funding via the California Institute of Regenerative Medicine, or CIRM which has granted funds for the study of zilovertamab in combination with ibrutinib and a novel anti-cancer stem cell targeted therapy, the grantee has certain obligations and the state or CIRM has certain rights. For example, the grantee has an obligation to share intellectual property, including research results, generated by CIRM-funded research, for research use in California. In addition, the California government can exercise march-in rights if it determines that action is necessary because we or the grantee failed to achieve practical application of the CIRM-funded technology, because we failed to comply with agreed to access and pricing requirements, or because action is necessary to address a public health emergency declared by the governor of California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent applications that we own or license;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or predecessors might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our or our licensors&#8217; pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on licensee relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including milestone payments and future royalty revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaborative arrangements to develop and commercialize our unpartnered assets. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully, our product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know&#8209;how or technologies developed with our collaborators. Such disputes or litigation could adversely affect our rights to one or more of our product candidates and could delay, interrupt or terminate the collaborative research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. In addition, a significant downturn or deterioration in the business or financial condition of our collaborators or partners could result in a loss of expected revenue and our expected returns on investment. The occurrence of any of these problems could be time&#8209;consuming and expensive and could adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our or our licensee&#8217;s research, development and commercialization activities may be subject to claims that we or our licensee infringes or otherwise violates patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our or our licensee&#8217;s ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third&#8209;party U.S. and foreign issued patents and pending patent applications exist in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fields in which we are developing product candidates. There may be third&#8209;party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes these patents. Any claims of patent infringement asserted by third parties would be time-consuming and could:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result in costly litigation that may cause negative publicity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divert the time and attention of our technical personnel and management;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cause development delays;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject us to an injunction preventing us from making, using, selling, offering for sale, or importing our products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to develop non&#8209;infringing technology, which may not be possible on a cost&#8209;effective basis;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject us to significant liability to third parties; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non&#8209;exclusive, which could result in our competitors gaining access to the same technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although no third party has asserted a claim of patent infringement against us as of December 31, 2023, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially reasonable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, the foregoing proceedings could be very expensive, particularly for a company of our size, and time-consuming. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of our competitors may be better able to sustain the costs of litigation or administrative proceedings.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our drug product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the U.S. and abroad that is relevant to or necessary for the commercialization of our current and future products and product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending patent application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our drug product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, and we may incorrectly conclude that a third-party patent is invalid and/or unenforceable. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our drug product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Further, our or our licensors&#8217; issued patents could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we hold or license is not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our or our licensors&#8217; patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld relevant and material information from the USPTO or made a misleading statement during prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our or our licensors&#8217; intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We or our licensors may not have sufficient financial or other resources to conduct or participate in such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we or our licensors can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or attempt to license rights from the prevailing party.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivation or interference proceedings provoked by third parties or brought by us or our licensors or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our or our licensors&#8217; patents or patent applications. An unfavorable outcome could require us to cease using the related technology or attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Our or our licensors&#8217; defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law with respect to patent applications filed after March 16, 2013. These include provisions that affect the way patent applications filed after March 16, 2013 are prosecuted and also affect patent litigation. In particular, under the Leahy-Smith Act, the U.S. transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third-party was first to invent the claimed invention. A third-party that files a patent application in the USPTO after March 2013, but before us, could therefore be awarded a patent covering an invention of ours, even if we had made the invention before it was made by such third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the relevant prior art will allow our technology to be patentable over the prior art. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (1) file any patent application related to our product candidates or (2) invent any of the inventions claimed in our or our licensors&#8217; patents or patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use the USPTO procedures to invalidate our or our licensors&#8217; patent claims that would not have been invalidated if first challenged by the third-party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. For example, U.S. Supreme Court rulings, such as Amgen Inc. v. Sanofi, 598 U.S. 594, 143 S. Ct. 1243 (2023), may limit the breadth of certain genus patent claims covering composition of matter of pharmaceutical products if enough compounds with shared claimed features are not provided. As such, we cannot guarantee that we will be able to obtain patents covering our drug product candidates. These cases and others like them have created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways. In addition, the complexity and uncertainty of European patent laws also have increased in recent years. Any of the foregoing could have a material adverse effect on our owned and in-licensed patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the U.S. and other countries may diminish the value of our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intellectual property rights and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our or our licensors&#8217; patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in June 2023, the European Patent Package, or EU Patent Package, regulations were implemented with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court, or the UPC, for litigation involving European patents. As a result, all European patents, including those issued prior to ratification of the EU Patent Package, will by default automatically fall under the jurisdiction of the UPC. We may opt our European patents out of the UPC during first seven years of the UPC&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our current or future European patents could remain under the jurisdiction of the UPC. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries and our European patent applications, if issued, could be challenged in the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents and allow for the possibility of a competitor to obtain pan-European injunctions. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and consequently, on our business, financial condition, prospects and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non&#8209;provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for our product candidates, our business may be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our or our licensors&#8217; U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch Waxman Amendments. The Hatch Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our or our licensors&#8217; patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we and our licensors have issued patents and pending patent applications in the U.S. and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. We may need to share our trade secrets and proprietary know-how with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensors&#8217; efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, geo-political actions in the U.S. and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the U.S. and foreign government actions related to Russia&#8217;s conflict in Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the U.S. without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non&#8209;compliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our and our licensors&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent office&#8217;s require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we rely on the protection of our trade secrets, including unpatented know&#8209;how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know&#8209;how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The trading price of the shares of our common stock may be highly volatile, and purchasers of our common stock may incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above their purchase price. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our or our collaborators ability to enroll patients in our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of our clinical trials and preclinical studies, and the results of the trials of our competitors or those of other companies in our market sector;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments in the U.S. and foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success or failure of our efforts to acquire, license or develop additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">innovations or new products developed by us or our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements regarding the results of discovery efforts and preclinical, clinical and commercial activities by us, or those of our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing, supply or distribution delays or shortages;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achievement of expected product sales and profitability;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of short positions by holders or non&#8209;holders of our common stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an inability to obtain additional funding;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our stock by insiders and stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry and market conditions or other events or factors, many of which are beyond our control;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intellectual property, product liability or other litigation against us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our stockholders in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. As of December 31, 2023, 2,687,016 shares of our outstanding common stock are freely tradable, without restriction, in the public market, unless they are purchased by one of our affiliates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, up to 832,060 shares of common stock that are either subject to outstanding warrants, options or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a classified board of directors with three&#8209;year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the exclusive right of our board of directors, unless the board of directors&#8217; grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prohibition on removal of directors without cause due to the classified board of directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the required approval of at least 66&#8209;2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal certain provisions of our amended and restated certificate of incorporation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to the anti&#8209;takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use net operating loss, or NOL, carryforwards and other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward and, subject to limitations, offset future taxable income, if any, until such unused losses expire (if at all). As of December 31, 2023, we had federal and state NOL carryforwards of approximately $119.5 million and $70.4 million, respectively. Approximately $93.2 million and none,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, of NOLs do not expire, and the remaining federal and state NOL carryforwards will begin to expire in 2033 and 2029, respectively, unless previously utilized. As of December 31, 2023, we had federal and state research and development credit carryforwards of approximately $4.3 million and $2.9 million, respectively. The federal research and development credit carryforwards will begin expiring in 2034, unless previously utilized. The state research and development credits do not expire.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal NOLs generated in taxable years ending after December 31, 2017 may be carried forward indefinitely but federal NOLs generated in taxable years beginning after December 31, 2017 may only be used to offset 80% of our taxable income annually. Under Sections 382 and 383 of the Code, our NOL and research and development tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders (or certain groups of stockholders) over a three&#8209;year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including changes resulting from our Merger, as described elsewhere. We have not yet determined the amount of the cumulative change in our ownership resulting from the Merger or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our stockholders prior to the Merger who hold contingent value rights, or CVRs, may not receive any payment on the CVRs and the CVRs may otherwise expire valueless.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 7, 2019, in connection with the Merger, we entered into a CVR Agreement, which was subsequently amended on November 1, 2021. Pursuant to the CVR Agreement, our stockholders of record as of immediately prior to the Merger received one CVR for each share of our common stock held immediately prior to the Merger.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i) 50% of certain net proceeds we receive during the 15&#8209;year period after the closing of the Merger, or the CVR Term, from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the 10&#8209;year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10&#8209;year period); and (ii) 5% of our net sales of products during the CVR Term incorporating the DAARI technology. As of December 31, 2023, no transactions or net sales relating to the DAARI technology had occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CVRs are not transferable, will not have any voting or dividend rights, and interest will not accrue on any amounts potentially payable on the CVRs. Accordingly, the right of any stockholder of record as of immediately prior to the Merger to receive any future payment on or derive any value from the CVRs will be contingent solely upon the achievement of the foregoing events within the time periods specified in the CVR Agreement and if these events are not achieved for any reason within the time periods specified in the CVR Agreement, no payments will be made under the CVRs, and the CVRs will expire valueless. In addition, we (as successor in interest to GTx) have agreed only to use commercially reasonable efforts to develop DAARI products, subject to certain limitations, which allows for the consideration of a variety of factors in determining the efforts that we are required to use to develop DAARI products, and we are not required to take all possible actions to continue efforts to develop DAARI products. Accordingly, under certain circumstances we may not be required to continue efforts to develop DAARI products, or may allocate resources to other projects, which would have an adverse effect on the value, if any, of the CVRs. Furthermore, the CVRs will be unsecured obligations of our company and all payments under the CVRs, all other obligations under the CVR Agreement and the CVRs and any rights or claims relating thereto will be subordinated in right of payment to the prior payment in full of all of our current or future senior obligations. Finally, the U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the IRS, would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Capital Market. In order to maintain our listing, we must meet minimum financial and other requirements, such as the minimum closing bid price of at least $1.00, stockholders&#8217; equity, round lot holders requirements and the corporate governance requirements. If we fail to satisfy such requirements, Nasdaq may take steps to delist our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we are currently in compliance with the Nasdaq Capital Market continued listing requirements, we have in the past been subject to notifications from Nasdaq that we were not in compliance with certain listing requirements and we cannot assure you that we will be able to continue to comply with such requirements in the future. A delisting of our common stock would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our securities when you wish to do so. Such a delisting could also result in a limited amount of news and analyst coverage for the company; and a decreased ability for us to issue additional securities or obtain additional financing in the future. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, or prevent future non&#8209;compliance with Nasdaq&#8217;s listing requirements.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is subject to risks arising from epidemic diseases, such as the COVID&#8209;19 pandemic.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A pandemic, such as COVID-19, or other public health epidemic, poses the risk that we or our employees, contractors, including our CROs, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While it is not possible at this time to estimate the full impact that COVID&#8209;19 or any future healthcare emergency could have on our business, the measures taken by the governments of countries affected could, in addition to disrupting our clinical trials, disrupt the supply chain and the manufacture or shipment of product candidates for use in our clinical trials or in commercial distribution, which could delay our ongoing clinical trials and increase development costs, or impair our ability to successfully commercialize our product candidates following any regulatory approval, and in either case have a material adverse effect on our business, financial condition and results of operations. Any healthcare emergency and the mitigation measures put in place by governments have had, and could in the future have, an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID&#8209;19 pandemic, or any other outbreak of an epidemic disease, impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes&#8209;Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes&#8209;Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd&#8209;Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that apply to us. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules and regulations applicable to public companies have substantially increased and may continue to increase our legal and financial compliance costs and to make some activities more time&#8209;consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. In the event one or more of the analysts who covers us downgrades our stock, or if we fail to otherwise meet the expectations of one or more of these analysts, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 of Sarbanes&#8209;Oxley, we are required to report upon the effectiveness of our internal control over financial reporting. Additionally, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have been required to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in the future, in securities class action litigation that could divert management&#8217;s attention, adversely affect our business and subject us to significant liabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following volatility in the market price of its securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any future lawsuits to which we may become a party are subject to inherent uncertainties and will likely be expensive and time&#8209;consuming to investigate, defend and resolve, and will divert our management&#8217;s attention and financial and other resources. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of future lawsuits, and we may not prevail. Any litigation to which we may become a party may result in an onerous or unfavorable judgment that may not be reversed upon appeal or in payments of substantial monetary damages or fines, or we may decide to lawsuits on similarly unfavorable terms, which could adversely affect our business, financial condition, results of operations or stock price.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, rising interest and inflation rates, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the U.S. and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by affected countries and others could exacerbate market and economic instability. Further, the closure of financial institutions, such as Silicon Valley Bank in 2023 created bank&#8209;specific and broader financial institution liquidity risk and concerns. Future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market&#8209;wide liquidity shortages, impair the ability of companies to access near&#8209;term working capital needs, and create additional market and economic uncertainty. There can be no assurance that any future deterioration in credit and financial markets and confidence in economic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause short&#8209;term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, financial institutions, manufacturers and other partners may be adversely affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B.	U</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nresolved Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C.	Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our cybersecurity risk management program includes:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a security team principally responsible for managing our security controls and our response to cybersecurity incidents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cybersecurity awareness training of our employees, incident response personnel, and senior management; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled &#8220;Risk Factor&#8212;Risks Related to Our Business Operations and Industry&#8212;Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer cyberattacks or other security breaches, which could have a material adverse effect on our business, results of operation, and financial condition, and result in a material disruption of our product development programs.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity Governance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (&#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Head of IT or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management team, including our Chief Executive Officer, General Counsel, and Head of IT, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel. Our management team&#8217;s experience includes a Head of IT with over 30 years&#8217; experience leading the IT and cybersecurity functions for companies similar to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management team supervises efforts to identify, protect, detect, respond and recover cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the IT environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive offices are located in San Diego, California, where we lease 3,748 square feet of office space used primarily for corporate, research, development, clinical, regulatory, manufacturing and quality functions. Such lease expires on September 30, 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedingsfrom_q3_form_10q"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal Proceedi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ngs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT&#8221;. As of March 1, 2024, there were approximately 88 holders of record of our common stock.  This number was derived from our stockholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eserved].</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion should be read in conjunction with the consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and future financial performance, includes forward-looking statements that are based upon current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should review the &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of important factors that could cause our actual results and the timing of selected events to differ materially from those described in or implied by the forward-looking statements contained in the following discussion and analysis. Please also see the section within Part I of this Annual Report entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for cancers with critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on prostate cancer and hematological malignancies. Our pipeline includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#149; ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) product candidate with a novel mechanism of action that includes inhibition of androgen receptor (AR) function and degradation of the AR protein mediated by interaction with both the ligand binding domain (LBD) and N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated AR, and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR LBD, and splice variants with loss of the AR LBD. ONCT-534 is a potential monotherapy treatment for patients with advanced prostate cancer and other AR-driven diseases, including relapsed or refractory metastatic castration-resistant prostate cancer, or mCRPC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, we commenced Study ONCT-534-101, a Phase 1/2, single-arm, open-label, multi-center study to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of ONCT-534 in patients with mCRPC who have relapsed or are refractory to approved ARPIs including enzalutamide, abiraterone, apalutamide and darolutamide. The Phase 1 portion of the study utilizes an adaptive Bayesian Optimal Interval (BOIN) design with five ONCT-534 dosing cohorts ranging from 40 mg to 600 mg per day.  After the safety and tolerability and preliminary antitumor activity of ONCT-534 have been assessed in the Phase 1 portion of this study, Phase 2 will commence to further evaluate the safety and preliminary antitumor activity of ONCT-534 to support selecting an optimal dose. Study ONCT-534-101 (NCT05917470) has dosed and continues to enroll patients in the Phase 1 portion of the study.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#149; ONCT-808, our lead cell therapy product candidate, is an investigational autologous chimeric antigen receptor T, or CAR T, cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab, as defined below. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. Oncternal has dosed patients under Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#149; Zilovertamab is an investigational, humanized, potentially first-in-class, monoclonal antibody designed to: (i) bind to ROR1, a growth factor receptor that is widely expressed on many tumor and that activates pathways leading to increased tumor proliferation, invasiveness and drug resistance, and (ii) inhibit ROR1 function. Zilovertamab has been evaluated in a Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), which resulted in 100% progression free survival (PFS) at 42 months in CLL patients expressing a p53 mutation/del(17p), a population underserved by current treatment options. Zilovertamab is also being evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (NCT05156905).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the inception of privately-held Oncternal Therapeutics, Inc. in 2013, we have devoted most of our resources to organizing and staffing, business planning, raising capital, acquiring product candidates and securing related intellectual property rights and advancing our ONCT-534, ONCT-808, zilovertamab and ONCT-216 clinical and preclinical development programs. Through December 31, 2023, we have funded our operations primarily through: (i) gross proceeds of $136.3 million from the issuance of common stock, (ii) gross proceeds of $49.0 million from the issuance of convertible preferred stock that was subsequently converted into common stock, (iii) receipt of $14.5 million in subaward grant payments received from UC San Diego as well as $1.6 million received from the National Institutes of Health, or NIH, and (iv) cash proceeds of $18.3 million received in connection with the closing of the merger with GTx, Inc. in June 2019, or the GTx Merger. As of December 31, 2023, we had cash, cash equivalents and short-term investments of $34.3 million and no debt.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses in each year since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss was $39.5 million for the year ended December 31, 2023. As of December 31, 2023, we had an accumulated deficit of $197.8 million. Substantially all of our net losses have resulted from costs incurred in connection with: (i) advancing our research and development programs, (ii) general and administrative costs associated with our operations, including the costs associated with operating as a public company, and (iii) in-process research and development costs associated with the GTX Merger. We expect to continue to incur significant and increasing operating losses for at least the next several years. We expect that our expenses and capital funding requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance ONCT-534 through clinical development, initially in castration resistant prostate cancer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance ONCT-808 through clinical development, initially in hematological malignancies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to develop additional product candidates; acquire or in-license other product candidates and technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our planned product development and future commercialization efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will not generate product sales revenue unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, we believe we will need substantial additional funding to support our continuing operations and pursue our business strategy. Until such time as we can generate significant product sales revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government funding, or other sources, including potentially collaborations, licenses and other similar arrangements. We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in licenses or acquisitions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate some or all of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management concluded that the balance of cash, cash equivalents and short-term investments may not be sufficient to fund our planned expenditures and meet our obligations for at least the twelve months following the financial statement issuance date without entering into one or more collaborations or raising additional funding or making changes to operating plans or programs to reduce expenses. As a result, there is substantial doubt about our ability to continue as a going concern for twelve months following the issuance date of the consolidated financial statements as of December 31, 2023. We believe that our cash, cash equivalents and short-term investments provide sufficient cash to fund our projected operating requirements into the first quarter of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grant Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our grant revenue has been derived from a California Institute for Regenerative Medicine, or CIRM, grant subaward with UC San Diego and research and development grants from the NIH.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2017, CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance our Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including CLL and MCL. Oncternal conducted this study in collaboration with UC San Diego and received $14.5 million in development milestones under research subaward agreements throughout the award project period from October 1, 2017 to March 31, 2022. In addition, we were committed to certain co-funding requirements and to provide UC San Diego progress and financial update reports throughout the award project period. We received final subaward payments of $0.7 million in the year ended December 31, 2022. As of December 31, 2023, we believe we have met our obligations under the CIRM award and UC San Diego subawards and we have no further obligations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NIH has awarded us three research and development grants for up to $4.0 million to support preclinical activities for our ONCT-534 and ONCT-216 programs, including $1.0 million payable to subawardees. Under the terms of the grant awards, we are entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and we are required to provide periodic progress performance reports. During the year ended December 31, 2023, we received $0.3 million in award payments from the NIH, recorded $0.8 million in grant revenue and had $0.5 million in unbilled receivables as of December 31, 2023, which has been included in prepaid and other assets. During the year ended December 31, 2022, we received $1.2 million in award payments from the NIH, recorded $1.1 million in grant revenue and had $0.1 million in unbilled receivables as of December 31, 2022, which has been included in prepaid and other assets.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for the preclinical and clinical development of our product candidates, ONCT-534, ONCT-808, zilovertamab, and ONCT-216, which include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses under agreements with third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to develop and manufacture preclinical study and clinical trial material;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">salaries and employee-related costs, including stock-based compensation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs incurred under our collaboration and third-party licensing agreements; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory, regulatory and vendor expenses related to the execution of preclinical and clinical trials.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We accrue all research and development costs in the period for which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred and then expensed as the related goods are delivered and as services are performed. Any unearned advances would be refunded when known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our research and development expenses to increase substantially for the foreseeable future as we: (i) continue to invest in developing our product candidates clinically and preclinically, advance preclinical assets into the clinic and as we begin to conduct larger global clinical trials, and (ii) invest in additional operational personnel to support our planned product development efforts. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, especially for global studies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our direct research and development expenses are tracked by product candidate and consist primarily of external costs, such as fees paid under third-party license agreements and to outside consultants, contract research organizations, or CROs, contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">work across multiple programs and, therefore, we do not track our costs by product candidate unless we can include them as subaward costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development, including any potential expanded dosing beyond the original protocols based in part on ongoing clinical success and the potential effects of the COVID-19 pandemic. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments of each product candidate&#8217;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, insurance costs, facility costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. Personnel-related costs consist of salaries, benefits and stock-based compensation. We expect our general and administrative expenses will increase significantly as we: (i) incur additional costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs, (ii) hire additional personnel, and (iii) protect our intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Income</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income consists of interest and dividends earned on our cash equivalents and short-term investments, which primarily consist of money market funds and U.S. Treasury securities. In a significantly rising interest rates environment, our interest income on our invested balances is expected to increase as rates increase. Historically, our interest income has not been significant due to low interest earned on invested balances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.8%;"/>
    <td style="width:1.102%;"/>
    <td style="width:1%;"/>
    <td style="width:16.156%;"/>
    <td style="width:1%;"/>
    <td style="width:1.958%;"/>
    <td style="width:1%;"/>
    <td style="width:16.156%;"/>
    <td style="width:1%;"/>
    <td style="width:1.958%;"/>
    <td style="width:1%;"/>
    <td style="width:15.87%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">785</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,490</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(705</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,980</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,227</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,746</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,457</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(711</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,437</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,938</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(41,714</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(44,947</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,233</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,235</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">777</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,458</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(39,479</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(44,170</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,691</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grant Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grant revenue for the year ended December 31, 2023 was $0.8 million, compared to $1.5 million for the year ended December 31, 2022. The decrease of $0.7 million was primarily due to a decrease in CIRM subaward revenue of $0.4 million due to the completion of the subaward in the first quarter of 2022 and a decrease in revenue under the NIH awards of $0.3 million due to the timing of grant activities.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for the periods indicated (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.404%;"/>
    <td style="width:1.01%;"/>
    <td style="width:1%;"/>
    <td style="width:16.182%;"/>
    <td style="width:1%;"/>
    <td style="width:2.02%;"/>
    <td style="width:1%;"/>
    <td style="width:16.182%;"/>
    <td style="width:1%;"/>
    <td style="width:2.02%;"/>
    <td style="width:1%;"/>
    <td style="width:16.182%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase/</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ONCT-534</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,584</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,346</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ONCT-808</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,698</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,349</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(651</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Zilovertamab</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,728</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,818</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,090</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ONCT-216</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,371</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,285</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unallocated research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,657</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,204</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,980</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,227</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses for the years ended December 31, 2023 and 2022 were $29.8 million and $33.0 million, respectively, a decrease of $3.2 million. The decrease was due to following offsetting factors: (i) a $3.7 million net decrease in direct product candidate costs, and (ii) a $0.5 million increase in unallocated research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Direct expenses for ONCT-534 increased $3.3 million for the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to a: (i) $2.1 million increase in clinical activities with the initiation of our Phase 1/2 clinical study, (ii) $1.6 million increase in manufacturing costs, and (iii) $0.4 million decrease in preclinical and other costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Direct expenses for ONCT-808 decreased $0.7 million for the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to a: (i) $2.4 million increase in clinical trial costs with the initiation of our Phase 1/2 clinical study, (ii) $1.7 million decrease in manufacturing costs, and (iii) $1.4 million decrease in collaboration and license related costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Direct expenses for zilovertamab decreased $4.1 million for the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to the following partially offsetting factors: (i) a $2.0 million decrease in clinical trial costs primarily related to the reprioritization of the program in April 2023, and (ii) a $2.1 million decrease in manufacturing and other costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Direct expenses for ONCT-216 decreased $2.3 million for the year ended December 31, 2023 as compared to the year ended December 31, 2022, due primarily to lower clinical trial activity and manufacturing costs associated with the de-prioritization of this program in 2022 as well as the sale of clinical trial supplies to SPH USA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unallocated expenses increased $0.5 million for the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to higher personnel costs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses for the years ended December 31, 2023 and 2022 were $12.7 million and $13.5 million, respectively, a decrease of $0.7 million. The decrease is primarily due to the following partially offsetting factors: (i) lower legal costs of $0.7 million, (ii) lower corporate insurance costs of $0.4 million, (iii) lower professional services and other costs of $0.2 million, and (iv) higher personnel costs of $0.6 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses and negative cash flows from operations since inception. As of December 31, 2023, we had an accumulated deficit of $197.8 million and anticipate that we will continue to incur net losses for the foreseeable future. As of December 31, 2023, we had $34.3 million in cash, cash equivalents and short-term investments and no debt. We believe the balance of cash, cash equivalents and short-term investments may not be sufficient to fund our projected operating requirements and meet our obligations for at least the twelve months following the financial statement issuance date without entering into one or more collaborations or raising additional funding or making changes to our operating plans or programs to reduce expenses. As a result, there is substantial doubt about our ability to continue as a going concern for twelve months following the issuance date of the consolidated financial statements as of December 31, 2023. However, we believe that our cash, cash equivalents and short-term investments provide sufficient cash to fund our projected operating requirements into the first quarter of 2025. Our future capital requirements and the adequacy of available funds will depend on many factors, including those described in &#8220;Risk Factors&#8221;.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our net cash flow activity for each of the periods presented (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.054%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:13.754000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:13.754000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(32,164</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36,704</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">651</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26,498</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,068</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,579</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(30,445</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(53,623</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, net cash used in operating activities was $32.2 million, resulting from our net loss of $39.5 million, which was offset by net non-cash charges of $6.0 million primarily related to stock-based compensation and accretion of discounts on short-term investments. The net loss of $39.5 million was driven primarily by our ongoing clinical, preclinical and manufacturing development activities that were partially offset by grant revenue. In addition, there was a $1.3 million net change in operating assets and liabilities which primarily consisted of the following offsetting activities, a: (i) $2.6 million decrease in prepaid and other assets and operating lease liability, and (ii) $1.3 million decrease in accounts payable, accrued expenses and deferred compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, net cash used in operating activities used $36.7 million, resulting from our net loss of $44.2 million and changes in our operating assets and liabilities of $0.1 million, partially offset by net non-cash charges of $7.5 million related to stock-based compensation and lease expense. The net loss of $44.2 million was driven by our ongoing clinical development activities partially offset by grant revenue. The $0.1 million change in operating assets and liabilities primarily consisted of the following partially offsetting activities, a: (i) $2.3 million increase in prepaid and other assets and operating lease liability, and (iii) $2.2 million increase in accounts payable and accrued expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, net cash provided by investing activities was $0.7 million consisting of net maturities of available-for-sale securities. During the year ended December 31, 2022, net cash used in investing activities was $26.5 million consisting of net purchases of available-for-sale securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financing activities provided net cash of $1.1 million for year ended December 31, 2023, which consisted primarily of net proceeds from the issuance of shares of common stock under our at-the-market (ATM) equity offering program offset by shares repurchased for tax withholding obligations related to the vesting of restricted stock units.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financing activities provided net cash of $9.6 million for year ended December 31, 2022, which consisted primarily of net proceeds from the issuance of shares of common stock under the ATM program offset by shares repurchased for tax withholding obligations related to the vesting of restricted stock units.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating Capital Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that we will continue to incur losses for the foreseeable future, and we expect the losses to increase as we continue the research and development of, and seek regulatory approvals for, our product candidates and conduct additional research and development activities. Our product candidates have not yet achieved regulatory approval and we may not be successful in achieving commercialization of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our existing cash, cash equivalents and short-term investments may not be sufficient to fund our operations for a period of at least twelve months from the date of this report without entering into one or more collaborations or raising additional funding or making changes to our operating plans or programs to reduce expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional capital for the research and development of our product candidates, and we may be forced to seek additional funds sooner than expected to pursue our research and development activities. We expect to finance our capital requirements in the foreseeable future through a combination of the sale of public or private equity or debt securities, government</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">funding, or other sources, including potentially collaborations, licenses and other similar arrangements. There can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. Any of these events could significantly harm our business, operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional capital for the research and development of our product candidates, and we may be forced to seek additional funds sooner than expected to pursue our research and development activities. We expect to finance our capital requirements in the foreseeable future through a combination of the sale of public or private equity or debt securities, government funding, or other sources, including potentially collaborations, licenses and other similar arrangements. There can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. Any of these events could significantly harm our business, operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our forecast of the period of time through which our existing cash, cash equivalents, and short-term investments will be adequate to support our operations is a forward-looking statement and involves significant risks and uncertainties. We have based this forecast on assumptions that may prove to be wrong, and actual results could vary materially from our expectations, which may adversely affect our capital resources and liquidity. We could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the type, number, scope, progress, expansions, results, costs and timing of our clinical trials of our DAARI and ROR1 CAR T product candidates or additional indications of our current product candidates as well as other product candidates that we may choose to pursue in the future;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and capacity for CAR T development and lentivirus manufacturing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of seeking and obtaining worldwide regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with hiring additional personnel, CROs and consultants as our preclinical and clinical activities increase;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements, including milestone or other payments under our existing in-license agreements and any in-license agreements that we may enter into in the future; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs associated with any products or technologies that we may in-license or acquire; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities for, and the pricing and reimbursement of, any products for which we may receive regulatory approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot continue or expand our research and development operations, or otherwise capitalize on our business opportunities, because we lack sufficient capital, our business, operations, financial condition and prospects could be materially adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, we entered into an Open Market Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Sales Agreement) with Jefferies LLC, pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million. We have no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. During the year ended December 31, 2023, we sold 55,274 shares under the Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under current SEC regulations, if at any time our public float is less than $75.0 million, and for so long as our public float remains less than $75.0 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the baby shelf rules. As of December 31, 2023, our calculated public float was less than $75.0 million. In April 2021, our Form S-3 registration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">statement became effective. Future sales of our common stock, if any, will depend on a variety of factors including, but not limited to, the expected timing for achieving key milestones, including Initiating, completing and announcing results of clinical trials of our ROR1 CAR T and DAARI product candidates, prevailing market conditions, the trading price of our common stock and our capital needs. There can be no assurance that we will be successful in consummating future sales of our securities based on prevailing market conditions or in the quantities or at the prices that we deem appropriate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are party to a number of license agreements, pursuant to which we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under those agreements. As of December 31, 2023, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. See Notes 4 and 5 to our consolidated financial statements included elsewhere in this Annual Report for a description of these agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of the financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our estimates are based on our historical trends and other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. Certain service providers invoice us in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: (i) CROs and other third parties in connection with clinical studies and preclinical development activities; (ii) investigative sites in connection with clinical studies; and (iii) third parties related to product manufacturing, development and distribution of clinical supplies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ive Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statement_or_supplement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statement and O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ther Supplementary Information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Consolidated Financial Statements and supplementary data of Oncternal Therapeutics, Inc. required by this Item are described in Item 15 of this Annual Report and are presented beginning on page F-1.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="reportindependentregisteredpublicacc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders and Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego, California</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Going Concern Uncertainty</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses and negative cash flows from operations since inception. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Trial Accruals</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Notes 1 and 2 to the consolidated financial statements, the Company has recorded $2.0 million for accrued liabilities related to clinical trials as of December 31, 2023. The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued clinical trial liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We identified the estimation of clinical trial accruals as a critical audit matter. Significant judgment was required by management in estimating the progress of services and the associated costs incurred used to determine the accrued liabilities for clinical trial expenses. Auditing these elements involved especially challenging and subjective auditor judgment due to the nature and extent of auditor effort required to address the matter.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary procedures we performed to address this critical audit matter included:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reviewing the Company&#8217;s contractual agreements with certain third parties and applicable change orders to assess the impact to the amounts recorded. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Testing the completeness and accuracy of clinical trial accruals by comparing invoices for certain third parties received by the Company subsequent to December 31, 2023, to the amounts recognized by the Company as of that date.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Testing clinical trial accruals for completeness and accuracy by confirming amounts invoiced, services rendered, and payments received, directly with certain clinical research organizations, recalculating the expected accrual amounts and comparing to the recorded amounts.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da03a402-644c-4b72-b1aa-e5544cc3dca8" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BDO USA, P.C.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company's auditor since 2016.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dcf1647-373f-49c1-b298-d46d8897c705" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 7, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolida</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ted Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except par value)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.8%;"/>
    <td style="width:1.78%;"/>
    <td style="width:1%;"/>
    <td style="width:14.32%;"/>
    <td style="width:1%;"/>
    <td style="width:1.78%;"/>
    <td style="width:1%;"/>
    <td style="width:14.32%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d05e64d-6b13-4871-bdb6-c32b9d0be886" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a59b23a0-1f2d-486d-b457-3f3439cf17a4" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8a6697d-c2f7-4b70-ae51-9cffe44259b1" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,558</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e86252c0-5ec5-48ec-98e8-c27cded898fc" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,582</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e0a29b4-60cb-4e8b-85ed-8d4592abf0d6" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,804</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78af9f81-9fac-442c-81ae-a5951b8d5c30" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31965d95-0113-49f3-83c0-466468f5231c" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c887f52a-4825-4e50-939f-b668ea87fd99" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,290</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f32958c1-c193-4963-b50f-5f2c980182d6" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3">258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f341cb38-35ec-49d8-92e4-e087abbdfeab" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3">87</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9107ac4-027b-45bd-babb-0094be8d0bba" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b3a649c-0ed9-4484-93a7-c704e5a9299c" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,274</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe1db68b-dcff-44c2-a23f-502010594d18" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,729</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48914609-387b-4fc1-bfd7-ab8bb030325c" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,651</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a4c2748-6c4d-4a76-ac79-8da8dcf1e759" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84db9ae4-b12f-40e9-b46b-11fa7cfc440a" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,917</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_979ae2a2-ccc5-42cc-971d-5bbc87ce8103" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,877</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ce8ced8-5fda-4924-a003-ed4b1923a088" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,678</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease, current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4458b57a-bb62-41ef-adf0-c199cd54eac9" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3">173</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_003338e8-bbdb-4aaa-bad9-3d254b049029" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3">87</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bb9fbb1-3976-4054-b21a-be58cceb0b66" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e1da1e1-427a-47e0-af8f-4bba73e94af0" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9fbd97d-a8ea-4fae-8466-3aacdb2aa58a" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b5450af-20b1-4752-acbb-78d538593315" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease, net of current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf3fb3f8-4a2e-4a13-a4d0-b60e625cb254" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77411462-e7aa-4583-91f4-cbeb8dde1c98" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bc6c65f-f03e-4193-99c0-5559b0660c12" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecb3566f-593e-45ad-8a4f-a89a6af5780a" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_c51b8fcc-6943-4e4a-ba2d-2e171034ab9b;"><span style="-sec-ix-hidden:F_6a5f452d-b332-4939-a1c1-8e54f1e5256f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 4)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7d4cbe2-2bdf-42fc-b8eb-9e1511ba467b" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_ea5aba8e-1be2-4eb7-9098-2921d56a0e56" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, authorized shares &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e3fd3dc-5da4-4a70-a6a9-3d4dd0cd5e94" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8cf08ae3-1b4b-4fc5-8251-d2a2177f3de6" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">5,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;at<br/>&#160;&#160;&#160;December 31, 2023 and 2022; issued and outstanding<br/>&#160;&#160;&#160;shares &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_629bc0a9-f086-4dc1-8f4c-1321b988bcc6" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7525ef1e-e39a-49dc-9d29-38866e3fe1ae" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_885115c8-2bf7-47e5-80b2-483ea8c8ba60" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bc9af3e8-81d9-4a1f-b29f-a312bf24f4fe" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a70709f7-6038-43e1-aae2-7a00c5f54ace" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75f60bd2-c81a-4268-b8a4-875d57edc282" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3cdd683-ff47-43fb-8610-aff515210255" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_60a4e10d-b86f-4b33-ab0d-c21ce974f168" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; authorized shares &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eca027be-c8af-495a-9854-9320e165faae" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1b1bc9f9-1722-42de-aeff-647cf4b0f304" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">120,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>&#160;&#160;&#160;at December 31, 2023 and 2022; issued and outstanding<br/>&#160;&#160;&#160;shares &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95b89420-de2f-4568-bd45-73cfaca6e88c" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3f7f65e5-e0df-4e50-9fe4-a90546f76fe4" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,948</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edb007c4-9009-4b07-9be9-befe9ca6fb3b" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7c8d5ae0-869e-4f63-b218-4b57a4efded2" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,874</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;at December 31, 2023 and 2022, <br/>&#160;&#160;&#160;respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee933cbc-b95d-4505-9523-ee8d589ef804" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daa650d6-aef3-4386-b86b-ffa3568c43e6" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d44122d7-d11b-4d6f-92cb-0482fe6a3bbf" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,825</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44b64fff-1011-4edf-9cc9-b87d8566b5e5" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c809ec37-7e79-4f57-9dea-72777cdeb179" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dfc5a86-f0fa-4a8d-8610-9769f58df0c9" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ba1ab22-d522-4a65-84c8-8697714e6bfd" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">197,779</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ffd2c99-c9b7-49f5-bcb2-1f884ddf8a24" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">158,300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68a3ce19-3990-44d1-8f9d-fe9b5cdeccbe" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ebad1fd-5752-4f91-a022-e6f1f420db6c" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fad6f91-48d7-4cab-befb-6c699b875622" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,729</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb112e88-d154-420a-8745-b9f356d3cbf9" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,651</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(thousands, except per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.58%;"/>
    <td style="width:2.16%;"/>
    <td style="width:1%;"/>
    <td style="width:17.82%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:17.82%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_545bfd90-7ab1-4031-9271-88d166669256" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">785</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14e883a6-d555-474e-9449-61fd805996f3" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,490</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faf32110-ad7e-43b5-b636-eb9dde63dad2" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,753</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_411438ef-cdfd-4897-b363-699e5cec6635" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,980</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ca16fce-d20c-45b2-afb4-9b6a00d7e19a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f24750f-2992-4c0e-adf3-d291d91f1cfc" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,457</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dd1d7ba-3e8c-4862-95a6-802a1b2576f7" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8cf893f-b320-4406-bdc7-1ed8101b4fb7" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,437</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da8be38b-64e0-412d-afbd-01861c3ca6ca" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,714</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57b273b6-5289-4c2c-b9cb-78e9a0c0d2f4" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b15f2fa0-39c5-4662-9694-91778a30e3c4" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02a0c224-ff29-4833-855e-3cceaf3553c5" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7380cc02-1572-415f-b2f6-58e46cf76ebf" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,479</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ff6e934-2cee-4eb8-bb94-24916f24f4bf" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,170</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive income</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on available-for-sale securities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c973cf0f-0466-4128-98c9-07c659835e10" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1c632da-a128-49f5-932a-81d93a5e5038" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab0bbe16-7363-4f87-bd77-9362c9505d8d" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,485</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a446a116-3864-4984-b970-ef84d5860fb9" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7faf2d43-be14-4bb1-8871-6d81a64482b6" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_201d1c4f-a503-4168-816c-83e6b1f7c679" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">13.43</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98f1cc88-5b6c-407a-9189-f5f4e967afda" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_30158169-2d1a-47ea-b038-f0be182dcd6b" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">16.80</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ce3999f-73fb-48e3-83b9-679e56e57f2a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8bd17dea-9eaf-4d9d-90a7-804248542ef0" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,940</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e14fa655-a680-4197-be5a-a945c7868a5a" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ad634c8a-c86a-426a-a014-83416ca45001" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,630</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6956472-c16e-494e-ba5a-2129fea85ad2" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8559b416-0c57-4006-a4b2-bbe78ae0467d" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_549c6f3c-8365-4463-9190-6d6c15bcb264" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_baef4213-61ef-4165-9e5c-4b953cf503ca" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion of discounts on short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_851594e4-86ad-4e11-9878-02cf155e0543" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_642a576c-9279-48cf-8fe4-4ffe6083d60e" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncash lease expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35d9c405-0d35-4c4a-8124-ccdd21219dc4" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f4b7c29-4e35-4afc-a779-91d74bc2a80c" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="onct:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3">179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01d162b5-77c0-4953-ae7d-64c43f0efdb5" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,624</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a2144f9-6461-4c1d-b7a4-d45985f1e735" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3201021-28be-44c0-bed3-171acdde2f7b" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f71a8c-40bb-47a6-bb44-053570352b18" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">958</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d6d0acd-1dd6-48e5-987a-2d7ac55cdd1a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9b35030-7035-4bef-b06a-0a82c7ef1638" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d4577f5-4aae-4993-9813-15be7d2bde26" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncreaseDecreaseInDeferredCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff53fa80-a3f6-47ef-a96c-ad4110e20342" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncreaseDecreaseInDeferredCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d536f3d-1485-4fd8-b6ec-578db7b2a7c9" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38dc56d3-45d4-4e16-9094-046a1c03a899" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62c7281c-d149-40d2-9d0a-b7146b23692c" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,164</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13954250-b35c-44cc-81a8-27d3176158d5" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,704</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_128153ec-c1d5-4806-bbc5-04a427e16806" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50edae7d-fb22-4f20-8fdb-b11c27bf9855" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,498</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturities of available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f58c7f01-fe45-40ce-b505-6aa6bbd3203f" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41a45fc6-91c6-4ed0-a6cd-128b4a415ffc" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b266694-75d1-4e59-8ab2-f73caf06d369" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">651</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ec2e686-e4f0-4a05-bf5a-bbf0a825531d" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,498</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the issuance of common stock,<br/>&#160;&#160;&#160;net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df20756-6ef7-4ebf-adc0-1dac1c4d5b78" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f083bc8-71a3-4149-9438-448f6567d2d1" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,582</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchases of common stock for tax withholding obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72898f4c-404b-4439-af62-0d855541b428" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efa59dd0-2612-45d7-9671-5f28131a282f" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1865bba-4faa-457d-a3e1-adc9e3b10c7e" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,068</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74c41bf4-e556-43fa-ad03-206ea8424445" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,579</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cd8ee6f-1d1c-46f3-b2ae-91a1d418a8d3" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30,445</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae6d4b63-a6fd-430c-a5f9-7a1da756e17d" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_703a878a-7ae1-4cc3-bb41-a3aa91057d66" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_789defe3-510e-4aa2-b3e5-dc63db9ee5df" contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f81ebeb-1957-4496-adac-328e65ed1483" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1902cfcd-1854-4bf0-a0ea-e9386ebc0932" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of non-cash investing and financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets obtained in exchange for operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3695b07-a8a4-4a4d-afec-dd34e60f009a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b223f3f2-45fa-4ea4-aa4a-5258c82ef0df" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.52%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:8.247%;"/>
    <td style="width:1%;"/>
    <td style="width:1.061%;"/>
    <td style="width:1%;"/>
    <td style="width:7.7669999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1.061%;"/>
    <td style="width:1%;"/>
    <td style="width:7.7669999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1.161%;"/>
    <td style="width:1%;"/>
    <td style="width:7.7669999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1.061%;"/>
    <td style="width:1%;"/>
    <td style="width:7.7669999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1.061%;"/>
    <td style="width:1%;"/>
    <td style="width:7.7669999999999995%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive Income</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_278bbafa-78fe-426e-841e-83e2d81f4ff7" contextRef="C_b28e1922-05f1-4509-a2c3-99e3ae9adb2f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">2,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fbef201-9e5f-4338-aaf8-4f43017f1ba3" contextRef="C_b28e1922-05f1-4509-a2c3-99e3ae9adb2f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26158b6f-1249-4203-b3ff-43e9d93358cd" contextRef="C_a954e431-fdf8-4bae-8667-e303c67e3782" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,248</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cfd7676-a20b-40c3-b58f-9463f4268b9b" contextRef="C_098930be-5884-474e-975f-9a2650ccb706" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114,130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_214ec329-df50-4820-8ef5-a2fb5c3e5da7" contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,120</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of issuance cost of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c017e56b-170f-4dc3-b36e-25ea2fda7fa5" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bf82836-c3c2-41a4-bb21-76b7f134c873" contextRef="C_cfadbdac-a035-479c-8d33-fb8090124ed6" name="onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82ccf4a8-ba0f-482a-9b9a-3aa0da4f6c08" contextRef="C_cfadbdac-a035-479c-8d33-fb8090124ed6" name="onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1f3e58-629c-4249-86de-2b05457a4d35" contextRef="C_d80acc3e-af09-4afd-b5cf-5196b734c37c" name="onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,581</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6b42eb2-2963-4619-b18b-2ef70c204566" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,582</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares repurchased for settlement of minimum statutory tax withholdings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79344d83-a309-4623-921f-351fb8ce39c6" contextRef="C_d80acc3e-af09-4afd-b5cf-5196b734c37c" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86f96b0a-8fb9-4620-a973-775319c0c347" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_124bb71e-93d1-4817-953e-13e99f0a627f" contextRef="C_d80acc3e-af09-4afd-b5cf-5196b734c37c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_458f17ed-1617-47b7-a984-28a4a6e111df" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5604f27c-3e64-491c-b62c-73523b420443" contextRef="C_2fc5f62a-291e-46d8-9a20-5a29e0475095" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f95ebb5-7111-49d1-871d-27e6346b481e" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93e33bbc-33a3-45b2-946e-b8e7b7773720" contextRef="C_bf9fff34-6f4a-4470-8d7d-50c7f427439f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcf922ce-aa3a-4010-b45e-bb65d7cf9d47" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_822fa259-8ca0-4ed4-9448-0fad234eea08" contextRef="C_f73bd1b2-ebe8-43b0-9837-980ac35e9116" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">2,874</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e3ff626-f6ac-42b2-8304-3305137bc4a3" contextRef="C_f73bd1b2-ebe8-43b0-9837-980ac35e9116" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd3d8b58-5783-4d85-ba18-4bd1fe88afb2" contextRef="C_bb2712dc-866f-414f-a8f2-3c9dde12d934" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8052cbf1-74d7-4968-9285-4d60b9fc8c9c" contextRef="C_d4d11d3c-bc06-418b-a44d-1f7e43dc53ca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7f47c6e-b33f-475e-b83f-b42bc5986db8" contextRef="C_8e7e0a37-b10a-43a8-b067-4e1f34e10da0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">158,300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6bb20a4-0138-4ef9-9d58-f90ceacef909" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of issuance cost of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09685ad2-c995-4000-9604-cbf142680c26" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8efb8a4c-a2e1-4025-b052-6f68ff0d579d" contextRef="C_86f3153e-89c6-4d7e-ae5d-a42564364970" name="onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2d526e7-ab4a-41e0-bce1-1e961bd74fda" contextRef="C_f27580a4-262d-49d1-b2c6-fb20b05f065f" name="onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25b819b3-6fd5-4540-abca-f682b3988aab" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15937d6e-428d-48ef-ada6-9d4361a3bb2f" contextRef="C_86f3153e-89c6-4d7e-ae5d-a42564364970" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares repurchased for settlement of minimum statutory tax withholdings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5df447ce-aa17-487e-9755-626748572de6" contextRef="C_86f3153e-89c6-4d7e-ae5d-a42564364970" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69e6840b-4cb4-4e10-82b9-5049e5b7645e" contextRef="C_f27580a4-262d-49d1-b2c6-fb20b05f065f" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c9ab630-b81e-4178-b6f4-cac762e274c9" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3ade514-9342-4d6a-a235-7440a9020edb" contextRef="C_f27580a4-262d-49d1-b2c6-fb20b05f065f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b244eaf-6f5b-4214-b382-b791951b9084" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dd3adfd-81ed-4372-8bdf-485e6eedfd86" contextRef="C_2eeadccf-0f17-4175-823b-dbcd8f8dac1a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1410ce7-fb70-4f5e-a903-9dd55a46ab27" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1c44ded-9813-4eb2-8c9f-ea2b59b0f4d1" contextRef="C_4d7bbaa5-7054-4572-8d82-9320f96f8511" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ecb19b1-f04f-4a3e-b477-669554c0cfbc" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a55535e2-7be7-44f9-bcd5-11c937e97753" contextRef="C_83e4c228-480e-409e-8176-6d50e59820db" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">2,948</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_098a75bf-2e45-492a-bbc4-fd763f8576e2" contextRef="C_83e4c228-480e-409e-8176-6d50e59820db" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_062d2721-202d-4842-9bb6-939f2e4f34cb" contextRef="C_62fa3949-0347-4273-b069-49f2fd0e5194" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,825</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3651eee4-837e-43d2-9f4a-ae2b46375cbe" contextRef="C_a3d6b78d-a32d-49a2-80f4-722dd0cb10ca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_549c4ac7-8a96-4715-bce5-3c3bd3924bce" contextRef="C_30d36d96-6cac-47d1-9709-bc013ca4bfac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">197,779</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_749ef4a1-3aab-4438-90b6-0b187a7bbbda" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_consolidated_financia"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolid</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ated Financial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f25df9fe-384d-460b-9058-c2876b21c07a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Oncternal,&#8221; or the &#8220;combined company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers and ONCT-808, a CAR T (chimeric antigen receptor T-cells) product candidate that targets ROR1, and zilovertamab, a humanized monoclonal antibody that binds to ROR1. Oncternal&#8217;s program activities previously included ONCT-216, an investigational small molecule designed to inhibit the E26 Transformation Specific (&#8220;ETS&#8221;) family of oncoproteins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17e5a266-615a-49f1-acd4-f6cc8ce53745" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6f77880-d7ff-4592-ae58-76cb85597d20" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:GoingConcernPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e81be9e1-d179-43d6-9298-0403c77d7ed3" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, cash equivalents, and short-term investments, no debt and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e9f7a0b-1ec3-4d61-b268-a3f6d796977a" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">197.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. From its inception, the Company has incurred recurring operating losses and negative cash flows from operations. The Company has concluded that the balance of cash, cash equivalents and short-term investments will not be sufficient to fund its planned expenditures and meet its obligations for the twelve months following the financial statement issuance date without raising additional funding or making changes to its operating plans or programs to reduce expenses. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for twelve months following the issuance date of these consolidated financial statements. The consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">          </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of its pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had capacity to issue up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58baebb7-bbf2-4d97-9e9b-4e923dada47d" contextRef="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock under its at-the-market (&#8220;ATM&#8221;) equity offering program. Through December 31, 2023, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1b7cf3d-04f6-4ebb-bacd-94071ed7a151" contextRef="C_cbe31993-74d8-4712-92b5-682ceee9fb09" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">457,342</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a612739-1e93-43aa-8dbc-fea090f49bcb" contextRef="C_cbe31993-74d8-4712-92b5-682ceee9fb09" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the ATM program. There can be no assurance that the Company will be able to sell any additional shares of its common stock under the ATM program and no assurance regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM program may be at prices that result in additional dilution to existing stockholders of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9649b97-c14c-471a-adc0-636951129ed4" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:NasdaqListingAndReverseStockSplitPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq Listing and Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2023, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that because the closing bid price for the Company&#8217;s common stock had closed below $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff39426b-1160-4699-b635-ca1a79d95b0c" contextRef="C_24db6605-9fb8-4748-a200-1daa7520b56f" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Requirement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 8, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6befb006-e366-4d35-9f39-6fdddfadc6d6" contextRef="C_dd4a10dd-2b20-4eb7-a455-5be36a531fe8" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company regained compliance with the Nasdaq listing rules. Each of the Company&#8217;s shareholders received one new share of common stock for every 20 shares such shareholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#8217;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock was not adjusted as a result of the Reverse Stock Split. The Reverse Split also affected the Company&#8217;s outstanding common stock options and warrants, and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data, common stock options and warrants included in these consolidated financial statements, including the exercise price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_716a8897-3fa4-4611-85c4-2319e022cd25" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of accruals for research and development costs. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c7eb4e5-7dab-4018-8e6e-e0c257789246" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist of Level 1 financial instruments in the fair value hierarchy (see Note 6 &#8211; Fair Value) and include cash in readily available checking accounts, money market accounts and commercial paper.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7d24eda-dfa0-4ab3-9e7b-3fa28ca1d9bf" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consist of U.S. treasury notes and bills, certificates of deposit, commercial paper and U.S. government sponsored enterprise securities with maturities of less than one year from the balance sheet date and are debt securities considered to be Level 1 and Level 2 financial instruments in the fair value hierarchy (see Note 6 &#8211; Fair Value).  The Company determines the appropriate classification of marketable securities at the time of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">purchase and reevaluates such designation at each balance sheet date.  The Company has classified all of its marketable securities at December 31, 2023 and 2022 as &#8220;available-for-sale&#8221; pursuant to ASC 320 Investments &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company records available-for-sale securities at fair value as determined by prices for identical or similar securities, with the unrealized gains and losses included as a separate component of other accumulated comprehensive income (loss).  In accordance with policy, the Company does not invest in or hold equity securities in its investment portfolio.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adjusts the cost of available-for-sale debt securities for amortization of premiums or accretion of discounts to maturity.  The Company includes interest and dividends on securities classified as available-for-sale in interest income.  Such amortization and accretion are included in interest income.  The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realized gains or losses on available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company records unrealized gains and losses on available-for-sale marketable securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders&#8217; equity on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in short-term investments in the accompanying consolidated balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which the Company determines the accrued interest will not be collected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates short-term investments for other-than-temporary impairment at the balance sheet date.  Factors considered in determining whether a loss is other-than temporary include how significant the decline in value is as a percentage of the original cost, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company&#8217;s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized loss positions until their amortized cost basis has been recovered.  As of December 31, 2023 and 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1180fe21-ceef-46d2-9798-ae6e0686b9d8" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f012fb60-3672-4f3b-a305-8a6d187542ae" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment charges on short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company obtains the fair value of its available-for-sale marketable securities from a professional pricing service. The fair values of available-for-sale marketable securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank. The service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service or mathematical calculations. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, credit spreads, current market and contractual prices for the underlying instruments or debt, as well as other relevant economic measures.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_474fe9a4-5689-4ff2-9961-c6e26de7820a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred compensation represents the accrual of retention bonuses for certain executives and certain other members of senior management.  The retention bonuses were entered into in connection with the waiver of annual cash performance bonuses of such personnel for the year ended December 31, 2023 and a temporary reduction of the chief executive officer&#8217;s salary from April 2023 through December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf91c41a-e1d7-49d9-aed3-606bdee0a988" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:ConcentrationRiskCreditRiskPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dcf2787-6f39-4ae0-a09c-421008e89bf4" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:PatentCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_115fb645-b971-4515-8fbd-3696f1ae9e81" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, which include clinical trial accruals, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae1ed852-f00d-4ece-a2bf-b6ed4c80efb1" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as an exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop its own assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, and accrued compensation. The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has short-term investments that are measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented (see Note 6).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36ab95ef-3e2b-4b93-b8c8-157ac7b81ae8" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue from certain grant awards or a research subaward (the &#8220;Grant Awards&#8221;) (see Note 5), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_073b6acc-fcd6-4181-b4d1-b919d5bb8d25" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e930ad23-b5de-4128-aa3b-404d1fbe3f5b" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36c1b999-5311-47ae-babb-58ee7edc3142" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1bbf1e5-9952-41d4-978e-48446f4373f9" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment in the United States.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e6690c1-7b30-4eb1-93d1-0cc2c1f405cb" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4832dc7-e5eb-4619-9e05-53167578e779" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:52.33%;"/>
          <td style="width:1.88%;"/>
          <td style="width:1%;"/>
          <td style="width:19.956%;"/>
          <td style="width:1%;"/>
          <td style="width:1.88%;"/>
          <td style="width:1%;"/>
          <td style="width:19.956%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16927502-aa83-4c25-a8af-cc7f64e65a57" contextRef="C_f23d092f-edc0-4d76-893a-ca1ffe860492" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">170,521</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c86e5240-4a83-4e88-8ee2-753aab403833" contextRef="C_f742e918-e6dc-4348-81a6-2801923bd3ec" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">170,521</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6de7473-fbe8-4eeb-92df-fdcc49a7e22e" contextRef="C_ebd6887c-a70a-4f63-862c-61c7842c1226" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">548,073</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7317b883-af5b-4ca6-982b-d15c65f6cfe6" contextRef="C_a7fcd6fe-26a1-4370-be58-59d9b95517db" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">425,785</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dad2efc-1529-450d-9878-6defde821ca2" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,557</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81cf4598-0565-41d3-81d9-d6a7c8bcbf1a" contextRef="C_5b521705-9521-4715-a360-b03c0afb492c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,454</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae9d5a26-85dc-440c-b797-7211f0988d93" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">737,151</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3b1d5a0-574d-44a5-a047-e4a7c1b2be91" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">646,760</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_993cedb7-618c-4e32-8413-99aadd3bba36" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Statements (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net loss. This update is effective for the Company and was adopted on January 1, 2023, which did not have a material impact on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Standards Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting &#8211; Improvements to Reportable Segment Disclosures (Topic 280), which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. Topic 280 includes amendments which a) introduce a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker&#8239;(CODM), b) extend &#8239;certain annual disclosures to interim periods, c) clarify single reportable segment entities must apply ASC 280 in its entirety, d) permit more than one measure of segment profit or loss to be reported under certain conditions, and e) require disclosure of the title and position of the CODM.  This update is effective for all public entities beginning after December 15, 2023. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Tax &#8211; Improvements to Income Tax Disclosures, which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. The standard requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This update is effective for all public entities beginning after December 15, 2024. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bb4c7c9-50df-4e61-bc2c-c5f18ccf28ed" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance Sheet Details</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e803ee86-030c-4c42-9262-fb24f04f659c" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:ScheduleOfAccountsPrepaidAndOtherTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid and other consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.429%;"/>
        <td style="width:2.681%;"/>
        <td style="width:1%;"/>
        <td style="width:22.605%;"/>
        <td style="width:1%;"/>
        <td style="width:2.681%;"/>
        <td style="width:1%;"/>
        <td style="width:22.605%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30bbed3e-eff4-4dcf-b145-6674072d7a02" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:PrepaidResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_975348be-23f9-4cbd-8628-d8ebe3c4dffa" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:PrepaidResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb211e2a-3442-4b3c-97cf-2aa00c022cb6" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:PrepaidClinicalTrialsExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54ee9359-3bbc-4c17-af85-ee8771ea46e3" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:PrepaidClinicalTrialsExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,616</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac1a39b1-716a-4237-8ab5-d925272f9b2e" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e80aec49-02ee-4045-a60c-7202d7d45890" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">669</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fda8f267-8fa7-4d29-aaeb-38c6d20b3fa4" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_072d2b41-2b1b-4879-8399-b3f6856508c7" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party receivable (see Note 4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74019477-af8e-4816-9f7f-50c5b89064e6" contextRef="C_64618a52-3613-4a92-9d8a-011deabe6e3d" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77319c26-fc69-4dbb-8609-3385fbddba41" contextRef="C_c7417c2f-59d7-47f2-b82f-869b45d68de1" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant and other receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5b98335-7d95-49dd-a69a-30fc8b881a96" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:OtherReceivablesNetCurrentIncludingGrant" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e05e34fd-7ed2-4840-af19-cee4a6c5fe57" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:OtherReceivablesNetCurrentIncludingGrant" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bf13fe1-194c-4084-8d1e-b81a929c04de" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,804</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f517a29-200b-40c6-9727-4ab04ca82303" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,566</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ae633e0-2675-4708-a8e7-fcb6861efc99" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.991%;"/>
        <td style="width:2.959%;"/>
        <td style="width:1%;"/>
        <td style="width:22.415999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.719%;"/>
        <td style="width:1%;"/>
        <td style="width:22.915%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45c82ae7-924a-4a6b-b9f5-d71200b9d92c" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3359a919-b985-4f8d-90b9-d3a1d07a8382" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6799252-65b1-498a-8853-aba20d29be0c" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:AccruedClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,018</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_732d8c34-3376-4382-8b92-e88cbbea18c3" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:AccruedClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">868</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legal fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba46fed7-5e70-43ab-9d78-f1e4ebf82dc7" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15cd343f-47df-4ad7-a6ac-4e8b9b86bdbf" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fed1302a-5d6a-4494-ad34-8dbaf5706787" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,579</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d9da905-4c03-4db6-8549-d4c54556a7bb" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,691</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7904746f-4239-4ef1-b7fb-1d37eb9e19a6" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e29fe43-eb13-4196-ac5a-db6ed9fe1974" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9be47a57-8421-4e0f-b5b6-012f720205d4" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,877</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0f7247a-f828-47a9-9742-fc3197be2c3c" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,678</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99451c80-980f-44ec-9f18-7486a32b2fdc" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term Investments</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests in available-for-sale marketable securities consisting of money market funds, commercial paper, certificates of deposit, U.S. Treasury securities and U.S. government sponsored enterprise securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available-for-sale marketable securities with original maturities of more than three months from the date of purchase as of December 31, 2023 have been classified as short-term investments and are measured at a fair value on a recurring basis, and were as follows (in thousands):</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_61d78e6c-756c-49d0-a6ec-673f0a69495a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true" continuedAt="F_61d78e6c-756c-49d0-a6ec-673f0a69495a_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.606%;"/>
        <td style="width:2.08%;"/>
        <td style="width:14.743%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:9.862%;"/>
        <td style="width:1%;"/>
        <td style="width:1.92%;"/>
        <td style="width:1%;"/>
        <td style="width:7.942%;"/>
        <td style="width:1%;"/>
        <td style="width:2.4%;"/>
        <td style="width:1%;"/>
        <td style="width:7.461%;"/>
        <td style="width:1%;"/>
        <td style="width:2.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.502%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">Maturity (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4045e83e-e145-4916-ac12-279bb44f5b92" contextRef="C_adabef98-d9b7-4120-a5c5-cb803bd266ce" name="onct:MaturitySecuritiesDebtMaturitiesPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e541fabc-9ad4-468f-a9e1-f50a02452091" contextRef="C_c6b88d8c-42b2-44bd-afc8-e948c76c63df" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,840</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75155b16-1128-4907-844d-ce38e4dd946f" contextRef="C_cf6a6ea3-bfb5-4119-956f-554febc07729" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e05d370f-619a-42c6-908e-3f288b4a7368" contextRef="C_cf6a6ea3-bfb5-4119-956f-554febc07729" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd7e463e-d600-4f47-97b1-c1a28857e7fd" contextRef="C_c6b88d8c-42b2-44bd-afc8-e948c76c63df" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,844</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0465659e-7512-49b9-97f9-d4e12304f84c" contextRef="C_3fb8e0da-acaa-47c5-a6c1-2e4c104b6914" name="onct:MaturitySecuritiesDebtMaturitiesPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ada8cdee-9e0a-443a-91af-94a88043f8f3" contextRef="C_c7403617-2bd9-4378-8e28-1026eb094276" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,738</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff29fa2b-4360-4f7f-a955-3e5e0c789684" contextRef="C_80c0e7a1-8307-44d0-921c-0a9be8697b02" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf905912-97a3-492f-9a6d-e3e9fddb1a3b" contextRef="C_80c0e7a1-8307-44d0-921c-0a9be8697b02" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e864e2e-d460-4183-8e64-86dc6acdccf8" contextRef="C_c7403617-2bd9-4378-8e28-1026eb094276" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_27080be1-9d5a-4144-b1f5-b12dc4215d5a" contextRef="C_dc68c081-7397-41f0-9a80-0bb2d48bf304" name="onct:MaturitySecuritiesDebtMaturitiesPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9efce03-a2f8-4534-8faa-bbb0d8109eee" contextRef="C_2ee21224-3ff5-40c8-8d3b-f3bc87c0f528" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bd301a8-1215-494d-a3d1-6123c5567c07" contextRef="C_ac63083b-0e54-4d72-845f-1395615d3acc" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_946ddb81-2e5d-4902-ab30-e8226d08ba7f" contextRef="C_ac63083b-0e54-4d72-845f-1395615d3acc" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_598d00b9-c88f-47c1-ba06-252fa3153808" contextRef="C_2ee21224-3ff5-40c8-8d3b-f3bc87c0f528" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c5b46b9-7b6b-4df3-9675-a3fe5bf08235" contextRef="C_8bff7594-8784-4e75-992e-1abf18d3a26a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,555</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c20fc62e-9316-4141-843f-ef42a6536dff" contextRef="C_18a29548-1851-4d54-88f2-fd40d4620a4f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16169e00-39b1-4ed1-b097-9f8bb51ede0b" contextRef="C_18a29548-1851-4d54-88f2-fd40d4620a4f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07aa9719-7467-4112-aa29-4f035892b445" contextRef="C_8bff7594-8784-4e75-992e-1abf18d3a26a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available-for-sale marketable securities with original maturities of more than three months from the date of purchase as of December 31, 2022 have been classified as short-term investments and are measured at a fair value on a recurring basis, and were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_61d78e6c-756c-49d0-a6ec-673f0a69495a_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.606%;"/>
        <td style="width:2.08%;"/>
        <td style="width:14.743%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:9.862%;"/>
        <td style="width:1%;"/>
        <td style="width:1.92%;"/>
        <td style="width:1%;"/>
        <td style="width:7.942%;"/>
        <td style="width:1%;"/>
        <td style="width:2.4%;"/>
        <td style="width:1%;"/>
        <td style="width:7.461%;"/>
        <td style="width:1%;"/>
        <td style="width:2.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.502%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_72dd7453-9f8b-4766-86d6-a2174e794661" contextRef="C_7969de4f-8469-45fc-82de-c6f6103bd889" name="onct:MaturitySecuritiesDebtMaturitiesPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c914e28a-a5e7-41cc-8a0a-0df97418664e" contextRef="C_3a6930d4-f451-44ee-affa-37ae8d65ee2b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,681</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afba6d6d-4395-4505-87de-7877f051fb7a" contextRef="C_075d13c8-bda5-4ad2-bc71-30df6eefa0e7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45cd6caf-d580-44b0-8019-01a3057b38f1" contextRef="C_075d13c8-bda5-4ad2-bc71-30df6eefa0e7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed6febc3-c0e7-433b-b5f6-3a1e0c962a49" contextRef="C_3a6930d4-f451-44ee-affa-37ae8d65ee2b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_6690a836-45c9-4beb-921d-ec0a497dc2e0" contextRef="C_f873de6c-929f-4ec4-8634-115ea3443d28" name="onct:MaturitySecuritiesDebtMaturitiesPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c24961b-3c0f-427d-8e95-6103c564245b" contextRef="C_c3f1feeb-4862-4bb4-888b-eed88eeb8df2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ee1e1737-1e34-4355-a0d8-679b3a702be0;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d047d197-df26-4f47-b9d6-c2ba6a57762f" contextRef="C_eaf7c44c-5611-4b86-8805-7a0f392d4123" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d0e5a5d-1ca4-4dda-82f0-eb7c7ef5edca" contextRef="C_c3f1feeb-4862-4bb4-888b-eed88eeb8df2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_966c1dad-a698-4861-93ec-c9d488f3fae2" contextRef="C_467dc9e5-7495-40f7-ab23-9880e9cfc171" name="onct:MaturitySecuritiesDebtMaturitiesPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26a2ed1c-d163-4278-ae73-dc97cd2d8c57" contextRef="C_10b44321-be1f-47e8-a18e-447594cad864" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,956</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db24a623-6f6f-4492-b8e8-175f779c8b78" contextRef="C_9bd0a19a-3bcb-4dee-819e-826450508497" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8602ceab-25fc-4d72-a93c-15eb007ea4ca" contextRef="C_9bd0a19a-3bcb-4dee-819e-826450508497" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2de642ee-cadd-4590-9293-6342a9d2a9db" contextRef="C_10b44321-be1f-47e8-a18e-447594cad864" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,958</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0677993-412c-459b-b497-ff92b4ecf87a" contextRef="C_08168037-6b24-4204-95ca-d790554ec7eb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,573</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f072160-f111-410b-986f-1665af963529" contextRef="C_42761111-9f62-4a8d-88a7-53d404e3f90e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e6c8a38-445f-45f5-93ed-657a976314ad" contextRef="C_42761111-9f62-4a8d-88a7-53d404e3f90e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f06a1eaf-3168-4735-b1a4-bf4a03451dc2" contextRef="C_08168037-6b24-4204-95ca-d790554ec7eb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined there were no other-than-temporary declines in the value of any available-for-sale securities as of December 31, 2023. All the Company&#8217;s available-for-sale marketable securities mature within one year. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7068e389-dbb1-4fd2-b1a1-ecfa2021de8c" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cdd6c390-783a-4b20-9651-873f983629d7" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for credit losses as of December 31, 2023 and 2022. During the years ended December 31, 2023, and 2022, the Company recognized an unrealized loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc767e40-5bbf-457f-8683-0aeb4f624bc7" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an unrealized gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f42ed21b-75da-4d7e-9a7e-81d245dc957c" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in the accompanying consolidated statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0942af95-94b2-4cac-8c0c-f1444938ea88;"><span style="-sec-ix-hidden:F_cdb93c50-11db-48e2-b68f-a8c32248923f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest receivable</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on available-for-sale securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c12d718-8ad4-493a-86d2-827850cdfd33" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c83a075d-266c-47a1-8e61-3d622e0c356d" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">116,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at December 31, 2023 and 2022, respectively. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e18033b5-fd88-4312-bc4d-8fa0f5989ede" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7df48caa-f383-42b2-854b-3f3be5a58b4a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t written off any accrued interest receivable in any of the periods presented in these consolidated financial statements.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7f6012f-4a2b-43ef-bc84-d15fdab40767" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments, Contingencies and Related Party Transactions</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6570b602-1aa5-4a2c-8347-494ba1c76a77" contextRef="C_cfcce48d-55f4-42fa-bc8b-242ea98fde12" name="onct:RentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b535d4bf-ecd5-4e7e-953b-e41ec2d72f70" contextRef="C_c9b0328c-d0e2-4383-b5a2-733916d1b3cc" name="onct:RentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022. From May 2019 through April 2022, the Company leased office space in San Diego, California. In April 2022, the Company entered into a sublease agreement for office space in San Diego, California which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cb4bed05-8324-4d04-8ccd-d2135d259695;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;San Diego Lease&#8221;). In May 2023, the Company entered into a lease agreement for the same office space which expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22190ddd-b8a9-433a-aaed-da0a553dec77" contextRef="C_721f94da-46a0-4238-a04c-81022ac3098d" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Base rent under such lease is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a66e31a7-0cc9-473b-8169-3fa0b6ef8d12" contextRef="C_721f94da-46a0-4238-a04c-81022ac3098d" name="onct:AnnualBaseRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> annually and the monthly rent expense will be recognized on a straight-line basis over the effective term of the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25131c30-3517-495a-9ea3-1ee475b6317d" contextRef="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. As of December 31, 2023, the Company has recognized a net operating lease right-of-use asset and a lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef47170b-7e43-4e4b-b4d2-e1ac771b21ca" contextRef="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that matures in September 2025, which has a weighted average remaining lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cc521f2-cd99-4113-8e8c-145f9d1ba67b" contextRef="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. As of December 31, 2022, the Company&#8217;s lease had a weighted average remaining lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d278b212-3836-497c-96e4-5e7a60858114" contextRef="C_7f9b6b80-f252-4916-a2f7-309b047bf50e" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23ed6bf0-0aa0-4aeb-9fc5-9a2cec46ff28" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.52%;"/>
        <td style="width:3.78%;"/>
        <td style="width:1%;"/>
        <td style="width:32.7%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_018827ca-da6b-43af-b1d7-73b87365ac18" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00c768d8-295e-4c01-aede-6f2fb12eb85d" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bea46202-99bf-4b7b-8def-6c1adb7a8241" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1c359a6-9a66-40cb-935f-9c23494074bc" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69098570-f09c-4392-8631-ed5334358e0f" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">318</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90e60ae7-644b-4f9a-8cbb-402617daa988" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, long-term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_523ed84a-ecf3-49e2-b778-48e7497e2024" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;) entered into a Materials Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During 2023, the Company sold $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79624140-1fbd-47f8-82c1-3e6fb3218185" contextRef="C_caa34144-abe4-4bd3-99a2-59f166c310aa" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of materials to SPH USA which was recorded as an offset to ONCT-216 operating expenses. As of December 31, 2023 and 2022, the Company had amounts receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20fee4c9-31a1-41ab-a362-c1ce801f86ef" contextRef="C_a20da3ab-11b5-4858-a9c2-a02c8c66bf0b" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c89a11db-473b-47e6-88ed-72e8bff2a818" contextRef="C_22cf68f2-c77f-4eed-9ca5-da8ef5c46854" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, from SPH USA related to license agreement. SPH USA is the Company&#8217;s largest stockholder and an affiliate of one of the Company&#8217;s directors.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6a016a9-acb0-43c6-91a8-d847c7c52c3a" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License, Collaboration, Grants, Research Subaward and CVR Agreements</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2015, and as amended and restated in March 2022 and August 2022, the Company and UTRF entered into a license agreement (the &#8220;DAARI License Agreement&#8221;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader technologies owned or controlled by UTRF, including all improvements thereto, which is now known as the dual action androgen receptor inhibitor, or DAARI program. Under the DAARI License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the DAARI program to advance one or more lead compounds into clinical development.  The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expenses under this agreement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ba877d4-5f38-41b1-a62d-1e9b3cb06102" contextRef="C_c896d669-13f7-473c-89c3-89994dcf773a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cbbb665-43f2-45f7-8240-9e0624694f6e" contextRef="C_aaaac3ff-7e7c-4e08-9dcf-37c2593ea85b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2016, and as amended and restated in August 2018, and as amended thereafter through January 2024, the Company entered into a license agreement (as amended and restated, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee61fd26-321d-4096-85d2-c4b9878f83f1" contextRef="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0" name="onct:UpfrontLicenseFeesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was paid and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8405d5c8-315d-46d2-aaa3-ec6ad1c3c2eb" contextRef="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,355</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued, (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ad505bb-749a-43f4-a00f-356d96c8a39f" contextRef="C_e681e21e-1bbb-4c53-855b-c79b986ff160" name="onct:AnnualLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain annual patent costs, (iv) certain development and regulatory milestones aggregating from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff05691-5a04-4c29-a45a-ee477507c3be" contextRef="C_124609d2-2d46-4cef-af3e-ff9ad6a610d3" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77dab53a-2fe1-4f15-9df0-2bbfcc4974fe" contextRef="C_3c0da6fd-d05b-4a5b-92ed-45a0294999a0" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_594b9f87-ef4f-40d2-a5d7-a722c13a718d" contextRef="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0" name="onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f924d9b-2160-48df-9c73-b09978be075d" contextRef="C_124609d2-2d46-4cef-af3e-ff9ad6a610d3" name="onct:AdvanceLicensedAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a41bfc9-28c8-420d-8a83-228b51785b64" contextRef="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_784839bd-aca2-4264-8f63-f3d531aef142" contextRef="C_84d1bde4-f42c-44ac-a1d9-1e1ecae3e8c8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in license maintenance fees as research and development expense for each of the years ended December 31, 2023 and 2022, and (ii) approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0858667-8ee3-46f3-99cf-4cc1c297bedc" contextRef="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_22c4f78b-9cdc-4116-b99a-41d290ec784d" contextRef="C_84d1bde4-f42c-44ac-a1d9-1e1ecae3e8c8" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in patent costs as general and administrative expense for each of the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> anniversary of the first commercial sale of a licensed product. The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. The Company may terminate the agreement at any time upon at least </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca9cdd63-418c-47e2-b925-76e400ec25e6" contextRef="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2" name="onct:NumberOfDaysInWrittenNoticeOfTermination" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; written notice.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_989f22dd-f0f9-402a-bbde-021ff40d4fa8" contextRef="C_cd959724-6c14-44e2-acc1-de40c1c6b60a" name="onct:ResearchAgreementTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> agreement that expires on December 31, 2025, the Regents will receive payments aggregating $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a76dad2b-18e9-4ee9-94d9-af0da4d0df8b" contextRef="C_cd959724-6c14-44e2-acc1-de40c1c6b60a" name="onct:ResearchAgreementResearchFundingAmountReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with quarterly payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ec82cba-3e99-4b1b-a740-a1a70fa6138f" contextRef="C_cd959724-6c14-44e2-acc1-de40c1c6b60a" name="onct:ResearchAgreementResearchFundingAmountPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61f2ce6f-9e40-4dd8-8c31-c6d290de1fd6" contextRef="C_fddd24a2-50cf-4852-b216-6ce6bed4bb65" name="onct:ResearchAgreementResearchFundingAmountPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">131,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2023, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e31636cd-27bf-4137-b5ea-443b78127e62" contextRef="C_1fbc6ca3-a3dc-4149-94d7-cb8b93ecb98d" name="onct:ResearchAgreementResearchFundingAmountPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e9a9867b-0f7c-4251-a93e-a15c92b35335" contextRef="C_23c75ad6-c16c-4b5c-a758-b8db79ffc925" name="onct:ResearchAgreementResearchFundingAmountPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">137,813</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2024 and 2025. The Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd27afb9-bad5-44a7-945f-24fd75cf4e9d" contextRef="C_0ec0d6a2-b31e-4889-b743-4923e7241cd7" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b91d5524-3183-4e4f-9790-3e1600eaebdd" contextRef="C_a4cb10c4-5548-41a5-bded-833419a5f7c4" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development expense under this agreement in each of the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Award</span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">            </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2017, and as amended and restated in December 2020, CIRM awarded an $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7213ba5-85ae-4ac3-ab92-a241b904028b" contextRef="C_a773db65-a5e7-4e4b-84c4-30dbe6ad792f" name="onct:ResearchAndDevelopmentGrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million grant to researchers at UC San Diego to advance the Company&#8217;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. This study is known as CIRM-0001, or Cirmtuzumab and Ibrutinib for Relapsed Lymphoma or Leukemia (the &#8220;CIRLL study&#8221;). The Company: (i) conducted this study in collaboration with UC San Diego, (ii) received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7928a878-1c1e-4dfc-8d46-0075981c91e7" contextRef="C_a773db65-a5e7-4e4b-84c4-30dbe6ad792f" name="onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in development milestones under research subaward agreements during the award project period from October 1, 2017 through March 31, 2022, (iii) was committed to and met certain co-funding requirements, and (iv) was required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. As of December 31, 2023, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The National Institutes of Health (&#8220;NIH&#8221;) Grant Awards</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NIH has awarded the Company three research and development grants for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ab0c3c5-43e2-440d-897b-e27ec1e5d0c9" contextRef="C_39371a89-6f01-47df-bc36-a1e47990e15b" name="onct:ResearchAndDevelopmentGrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to support preclinical activities for the Company&#8217;s ONCT-534 and ONCT-216 programs, including $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d251f730-56fe-4f45-86cb-ecb52dc736d7" contextRef="C_b99fc277-6a5f-4381-b86d-98c34d084f57" name="onct:AccruedClinicalTrials1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payable to subawardees. Under the terms of the grant awards, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and the Company is required to provide periodic progress performance reports. During the years ended December 31, 2023 and 2022, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_930ccb91-4d1c-4d82-9511-56f8acd67728" contextRef="C_39371a89-6f01-47df-bc36-a1e47990e15b" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bfdf15f-2468-422a-bea0-d239d097a1f0" contextRef="C_56a6188c-3033-46da-a539-5db40eb23bba" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in award payments from the NIH. During the years ended December 31, 2023 and 2022, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd2bfc5b-59b4-4b06-aa67-cd63c8a515af" contextRef="C_39371a89-6f01-47df-bc36-a1e47990e15b" name="onct:AwardPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22ece729-f553-417d-9b15-9688b4db8f53" contextRef="C_56a6188c-3033-46da-a539-5db40eb23bba" name="onct:AwardPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in NIH grant revenue and had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd2b3fb5-f429-43a4-9648-42bc8d338776" contextRef="C_b99fc277-6a5f-4381-b86d-98c34d084f57" name="us-gaap:UnbilledContractsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00aef100-15ae-47b8-a55b-29afd871b8bb" contextRef="C_2b0d5398-0c7c-48f9-837d-be8269901856" name="us-gaap:UnbilledContractsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in unbilled receivables as of December 31, 2023 and 2022, respectively, which has been included in prepaid and other assets.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SPH USA, a Related Party</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License and Development Agreement (&#8220;LDA&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2018, and as amended in August 2020, the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country/region-by-country/region or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) either party in the event the other party declares insolvency or bankruptcy. There has been no significant activity under this agreement for the years ended December 31, 2023 and 2022. See Note 4.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the GTx merger agreement entered into in June 2019 (the &#8220;Merger&#8221;), the Company, a representative of holders of the CVRs, and Computershare, Inc. as rights agent entered into the CVR Agreement. Pursuant to the CVR Agreement, the Company&#8217;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#8217;s common stock held immediately prior to the Merger.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i) 50% of certain net proceeds received by the Company during the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab347495-9255-4d8c-b6d1-fd065db5b637" contextRef="C_806fe93c-57b0-45eb-9528-ffd11fc44374" name="onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year period after the closing of the Merger (the &#8220;CVR Term&#8221;) from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_009ad011-025c-4732-831b-9683b67a16c0" contextRef="C_806fe93c-57b0-45eb-9528-ffd11fc44374" name="onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10-year period); and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_842823ed-5f42-44e9-a4fc-448d1cedccad" contextRef="C_806fe93c-57b0-45eb-9528-ffd11fc44374" name="onct:PercentageOfNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net sales of products by Parent or its affiliates during the CVR Term incorporating the DAARI technology. As of December 31, 2023, no transactions or net sales relating to the DAARI technology had occurred.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_332e9631-2235-4cc5-a4b5-b4946798eb1d" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0a1c8d7-e3b6-49a6-a2fe-e975c8c0ed4e" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and December 31, 2022, the following fair value hierarchy tables presents the Company&#8217;s financial assets measured at fair value on a recurring basis (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.28%;"/>
        <td style="width:2.18%;"/>
        <td style="width:1%;"/>
        <td style="width:10.38%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:12.72%;"/>
        <td style="width:1%;"/>
        <td style="width:2.5%;"/>
        <td style="width:1%;"/>
        <td style="width:16.4%;"/>
        <td style="width:1%;"/>
        <td style="width:2.5%;"/>
        <td style="width:1%;"/>
        <td style="width:11.040000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfdb684e-8124-468a-bed5-a918fd259f9e" contextRef="C_494fe420-acc3-40f1-a076-42280b1684de" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,844</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3013ae30-5563-44fb-9f59-49bee3439871" contextRef="C_945c64cc-8fd5-4390-8555-ead6c7c1f64a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,912</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d61a9d6-a18a-41fd-b5ec-e89a40b9d0ac" contextRef="C_199ad02d-9d2d-4836-8616-89dc61afce31" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,932</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf6086e1-4cc8-405b-9c6e-464a84a005c8" contextRef="C_239353fd-6f89-4cb6-b125-6d9371f0edeb" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f88b1dd2-bc28-4f4f-9830-8c4b331e53d8" contextRef="C_9a46d83e-f6dd-44d4-909e-9d8f3ea263ed" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31714ad1-940a-4370-833c-3186d1c56778" contextRef="C_54d18d54-d3a4-492f-b13b-e21ffaa85ccf" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fafd1a63-5ae9-4816-a6c9-0240e5f5a36a" contextRef="C_ff6125a7-fb79-405a-8961-0ede053bee4e" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbb8d1fa-e1f6-40b6-afb8-d6513d7de6a3" contextRef="C_46c60dff-cac9-4018-8575-385d2a411a84" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccf6eddf-bcad-4765-89b4-b53823f8fe48" contextRef="C_26ab1cc2-d243-44c9-9db3-5cbed36397d9" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86a15084-6ae7-415c-aa6b-dba77d171f35" contextRef="C_188444b1-f178-47d3-9b2d-59943870aebd" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2ea3e3f-1048-44c7-8485-8aaea0239c3b" contextRef="C_f4a3a9c0-78f1-4226-a01b-c86a4a08a0b1" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59f51588-3641-4233-a504-49d9a9b09b5e" contextRef="C_ec9bb144-86a5-4e9b-906e-419e8387d5a5" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cedfc8b6-0778-4f35-b1be-b1c9d164c593" contextRef="C_559906c9-0c59-49e6-96f8-3366e04dca58" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abc18e1a-2836-420a-b6e5-d565175bff85" contextRef="C_e4d53eba-2e84-48f2-b931-0b43041273df" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,912</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e79be1-bce2-47d7-8c3d-726f1648b03c" contextRef="C_b4b57fdc-9184-48da-aa31-8dfde603a140" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e18e241-c9bf-4e68-b3cd-e023e4691e31" contextRef="C_cdc3f0e1-0d49-4984-a42d-fbfadb17116b" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.28%;"/>
        <td style="width:2.18%;"/>
        <td style="width:1%;"/>
        <td style="width:10.38%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:12.72%;"/>
        <td style="width:1%;"/>
        <td style="width:2.5%;"/>
        <td style="width:1%;"/>
        <td style="width:16.4%;"/>
        <td style="width:1%;"/>
        <td style="width:2.5%;"/>
        <td style="width:1%;"/>
        <td style="width:11.040000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba3d0d51-3061-4b95-a3aa-45b44aa5a049" contextRef="C_22537a93-b320-44dd-a549-708fcd3422dc" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81a4c810-1a7d-40b4-8f08-fd3c90c4b441" contextRef="C_f14623dc-d310-4e54-b789-c60026ee8444" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c143f897-0b70-4859-bf83-af78dae07f72" contextRef="C_3ed66ec3-01b3-42a3-840a-a1a07973fcfa" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98d2512f-0ec8-4e6f-89d6-9913f7b53663" contextRef="C_8d67c732-6cc2-4ca8-b0fb-1ec761145cf2" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74fa843f-3412-44d7-a0f0-80ef0f3e98fc" contextRef="C_e4bde5a8-ae87-4557-801d-ca9157cf9106" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61ebf69a-622e-4f27-b585-eb679db8292c" contextRef="C_fd81aada-e08c-4c52-98c2-314c93335b95" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f21092a9-c684-4702-b03e-8fa41f7e2466" contextRef="C_57f4bb0b-624b-482c-99f5-8c8960913a1f" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b7db6fb-53c4-4e77-b4ec-d445149e0f68" contextRef="C_6d3b13ce-5124-4fca-9299-dd3bdf5074c5" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_125b79eb-fecd-41b3-a88e-7aeb95a45f95" contextRef="C_612bfa44-754f-486e-bf9e-c145316436ad" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,958</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa8e258e-4129-48c0-ae98-54e01f326cd9" contextRef="C_07c0adf7-ec21-415e-8412-b371f3a6a24a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd28928b-677d-4041-be0b-ee3046536694" contextRef="C_6d9980d5-e3a0-4b27-8681-b22f63c165b1" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,958</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_743d83f5-7820-45b8-8d7e-9e56ea205197" contextRef="C_4c46c1db-0184-4718-8ed6-39821e77c4c8" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_424da17d-2056-4c05-afd6-b9cffc903a4c" contextRef="C_406903e5-8180-4559-aaf2-4760656464dd" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9dc32bf-1717-4ed3-b654-b6b6bee765b4" contextRef="C_fa85d7fe-bbad-46f8-a7b1-37cddaed1e71" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1d17455-febf-44d3-92b5-f0024d5eb716" contextRef="C_f8ac1f25-733f-4759-8f62-55c4db818235" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,894</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c6c47f5-1234-4444-bd22-4a4c923c2784" contextRef="C_b56bb628-693a-44de-82e4-d1feaf30ec85" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of short-term investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its money market funds, treasury notes and treasury bills as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices for identical assets in active markets without any valuation adjustment.  The Company classifies its commercial paper and U.S. government sponsored enterprise securities as Level 2 assets under the fair value hierarchy, as these assets have been valued using information obtained through a third-party pricing service at each balance sheet date, using observable market inputs that may include trade information, broker or dealer quotes, bids, offers, or a combination of these data sources. The Company does not hold any short-term investments classified as Level 3, which are securities valued using unobservable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The Company did not transfer any investment securities between the classification levels during the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cd5911d-be86-41ec-88f6-e25dc80a8471" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC, pursuant to which the Company is able to offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ce0d8c6-d14e-4d6f-9fc9-7be23eba89c0" contextRef="C_060e4155-636b-4f25-aae8-2486660150ed" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company has no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. During the years ended December 31, 2023 and 2022, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c1686e3-bf15-4fd2-af82-ea2a1a83c4ce" contextRef="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">55,274</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8ff019e-9bba-44e2-b7ee-24edb63f781e" contextRef="C_3ee2b049-c3a9-4492-adeb-159a901587f6" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">402,068</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bf321de-08a2-463a-bd17-4ffce5a33c8a" contextRef="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_486f9aca-1a1e-4d48-8851-7c1f3cd40dd5" contextRef="C_3ee2b049-c3a9-4492-adeb-159a901587f6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7af57c4-9e5e-40f2-9276-f8c413e02387" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:ScheduleOfWarrantActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of warrant activity and changes in warrants outstanding is presented below:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.54%;"/>
        <td style="width:1.032%;"/>
        <td style="width:1%;"/>
        <td style="width:12.51%;"/>
        <td style="width:1%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1%;"/>
        <td style="width:12.241%;"/>
        <td style="width:1%;"/>
        <td style="width:1.032%;"/>
        <td style="width:1%;"/>
        <td style="width:12.427%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares Underlying Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1541201d-e5b9-465c-8f2e-6933bfcd4090" contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,746</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2c06f53-2d88-4e62-a955-8692365bde50" contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">210.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_687a3271-7371-4101-b375-73612af0782e" contextRef="C_76233f9f-1322-4238-beea-ec554143cbd5" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dc57936-02d1-48c9-8288-e249685a524c" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="onct:WarrantsExpired" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bd343a1-3602-4124-b951-1020dfedb2c3" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="onct:WarrantExpiredPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">772.80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84d25b4f-f0cd-47f5-8700-cac7ff91321f" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7956ee1-292a-4ba1-8032-ac752013b388" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">74.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9235ab10-b46f-4850-80b5-d8cc7724a687" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.94</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued / Exercised / Forfeited / Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb44762d-334a-4e3e-b5c9-1494a9ce2abd" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:WarrantsExpired" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero"><ix:nonFraction id="F_e08a74cf-81df-44d7-b11b-b4e660cd6fa1" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:WarrantsIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero"><ix:nonFraction id="F_cdabef1c-c521-4cd1-975e-77b0b2620eff" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:ExerciseOfWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero"><ix:nonFraction id="F_a59d1cbd-7851-4db0-95eb-ba5e30c581d2" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:WarrantsCancelled" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2b885c8-8ee9-4709-9f7f-727f4e571da7" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:WarrantExpiredPricePerShare" unitRef="U_USDollarShare" decimals="0" format="ixt:fixed-zero"><ix:nonFraction id="F_440a23a5-74de-4cab-81dd-e0ed1c5db81c" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:WarrantsIssuedPricePerShare" unitRef="U_USDollarShare" decimals="0" format="ixt:fixed-zero"><ix:nonFraction id="F_0d1a442c-ee9a-4485-a6ae-cb2f171abec4" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:WarrantExercisedPricePerShare" unitRef="U_USDollarShare" decimals="0" format="ixt:fixed-zero"><ix:nonFraction id="F_90590764-4bd1-45a5-ab26-cd93a28254e5" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:WarrantForfeitedPricePerShare" unitRef="U_USDollarShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_309c3ed9-dcdd-4941-8eea-ff902e1e6b61" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_887fb373-395f-46d6-ae0a-74cfcfbb57cc" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">74.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0e495459-7f14-4693-b1c0-7bcec095aa14" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.94</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, all warrants met the criteria for classification in stockholders&#8217; equity.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contemporaneous with the Merger closing: (i) Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (&#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4318e631-a871-4386-bc8b-f5ef34cf3c48" contextRef="C_ed194973-5fdd-4e52-855b-ebf609d37cc3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">97,708</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, and (b) an annual increase on the first day of each calendar year beginning January 1, 2020, and ending on and including January 1, 2029, equal to the lesser of (A) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76a4fc84-9dc2-451c-a512-2a986151133f" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as is determined by the Board, are reserved for issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2015, Oncternal adopted the 2015 Plan which provided for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the options issued under the 2015 Plan expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f64a06d5-d031-40c9-98e7-832f191cfbdb" contextRef="C_e9b3636c-d8fd-4fc6-949c-e35056896198" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32b31c9c-0551-4d74-acde-b15b613d49bc" contextRef="C_e9b3636c-d8fd-4fc6-949c-e35056896198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan was terminated as to new grant awards in June 2019.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the stock options issued under the 2019 Plan expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f52b58cc-4caa-4a8d-aa69-5402c9880a7b" contextRef="C_d70503fc-4a1c-4d6b-9214-610f9b23fc86" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58668e0f-cd23-47b2-be0c-fd43bdb506a6" contextRef="C_d70503fc-4a1c-4d6b-9214-610f9b23fc86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period. Certain stock option grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of non-statutory stock options to certain new hires who satisfy the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of the 2019 Plan. As amended in May 2021 and December 2021, the Company has reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_697d1f2a-ffcd-45ee-a8fc-e097da89db53" contextRef="C_008b4d81-ffe3-4ba2-bbc8-a66325c8241c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">140,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for the issuance of common stock under the Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_417360e1-10ba-44a1-979c-ee0ee91f3669" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.19%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.002%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.382000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:7.481%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac7d8d1b-bafa-4d7c-bfba-825d96638219" contextRef="C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">425,766</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78b5ba93-140b-4fb5-ac29-f244a363f7e6" contextRef="C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">83.25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a40e0690-ad81-492d-81eb-5de7093d3870" contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,794</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e266e909-2a3e-4334-9fe4-a73aed5b7fbb" contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_258e998a-2c05-413e-bf32-a23c3534f893" contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,487</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ef2a86a-7f02-4948-b27f-95c04821d61f" contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">69.09</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f6b9363-979e-4821-b8cd-8905f6e836c3" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">548,073</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_077d2a23-d81d-4c75-ac01-fa40f4b2b6e4" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">56.51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_560c38ba-1690-4b71-a9a5-c1d8d0972ba8" contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493" name="onct:WeightedAverageContractualTermOutstanding" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_945a268e-3315-4eac-bcd1-287682347f51" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e994319a-e460-40d6-8181-e359ac9839a3" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">548,073</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f160fe2-00ad-44ee-b5ef-7c4e8243c1a1" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">56.51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d37145b4-44ad-4fee-aa3a-2bd12658fffd" contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad38d88a-5b55-4fa3-9048-b10bfbf7bbd5" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47cf1ecb-d737-4ad1-9692-c157f0e95064" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">279,184</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50d0a78c-731d-414c-931d-6631bea4060f" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">74.09</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cca59f2a-2602-4a43-a36b-025c9b5bd296" contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ae45988-77ba-430a-92d4-7fe08d2a6502" contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,418</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value per share of option grants for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ae67051-776c-43ad-8596-3db901091d01" contextRef="C_ef53d5cd-37dc-49c8-870b-ecc190d62e21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_628d7156-a0a4-4640-82d0-a41fa5bf57ad" contextRef="C_d3b5002b-9469-4aba-b020-3e3c596b6535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">25.81</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at December 31, 2023 of the option exercise and the exercise price of that stock option. There were no stock options exercised during the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Company repriced certain stock options held by employees and consultants. The repricing action was taken by the Company's board of directors to align the stock options with current market conditions and to retain key employees. The board of directors determined that the original exercise prices of the stock options were no longer reflective of the current market value of the Company's common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the repricing, the exercise prices of the stock options were adjusted to reflect the fair value of the Company's common stock as of October 2, 2023. The vesting schedules and other terms of the stock options were unchanged. The repricing was implemented through an amendment to the existing stock option agreements, which was approved by the board of directors. The repriced stock options are subject to terms such that any exercises prior to a premium end date shall use the original exercise price prior to the repricing amendment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the repriced stock options was determined using the Black-Scholes option-pricing model.  The incremental fair value of vested stock options resulted in a one-time charge to stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83cdc66d-fd2c-46b0-90b0-f1f130fa5d45" contextRef="C_88e26592-4d13-462a-9b53-e67a374ae51e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  The incremental fair value of unvested options of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe703cc4-0a3e-4b3c-b816-3dca24a5399a" contextRef="C_4a9ea6d5-a2b4-44b7-a30b-0362d9e0d9d8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be recognized over the remaining vesting period of the stock options.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Awards</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit awards (&#8220;RSUs&#8221;) are rights to receive shares of the Company&#8217;s common stock upon satisfaction of specific vesting conditions. The Company began issuing RSUs in the first quarter of 2022. The RSUs generally vest over an 18 month to two-year period. RSUs activity under the 2019 Plan is summarized as follows:</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_f52c1f48-c71b-4df6-9137-78e858370537" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.02%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:15.34%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:15.34%;"/>
        <td style="width:1%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:14.860000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Restricted Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f22b70ae-b134-46cc-a61e-75c4d95f230f" contextRef="C_e420a3e6-0b0a-450b-a468-f2a3164e557e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,438</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13b53c95-277c-4216-aa63-8b389ba0d610" contextRef="C_e420a3e6-0b0a-450b-a468-f2a3164e557e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">32.80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77682716-4c19-404d-a81f-4ef1003657c4" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0a8e5b6-e095-457e-8c73-74682548fedf" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,537</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6508ee45-c543-463d-8abf-034109ce6c2e" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">35.56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/ Repurchased</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb69bca6-44a5-49ca-b29a-de107282b3d6" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f46f77c2-07d8-4805-8e55-1ddf18fa1188" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">32.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b5f3e2f-0ee3-4bde-b69b-af92913bb75a" contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1f24b7ac-9d89-4caa-bdec-7f2148d25afc" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fffce008-2466-4ae4-a48e-4b70982eddaa" contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Units expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce8fa99a-eaea-49c0-8a1f-81b8bbc44766" contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4dbcb504-d9e5-4338-aef1-49604f1d5a71" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80cf08cd-65fb-4d2c-a504-4963b28447eb" contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value per share of RSU grants for the years ended December 31, 2023 and 2022 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89f15d3b-b920-4432-b288-ad498267bdbf" contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_599a2c6b-d542-4c8d-9dcf-f3f1cb644440" contextRef="C_5b521705-9521-4715-a360-b03c0afb492c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">33.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The total fair value of shares vested during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9be51a5f-03de-49c7-878a-bc71db98e4e9" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The total fair value of shares vested during the year ended December 31, 2022 was nominal.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d7b939d-0f4e-4a68-a51f-b84378007d5e" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.227%;"/>
        <td style="width:1.546%;"/>
        <td style="width:1%;"/>
        <td style="width:9.588%;"/>
        <td style="width:1%;"/>
        <td style="width:1.031%;"/>
        <td style="width:1%;"/>
        <td style="width:9.607999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0b8d427-ddc3-4687-9b82-a5f67f0102f2" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebf857e6-1317-474f-98df-7cc51884c88c" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aca15514-6ac8-4304-9a85-58c30f176092" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">100.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07683edd-7ddc-4130-90bc-e1c6c005f98a" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">100.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4a2e01f3-5d4b-4c76-9074-dd35f1c346d1" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_425c4eb1-cad8-4c43-87f7-cc1ac0bca3a3" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The expected volatility assumption is based on a blend of volatilities of the Company&#8217;s share price and a peer group of similar companies whose share prices are publicly available. The volatility of the Company&#8217;s shares price was measured using the closing share price beginning June 10, 2019, the date of the closing of the Merger, through the current period.  The peer group was developed based on companies in the life sciences industry with comparable characteristics to the Company including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term represents the period of time that options are expected to be outstanding. Due to limited historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs represent rights to receive shares of common stock contingent upon satisfaction of specific vesting conditions. The stock-based compensation expense for these awards was determined using the closing price on the grant date applied to the total number of shares that were anticipated to fully vest.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fa6aa1f-64dc-493e-827a-b9b4ceb03324" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:17%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:15%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd080b49-c060-45b8-9cfa-9998a8b93ddd" contextRef="C_97f0b34a-98a0-4cbd-85a6-33dc53e598fe" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,064</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af581ba4-f835-491b-99d6-fb8a7f9aafd7" contextRef="C_bf19402d-8314-4a7e-802d-f56c3da68afb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,055</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43ac928c-f167-4367-b066-ec2aae91b7ed" contextRef="C_441dc867-c190-4ac7-8f43-7108e23f4032" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,436</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4cf5325-5fe6-4852-9302-31dc0866ff8d" contextRef="C_8ae3137a-dca4-44e8-9e74-9a641eabeef4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,376</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcf4633c-d151-418c-9ae1-0fdae7cb9d78" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d2f0c76-4389-43a5-9b3d-b9a85461dabf" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,431</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the unrecognized compensation cost related to non-vested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77720134-86a4-4872-ae8e-1dbcccd0f0d4" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9da5f2a0-f3c1-4f69-bc30-0d730c5c1b47" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the unrecognized compensation cost related to non-vested restricted stock units was nominal, which is expected to be recognized in the first quarter of 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd7bdb9c-2591-4d99-96b4-ba321d2ce381" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfStockByClassTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.232%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:15.503%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:15.503%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6543f7ee-1655-4b72-821e-60a790d513a9" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:CommonStockWarrantsReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">170,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c3281de-281d-4456-8edd-ecceac98c0a0" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:CommonStockWarrantsReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">170,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6befe4cd-0acc-46d4-bb22-60f6b45117dc" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:CommonStockOptionsOutstandingForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">548,073</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc5b56da-3c83-4a83-ad13-626aaa175cb7" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:CommonStockOptionsOutstandingForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">425,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock unit awards unvested and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fdaafbb-c953-49d9-92b3-e10af597d343" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e58e234-a057-4d71-b67a-c3db4e91c6de" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock available for issuance under Inducement Plan and 2019 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ac81b03-f817-4187-abc1-e1c6f0264323" contextRef="C_534fa586-63e2-4243-8afa-2b2e6ad52e2b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">94,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d22a1c1f-8ac8-4fe2-9d15-2a97386c1d26" contextRef="C_885b6bbf-2f96-47f6-8d8a-193adfbcc27b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">61,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1851d572-0779-4593-9d6a-19d488a0dd03" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">832,060</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc3475a8-e206-4e2a-9aba-a877370ef8fc" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">708,260</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6abdad20-2ef3-4f64-b670-ab0f6f7a99ba" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2414d7d9-4a09-48f8-80b0-ffac8b7694c0" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.848%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:16.997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:16.997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52a24472-c1f8-4850-a68b-44e87ecbbfa3" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e55d9e19-c4f3-43f9-b291-da551dd511a4" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,276</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e59ba9b-8342-4f36-b192-a27b54a99816" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_719574d3-08c7-478a-bee6-d7f4b5e155ff" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,820</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_068f9eda-a3ba-4aa1-868a-9d5d235a3e72" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="onct:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dccba76-eba1-4c0b-bc7c-5a7739328578" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="onct:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e8667b4-0567-4714-9417-178acc68fe41" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b0fa47b-ce5d-486e-9386-08fb1f6263f3" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3329f2ea-bed4-409b-a4b2-20053c2f1767" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,910</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae512e01-fd90-4367-afe0-d1c4aa5da298" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,747</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c94e5e1a-c2c6-40a0-8f25-c7cb7cc46fd1" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9991e7f-4d42-4c17-9fd2-c3153c2c0d22" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5077501e-e48d-479f-9842-f6ab244e48c6" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59d80508-2332-4edc-88f2-473ee109f328" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d0bfc6f-900f-410c-80b1-9921ca7d92a6" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,660</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05652010-ed31-48df-8dc3-80f6acb54fdb" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,057</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c70af50b-401e-466a-b5c8-e78c682e3367" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16ed4218-0dd3-434d-8a3a-95c6ee23d3f8" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae23d3bc-b615-4ced-a4f7-e000f0d78c27" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:18%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25ee5eae-1729-4f73-a461-c48d55d9dda4" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92676d63-698a-447b-88d8-65fbf948ef99" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,889</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8384f59-78f4-4c7e-b32a-1d66107bbb75" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,958</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c90c0b9e-18b6-40fb-8ef2-b554eb6a1d74" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,804</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2584bf9-7852-4700-bf74-04e3b38a3d00" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26bb63e4-78e1-4857-b57c-75050361826f" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05dc122f-d051-4612-b4cf-f7552016344c" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,501</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2d6acb5-084e-4d5a-9032-74678254445b" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,153</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7a4611a-7650-40a3-9b8c-3b0edc3b99e3" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,406</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edcce877-01fb-41d3-8ce6-709afd02086a" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,188</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29f0a94f-5377-405e-9a38-05203456765a" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bc10fe4-aefe-45cd-89a2-616f17ea8fe0" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da039d66-d1fe-4bc8-bd39-22ade80056d0" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d004e3bc-ee5c-4685-85ed-83da5b7b2704" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,923</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbffa3e9-9129-470a-aadb-b368e4f5c0a2" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,561</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a23da573-b5a2-4bbd-9512-eb548241078b" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2d3c37f-8828-405e-939d-298460e0bfa3" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaa631b6-291e-4d3b-8456-f87a2b92611d" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9d8eaf6-97dc-4afc-a084-daf25fc70c6b" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="onct:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec7ecc39-aa22-4443-ad52-ff2888660257" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="onct:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1da45e83-faa7-4c3d-aea4-8a4b31f48ad0" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c86d825c-351a-496c-8b16-48a8e02c05b8" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fd077d9-23c1-4939-afa9-73180e96407d" contextRef="C_3f9e4329-2631-4545-b375-e1684aab746d" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48049a75-089b-43a4-9bb5-1a04557872bd" contextRef="C_94005552-abb1-417c-87b6-43d4fedeb7de" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company's deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of the Company's deferred tax assets, management considers all available evidence, both positive and negative.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#8220;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#8221; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2023. Accordingly, a valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77f095ce-dd40-488a-b21c-70383951dd50" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">66.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been recorded to offset this deferred tax asset. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7860986d-3624-4391-b901-e9dce3680d3c" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dd73acc-1b23-42e5-90ec-d2d9921f849a" contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company had federal and state net operating loss (NOL) carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f7565b0-6cac-4360-ae3b-7bd191807f4c" contextRef="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">119.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf9fcce5-193a-4397-9b3f-780d8177ae50" contextRef="C_390cdc10-d67e-4245-b090-a0003a2a440e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Of the federal and state net operating losses at December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9899e2c-7926-40b9-862e-8000e53c0482" contextRef="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4" name="onct:OperatingLossCarryforwardsNonExpirePortion" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">93.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f42900e-c4d4-44fe-a9bc-9a5914463927" contextRef="C_390cdc10-d67e-4245-b090-a0003a2a440e" name="onct:OperatingLossCarryforwardsNonExpirePortion" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne, respectively, do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a8071e4-0eef-45a3-9072-46ce8a5b4193" contextRef="C_1324e5fb-9834-45ea-8fde-84ef2eed74cf" name="onct:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2bd9fbe-4461-43c7-8b7d-1ddda71485b2" contextRef="C_befd2887-568e-464a-9888-a3946d8ca800" name="onct:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, unless previously utilized. At December 31, 2023, the Company also had federal and state research and development credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_991c43ba-1aa8-4ca9-b02d-98652aa27963" contextRef="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3dab805-3bba-47d9-a77f-c1e739380855" contextRef="C_390cdc10-d67e-4245-b090-a0003a2a440e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal research and development credit carryforwards will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1c019b1-1d2e-43ff-9262-0b3b1af8b91b" contextRef="C_1324e5fb-9834-45ea-8fde-84ef2eed74cf" name="onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unless previously utilized. The state research and development credits do not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating losses and credits may be subject to substantial annual limitations due to federal and state ownership change limitations provided by the Internal Revenue Code Section 382 and 383 and similar state provisions. Such annual limitations could result in the expiration of the net operating losses and credits before their utilization. The Company has not performed a Section 382 analysis to determine whether ownership changes will impact the use of net operating loss carryforwards and credits carryforwards and limit their ability to offset future taxable income. For financial statement purposes, the Company has included the federal and state net operating losses and credits in the schedule of deferred tax assets offset with a full valuation allowance. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by historical ownership changes will not impact the Company&#8217;s effective tax rate in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be recognized. At December 31, 2023 and 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03017f21-2a27-4116-8091-6dc46511aa98" contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d5e64b24-fd61-4077-a5a2-88cfefb0d445" contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#8217;s 2014 through 2023 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b4cc966-422b-4257-8806-1e30fde1c3eb" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized interest or penalties in its consolidated statements of operations since inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2023, the end of the period covered by this Annual Report. Based on the evaluation of these disclosure controls and procedures, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management's Report on Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, as management of Oncternal Therapeutics, Inc., are responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Securities Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles. Any system of internal control, no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and misstatements due to error or fraud may occur and not be detected. Also, because of changes in conditions, internal control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance that the objectives of the internal control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023 using the criteria for effective internal control over financial reporting as described in "Internal Control &#8212; Integrated Framework," issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on this evaluation, we concluded that, as of December 31, 2023, our internal control over financial reporting was effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting during the fourth quarter of 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10b5-1 Trading Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, our officers (as defined in Rule 16a&#8211;1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2023, none of our officers or directors </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fbe8857-5707-4f0e-8238-d54d3cf9a57e" contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_1fd1fd70-ad09-4bb5-8101-ee400bfd2a68" contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5aeb53ab-a747-4b00-a55d-053de4b6b89a" contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374" name="onct:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d6060915-2128-4778-b891-a452bd901176" contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374" name="onct:Rule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_110a205b-da8b-4565-8de6-86227479b2fe" contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_73366469-403b-4c0b-91ea-805dc0a1b51a" contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> any such trading arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restated Charter</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 4, 2024, the Company filed a restated certificate of incorporation (the &#8220;Restated Charter&#8221;) that integrated into one document the Company&#8217;s restated certificate of incorporation, as amended and supplemented to date. The Restated Charter only restated and integrated, and did not further amend, the provisions of the Company&#8217;s restated certificate of incorporation. The filing of the Restated Charter was authorized by the Board in accordance with Section 245 of the Delaware General Corporation Law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign J</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">urisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this item will be contained in our definitive Proxy Statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2024 Annual Meeting of Stockholders or the Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2023, under the headings &#8220;Executive Officers,&#8221; &#8220;Election of Directors,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221; and &#8220;Delinquent Section 16(a) Reports,&#8221; and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding executive compensation is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; in our Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Ow</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Proxy Statement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by Item 201(d) of Regulation S-K is incorporated by reference to the information set forth in the section titled &#8220;Executive Compensation&#8221; in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding certain relationships and related transactions and director independence is incorporated by reference to the information set forth in the sections titled &#8220;Transactions with Related Parties&#8221; and &#8220;Election of Directors &#8211; Independence of the Board of Directors,&#8221; respectively, in our Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tant Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding principal accountant fees and services is incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits and Fina</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ncial Statement Schedules.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Documents filed as part of this report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements of Oncternal Therapeutics, Inc. listed below are set forth in Item 8 of this Annual Report for the year ended December 31, 2023:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.318%;"/>
    <td style="width:1.92%;"/>
    <td style="width:5.761%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reportindependentregisteredpublicacc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; San Diego, California; PCAOB ID#</span><span><ix:nonNumeric id="F_906ea54f-8bf3-4589-8552-6cc127b629f1" contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">243</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Notes to Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These schedules have been omitted because the required information is included in the financial statements or notes thereto or because they are not applicable or not required.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this Annual Report and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 16. FORM </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-K SUMMARY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:46.423%;"/>
    <td style="width:1.019%;"/>
    <td style="width:6.055%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:8.074%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation by Reference</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File no.</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;3.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restated Certificate of Incorporation of the Registrant dated March 4, 2024</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Jun-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex41_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement dated May 19, 2020, between the Registrant and the purchasers signatory thereto (&#8220;May 2020 Purchase Agreement&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21-May-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex42_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Placement Agent Warrant, issued by Registrant pursuant to the May 2020 Purchase Agreement</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21-May-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement dated July 17, 2020, between the Registrant and the purchasers signatory thereto (the &#8220;July 2020 Purchase Agreement&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21-Jul-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Placement Agent Warrant, issued by Registrant pursuant to the July 2020 Purchase Agreement</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21-Jul-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312520236278/d32449dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated August 27, 2020, between the Registrant and H.C. Wainwright &amp; Co., LLC (&#8220;H.C. Wainwright&#8221;)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31-Aug-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.6</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312520298237/d76696dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated November 17, 2020, between the Registrant and H.C. Wainwright</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19-Nov-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.7</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312520315323/d67428dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated December 9, 2020, between the Registrant and H.C. Wainwright</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">  </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11-Dec-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;4.8*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex4_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities of the Registrant</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;) dated June 7, 2019, between the Registrant, Marc S. Hanover, as the Holders&#8217; Representative (&#8220;Holders&#8217; Representative&#8221;), and Computershare Investor Services, as Rights Agent (&#8220;Rights Agent&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Jun-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.1A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459021054536/onct-ex101_100.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to CVR Agreement dated November 1, 2021, between the Registrant, Holders&#8217; Representative, and Rights Agent</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4-Nov-21</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.2&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1047.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exclusive License Agreement between Georgetown University and the Registrant dated March 26, 2014 (the &#8220;Georgetown License Agreement&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-230758</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.47</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Apr-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.2A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1048.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to the Georgetown License Agreement dated March 17, 2016</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-230758</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.48</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Apr-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:46.423%;"/>
    <td style="width:1.019%;"/>
    <td style="width:6.055%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:8.074%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.3&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1054.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement between Oncternal Therapeutics, Inc. and Velos Biopharma Holdings, LLC dated February 6, 2018</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-230758</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.54</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Apr-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.4&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1055.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and UC San Diego dated August 31, 2018 (the &#8220;UCSD License Agreement&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-230758</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.55</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Apr-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.4A&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1056.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment #1 to the UCSD License Agreement Amended dated March 25, 2019</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-230758</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.56</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Apr-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.4B&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex1013_766.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment #2 to the UCSD License Agreement dated May 15, 2019</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16-Mar-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.4C&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459021012588/onct-ex1014_496.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment #3 to the UCSD License Agreement dated February 5, 2021</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11-Mar-21</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4D</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017024006493/onct-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment #4 to the UCSD License Agreement dated January 22, 2024</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23-Jan-24</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:48.95pt;vertical-align:top;"><p style="margin-left:24.45pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.5&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459022009702/onct-ex105_807.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated License Agreement between the University of Tennessee Research Foundation and the Registrant dated March 9, 2022 (the &#8220;UTRF License Agreement&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3-Nov-22</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5A&#134;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017022021928/onct-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the UTRF License Agreement</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;dated August 22, 2022</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">005-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3-Nov-22</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5B&#134;*</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex10_5b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to the UTRF License Agreement dated March 4, 2024</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.6#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex102_215.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement dated September 5, 2019 between the Registrant and Gunnar F. Kaufmann, Ph.D.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Nov-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023017928/onct-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter agreement with Gunnar Kaufmann, Ph.D. dated March 31, 2023</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4-May-23</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6B#&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023041395/onct-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;min-width:fit-content;">Advisory Services Agreement effective June 14, 2023 between the Registrant and Gunnar F. Kaufmann, Ph.D</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Aug-23</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.7#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex104_212.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement dated September 12, 2019 between the Registrant and James B. Breitmeyer, M.D.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Nov-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023017928/onct-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter agreement with James B. Breitmeyer, M.D. dated March 31, 2023</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4-May-23</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.8#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex105_211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement dated September 5, 2019 between the Registrant and Richard G. Vincent</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Nov-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023017928/onct-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter agreement with Richard G. Vincent dated March 31, 2023</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4-May-23</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.9#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459021041698/onct-ex101_51.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Employment Agreement dated January 6, 2021 between the Registrant and Raj Krishnan, Ph.D.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5-Aug-21</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023017928/onct-ex10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter agreement with Raj Krishnan, Ph.D. dated March 31, 2023</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4-May-23</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.10#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459021041698/onct-ex102_52.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement dated April 12, 2021 between the Registrant and Chase Leavitt</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5-Aug-21</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:46.423%;"/>
    <td style="width:1.019%;"/>
    <td style="width:6.055%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:8.074%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023017928/onct-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter agreement with Chase Leavitt dated March 31, 2023</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4-May-23</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.11#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459021041698/onct-ex103_49.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement dated May 17, 2021 between the Registrant and Salim Yazji, M.D.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5-Aug-21</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023017928/onct-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter agreement with Salim Yazji, M.D. dated March 31, 2023</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4-May-23</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.12#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000095017023007062/onct-ex10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Annual Incentive Plan of the Registrant</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9-Mar-22</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.13#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex1031_767.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16-Mar-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.14#*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-Employee Director Compensation Program of Registrant</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.15#*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex10_15.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2015 Equity Incentive Plan of Private Oncternal, as amended (the &#8220;2015 Plan&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.15A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1058.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement under the 2015 Plan</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-230758</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.58</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Apr-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.15B#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1059.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Early Exercise Stock Option Agreement under the 2015 Plan</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-230758</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.59</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-Apr-19</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:18.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.16#*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex10_16.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2019 Incentive Award Plan of the Registrant (the &#8220;2019 Plan&#8221;)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.16A#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459022009702/onct-ex10181_736.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement under the 2019 Plan</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Mar-22</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.16B#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459022009702/onct-ex10182_1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit under the 2019 Plan</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Mar-22</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.17#*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex10_17.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2021 Employment Inducement Incentive Award Plan of the Registrant, as amended (the &#8220;Inducement Plan&#8221;)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10.17A#</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459022009702/onct-ex10191_735.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option under the Inducement Plan</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Mar-22</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;21.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex211_764.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-50549</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16-Mar-20</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;23.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;24.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (see Signature Page)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;31.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Executive Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;31.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Financial Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;32.1&#135;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;32.2&#135;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="onct-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Policy for Recovery of Erroneously Awarded Compensation</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:46.423%;"/>
    <td style="width:1.019%;"/>
    <td style="width:6.055%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
    <td style="width:8.074%;"/>
    <td style="width:1.019%;"/>
    <td style="width:11.111%;"/>
    <td style="width:1.019%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;101.INS*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;101.SCH*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;104*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#135;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furnished herewith</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Management contract or compensatory plan</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signa</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.04%;"/>
    <td style="width:1.3%;"/>
    <td style="width:3.84%;"/>
    <td style="width:44.82%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Oncternal Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 7, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James B. Breitmeyer</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James B. Breitmeyer, M.D., Ph.D.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that each person whose signature appears below constitutes and appoints Dr. James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent, and each of them, as his or her true and. lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.887%;"/>
    <td style="width:1.28%;"/>
    <td style="width:39.748%;"/>
    <td style="width:1.3%;"/>
    <td style="width:21.784%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James B. Breitmeyer</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Member of the Board of Directors</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James B. Breitmeyer, M.D., Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Richard G. Vincent</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Richard G. Vincent</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David F. Hale</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David F. Hale</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael G. Carter</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael G. Carter, M.B., ChB, FRCP</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jill DeSimone</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jill DeSimone</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Daniel L. Kisner</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Daniel L. Kisner</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ William R. LaRue</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William R. LaRue</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Rosemary Mazanet</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rosemary Mazanet, M.D., Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Xin Nakanishi</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Xin Nakanishi, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert Wills</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert Wills, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Charles P. Theuer</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>onct-ex3_1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html>
 <head>
  <title>EX-3.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 3.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RESTATED<br>CERTIFICATE OF INCORPORATION<br>OF<br>ONCTERNAL THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Pursuant to Section 245 of the General Corporation Law of the State of Delaware)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the &#x201c;Corporation&#x201d;), does hereby certify as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FIRST</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The name of the Corporation is Oncternal Therapeutics, Inc.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECOND</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Corporation, which was originally known as GTx, Inc., originally filed its Certificate of Incorporation with the Secretary of State of the State of Delaware on September 4, 2003.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">THIRD</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Restated Certificate of Incorporation hereby restates and integrates into a single instrument and does not further amend the provisions of the Corporation&#x2019;s Certificate of Incorporation as thereto amended or supplemented, and there is no discrepancy between those provisions and the provisions of the restated certificate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FOURTH</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Restated Certificate of Incorporation was duly adopted by the Board of Directors of the Corporation in accordance with the provisions of Section 245 of the General Corporation Law of the State of Delaware, setting forth this Restated Certificate of Incorporation and declaring this Restated Certificate of Incorporation to be advisable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FIFTH</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Certificate of Incorporation of this Corporation is hereby restated in its entirety to read as follows:</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;I</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The name of the corporation is Oncternal Therapeutics, Inc. (the &#x201c;Corporation&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;II</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The address of the Corporation&#x2019;s registered office in the State of Delaware is:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">251 Little Falls Drive<br>Wilmington, Delaware 19808<br>County of New Castle</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The name of its registered agent at such address is The Prentice&#x2011;Hall Corporation System, Inc.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;III</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (&#x201c;DGCL&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;IV</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Authorized Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total number of shares which the Corporation shall have authority to issue is one hundred twenty-five million (125,000,000), consisting of one hundred twenty million (120,000,000) shares of Common Stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), and five million (5,000,000) shares of Preferred Stock, par value $0.001 per share (the &#x201c;Preferred Stock&#x201d;).</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective at 12:01 a.m., Eastern Time, on January 8, 2024 (the &#x201c;Effective Time&#x201d;) pursuant to the DGCL of this Certificate of Amendment of the Restated Certificate of Incorporation of the Corporation, as amended, each 20 shares of the Corporation&#x2019;s common stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time (the &#x201c;Old Shares&#x201d;) shall automatically be combined into one validly issued, fully paid and non-assessable share of common stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described below (the &#x201c;Reverse Stock Split&#x201d;). The Corporation shall not issue fractional shares in connection with the Reverse Stock Split. Holders of Old Shares who would otherwise be entitled to receive a fraction of a share on account of the Reverse Stock Split shall receive, upon surrender of the stock certificates formerly representing the Old Shares, in lieu of such fractional share, an amount in cash equal to the product of (1) the closing sale price per share of the common stock as reported by The Nasdaq Capital Market on the last trading day preceding the Effective Time by (2) the number of Old Shares held by such holder that would otherwise have been exchanged for such fractional share interests.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Preferred Stock may be issued from time to time in one or more series.  The Board of Directors is hereby expressly authorized at any time and from time to time to provide for the issuance of all or any of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares to the fullest extent as may now or hereafter be permitted by the DGCL.  The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding.  In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which as used herein, shall mean the certificate of incorporation of the Corporation, as amended from time to time, including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the rights of the holders of any series of Preferred Stock then outstanding, the holders of shares of Common Stock shall be entitled to receive, when and if declared by the Board of Directors, out of the assets of the Corporations which are by law available therefor, dividends payable either in cash, in property or in shares of capital stock.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dissolution, Liquidation or Winding Up</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  In the event of any dissolution, liquidation or winding up of the affairs of the Corporation, after distribution in full of the preferential amounts, if any, to be distributed to the holders of shares of any series of Preferred Stock then outstanding, the holders of Common Stock shall be entitled, unless otherwise provided by law or this Certificate of Incorporation, to receive all of the remaining assets of the Corporation of whatever kind available for distribution to stockholders ratably in proportion to the number of shares of Common Stock held by them respectively.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;V</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management of Business</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The business and affairs of the Corporation shall be managed by or under the direction of its Board of Directors.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Number of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The authorized number of directors of the Corporation shall be determined from time to time exclusively by resolution adopted by the affirmative vote of a majority of the authorized number of directors at any regular or special meeting of such Board of Directors, within any limits prescribed in the Bylaws of the Corporation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Classes of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes, as nearly equal in number as possible, designated as Class I, Class II and Class III, respectively.  At the annual meeting of stockholders held in 2005, the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">term of office of the Class I directors shall expire and Class I directors shall be elected for a term ending on the date of the third annual meeting of stockholders following the annual meeting at which such director was elected.  At the annual meeting of stockholders held in 2006, the term of office of the Class II directors shall expire and Class II directors shall be elected for a term ending on the date of the third annual meeting of stockholders following the annual meeting at which such director was elected.  At the annual meeting of stockholders held in 2007, the term of office of the Class III directors shall expire and Class III directors shall be elected for a term ending on the date of the third annual meeting of stockholders following the annual meeting at which such director was elected.  At each succeeding annual meeting of stockholders, directors shall be elected for a term ending on the date of the third annual meeting of stockholders following the annual meeting at which such director was elected to succeed the directors of the class whose terms expire at such annual meeting.  If any newly created directorship may, consistently with the rule that the three classes shall be as nearly equal in number as possible, be allocated to more than one class, the Board of Directors shall allocate it to the available class whose term of office is due to expire at the earliest date following such allocation.  Notwithstanding any provision of this section to the contrary, each director shall serve until his or her successor is duly elected and qualified or until his or her death, resignation, disqualification or removal.  No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vacancies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the rights of the holders of any series of Preferred Stock then outstanding, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders.  Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#x2019;s successor shall have been elected and qualified or until his or her death, resignation, disqualification or removal.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Elections</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The directors of the Corporation need not be elected by written ballot unless the Bylaws of the Corporation so provide.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;VI</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Action by Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  No action required or permitted to be taken by the stockholders of the Corporation shall be taken except at a duly called annual or special meeting of stockholders of the Corporation, and no action shall be taken by the stockholders by written consent.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Special Meetings of Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Special meetings of stockholders of the Corporation may be called only by the Chairman of the Board, the Chief Executive Officer or by the Board of Directors acting pursuant to a resolution adopted by a majority of the authorized number of directors, and any power of stockholders to call a special meeting is specifically denied.  Only such business shall be considered at a special meeting of stockholders as shall have been stated in the notice for such meeting.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;VII</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Corporation.  Any adoption, amendment or repeal of the Bylaws of the Corporation by the Board of Directors shall require the approval of a majority of the directors then in office.  The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Restated Certificate of Incorporation, the affirmative vote of the holders of at least sixty&#x2011;six and two&#x2011;thirds percent (66 &#x2154;%) of the voting power of all of the then&#x2011;outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws of the Corporation.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;VIII</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be liable to the Corporation or its stockholders for monetary damages for breach of his or her fiduciary duty as director.  If the DGCL or any other statute of the State of Delaware hereafter is amended to authorize the further elimination or limitation of the liability of directors of the Corporation, then the liability of a director of the Corporation shall be limited to the fullest extent permitted by the statutes of the State of Delaware, as so amended, and such elimination or limitation of liability shall be in addition to, and not in lieu of, the limitation on the liability of a director provided by the foregoing provisions of this Article VIII.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Corporation shall indemnify each person who is or was a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that the person is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, from and against all expense, liability and loss (including, without limitation, attorney&#x2019;s fees, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred or suffered by such person in connection with such action, suit or proceeding, to the fullest extent permitted under the DGCL, as it exists on the date hereof or as it may hereafter be amended; provided, however, that, except with respect to proceedings to enforce rights to indemnification, the Corporation shall not be required to indemnify any such person seeking indemnification in connection with an action, suit or proceeding (or part thereof) initiated by such person unless such action, suit or proceeding (or part thereof) was authorized by the Board of Directors.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Repeal and Modification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Any repeal or modification of the foregoing provisions of this Article VIII shall not affect adversely any right or protection of any director, officer, employee or agent of the Corporation existing at the time of such repeal or modification.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">article&nbsp;IX</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reservation of Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, except as provided in section B of this Article IX, and all rights conferred upon the stockholders herein are granted subject to this reservation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Requisite Vote</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the voting stock of the Company required by law, this Certificate of Incorporation or any certificate of designation of Preferred Stock, the affirmative vote of the holders of at least sixty&#x2011;six and two&#x2011;thirds percent (66 &#x2154;%) of the voting power of all of the then&#x2011;outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII, VIII and IX of this Certificate of Incorporation.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, this Restated Certificate of Incorporation, which restates and integrates the certificate of incorporation of the Corporation, and which has been duly adopted in accordance with Section 245 of the Delaware General Corporation Law, has been executed on behalf of Oncternal Therapeutics, Inc. by the undersigned officer, thereunto duly authorized, this 4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day of March, 2024.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By: /s/ Chase Leavitt</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chase Leavitt</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Secretary</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>3
<FILENAME>onct-ex4_8.htm
<DESCRIPTION>EX-4.8
<TEXT>
<html>
 <head>
  <title>EX-4.8</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.8</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of the Registrant&#x2019;s SECURITIES Registered Pursuant to Section 12 Of the Securities Exchange Act of 1934</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">we</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">us</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">our</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: common stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="descriptionofcapitalstock_121431"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summary of the terms of our common stock does not purport to be complete and is subject to and qualified in its entirety by reference to our Restated Certificate of Incorporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">certificate of incorporation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and Amended and Restated Bylaws (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bylaws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which are filed as exhibits to our most recent Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our certificate of incorporation and our bylaws for additional information.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under our certificate of incorporation, the total number of shares of all classes of stock that we have authority to issue is 125,000,000, consisting of 120,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summary description of our capital stock is based on the provisions of our certificate of incorporation and bylaws, the applicable provisions of the General Corporation Law of the State of Delaware (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DGCL</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the agreements described below. This information may not be complete in all respects and is qualified entirely by reference to the provisions of our certificate of incorporation and bylaws, the DGCL and such agreements. For information on how to obtain copies of our certificate of incorporation, bylaws and such agreements, which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this Exhibit is a part.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of our common stock are entitled to one vote for each share held of record on all matters properly submitted to a vote of stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the certification of incorporation that relates to solely to the terms of any outstanding series of preferred stock if the holders such preferred stock are entitled to vote thereon by law or pursuant to the certification of incorporation. The holders of our common stock do not have cumulative voting rights in the election of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dissolution, Liquidation or Winding Up</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rights and Preferences</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. The rights of the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any preferred stock that we may designate and issue in the future.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Listing</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;ONCT.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. Its address is 150 Royall Street, Canton, MA 02021.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="descriptionofwarrants_121440"><font id="planofdistribution_121446">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-Takeover Effects of Provisions of Delaware Law and Our Charter Documents</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delaware Takeover Statute</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation such as us from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a period of three years following the time that the stockholder became an interested stockholder, unless:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prior to the time the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at or subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 203 defines a business combination to include:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority-owned subsidiary);</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section 203, provided by or through the corporation.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Charter Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our certificate of incorporation and bylaws provide that our board of directors be divided into three classes of directors, as nearly equal in number as possible, with each class serving a staggered three-year term. The</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">classification system of electing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us since the classification of the board of directors generally increases the difficulty of replacing a majority of directors. In addition, our certificate of incorporation and bylaws:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at a stockholder meeting;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that the authorized number of directors may be changed only by resolution of the board of directors; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote is required to amend a corporation&#x2019;s bylaws, unless a corporation&#x2019;s certificate of incorporation requires a greater percentage or also confers the power upon the corporation&#x2019;s directors. Our bylaws may be amended or repealed by:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the affirmative vote of a majority of our directors then in office; or</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the affirmative vote of the holders of at least 66-2/3% of the voting power of all then-outstanding shares of our capital stock entitled to vote generally in the election of directors</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing provisions of our certificate of incorporation may be amended or repealed only with the affirmative vote of a majority of our directors and the affirmative vote of the holders of at least 66-2/3% of the voting power of all then-outstanding shares of our capital stock entitled to vote generally in the election of directors. These and other provisions contained in our certificate of incorporation and bylaws could delay or discourage some types of transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares over then current prices, and may limit the ability of stockholders to remove current management or approve transactions that stockholders may deem to be in their best interests and, therefore, could adversely affect the price of our common stock.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>4
<FILENAME>onct-ex10_14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html>
 <head>
  <title>EX-10.14</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">EXHIBIT 10.14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ONCTERNAL THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NON-EMPLOYEE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> DIRECTOR COMPENSATION PROGRAM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This program has been updated to reflect the Company&#x2019;s one-for-twenty reverse stock split effected by the Company on January 8, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Non-employee members of the board of directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Oncternal Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Program</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) effective from and after March 18, 2021 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time in its sole discretion. The terms and conditions of this Program shall supersede any prior cash and/or equity compensation arrangements between the Company and any of its Non-Employee Directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cash Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Retainers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each Non-Employee Director shall be eligible to receive an annual retainer of $40,000 for service on the Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Additional Annual Retainers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In addition, a Non-Employee Director shall receive the following additional annual retainers, as applicable:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Chairperson of the Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual retainer of $35,000 for such service.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Audit Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.   A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service.  Each Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $7,500 for such service.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $10,000 for such service.  Each Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nominating and Corporate Governance Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.   A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $8,000 for such service.  Each Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $4,000 for such service.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Science &amp; Technology Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each Non-Employee Director serving as a member of the Science &amp; Technology Committee shall receive an additional annual retainer of $8,000 for such service.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment of Retainers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter.  In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Equity Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Non-Employee Directors shall be granted the equity awards described below.  The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#x2019;s 2019 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and shall be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms previously approved by the Board, setting forth the vesting schedule applicable to such awards and such other terms as may be required by the Equity Plan.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan.  For the avoidance of doubt, the share numbers in this Section 2 shall be subject to adjustment as provided in the Equity Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Initial Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each Non-Employee Director who is initially elected or appointed to the Board following the Effective Date shall be automatically granted an option to purchase 2,500 shares of the Company&#x2019;s common stock, on the date of such initial election or appointment.  The awards described in this Section 2(b) shall be referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  No Non-Employee Director shall be granted more than one (1) Initial Award.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="ole_link2"><font id="ole_link1"></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  A Non-Employee Director who (i) is serving on the Board as of the date of any annual meeting of the Company&#x2019;s stockholders and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted an option to purchase </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1,250 shares of the Company&#x2019;s common stock, or with respect to the Non-Employee Director serving as Chairperson of the Board, an option to purchase 1,875 shares of the Company's common stock, on the date of such annual meeting.  The awards described in this Section 2(c) shall be referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an annual meeting of the Company&#x2019;s stockholders shall only receive an Initial Award in connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well.  In the event a Non-Employee Director has not been serving as a member of the Board for twelve (12) months as of the date of any Subsequent Award, the Board may determine to prorate the Subsequent Award to such Non-Employee Director to reflect the number of months served since such initial election through the date of the Subsequent Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link7"><font id="ole_link8"></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination of Employment of Employee Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(b) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(c) above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Terms of Awards Granted to Non-Employee Directors</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  One thirty-sixth of each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through each such vesting date. One-twelfth of each Subsequent Award shall vest and/or become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that each Subsequent Award options shall be fully vested on the one-year anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through such vesting date.  Unless otherwise determined by the Board, no portion of an Initial Award or Subsequent Award which is unvested and/or exercisable at the time of a Non-Employee Director&#x2019;s termination of service on the Board shall become vested and/or exercisable thereafter.  All of a Non-Employee Director&#x2019;s Initial Awards and Subsequent Awards shall vest in full upon the occurrence of a Change in Control (as defined in the Equity Plan).</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The term of each stock option granted to a Non-Employee Director shall be ten (10) years from the date the option is granted.  Upon a Non-Employee Director&#x2019;s cessation of service on the Board for any reason, his or her options to purchase shares of the Company&#x2019;s common stock granted under this Program shall remain exercisable for twelve (12) months following the cessation of his or her service on the Board (or such longer period as the Board may determine in its discretion on or after the date of grant of such stock options).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>onct-ex10_15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html>
 <head>
  <title>EX-10.15</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="border-top:0.5pt solid;padding-top:6pt;border-right:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;border-left:0.5pt solid;margin-top:0;font-family:Times New Roman;margin-bottom:0;padding-right:1.107%;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</font></p>
  <p style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:0.5pt solid;padding-right:1.107%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2015 EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This plan document has been updated to reflect the Company&#x2019;s one-for-twenty reverse stock split effected by the Company on January 8, 2024 and the adjustments for the merger of the Company with GTx, Inc. in June 2019.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	The purpose of the Plan is to advance the interests of the Company&#x2019;s stockholders by enhancing the Company&#x2019;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning the interests of such persons with those of the Company&#x2019;s stockholders. Capitalized terms used in the Plan are defined in Section 11 below.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eligibility</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administration and Delegation</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administration.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Plan will be administered by the Administrator. The Administrator shall have authority to determine which Service Providers will receive Awards, to grant Awards and to set all terms and conditions of Awards (including, but not limited to, vesting, exercise and forfeiture provisions). In addition, the Administrator shall have the authority to take all actions and make all determinations contemplated by the Plan and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Administrator may correct any defect or ambiguity, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem necessary or appropriate to carry the Plan and any Awards into effect, as determined by the Administrator. The Administrator shall make all determinations under the Plan in the Administrator&#x2019;s sole discretion and all such determinations shall be final and binding on all persons having or claiming any interest in the Plan or in any Award.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Appointment of Committees.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> To the extent permitted by Applicable Laws, the Board may delegate any or all of its powers under the Plan to one or more Committees. The Board may abolish any Committee at any time and re-vest in itself any previously delegated authority.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Available for Awards</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Number of Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Subject to adjustment under Section 8 hereof, Awards may be made under the Plan covering up to 31,556 shares of Common Stock. If any Award expires or lapses or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at or below the original issuance price), in any case in a manner that results in any shares of Common Stock covered by such Award not being issued or being so reacquired by the Company, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of Award and/or to satisfy any applicable tax withholding obligation (including shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) shall be added to the number of shares of Common Stock </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares of Common Stock issued under the Plan may consist in whole or in part of authorized but unissued shares, shares purchased on the open market or treasury shares.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Substitute Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted prior to such merger or consolidation by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Administrator deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section 4(a) hereof, except as may be required by reason of Section 422 of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Administrator may grant Options to any Service Provider, subject to the limitations on Incentive Stock Options described below. The Administrator shall determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to Applicable Laws, as it considers necessary or advisable.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Stock Options.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Administrator may grant Options intended to qualify as Incentive Stock Options only to employees of the Company, any of the Company&#x2019;s present or future &#x201c;parent corporations&#x201d; or &#x201c;subsidiary corporations&#x201d; as defined in Sections 424(e) or (f) of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. All Options intended to qualify as Incentive Stock Options shall be subject to and shall be construed consistently with the requirements of Section 422 of the Code. Neither the Company nor the Administrator shall have any liability to a Participant, or any other party, (i) if an Option (or any part thereof) which is intended to qualify as an Incentive Stock Option fails to qualify as an Incentive Stock Option or (ii) for any action or omission by the Administrator that causes an Option not to qualify as an Incentive Stock Option, including without limitation, the conversion of an Incentive Stock Option to a Non-Qualified Stock Option or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements under the Code applicable to an Incentive Stock Option. Any Option that is intended to qualify as an Incentive Stock Option, but fails to so qualify for any reason, including without limitation, the portion of any Option becoming exercisable in excess of the $100,000 limitation described in Treasury Regulation Section 1.422-4, shall be treated as a Non-Qualified Stock Option for all purposes.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise Price.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Administrator shall establish the exercise price of each Option and specify the exercise price in the applicable Award Agreement. The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is granted. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the Option, owns (or is treated as owning under Section 424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a &#x201c;parent corporation&#x201d; or &#x201c;subsidiary corporation&#x201d; thereof within the meaning of Sections 424(e) or 424(f) of the Code, respectively), the per share exercise price shall be no less than 110% of the Fair Market Value on the date the Option is granted.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Duration of Options.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Each Option shall be exercisable at such times and subject to such terms and conditions as the Administrator may specify in the applicable Award Agreement, provided that the term of any Option shall not exceed ten years. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the Option, owns (or is treated as owning under Section 424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a &#x201c;parent corporation&#x201d; or &#x201c;subsidiary corporation&#x201d; thereof within the meaning of Sections 424(e) or 424(f) of the Code, respectively), the term of the Option shall not exceed five years.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise of Option; Notification of Disposition.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Options may be exercised by delivery to the Company of a written notice of exercise, in a form approved by the Administrator (which may be an electronic form), signed by the person authorized to exercise the Option, together with payment in full (i) as specified in Section 5(f) hereof for the number of shares for which the Option is exercised and (ii) as specified in Section 9(e) hereof for any applicable withholding taxes. Unless otherwise determined by the Administrator, an Option may not be exercised for a fraction of a share of Common Stock. If an Option is designated as an Incentive Stock Option, the Participant shall give prompt notice to the Company of any disposition or other transfer of any shares of Common Stock acquired from the Option if such disposition or transfer is made (i) within two years from the grant date with respect to such Option or (ii) within one year after the transfer of such shares to the Participant (other than any such disposition made in connection with a Change in Control). Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Payment Upon Exercise.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for in cash or by check, payable to the order of the Company, or, to the extent permitted by the Administrator, by:</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(A) delivery of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (A) such method of payment is then permitted under Applicable Laws, (B) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Company at any time, and (C) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">surrendering shares of Common Stock then issuable upon exercise of the Option valued at their Fair Market Value on the date of exercise;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">delivery of a promissory note of the Participant to the Company on terms determined by the Administrator;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">delivery of property of any other kind which constitutes good and valuable consideration as determined by the Administrator; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any combination of the above permitted forms of payment (including cash or check).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Early Exercise of Options</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may provide in the terms of an Award Agreement that the Service Provider may exercise an Option in whole or in part prior to the full vesting of the Option in exchange for unvested shares of Restricted Stock with respect to any unvested portion of the Option so exercised. Shares of Restricted Stock acquired upon the exercise of any unvested portion of an Option shall be subject to such terms and conditions as the Administrator shall determine.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock; Restricted Stock Units.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such shares if issued at no cost) in the event that conditions specified by the Administrator in the applicable Award Agreement are not satisfied prior to the end of the applicable restriction period or periods established by the Administrator for such Award. In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during applicable restriction period or periods, as set forth in an applicable Award Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Terms and Conditions for All Restricted Stock and Restricted Stock Unit Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator shall determine and set forth in the applicable Award Agreement the terms and conditions applicable to each Restricted Stock and Restricted Stock Unit Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, in each case, if any.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Provisions Relating to Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such shares, unless otherwise provided by the Administrator in the applicable Award Agreement. In addition, unless otherwise provided by the Administrator, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each dividend payment will be made as provided in the applicable Award Agreement, but in no event later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the later of (A) the date the dividends are paid to stockholders of that class of stock, and (B) the date the dividends are no longer subject to forfeiture.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Certificates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company may require that any stock certificates issued in respect of shares of Restricted Stock be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Provisions Relating to Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon the vesting of a Restricted Stock Unit, the Participant shall be entitled to receive from the Company one share of Common Stock or an amount of cash or other property equal to the Fair Market Value of one share of Common Stock on the settlement date, as provided in the applicable Award Agreement. The Administrator may provide that settlement of Restricted Stock Units shall occur upon or as soon as reasonably practicable after the vesting of the Restricted Stock Units or shall instead be deferred, on a mandatory basis or at the election of the Participant, in a manner that complies with Section 409A.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. A Participant shall have no voting rights with respect to any Restricted Stock Units unless and until shares are delivered in settlement thereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. To the extent provided by the Administrator, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which the Dividend </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Equivalents are paid, as determined by the Administrator, subject, in each case, to such terms and conditions as the Administrator shall establish and set forth in the applicable Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Other Stock-Based Awards may be granted hereunder to Participants, including, without limitation, Awards entitling Participants to receive shares of Common Stock to be delivered in the future. Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan, as stand-alone payments and/or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock, cash or other property, as the Administrator shall determine. Subject to the provisions of the Plan, the Administrator shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price, transfer restrictions, vesting conditions and other terms and conditions applicable thereto, which shall be set forth in the applicable Award Agreement.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adjustments for Changes in Common Stock and Certain Other Events</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Administrator determines that any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or exchange of Common Stock or other securities of the Company, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, or other similar corporate transaction or event, as determined by the Administrator, affects the Common Stock such that an adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award, then the Administrator may, in such manner as it may deem equitable, adjust any or all of:</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the number and kind of shares of Common Stock (or other securities or property) with respect to which Awards may be granted or awarded (including, but not limited to, adjustments of the limitations in Section 3 hereof on the maximum number and kind of shares which may be issued);</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the number and kind of shares of Common Stock (or other securities or property) subject to outstanding Awards;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the grant or exercise price with respect to any Award; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the terms and conditions of any Awards (including, without limitation, any applicable financial or other performance &#x201c;targets&#x201d; specified in an Award Agreement).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event of any transaction or event described in Section 8(a) hereof (including without limitation any Change in Control) or any unusual or nonrecurring transaction or event affecting the Company or the financial statements of the Company, or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event and either automatically or upon the Participant&#x2019;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (i) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (ii) to facilitate such transaction or event or (iii) give effect to such changes in Applicable Laws or accounting principles</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of such Award or realization of the Participant&#x2019;s rights had such Award been currently exercisable, payable and fully vested, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of such Award or realization of the Participant&#x2019;s rights, in any case, is equal to or less than zero, then such Award may be terminated without payment;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that such Award shall vest and, to the extent applicable, be exercisable as to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and applicable exercise or purchase price, in all cases, as determined by the Administrator;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards, and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards which may be granted in the future;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To replace such Award with other rights or property selected by the Administrator; and/or</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the provisions of Section 8(b) above, if a Change in Control occurs and a Participant&#x2019;s Awards are not continued, converted, assumed, or replaced with a substantially similar award by (i) the Company, or (ii) a successor entity or its parent or subsidiary (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assumption</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and provided that the Participant has not had a Termination of Service, then the Administrator may provide that, immediately prior to the Change in Control, such Awards shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse, in which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (A) which may be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, earn-out or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and (B) determined by reference to the number of shares subject to such Awards and net of any applicable exercise price; provided that to the extent that any Awards constitute &#x201c;nonqualified deferred compensation&#x201d; that may not be paid upon the Change in Control under Section 409A without the imposition of taxes thereon under Section 409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents); and provided, further, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to the contrary in this Section 8, the Administrator will equitably adjust each </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">outstanding Award, which adjustments may include adjustments to the number and type of securities subject to each outstanding Award and/or the exercise price or grant price thereof, if applicable, the grant of new Awards to Participants, and/or the making of a cash payment to Participants, as the Administrator deems appropriate to reflect such Equity Restructuring. The adjustments provided under this Section 8(e) shall be nondiscretionary and shall be final and binding on the affected Participant and the Company; provided that whether an adjustment is equitable shall be determined by the Administrator.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, including any Equity Restructuring, or if necessary to comply with Applicable Laws or the Code, or for reasons of administrative convenience, the Administrator may, in its sole discretion, refuse to permit the exercise of any Award during a period of up to thirty days prior to the consummation of any such transaction; provided, however, that in the event the vested portion of an Award is not exercisable on the date the Award would otherwise expire pursuant to the terms set forth in the Award Agreement governing such Award as a result of the Administrator&#x2019;s exercise of discretion pursuant to this Section 8(e), then the expiration of the Award shall be extended through the date that is thirty days following the date on which the Administrator first permits the Award to be exercised (but in no event shall the expiration of the Award be extended beyond the tenth anniversary of the date of grant of such Award.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no Participant shall have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Common Stock subject to an Award or the grant or exercise price of any Award. The existence of the Plan, any Award Agreements and the Awards granted hereunder shall not affect or restrict in any way the right or power of the Company to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including without limitation, securities with rights superior to those of the Common Stock or which are convertible into or exchangeable for Common Stock. The Administrator may treat Participants and Awards (or portions thereof) differently under this Section 8.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Provisions Applicable to Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transferability of Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Except as the Administrator may otherwise determine or provide in an Award Agreement or otherwise, in any case in accordance with Applicable Laws, Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Documentation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Each Award shall be evidenced in an Award Agreement, which may be in such form (written, electronic or otherwise) as the Administrator shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Discretion.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Status.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Administrator shall determine the effect on an Award of the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#x2019;s Service Provider status and the extent to which, and the period during which, the Participant, the Participant&#x2019;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Withholding.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Each Participant shall pay to the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with Awards to such Participant no later than the date of the event creating the tax liability. Except as the Administrator may otherwise determine, all such payments shall be made in cash or by certified check. Notwithstanding the foregoing, to the extent permitted by the Administrator, Participants may satisfy such tax obligations in whole or in part by delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value. The Company may, to the extent permitted by Applicable Laws, deduct any such tax obligations from any payment of any kind otherwise due to a Participant.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment of Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Administrator may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or settlement, and converting an Incentive Stock Option to a Non-Qualified Stock Option. The Participant&#x2019;s consent to such action shall be required unless (i) the Administrator determines that the action, taking into account any related action, would not materially and adversely affect the Participant, or (ii) the change is permitted under Section 8 and 10(f) hereof.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conditions on Delivery of Stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in the opinion of the Company&#x2019;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy the requirements of any Applicable Laws. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is determined by the Administrator to be necessary to the lawful issuance and sale of any securities hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acceleration.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Administrator may at any time provide that any Award shall become immediately vested and/or exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Right To Employment or Other Status.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> No person shall have any claim or right to be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an applicable Award Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Rights As Stockholder; Certificates.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Subject to the provisions of the applicable Award Agreement, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">holder of such shares. Notwithstanding any other provision of the Plan, unless otherwise determined by the Administrator or required by any Applicable Laws, the Company shall not be required to deliver to any Participant certificates evidencing shares of Common Stock issued in connection with any Award and instead such shares of Common Stock may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan deemed necessary or appropriate by the Administrator in order to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date and Term of Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Plan shall become effective on the date on which it is adopted by the Board. No Awards shall be granted under the Plan after the completion of ten years from the earlier of (i) the date on which the Plan was adopted by the Board or (ii) the date the Plan was approved by the Company&#x2019;s stockholders, but Awards previously granted may extend beyond that date in accordance with the terms of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment of Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Administrator may amend, suspend or terminate the Plan or any portion thereof at any time; provided that no amendment of the Plan shall materially and adversely affect any Award outstanding at the time of such amendment without the consent of the affected Participant. Awards outstanding under the Plan at the time of any suspension or termination of the Plan shall continue to be governed in accordance with the terms of the Plan and the applicable Award Agreement, as in effect prior to such suspension or termination. The Board shall obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions for Foreign Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company intends that all Awards be structured in compliance with, or to satisfy an exemption from, Section 409A, such that no adverse tax consequences, interest, or penalties under Section 409A apply in connection with any Awards. Notwithstanding anything herein or in any Award Agreement to the contrary, the Administrator may, without a Participant&#x2019;s prior consent, amend this Plan and/or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and actions with retroactive effect) as are necessary or appropriate to preserve the intended tax treatment of Awards under the Plan, including without limitation, any such actions intended to (A) exempt this Plan and/or any Award from the application of Section 409A, and/or (B) comply with the requirements of Section 409A, including without limitation any such regulations, guidance, compliance programs and other interpretative authority that may be issued after the date of grant of any Award. The Company makes no representations or warranties as to the tax treatment of any Award under Section 409A or otherwise. The Company shall have no obligation under this Section 10(f) or otherwise to take any action (whether or not described herein) to avoid the imposition of taxes, penalties or interest under Section 409A with respect to any Award and shall have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute non-compliant, &#x201c;nonqualified deferred compensation&#x201d; subject to the imposition of taxes, penalties and/or interest under Section 409A.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. With respect to any Award that constitutes &#x201c;nonqualified deferred compensation&#x201d; under Section 409A, any payment or settlement of such Award that is to be made upon a termination of a Participant&#x2019;s Service Provider relationship shall, to the extent necessary to avoid the imposition of taxes under Section 409A, be made only upon </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Participant&#x2019;s &#x201c;separation from service&#x201d; (within the meaning of Section 409A), whether such &#x201c;separation from service&#x201d; occurs upon or subsequent to the termination of the Participant&#x2019;s Service Provider relationship. For purposes of any such provision of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean &#x201c;separation from service.&#x201d;</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Payments to Specified Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#x201c;nonqualified deferred compensation&#x201d; that are otherwise required to be made under an Award to a &#x201c;specified employee&#x201d; (as defined under Section 409A and determined by the Administrator) as a result of his or her &#x201c;separation from service&#x201d; shall, to the extent necessary to avoid the imposition of taxes under Code Section </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">409A(a)(2)(B)(i),</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> be delayed until the expiration of the six-month period immediately following such &#x201c;separation from service&#x201d; (or, if earlier, until the date of death of the specified employee) and shall instead be paid (in a manner set forth in the Award agreement) on the day that immediately follows the end of such six-month period or as soon as administratively practicable thereafter (without interest). Any payments of &#x201c;nonqualified deferred compensation&#x201d; under such Award that are, by their terms, payable more than six months following the Participant&#x2019;s &#x201c;separation from service&#x201d; shall be paid at the time or times such payments are otherwise scheduled to be made.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations on Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as an Administrator, director, officer, other employee or agent of the Company. The Company will indemnify and hold harmless each director, officer, other employee and agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be granted or delegated, against any cost or expense (including attorneys&#x2019; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#x2019;s approval) arising out of any act or omission to act concerning this Plan unless arising out of such person&#x2019;s own fraud or bad faith.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lock-Up Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company may, at the request of any representative of the underwriters (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Managing Underwriter</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or otherwise, in connection with any registration of the offering of any securities of the Company under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any shares of Common Stock or other securities of the Company during a period of up to one hundred eighty days following the effective date of a registration statement of the Company filed under the Securities Act.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Right of First Refusal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Before any shares of Common Stock held by a Participant or any permitted transferee (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) may be sold, pledged, assigned, hypothecated, transferred, or otherwise disposed of (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Company or its assignee(s) shall have a right of first refusal to purchase the shares of Common Stock proposed to be Transferred on the terms and conditions set forth in this Section 10(i) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Right of First Refusal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). In the event that the Company&#x2019;s charter, bylaws and/or a stockholders&#x2019; agreement applicable to the shares of Common Stock contain a right of first refusal with respect to the shares of Common Stock, such right of first refusal shall apply to the shares of Common Stock to the extent such provisions are more restrictive than the Right of First Refusal set forth in this Section 10(i) and the Right of First Refusal set forth in this Section 10(i) shall not in any way restrict the operation of the Company&#x2019;s charter, bylaws or the operation of any applicable stockholders&#x2019; agreement.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="ole_link1"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event any Holder desires to Transfer any shares of Common Stock, the Holder shall deliver to the Company a written notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) stating: (A) the Holder&#x2019;s bona fide intention to sell or otherwise Transfer such </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">shares of Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">; (B) the name of each proposed purchaser or other transferee (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Proposed Transferee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); (C) the number of shares of Common Stock to be Transferred to each Proposed Transferee; and (D) the price for which the Holder proposes to Transfer the shares of Common Stock (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Offered Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the Holder shall offer such shares of Common Stock at the Offered Price to the Company or its assignee(s).</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Within twenty-five days after receipt of the Notice, the Company and/or its assignee(s) may elect in writing to purchase all, but not less than all, of the shares of Common Stock proposed to be Transferred to any one or more of the Proposed Transferees by delivery of a written exercise notice to the Holder (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The purchase price (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for the shares of Common Stock repurchased under this Section 10(i) shall be the Offered Price.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check or wire transfer), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof, within five days after delivery of the Company Notice or in the manner and at the times mutually agreed to by the Company and the Holder. Should the Offered Price specified in the Notice be payable in property other than cash, the Company or its assignee shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property, as determined by the Administrator.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If all or a portion of the shares of Common Stock proposed in the Notice to be Transferred are not purchased by the Company and/or its assignee(s) as provided in this Section 10(i), then the Holder may sell or otherwise Transfer such shares of Common Stock to that Proposed Transferee at the Offered Price or at a higher price; provided that such sale or other Transfer is consummated within sixty days after the date of the Notice; and provided, further, that any such sale or other Transfer is effected in accordance with any Applicable Laws and the Proposed Transferee agrees in writing that the provisions of this Plan and the applicable Award Agreement and any other applicable agreements governing the shares of Common Stock to be Transferred shall continue to apply to the shares of Common Stock in the hands of such Proposed Transferee. If the shares of Common Stock described in the Notice are not Transferred to the Proposed Transferee within such sixty-day period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal, as provided herein, before any shares of Common Stock held by the Holder may be sold or otherwise Transferred.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anything to the contrary contained in this Section 10(i) notwithstanding and to the extent permitted by the Administrator, the Transfer of any or all of the shares of Common Stock during a Participant&#x2019;s lifetime or upon a Participant&#x2019;s death by will or intestacy to the Participant&#x2019;s Immediate Family or a trust for the benefit of the Participant&#x2019;s Immediate Family shall be exempt from the Right of First Refusal. As used herein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Immediate Family</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister or stepchild (whether or not adopted). In such case, the transferee or other recipient shall receive and hold the shares of Common Stock so Transferred subject to the provisions of this Plan (including the Right of First Refusal), the applicable Award Agreement and any other applicable agreements governing the shares of Common Stock to be Transferred, and there shall be no further Transfer of such shares of Common Stock except in accordance with the terms of this Section 10(i) (or otherwise as expressly provided under the Plan).</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Right of First Refusal shall terminate as to all shares of Common Stock if the Company becomes a Publicly Listed Company upon such occurrence.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. As a condition of receipt of any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Company and its subsidiaries and affiliates for the exclusive purpose of implementing, administering and managing the Participant&#x2019;s participation in the Plan. The Company and its subsidiaries and affiliates may hold certain personal information about a Participant, including but not limited to, the Participant&#x2019;s name, home address and telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its subsidiaries and affiliates, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company and its subsidiaries and affiliates may transfer the Data amongst themselves as necessary for the purpose of implementation, administration and management of a Participant&#x2019;s participation in the Plan, and the Company and its subsidiaries and affiliates may each further transfer the Data to any third parties assisting the Company in the implementation, administration and management of the Plan. These recipients may be located in the Participant&#x2019;s country, or elsewhere, and the Participant&#x2019;s country may have different data privacy laws and protections than the recipients&#x2019; country. Through acceptance of an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Participant&#x2019;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Company or the Participant may elect to deposit any shares of Common Stock. The Data related to a Participant will be held only as long as is necessary to implement, administer, and manage the Participant&#x2019;s participation in the Plan. A Participant may, at any time, view the Data held by the Company with respect to such Participant, request additional information about the storage and processing of the Data with respect to such Participant, recommend any necessary corrections to the Data with respect to the Participant or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local human resources representative. The Company may cancel Participant&#x2019;s ability to participate in the Plan and, in the Administrator&#x2019;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws his or her consents as described herein. For more information on the consequences of refusal to consent or withdrawal of consent, Participants may contact their local human resources representative.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Severability. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event any portion of the Plan or any action taken pursuant thereto shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provisions had not been included, and the illegal or invalid action shall be null and void.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governing Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of any contradiction between the Plan and any Award Agreement or any other written agreement between a Participant and the Company or any Subsidiary of the Company that has been approved by the Administrator, the terms of the Plan shall govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan shall not apply.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding choice-of-law principles of the law of any state that would require the application of the laws of a jurisdiction other than such state.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restrictions on Shares; Claw-Back Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Shares of Common Stock acquired in respect of Awards shall be subject to such terms and conditions as the Administrator shall determine, including, without limitation, restrictions on the transferability of shares of Common Stock, the right of the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company to repurchase shares of Common Stock, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, tag-along rights, bring-along rights, redemption and co-sale rights and voting requirements. Such terms and conditions may be additional to those contained in the Plan and may, as determined by the Administrator, be contained in the applicable Award Agreement or in an exercise notice, stockholders&#x2019; agreement or in such other agreement as the Administrator shall determine, in each case in a form determined by the Administrator. The issuance of such shares of Common Stock shall be conditioned on the Participant&#x2019;s consent to such terms and conditions and the Participant&#x2019;s entering into such agreement or agreements. All Awards (including any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such claw-back policy and/or in the applicable Award Agreement. Notwithstanding the foregoing, it shall be a condition to the issuance of any shares of Common Stock pursuant to an Award under this Plan that the Participant shall agree in writing to be bound by the terms and conditions of, and become a party to, any stockholders&#x2019; agreement of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Titles and Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The titles and headings of the Sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conformity to Securities Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Participant acknowledges that the Plan is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan and all Awards granted hereunder shall be administered only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by Applicable Laws, the Plan and all Award Agreements shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As used in the Plan, the following words and phrases shall have the following meanings:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board or a Committee to the extent that the Board&#x2019;s powers or authority under the Plan have been delegated to such Committee.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted or issued under the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, individually or collectively, a grant under the Plan of Options, Restricted Stock, Restricted Stock Units or Other Stock-Based Awards.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written agreement evidencing an Award, which agreements may be in electronic medium and shall contain such terms and conditions with respect to an Award as the Administrator shall determine, consistent with and subject to the terms and conditions of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; with respect to a Participant, means &#x201c;Cause&#x201d; (or any term of similar effect) as defined in such Participant&#x2019;s employment agreement with the Company if such an agreement exists and contains a definition of Cause (or term of similar effect), or, if no such agreement exists or such agreement does not contain a definition of Cause (or term of similar effect), then Cause shall include, but not be limited to: (i) the Participant&#x2019;s unauthorized use or disclosure of confidential information or trade secrets of the Company or any material breach of a written agreement between the Participant and the Company, including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement; (ii) the Participant&#x2019;s commission of, indictment for or the entry of a plea of guilty or </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">nolo contendere</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> by the Participant to, a felony under the laws of the United States or any state thereof or any crime involving dishonesty or moral turpitude (or any similar crime in any jurisdiction outside the United States); (iii) the Participant&#x2019;s gross negligence or willful misconduct or the Participant&#x2019;s willful or repeated failure or refusal to substantially perform assigned duties; (iv) any act of fraud, embezzlement, material misappropriation or dishonesty committed by the Participant against the Company; or (v) any acts, omissions or statements by a Participant which the Company reasonably determines to be materially detrimental or damaging to the reputation, operations, prospects or business relations of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) a merger or consolidation of the Company with or into any other corporation or other entity or person, (ii) a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or substantially all of the Company&#x2019;s assets, or (iii) any other transaction, including the sale by the Company of new shares of its capital stock or a transfer of existing shares of capital stock of the Company, the result of which is that a third party that is not an affiliate of the Company or its stockholders (or a group of third parties not affiliated with the Company or its stockholders) immediately prior to such transaction acquires or holds capital stock of the Company representing a majority of the Company&#x2019;s outstanding voting power immediately following such transaction; provided that the following events shall not constitute a &#x201c;Change in Control&#x201d;: (A) a transaction (other than a sale of all or substantially all of the Company&#x2019;s assets) in which the holders of the voting securities of the Company immediately prior to the merger or consolidation hold, directly or indirectly, at least a majority of the voting securities in the successor corporation or its parent immediately after the merger or consolidation; (B) a sale, lease, exchange or other transaction in one transaction or a series of related transactions of all or substantially all of the Company&#x2019;s assets to an affiliate of the Company; (C) an initial public offering of any of the Company&#x2019;s securities; (D) a reincorporation of the Company solely to change its jurisdiction; or (E) a transaction undertaken for the primary purpose of creating a holding company that will be owned in substantially the same proportion by the persons who held the Company&#x2019;s securities immediately before such transaction. Notwithstanding the foregoing, if a Change in Control would give rise to a payment or settlement event with respect to any Award that constitutes &#x201c;nonqualified deferred compensation,&#x201d; the transaction or event constituting the Change in Control must also constitute a &#x201c;change in control event&#x201d; (as defined in Treasury Regulation &#167;1.409A-3(i)(5)) in order to give rise to the payment or settlement event for such Award, to the extent required by Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means one or more committees or subcommittees of the Board, which may be comprised of one or more directors and/or executive officers of the Company, in either case, to the extent permitted in accordance with Applicable Laws.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the common stock of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Oncternal Therapeutics, Inc., a Delaware corporation, or any successor thereto. Except where the context otherwise requires, the term &#x201c;Company&#x201d; includes any of the Company&#x2019;s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Code and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a significant interest, as determined by the Administrator.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">means any person, including any advisor, engaged by the Company or a parent or subsidiary of the Company to render services to such entity.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Designated Beneficiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">means the beneficiary or beneficiaries designated, in a manner determined by the Administrator, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#x2019;s death or incapacity. In the absence of an effective designation by a Participant, &#x201c;Designated Beneficiary&#x201d; shall mean the Participant&#x2019;s estate.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> means a member of the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a permanent and total disability within the meaning of Section 22(e)(3) of the Code, as it may be amended from time to time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a right granted to a Participant pursuant to Section 6(d)(3) hereof to receive the equivalent value (in cash or shares of Common Stock) of dividends paid on shares of Common Stock.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person, including officers and Directors, employed by the Company (within the meaning of Section 3401(c) of the Code) or any parent or subsidiary of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Restructuring</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as determined by the Administrator, a non-reciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the shares of Common Stock (or other securities of the Company) or the share price of Common Stock (or other securities of the Company) and causes a change in the per share value of the Common Stock underlying outstanding Awards.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> means the Securities Exchange Act of 1934, as amended.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date, the value of Stock determined as follows: (i) if the Common Stock is listed on any established stock exchange, its Fair Market Value shall be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the first market trading day immediately prior to such date during which a sale occurred, as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or such other source as the Administrator deems reliable; (ii) if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the last sales price on such date, or if no sales occurred on such date, then on the date immediately prior to such date on which sales prices are reported, as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or such other source as the Administrator deems reliable; or (iii) in the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined by the Administrator.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean (a) a change in the Participant&#x2019;s position with the Company (or its subsidiary employing the Participant) that materially reduces the Participant&#x2019;s authority, duties or responsibilities, (b) a material diminution in the Participant&#x2019;s level of base compensation, except in connection with a general reduction in the base compensation of the Company&#x2019;s personnel with similar status and responsibilities or (c) a relocation of the Participant&#x2019;s place of employment by more than 50 miles, provided that such change, reduction or relocation is effected by the Company (or its subsidiary employing the Participant) without the Participant&#x2019;s consent. Notwithstanding the foregoing, Good Reason shall only exist if Participant shall have provided the Company with written notice within sixty (60) days of the initial occurrence of any of the foregoing events or conditions, and the Company or any successor or affiliate fails to eliminate the conditions constituting Good Reason within thirty (30) days after receipt of </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">15</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">written notice of such event or condition from Participant. Participant's resignation from employment with the Company for &#x201c;Good Reason&#x201d; must occur within six (6) months following the initial occurrence of one of the foregoing events or conditions. Notwithstanding the foregoing, if Participant is a party to a written employment or consulting agreement with the Company (or its subsidiary) in which the term &#x201c;good reason&#x201d; is defined, then &#x201c;Good Reason&#x201d; shall be as such term is defined in the applicable written employment or consulting agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an &#x201c;incentive stock option&#x201d; as defined in Section 422 of the Code.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(w)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Qualified Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">means an Option that is not intended to be or otherwise does not qualify as an Incentive Stock Option.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an option to purchase Common Stock.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Stock-Based Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(z)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> means a Service Provider who has been granted an Award under the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(aa)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this 2015 Equity Incentive Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(bb)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Publicly Listed Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that the Company or its successor (i) is required to file periodic reports pursuant to Section 12 of the Exchange Act and (ii) the Common Stock is listed on one or more National Securities Exchanges (within the meaning of the Exchange Act) or is quoted on NASDAQ or a successor quotation system.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(cc)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Common Stock awarded to a Participant pursuant to Section 6 hereof that is subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(dd)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an unfunded, unsecured right to receive, on the applicable settlement date, one share of Common Stock or an amount in cash or other consideration determined by the Administrator equal to the value thereof as of such payment date, which right may be subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ee)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Section 409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ff)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended from time to time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(gg)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Employee, Consultant or Director.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(hh)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date the Participant ceases to be a Service Provider.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">16</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ONCTERNAL THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2015 EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CALIFORNIA SUPPLEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator has adopted this supplement for purposes of satisfying the requirements of Section 25102(o) of the California Corporations Code and the regulations issued thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 25102(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Notwithstanding anything to the contrary contained in the Plan and except as otherwise determined by the Administrator, the provisions set forth in this supplement shall apply to all Awards granted under the Plan to a Participant who is a resident of the State of California on the date of grant (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">California Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and which are intended to be exempt from registration in California pursuant to Section 25102(o). This supplement shall not apply to Awards granted to California Participants or after the date on which the Company becomes a Publicly Listed Company. Definitions in the Plan are applicable to this supplement.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Limitations On Options</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Maximum Duration of Options.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> No Options granted to California Participants will be granted for a term in excess of 10 years.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Minimum Exercise Period Following Termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Unless a California Participant&#x2019;s Service Provider relationship is terminated for Cause, in the event of termination of such Participant&#x2019;s Service Provider relationship, to the extent required by Applicable Laws, he or she shall have the right to exercise an Option, to the extent that he or she was otherwise entitled to exercise such Option on the date employment terminated, as follows: (i) at least six months from the date of termination, if termination was caused by such Participant&#x2019;s death or Disability and (ii) at least 30 days from the date of termination, if termination was caused other than by such Participant&#x2019;s death or Disability.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Limitations For Restricted Stock Awards, Restricted Stock Units and Other Stock-Based Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The terms of all Restricted Stock Awards, Restricted Stock Units and Other Stock-Based Awards granted to California Participants shall comply, to the extent applicable, with Section 260.140.41 or Section 260.140.42 of the California Code of Regulations.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator will make such adjustments to an Award held by a California Participant as may be required by Section 260.140.41 or Section 260.140.42 of the California Code of Regulations.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Requirement To Provide Information To California Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> To the extent required by Section 260.140.46 of the California Code of Regulations, the Company shall provide to each California Participant and to each California Participant who acquires Common Stock pursuant to the Plan, not less frequently than annually, copies of annual financial statements (which need not be audited). The Company shall not be required to provide such statements to key persons whose duties in connection with the Company assure their access to equivalent information. In addition, this information requirement shall not apply to the Plan to the extent that it complies with all conditions of Rule 701 of the Securities Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 701</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as determined by the Administrator; provided that for purposes of determining such compliance, any registered domestic partner shall be considered a &#x201c;family member&#x201d; as that term is defined in Rule 701.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stockholder Approval; Additional Limitations On Timing Of Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Plan will be submitted for the approval of the Company&#x2019;s stockholders within twelve (12) months after the date of the Board&#x2019;s adoption of the Plan. Awards may be granted or awarded prior to such stockholder approval; provided that no Award granted to a California Participant shall become exercisable, vested or realizable, </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as applicable to such Award, unless the Plan has been approved by the Company&#x2019;s stockholders within twelve months before or after the date the Plan was adopted by the Administrator; and provided, further, that if such approval has not been obtained at the end of said twelve-month period, all Awards previously granted or awarded under the Plan to California Participants shall thereupon be canceled and become null and void.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>6
<FILENAME>onct-ex10_16.htm
<DESCRIPTION>EX-10.16
<TEXT>
<html>
 <head>
  <title>EX-10.16</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="border-top:0.5pt solid;padding-top:6pt;border-right:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;border-left:0.5pt solid;margin-top:0;font-family:Times New Roman;margin-bottom:0;padding-right:1.107%;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</font></p>
  <p style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:0.5pt solid;padding-right:1.107%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2019 INCENTIVE AWARD PLAN</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This plan document has been updated to reflect the Company&#x2019;s one-for-twenty reverse stock split effected by the Company on January 8, 2024.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE I.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Purpose</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Plan&#x2019;s purpose is to enhance the Company&#x2019;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE II.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Eligibility</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE III.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Administration and Delegation</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#x2019;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Appointment of Committees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries. The Board may abolish any Committee or re-vest in itself any previously delegated authority at any time.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE IV.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Available for Awards</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to adjustment under Article VIII and the terms of this Article IV, Awards may be made under the Plan covering up to the Overall Share Limit. As of the Effective Date, the Company will cease granting awards under the Prior Plan; however, Prior Plan Awards will remain subject to the terms of the applicable Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Share Recycling</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards or Prior Plan Awards shall not count against the Overall Share Limit.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Stock Option Limitations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding anything to the contrary herein, no more than 357,142 Shares may be issued pursuant to the exercise of Incentive Stock Options.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Substitute Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In connection with an entity&#x2019;s merger or consolidation with the Company or the Company&#x2019;s acquisition of an entity&#x2019;s property or stock, the Administrator may grant Awards in substitution for any Options or other stock or stock-based awards granted before such merger or consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be added to the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees or Directors prior to such acquisition or combination.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Non-Employee Director Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any provision to the contrary in the Plan, the Administrator may establish compensation for non-employee Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the terms, conditions and amounts of all such non-employee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee Director as compensation for services as a non-employee Director during any fiscal year of the Company may not exceed $750,000 increased to $1,000,000 in the fiscal year of a non-employee Director&#x2019;s initial service as a non-employee Director. The Administrator may make exceptions to this limit for individual non-employee Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the non-employee Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee Directors.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE V.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Stock Options and Stock Appreciation Rights</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator will establish each Option&#x2019;s and Stock Appreciation Right&#x2019;s exercise price and specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Duration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten (10) years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (other than an Incentive Stock Option) (i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a &#x201c;lock-up&#x201d; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is thirty (30) days after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten- (10)-year term of the applicable Option or Stock Appreciation Right. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&#x2019;s Termination of Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of such notice, the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#x2019;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii) the effective date of the Participant&#x2019;s Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such Termination of Service).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i) as specified in Section 5.5 for the number of Shares for which the Award is exercised and (ii) as specified in Section 9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment Upon Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B) the Participant&#x2019;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#x2019;s exercise valued at their Fair Market Value on the exercise date;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE VI.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Restricted Stock; Restricted Stock Units</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the Company&#x2019;s right to repurchase all or part of such Shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such Shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Participants holding Shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Certificates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of Shares of Restricted Stock, together with a stock power endorsed in blank.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#x2019;s election, in a manner intended to comply with Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE VII.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Other Stock or Cash Based Awards</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE VIII.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Adjustments for Changes in Common Stock <br>and Certain Other Events</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Equity Restructuring</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the Award&#x2019;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section 8.1 will be nondiscretionary and final and binding on the affected </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#x2019;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#x2019;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#x2019;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that such Award shall vest and, to the extent applicable, be exercisable as to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of Shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To make adjustments in the number and type of Shares (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article IV hereof on the maximum number and kind of Shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To replace such Award with other rights or property selected by the Administrator; and/or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effect of Non-Assumption in a Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding the provisions of Section 8.2 above, if a Change in Control occurs and a Participant&#x2019;s Awards are not continued, converted, </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">assumed, or replaced with a substantially similar award by (a) the Company, or (b) a Successor Entity (as defined below) or its parent or subsidiary (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assumption</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and provided that the Participant has not had a Termination of Service, then, immediately prior to the Change in Control, such Awards shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse, in which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (i) which may be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, earn-out or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and (ii) determined by reference to the number of Shares subject to such Awards and net of any applicable exercise price; provided that to the extent that any Awards constitute &#x201c;nonqualified deferred compensation&#x201d; that may not be paid upon the Change in Control under Section 409A without the imposition of taxes thereon under Section 409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents); and provided, further, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administrative Stand Still</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of any pending stock dividend, stock split, combination or exchange of Shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty (60) days before or after such transaction.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as expressly provided in the Plan or the Administrator&#x2019;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as expressly provided with respect to an Equity Restructuring under Section 8.1 above or the Administrator&#x2019;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#x2019;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#x2019;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat Participants and Awards (or portions thereof) differently under this Article VIII.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE IX.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>General Provisions Applicable to Awards</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#x2019;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, will include references to a Participant&#x2019;s authorized transferee that the Administrator specifically approves.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Documentation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination of Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator will determine how the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#x2019;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#x2019;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#x2019;s Awards by the date of the event creating the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant. In the absence of a contrary determination by the Company (or, with respect to withholding pursuant to clause (ii) below with respect to Awards held by individuals subject to Section 16 of the Exchange Act, a contrary determination by the Administrator), all tax withholding obligations will be calculated based on the minimum applicable statutory withholding rates. Subject to any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii) to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the Award creating the tax obligation, valued at their Fair Market Value on the date of delivery, (iii) if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. Notwithstanding any other provision of the Plan, the number of Shares which may be so delivered or retained pursuant to clause (ii) of the immediately preceding sentence shall be limited to the number of Shares which have a Fair Market Value on the date of delivery or retention no greater than the aggregate amount of such liabilities based on the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America); provided, however, to the extent such Shares were acquired by Participant from the Company as compensation, the Shares must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#x2019;s earnings for financial reporting purposes; provided, further, that, any such Shares delivered or retained shall be rounded up to the nearest whole Share to the extent rounding up to the nearest whole Share does not result in the liability classification of the applicable Award under generally accepted accounting principles in the United States of America. If any tax withholding obligation will be satisfied under clause (ii) above by the Company&#x2019;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#x2019;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#x2019;s acceptance of an Award under the Plan will constitute the Participant&#x2019;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment of Award; Repricing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a Non-Qualified Stock Option. The Participant&#x2019;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#x2019;s rights under the Award, or (ii) the change is permitted under Article VIII or pursuant to Section 10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conditions on Delivery of Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i) all Award conditions have been met or removed to the Company&#x2019;s satisfaction, (ii) as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#x2019;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Additional Terms of Incentive Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections 424(e) or (f) of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&#x2019;s grant date, and the term of the Option will not exceed five (5) years. All Incentive Stock Options will be subject to and construed consistently with Section 422 of the Code. By accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i) two years from the grant date of the Option or (ii) one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#x201c;incentive stock option&#x201d; under Section 422 of the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &#x201c;incentive stock option&#x201d; under Section 422 of the Code for any reason, including becoming exercisable with respect to Shares having a Fair Market Value exceeding the $100,000 limitation under Treasury Regulation Section 1.422-4, will be a Non-Qualified Stock Option.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE X.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Miscellaneous</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Right to Employment or Other Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Rights as Stockholder; Certificates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date and Term of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Plan was approved by the Board on April 16, 2019. The Plan shall be effective (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on the day prior to the date of the closing of the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of March 6, 2019 by and among the Company, Grizzly Merger Sub, Inc. and Oncternal Therapeutics, Inc. (as amended, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Merger Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), provided that it is approved by a majority of the Company&#x2019;s stockholders at a duly held meeting prior to such date and occurring within twelve (12) months following the date the Board approved Plan, and provided further that the effectiveness of the Plan is subject to the consummation of the transactions contemplated by the Merger Agreement. If the Plan is not approved by the Company&#x2019;s stockholders within the foregoing time frame, or if the Merger Agreement is terminated prior to the consummation of the transactions contemplated thereby, the Plan will not become effective. The Plan shall remain in effect until the tenth (10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) anniversary of the date the Board adopted the Plan, but Awards previously granted may extend beyond that date in accordance with the Plan. The Plan will be submitted for approval of the Company's stockholders within twelve (2) months following the date the Board approved the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#x2019;s consent. No Awards may be granted under the Plan during any suspension period or after the Plan&#x2019;s termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Provisions for Foreign Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company intends that all Awards be structured to comply with, or be exempt from, Section 409A, such that no adverse tax consequences, interest, or penalties under Section </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#x2019;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to (A) exempt this Plan or any Award from Section 409A, or (B) comply with Section 409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#x2019;s grant date. The Company makes no representations or warranties as to an Award&#x2019;s tax treatment under Section 409A or otherwise. The Company will have no obligation under this Section 10.6 or otherwise to avoid the taxes, penalties or interest under Section 409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#x201c;nonqualified deferred compensation&#x201d; subject to taxes, penalties or interest under Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If an Award constitutes &#x201c;nonqualified deferred compensation&#x201d; under Section 409A, any payment or settlement of such Award upon a termination of a Participant&#x2019;s Service Provider relationship will, to the extent necessary to avoid taxes under Section 409A, be made only upon the Participant&#x2019;s &#x201c;separation from service&#x201d; (within the meaning of Section 409A), whether such &#x201c;separation from service&#x201d; occurs upon or after the termination of the Participant&#x2019;s Service Provider relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms means a &#x201c;separation from service.&#x201d;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payments to Specified Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#x201c;nonqualified deferred compensation&#x201d; required to be made under an Award to a &#x201c;specified employee&#x201d; (as defined under Section 409A and as the Administrator determines) due to his or her &#x201c;separation from service&#x201d; will, to the extent necessary to avoid taxes under Section 409A(a)(2)(B)(i) of the Code, be delayed for the six- (6)-month period immediately following such &#x201c;separation from service&#x201d; (or, if earlier, until the specified Employee&#x2019;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six- (6)month period or as soon as administratively practicable thereafter (without interest). Any payments of &#x201c;nonqualified deferred compensation&#x201d; under such Award payable more than six (6) months following the Participant&#x2019;s &#x201c;separation from service&#x201d; will be paid at the time or times the payments are otherwise scheduled to be made.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitations on Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other Employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other Employee or agent of the Company or any Subsidiary. The Company will indemnify and hold harmless each director, officer, other Employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#x2019;s administration or interpretation, against any cost or expense (including attorneys&#x2019; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#x2019;s approval) arising from any act or omission concerning this Plan unless arising from such person&#x2019;s own fraud or bad faith.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#x2019;s participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#x2019;s name, address and telephone number; birthdate; social security, insurance number or other </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#x2019;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#x2019;s country, or elsewhere, and the Participant&#x2019;s country may have different data privacy laws and protections than the recipients&#x2019; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#x2019;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#x2019;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section 10.8 in writing, without cost, by contacting the local human resources representative. The Company may cancel Participant&#x2019;s ability to participate in the Plan and, in the Administrator&#x2019;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section 10.8. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#x2019;s choice-of-law principles requiring the application of a jurisdiction&#x2019;s laws other than the State of Delaware.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Claw-back Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. All Awards (including, without limitation, any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any Shares underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as and to the extent set forth in such claw-back policy or the Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Titles and Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#x2019;s text, rather than such titles or headings, will control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conformity to Securities Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Relationship to Other Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.16</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Broker-Assisted Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section 9.5: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b) such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (c) the applicable Participant will be responsible for all broker&#x2019;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f) in the event the proceeds of such sale are insufficient to satisfy the Participant&#x2019;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#x2019;s obligation.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE XI.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Definitions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As used in the Plan, the following words and phrases will have the following meanings:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board or a Committee to the extent that the Board&#x2019;s powers or authority under the Plan have been delegated to such Committee.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (a) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#x201c;cause&#x201d; is defined, &#x201c;Cause&#x201d; as defined in such agreement, and (b) if no such agreement exists, (i) the Administrator&#x2019;s determination that the Participant failed to substantially perform the Participant&#x2019;s duties (other than any such failure resulting from the Participant&#x2019;s Disability); (ii) the Administrator&#x2019;s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#x2019;s immediate supervisor; (iii) the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participant&#x2019;s conviction, plea of no contest, plea </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral turpitude; (iv) the Participant&#x2019;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#x2019;s duties and responsibilities for the Company or any of its Subsidiaries; or (v) the Participant&#x2019;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means and includes each of the following:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any &#x201c;person&#x201d; or related &#x201c;group&#x201d; of &#x201c;persons&#x201d; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#x201c;person&#x201d; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#x2019;s securities outstanding immediately after such acquisition; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">During any period of two (2) consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#x2019;s stockholders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two- (2)-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company&#x2019;s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">which results in the Company&#x2019;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#x2019;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Successor Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#x2019;s outstanding voting securities immediately after the transaction, and</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, (x) the transactions contemplated by the Merger Agreement shall not constitute a Change in Control for purposes of this Plan, and (y) if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#x201c;change in control event&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule 16b-3, it is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule 16b-3, a &#x201c;non-employee director&#x201d; within the meaning of Rule 16b-3; however, a Committee member&#x2019;s failure to qualify as a &#x201c;non-employee director&#x201d; within the meaning of Rule 16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the common stock of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Oncternal Therapeutics, Inc., a Delaware corporation (f/k/a GTx, Inc.), or any successor.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser: (a) renders bona fide services to the Company; (b) renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#x2019;s securities; and (c) is a natural person.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Designated Beneficiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#x2019;s rights if the Participant dies or becomes incapacitated. Without a Participant&#x2019;s effective designation, &#x201c;Designated Beneficiary&#x201d; will mean the Participant&#x2019;s estate.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Board member.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a permanent and total disability under Section 22(e)(3) of the Code, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.16</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.17</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any employee of the Company or its Subsidiaries.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">15</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.18</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Restructuring</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.19</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.20</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date, the value of a Share determined as follows: (a) if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or another source the Administrator deems reliable; (b) if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or another source the Administrator deems reliable; or (c) without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.21</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (a) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#x201c;good reason&#x201d; is defined, &#x201c;Good Reason&#x201d; as defined in such agreement, and (b) if no such agreement exists, (i) a change in the Participant&#x2019;s position with the Company (or its Subsidiary employing the Participant) that materially reduces the Participant&#x2019;s authority, duties or responsibilities or the level of management to which he or she reports, (ii) a material diminution in the Participant&#x2019;s level of compensation (including base salary, fringe benefits and target bonuses under any corporate performance-based incentive programs) or (iii) a relocation of the Participant&#x2019;s place of employment by more than 50 miles, provided that such change, reduction or relocation is effected by the Company (or its Subsidiary employing the Participant) without the Participant&#x2019;s consent.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.22</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Greater Than 10% Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an individual then owning (within the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company, its parent or subsidiary corporation, as defined in Section 424(e) and (f) of the Code, respectively.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.23</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Option intended to qualify as an &#x201c;incentive stock option&#x201d; as defined in Section 422 of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.24</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Qualified Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Option not intended or not qualifying as an Incentive Stock Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.25</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an option to purchase Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.26</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Stock or Cash Based Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.27</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overall Share Limit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the sum of (a) 83,938 Shares; (b) any Shares which are subject to Prior Plan Awards as of the Effective Date which become available for issuance under the Plan pursuant to Article IV (which number added to the Overall Share Limit pursuant to this clause (b) shall not exceed 13,917 Shares); and (c) an annual increase on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029, equal to the lesser of (i) 5% of the aggregate number </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">16</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of Shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of Shares as is determined by the Board.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.28</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Service Provider who has been granted an Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.29</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Criteria</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#x2019; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#x2019;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. The Committee may provide for exclusion of the impact of an event or occurrence which the Committee determines should appropriately be excluded, including (a) restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges or events, (b) asset write-downs, (c) litigation or claim judgments or settlements, (d) acquisitions or divestitures, (e) reorganization or change in the corporate structure or capital structure of the Company, (f) an event either not directly related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g) foreign exchange gains and losses, (h) a change in the fiscal year of the Company, (i) the refinancing or repurchase of bank loans or debt securities, (j) unbudgeted capital expenditures, (k) the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l) conversion of some or all of convertible securities to Common Stock, (m) any business interruption event (n) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles, or (o) the effect of changes in other laws or regulatory rules affecting reported results.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.30</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Oncternal Therapeutics, Inc. 2019 Incentive Award Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.31</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prior Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the GTx, Inc. 2013 Equity Incentive Plan, as amended to date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.32</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prior Plan Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an award outstanding under the Prior Plan as of the Plan&#x2019;s effective date under Section 10.3.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">17</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.33</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Shares awarded to a Participant under Article VI subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.34</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.35</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.36</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Section 409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.37</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.38</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Employee, Consultant or Director.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.39</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means shares of Common Stock.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.40</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a stock appreciation right granted under Article V.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.41</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.42</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Substitute Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.43</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date the Participant ceases to be a Service Provider.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">* * * * *</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">18</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>7
<FILENAME>onct-ex10_17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html>
 <head>
  <title>EX-10.17</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="border-top:0.5pt solid;padding-top:6pt;border-right:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;border-left:0.5pt solid;margin-top:0;font-family:Times New Roman;margin-bottom:0;padding-right:1.107%;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc.</font></p>
  <p style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:0.5pt solid;padding-right:1.107%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This plan document has been updated to reflect the Company&#x2019;s one-for-twenty reverse stock split effected by the Company on January 8, 2024.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE I.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Purpose</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Plan&#x2019;s purpose is to enhance the Company&#x2019;s ability to attract, retain and motivate Eligible Persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE II.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Eligibility</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Eligible Persons are eligible to be granted Awards under the Plan, subject to the limitations described herein.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE III.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Administration and Delegation</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Plan is administered by the Committee. The Administrator has authority to determine which Eligible Persons receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#x2019;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award. The Board may abolish the Committee or re-vest in itself any previously delegated authority at any time; provided, however, that any action taken by the Board in connection with the administration of the Plan shall not be deemed approved by the Board unless such actions are approved by a majority of the Independent Directors. Awards under the Plan will be approved by (a) the Company&#x2019;s Compensation Committee comprised entirely of Independent Directors or (b) a majority of the Company&#x2019;s Independent Directors.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3.2	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Actions Required Upon Grant of Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Following the issuance of any Award under the Plan, the Company shall, in accordance with the listing requirements of the applicable securities exchange, (a) promptly issue a press release disclosing the material terms of the grant, including the recipient(s) of the grant and the number of shares involved (and if the disclosure relates to an award to only one person, or to executive officers, or the award was individually negotiated, then the disclosure must include the identity of the recipient), and (b) notify the applicable securities exchange of such grant no later than the earlier to occur of (i) five calendar days after entering into the agreement to issue the Award or (ii) the date of the public announcement of the Award.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE IV.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Available for Awards</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to adjustment under Article VIII and the terms of this Article IV, Awards may be made under the Plan covering up to the Overall Share Limit. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Share Recycling</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If all or any part of an Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award, the unused Shares covered by the Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not count against the Overall Share Limit.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE V.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Stock Options and Stock Appreciation Rights</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may grant Options or Stock Appreciation Rights to Eligible Persons subject to the limitations in the Plan. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement. All Options granted under the Plan shall be Non-Qualified Stock Options.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator will establish each Option&#x2019;s and Stock Appreciation Right&#x2019;s exercise price and specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Duration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten (10) years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a &#x201c;lock-up&#x201d; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is thirty (30) days after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten- (10)-year term of the applicable Option or Stock Appreciation Right. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&#x2019;s Termination of Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of such notice, the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#x2019;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii) the effective date of the Participant&#x2019;s Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such Termination of Service).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i) as specified in Section 5.5 for the number of Shares for which the Award is exercised and (ii) as specified in Section 9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment Upon Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B) the Participant&#x2019;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#x2019;s exercise valued at their Fair Market Value on the exercise date;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE VI.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Restricted Stock; Restricted Stock Units</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Eligible Person, subject to the Company&#x2019;s right to repurchase all or part of such Shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such Shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to Eligible Persons Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Participants holding Shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Certificates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of Shares of Restricted Stock, together with a stock power endorsed in blank.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#x2019;s election, in a manner intended to comply with Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE VII.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Other Stock or Cash Based Awards</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">long-term cash bonus awards, in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal, transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE VIII.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Adjustments for Changes in Common Stock <br>and Certain Other Events</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Equity Restructuring</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the Award&#x2019;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section 8.1 will be nondiscretionary and final and binding on the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#x2019;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#x2019;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#x2019;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that such Award shall vest and, to the extent applicable, be exercisable as to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of Shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To make adjustments in the number and type of Shares (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article IV hereof on the maximum number and kind of Shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To replace such Award with other rights or property selected by the Administrator; and/or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effect of Non-Assumption in a Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding the provisions of Section 8.2 above, if a Change in Control occurs and a Participant&#x2019;s Awards are not continued, converted, assumed, or replaced with a substantially similar award by (a) the Company, or (b) a Successor Entity (as defined below) or its parent or subsidiary (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assumption</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and provided that the Participant has not had a Termination of Service, then, immediately prior to the Change in Control, such Awards shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse, in which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (i) which may be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, earn-out or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and (ii) determined by reference to the number of Shares subject to such Awards and net of any applicable exercise price; provided that to the extent that any Awards constitute &#x201c;nonqualified deferred compensation&#x201d; that may not be paid upon the Change in Control under Section 409A without the imposition of taxes thereon under Section 409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents); and provided, further, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administrative Stand Still</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of any pending stock dividend, stock split, combination or exchange of Shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty (60) days before or after such transaction.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as expressly provided in the Plan or the Administrator&#x2019;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as expressly provided with respect to an Equity Restructuring under Section 8.1 above or the Administrator&#x2019;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#x2019;s grant or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#x2019;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat Participants and Awards (or portions thereof) differently under this Article VIII.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE IX.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>General Provisions Applicable to Awards</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as the Administrator may determine or provide in an Award Agreement or otherwise, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#x2019;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, will include references to a Participant&#x2019;s authorized transferee that the Administrator specifically approves.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Documentation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination of Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator will determine how the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#x2019;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#x2019;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#x2019;s Awards by the date of the event creating the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant. In the absence of a contrary determination by the Company (or, with respect to withholding pursuant to clause (ii) below with respect to Awards held by individuals subject to Section 16 of the Exchange Act, a contrary determination by the Administrator), all tax withholding obligations will be calculated based on the minimum applicable statutory withholding rates. Subject to any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii) to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the Award creating the tax obligation, valued at their Fair Market Value on the date of delivery, (iii) if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. Notwithstanding any other provision of the Plan, the number of Shares which may be so delivered or retained pursuant to clause (ii) of the immediately preceding sentence shall be limited to the number of Shares which have a Fair Market Value on the date of delivery or retention no greater than the aggregate amount of such liabilities based on the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America); provided, however, to the extent such Shares were acquired by Participant from the Company as compensation, the Shares must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#x2019;s earnings for financial reporting purposes; provided, further, that, any such Shares delivered or retained shall be rounded up to the nearest whole Share to the extent rounding up to the nearest whole Share does not result in the liability classification of the applicable Award under generally accepted accounting principles in the United States of America. If any tax withholding obligation will be satisfied under clause (ii) above by the Company&#x2019;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#x2019;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#x2019;s acceptance of an Award under the Plan will constitute the Participant&#x2019;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment of Award; Repricing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type and changing the exercise or settlement date. The Participant&#x2019;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#x2019;s rights under the Award, or (ii) the change is permitted under Article VIII or pursuant to Section 10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conditions on Delivery of Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i) all Award conditions have been met or removed to the Company&#x2019;s satisfaction, (ii) as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#x2019;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE X.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Miscellaneous</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Right to Employment or Other Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Rights as Stockholder; Certificates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date and Term of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Plan shall be effective on the date approved by the Board. The Plan shall remain in effect until terminated by the Administrator, but Awards previously granted may extend beyond that date in accordance with the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#x2019;s consent. No Awards may be granted under the Plan during any suspension period or after the Plan&#x2019;s termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Provisions for Foreign Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company intends that all Awards be structured to comply with, or be exempt from, Section 409A, such that no adverse tax consequences, interest, or penalties under Section 409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#x2019;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to (A) exempt this Plan or any Award from Section 409A, or (B) comply with Section 409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#x2019;s grant date. The Company makes no representations or warranties as to an Award&#x2019;s tax treatment under Section 409A or otherwise. The Company will have no obligation under this Section 10.6 or otherwise to avoid the taxes, penalties or interest under Section 409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#x201c;nonqualified deferred compensation&#x201d; subject to taxes, </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">penalties or interest under Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If an Award constitutes &#x201c;nonqualified deferred compensation&#x201d; under Section 409A, any payment or settlement of such Award upon a termination of a Participant&#x2019;s Service Provider relationship will, to the extent necessary to avoid taxes under Section 409A, be made only upon the Participant&#x2019;s &#x201c;separation from service&#x201d; (within the meaning of Section 409A), whether such &#x201c;separation from service&#x201d; occurs upon or after the termination of the Participant&#x2019;s Service Provider relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms means a &#x201c;separation from service.&#x201d;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payments to Specified Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#x201c;nonqualified deferred compensation&#x201d; required to be made under an Award to a &#x201c;specified employee&#x201d; (as defined under Section 409A and as the Administrator determines) due to his or her &#x201c;separation from service&#x201d; will, to the extent necessary to avoid taxes under Section 409A(a)(2)(B)(i) of the Code, be delayed for the six- (6)-month period immediately following such &#x201c;separation from service&#x201d; (or, if earlier, until the specified employee&#x2019;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six- (6)month period or as soon as administratively practicable thereafter (without interest). Any payments of &#x201c;nonqualified deferred compensation&#x201d; under such Award payable more than six (6) months following the Participant&#x2019;s &#x201c;separation from service&#x201d; will be paid at the time or times the payments are otherwise scheduled to be made.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitations on Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other Employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other Employee or agent of the Company or any Subsidiary. The Company will indemnify and hold harmless each director, officer, other Employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#x2019;s administration or interpretation, against any cost or expense (including attorneys&#x2019; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#x2019;s approval) arising from any act or omission concerning this Plan unless arising from such person&#x2019;s own fraud or bad faith.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#x2019;s participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#x2019;s name, address and telephone number; birthdate; social security, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#x2019;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#x2019;s country, or elsewhere, and the Participant&#x2019;s country may have different data privacy laws and protections than the recipients&#x2019; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#x2019;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant will be held only as long as necessary to implement, administer, and manage the Participant&#x2019;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section 10.8 in writing, without cost, by contacting the local human resources representative. The Company may cancel Participant&#x2019;s ability to participate in the Plan and, in the Administrator&#x2019;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section 10.8. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#x2019;s choice-of-law principles requiring the application of a jurisdiction&#x2019;s laws other than the State of Delaware.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Claw-back Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. All Awards (including, without limitation, any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any Shares underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as and to the extent set forth in such claw-back policy or the Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Titles and Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#x2019;s text, rather than such titles or headings, will control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conformity to Securities Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Relationship to Other Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.16</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Broker-Assisted Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section 9.5: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b) such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">receive an average price; (c) the applicable Participant will be responsible for all broker&#x2019;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f) in the event the proceeds of such sale are insufficient to satisfy the Participant&#x2019;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#x2019;s obligation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.17</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. It is expressly intended that approval of the Company&#x2019;s stockholders not be required as a condition of the effectiveness of the Plan, and the Plan&#x2019;s provisions shall be interpreted in a manner consistent with such intent for all purposes. Specifically, Nasdaq Stock Market Rule 5635(c) generally requires stockholder approval for stock option plans or other equity compensation arrangements adopted by companies whose securities are listed on the Nasdaq Stock Market pursuant to which stock awards or stock may be acquired by officers, directors, employees or consultants of such companies. Nasdaq Stock Market Rule 5635(c)(4) provides an exemption in certain circumstances for &#x201c;employment inducement&#x201d; awards (within the meaning of Nasdaq Stock Market Rule 5635(c)(4)). Notwithstanding anything to the contrary herein, if the Company&#x2019;s securities are traded on the Nasdaq Stock Market, then Awards under the Plan may only be made to Employees who have not previously been an Employee or director of the Company or any Subsidiary, or following a bona fide period of non-employment by the Company or any Subsidiary, in each case as an inducement material to the Employee&#x2019;s entering into employment with the Company or any Subsidiary. Awards under the Plan will be approved by (a) the Company&#x2019;s Compensation Committee comprised entirely of Independent Directors or (b) a majority of the Company&#x2019;s Independent Directors. Accordingly, pursuant to Nasdaq Stock Market Rule 5635(c)(4), the issuance of Awards and the shares issuable upon exercise or vesting of such Awards pursuant to the Plan are not subject to the approval of the Company&#x2019;s stockholders.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE XI.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Definitions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As used in the Plan, the following words and phrases will have the following meanings:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Committee.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (a) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#x201c;cause&#x201d; is defined, &#x201c;Cause&#x201d; as defined in such agreement, and (b) if no such agreement exists, (i) the Administrator&#x2019;s determination that the Participant failed to substantially perform the Participant&#x2019;s duties (other than any such failure resulting from the Participant&#x2019;s Disability); (ii) the Administrator&#x2019;s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#x2019;s immediate supervisor; (iii) the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participant&#x2019;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral turpitude; (iv) the Participant&#x2019;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#x2019;s duties and responsibilities for the Company or any of its Subsidiaries; or (v) the Participant&#x2019;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means and includes each of the following:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any &#x201c;person&#x201d; or related &#x201c;group&#x201d; of &#x201c;persons&#x201d; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#x201c;person&#x201d; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#x2019;s securities outstanding immediately after such acquisition; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">During any period of two (2) consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#x2019;s stockholders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two- (2)-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company&#x2019;s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">which results in the Company&#x2019;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#x2019;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Successor Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#x2019;s outstanding voting securities immediately after the transaction, and</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, (x) the transactions contemplated by the Merger Agreement shall not constitute a Change in Control for purposes of this Plan, and (y) if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#x201c;change in control event&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee of the Board comprised of two or more Directors, each of whom is intended to qualify as a Non-Employee Director and an Independent Director.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the common stock of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Oncternal Therapeutics, Inc., a Delaware corporation, or any successor.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser: (a) renders bona fide services to the Company; (b) renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#x2019;s securities; and (c) is a natural person.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Designated Beneficiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#x2019;s rights if the Participant dies or becomes incapacitated. Without a Participant&#x2019;s effective designation, &#x201c;Designated Beneficiary&#x201d; will mean the Participant&#x2019;s estate.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Board member.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a permanent and total disability under Section 22(e)(3) of the Code, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.16</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.17</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eligible Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any prospective Employee who has not previously been an Employee or Director of the Company or any Subsidiary, or who is commencing employment with the Company or any Subsidiary following a bona fide period of non-employment by the Company or any Subsidiary, if he or she is granted an Award in connection with his or her commencement of employment with the Company or any Subsidiary and such grant is an inducement material to his or her entering into employment with the Company or any Subsidiary (within the meaning of Nasdaq Stock Market Rule IM-5636-1 or any successor rule, if the Company&#x2019;s securities are traded on the Nasdaq Stock Market, and/or the applicable requirements of any other established stock exchange on which the Company&#x2019;s securities are traded, as applicable, as such rules and requirements may be amended from time to time). The Administrator may in its discretion adopt procedures from time to time to ensure that a prospective Employee is eligible to participate in the Plan prior to the granting of any Awards to such individual under the Plan (including without limitation a requirement that each such prospective Employee certify to the Company prior to the receipt of an Award under the Plan that he or she has not been previously employed by the Company or any Subsidiary, or if previously employed, has had a bona fide period of non-employment, and that the grant of Awards under the Plan is an inducement material to his or her agreement to enter into employment with the Company or any Subsidiary).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.18</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any employee of the Company or its Subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.19</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Restructuring</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.20</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.21</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date, the value of a Share determined as follows: (a) if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or another source the Administrator deems reliable; (b) if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or another source the Administrator deems reliable; or (c) without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.22</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (a) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#x201c;good reason&#x201d; is defined, &#x201c;Good Reason&#x201d; as defined in such agreement, and (b) if no such agreement exists, (i) a change in the Participant&#x2019;s position with the Company (or its Subsidiary employing the Participant) that materially reduces the Participant&#x2019;s authority, duties or responsibilities or the level of management to which he or she reports, (ii) a material diminution in the Participant&#x2019;s level of compensation (including base salary, fringe benefits and target bonuses under any corporate performance-based incentive programs) or (iii) a relocation of the Participant&#x2019;s place of employment by more than 50 miles, provided that such change, reduction or relocation is effected by the Company (or its Subsidiary employing the Participant) without the Participant&#x2019;s consent.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.23</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Independent Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Director of the Company who is not an Employee of the Company or any Subsidiary and who qualifies as &#x201c;independent&#x201d; within the meaning of Nasdaq Stock </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">15</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Market Rule 5605(a)(2), or any successor rule, if the Company&#x2019;s securities are traded on the Nasdaq Stock Market, and/or the applicable requirements of any other established stock exchange on which the Company&#x2019;s securities are traded, as applicable, as such rules and requirements may be amended from time to time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.24</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a &#x201c;non-employee director&#x201d; within the meaning of Rule 16b-3.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.25</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Qualified Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Option not intended or not qualifying as an &#x201c;incentive stock option&#x201d; as defined in Section 422 of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.26</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an option to purchase Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.27</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Stock or Cash Based Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.28</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overall Share Limit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means 140,000 Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.29</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Eligible Person who has been granted an Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.30</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.31</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Shares awarded to a Participant under Article VI subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.32</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.33</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.34</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Section 409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.35</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.36</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Employee, Consultant or Director.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.37</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means shares of Common Stock.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.38</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a stock appreciation right granted under Article V.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.39</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.40</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date the Participant ceases to be a Service Provider.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">* * * * *</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">16</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5B
<SEQUENCE>8
<FILENAME>onct-ex10_5b.htm
<DESCRIPTION>EX-10.5B
<TEXT>
<html>
 <head>
  <title>EX-10.5B</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.5B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Item 601(b)(10). Such excluded information is not material and would likely cause</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">competitive harm to the registrant if publicly disclosed.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">SECOND AMENDMENT TO THE AMENDED AND RESTATED LICENSE <br>AGREEMENT BETWEEN THE UNIVERSITY OF TENNESSEE <br>RESEARCH FOUNDATION AND ONCTERNAL THERAPEUTICS, INC.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Second Amendment to the Amended and Restated License Agreement Between the University of Tennessee Research Foundation and Oncternal Therapeutics, Inc. (&#x201c;First Amendment&#x201d;), effective as of the latest date of signing below, between the University of Tennessee Research Foundation, having an office at 910 Madison Avenue, Suite 827, Memphis TN 38163 (&#x201c;UTRF&#x201d;) and Oncternal Therapeutics, Inc., a company organized and existing under the laws of California and having its principal place of business at 12230 El Camino Real, Suite 230, San Diego, CA 92130 (&#x201c;LICENSEE&#x201d;), herein after referred to as the &#x201c;Parties.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BACKGROUND</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, UTRF and LICENSEE entered into the Amended and Restated License Agreement between University of Tennessee Research Foundation and Oncternal Therapeutics, Inc. (&#x201c;Agreement&#x201d;) having an Effective Date of March 9, 2022;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, UTRF and LICENSEE entered into a First Amendment to the Amended and Restated License between University of Tennessee Research Foundation and Oncternal Therapeutics (&#x201c;First Amendment&#x201d;) having an Effective Date of August 22, 2022 adding additional patents and invention disclosures to Article 1.6 and to update the table of Licensed Patents in Appendix A; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, the Parties desire to amend the Agreement to include additional invention disclosures within Article 1.6 and to update the table of Licensed Patents in Appendix A;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, the Parties hereto agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 1 AMENDMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.1	Article 1.6 is amended to read as follows:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.6	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Invention Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the UTRF file numbers:</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(h)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	[***].</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.5B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(j)	[***].</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.2	Delete Appendix A in the First Amendment in its entirety and replace with the Appendix A attached to this Second Amendment.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.3	ALL OTHER PROVISIONS of the Agreement and First Amendment shall remain in full force and effect.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 2 MISCELLANEOUS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.1	This Second Amendment is entered into in the State of Tennessee and shall be construed, interpreted and applied in accordance with the laws of the State of Tennessee without giving effect to any conflict of laws provisions thereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.2	The Parties hereto acknowledge that this Second Amendment together with the Agreement and First Amendment sets forth the entire understanding and agreement hereto as to the subject matter thereof and supersedes all prior understandings and agreements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.3	The provisions of this Second Amendment are severable, and in the event that any provision shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Parties execute this Second Amendment by their duly authorized representatives and acknowledge that they understand and agree to be bound by its terms and conditions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.5B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.26%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:49.22%;"></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (&#x201c;UTRF&#x201d;)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ONCTERNAL THERAPEUTICS, INC.<br>(&#x201c;LICENSEE&#x201d;)</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Signature: /s/ Todd A. Ponzio, Ph.D.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James B. Breitmeyer, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: 	Todd A. Ponzio, Ph.D.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: James B. Breitmeyer, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title: VP, UTRF</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Title: President &amp; CEO</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 4, 2024</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 4, 2024</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.5B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">APPENDIX A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>onct-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No.333-254985) and Form S-8 (Nos. 333-233288, 333-254581, and 333-263703) of Oncternal Therapeutics, Inc. (the Company) of our report dated March 7, 2024, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company&#x2019;s ability to continue as a going concern.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ BDO USA, P.C.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 7, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Trebuchet MS',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Trebuchet MS',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>onct-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, James B. Breitmeyer, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Oncternal Therapeutics, Inc.;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"></td>
    <td style="width:2%;"></td>
    <td style="width:49%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James B. Breitmeyer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated: March 7, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>onct-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Richard G. Vincent, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Oncternal Therapeutics, Inc.;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"></td>
    <td style="width:2%;"></td>
    <td style="width:49%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Richard G. Vincent</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated: March 7, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>onct-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Oncternal Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, James B. Breitmeyer, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.84%;"></td>
    <td style="width:46.16%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James B. Breitmeyer</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 7, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>13
<FILENAME>onct-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Oncternal Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Richard G. Vincent, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.84%;"></td>
    <td style="width:46.16%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Richard G. Vincent</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 7, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\109979343.1||</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>14
<FILENAME>onct-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">EXHIBIT 97.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="oncternal_therapeutics_inc_"><img src="img224024147_0.jpg" alt="img224024147_0.jpg" style="width:254px;height:71px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;" id="x7a70fc23cb2e32cf50a6c7f2f3e44d0d509e11c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Policy for Recovery of Erroneously Awarded Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Oncternal Therapeutics, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Oncternal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) has adopted this Policy for Recovery of Erroneously Awarded Compensation (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;), effective as of October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;). Capitalized terms used in this Policy but not otherwise defined are defined under the heading &#x201c;Definitions.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="persons_subject_to_policy"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Persons Subject to Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Policy applies to current and former Officers of Oncternal.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="compensation_subject_to_policy"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Compensation Subject to Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Policy applies to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date on which Incentive-Based Compensation is &#x201c;received&#x201d; shall be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is &#x201c;received&#x201d; in Oncternal&#x2019;s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied, without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="recovery_of_compensation"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recovery of Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">If Oncternal is required to prepare a Restatement, Oncternal shall recover, reasonably promptly, the portion of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) of Oncternal has determined that recovery would be Impracticable. Recovery shall be required in accordance with the preceding sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by Oncternal. For clarity, the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any person&#x2019;s right to voluntarily terminate employment for &#x201c;good reason,&#x201d; or due to a &#x201c;constructive termination&#x201d; (or any similar term of like effect) under any plan, program or policy of or agreement with Oncternal or any of its affiliates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="x9039599d90eb2a7e9e4ae8bab165cf25f084222"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Manner of Recovery; Limitation on Duplicative Recovery</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Committee shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation, reduction or cancellation by Oncternal or an affiliate of Oncternal of Incentive-Based Compensation or Erroneously Awarded Compensation, reimbursement or repayment by any person subject to this Policy of the Erroneously Awarded Compensation, and, to the extent permitted by law, an offset of the Erroneously Awarded Compensation against other compensation payable by Oncternal or an affiliate of Oncternal to such person. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation already recovered by Oncternal pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously Awarded Compensation already recovered by Oncternal from the recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">of such Erroneously Awarded Compensation may be credited to the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="administration"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such purpose. The Board may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law, and in such event references in this Policy to the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; shall be deemed to be references to the Board. Subject to any permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including Oncternal and its affiliates, equityholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of Oncternal, as permitted under applicable law, including any Applicable Rules.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="interpretation"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Interpretation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Policy will be interpreted and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent with such Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="no_indemnification_no_liability"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No Indemnification; No Liability</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Oncternal shall not indemnify or insure any person against the loss of any Erroneously Awarded Compensation pursuant to this Policy, nor shall Oncternal directly or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such person&#x2019;s potential obligations under this Policy. None of Oncternal, an affiliate of Oncternal or any member of the Committee or the Board shall have any liability to any person as a result of actions taken under this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="application_enforceability"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Application; Enforceability</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Except as otherwise determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any other clawback, recoupment, forfeiture or similar policies or provisions of Oncternal or its affiliates, including any such policies or provisions of such effect contained in any employment agreement, bonus plan, incentive plan, equity-based plan or award agreement thereunder or similar plan, program or agreement of Oncternal or an affiliate or required under applicable law (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Other Recovery Arrangements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;). The remedy specified in this Policy shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available to Oncternal or an affiliate of Oncternal.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="severability"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Severability</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The provisions in this Policy are intended to be applied to the fullest extent of the law; provided, however, to the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="amendment_and_termination"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Amendment and Termination</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will terminate automatically when Oncternal does not have a class of securities listed on a national securities exchange or association.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="definitions"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Definitions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Applicable Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the national securities exchange or association on which Oncternal&#x2019;s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange Commission or any national securities exchange or association on which Oncternal&#x2019;s securities are listed.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means the amount of Incentive-Based Compensation received by a current or former Officer that exceeds the amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting Measure, as determined on a pre-tax basis in accordance with the Applicable Rules.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Financial Reporting Measure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means any measure determined and presented in accordance with the accounting principles used in preparing Oncternal&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP/IFRS financial measures, as well as stock or share price and total equityholder return.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means United States generally accepted accounting principles.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">IFRS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means international financial reporting standards as adopted by the International Accounting Standards Board.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Impracticable</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means: (a) the direct costs paid to third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation; provided that Oncternal: (i) has made reasonable attempts to recover the Erroneously Awarded Compensation; (ii) documented such attempt(s); and (iii) provided such documentation to the relevant listing exchange or association; or (b) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of Oncternal, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures and received by a person: (a) after beginning service as an Officer; (b) who served as an Officer at any time during the performance period for that compensation; (c) while the issuer has a class of its securities listed on a national securities exchange or association; and (d) during the applicable Three-Year Period.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means each person who serves as an executive officer of Oncternal, as defined in Rule 10D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x2011;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">1(d) under the Exchange Act.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means an accounting restatement to correct Oncternal&#x2019;s material noncompliance with any financial reporting requirement under securities laws, including restatements that correct an error</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">in previously issued financial statements: (a) that is material to the previously issued financial statements; or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Three-Year Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the Board, or the officer or officers of Oncternal authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that Oncternal is required to prepare such Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs Oncternal to prepare such Restatement. The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Three-Year Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; also includes any transition period (that results from a change in Oncternal&#x2019;s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence. However, a transition period between the last day of Oncternal&#x2019;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img205696091_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 73#^X# 2(  A$! Q$!_\0
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MU\]T4 ?0G]N:1_T%;'_P(3_&C^W-(_Z"MC_X$)_C7SW10!]"?VYI'_05L?\
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MU\]T4 ?0G]N:1_T%;'_P(3_&C^W-(_Z"MC_X$)_C7SW10!]"?VYI'_05L?\
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MQKY[HH ^A/[<TC_H*V/_ ($)_C1_;FD?]!6Q_P# A/\ &OGNB@#Z$_MS2/\
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MQKY[HH ^A/[<TC_H*V/_ ($)_C1_;FD?]!6Q_P# A/\ &OGNB@#Z$_MS2/\
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MU\]T4 ?0G]N:1_T%;'_P(3_&C^W-(_Z"MC_X$)_C7SW10!]"?VYI'_05L?\
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MY[HH ^A/[<TC_H*V/_@0G^-']N:1_P!!6Q_\"$_QKY[HH ^A/[<TC_H*V/\
MX$)_C1_;FD?]!6Q_\"$_QKY[HH ^A/[<TC_H*V/_ ($)_C1_;FD?]!6Q_P#
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MY[HH ^A/[<TC_H*V/_@0G^-']N:1_P!!6Q_\"$_QKY[HH ^A/[<TC_H*V/\
MX$)_C1_;FD?]!6Q_\"$_QKY[HH ^A/[<TC_H*V/_ ($)_C1_;FD?]!6Q_P#
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MSW10!]"?VYI'_05L?_ A/\:/[<TC_H*V/_@0G^-?/=% 'T)_;FD?]!6Q_P#
MA/\ &C^W-(_Z"MC_ .!"?XU\]T4 ?0G]N:1_T%;'_P "$_QH_MS2/^@K8_\
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MSW10!]"?VYI'_05L?_ A/\:/[<TC_H*V/_@0G^-?/=% 'T)_;FD?]!6Q_P#
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MU\]T4 ?0G]N:1_T%;'_P(3_&C^W-(_Z"MC_X$)_C7SW10!]"?VYI'_05L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5U/P\_P"1SM/]R3_T URU=3\//^1SM/\ <D_] - '
M6_%7_D"V/_7P?_037E->K?%7_D"V/_7P?_037E- !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &KX9_P"1ITK_ *^XO_0A7JOQ$_Y$RZ_WX_\ T,5Y5X9_Y&G2O^ON+_T(
M5ZK\1/\ D3+K_?C_ /0Q0!XK1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7K?PL_Y%R[_Z^S_Z M>25ZW\+/\ D7+O_K[/_H"T
M <3X_P#^1VU'_MG_ .BUKFJZ7Q__ ,CMJ/\ VS_]%K7-4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5<TC_D-6/\ U\1_^A"J=7-(
M_P"0U8_]?$?_ *$* /9_'/\ R)FI?[B_^AK7AE>Y^.?^1,U+_<7_ -#6O#*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /4OA
M1_R#]1_ZZI_(UZ%7GOPH_P"0?J/_ %U3^1KT*@"KJ?\ R";S_K@__H)KYUKZ
M*U/_ )!-Y_UP?_T$U\ZT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5[?X _Y$C3_^VG_HQJ\0KV_P!_R)&G_]M/\ T8U 'D&O?\C%
MJ?\ U]R_^AFL^M#7O^1BU/\ Z^Y?_0S6?0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7I
M/PF^_JWTA_\ 9Z\VKTGX3??U;Z0_^ST 9OQ2_P"1HM_^O-/_ $-ZXBNW^*7_
M "-%O_UYI_Z&]<10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !74_#S_D<[3_<D_\ 0#7+5U/P\_Y'.T_W
M)/\ T T =;\5?^0+8_\ 7P?_ $$UY37JWQ5_Y MC_P!?!_\ 037E- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &KX9_Y&G2O^ON+_P!"%>J_$3_D3+K_ 'X__0Q7E7AG
M_D:=*_Z^XO\ T(5ZK\1/^1,NO]^/_P!#% 'BM%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>M_"S_D7+O_ *^S_P"@+7DE>M_"
MS_D7+O\ Z^S_ .@+0!Q/C_\ Y';4?^V?_HM:YJNE\?\ _([:C_VS_P#1:US5
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7-(_P"0
MU8_]?$?_ *$*IU<TC_D-6/\ U\1_^A"@#V?QS_R)FI?[B_\ H:UX97N?CG_D
M3-2_W%_]#6O#* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /4OA1_R#]1_P"NJ?R->A5Y[\*/^0?J/_75/Y&O0J *NI_\@F\_
MZX/_ .@FOG6OHK4_^03>?]<'_P#037SK0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7M_@#_D2-/_ .VG_HQJ\0KV_P  ?\B1I_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !74_#S_ )'.T_W)/_0#
M7+5U/P\_Y'.T_P!R3_T T =;\5?^0+8_]?!_]!->4UZM\5?^0+8_]?!_]!->
M4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 :OAG_ )&G2O\ K[B_]"%>J_$3_D3+K_?C
M_P#0Q7E7AG_D:=*_Z^XO_0A7JOQ$_P"1,NO]^/\ ]#% 'BM%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>M_"S_D7+O_K[/_H"
MUY)7K?PL_P"1<N_^OL_^@+0!Q/C_ /Y';4?^V?\ Z+6N:KI?'_\ R.VH_P#;
M/_T6M<U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5S2/^0U8_P#7Q'_Z$*IU<TC_ )#5C_U\1_\ H0H ]G\<_P#(F:E_N+_Z&M>&
M5[GXY_Y$S4O]Q?\ T-:\,H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ]2^%'_(/U'_KJG\C7H5>>_"C_ )!^H_\ 75/Y&O0J
M *NI_P#()O/^N#_^@FOG6OHK4_\ D$WG_7!__037SK0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7M_@#_D2-/_[:?^C&KQ"O;_ '
M_(D:?_VT_P#1C4 >0:]_R,6I_P#7W+_Z&:SZT->_Y&+4_P#K[E_]#-9] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>D_";[^K?2'_P!GKS:O2?A-]_5OI#_[/0!F_%+_
M )&BW_Z\T_\ 0WKB*[?XI?\ (T6__7FG_H;UQ% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=3\//^1SM
M/]R3_P! -<M74_#S_D<[3_<D_P#0#0!UOQ5_Y MC_P!?!_\ 037E->K?%7_D
M"V/_ %\'_P!!->4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 :OAG_D:=*_Z^XO_ $(5
MZK\1/^1,NO\ ?C_]#%>5>&?^1ITK_K[B_P#0A7JOQ$_Y$RZ_WX__ $,4 >*T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZW\+
M/^1<N_\ K[/_ * M>25ZW\+/^1<N_P#K[/\ Z M '$^/_P#D=M1_[9_^BUKF
MJZ7Q_P#\CMJ/_;/_ -%K7-4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"NI^'G_(YVG^Y)_Z :Y:NI^'G_(YVG^Y)_Z : .M^*O_ "!;'_KX/_H)KRFO
M5OBK_P @6Q_Z^#_Z":\IH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **MZ=IEYJ]V+6Q@,TQ&[:"!QZY/%7-4\+Z
MUHUL+F_LC%"6"[Q(K#)_W2?2@#(HJ6WMI[N416T$DTAZ)&A8G\!4MWIM_8!3
M>65S;AN%,T3)GZ9% %6BBB@ HHHH **559V"J"6)P !R35V71=5@@,\VF7D<
M(&3(\#!0/J10!1HHHH **** "BBB@ HHHH **V].\(Z[JMFEW96!E@?.U_-1
M<X)!ZD=P:R[VRN-/O)+2[B,4\9PZ$CCOVH @HHHH **** "BBB@ HHHH ***
M* -7PS_R-.E?]?<7_H0KU7XB?\B9=?[\?_H8KRKPS_R-.E?]?<7_ *$*]5^(
MG_(F77^_'_Z&* /%:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***T-*T34=;E>/3K8SM& 6PRK@'W)'I0!GT5IZMX
M?U70Q&=1M# )"0AWJP)'7E2?6LR@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *];^%G_(N7?_7V?_0%KR2O6_A9_P BY=_]?9_] 6@#B?'_ /R.
MVH_]L_\ T6M<U72^/_\ D=M1_P"V?_HM:YJ@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKHH_ OB26%94TQBC#(
MS+&#CZ;LUSS*R,58$,#@@CD&@!**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "KFD?\AJQ_P"OB/\ ]"%4ZN:1_P AJQ_Z^(__ $(4 >S^.?\ D3-2
M_P!Q?_0UKPRO<_'/_(F:E_N+_P"AK7AE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !16AI6B:CK<KQZ=;&=HP"V&
M5< ^Y(]*?JWA_5=#$9U&T, D)"'>K D=>5)]: ,RBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ]2^%'_ "#]1_ZZI_(UZ%7GOPH_Y!^H_P#7
M5/Y&O0J *NI_\@F\_P"N#_\ H)KYUKZ*U/\ Y!-Y_P!<'_\ 037SK0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7;_#;2+'4]2O)+VW2X$,:[
M$D4,N2>I!ZGC]37$5Z)\*/\ C\U/_KG'_,T =Z?#FAD8_L;3_P#P&3_"O*O'
MWAZWT+5XGLXS':W*%E3.0K _,![<@_C7IVKZF-.UK1U=@(KJ22!B3W(!7]0!
M^-4?'^EC4O"UQ(J@S6G[]#Z ?>_\=S^5 'B==+X'T*+7?$ 2Y0M:P(99!CAN
MP4GMDG/T!KFJ]C^&VEBR\-?:W3$MXY?)7!V#A1[C@D?[U &\/#NACC^Q]/X_
MZ=D_PKS;XE:58Z;J%D]E:QV_G1MO6)0JG!&#@<#K7?Z)J0U+6];*D&.VE2W0
M@'^$'/\ X\6KC/BO_P ?FF?]<Y/YB@#SNBKNE:7=ZSJ$=E9Q[Y7[G@*.Y)[
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M^1<N_P#K[/\ Z M '$^/_P#D=M1_[9_^BUKFJZ7Q_P#\CMJ/_;/_ -%K7-4
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M86UQ*+ID#31!\*%4X&?J:ZB[L/"E@ZI>6FBV[,,J)HXD)'MFL7X6?\BQ<_\
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ME7O/B^>.W\):F\I 5H&09_O-\H_4BO!J "BBB@ HHHH **** "BBB@ HHHH
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M&:SZT->_Y&+4_P#K[E_]#-9] !1110 4444 %%%% !7<?"S_ )&>Y_Z\V_\
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M8^(K2,GY5M P'N7;/\A7"UZ;\4]+=X[/5(X\K'F&9@#D G*Y]L[OQ(]:\RH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 7='_P"0W8?]?,?_ *$*^A)?]2_^Z:^>]'_Y#=A_
MU\Q_^A"OH27_ %+_ .Z: /FZOHZU_P"/.#_KFO\ *OG&OHZU_P"/.#_KFO\
M*@#R'Q+XYU:^U">"TN)+.UCD*HL3;78 ]68<]N@_6N^\"ZY<Z[X?,MX0T\,I
MA9Q_&  03[\X_"O&;_\ Y"-S_P!=7_F:]2^%?_(O7?\ U]G_ - 6@#F_BB@7
MQ1 1U:T0G_OIQ_2O1O"MBNG>%].MPN#Y*N_^\WS']37G?Q3_ .1GMO\ KS7_
M -#>O4-)D6;1K&5,;'MXV7&>A4>M 'EGC+Q?J4VO7%K8WL]M;6SF("%RA9AP
MQ)&">>W3BNI\ >*KS7$GL[_$D\"AUG  W*3C! [CU[_S\S\11O#XEU-)%*L+
MJ0X(QP6)!_$<UUWPI4G5-0;!VB%03CC.[_ZQH VOBI_R+UI_U]C_ - :L7X4
M_P#(6O\ _K@/_0JVOBI_R+UI_P!?8_\ 0&K%^%/_ "%K_P#ZX#_T*@#7^*O_
M "!++_KY_P#9357X5:?'Y-]J3 &0L($X^Z -QY]\K^56OBK_ ,@2R_Z^?_93
M4GPL8'PU=+GD7C$C_@"?X4 5_B9KUU8K::=9W#0M*#+*8V*MMZ*,CL3N_*O/
M-)US4=$N!-8W+1\Y9.J/[$5U_P 5;?;J]A=<XD@,?M\K9_\ 9ZX"@#1NM:N[
MO7CK#[%NO-64;1\H*XQ@$].!6E?^*_$7B&4Q+-,%(_U%FK*,>X')_$U4\,:-
M_;NOVUDQ(A)+RD=D')_/I^->RWEQI?A+17N!;K#;1X CA098GH/<_6@#ROPS
M8^(],UVREAL-2@B:=!,?(<(R9P=W&,8)^E>K^)%#^%]5!Z?9)3^2$UR=I\3T
MO-4M[2/26"SRI&':XY&X@9QM]_6NN\1?\BQJW_7G-_Z : /%- U*^M=3LX+>
M]N889+E-\<<K*K98 Y .#Q7O%R2MK,02"$8@CMQ7S[H__(;L/^OF/_T(5] W
M7_'G/_US;^5 '@$VN:M<PM#/JE[+$XPR/<.RD>X)KL?A3_R%K_\ ZX#_ -"K
MS^O0/A3_ ,A:_P#^N _]"H U_BK_ ,@2R_Z^?_9353X5:;'Y=]JC<R[A;I_L
MC 9OS^7\O>K?Q5_Y EE_U\_^RFI/A8X/ARZ3N+MB?Q1/\* (_B7KMUI]K:V%
MI,\+7!+R/&V&VC&!Z\D^O:O.='UJ]T2^BN;29U"-EH]QVR#N"/?_ #TKL/BL
MC#4M.D*G8T+*#ZD'G^8KSZ@#Z.(AO;/#J)()X\%6Y#*PZ'\#7@MK;_8_%<-M
MG/DWRQ]?1\?TKWFRB,%A;Q-U2)5/X "O##*DWC;S8V#(^H[E8'((,F0: /=I
MYEM[>6=P2L:%R!UP!FO%-4\=:YJ-[YT5W):1JV8XH&P!SQG^][YX/I7LNI_\
M@F\_ZX/_ .@FOG6@#WWPOJLNM>'+2_G51-(I#[>A*L5S^.,_C7DOCU GC740
MO3*'\XU->D_#W_D2[+_>D_\ 0VKSCQ__ ,COJ/\ VS_]%K0!S5%%% !1110
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M,N?F@8XC9<\C;T'UZU[<RK+$5/*NN/P-?-M?2,7^I3_=% 'S]H7_ ",.F?\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KVGX=?\B;;?\
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M@ HHHH *N:1_R&K'_KXC_P#0A5.KFD?\AJQ_Z^(__0A0![/XY_Y$S4O]Q?\
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M0?A1_P ?FI_]<X_YFNJ\;>))O#NE1/:QJUS.^Q&<95 !DG'<_P"?8\K\*/\
MC\U/_KG'_,U>^*W_ "#M._ZZO_(4 <[X9\8ZROB2V6ZO9;F&ZE2*2.5L@9.,
MJ.V,YXZUZAXE0/X7U4-T^R2G\E)KP_0O^1ATS_K[B_\ 0Q7N7B+_ )%C5O\
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MSVW@-C_QZNN_X6S_ -03_P FO_L*X77-5;6]:N=1>,1&8@[ <[0  !G SP*
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MF?\ 7.3^8KA+34+VP+&SN[BV+\,89"F[ZX-)=7UW?.'O+J>X91@--(7('XT
M=C\.?$<.F7DVFWD@2"Y8-&[' 63I@_48Y]AZUZ#XB\-67B6TCCN"R21G,4R=
M5SU'N#Q7@M;%AXJUS3(1#::E,D8QA&PX'L P.!0!Z1H'PZL]'U".]N+MKR6)
MMT0\L(JGL2,G)'4<U+X\\30Z5I$UC!*K7]RICV \QH1RQ]..GUSVKSJ?QQXD
MN(C&^JR!3WC1$/YJ :P7=I'9W8L[$EF8Y)/J: -GPGK*Z%XBM[N5B+<YCFP,
M_(>_X'!X]*]NN+>SUC36AE$=Q9W"#H<A@>001^!!KYVK5TSQ+K.CQF*POY(H
MS_RS(#J/H&! Z]J /6=.\#:#H]TUZL32,A+J;APRQ=^.!TQU.3[UO65[;ZA:
MK<VDHEA9F577H=K%3CVR#S7A>H^*=;U6$PWFHRO$>J* @/U"@9JK;ZSJEI L
M-MJ5Y#$N<1Q3LJC\ : +=Y=_8/&L]X5W"#46EV^NV3/]*]P<6FLZ4ZK();2[
MB*[D/56&.#7SNS,[%F)+$Y))Y)K2TSQ#J^CJ5L+Z6%#SLX9?R.10!Z):?"W3
M8+PRW5[-<6XY$.W9_P!],#S^&*[:SN;:[M4FLY4E@.51XSE3@X.#WY!KPS4/
M%NO:I;FWN]1D:(_>1%5 P]#M R/8U2M]8U.T@$%MJ-W#",XCCG95YZ\ T &L
M?\AN_P#^OF3_ -"-?0-K_P ><'_7-?Y5\Y,S.Q9B2Q.22>2:OKKVL+$(UU:^
M$8& HN'QCTQF@"O?_P#(1N?^NK_S-?1,7^I3_=%?-U:"Z]K"Q"-=6OA&!@*+
MA\8],9H SZ]L\ :DE_X4MH]ZF6US#(HXQ@_+_P".X_6O$ZMZ=JE]I-S]HL;F
M2"3H2IX/U'0_C0![)JO@71]8U=M1N?M E<#>B2 (^!C)XSTQT(Z5XWJD$=KJ
MUY;PY\J*=T3)SP&(%:[^._$LD91M48#_ &8D4_F%S7/,S.Q9B2Q.22>2: /2
MOA9JX*W>D2$Y'[^+)[<!A_(_G7I#,$4LQP ,DUX]\-=-:\\2F[.X1V<9?*G'
MS-\H!_ M^5=[X\U(:;X3N@"!)<_Z.@()SN^]_P".AJ /'M9U%M6UF[OV)_?2
MEE#  A?X1QZ# JC110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7M_@#_ )$C3_\ MI_Z,:O$*]O\ ?\ (D:?_P!M/_1C4 >0:]_R,6I_]?<O
M_H9K/K0U[_D8M3_Z^Y?_ $,UGT %%%% !1110 4444 %=Q\+/^1GN?\ KS;_
M -#2N'J:VN[FRE\VUN)8),8WQ.5./J* /7_B5_R*+?\ 7=/ZUXU5N[U34+]%
M2\O[JX13D+-,S@'UY-5* "M_P3_R.6F_]=#_ .@FL"GQ3202K+#(\<BG*NC$
M$'V(H ]T\9_\B?J?_7+^HKPBKMSK&J7D)ANM2O)XCR4EG9E/X$U2H ['X?\
MB.#1-2EMKQ]EK=[1YA/RQN,X)] <X)^E>F:_H%GXDTX6]P2N#OBE0\J?4>H-
M>!5K:?XGUK2XQ%9ZC-'&.B'#*/P8$=J /1M'^&EEIVI)>7%[)=")P\4?EA "
M#D;N3GMZ=/PK3\9>)H-"TF:*.9#J$R;8HP?F7/&\CT'/7J17F,WCGQ+/&T;Z
MHX5@02D:(?P( (K!EFDGE:6:1Y)&.6=V))/N30!H^'-5_L77[2^.?+1\2 =T
M/!_0Y_"O=P;/5M.R#'<6EPF..5=37SI6GIGB+5]&4K87TD*'^#AE_P"^2"*
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MX0M_$XA=KE[>>$%5<(&!!(ZCC/3U[TF@^&M)\)NN)]][<DQK)*V&<==JKZ<
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M45[<QW#C#2I*P=A[G.3T%-N[^\OW5[R[GN&484S2%R![9H ]9^&VIP7/AI;
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MWG_7!_\ T$U\ZU?EUS5YX6AEU2]DB8;61[ARI'H1FJ% 'MGP]_Y$NR_WI/\
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MM[^<6OC7Q%9PK#%JDI1>!YBK(?S8$U1U'7-3U699;Z]EE9#E<G 4^H X'X4
M>O\ C_\ Y$C4?^V?_HQ:XKX<Z7INKC5;?4+:*<[(]@8?,HRV2IZC^'I7)7&L
M:G=P&"YU&[FA.,QR3LR\=.":K03S6TRS6\KQ2IRKQL58?0B@#T^?X4V;W(:#
M4YHX=V3&T88X] <C\\&NR@BL_#^BQQ-*$M;2+&^0@< =3[FO'$\=^)8XPBZH
MQ'^U$C'\RN:S=2US4]8*F_O99PO12<*.O.!QGD\T 2W&M2/XHDUF+(;[5YZ
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M.%88)2-%;\P 10![#H]OINFPMI.G.O\ HH!DC#[F4MDY;W."?_K8KR_XF_\
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M>$U)-/+<S--/*\LK?>=V+$_4FHZ "BBB@ HHHH **** "BBB@ HHHH ****
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M0U[_ )&+4_\ K[E_]#-9] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>D_";[^K?2'_V>
MO-J])^$WW]6^D/\ [/0!F_%+_D:+?_KS3_T-ZXBNW^*7_(T6_P#UYI_Z&]<1
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !74_#S_D<[3_ ')/_0#7+5U/P\_Y'.T_W)/_ $ T =;\5?\
MD"V/_7P?_037E->K?%7_ ) MC_U\'_T$UY30 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!J^&?^1ITK_K[B_]"%>J_$3_ )$RZ_WX_P#T,5Y5X9_Y&G2O^ON+_P!"%>J_
M$3_D3+K_ 'X__0Q0!XK1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7K?PL_P"1<N_^OL_^@+7DE>M_"S_D7+O_ *^S_P"@+0!Q
M/C__ )';4?\ MG_Z+6N:KI?'_P#R.VH_]L__ $6M<U0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5S2/^0U8_]?$?_H0JG5S2/^0U
M8_\ 7Q'_ .A"@#V?QS_R)FI?[B_^AK7AE>Y^.?\ D3-2_P!Q?_0UKPR@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#U+X4?\
M(/U'_KJG\C7H5>>_"C_D'ZC_ -=4_D:]"H JZG_R";S_ *X/_P"@FOG6OHK4
M_P#D$WG_ %P?_P!!-?.M !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>W^ /\ D2-/_P"VG_HQJ\0KV_P!_P B1I__ &T_]&-0!Y!K
MW_(Q:G_U]R_^AFL^M#7O^1BU/_K[E_\ 0S6?0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7I/PF^_JWTA_P#9Z\VKTGX3??U;Z0_^ST 9OQ2_Y&BW_P"O-/\ T-ZXBNW^
M*7_(T6__ %YI_P"AO7$4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5U/P\_Y'.T_W)/\ T URU=3\//\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5ZW\+/^1<N_P#K[/\ Z M>
M25ZW\+/^1<N_^OL_^@+0!Q/C_P#Y';4?^V?_ *+6N:KI?'__ ".VH_\ ;/\
M]%K7-4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5<
MTC_D-6/_ %\1_P#H0JG5S2/^0U8_]?$?_H0H ]G\<_\ (F:E_N+_ .AK7AE>
MY^.?^1,U+_<7_P!#6O#* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /4OA1_R#]1_ZZI_(UZ%7GOPH_Y!^H_]=4_D:]"H JZG
M_P @F\_ZX/\ ^@FOG6OHK4_^03>?]<'_ /037SK0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7M_@#_D2-/\ ^VG_ *,:O$*]O\ ?
M\B1I_P#VT_\ 1C4 >0:]_P C%J?_ %]R_P#H9K/K0U[_ )&+4_\ K[E_]#-9
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>D_";[^K?2'_V>O-J])^$WW]6^D/\ [/0!
MF_%+_D:+?_KS3_T-ZXBNW^*7_(T6_P#UYI_Z&]<10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !74_#S_D
M<[3_ ')/_0#7+5U/P\_Y'.T_W)/_ $ T =;\5?\ D"V/_7P?_037E->K?%7_
M ) MC_U\'_T$UY30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!J^&?^1ITK_K[B_]"%>J
M_$3_ )$RZ_WX_P#T,5Y5X9_Y&G2O^ON+_P!"%>J_$3_D3+K_ 'X__0Q0!XK1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K?PL
M_P"1<N_^OL_^@+7DE>M_"S_D7+O_ *^S_P"@+0!Q/C__ )';4?\ MG_Z+6N:
MKI?'_P#R.VH_]L__ $6M<U0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>W^ /\
MD2-/_P"VG_HQJ\0KV_P!_P B1I__ &T_]&-0!Y!KW_(Q:G_U]R_^AFL^M#7O
M^1BU/_K[E_\ 0S6?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7I/PF^_JWTA_P#9Z\VK
MTGX3??U;Z0_^ST 9OQ2_Y&BW_P"O-/\ T-ZXBNW^*7_(T6__ %YI_P"AO7$4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5U/P\_Y'.T_W)/\ T URU=3\//\ D<[3_<D_] - '6_%7_D"
MV/\ U\'_ -!->4UZM\5?^0+8_P#7P?\ T$UY30 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5<TC_D-6/_ %\1_P#H0JG5
MS2/^0U8_]?$?_H0H ]G\<_\ (F:E_N+_ .AK7AE>Y^.?^1,U+_<7_P!#6O#*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /4O
MA1_R#]1_ZZI_(UZ%7GOPH_Y!^H_]=4_D:]"H JZG_P @F\_ZX/\ ^@FOG6OH
MK4_^03>?]<'_ /037SK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7M_@#_D2-/\ ^VG_ *,:O$*]O\ ?\B1I_P#VT_\ 1C4 >0:]
M_P C%J?_ %]R_P#H9K/K0U[_ )&+4_\ K[E_]#-9] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>D_";[^K?2'_V>O-J])^$WW]6^D/\ [/0!F_%+_D:+?_KS3_T-ZXBN
MW^*7_(T6_P#UYI_Z&]<10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !74_#S_D<[3_ ')/_0#7+5U/P\_Y
M'.T_W)/_ $ T =;\5?\ D"V/_7P?_037E->K?%7_ ) MC_U\'_T$UY30 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!J^&?^1ITK_K[B_]"%>J_$3_ )$RZ_WX_P#T,5Y5
MX9_Y&G2O^ON+_P!"%>J_$3_D3+K_ 'X__0Q0!XK1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7K?PL_P"1<N_^OL_^@+7DE>M_
M"S_D7+O_ *^S_P"@+0!Q/C__ )';4?\ MG_Z+6N:KI?'_P#R.VH_]L__ $6M
M<U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S2/^
M0U8_]?$?_H0JG5S2/^0U8_\ 7Q'_ .A"@#V?QS_R)FI?[B_^AK7AE>Y^.?\
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M_P"/_&C^V/#7_01TG_O_ !_XU\LT4?48]P^L/L?4W]L>&O\ H(Z3_P!_X_\
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M $$=)_[_ ,?^-']L>&O^@CI/_?\ C_QKY9HH^HQ[A]8?8^IO[8\-?]!'2?\
MO_'_ (T?VQX:_P"@CI/_ '_C_P :^6:*/J,>X?6'V/J;^V/#7_01TG_O_'_C
M1_;'AK_H(Z3_ -_X_P#&OEFBCZC'N'UA]CZF_MCPU_T$=)_[_P ?^-']L>&O
M^@CI/_?^/_&OEFBCZC'N'UA]CZF_MCPU_P!!'2?^_P#'_C1_;'AK_H(Z3_W_
M (_\:^6:*/J,>X?6'V/J;^V/#7_01TG_ +_Q_P"-']L>&O\ H(Z3_P!_X_\
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M *".D_\ ?^/_ !KY9HH^HQ[A]8?8^IO[8\-?]!'2?^_\?^-']L>&O^@CI/\
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M (UX)\2O^2A:O_OI_P"BUKE*<,$I13ON*5=IVL?4W]L>&O\ H(Z3_P!_X_\
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M_P!_X_\ &OEFBCZC'N'UA]CZF_MCPU_T$=)_[_Q_XT?VQX:_Z".D_P#?^/\
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M_O\ Q_XT?VQX:_Z".D_]_P"/_&OEFBCZC'N'UA]CZF_MCPU_T$=)_P"_\?\
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M +?V>S_YXP?]\BC[/9_\\8/^^152B@"W]GL_^>,'_?(H^SV?_/&#_OD54HH
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MJE% %O[/9_\ /&#_ +Y%'V>S_P">,'_?(JI10!;^SV?_ #Q@_P"^11]GL_\
MGC!_WR*J44 6_L]G_P \8/\ OD4?9[/_ )XP?]\BJE% %O[/9_\ /&#_ +Y%
M'V>S_P">,'_?(JI10!;^SV?_ #Q@_P"^11]GL_\ GC!_WR*J44 6_L]G_P \
M8/\ OD4?9[/_ )XP?]\BJE% %O[/9_\ /&#_ +Y%'V>S_P">,'_?(JI10!;^
MSV?_ #Q@_P"^11]GL_\ GC!_WR*J44 6_L]G_P \8/\ OD4?9[/_ )XP?]\B
MJE% %O[/9_\ /&#_ +Y%'V>S_P">,'_?(JI10!;^SV?_ #Q@_P"^11]GL_\
MGC!_WR*J44 6_L]G_P \8/\ OD4?9[/_ )XP?]\BJE% %O[/9_\ /&#_ +Y%
M'V>S_P">,'_?(JI10!;^SV?_ #Q@_P"^11]GL_\ GC!_WR*J44 6_L]G_P \
M8/\ OD4?9[/_ )XP?]\BJE% %O[/9_\ /&#_ +Y%'V>S_P">,'_?(JI10!;^
MSV?_ #Q@_P"^11]GL_\ GC!_WR*J44 6_L]G_P \8/\ OD4?9[/_ )XP?]\B
MJE% %O[/9_\ /&#_ +Y%'V>S_P">,'_?(JI10!;^SV?_ #Q@_P"^11]GL_\
MGC!_WR*J44 6_L]G_P \8/\ OD4?9[/_ )XP?]\BJE% %O[/9_\ /&#_ +Y%
M'V>S_P">,'_?(JI10!;^SV?_ #Q@_P"^11]GL_\ GC!_WR*J44 6_L]G_P \
M8/\ OD4?9[/_ )XP?]\BJE% %O[/9_\ /&#_ +Y%'V>S_P">,'_?(JI10!;^
MSV?_ #Q@_P"^11]GL_\ GC!_WR*J44 6_L]G_P \8/\ OD4?9[/_ )XP?]\B
MJE% %O[/9_\ /&#_ +Y%'V>S_P">,'_?(JI10!;^SV?_ #Q@_P"^11]GL_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /I?PO\ \BEHW_7C!_Z+6M6LKPO_ ,BEHW_7
MC!_Z+6M6O G\3/1CL%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '1_P"M
M3_>%:-9T?^M3_>%:- '+?$?_ ))]J_\ UR7_ -#6OFFOI;XC_P#)/M7_ .N2
M_P#H:U\TUZF!^!^IR8CXD%%%%=I@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7MWP?_ .1(U;_KY?\ ]%K7B->W?!__ )$C5O\ KY?_ -%K
M7-B_X9K1^(\1HHHKI,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O0O@U_R.TG_7G)_P"A
M)7GM>A?!K_D=I/\ KSD_]"2L<1_"D73^-&1\2O\ DH6K_P"^G_HM:Y2NK^)7
M_)0M7_WT_P#1:URE52_AQ]$*?Q,****T)"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^E_"_P#R*6C?]>,'
M_HM:U:RO"_\ R*6C?]>,'_HM:U:\"?Q,]&.P4445(PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^E_"__ "*6C?\
M7C!_Z+6M6LKPO_R*6C?]>,'_ *+6M6O G\3/1CL%%%%2,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>W?!_\ Y$C5O^OE_P#T6M>(U[=\
M'_\ D2-6_P"OE_\ T6M<V+_AFM'XCQ&BBBNDR"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*]"^#7_([2?]><G_ *$E>>UZ%\&O^1VD_P"O.3_T)*QQ'\*1=/XT9'Q*_P"2
MA:O_ +Z?^BUKE*ZOXE?\E"U?_?3_ -%K7*55+^''T0I_$PHHHK0D**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#Z7\+_ /(I:-_UXP?^BUK5K*\+_P#(I:-_UXP?^BUK5KP)_$ST8[!1114C
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@G_H*K_X"2__ !%'_"S?!/\ T%5_\!)?_B*/8U/Y7]P<\>YOT5@?\+-\$_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O;O@__
M ,B1JW_7R_\ Z+6O$:]N^#__ ")&K?\ 7R__ *+6N;%_PS6C\1XC111729!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>A?!K_ )':3_KSD_\ 0DKSVO0O@U_R.TG_ %YR
M?^A)6.(_A2+I_&C(^)7_ "4+5_\ ?3_T6M<I75_$K_DH6K_[Z?\ HM:Y2JI?
MPX^B%/XF%%%%:$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?1L?_)&3_V 3_Z(KYRKZ-C_ .2,G_L G_T1
M7SE7'@_M>IO6Z!111788!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@!T?^M3_>%:-9T?\ K4_WA6C0!RWQ'_Y)]J__ %R7_P!#6OFFOI;XC_\
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MD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Z%\&O\ D=I/^O.3_P!"2O/:]"^#7_([2?\
M7G)_Z$E8XC^%(NG\:,CXE?\ )0M7_P!]/_1:URE=7\2O^2A:O_OI_P"BUKE*
MJE_#CZ(4_B84445H2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!]&Q_\D9/_8!/_HBOG*OHV/\ Y(R?^P"?
M_1%?.5<>#^UZF];H%%%%=A@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >Q_"CQQYBQ^&M2D&Y1BSE8]1_SS/]/R]*].GB\MLC[IZ5\H([Q2+)
M&S(ZD,K*<$$="#7T1\/?&<?BW2#;71 U.V4"9?\ GH.@<?U]#]17F8NA9\\=
MCJHU+^ZSHJ*=(AC<J?PIM<)T!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Z/
M_6I_O"M&LZ/_ %J?[PK1H Y;XC_\D^U?_KDO_H:U\TU]+?$?_DGVK_\ 7)?_
M $-:^::]3 _ _4Y,1\2"BBBNTP"BBB@ HHHH *]8^!W_ !_ZS_URB_FU>3UZ
MQ\#O^/\ UG_KE%_-JY\5_"9I2^-'K^H7#VNFW5Q&%+Q0NZANA(!/->(K\:_$
M0=2]CI97/($<@)'UWU[3K/\ R ]0_P"O:3_T$U\FUR8.G":?,KFU:3BU8]MT
M'XSV=Y=K;ZS8_8E? %Q&^] ?]H8R![C/]:]01TDC62-E9& *LIR"#W%?(5>X
M?!C7);W1KS29Y&<V3J\);M&V?E'T()_X%^3Q.&C&// *55MV9@?%CP5#I4B:
M[IL/EVT\FVYC4<(YY# =@><^^/6O+J^JO$VEIK/AG4=/?'[Z!@I(SAARIQ[$
M U\JUOA*CG"SZ&=:/+*Z"BOKV.-(HUCC1411A548 'L*^>?BQ#%!X\N1%$D8
M:*-F"*!DD<D^]%'%>UERVL%2ER*]SB***^NK6-(K6)(T5%"# 48'2KKU_96T
MO<FG3Y^I\BT5WOQ?ABA\<'RHD3?;1LVU0-QY&3ZG 'Y59^$?AO3-=U._N-2M
MUN19K&8XGY0EBW+#OC;T/'-5[9*G[1BY'S<IP-I87E^Y2SM)[AEQD0QER/RJ
M^?"GB)1EM U0#U-G)_A7U"SVNGVPW-#;0+P,D(H]O2JUGKVCZA/Y%EJUC<RX
MSY<-RCMCUP#7)]=D]5$V]@NK/E6XMI[2=H+F&2&9/O1R*59?J#45?6&K:)IN
MNV;6NIV<5Q$>FX<J?53U!]Q7S3XLT!O#7B6[TO+M%&P:%W&"Z$9!]_0X[@UT
M4,2JNEK,SJ4G#4Z[X*?\CE>?]@]__1D=>X7W_'A<_P#7)OY&O#_@I_R.5Y_V
M#W_]&1U[A??\>%S_ -<F_D:XL7_&-Z/P'R/1117K'&%%%% !7K'P3T<O>ZCK
M+J=L2"VB.1@L?F;WR %_[Z_+R>OI[P/H:^'_  C8V?E[)V037&<9,C#)R1UQ
MPOT45R8R?+3MW-J,;ROV->ZU"WL[FS@F?;)=RF*(>K!6;^2G\<4NHV,6IZ9=
M6$XS%<1-$WT88KQOXI>)Y+?Q[IJ6K G1]LN!D'S&(8@GTVA/S->SVMS%>V<%
MU VZ&:-9$;U4C(/Y&O/G3<(QEW.F,E)M'R??V,^F:A<6-TFR>WD:-Q[@XX]J
MK5Z)\8]'^P^*X]01<1W\08G_ *:)A6_38?QKSNO8ISYX*1Q2CRMH*?##+<2K
M%!$\LC'"HBEB?H!6WX0\+W/BS78["$F.%1ON)L9\M!_4G@#W] :^C=#\.:5X
M<M!;Z99QP@@!Y,9>3&>6;J>I^F>,5C7Q,:6F[+ITG/4^:O\ A%O$.PO_ &#J
MFP#);[')C^59DT,MO*T4\3Q2*<,CJ5(^H-?5LVN:3;W?V2;5+*.Y_P">+W"!
M_P#ODG/8UD^-/#>F:[H%ZUW;1_:8H':&X"_/&0,CGKC(Y%8QQKNE*);H::,^
M9:^O(?\ 41_[H_E7"_" 6X\"QF'R_--Q(9MI&=V>-WOMV_ABN]K#%U>>7+;8
MTHPY5?N> ?&/_D>!_P!>D?\ -J\_KZ_KQSXY"+[1HA&SSMDV['WMN4VY]L[L
M?C6^&Q-[4[&=6E:\KG&^&?B%KGA6S>SLS;S6Q;>L5RA8(3UVD$$9],X_,Y/$
MWQ!USQ5:):7A@AME;<8K9"H<]MV22<>G3]*]3^#MM!'X+,ZQ*)9+IR[XY.
M.?I1\8[:"3P8)VB4S1W,>Q\<C.01GTYZ4_:P]MR\NM]PY)<E[G@5%%>[^ _A
MC9Z5:1W^N6\=SJ,F'6&0;DMQV&.A;U/;MZGIJUHTE=F4(.;LCQ>TT/5[^)9;
M/2[ZYC;H\-N[@_B![&I9O#6O6Z;YM$U*-?5[5P/U%?4=W>V>G6YFO+F"V@7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O0O@U_R.TG_ %YR?^A)7GM>A?!K_D=I/^O.3_T)*QQ'\*1=/XT9'Q*_
MY*%J_P#OI_Z+6N4KJ_B5_P E"U?_ 'T_]%K7*55+^''T0I_$PHHHK0D****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Z-C_Y(R?\ L G_ -$5\Y5]&Q_\D9/_ & 3_P"B*^<JX\']KU-ZW0**
M**[# **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *OZ-J]YH6JP
M:C8R%)X6S[,.ZGU!%4**32:LQ['U)H&NV7BO0XM0LS@GAXR>8G[J?\\C!JR0
M02",$5\]>!_%\_A+6EE)9["8A;F(=Q_>'^T/\1WKZ*62#4+.*]M)5EBE0.CH
M<AE/0UX^(HNE+38[:<^=>9#1117.:!1110 4444 %%%% !1110 4444 %%%%
M !1110!F2^(]#@F>&;6=.CEC8JZ/=("I'!!!/!IO_"4>'_\ H.Z9_P"!<?\
MC7S[XH_Y&W6?^OZ?_P!&-657HQP46D[G,Z[3V/I?_A*/#_\ T'=,_P# N/\
MQH_X2CP__P!!W3/_  +C_P :^:**KZC'N+ZP^Q]+_P#"4>'_ /H.Z9_X%Q_X
MT?\ "4>'_P#H.Z9_X%Q_XU\T44?48]P^L/L?2_\ PE'A_P#Z#NF?^!<?^-'_
M  E'A_\ Z#NF?^!<?^-?-%%'U&/</K#['TO_ ,)1X?\ ^@[IG_@7'_C1_P )
M1X?_ .@[IG_@7'_C7S111]1CW#ZP^Q]+_P#"4>'_ /H.Z9_X%Q_XT?\ "4>'
M_P#H.Z9_X%Q_XU\T44?48]P^L/L?2_\ PE'A_P#Z#NF?^!<?^-'_  E'A_\
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M_P#"4>'_ /H.Z9_X%Q_XT?\ "4>'_P#H.Z9_X%Q_XU\T44?48]P^L/L?2_\
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M_P )1X?_ .@[IG_@7'_C7S111]1CW#ZP^Q]+_P#"4>'_ /H.Z9_X%Q_XT?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O0O@U_
MR.TG_7G)_P"A)7GM>A?!K_D=I/\ KSD_]"2L<1_"D73^-&1\2O\ DH6K_P"^
MG_HM:Y2NK^)7_)0M7_WT_P#1:URE52_AQ]$*?Q,****T)"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'MGP?_Y%*Z_Z_G_]%QUZ!7G_ ,'_ /D4KK_K^?\ ]%QUZ!7B8C^+([Z?P(**
M**Q+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH =
M'_K4_P!X5HUG1_ZU/]X5HT <M\1_^2?:O_UR7_T-:^::^EOB/_R3[5_^N2_^
MAK7S37J8'X'ZG)B/B04445VF 4444 %%%% !7K'P._X_]9_ZY1?S:O)Z])^#
M^MZ;I&JZC'J-Y#:_:(D\MYF"*2I.1N/ ZUAB4W2:1I2=IH]JU9'DT:^CC5F=
MK>0*JC))*G@5\R?\(GXD_P"A?U7_ , I/\*^C_\ A+/#?_0P:5_X&Q_XT?\
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MW$LCSJS')8@  ,,<+GOUKL6\7>&T4L?$&EX'I=QD_D#7SCXKU?\ MWQ3J.I
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MF"'41"PG4M&\+[E..HY .1D=N]8-7&2DKHEIIV84444Q!1110 4444 %%%%
M!1110 4444 %%%% !1110 5Z%\&O^1VD_P"O.3_T)*\]KT+X-?\ ([2?]><G
M_H25CB/X4BZ?QHR/B5_R4+5_]]/_ $6M<I75_$K_ )*%J_\ OI_Z+6N4JJ7\
M./HA3^)A1116A(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'T;'_P D9/\ V 3_ .B*^<J^C8_^2,G_ + )
M_P#1%?.5<>#^UZF];H%%%%=A@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\E9O_B*W=$\0:7XCM)+K2KK[1#&_ELWELF&P#C# 'H17RG7NGP3_ .14OO\
MK^;_ - 2L:^%A3AS)LNG5E*5F=_JFJ66BZ;+J&H3>3:PXWR;2V,D*. ">I%<
MW_PM+P;_ -!G_P E9O\ XBCXI?\ ).-6_P"V/_HY*^<*6&PT*L.:0ZM5P=D>
MI?%/QEH?B/2K&TTFZ:Y>.<R.WE,@4;2/X@.3GMZ5Y;117H4Z:IQY4<TI.3NP
MHHHK0D]T^"?_ "*E]_U_-_Z E=GKOBG1O#7V?^U[S[-]HW>5^Z=]VW&?N@X^
M\.OK7&?!/_D5+[_K^;_T!*R_CG_S ?\ MX_]IUY4H*IB7%_UH=BDXTKHZ_\
MX6EX-_Z#/_DK-_\ $4C?%/P:%)&KEB!T%M+D_P#CM?.-%=/U&GW9E[>1+=3?
M:;N:?;M\QV?;G.,G.*]2^"D\%JVO3W$L<4<<<+-)(P4*N7R23T%>445T5:?/
M!P,HRY97/>M:^,6AZ=.T%A#-J3KG+H=D>?0,>3]0,>F:7PU\6]-US48K"\LI
M+">9]D3>8)$8GH"< @D\=,>]>"5H:'I=YK.LVMC8*YGD<89!]P9Y;V ZU@\)
M24?U-%6FV?5]?/\ \7-!ATGQ4MY;*$BU"/S648P) <-@>AX/U)KZ KPWXU:A
M!<>(;&QC8-+:P$RX/W2YR ?? !^C"N/!M^UT-J]N0\RJ2""6YN(K>%"\LKA$
M0=68G 'YU'7JOP>\*"ZNW\17D1,5NQ2T#=&?'S-COC.![Y[BO3JU%3BY,Y81
MYG8],\(>'(?"WAVWT^/YI?\ 63R8Y>0]?RX ]@*VXY4FC62)U=&&593D$>U<
M;\2_%9\->'3%:R :A>9CAYY1?XGQ[#@>Y'I6UX._Y$K1/^O&'_T 5X\HR<?:
M2ZL[4TGRH\W^.7^OT/\ W9_YI7D=>N?'+_7Z'_NS_P TKR.O4PO\%'+6^-A1
M11709!1110 4444 %%%% !1110 4444 %%%% !1110 5Z%\&O^1VD_Z\Y/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]L^#_\
MR*5U_P!?S_\ HN.O0*\_^#__ "*5U_U_/_Z+CKT"O$Q'\61WT_@04445B6%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Z/_ %J?
M[PK1K.C_ -:G^\*T: .6^(__ "3[5_\ KDO_ *&M?--?2WQ'_P"2?:O_ -<E
M_P#0UKYIKU,#\#]3DQ'Q(****[3 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O;O@__ ,B1JW_7R_\ Z+6O$:]N^#__ ")&K?\ 7R__ *+6
MN;%_PS6C\1XC111729!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >B_!= WC2Y)_AL7(X_VT']:]ZKP3X,S+'XUF0]9;*1%Y[[D/]#7O=>1C/XI
MV4/@/DW6)&FUR_E?[SW,C'ZEC5*M#7H#;>(M3@((,5W*AR?1R*SZ]:.R.1[A
M7N?P3D)\+W\?9;TM^:+_ (5X97O7P8M)(/!T\\B;5N+MVC/'S*%5<_F&'X5S
M8S^$:T/C.E\<@-X&UH$ C[*YY^E?/'A/_D<M#_["%O\ ^C%KZ ^(EVEGX!U>
M1P2'A\H >KD*/YYKY_\ "?\ R.6A_P#80M__ $8M8X3^%(NM\:/J>OG[0/$7
M_"+_ !1OVDD*V4][-!<9/ 4R'#'D#@X.3VS7T#7RIXF_Y&O6/^OZ;_T,UG@X
MJ7-%E5G:S1]5<,O8@C\Z^;OB)X8/AGQ1*D28L;K,]N0,  GYDZ ?*>P[%?6O
M6OA;XD_MWPLEM.^Z\L,0R9/+)_ WY#'U4U8^)/AL>(?"<YAA$E]9@SVY )8X
M^^HP,G*CIW(6IHR=&KRR'-*<+HZBP(;3K5E((,2$$=^!7@7Q<_Y'Z?\ ZX1?
MRKWC1O\ D!Z?_P!>T?\ Z"*\'^+G_(_3_P#7"+^5/!_Q6*M\!W?P40#PE>OW
M-\PZ>D:?XUUWC.0Q>"=;8=[*5?S4C^M<A\$Y5/A2^A!&];XL1[%$ _\ 0379
M^*[5[WPCJ]M$"TCV<H11U+;3@?G45?X[OW*A_#/EBBBBO8.(**** "O=/@G_
M ,BI??\ 7\W_ * E>%U[I\$_^14OO^OYO_0$KEQG\(VH_&;?Q2_Y)QJW_;'_
M -')7SA7T?\ %+_DG&K?]L?_ $<E?.%3@?X;]1U_B"BMOP?;VUWXPTFWO$22
MWDN45DD^ZW/ /KDXX[U]&?\ ")^&_P#H7]*_\ H_\*TK8A4FDT3"DYJY\L45
M]3_\(GX;_P"A?TK_ , H_P#"O&_B_I6FZ7XAL5T^VM[426N7B@147[S8;:!U
M/(S[>U32Q2J2Y4ASI.*O<['X)_\ (J7W_7\W_H"5W]_I&FZH8SJ&GVMWY6=G
MVB%9-N<9QD'&<#\J^8M'\3ZUH$<L>EZA+;1RD,ZK@@D=\$&I)/&'B660NVOZ
MF"?[MTZC\@<5E4PDY5').Q4:R4;-'T6_A#PTZ[3X?TL#_9M$!_05R'B3X0:1
M?6[RZ)FPNP"5C+EHG/H<Y*_AP/2N)\-?%77=/U.%=5N_ME@[!91*HW(O3<"!
MG(ZXYSC\:]_!! (.0:YYJK0DM36/)46Q\C7=I<6%Y-:74313PN4D1NJD5#7I
M'QGTQ+7Q3;7T:HHO+<;\=2Z'!)_X"5'X5YO7J4Y\\%(Y)1Y78^CD^%G@Y8U4
MZ2SD  LUS+D^YPV*W]*\/Z1H@;^S-.M[4N,,T: ,P]"W4CVKP%?BAXR50HUD
MX QS;1$_^@5N:+\9M8MIXDU>WAO+?@.\:^7+U&6X^4G&>,#ZBO/GAJ[6KO\
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MM"-SHJ*'-JSM)6M?AW\.%ADF0O;P%$R?]=.V3@=^6)/L![5X!H'_ ",>F?\
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MIQ<6['DVF>)];T>%H;#4[B&%D9#%NW)ANN%.0#[@9J#2];U31))'TR^GM6D
M#^4V-P'3(_SU->N^(OA1I.K61U+PS.L,DBF1(E??#*#D_*?X<_7'L*\5DC>*
M1HY$9)$)5E88*D=016M.=.JG9>I,HRCN?1>HZI?0_"1-3CN76^.F0RF?^+>5
M7)^O)KPK4/%>OZK9M:7VK74]NQ!:-G^5L<C([\\_A7M6J_\ )#X_^P1!_P"@
M)7S[6&$C&TG;J76;T]#H]!\;:QX:TNZL-,>&-;A]YE9-SJ<8^7G'Y@]*S;CQ
M!K-U/Y\^JWLDF=VYIVX/MSQ77_#OX>KXI#ZCJ+O'IL3[ B'#3,,$C/9>>3^
MKK;[6_AAX=E>S32;:]DA^1A%:K/@^F]S@GWR:N52$9M1C=]25&3C=NR+'P?\
M0ZAK&F:C9ZA<2W+6;HT<TK[FVON^4D\G!4]2>N.U>2>)K<Z/XRU.&U/D_9[Q
MS"8CM\L;LKC'0@8Z>E>Z^!=?\-ZY]O\ ^$?TC^S_ "?+\_\ T:.+?G=M^X3G
M&&Z^M>)>//\ D>]9_P"OEJSH/]]+2WD74^!:W/3_ (0:]JNM_P!L_P!IWTUU
MY/D>7YASMSYF<?D/RKC?&7C+Q'9>,=5M;75[F*"*<JD:-@*!VKH?@9_S'O\
MMW_]J5P/CS_D>]9_Z^6IPA'ZQ)6_K04F_9IE+1-/G\2>)[2RD>666\N!YTA;
M+D$Y=LGJ<9->Q?$WQ%+X3\.V.CZ.?LSW"&-70<Q1( ,*>Q.0,_7H<&O-_A<
M?B-I.1G_ %W_ **>O7/''B+PSHES9Q^(-%-^\B,86^S12[0",CYR".U*N_WT
M8VNNPZ:]QN]CY^MM2O;.^^VV]W-%=;MQF5R&)SG)/?FO>[:3_A87PK9[V,"Y
MEA?E!TFC)VL/J0#CW(KFO^$^^''_ $*7_E-M_P#XJKL?Q=\*6-@UMIVCWL"
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M0#^59-)-/8=K!6KHGAO5_$<TL6DV9N7B 9QO50H/3EB!657K'P._X_\ 6?\
MKE%_-JSK3<(.2*A'FE9GG.M>']4\.W:6VJVC6TKIO4%E8,/8J2*S:]2^-W_(
M<TO_ *]F_P#0J\MIT9N<%)A./+)I!115FST^]U&0QV-G<73CJL$3.1^ %:-V
M(*U%:=QX=URTB:6YT;488U!)>2U=0 .2<D5F4DT]AVL%%%%,04444 %%%% !
M1110 4444 %%%% !1110![9\'_\ D4KK_K^?_P!%QUZ!7G_P?_Y%*Z_Z_G_]
M%QUZ!7B8C^+([Z?P(****Q+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ='_K4_WA6C6='_ *U/]X5HT <M\1_^2?:O_P!<E_\
M0UKYIKZ6^(__ "3[5_\ KDO_ *&M?-->I@?@?J<F(^)!1117:8!1110 4444
M %%%% !15S2]*OM9OTL=.MVN+EP2J+@< 9)R>!72?\*M\9?] ;_R:A_^+J)5
M(1TD[%*+>R./HK3UKP]JWAVXCAU6R>V>0%DR0RL!UPP)!_/N/6LRJ335T)JV
MX445LZ'X4USQ(LKZ38/<)$0'?>J*">V6(!/L*&U%78)-[&-178?\*M\9?] ;
M_P FH?\ XNC_ (5;XR_Z W_DU#_\74>VI_S+[Q\DNQQ]%;NI^#/$>CQ&6^TB
MYCB ):15WJH'4DKD#\?Z5A5:DI:IB::W"BBBF(***U=$\-:QXCDECTFR:Y,0
M!D(95"YSC)8@<X/Y4FTE=C2OL95%=+J7P_\ %.DV,E[>:2Z6\0W.Z2I)M'J0
MK$X]ZYJE&49:Q=P::W"BBBJ$%%%% !1176?#K0+'Q'XK2RU%6>V6%Y616*[B
M, #(Y[Y_"IG)1BY/H-*[LCDZ*^C)?A7X/DC94TMHV(X=;F4D?FQ%?.=9T:\:
MM^7H5.FX;A1116Q 445[)X?^#FFW>BVMUJM]>"YGB60I;LBJF1G'*G)P16=2
MK&FKR+C!RV/&Z*[?XA>!(_!\MI-:7,D]I<[E_>XWHXQUQC(.?3L:J?#K0+'Q
M'XK2RU%6>V6%Y616*[B, #(Y[Y_"CVL7#G6P<CYN4Y.BOHR7X5^#Y(V5-+:-
MB.'6YE)'YL17SG4T:\:M^7H$Z;AN%%%%;$!117KGA3X1Z?JOA^UU'5+ZZ$ET
M@E2.V*J%0C(R64Y./IUQVS6=2K&FKR*C!R=D>1T5WWQ#^'L'A&"VO;&[EFM)
MG\IDGQO5\$CD  C /88QWSQP-.$XSCS1"47%V844459(4444 %%%% !1110
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M/X#'U:N9OOC??2PE;'1H+>0_QS3&4#\ %KS;5-7O];OFO=2NI+FX88WN>@]
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M%73%S1E%)NUCH?A3X3U'PWIM[<ZDHBFOC'BW/WHU3=@L?4[NG;'O@>2>//\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** '1_ZU/]X5HUG1_ZU/\ >%:- '+?$?\ Y)]J_P#UR7_T-:^::^EOB/\
M\D^U?_KDO_H:U\TUZF!^!^IR8CXD%%%%=I@%%%% !1110 444JJSNJ(I9F.
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MO5=6L=$TZ2_U&?R;6,@.^QFQD@#A03U(K @^)?@^XF6)-:C#-T,D,B+^+,H
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M+6O$:]N^#_\ R)&K?]?+_P#HM:YL7_#-:/Q'B-%%%=)D%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 :NE>)=:T3C3=3N;=/^>:OE/^^3Q^
ME;0^*'C)1@:R?QMHC_[)7(45#IPEJTBE*2V9T5]X[\4:C&([C6[K:.T3"+/U
MV 9_&N=HHIQBH[(3;>X4JLR.KHQ5E.00<$&DHJA&N?%7B(H4.O:H5(P5-Y)C
M'YUD444DDMAW;"I;>YGM)UGMII(9D^[)&Q5E^A%144Q&Q_PEGB3_ *&#5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#Z-C_Y(R?\ L G_ -$5\Y5]&Q_\D9/_ & 3_P"B*^<JX\']
MKU-ZW0****[# **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB>&T5L:_X8U7PW<>7J$&$+%4F3F-^ >#^/>L>N^,E)71SM-:,****8@HHHH
M**** "BBB@ HHHH **** "BBB@ KZ(^$W_)/[3_KK+_Z&:^=Z^B/A-_R3^T_
MZZR_^AFN/&_P_F;T/B.8\6?%37-"\47^F6MKISP6[A4:6-RQ^4'G#@=_2N?N
M?C'XHGC*QK86Q(QOBA)(]_F8C]*QOB-_R4#6/^NJ_P#H"UR]73H4W!-KH3*I
M*[5R[J>KZAK-T;G4;N6YE/\ %(V<?0=!T[52HJYI*Q/K-BDZAH6N(Q(",@KN
M&?TKHT2T,]V>Q>!/A=86^GV^IZ]!]INYD$BVLJ_)$". RGJV#SGH>W&:VM0^
M(WA#PX7LK=_-:'"&&PA!5<=@>%X'H>.E;?C&6>#P9K$MLS+,EI(0R$@KQR01
MZ#-?+E>=1A]8;E-G3.7L[*)]":1\5]"UG5K;3;>TU%9KAPB-)&@4$^N')_2I
M/BS_ ,D_N_\ KK%_Z&*\F^&NE7NH^-;&:VA9H;202SR=%1><9/J>P_P->L_%
MG_DG]W_UUB_]#%3.G"G7BHCC)RIML^=Z^C_A;_R3C2?^VW_HYZ^<*^COA:0?
MASI8'8S _P#?UZZ,=_#7J9T/B/!?$W_(UZQ_U_3?^AFLNMCQ9#)!XOUF.5"K
M"]F.",<%R0?H00?QK'KJA\*,7N>N? W_ %^N?[L'\WK+^-?_ ".5G_V#T_\
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M3?C(D3>"$:3;O6[C,>3@YPW3UXS7)'FH55"]TS9VJ0<K:G@5%%%>@<P4444
M%%%% !1110 4444 %%%% !1110![9\'_ /D4KK_K^?\ ]%QUZ!7G_P '_P#D
M4KK_ *_G_P#1<=>@5XF(_BR.^G\""BBBL2PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** '1_ZU/]X5HUG1_ZU/\ >%:- '+?$?\
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M!/7/\\CM5X:"J5.:3U%5DXQLD9%%%%>J<85[!\#/^8]_V[_^U*\?KV#X&?\
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M:T.TLM$MX+*2U67:K2QL7 9\D9# =2>U=?\ '#_D$Z3_ -=W_P#017C^F?\
M(6L_^NZ?^A"M,/",J"4D34;530^M:\E\9_%#6_#OBR]TJTM=/>"#R]K31N6.
MZ-6.2' ZD]J]:KYP^*7_ "4?5O\ MC_Z)2N3"0C.;4ET-JTG&-T9WBGQ?J7B
MZZ@GU!;=/(0HB0(549.2>23D\=^U>[_#_P .Q>'?"EK'Y>VZN46>Y)Y.]@./
MH!QCZ^M?.VCPI<:W802#,<ES&C CJ"P!KZRK;&/EBH1V,Z&K<F<1\0O'H\(P
MP6UI$DVHW*EE#GY8EZ;B.IR>@]CSQSYC9_%OQ7;WGG3W,%U$3S!) JJ!GL5
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M]N^#_P#R)&K?]?+_ /HM:YL7_#-:/Q'B-%%%=)D%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5Z%\&O^1VD_P"O.3_T)*\]KT+X-?\ ([2?]><G_H25CB/X4BZ?QHR/B5_R
M4+5_]]/_ $6M<I75_$K_ )*%J_\ OI_Z+6N4JJ7\./HA3^)A1116A(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'T;'_P D9/\ V 3_ .B*^<J^C8_^2,G_ + )_P#1%?.5<>#^UZF];H%%
M%%=A@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445;TS3;K6-2@T^R
MB,EQ.VU%_J?0#J32;MJP-;P=X5N?%NMI9Q$QVZ?/<3 ?<3_$]!_]:OH^"WMM
M)T^"PLHUBAA0(B+_  C_ !K.\,>';3PAH$=E %>8_--+C!E?N?IV ]*O,Q9B
M3U->/B*_M9:;([:5/E7F)1117.:A1110 4444 %%%% !1110 4444 %%%% !
M1110!'/!#=0/!<11S0N,-'(H96'N#UKSCQ-\*+:ZWW.@LMM+P?LTC'RSUS@\
MD'IQT^E>ET5I3JRIN\63*"EN?+%U;365W-:W";)H9&CD7(.U@<$9''45%6KX
MH_Y&W6?^OZ?_ -&-657N1=TF<#T84444Q!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ]5;&3C((./>L^O7335T<;5@KV#X&?\ ,>_[=_\ VI7C]>P? S_F/?\ ;O\
M^U*PQ?\ !?\ 74TH_&CT3QC_ ,B5K?\ UXS?^@&OENOJ3QC_ ,B5K?\ UXS?
M^@&OENL<#\++Q&Z/J#P/_P B/HO_ %Z)_*O/_CG_ ,P'_MX_]IUZ!X'_ .1'
MT7_KT3^5>?\ QS_Y@/\ V\?^TZYZ'^\??^II4_A'C]?1_P +?^2<:3_VV_\
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M?*.MZ)?^'M4ET[48?+FCY!'*NO9E/<'_ .MU!%?4NH7\&EZ?/?73%;>!=\C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]"^#7_ ".TG_7G)_Z$
ME>>UZ%\&O^1VD_Z\Y/\ T)*QQ'\*1=/XT9'Q*_Y*%J_^^G_HM:Y2NK^)7_)0
MM7_WT_\ 1:URE52_AQ]$*?Q,****T)"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8?\ "K?&7_0&_P#)J'_XNC_A5OC+_H#?^34/_P 71[:G_,OO#DEV./HKL/\
MA5OC+_H#?^34/_Q='_"K?&7_ $!O_)J'_P"+H]M3_F7WAR2[''T5V'_"K?&7
M_0&_\FH?_BZ/^%6^,O\ H#?^34/_ ,71[:G_ #+[PY)=CCZ*[#_A5OC+_H#?
M^34/_P 71_PJWQE_T!O_ ":A_P#BZ/;4_P"9?>')+L<?178?\*M\9?\ 0&_\
MFH?_ (NC_A5OC+_H#?\ DU#_ /%T>VI_S+[PY)=CCZ*[#_A5OC+_ * W_DU#
M_P#%T?\ "K?&7_0&_P#)J'_XNCVU/^9?>')+L<?178?\*M\9?] ;_P FH?\
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M_H#?^34/_P 71_PJWQE_T!O_ ":A_P#BZ/;4_P"9?>')+L<?178?\*M\9?\
M0&_\FH?_ (NC_A5OC+_H#?\ DU#_ /%T>VI_S+[PY)=CCZ*[#_A5OC+_ * W
M_DU#_P#%T?\ "K?&7_0&_P#)J'_XNCVU/^9?>')+L<?178?\*M\9?] ;_P F
MH?\ XNC_ (5;XR_Z W_DU#_\71[:G_,OO#DEV./HKL/^%6^,O^@-_P"34/\
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M@ HHHH **** "BBB@ HHHH **** /;/@_P#\BE=?]?S_ /HN.O0*\_\ @_\
M\BE=?]?S_P#HN.O0*\3$?Q9'?3^!!1116)84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7H7P:_Y':3_ *\Y/_0DKSVO
M0O@U_P CM)_UYR?^A)6.(_A2+I_&C(^)7_)0M7_WT_\ 1:URE=7\2O\ DH6K
M_P"^G_HM:Y2JI?PX^B%/XF%%%%:$A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?3GA2X=/!^BJ N!8P=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110![9\'_^12NO^OY__1<=>@5Y
M_P#!_P#Y%*Z_Z_G_ /1<=>@5XF(_BR.^G\""BBBL2PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** '1_ZU/\ >%:-9T?^M3_>%:-
M'+?$?_DGVK_]<E_]#6OFFOI;XC_\D^U?_KDO_H:U\TUZF!^!^IR8CXD%%%%=
MI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7MWP?_Y$C5O^
MOE__ $6M>(U[=\'_ /D2-6_Z^7_]%K7-B_X9K1^(\1HHHKI,@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "O0O@U_R.TG_7G)_Z$E>>UZ%\&O\ D=I/^O.3_P!"2L<1_"D7
M3^-&1\2O^2A:O_OI_P"BUKE*ZOXE?\E"U?\ WT_]%K7*55+^''T0I_$PHHHK
M0D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#Z7\+_\ (I:-_P!>,'_HM:U:RO"__(I:-_UXP?\ HM:U:\"?
MQ,]&.P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/B=Y&MU+LQC!)W8SG)ZYKYRK&E651M);%S@XV"BBBMB HHHH **** "BBB@
MKT3X5>%M'\2W&J?VM:FX6W2/RU\QD +%LGY2#_"*\[KUSX&_Z_7/]V#^;UAB
M6XTFT:4DG-7.7^)WA_3?#GB:"TTN PP26BRE"[/\Q=QU8D]%%<77I'QK_P"1
MRL_^P>G_ *,DKS>JH-NFFQ5%:3L%%%%:D!1110 4444 %%%% !1110 4444
M%%%% 'MGP?\ ^12NO^OY_P#T7'7H%>?_  ?_ .12NO\ K^?_ -%QUZ!7B8C^
M+([Z?P(****Q+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O0O@U_R.TG_
M %YR?^A)7GM>A?!K_D=I/^O.3_T)*QQ'\*1=/XT9'Q*_Y*%J_P#OI_Z+6N4K
MJ_B5_P E"U?_ 'T_]%K7*55+^''T0I_$PHHHK0D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z7\+_\BEHW
M_7C!_P"BUK5K*\+_ /(I:-_UXP?^BUK5KP)_$ST8[!1114C"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#YH\4?\ (VZS_P!?T_\ Z,:LJM7Q1_R-NL_]
M?T__ *,:LJO?A\*/.EN%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH *]J
M^!__ ""=6_Z[I_Z":\5KVKX'_P#()U;_ *[I_P"@FN;%_P )FM'XT<S\9_\
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M1^(\1HHHKI,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O0O@U_P CM)_UYR?^A)7GM>A?
M!K_D=I/^O.3_ -"2L<1_"D73^-&1\2O^2A:O_OI_Z+6N4KJ_B5_R4+5_]]/_
M $6M<I54OX<?1"G\3"BBBM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /I?PO_ ,BEHW_7C!_Z+6M6LKPO
M_P BEHW_ %XP?^BUK5KP)_$ST8[!1114C"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!T?\ K4_WA6C6='_K4_WA6C0!RWQ'_P"2?:O_ -<E_P#0UKYIKZ6^
M(_\ R3[5_P#KDO\ Z&M?-->I@?@?J<F(^)!1117:8!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5[=\'_P#D2-6_Z^7_ /1:UXC7MWP?_P"1
M(U;_ *^7_P#1:US8O^&:T?B/$:***Z3(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT+X-
M?\CM)_UYR?\ H25Y[7H7P:_Y':3_ *\Y/_0DK'$?PI%T_C1D?$K_ )*%J_\
MOI_Z+6N4KJ_B5_R4+5_]]/\ T6M<I54OX<?1"G\3"BBBM"0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /I?
MPO\ \BEHW_7C!_Z+6M6LKPO_ ,BEHW_7C!_Z+6M6O G\3/1CL%%%%2,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5O\ KY?_ -%K7B->W?!__D2-6_Z^7_\ 1:US8O\ AFM'XCQ&BBBNDR"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *]"^#7_ ".TG_7G)_Z$E>>UZ%\&O^1VD_Z\Y/\ T)*Q
MQ'\*1=/XT9'Q*_Y*%J_^^G_HM:Y2NK^)7_)0M7_WT_\ 1:URE52_AQ]$*?Q,
M****T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^E_"_\ R*6C?]>,'_HM:U:RO"__ "*6C?\ 7C!_Z+6M
M6O G\3/1CL%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FCQ1_R
M-NL_]?T__HQJRJU?%'_(VZS_ -?T_P#Z,:LJO?A\*/.EN%%%%4(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#VSX/\ _(I77_7\_P#Z+CKT"O/_ (/_ /(I
M77_7\_\ Z+CKT"O$Q'\61WT_@04445B6%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>A?!K_D=I/\ KSD_]"2O/:]"^#7_ ".TG_7G)_Z$E8XC^%(NG\:,CXE?
M\E"U?_?3_P!%K7*5U?Q*_P"2A:O_ +Z?^BUKE*JE_#CZ(4_B84445H2%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!]+^%_^12T;_KQ@_P#1:UJUE>%_^12T;_KQ@_\ 1:UJUX$_B9Z,=@HH
MHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\T>*/\ D;=9_P"OZ?\
M]&-656KXH_Y&W6?^OZ?_ -&-657OP^%'G2W"BBBJ$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110![9\'_P#D4KK_ *_G_P#1<=>@5Y_\'_\ D4KK_K^?_P!%
MQUZ!7B8C^+([Z?P(****Q+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ='_ *U/]X5HUG1_ZU/]X5HT <M\1_\ DGVK_P#7)?\
MT-:^::^EOB/_ ,D^U?\ ZY+_ .AK7S37J8'X'ZG)B/B04445VF 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>W?!_\ Y$C5O^OE_P#T6M>(
MU[=\'_\ D2-6_P"OE_\ T6M<V+_AFM'XCQ&BBBNDR"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *]"^#7_([2?]><G_ *$E>>UZ%\&O^1VD_P"O.3_T)*QQ'\*1=/XT9'Q*
M_P"2A:O_ +Z?^BUKE*ZOXE?\E"U?_?3_ -%K7*55+^''T0I_$PHHHK0D****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#Z7\+_ /(I:-_UXP?^BUK5K*\+_P#(I:-_UXP?^BUK5KP)_$ST8[!1
M114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YH\4?\C;K/_7]/_P"C
M&K*K5\4?\C;K/_7]/_Z,:LJO?A\*/.EN%%%%4(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#VSX/_\ (I77_7\__HN.O0*\_P#@_P#\BE=?]?S_ /HN.O0*
M\3$?Q9'?3^!!1116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ8S^9?U\@^N8?L_Z^9VW_"D=*_Z"U[_WRO\ A1_PI'2O^@M>_P#?*_X5Q/\
MPMCQ=_S_ $/_ (#I_A1_PMCQ=_S_ $/_ (#I_A1]4QG\R_KY!]<P_9_U\SMO
M^%(Z5_T%KW_OE?\ "C_A2.E?]!:]_P"^5_PKB?\ A;'B[_G^A_\  =/\*/\
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M'_P'3_"C_A;'B[_G^A_\!T_PH^J8S^9?U\@^N8?L_P"OF=M_PI'2O^@M>_\
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M^%L>+O\ G^A_\!T_PH_X6QXN_P"?Z'_P'3_"CZIC/YE_7R#ZYA^S_KYG;?\
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M_?*_X4?\*1TK_H+7O_?*_P"%<3_PMCQ=_P _T/\ X#I_A1_PMCQ=_P _T/\
MX#I_A1]4QG\R_KY!]<P_9_U\SMO^%(Z5_P!!:]_[Y7_"C_A2.E?]!:]_[Y7_
M  KB?^%L>+O^?Z'_ ,!T_P */^%L>+O^?Z'_ ,!T_P */JF,_F7]?(/KF'[/
M^OF=M_PI'2O^@M>_]\K_ (4?\*1TK_H+7O\ WRO^%<3_ ,+8\7?\_P!#_P"
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M.G^%'U3&?S+^OD'US#]G_7S.V_X4CI7_ $%KW_OE?\*/^%(Z5_T%KW_OE?\
M"N)_X6QXN_Y_H?\ P'3_  H_X6QXN_Y_H?\ P'3_  H^J8S^9?U\@^N8?L_Z
M^9VW_"D=*_Z"U[_WRO\ A1_PI'2O^@M>_P#?*_X5Q/\ PMCQ=_S_ $/_ (#I
M_A1_PMCQ=_S_ $/_ (#I_A1]4QG\R_KY!]<P_9_U\SMO^%(Z5_T%KW_OE?\
M"C_A2.E?]!:]_P"^5_PKB?\ A;'B[_G^A_\  =/\*/\ A;'B[_G^A_\  =/\
M*/JF,_F7]?(/KF'[/^OF=M_PI'2O^@M>_P#?*_X4?\*1TK_H+7O_ 'RO^%<3
M_P +8\7?\_T/_@.G^%'_  MCQ=_S_0_^ Z?X4?5,9_,OZ^0?7,/V?]?,[;_A
M2.E?]!:]_P"^5_PH_P"%(Z5_T%KW_OE?\*XG_A;'B[_G^A_\!T_PH_X6QXN_
MY_H?_ =/\*/JF,_F7]?(/KF'[/\ KYG;?\*1TK_H+7O_ 'RO^%'_  I'2O\
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MIC/YE_7R#ZYA^S_KYG;?\*1TK_H+7O\ WRO^%'_"D=*_Z"U[_P!\K_A7$_\
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MZE_X$O\ XT?\)CXE_P"@_J7_ ($O_C1]5Q/\Z^X/KE'^5G:_\*0U3_H+V?\
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M]5Q/\Z^X/KE'^5G:_P#"D-4_Z"]G_P!\-1_PI#5/^@O9_P#?#5Q7_"8^)?\
MH/ZE_P"!+_XT?\)CXE_Z#^I?^!+_ .-'U7$_SK[@^N4?Y6=K_P *0U3_ *"]
MG_WPU'_"D-4_Z"]G_P!\-7%?\)CXE_Z#^I?^!+_XT?\ "8^)?^@_J7_@2_\
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M_P"@_J7_ ($O_C1_PF/B7_H/ZE_X$O\ XT?5<3_.ON#ZY1_E9VO_  I#5/\
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M5_PF/B7_ *#^I?\ @2_^-'_"8^)?^@_J7_@2_P#C1]5Q/\Z^X/KE'^5G:_\
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MO[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^=
M$OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_O
MM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/
M-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?
M;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>
M;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_
M>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH
M^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1
MO[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^=
M$OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_O
MM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/
M-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?
M;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>
M;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_
M>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH
M^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1
MO[PH^R-_>%1>;)_?;\Z/-D_OM^= $OV1O[PH^R-_>%1>;)_?;\Z/-D_OM^=
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M_P ")O\ XJNF\V3^^WYT>;)_?;\Z/;5/YG]X<D>QS/\ PJOPI_T"Q_X$3?\
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M$W_Q5=-YLG]]OSH\V3^^WYT>VJ?S/[PY(]CF?^%5^%/^@6/_  (F_P#BJ/\
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M3^^WYT>;)_?;\Z/;5/YG]X<D>QS/_"J_"G_0+'_@1-_\51_PJOPI_P! L?\
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M]]OSH\V3^^WYT>VJ?S/[PY(]CF?^%5^%/^@6/_ B;_XJC_A5?A3_ *!8_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KVSX0?\ (D:M_P!?+_\ HM:\3KVS
MX0?\B1JW_7R__HM:X<Q_@?-'9@?XWR9XG1117<<84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7H7P;_P"1VD_Z\Y/_ $)*\]KT+X-_\CM)_P!><G_H25S8S^!+T-\+_&CZ
MF/\ $G_DH6K_ .^G_HM:Y6NJ^)/_ "4+5_\ ?3_T6M<K5X?^##T7Y$UOXLO5
MA1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!]*^&/^13T;_KQ@_P#1:UJUE>&/^13T;_KQ@_\ 1:UJ
MU\A4^-^I]/3^!!1114%A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_\ 6I_O"M&L
MZ/\ UJ?[PK1H Y?XC?\ )/\ 5_\ KDO_ *&M?-5?2OQ&_P"2?ZO_ -<E_P#0
MUKYJKWLJ_A/U_1'C9E_$7H%%%%>H><%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7MGP@_Y$C5O^OE__ $6M>)U[9\(/^1(U;_KY?_T6M<.8
M_P #YH[,#_&^3/$Z***[CC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]"^#?_ ".TG_7G
M)_Z$E>>UZ%\&_P#D=I/^O.3_ -"2N;&?P)>AOA?XT?4Q_B3_ ,E"U?\ WT_]
M%K7*UU7Q)_Y*%J_^^G_HM:Y6KP_\&'HOR)K?Q9>K"BBBMC(**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z5
M\,?\BGHW_7C!_P"BUK5K*\,?\BGHW_7C!_Z+6M6OD*GQOU/IZ?P(****@L**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ='_K4_WA6C6='_ *U/]X5HT <O\1O^2?ZO
M_P!<E_\ 0UKYJKZ5^(W_ "3_ %?_ *Y+_P"AK7S57O95_"?K^B/&S+^(O0**
M**]0\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O;/A!_R)
M&K?]?+_^BUKQ.O;/A!_R)&K?]?+_ /HM:X<Q_@?-'9@?XWR9XG1117<<8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7H7P;_Y':3_KSD_]"2O/:]"^#?\ R.TG_7G)_P"A
M)7-C/X$O0WPO\:/J8_Q)_P"2A:O_ +Z?^BUKE:ZKXD_\E"U?_?3_ -%K7*U>
M'_@P]%^1-;^++U84445L9!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?2OAC_D4]&_Z\8/_ $6M:M97AC_D
M4]&_Z\8/_1:UJU\A4^-^I]/3^!!1114%A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#H_]:G^\*T:SH_\ 6I_O"M&@#E_B-_R3_5_^N2_^AK7S57TK\1O^2?ZO_P!<
ME_\ 0UKYJKWLJ_A/U_1'C9E_$7H%%%%>H><%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7MGP@_Y$C5O^OE__1:UXG7MGP@_Y$C5O^OE_P#T
M6M<.8_P/FCLP/\;Y,\3HHHKN.,**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT+X-_\CM)_
MUYR?^A)7GM>A?!O_ )':3_KSD_\ 0DKFQG\"7H;X7^-'U,?XD_\ )0M7_P!]
M/_1:URM=5\2?^2A:O_OI_P"BUKE:O#_P8>B_(FM_%EZL****V,@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /I7PQ_R*>C?]>,'_HM:U:RO#'_(IZ-_UXP?^BUK5KY"I\;]3Z>G\""BBBH+
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** '1_ZU/\ >%:-9T?^M3_>%:- '+_$;_DG
M^K_]<E_]#6OFJOI7XC?\D_U?_KDO_H:U\U5[V5?PGZ_HCQLR_B+T"BBBO4/.
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KVSX0?\B1JW_7R
M_P#Z+6O$Z]L^$'_(D:M_U\O_ .BUKAS'^!\T=F!_C?)GB=%%%=QQA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>A?!O_D=I/\ KSD_]"2O/:]"^#?_ ".TG_7G)_Z$E<V,
M_@2]#?"_QH^IC_$G_DH6K_[Z?^BUKE:ZKXD_\E"U?_?3_P!%K7*U>'_@P]%^
M1-;^++U84445L9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?2OAC_D4]&_Z\8/_1:UJUE>&/\ D4]&_P"O
M&#_T6M:M?(5/C?J?3T_@04445!84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Z/_6I
M_O"M&LZ/_6I_O"M&@#E_B-_R3_5_^N2_^AK7S57TK\1O^2?ZO_UR7_T-:^:J
M][*OX3]?T1XV9?Q%Z!1117J'G!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z5\,
M?\BGHW_7C!_Z+6M6LKPQ_P BGHW_ %XP?^BUK5KY"I\;]3Z>G\""BBBH+"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** '1_ZU/]X5HUG1_ZU/\ >%:- '+_ !&_Y)_J
M_P#UR7_T-:^:J^E?B-_R3_5_^N2_^AK7S57O95_"?K^B/&S+^(O0****]0\X
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O;/A!_R)&K?]?+
M_P#HM:\3KVSX0?\ (D:M_P!?+_\ HM:X<Q_@?-'9@?XWR9XG1117<<84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7H7P;_ .1VD_Z\Y/\ T)*\]KT+X-_\CM)_UYR?^A)7
M-C/X$O0WPO\ &CZF/\2?^2A:O_OI_P"BUKE:ZKXD_P#)0M7_ -]/_1:URM7A
M_P"##T7Y$UOXLO5A1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!]-^')[:R\ :7>71588--CEE<KG:
MJQ@DX')X%9__  LSP5_T%5_\!)?_ (BB/_DC1_[ )_\ 1%?.E>%AL'"NYN3>
MC/9Q&*G145%+5'T7_P +,\%?]!5?_ 27_P"(H_X69X*_Z"J_^ DO_P 17SI1
M75_95'N_P_R.;^T:O9?C_F?1?_"S/!7_ $%5_P# 27_XBC_A9G@K_H*K_P"
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M4>[_  _R#^T:O9?C_F?1?_"S/!7_ $%5_P# 27_XBC_A9G@K_H*K_P" DO\
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MI11_95'N_P /\@_M&KV7X_YGT7_PLSP5_P!!5?\ P$E_^(H_X69X*_Z"J_\
M@)+_ /$5\Z44?V51[O\ #_(/[1J]E^/^9]%_\+,\%?\ 057_ ,!)?_B*/^%F
M>"O^@JO_ ("2_P#Q%?.E%']E4>[_  _R#^T:O9?C_F?1?_"S/!7_ $%5_P#
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M9G@K_H*K_P" DO\ \17SI11_95'N_P /\@_M&KV7X_YGT7_PLSP5_P!!5?\
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M^(H_X69X*_Z"J_\ @)+_ /$5\Z44?V51[O\ #_(/[1J]E^/^9]%_\+,\%?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<HZE64X((P0:N,XSUB[D2A*/Q*PE%%%62%%206\UU.D%O#)-,YPD<:EF8^@
MY-=4OPP\8LH8:,<$9YN8@?\ T.LYU80^)I%QISG\*;.1HJSJ&GW>E7\MC?0M
M#<PG#QL02.,]O8U6JTTU=$M-.S"BBBF(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *]L^$'_(D:M_U\O_ .BUKQ.O;/A!_P B1JW_ %\O
M_P"BUKAS'^!\T=F!_C?)GB=%%%=QQA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>A?!O\
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MC+EM=G90P4ZJYKV1\L45]>%0PPP!'H:YW7O OA_Q!"XN;".*=N?M-NH20$#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?1<?_ "1H_P#8!/\ Z(KYTKZ+
MC_Y(T?\ L G_ -$5\Z5YF7?;]3T,?]CT"BBBO3//"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "NN^'WB]_"NN 3LQTZY(2X3^[Z./<?RS[5R-
M%14IQJ1<);,N$W"2E'='UE,J2QK/$RLC $,IR".Q%5Z\Y^$OC+SHAX;U"0;T
M!-F['[R]X_PZCVR.PKTN>+RWX^Z>E?+5Z,J,W"1]%1JJK!21%1116)J%%%%
M!1110 4444 %%%% !1110 4444 %%%% !17#W_Q3T/3]1N;*:UU%I;>5XG*1
MH02I(.,OTXJO_P +?\/_ //GJ?\ WZC_ /BZZ5@Z[5U%F#Q5%:<QZ!17G_\
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M_P /_P#/GJ?_ 'ZC_P#BZ/J=?^5A]:H_S'H%%>?_ /"W_#__ #YZG_WZC_\
MBZ/^%O\ A_\ Y\]3_P"_4?\ \71]3K_RL/K5'^8] HKS_P#X6_X?_P"?/4_^
M_4?_ ,71_P +?\/_ //GJ?\ WZC_ /BZ/J=?^5A]:H_S'H%%>?\ _"W_  __
M ,^>I_\ ?J/_ .+H_P"%O^'_ /GSU/\ []1__%T?4Z_\K#ZU1_F/0**\_P#^
M%O\ A_\ Y\]3_P"_4?\ \71_PM_P_P#\^>I_]^H__BZ/J=?^5A]:H_S'H%%>
M?_\ "W_#_P#SYZG_ -^H_P#XNC_A;_A__GSU/_OU'_\ %T?4Z_\ *P^M4?YC
MT"BO/_\ A;_A_P#Y\]3_ ._4?_Q='_"W_#__ #YZG_WZC_\ BZ/J=?\ E8?6
MJ/\ ,>@45Y__ ,+?\/\ _/GJ?_?J/_XNC_A;_A__ )\]3_[]1_\ Q='U.O\
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M /BZ/^%O^'_^?/4_^_4?_P 71]3K_P K#ZU1_F/0**\__P"%O^'_ /GSU/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ%N]UIMU;QE0\L+HI;H"01S7B2_!7Q"7 >^TL+GDB20D#Z;*]PN;A+6TFN)
MQ2)&=@O4@#/%<3IWQ<\,7]TL$C7=EN("O<Q@)D^I5CCZG KAPM3$0B_8J_<[
M,1"C-KVK+O@GP':>#XI9?.^U7\PVO.5V@+G.U1V'3//.!5KQIXKMO"FARSO(
MOVV566TB/)=\=2/[HX)_+J171,-\9 8C<.&7J/<5\Z_$3PUJ>A:\9KV[GOK>
MY),%W,<L?5&]",]N".1CH+PT%BJUZLM?S)Q$GAZ5J:T_(XZBBBOHSP38\)_\
MCCH?_80@_P#1BU]2U\M>$_\ D<=#_P"PA!_Z,6OJ6O#S;XX^A[&6_!(^;OB7
M_P E#U;_ 'H__1:UR==9\2_^2AZM_O1_^BUKDZ];#_P8>B_(\RO_ !9>K"BB
MBMC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]L^$'_(
MD:M_U\O_ .BUKQ.O;/A!_P B1JW_ %\O_P"BUKAS'^!\T=F!_C?)GB=%%%=Q
MQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 6+&SEU#4+:R@QYMQ
M*L2;NFYB ,_B:^IM%TBVT+1[73+0'R8$V@GJQZEC[DY->%?"6Q2\\=P2.?\
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MTRNE*%-REU,\PJ1E-170****],\\**** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 Z/_6I_O"M&LZ/_ %J?[PK1H Y?XC?\D_U?_KDO
M_H:U\U5]*_$;_DG^K_\ 7)?_ $-:^:J][*OX3]?T1XV9?Q%Z!1117J'G!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &AH/_(Q:9_U]Q?\
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MW4]@>*K4J8VJE%'73A#"4VY,\Y^*.M#6/&MPL4@>"S46\9!R"1RQ_P"^B1^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGK_D#KX?#QM3U]/\P^)7BQ/$_B!5M'W:?9J8X6[.Q/S/TSS@#_@.>]8GA/\
MY''0_P#L(0?^C%K'J[H]\NF:W87[H76UN8YB@."P5@<?I7M*DH4O9P['DNHY
MU.>7<^L*^5O$O_(U:Q_U_3?^AFO83\:O#VPD6.J;L<#RX\9^N^O%-2O#J.J7
M=\4\LW,SS%,YV[F)QG\:\_+:%2G*3FK'=CZT*D8J#N16MS-97<-W;OLG@D62
M-\ [64Y!Y]Q7U)X<UN'Q%X?L]4A 43IET'\#CAE_ @_7K7RM7:^ O'TGA"26
MVN86N--F;>R)C>CXQN7/!R  0?0>G.^/PSK0O'=&."Q"I3M+9GT17SW\6_\
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M^;^#OB)J/A*-K7REO+!B6$#OM*-W*M@XSZ8(_6O4;+XN^%;I-TTUU9MG&V:
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M@ HHHH **** "BBB@ HHHH **** /HN/_DC1_P"P"?\ T17SI7T7'_R1H_\
M8!/_ *(KYTKS,N^WZGH8_P"QZ!1117IGGA1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!T?^M3_>%:-9T?^M3_ 'A6C0!R_P 1O^2?ZO\ ]<E_]#6OFJOI7XC?\D_U
M?_KDO_H:U\U5[V5?PGZ_HCQLR_B+T"BBBO4/."BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KVSX0?\B1JW_7R_\ Z+6O$Z]L^$'_ ")&K?\
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M>G /GOQ#\))X4UY4M=_V"Z4R0;CDK@_,F>IQD<GL1UY-=[H_P=;2-:L=17Q
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M*_3_ "/'O^%=>+?^@)-_WVG^-'_"NO%O_0$F_P"^T_QK?_X73XC_ .?+2O\
MOU)_\71_PNGQ'_SY:5_WZD_^+J^?&?RQ(Y<)_,ST/PQIUWI/PL%C?P-!<Q6U
MSOC8@D99R.GL17SK7TEHVM7/B+X;OJMVD23SVUQN6$$*-I=1@$D] .]?-M9Y
M?S<]3FWO_F:8VW+3Y=K?Y'T/\)_^2?VG_767_P!#-?/%?0_PG_Y)_:?]=9?_
M $,U\\4\%_'K>O\ F+%_PJ7I_D%%%%>D< 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!]%Q_\ )&C_ -@$_P#HBOG2
MOHN/_DC1_P"P"?\ T17SI7F9=]OU/0Q_V/0****],\\**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT'5/#]VMKJMH]M*R[E!(8,/4$$@_G7>_"[QIHOAS3[VRU:=[<R2B5)/+9U/
M&/E!.>/2LWXH>*]-\3ZI9#2V,L%M$P,Q4KO9CT (!P,#GW]JY%6K/$.#C[O<
MZ72I*AS\WO=C@Z***[#E"BBB@ HHHH **** "BBB@ HHKM?AUX.L?%]W?1W\
M]S$ENBLOD%0223U)!]*SJU(TX.<MD73INI)1CNSBJ*[#XA^$;/PCJMK;V-Q/
M+#/#O_?X+*0<=0!_*N/ITZD:D5..S"I!PDXRW044459 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'M7P@_Y%.Z_P"OY_\ T7'7H%>?_"#_ )%.
MZ_Z_G_\ 1<=>@5\MC/X\O4^BPO\ !B%%%%<QT!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %%%% !7MGP@_Y$C5O^OE_P#T6M>)U[9\(/\
MD2-6_P"OE_\ T6M<.8_P/FCLP/\ &^3/$Z***[CC"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>W@1EDD2 1"4G!!QU./>NFEBE5ERQB[=VC"IA_9QNY+T.1HHHKJ.8]O^"?\
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MO-]2TR]T>^DLM0MWM[A/O(_\\]"/<5ZI\/?B3JNI:[;Z-K#)<K< K'.$"NK
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M:SXHF*Z=;9B4X>XD.V-#C."?7IP,GD55\.Z/)X@\066EQMM-Q)AF_NJ!EC^
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M;6FN:3LS:6/I1?+%71[!XL^%VCZM9S3Z7;QV&H*N8_)&V)R.S*.!GU'Z]*\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"'(^3Z***]H\D]^^#UV;CP082 /LUU)&.>H(5\_FQ_*N$^,EB+;QE%<JH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]%Q_\D:/_8!/
M_HBOG2OHN/\ Y(T?^P"?_1%?.E>9EWV_4]#'_8] HHHKTSSPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;MY'SC15S5K-=.UF^L4<NMM<20ACU(5B,_I5.O;335T>2U9V84444Q!1110
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MRIT:U:NJM562-)U:5*BZ5-W;,^BBBO4/."BBB@ HHHH **** "BBB@ HHHH
M**** /:OA!_R*=U_U_/_ .BXZ] KS_X0?\BG=?\ 7\__ *+CKT"OEL9_'EZG
MT6%_@Q"BBBN8Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[8 RQ.2>*^N:^0J^O:SS;['S_0TRS[?R_4\"^,7_ "/ _P"O2/\ FU:_P/\
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M_4A1C)]^*\=^-O\ R'-,_P"O9O\ T*LL!;ZSIMJ:8V_U?7?0SO@[_P CP?\
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MU;_KY?\ ]%K7#F/\#YH[,#_&^3/$Z***[CC"BBB@ HHHH **** /I[P1*)O
M^BL#TM$7\AC^E>$?$2'R/'^L(01F4/S_ +2AOZUZK\'M1^U^"S:$C=9W#H!G
MG:WS@_FS?E7#?&/3S:^,8[L+\EW;*Q; &67*D?D%_.O%PG[O&3@_/_,];%>_
MA8R7D4_A3HW]J>-89W3=#8H;ALID;NB#/8Y.X?[M>YZWXATOP[:QW.JW7V>*
M1_+1MC/EL$XPH)Z"O./A)=Z'H^@W=S>ZMI]O>74V"DMRJ,$4?+D,1W+'CU'X
M<_\ %OQ%9ZUK=G;:?<Q7-O9Q',L3;E+N1D C@\*O(]<=J*U)XG%\KORK^OS"
ME46'PW,MW_7Y'I?_  M'P;_T&/\ R6F_^(K3T3QAH/B*ZDMM*U 7$T:>8R>4
MZ$+D#/S 9Y(_.OEZNB\"ZVOA_P 7V-[*^RW+>5.3T"-P2?8'!_"M*N5TU!N#
M=_Z\B*>8S<TI)6/2OC3HQN-(LM7C0EK60Q2D?W'Z$_1AC_@59'P0<#5-7CYR
MT,;#\&/^->@ZYKGAC5="OK"77]+VSP.G%Y&2"1P1SU!P:\,\#^)%\+^)X+^4
M,;9E,4X49.P^GT(!_"HPZG4PDJ5M5M^95=PIXF-2^C_X8]2^,]I--X4M;B--
MT<%T#(1_""I /TS@?B*\M\#Z-?:OXKT_[' SI;7$<TS_ ,,:JP.2?P./6OHV
MSO\ 3M;LO-M+BWO+9Q@["&!'H1_0USVO>+/#O@?36AMTMA< 9BL;4*N2><D#
MA1WS^6:QP^*G"FZ$8WD:U\/"53VTI61T.L_\@/4/^O:3_P!!-?)]?2>H^+_#
M\WAJZ<ZWIQD>T8^6ERI;)0\!<YS[=:^;*ZLKA**E='/F,E)QLSZ]KY%FADMY
MY(95*21L4=3V(."*^D?!/BZQ\2:';8N$%_%&J7$+'#;P,$@=P>HQ_.I?$MKH
M.FZ+J^HW%E81SO:R!Y3$@DE)'"Y/)).!CN<5QX2M+"U)0E'5V.K$TEB(*<7H
MCE?@G<H_AS4;4,N^.[\PC/(#(H'_ * :R_C=8S?:-*U #,!1X"?[K9W#\QG\
MC7$^"?%LWA'6OM/EF6TF 2XB'4KZK[C]>1WR/?+?5/#OB_2S"D]K>VTPPT#D
M9SP>5/((XK:NIX?%>VM>+,:+C7P_LKV:/F.VMIKRZAM;=#)-,ZQQH.K,3@#\
MS7UC;Q)96$41("01!<]@%'_UJQ+'PIX6\-3R:E;V-K:2 %C/+(3Y8YR07)"<
M$],<5P_Q$^)5C-IMQHFB3>>\Z[)[E,>6$/WE4_Q$C@D<8/!STFO4ECIQC33L
MBZ,%A(2E-ZL\XMKM=0\=PWJ JEQJ8E4,,$!I<\_G7TIK/_(#U#_KVD_]!-?+
MNC2QP:YI\TKA(X[F-F8]  P)-?1.L^+?#IT*_P!NNZ<Y:W<!4N49B2IP H.2
M:US&#<X**,\#-<DW)GCOPIO/LOCZT0@8N(Y(22>GREA^J@?C7L'Q$T^?4O F
MJ06XS(J+*%YY",&(&.^ :^;[6YFLKN&[MWV3P2+)&^ =K*<@\^XKZ(\*?$31
M_$=K$DMQ%9ZA@![>5MN6Y^X3]X<?44\PI3C4C7BKV_0G!5(RIRHR=KGSE7T#
M\(M-EL/!(FF4J;RX>= 1@[<!1^>TGZ$5KR^ _"=Q??V@^CVS2YW$@L$)[DH#
MM/XBJWB/Q_H/A>T,4<T5S=JNV*TMF!VD#@,1P@Z>^.@-98C%O%15*E%W-:&&
M6'DZE22/-OC'>"\\8V]E#\[6ULJ,JC)WL2V/R*_G7K.E::G@_P '+:V\<MVU
MG;M(43):9\%FVCMDYP*^:[V[O-:U66ZG+SW=U+N.T$EF)X 'Z ?05]0:+-J/
M]@VTVN+#!>B+=<;&^5?<GH..O8'/:GCH.E1IT[Z+<6#FJE6<^YQ ^-&AJFV;
M3=32<<,FQ"%/IDL#^E<)XT^)5[XIMVT^WMQ9Z:6!9"VYY<'(W'H!T.!W'4UZ
MR/B-X.GD:(ZQ"2N<[XG"\<<$K@_A6E=:/H'B?3E>:TM+RVF7*3(!DCU5AR._
M0UE3J4J$E*5)KU?_  #2<*E:+C&HF>(?"F\^R^/K1"!BXCDA))Z?*6'ZJ!^-
M>P?$33Y]2\":I!;C,BHLH7GD(P8@8[X!KPKQ'I,_@SQA);6\Y+6LJ36TQP3C
MAD)[9'?CJ/2O;?"GQ$T?Q':Q)+<16>H8 >WE;;EN?N$_>''U%;XV,G.&)IJZ
MT_S,<)*/+*A/1GSE7T#\(M-EL/!(FF4J;RX>= 1@[<!1^>TGZ$5KR^ _"=Q?
M?V@^CVS2YW$@L$)[DH#M/XBJWB/Q_H/A>T,4<T5S=JNV*TMF!VD#@,1P@Z>^
M.@-1B,6\5%4J47<NAAEAY.I4DCS7XRWZ7/BZ"T0@_9;55?U#,2V/R*G\:]7\
M".)/ NC,,X%LJ\^W']*^;-0O[G5-1N+^[D,EQ.YD=O<^GH.P'85ZO\*/&MC:
MZ;_8&I7"6[QN6MI)#M1@QR5R>AW$GWS6V+PTEA8QCKRF.%KQ>(E)Z7..^)UI
M-:^/]1,J86;9+&?[RE0,_F"/PKN_@QHU]96>H:C<P-%;W8C$!?@N%W9('I\P
MY[UZ/>6NFW217%]!:3+"?,CDG16"'KN!/3ZUS*?$C0)/$L>DPWEN+=8V:2\D
MD"1!AC"*3P>_/3CC.>.:6)J5J'LH1V6K]#H6'A2K>UE+=Z?,YWXW?\@K2?\
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M8FW*7<C(!'!X5>1ZX[5G4IRQ6)Y9)I)?U^)=.<</A^:+NW_7Y'I?_"T?!O\
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MR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^BX_^2-'_L G_P!$5\Z5]%Q_\D:/_8!/_HBOG2O,R[[?J>AC
M_L>@4445Z9YX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.=5N-7\$V,US"R-$/LZNS ^:J?+N_3'/<&OG*WMY;NZBMH$WS3.(T7.-S$X
M_.OJK1M+@T31K33;9<16\80?[1[L?<G)/N:\W-91Y(QZG?EL7SN70QOB#K/]
MB>"M0G5]LTR?9X</M.Y^,@^H&6_"OFFO6/C7K!>]T[1D8[8D-S*,#!)^5??(
M ;_OK\O)ZVRVER4>9]3+'U.:K;L%%%%>@<04444 %%%% !7MGP@_Y$C5O^OE
M_P#T6M>)U[9\(/\ D2-6_P"OE_\ T6M<.8_P/FCLP/\ &^3/$Z***[CC"BBB
M@ HHHH **** .^^$NOC2?%7V&5@L&HJ(LDXQ(,E/SR5^K"N]^,&C_;_"27Z+
MF6PE#D@9.QOE;]=I_"O!HY'BD62-V21"&5E."I'0@UT=]\0/%&I:?+87>JM)
M;2IL=/)C!8>A(7/ZUP5L+*5>-:#]?Z]#MI8F*HNE->AS5%%%=YQ!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!L^$[FSM/%NE7%^!
M]FCN49R3@+SPQ/H#@GZ5](^(=,DUOP[?:=!<"%[F$HLG4#/KCL>GXU\JUU.A
M_$/Q)H,,=O;WHFMHUVI!<+O51V /4 >@.*\_&86=649P>J.W"XF-).$UHR[_
M ,*G\7?:_)^PP^7G'G_:$V?7&=WZ5[/X0T-O"OA2WL+JXC=X@TDL@X1226/)
M[#U]L\5Y0?C3XD(P+/2Q[B*3_P"+KGM>\>>(?$4;PWE[LMG.3;P+L3IC![D>
MQ)K*K0Q6(2C4LD:TZV'H-RA=L=X_UZ'Q#XON[NV;=:IB&%L8W*O?Z$Y(]B*Y
MBBBO2A!0BHK9'GSDYR<GU"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *NZ1ITNKZQ9Z=#D/<S
M+&"%W;03RV/0#G\*I5:TW4KO2-0AO[";R;J$DH^T-C((/!!'0FIE>SY=QQM=
M7V/IS6=0MO"_A>XNU1$ALK?$,?W02!A%'IDX%?+UQ<2W=U+<SOOFF<R.V,;F
M)R3^=;.L^,_$/B"S%IJ>HM/ '#[!&B#(SC.T#/6L&N3!85T(OFU;.K%XE5FN
M79!1117:<@4444 %%%% !7H7P;_Y':3_ *\Y/_0DKSVO0O@W_P CM)_UYR?^
MA)7-C/X$O0WPO\:/J8_Q)_Y*%J_^^G_HM:Y6NJ^)/_)0M7_WT_\ 1:URM7A_
MX,/1?D36_BR]6%%%%;&04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'T=;127'P@2&&-Y)9-#V(B*2S,8<
M#J:\)_X1/Q'_ -"_JO\ X!R?X5]">%+GR_!^BKLSBQAYS_L"MC[7_L?K7SE+
M&2P\I)*]V>[4PJKQBV[61\Q_\(GXC_Z%_5?_  #D_P */^$3\1_]"_JO_@')
M_A7TY]K_ -C]:/M?^Q^M;_VM/^5&7]FP_F/F/_A$_$?_ $+^J_\ @')_A1_P
MB?B/_H7]5_\  .3_  KZ<^U_['ZT?:_]C]:/[6G_ "H/[-A_,?,?_")^(_\
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M_6C[7_L?K1_:T_Y4']FP_F/F/_A$_$?_ $+^J_\ @')_A1_PB?B/_H7]5_\
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M#D_PKZ<^U_['ZT?:_P#8_6C^UI_RH/[-A_,?,?\ PB?B/_H7]5_\ Y/\*/\
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MG^%'_")^(_\ H7]5_P# .3_"OIS[7_L?K1]K_P!C]:/[6G_*@_LV'\Q\Q_\
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M]K_V/UH^U_['ZT?VM/\ E0?V;#^8^8_^$3\1_P#0OZK_ . <G^%'_")^(_\
MH7]5_P# .3_"OIS[7_L?K1]K_P!C]:/[6G_*@_LV'\Q\Q_\ ")^(_P#H7]5_
M\ Y/\*/^$3\1_P#0OZK_ . <G^%?3GVO_8_6C[7_ +'ZT?VM/^5!_9L/YCYC
M_P"$3\1_]"_JO_@')_A1_P (GXC_ .A?U7_P#D_PKZ<^U_['ZT?:_P#8_6C^
MUI_RH/[-A_,?,?\ PB?B/_H7]5_\ Y/\*/\ A$_$?_0OZK_X!R?X5].?:_\
M8_6C[7_L?K1_:T_Y4']FP_F/F/\ X1/Q'_T+^J_^ <G^%'_")^(_^A?U7_P#
MD_PKZ<^U_P"Q^M'VO_8_6C^UI_RH/[-A_,?,?_")^(_^A?U7_P  Y/\ "C_A
M$_$?_0OZK_X!R?X5].?:_P#8_6C[7_L?K1_:T_Y4']FP_F/F/_A$_$?_ $+^
MJ_\ @')_A1_PB?B/_H7]5_\  .3_  KZ<^U_['ZT?:_]C]:/[6G_ "H/[-A_
M,?,?_")^(_\ H7]5_P# .3_"C_A$_$?_ $+^J_\ @')_A7TY]K_V/UH^U_['
MZT?VM/\ E0?V;#^8^8_^$3\1_P#0OZK_ . <G^%'_")^(_\ H7]5_P# .3_"
MOIS[7_L?K1]K_P!C]:/[6G_*@_LV'\Q\Q_\ ")^(_P#H7]5_\ Y/\*/^$3\1
M_P#0OZK_ . <G^%?3GVO_8_6C[7_ +'ZT?VM/^5!_9L/YCYC_P"$3\1_]"_J
MO_@')_A1_P (GXC_ .A?U7_P#D_PKZ<^U_['ZT?:_P#8_6C^UI_RH/[-A_,?
M,?\ PB?B/_H7]5_\ Y/\*/\ A$_$?_0OZK_X!R?X5].?:_\ 8_6C[7_L?K1_
M:T_Y4']FP_F/F/\ X1/Q'_T+^J_^ <G^%'_")^(_^A?U7_P#D_PKZ<^U_P"Q
M^M'VO_8_6C^UI_RH/[-A_,?,?_")^(_^A?U7_P  Y/\ "C_A$_$?_0OZK_X!
MR?X5].?:_P#8_6C[7_L?K1_:T_Y4']FP_F/F/_A$_$?_ $+^J_\ @')_A1_P
MB?B/_H7]5_\  .3_  KZ<^U_['ZT?:_]C]:/[6G_ "H/[-A_,?,?_")^(_\
MH7]5_P# .3_"O7OA=X*;0K%M8U*$QZA<+A(Y%PT$?N#T8]_; ]:[[[7_ +'Z
MU'+<&1=H&!WYK&OF$ZT.2UC6C@84I<U[C)9#(^>W84RBBO/.T**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:O$_\ R-FL_P#7]/\ ^C&K
M*K5\3_\ (V:S_P!?T_\ Z,:LJOKZ?P+T/F*GQL****L@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#VKX0?\BG=?]?S_P#HN.O0*\_^$'_(IW7_ %_/_P"B
MXZ] KY;&?QY>I]%A?X,0HHHKF.@**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!T?^M3_ 'A6C6='_K4_WA6C0!R_Q&_Y)_J__7)?
M_0UKYJKZ5^(W_)/]7_ZY+_Z&M?-5>]E7\)^OZ(\;,OXB] HHHKU#S@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -SPE
MXEE\*:XNI16R7'[MHVC9BN0?0]CD#L:] E^.,AC81>'U63'RLUWN _#8,_G7
MD=%<]7"T:LN::NS>GB:M-<L'9!111708!1110!J>'=9;P]KUKJJ0).UN21&Y
MP#E2.OXYKTE_CDY7Y/#RAO5KS(_] %>145SU<-2JOFFKLVIXBI25H.QH:WK%
MUK^L7.J7FP7%P06$8PHP  !DGL!6?116Z2BK(R;;=V%%%%,04444 %%%% !7
MMGP@_P"1(U;_ *^7_P#1:UXG7MGP@_Y$C5O^OE__ $6M<.8_P/FCLP/\;Y,\
M3HHHKN.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KT+X-_P#([2?]><G_ *$E>>UZ%\&_
M^1VD_P"O.3_T)*YL9_ EZ&^%_C1]3'^)/_)0M7_WT_\ 1:URM=5\2?\ DH6K
M_P"^G_HM:Y6KP_\ !AZ+\B:W\67JPHHHK8R"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^E?#'_ "*>C?\
M7C!_Z+6M6LKPQ_R*>C?]>,'_ *+6M6OD*GQOU/IZ?P(****@L**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /FKQ/_ ,C9K/\ U_3_ /HQJRJU?$__ "-F
ML_\ 7]/_ .C&K*KZ^G\"]#YBI\;"BBBK("BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *]L^$'_ ")&K?\ 7R__ *+6O$Z]L^$'_(D:M_U\
MO_Z+6N',?X'S1V8'^-\F>)T445W'&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z%\&_\
MD=I/^O.3_P!"2O/:]"^#?_([2?\ 7G)_Z$E<V,_@2]#?"_QH^IC_ !)_Y*%J
M_P#OI_Z+6N5KJOB3_P E"U?_ 'T_]%K7*U>'_@P]%^1-;^++U84445L9!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?2OAC_D4]&_Z\8/\ T6M:M97AC_D4]&_Z\8/_ $6M:M?(5/C?J?3T
M_@04445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-7B?_ )&S6?\
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MF7)VJI8L8I!SMR>H(Y'.>#Z<W0QCG/V52/+(FMA>6'M*;NCA***^BK27P?\
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M<>)Q<I4I4ZL>5O;[SJP^&BJBG3E=(\G^-7_(XV?_ &#T_P#1DE><5Z/\:O\
MD<;/_L'I_P"C)*\XKT,'_ CZ'#BOXT@HHHKJ.<**** "BBB@ HHHH **** "
MBBB@ HHHH ]J^$'_ "*=U_U_/_Z+CKT"O/\ X0?\BG=?]?S_ /HN.O0*^6QG
M\>7J?187^#$****YCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *]L^$'_ ")&K?\ 7R__ *+6
MO$Z]L^$'_(D:M_U\O_Z+6N',?X'S1V8'^-\F>)T445W'&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5Z%\&_\ D=I/^O.3_P!"2O/:]"^#?_([2?\ 7G)_Z$E<V,_@2]#?
M"_QH^IC_ !)_Y*%J_P#OI_Z+6N5KJOB3_P E"U?_ 'T_]%K7*U>'_@P]%^1-
M;^++U84445L9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?2OAC_D4]&_Z\8/\ T6M:M97AC_D4]&_Z\8/_
M $6M:M?(5/C?J?3T_@04445!84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?-7B?_ )&S6?\ K^G_ /1C5E5J^)_^1LUG_K^G_P#1C5E5]?3^!>A\Q4^-
MA1115D!1110 4444 %%%% !1110 4444 %%%% !7M/P1_P"05JW_ %W3_P!!
M->+5[3\$?^05JW_7=/\ T$UPYC_N[^7YG9@?XZ^9S7QF_P"1T@_Z\4_]#>O.
MZ]$^,W_(Z0?]>*?^AO7G=:X/^!'T,\5_&EZGK_P-_P"8]_V[_P#M2E^,WB2:
M/[/X=@RD<B"XN&_OC/R*.>F5)/T6D^!O_,>_[=__ &I6)\9O^1T@_P"O%/\
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M?7WQ5\)Z4Y@MWFNMK%2+.$;0?7+%01[C-6O#OQ)T;Q-JZ:;96U_',R,X::-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?2OAC_D4]&_Z\8/_ $6M:M97AC_D4]&_Z\8/_1:UJU\A4^-^I]/3^!!1
M114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_P#6I_O"M&LZ/_6I
M_O"M&@#E_B-_R3_5_P#KDO\ Z&M?-5?2OQ&_Y)_J_P#UR7_T-:^:J][*OX3]
M?T1XV9?Q%Z!1117J'G!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5[9\(/\ D2-6_P"OE_\ T6M>)U[9\(/^1(U;_KY?_P!%K7#F/\#YH[,#
M_&^3/$Z***[CC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGHW_ %XP?^BUK5K*\,?\BGHW_7C!_P"BUK5KY"I\;]3Z>G\""BBBH+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#YJ\3_P#(V:S_ -?T_P#Z,:LJM7Q/
M_P C9K/_ %_3_P#HQJRJ^OI_ O0^8J?&PHHHJR HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /:OA!_R*=U_U_/_ .BXZ] KS_X0?\BG=?\ 7\__ *+CKT"O
MEL9_'EZGT6%_@Q"BBBN8Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>A?!O_D=I/\ KSD_]"2O/:]"^#?_ ".TG_7G)_Z$E<V,_@2]#?"_QH^I
MC_$G_DH6K_[Z?^BUKE:ZKXD_\E"U?_?3_P!%K7*U>'_@P]%^1-;^++U84445
ML9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?2OAC_D4]&_Z\8/_1:UJUE>&/\ D4]&_P"O&#_T6M:M?(5/
MC?J?3T_@04445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-7B?_D;
M-9_Z_I__ $8U95:OB?\ Y&S6?^OZ?_T8U95?7T_@7H?,5/C844459 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'M7P@_Y%.Z_Z_G_]%QUZ!7G_ ,(/^13N
MO^OY_P#T7'7H%?+8S^/+U/HL+_!B%%%%<QT!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 .C_P!:G^\*T:SH_P#6I_O"M&@#E_B-
M_P D_P!7_P"N2_\ H:U\U5]*_$;_ ))_J_\ UR7_ -#6OFJO>RK^$_7]$>-F
M7\1>@4445ZAYP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>
MV?"#_D2-6_Z^7_\ 1:UXG7MGP@_Y$C5O^OE__1:UPYC_  /FCLP/\;Y,\3HH
MHKN.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KT+X-_\ ([2?]><G_H25Y[7H7P;_ .1V
MD_Z\Y/\ T)*YL9_ EZ&^%_C1]3'^)/\ R4+5_P#?3_T6M<K75?$G_DH6K_[Z
M?^BUKE:O#_P8>B_(FM_%EZL****V,@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /I7PQ_R*>C?]>,'_ *+6
MM6LKPQ_R*>C?]>,'_HM:U:^0J?&_4^GI_ @HHHJ"PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ^:O$__ "-FL_\ 7]/_ .C&K*K5\3_\C9K/_7]/_P"C
M&K*KZ^G\"]#YBI\;"BBBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]J^
M$'_(IW7_ %_/_P"BXZ] KS_X0?\ (IW7_7\__HN.O0*^6QG\>7J?187^#$**
M**YCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO;?^%B:%_P!//_?K_P"O1_PL30O^GG_OU_\ 7H^NXK_GW^8?5,/_ #GB7_"
M>*_^@'=?D/\ &C_A /%?_0#NOR'^->V_\+$T+_IY_P"_7_UZ/^%B:%_T\_\
M?K_Z]'UW%?\ /O\ ,/JF'_G/$O\ A /%?_0#NOR'^-'_  @'BO\ Z =U^0_Q
MKVW_ (6)H7_3S_WZ_P#KT?\ "Q-"_P"GG_OU_P#7H^NXK_GW^8?5,/\ SGB7
M_" >*_\ H!W7Y#_&C_A /%?_ $ [K\A_C7MO_"Q-"_Z>?^_7_P!>C_A8FA?]
M//\ WZ_^O1]=Q7_/O\P^J8?^<\2_X0#Q7_T [K\A_C1_P@'BO_H!W7Y#_&O;
M?^%B:%_T\_\ ?K_Z]'_"Q-"_Z>?^_7_UZ/KN*_Y]_F'U3#_SGB7_  @'BO\
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M)H7_ $\_]^O_ *]'_"Q-"_Z>?^_7_P!>CZ[BO^??YA]4P_\ .>)?\(!XK_Z
M=U^0_P :/^$ \5_] .Z_(?XU[;_PL30O^GG_ +]?_7H_X6)H7_3S_P!^O_KT
M?7<5_P ^_P P^J8?^<\2_P"$ \5_] .Z_(?XT?\ " >*_P#H!W7Y#_&O;?\
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MW%?\^_S#ZIA_YSQ+_A /%?\ T [K\A_C1_P@'BO_ * =U^0_QKVW_A8FA?\
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M /%?_0#NOR'^->V_\+$T+_IY_P"_7_UZ/^%B:%_T\_\ ?K_Z]'UW%?\ /O\
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M (6)H7_3S_WZ_P#KT?7<5_S[_,/JF'_G/$O^$ \5_P#0#NOR'^-'_" >*_\
MH!W7Y#_&O;?^%B:%_P!//_?K_P"O1_PL30O^GG_OU_\ 7H^NXK_GW^8?5,/_
M #GB7_" >*_^@'=?D/\ &C_A /%?_0#NOR'^->V_\+$T+_IY_P"_7_UZ/^%B
M:%_T\_\ ?K_Z]'UW%?\ /O\ ,/JF'_G/$O\ A /%?_0#NOR'^-'_  @'BO\
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M/_?K_P"O1]=Q7_/O\P^J8?\ G/$O^$ \5_\ 0#NOR'^-'_" >*_^@'=?D/\
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MH7_3S_WZ_P#KT?\ "Q-"_P"GG_OU_P#7H^NXK_GW^8?5,/\ SGB7_" >*_\
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M'_" >*_^@'=?D/\ &O;?^%B:%_T\_P#?K_Z]'_"Q-"_Z>?\ OU_]>CZ[BO\
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M (6)H7_3S_WZ_P#KT?7<5_S[_,/JF'_G/$O^$ \5_P#0#NOR'^-'_" >*_\
MH!W7Y#_&O;?^%B:%_P!//_?K_P"O1_PL30O^GG_OU_\ 7H^NXK_GW^8?5,/_
M #GB7_" >*_^@'=?D/\ &C_A /%?_0#NOR'^->V_\+$T+_IY_P"_7_UZ/^%B
M:%_T\_\ ?K_Z]'UW%?\ /O\ ,/JF'_G/$O\ A /%?_0#NOR'^-'_  @'BO\
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M/_?K_P"O1]=Q7_/O\P^J8?\ G/$O^$ \5_\ 0#NOR'^-'_" >*_^@'=?D/\
M&O;?^%B:%_T\_P#?K_Z]'_"Q-"_Z>?\ OU_]>CZ[BO\ GW^8?5,/_.>)?\(!
MXK_Z =U^0_QH_P"$ \5_] .Z_(?XU[;_ ,+$T+_IY_[]?_7H_P"%B:%_T\_]
M^O\ Z]'UW%?\^_S#ZIA_YSQ+_A /%?\ T [K\A_C1_P@'BO_ * =U^0_QKVW
M_A8FA?\ 3S_WZ_\ KT?\+$T+_IY_[]?_ %Z/KN*_Y]_F'U3#_P YXE_P@'BO
M_H!W7Y#_ !H_X0#Q7_T [K\A_C7MO_"Q-"_Z>?\ OU_]>C_A8FA?]//_ 'Z_
M^O1]=Q7_ #[_ ##ZIA_YSQ+_ (0#Q7_T [K\A_C1_P (!XK_ .@'=?D/\:]M
M_P"%B:%_T\_]^O\ Z]'_  L30O\ IY_[]?\ UZ/KN*_Y]_F'U3#_ ,YXE_P@
M'BO_ * =U^0_QH_X0#Q7_P! .Z_(?XU[;_PL30O^GG_OU_\ 7H_X6)H7_3S_
M -^O_KT?7<5_S[_,/JF'_G/$O^$ \5_] .Z_(?XT?\(!XK_Z =U^0_QKVW_A
M8FA?]//_ 'Z_^O1_PL30O^GG_OU_]>CZ[BO^??YA]4P_\YXE_P (!XK_ .@'
M=?D/\:/^$ \5_P#0#NOR'^->V_\ "Q-"_P"GG_OU_P#7H_X6)H7_ $\_]^O_
M *]'UW%?\^_S#ZIA_P"<\2_X0#Q7_P! .Z_(?XT?\(!XK_Z =U^0_P :]M_X
M6)H7_3S_ -^O_KT?\+$T+_IY_P"_7_UZ/KN*_P"??YA]4P_\YXE_P@'BO_H!
MW7Y#_&C_ (0#Q7_T [K\A_C7MO\ PL30O^GG_OU_]>C_ (6)H7_3S_WZ_P#K
MT?7<5_S[_,/JF'_G/$O^$ \5_P#0#NOR'^-'_" >*_\ H!W7Y#_&O;?^%B:%
M_P!//_?K_P"O1_PL30O^GG_OU_\ 7H^NXK_GW^8?5,/_ #GB7_" >*_^@'=?
MD/\ &C_A /%?_0#NOR'^->V_\+$T+_IY_P"_7_UZ/^%B:%_T\_\ ?K_Z]'UW
M%?\ /O\ ,/JF'_G/$O\ A /%?_0#NOR'^-'_  @'BO\ Z =U^0_QKVW_ (6)
MH7_3S_WZ_P#KT?\ "Q-"_P"GG_OU_P#7H^NXK_GW^8?5,/\ SGB7_" >*_\
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M:H_?\J *WDR?W#1Y,G]PU9^U1^_Y4?:H_?\ *@"MY,G]PT>3)_<-6?M4?O\
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MR?W#1Y,G]PU9^U1^_P"5'VJ/W_*@"MY,G]PT>3)_<-6?M4?O^5'VJ/W_ "H
MK>3)_<-'DR?W#5G[5'[_ )4?:H_?\J *WDR?W#1Y,G]PU9^U1^_Y4?:H_?\
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M_$?_ $+^J_\ @')_A7T_]JC]_P J/M4?O^5']K3_ )4']FP_F/F#_A$_$?\
MT+^J_P#@')_A1_PB?B/_ *%_5?\ P#D_PKZ?^U1^_P"5'VJ/W_*C^UI_RH/[
M-A_,>>_"O2]0T_PQ<Q7MC<VTAO68)/$48C8@S@]N#^5=SY,G]PU9^U1^_P"5
M'VJ/W_*O-JU'4FYOJ=]*'LX**Z%;R9/[AH\F3^X:L_:H_?\ *C[5'[_E6996
M\F3^X:/)D_N&K/VJ/W_*C[5'[_E0!6\F3^X:/)D_N&K/VJ/W_*C[5'[_ )4
M5O)D_N&CR9/[AJS]JC]_RH^U1^_Y4 5O)D_N&CR9/[AJS]JC]_RH^U1^_P"5
M %;R9/[AH\F3^X:L_:H_?\J/M4?O^5 %;R9/[AH\F3^X:L_:H_?\J/M4?O\
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M_P! 6O,Z],^'G_(L7_\ UW;_ - 6N3&_PON.K"?Q#S.BBBNLY0HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#V31?^0#IW_7K'_Z"*O51T7_D Z=_UZQ_^@BKU?-3^)GO
MP^%!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #H_]:G^\*T:SH_]:G^\*T:
M,/QC_P BEJ'^X/\ T(5XM7M/C'_D4M0_W!_Z$*\6KV,N_AOU/+QWQKT"BBBN
M\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *],^'G_(L7__
M %W;_P! 6O,Z],^'G_(L7_\ UW;_ - 6N3&_PON.K"?Q#S.BBBNLY0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "NN^'/\ R,S_ /7L_P#-:Y&NN^'/_(S/_P!>S_S6L,3_
M  9>AMA_XL3/\:?\C=J'^\O_ * M8-;WC3_D;M0_WE_] 6L&KH_PX^B)J_Q)
M>K"BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#V31?^0#IW_7K'_Z"*O51T7_D Z=_UZQ_^@BKU?-3
M^)GOP^%!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_]:G^\*T:SH_]:G^\
M*T: ,/QC_P BEJ'^X/\ T(5XM7M/C'_D4M0_W!_Z$*\6KV,N_AOU/+QWQKT"
MBBBN\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *],^'G_(
ML7__ %W;_P! 6O,Z],^'G_(L7_\ UW;_ - 6N3&_PON.K"?Q#S.BBBNLY0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "NN^'/\ R,S_ /7L_P#-:Y&NN^'/_(S/_P!>S_S6
ML,3_  9>AMA_XL3/\:?\C=J'^\O_ * M8-;WC3_D;M0_WE_] 6L&KH_PX^B)
MJ_Q)>K"BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#V31?^0#IW_7K'_Z"*O51T7_D Z=_UZQ_^@BK
MU?-3^)GOP^%!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_]:G^\*T:SH_]
M:G^\*T: ,/QC_P BEJ'^X/\ T(5XM7M/C'_D4M0_W!_Z$*\6KV,N_AOU/+QW
MQKT"BBBN\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *],^
M'G_(L7__ %W;_P! 6O,Z],^'G_(L7_\ UW;_ - 6N3&_PON.K"?Q#S.BBBNL
MY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "NN^'/\ R,S_ /7L_P#-:Y&NN^'/_(S/_P!>
MS_S6L,3_  9>AMA_XL3/\:?\C=J'^\O_ * M8-;WC3_D;M0_WE_] 6L&KH_P
MX^B)J_Q)>K"BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#V31?^0#IW_7K'_Z"*O51T7_D Z=_UZQ_
M^@BKU?-3^)GOP^%!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_]:G^\*T:
MSH_]:G^\*T: ,/QC_P BEJ'^X/\ T(5XM7M/C'_D4M0_W!_Z$*\6KV,N_AOU
M/+QWQKT"BBBN\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#V31?^0#IW_7K'_Z"*O51T7_D Z=_
MUZQ_^@BKU?-3^)GOP^%!1114E!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_]:G^
M\*T:SH_]:G^\*T: ,/QC_P BEJ'^X/\ T(5XM7M/C'_D4M0_W!_Z$*\6KV,N
M_AOU/+QWQKT"BBBN\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *],^'G_(L7__ %W;_P! 6O,Z],^'G_(L7_\ UW;_ - 6N3&_PON.K"?Q
M#S.BBBNLY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "NN^'/\ R,S_ /7L_P#-:Y&NN^'/
M_(S/_P!>S_S6L,3_  9>AMA_XL3/\:?\C=J'^\O_ * M8-;WC3_D;M0_WE_]
M 6L&KH_PX^B)J_Q)>K"BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#V31?^0#IW_7K'_Z"*O51T7_D
M Z=_UZQ_^@BKU?-3^)GOP^%!1114E!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_
M]:G^\*T:SH_]:G^\*T: ,/QC_P BEJ'^X/\ T(5XM7M/C'_D4M0_W!_Z$*\6
MKV,N_AOU/+QWQKT"BBBN\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *],^'G_(L7__ %W;_P! 6O,Z],^'G_(L7_\ UW;_ - 6N3&_PON.
MK"?Q#S.BBBNLY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "NN^'/\ R,S_ /7L_P#-:Y&N
MN^'/_(S/_P!>S_S6L,3_  9>AMA_XL3/\:?\C=J'^\O_ * M8-;WC3_D;M0_
MWE_] 6L&KH_PX^B)J_Q)>K"BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,^UA_W[?_XJCZC6#ZY2/1?L\O\ =_44?9Y?[OZBO.O^%E:S_P ^UA_W[?\
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M#ZY2/1?L\O\ =_44?9Y?[OZBO.O^%E:S_P ^UA_W[?\ ^*H_X65K/_/M8?\
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M(]%^SR_W?U%'V>7^[^HKSK_A96L_\^UA_P!^W_\ BJ/^%E:S_P ^UA_W[?\
M^*H^HU@^N4CT7[/+_=_44?9Y?[OZBO.O^%E:S_S[6'_?M_\ XJC_ (65K/\
MS[6'_?M__BJ/J-8/KE(]%^SR_P!W]11]GE_N_J*\Z_X65K/_ #[6'_?M_P#X
MJC_A96L_\^UA_P!^W_\ BJ/J-8/KE(]%^SR_W?U%'V>7^[^HKSK_ (65K/\
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M'_?M_P#XJCZC6#ZY2/1?L\O]W]11]GE_N_J*\Z_X65K/_/M8?]^W_P#BJ/\
MA96L_P#/M8?]^W_^*H^HU@^N4CT7[/+_ '?U%'V>7^[^HKSK_A96L_\ /M8?
M]^W_ /BJ/^%E:S_S[6'_ '[?_P"*H^HU@^N4CT7[/+_=_44?9Y?[OZBO.O\
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MTJ&N4Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ='_K4_WA6C6='_K4_P!X5HT 8?C'_D4M0_W!_P"A"O%J
M]I\8_P#(I:A_N#_T(5XM7L9=_#?J>7COC7H%%%%=YQ!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5Z9\//\ D6+_ /Z[M_Z M>9UZ9\//^18
MO_\ KNW_ * M<F-_A?<=6$_B'F=%%%=9RA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %==\
M.?\ D9G_ .O9_P":UR-==\.?^1F?_KV?^:UAB?X,O0VP_P#%B9_C3_D;M0_W
ME_\ 0%K!K>\:?\C=J'^\O_H"U@U='^''T1-7^)+U84445H9A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >P
MQ_\ )-S_ -@H_P#HJO'J]AC_ .2;G_L%'_T57CU<&!^WZG9B_L^@4445WG&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %*K%6#*2&!R".U)10!ZYX/\2)KMA]ENF_TZ%?GS_RT7^\/Z__ %ZV
M9(S&Y4_@:\3L+ZXTV]BN[5]DT9R#Z^Q]C7L^D:K;>(=*2ZA(#]'3/*-W%>+C
M,-[-\T=F>MA:_.N66Z'44I!4D$8(I*XCK"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** '1_ZU/]X5HUG1_ZU/\ >%:-
M &'XQ_Y%+4/]P?\ H0KQ:O:?&/\ R*6H?[@_]"%>+5[&7?PWZGEX[XUZ!111
M7><04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>F?#S_ )%B
M_P#^N[?^@+7F=>F?#S_D6+__ *[M_P"@+7)C?X7W'5A/XAYG11176<H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !77?#G_ )&9_P#KV?\ FM<C77?#G_D9G_Z]G_FM88G^
M#+T-L/\ Q8F?XT_Y&[4/]Y?_ $!:P:WO&G_(W:A_O+_Z M8-71_AQ]$35_B2
M]6%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 444J(TCJB*69C@*!DD^E "458NK"\L2HN[2>W+YV^;&4W8Z
MXS5>A-/5#:MN%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **DA@
MEN)EA@B>65N%1%+$_0"G7-I<V<HBNK>6"0C<%E0J<>N#2NKV'9VN0T444Q!1
M110 4444 %%%% !1110 4444 %%%6O[-O_LOVK[%<_9L9\[RFV8]<XQ2;2W&
MDWL5:***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ]AC_Y)N?^P4?_ $57CU>PQ_\
M)-S_ -@H_P#HJO'JX,#]OU.S%_9] HHHKO.,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MGPWK\V@:F
M)URT$F%FC_O+ZCW':L:BIE%23C+8J,G%W1[R'AOK6.ZMG$B.H967^(5!7GW@
M?Q/_ &9<C3KM_P#1)F^1B?\ 5,?Z'_/>O2;B':=ZC@]:\&O1=&?*]CVJ-558
MW17HHHK U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ='_K4_WA6C6='_K4_P!X5HT 8?C'_D4M0_W!_P"A"O%J]I\8_P#(
MI:A_N#_T(5XM7L9=_#?J>7COC7H%%%%=YQ!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Z9\//\ D6+_ /Z[M_Z M>9UZ9\//^18O_\ KNW_
M * M<F-_A?<=6$_B'F=%%%=9RA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+T,)1<7:6XE%=YIOP\46@N]:OOLR;-S1I@;/]YSP/R_&K)^'NDW\8DTO669
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M_P!M/_1;5L?$W_D*6/\ UQ/_ *%6/X&_Y'&P_P"VG_HMJV/B;_R%+'_KB?\
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *].\"^)Q?6XTF]?-Q&O[IV/^L4=OJ/Y?2O,:DAFE
MMITFA=DEC8,K*>016->BJL.5FM&JZ4KH]RFB,;_[)Z5'5/PUKT/B/2@7*K=Q
M@"9!V/\ >'L:O.A1BIZBO G!PDXRW/:C)27,AM%%%24%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% #H_]:G^\*T:SH_\ 6I_O"M&@
M##\8_P#(I:A_N#_T(5XM7M/C'_D4M0_W!_Z$*\6KV,N_AOU/+QWQKT"BBBN\
MX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH OZ/JUQHNI1WEL?F7AD/1U[@U[
M-9WEOK6FQ7EJP*N,CU![J?>O"JZ/PCXD;0;_ &3$FRG($J_W3_>']?:N+&8;
MVD>:.Z.O"U_9OEELST\C!P:*LS(LL:SQ$,K#.5.01ZU6KQ3U@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ='_K4_WA6C6='_ *U/
M]X5HT 8?C'_D4M0_W!_Z$*\6KVGQC_R*6H?[@_\ 0A7BU>QEW\-^IY>.^->@
M4445WG$%%%% !1110 4444 %;'AG15U[64LY)#'%M+NR_>P/3WR16/76_#K_
M )&<_P#7N_\ ,5E7DXTY-&E&*E429TW_  K71O\ GYO_ /OXG_Q-'_"M=&_Y
M^;__ +^)_P#$UV5>87'Q&U>&YEB6VL2J.5&4?/!_WJ\JE/$U;\LMCTJL:%.W
M,C8F^&>FLA$%]=(V.#)M<9^@ KD=?\(:AH*>?)MGM<X\Z/\ A/\ M#M_*NX\
M->-H]<O!93VWD7+*2A5LJ^!DCU!ZG\*ZJ:*.>%X945XW4JRL,@@]15?6:]&=
MJFI/U>C5C>!\^T5>UJQ_LS6KRS'W8I2%Y_AZC],5TG@'P^FHWDFH74:O;6YV
MHK=&DZ_H/YBO3G5C"G[1['GPI2E/D6Y#H?@/4-419[MOL=LP!4L,NX]AV^I_
M(UV%M\/]!@C EAFN&'5I)2,_]\XKJ&944LS!549))P *X35_B1%!,\.F6PGV
MY'G2G"D^H Y(_$5Y?ML1B)6A^!Z/LJ%%>\;+>!?#K# L"ON)I/\ XJLG4OAM
M:2(SZ;=20R]0DQW)],]1]>:R[?XFZ@KDW-A;2+V$19#^9+5WNCZU9ZY9"YM'
M) .'1N&0^A%$_K5'WI-_F./U>KHE^AXMJ>EWFD7C6UY"8W!X/\+#U![BJ=>U
M^)]"BU[27B*K]IC!:"0_PMZ?0XP?_K5XI7H8;$>VC?JC@Q%'V4K=&=OX5\%6
MFM:3]NO+B==[E46$@8 XYR#WS6Y_PK71O^?F_P#^_B?_ !-7/ /_ "*5O_OO
M_P"A&K?BK6+C0]%-Y;)$\@D5<2@D8/T(KSZE:LZSA%]3NA2I*DI270R/^%:Z
M-_S\W_\ W\3_ .)JA??#)=F;#4"&'\,Z\'\1T_(U1A^)FIK)F>RM'3TCW(?S
M)/\ *N]T/6;?7=-6\MU9!N*,C=58=OU!_&JJ2Q5'WI/04(X>KI%'B^HZ;=Z3
M>-:7D1CE7G'4$=B#W%5*]?\ '6EQW_AV:?8OGVH\Q&/4#/S#\OY"O(*[\-7]
MM#FZG%7I>RG;H*JEF"J"6)P .IKLM!^']U?JEQJ3M:P,,B,#]ZWY_=_'/TKI
M/!7ARQM-*M=2>,2WDR^8)&&=@/0+Z<=ZZ"+5[&?57TV&=9+I(S(ZKR% (')Z
M9YZ5R5\9)MQI+;J=-'"QLI5.O0YB7X;:0(G*75Z& )!+H1_Z#7E]?0<O^J?_
M '37SY6F!JSJ<W,[[$8RG&'+RJP4445WG$%%%% !113HXY)I!'$C.[=%49)_
M"@!M%7I=&U2")I9M-O(XU&69X&  ]R15&DFGL-IK<**='')-((XD9W;HJC)/
MX5;ET;5((VDFTV\C11DL\#  >N2*')+=@DWL4J***8@K=\*^'O\ A(=2>&21
MH[>)-\C+U] !_GL:PJ]7^'FG?9- :Z9<27<A;I_"O _7<?QKGQ55TZ;:W-\-
M352HD]B/_A6NC?\ /S?_ /?Q/_B:Y7Q?X3C\/"WGM999;>4E#YF,JW4<C&<C
M/;M7JOVR#[<;+S!]H$7F[,\[<XS^=9GBO2SJ_AZYMXU#3*!)%D#[R\\>F1D?
MC7FT<5451<[T.^KAZ;@^5:GBE%%%>T>2>O>  !X3@P.LCY_[ZJI\2A_Q3MN>
M_P!K7_T!ZN> ?^12M_\ ??\ ]"-4_B5_R+EO_P!?:_\ H#UXL?\ >_F>M+_=
MOD>6458MK"\O<_9;2>?'7RHRV/R%+<Z=?62AKJSN(%)P#+$R@GTY%>SS*]KG
ME6=KE:BBBF(**** "BBB@ HHHH **** "O3/AY_R+%__ -=V_P#0%KS.O3/A
MY_R+%_\ ]=V_] 6N3&_PON.K"?Q#S.BBBNLY0HHHH **** "BBB@ HHHH **
M** "BBB@!\43SS)%&I:1V"JH[D\ 5O?\(-XC_P"@=_Y'C_\ BJQK"X%IJ-M<
MLI9894D('4X(->E_\+*T;_GVO_\ OVG_ ,57-B*E:+7LXW.BC"E)/VCL<;_P
M@WB/_H'?^1X__BJ/^$&\1_\ 0._\CQ__ !5=E_PLK1O^?:__ ._:?_%5U.GW
MJZC80WB12Q),N]5E #8/0\$]1S7)/%XB"O**7]>ITPPU";M&3?\ 7H>+ZGX=
MU71X4FO[0Q1NVU6WJPSUQP35OPSX6G\1M.RSBWAAP#(4+9)[ <?CSZ>M=A\2
M[J)-&M;7</.DGWA<9^55()]N6'^<US7A#Q9%X?6>"Z@DD@E(<&+!96Z="1D?
MCVK>-6K4H<\5J8RI4X5N63T'>(? TVAZ<U\EZMS$A <>7L(R<9ZGOC\ZRO"^
MGV^J>([2SNE+02%MP!QG"$]?J*Z+Q1XXM-8T>2PL[:=?-9=[RX& "#P 3W%8
M_@;_ )'&P_[:?^BVJH2J^PDZF^OY"E&G[:*AMH=KK/@S0;?1+ZX@LC'+% \B
M,)G."%)'!)':O*:]TU__ )%S5/\ KTE_] ->%UG@)RE%\SN7C81C)<JL%%%%
M=YQ!1110 4444 %%%% !1110 4444 %%%% !1110 445ZWX4T+2I/#-E+-I]
MM-+(A9GEB5F))/<BL*]=48\S1M1HNK*R/)**ZCQ[96MAX@2.T@C@C:!7*QK@
M9);G'X5R]:4YJ<5)=2)PY).+Z!1115D!1110 4444 %%%% !1110 4444 %%
M%% !1110!TG@G2+/6=;DM[Z,R1) T@4,5R0RCJ.>YKI?%GA/1M.\.7-Y9VIA
MGB*;2)6;JX!R"3V-9'PU_P"1CN/^O1O_ $-*[+QS_P B=?\ _;/_ -&+7F5Z
MDUB8Q3TT/0HPB\.VUKJ>-T445Z9YX4444 %%%% !1110 4444 %%%% !1110
M 4444 %==\.?^1F?_KV?^:UR-==\.?\ D9G_ .O9_P":UAB?X,O0VP_\6)G^
M-/\ D;M0_P!Y?_0%K!K>\:?\C=J'^\O_ * M8-71_AQ]$35_B2]6%:.@?\C'
MI?\ U]Q?^ABLZGPRR031S1.4DC8,C#J"#D&KDKIHB+LTSTOXF?\ ('L_^OC_
M -E->8UIZGX@U36(TCO[HS(AW*-BK@_@!696.&I.E3Y9&M>HJD^9&CH'_(QZ
M7_U]Q?\ H8KN?B=_QX6'_75OY"O.8)I+>>.>%BDL;!T8=B#D&KNJ:]J>LB,7
M]T9A'DH-BJ!GZ 4JE&4JL9K9#A54:4H=63>&=571M?MKN1B(<E)<#/RGC].#
M^%>@>,O#$FOPPWM@4>YC3 7< )$)R,'IW)_&O**V='\4ZKHD?E6LX:#KY,HW
M*/IW'X5-:C)S52F]4.E5BHNG-:,5?".OLY4:9-GWP!^>:DO_  AJNF:2VHWB
MPQ(I ,>_+\G Z<?K6FWQ)UIA@06*^XC;_P"*K"U3Q%JNLC;>W;-%NR(E 5!^
M ZX]\TXO$-KFLD$E02]V[98\'?\ (VZ?_OG_ -!-=)\3_P#6Z9_NR?\ LM<-
M:7<]A=QW5M)Y<T9RC8!P?QJSJFMZCK+1-J%QYQB!"?(JXSUZ >E.5&3KQJ=$
MA1JI47#JS/KUKQ/_ ,DZD_ZXP?\ H25Y+6K<^)=7N],&G3WA>UVJNPHO1<8Y
MQGL.]%>C*I*#71A1JJ$9)]495>I_#7_D7+C_ *^V_P#0$KRRM33?$6JZ1;O!
M879AB=M[+L5N<8SR#Z"GB:3JT^6(8>HJ<^9E:>3R=7DEQG9.6QGKAJ]5\6:<
M_B+PRAL")6#+<1 '&\8(_DU>0,Q9BS$EB<DGJ:VM&\5ZKHD7DVTJO!G(AE7<
MH/MW'X'O45Z,I<LH;H=&K&/-&6S':?X/UJ^N_)-E+;J#AY9U*JON,]>G;->E
M7]M%9>"+NTAE\U(+-X]^1SA2#TK@+_Q]K=];F$/#;!N&:!"&(^I)Q^&*RH/$
M&J6VEOID5T5LW#*T>Q3PW7DC(K.I1K5;.5E9[&D*M*G=1N[F97K^A*FL^ 8[
M:-MA>V>W)Z[6 *__ %_QKR"M71O$>I:$S?8IAY;G+Q.NY6..OM^&.@K;$T75
MBN7=&6'JJG)\VS)YO!^NV]O<3S6)2.!"[DR+T'7&#SQS^%:_P\UF.QU*:PN)
M-D=T!Y99N!(.WX@_H!5/4?'FL:E926CK;0QRJ4<Q(<E3U')-<Q2Y)U:;C5LK
M]@YX4YJ5/\3T+Q?X*N[G47U'2HA*)CF6$$*5;NPSC(/?OD_ECZ9X!UB\N%%W
M$+2 'YG=@21[ =_K4.G^.M<L(_+,Z7*  *+A=Q'X@@G\2:GNOB'KEQ&40VUN
M3_%%&<_^/$UE&.*C'D5O4U<L/)\SOZ'3>.=5@TK0DT>U*K+,BIL'\$0_QQC\
MZ\_T#_D8]+_Z^XO_ $,51EFDGE:6:1Y)&.6=V))/N32P3R6UQ%/"VV6)PZ-C
M."#D&MJ5#V=-P6[,JE;GFI=$>C?$[_CPL/\ KJW\A7,>"M8CTC7U-Q)LMIU,
M4C$X53U!/XC'MDUG:IKVIZRL2ZA=&98B2@V*H&>O0#/2LVE2H6H^RF.I6O5]
MI$]/\:>$9M6F74M-57N-H66+('F =&!/?'KV _'E+/P+KMU.$DM1;IWDE<8'
MX#)-0Z7XQUG28EABN%E@5=JQS+N"_0]?PSBM";XC:W+&51+2$G^..,DC_OHD
M?I6488FG'DC9KN:2EAYOG=TSK-<O+?PEX12PMW'GM&881W)/WG_4GZD5PG@W
M4XM*\1PRSY$4@,3,!G;GH<?4"L>[O+B^N&N+J9YI6ZLYR?\ ]7M75_#G3H;K
M6IKJ4!C:H#&I'1CQG\ #^?M3]DJ-&7/K?<7M'5JQY=+;'3>(/ L&MZB]\EZ]
MO-)C>"F]3@8X&1C@"L=OAA)SMU9#Z9@Q_P"S5F>.=8OI/$<UJ)I(H;<*J(K%
M<Y ))]3S^6*Y^+6-3A=6CU"Z4KTQ,W'ZU-&GB/9JT_P*JU*/.[Q_$O:YX5U+
M0<27"+);DX$T1RN?0]P:F\#?\CC8?]M/_1;5WVI.US\/))=2 $S689]XVGS,
M#''8[L?C7E%C?7.FWD=W:2>7/'G:^ <9&#P>.A-72G*O2E%[ZHBI"-*I&2VT
M9V/Q-_Y"EC_UQ/\ Z%3?ASK"6NH3:;,P5;G#1$G^,=OQ'_H(]:Y74]7O]8G2
M:_N#,Z+L4[0H SGH !WJFK%6#*2&!R".HJUA[T/92)=?]][2)W_BWP5>W&IR
MZAID:S+.=TD0(4JW<C/7/7UR:H:-\/M1NYU;4E^R6P/S ,#(WTZ@?C^55K+Q
M_KEG L3/#<A> TZ$MC'J",_4\U%J/C?6]2C:(S);Q,"&2!=N1]3D_K6488I1
MY+KU-)2P[?/9^AJ>&/LFE?$&ZM(Y 86\R&$YR.H(&?PQ5KQ]X?U&\U./4+.V
M>XB,01A&-S*03VZD<CI[UY^K%6#*2&!R".HKJ;3X@ZY:PB-S;W&.-TR'=^8(
MJIT:D:BJ0U=K:DPJP<'3GHBUX7\'WJWT&I:D#96UNZR@2?*S$$$9!Z#/7/\
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MS6]E>-%$S;MNQ6Y]L@XK7$T75ARQ,\/55.?,S*KV&2 >)/ 20VS#?-;IM&>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>-^.?^1QO_\ MG_Z+6O+RY_O&O(]#'+W$_,[[P#_ ,BE;_[[_P#H1J+XA_\
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MN.\9^%M(TK0_M=C;-#*)57B1F!!SZDUSW@;_ )'&P_[:?^BVKN?B'_R*S?\
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MGC\*OZ3X/TC3;-8I;2&[FQ^\EGC#;C[ YP*WV8*I9C@ 9)KR37_&FHW^I/\
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MS!KROQ#HDF@:JUF[B12H>-_522!GWX->E>!VU/\ L22/5%N5D28B/[0I#;<
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M/+%:&,YRF^:044459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K5\-P7]QKUJNFMLN%;=O/15[D^V/SK-BBDGF2*)"\CL%55'))[5[#X7\/Q
M>'=+S*%:\E&9G'Z*/85S8JNJ4/-G1AZ+J3\D;5R5$8#<MVJG3G<R,6--KP3V
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T?^M3_>%:-9
MT?\ K4_WA6C0!A^,?^12U#_<'_H0KQ:O:?&/_(I:A_N#_P!"%>+5[&7?PWZG
MEX[XUZ!1117><04444 %%%% !1110 5UOPZ_Y&<_]>[_ ,Q7)5UOPZ_Y&<_]
M>[_S%88G^#+T-J'\6/J>L5Y*_CK7K74)@;F.:-'91')$N,9]@#^M>M5X#>_\
M?]S_ -=6_F:\_ 4XS<N97.[&3E%1Y78]LT'68==TJ.]B7822LD9.=C#J/Y'Z
M$5S?CWPY%=63ZO;1A;F$9FVC_6)ZGW'KZ?05A_#K5/LNL26#GY+M?ER>CJ"?
MU&?TKU!T62-HW&58$$'N#6=1/#5[QV_0N#6(H^\?/E>[Z+<-=Z'87#8W26Z,
MV.F=HS^M>,:WICZ/K%S8OG$;_(Q_B0\J?RQ7H'PYU5+C2'TUW436S%D7N4)S
MG\&)_,5UXZ//24XG+@WR5'!D'Q.MBUEI]UGB.1HR,==P!Z_\!/YUYM7O6IZ=
M!JVG36-R&\J48)4X((.01]"!7E&I^"=:TZ5_+MFNX1]V2 ;B1G ^7KG\_K2P
M5>')R2=FAXNC+GYTM&<Y71>![-KOQ5:D#Y8 TS^P P/U(JM:^%-=NW"IIDZ9
M.,S+Y8'_ 'UBO3/"OAB/P[:/O=9;N;'F2*. /[H]LYY[UKBL1"--I/5F>'H2
ME--K1'05XGXLN5N_%.H2J00)=@(_V0%_I7K'B#6(M$TB:[=AYF-L2G^)R.!_
MGTKP]F+,68DL3DD]37/EU-W<_D;XZ:T@>O> ?^12M_\ ??\ ]"-3>,M2N]*T
M W-E+Y4PE5=VT-P?8@BH? /_ "*5O_OO_P"A&HOB'_R*S?\ 79/ZUSV3Q5GW
M-[M8>Z['/:#\0;U;V*'5F26W<[6F"!63/<XX(]>/_K^E21QS1-%*BO&XVLK#
M((]"*^?*]E\&:I_:GAR L?WMO^X?)R3M P?Q&*WQV'C!*<%8QPE9R;A)W/.?
M%V@#0=6V0AOLLPWPYYQZKGV_D16!7L/C?23JGAZ1HU)GM3YR =P/O#\LGZ@5
MX]79A*WM:>NZ.7$TO9STV85V7PU_Y&.X_P"O1O\ T-*YF#2=2NH1-;Z?=S1-
MT>.%F4_B!78?#[3-0LM>GDNK&Y@C-JRAI8F4$[EXR1[&C%2C[*2N&'B_:1=C
MT>7_ %3_ .Z:^?*^@Y!F)P.N#7AO]@:S_P! F_\ _ 9_\*Y,NDES7?8Z<<F^
M6WF9U%.DC>*1HY$9)$)5E88*D=013:]0\X*ZWX=?\C.?^O=_YBN2KK?AU_R,
MY_Z]W_F*PQ/\&7H;4/XL?4]8KYZKZ%KYZKCRW[7R_4Z\?]GY_H=?\-_^1EE_
MZ]F_]"6O4;G_ (])O]QOY5Y=\-_^1EE_Z]F_]"6O4;G_ (])O]QOY5ACOXWW
M&N$_A'S_ %V7PU_Y&.X_Z]&_]#2N-KLOAK_R,=Q_UZ-_Z&E>GBOX,CS\/_%B
M>E:C_P @N[_ZXO\ ^@FO Z]\U'_D%W?_ %Q?_P!!->':78MJ6J6UDF<S2!21
MV'<_@,FN/+VE&39U8Y7E%(]5\#:8-/\ #<,A7$MU^^<^Q^[^F/SK3UO1+?7K
M-;6YFGCB5P_[E@"2 >N0>.:T$18XUC0850  .P%>?:YX^U#3];N[.TALWAA?
M8&=6)R!SDAAWS7)!5*U5RAON=,W"E349;&C_ ,*UT;_GYO\ _OXG_P 36]H>
MA6V@6DEM:RS/&\GF'S6!(. ., >@K@/^%E:S_P ^UA_W[?\ ^*J[I/Q#U"ZU
M>UM[RWM5@ED$;&)&##/ /+>N*WJ4,5*+YG=&,*V'4O=5F=KKNG#5=#O+/ +2
M1G9DX^<<K^H%>%U]"UXQXQTPZ9XEN4'^KG/GISV8G/ZY'X5>75-7!^I..AHI
MGH/@'_D4K?\ WW_]"-4_B5_R+EO_ -?:_P#H#U<\ _\ (I6_^^__ *$:TM?T
M2'7]+:SF=D(;?&X_A< @''<<GCWKG<U#$N3VN;J+EAU%=CPZN_\ A@&\_4B/
MN[8\_7+8_K7-7'A+7;>\-L=.FD;/#QKN0CUW=!^.#7IGA#09-!T@Q7!4W,KE
MY-IR!V S]/U)KNQE:'LFD[W./"TI^UNUL7M?./#FIY_Y])?_ $ UX77L/CG4
M!8^&)T!'F7)$*@^_)_0&O'JG+XM4V_,>.:<T@HHHKT#B"BBB@ HHHH ****
M"O3/AY_R+%__ -=V_P#0%KS.O3/AY_R+%_\ ]=V_] 6N3&_PON.K"?Q#S.BB
MBNLY0HHHH **** "BBB@ HHHH **** "BBB@ KT7X>^'MB'6KE#N;*6ZL!P.
M[_S _'U%<3HE@-3UNSLV("2R /SCY>I_' ->YQ11P1)%$BI&@"JJC  '85Y^
M/K.,>1=3MP=+F?.^AD^)M<CT'2'N,@W#_) A&<M_@.M>*N[RR-)(S.[$LS,<
MDD]237K'B+P=/XAU!;B35?*C1=L<0@W!?4_>ZD]\>GI61_PJ_P#ZC'_DM_\
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M1VDU*!W8LS3*2Q.23GK7OE?/5>Z:%J<>L:-;7B'EEQ(/1QP1^==68Q=HR.?
MR5Y(Q+KXA:39WD]M);7IDAD:-L(F,@X/\7M4/_"RM&_Y]K__ +]I_P#%53\5
M>![K4-3?4-->,F;F6)VVX;ID'T/O_P#JYV'P%XAEDVO:1PC^_),I'_CI)_2I
MITL+**;?XCG4Q,962_ Z'6/B#IMYH]W:VUM=^;/$T8,BJJC<,$Y!/8^E<KX.
M_P"1MT__ 'S_ .@FKNM^"IM#T;[=/>QR.'5#'&AQS_M$_P!*I>#O^1MT_P#W
MS_Z":Z81I*C+V6VOY&$I5'5C[3?0]DN?^/2;_<;^5?/]?0%S_P >DW^XW\J^
M?ZPRW:7R-L?O$*]K\)?\BIIW_7+^IKQ2O9?!,XG\)67(W(&1@.V&./TQ6F8+
M]VO4C _&_0XGXD?\C+%_U[+_ .A-7)1QO-*D4:[G=@J@=R>E>I^+_!]QK][!
M=V<\*2+'Y;K*2 0"2", \\G]*XV\TC_A%O%6G17%PDR!XIV<+M 7?SG_ +Y-
M7AJT'344];$XBE+VCDUI<]&T#PQ8:':QA84DN\#S)V&26[XST'TJ#4?'&BZ;
M/) TLL\L9PRP)G!],D@?K71=1P>O<5XO=>$]=BU%K?[!<3,6.)57*MR>2W09
M]S7!0A&M)NK([*TI4HI4T>JZ'KMKK]I)<VD<R(DGED2@ YP#V)]:YCXG?\>%
MA_UU;^0K>\)Z%)H&C^1-(&FE?S9 .BD@# ]>E8/Q._X\+#_KJW\A1145B4H;
M!6<GAVY;F/\ #7_D8[C_ *]&_P#0TKLO'/\ R)U__P!L_P#T8M<;\-?^1CN/
M^O1O_0TKLO'/_(G7_P#VS_\ 1BUKB/\ >X_(SH?[M+YGC=>U^$O^14T[_KE_
M4UXI7M?A+_D5-._ZY?U-;9C_  UZF.!^-^AP?Q(_Y&6+_KV7_P!":LSP=_R-
MNG_[Y_\ 036G\2/^1EB_Z]E_]":LSP=_R-NG_P"^?_036L/]U^1G/_>/F>R7
M/_'I-_N-_*O 8XWFE2*-=SNP50.Y/2O?KG_CTF_W&_E7A>DS);ZS8SRD"..X
MC=B?0,":YLO=HS:.C&J\HGKN@>&+#0[6,+"DEW@>9.PR2W?&>@^E0:CXXT73
M9Y(&EEGEC.&6!,X/IDD#]:Z+J.#U[BO%[KPGKL6HM;_8+B9BQQ*JY5N3R6Z#
M/N:PH0C6DW5D;5I2I12IH]5T/7;77[22YM(YD1)/+(E !S@'L3ZUS'Q._P"/
M"P_ZZM_(5O>$]"DT#1_(FD#32OYL@'120!@>O2L'XG?\>%A_UU;^0HHJ*Q*4
M-@K.3P[<MS'^&O\ R,=Q_P!>C?\ H:5V7CG_ )$Z_P#^V?\ Z,6N-^&O_(QW
M'_7HW_H:5Z;=VL-[:2VMPF^&52KKZBKQ4N7$J3Z6(PT>:@X][G@%>F_#-7_L
MF]8_<,X ^NT9_F*HW?PRF^UC['?Q_9B3GSE.]1VZ<-^E=OH^E0:+ID5E;DE4
MY+-U9CU-:XO$TYTN6+O<SPV'G"IS26QS?Q+8?\(];+GDW2D#_@#UY;7<_$G5
M%GOK?38WR( 7E _O'H/P'_H5<-73@HN-%7,,7).J[!11174<P4444 %%%% !
M1110 4444 %%%% !77?#G_D9G_Z]G_FM<C77?#G_ )&9_P#KV?\ FM88G^#+
MT-L/_%B9_C3_ )&[4/\ >7_T!:P:WO&G_(W:A_O+_P"@+6#5T?X<?1$U?XDO
M5A1116AF%%%% !1110 4444 %%%% !1110 45U>D>")-6T#^TTOEC8ARL1CR
M#M)'+9XZ>AKE*B-2,VU%[%RA**3:W"BBBK("BKVG:-J.JEOL-G+,%ZL!A0?3
M)XSSTK1D\%>(HT+-IK$#^[*C'\@U0ZL(NS:+5.;5TF8%%2302V\S0SQ/%*O#
M(ZE2/J#4=60%%%% !115W2-..K:K;V*R",S-C>1G'&>GX4FTE=C2;=D4J*W_
M !/X9/AN2V7[6+@3AB#Y>S&,>Y]:S=-TF^U>=H+"W,TBKN8 @ #ZD@5,:D)1
MYT]"G3DI<K6I2HJUJ&G7>EW9M;V!H9@ =IP<@]P1P?PJK5)IJZ)::=F%%%36
MEN;N]@ME8*9I%C!/;)Q3;MJ)*Y#172^)O"+^'+>"?[:MPDKE#^[V$'&?4Y[U
MS51"I&I'FB]"IPE!\LMPHHK0&@ZPP!&E7Q!Y!%N_^%4Y);L23>QGT5H_V!K/
M_0)O_P#P&?\ PH_L#6?^@3?_ /@,_P#A2YX]Q\DNQG45<GTG4K6$S7&GW<,2
M]7DA95'XD53III["::W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***5$:1U1%+,QP% R2?2@!**[+Q%X2T_0- BN)+F=[^0JH7
M*[">K<8S@#WKCT1Y9%CC5G=B%55&22>@ K.G5C47-'8N=.4':6XVBK-UIU]9
M*K7=G<6ZL<*98F0'Z9%5JM-/5$M-;A16GI_A_5M5C\RRL998\XW\*I^A. :M
M3>#?$-O&7?39"!VC=7/Y*2:EU8)V<E<I4YM729A44XQR"4Q%&$@;:4(YSZ8]
M:O\ ]@:S_P! F_\ _ 9_\*IR2W9*BWLC.HK1_L#6?^@3?_\ @,_^%']@:S_T
M";__ ,!G_P *7/'N/DEV,ZBK=QI6HV<7FW-A=01YQOEA91GZD54III["::W"
MBBK%@EM+?P1WCO';LX61TQE0>_--NRN"5W8KT5U7C#PG'X?6WGM))I+:0E&,
MI!*OU'0#J,]NQKE:BG4C4CS1V*G!PERR"BBBK("BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /88_\ DFY_[!1_]%5X]7L,?_)-S_V"C_Z*
MKQZN# _;]3LQ?V?0****[SC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBNN\$^&/[6N
MOMUVA^Q0M\JD<2MZ?0=_RJ*E2-.+E(NG!SERHW? GA@6D*ZO?1XG<9@1OX%_
MO?4_R^M=9-+YC<?='2GW$N?W:]!UJO7S]6K*K+FD>U3IJG'E04445F:!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #H_\ 6I_O"M&LZ/\
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M !H_M_1O^@M8?^!*?XUX714_V='^8?UZ78V?%EQ!=>*+Z:WD22)F&UT((.%
M."/<5C445WPCRQ4>QQRES2;[A72^!KZUT_Q$);N=(8VA9 [G SQW[=*YJBE4
M@IQ<7U"$N22DNA[F_B+18T+G5K(@?W9U)_('->&445EA\.J-[.]S6M7=6UUL
M=/X#O[73_$+27<Z0QO R!W.!G(/7MT->CWGB'1DLIB=5LV^1N$F5B>.P!R:\
M1HJ*V$C5GSME4L3*G'E2"NJ\ 7UK8:_+)=W$<"/;,BM(VT9W*<9/T-<K1714
M@IQ<7U,83Y)*2Z'M6I^(-&72[K&J6;$Q, J3*Q)(/8'-<!X!ETZWUN6XO[B&
M%HXCY)E<*,G@G)XSCC\37*45SPPBA"4$]S:>)<IJ36Q[;?>)](M+*:=-1M)7
M1"5CCF5BQQP, UXI)(\TKRR-N=V+,3W)ZTVBKP^'C1O9WN36KNK:_0****Z#
M ]GTGQ1IEWI5M-<:C:13M&/-1Y0A#=#P3GKFN7^(EWIE_:V4MK?03W$;LNV&
M0/\ *1U./<#\ZX"BN.G@XPJ<Z9U3Q4IPY&CU'P/K.F6WAJ*WN+^VAE21]R2R
M!#R<]^O6K&I^.+'3]:MH$FBN;-T/G20G=Y9SP01U[Y'_ .H^344/!0E-R;W&
ML7-045T/?+/4+/4(O-L[F*=.YC8''U]*9J&JV&EPF6]NHX5'8GD_0=37@U%8
M_P!G*_Q:&GU]V^'4WO%'B27Q#?AE#1VD7$43=?<GW_I6#117H0@H148['%*3
MD^9A1115$A1110 4444 %%%% !7IGP\_Y%B__P"N[?\ H"UYG7IGP\_Y%B__
M .N[?^@+7)C?X7W'5A/XAYG11176<H4444 %%%% !1110 4444 %%%% !111
M0!:TV_DTS4K>]B4,\+[@K=#[5W/_  M#_J#_ /DS_P#85YY16-2A3J.\U<UI
MUITU:+/0_P#A:'_4'_\ )G_["C_A:'_4'_\ )G_["O/**S^I4/Y?Q9?UNMW_
M ".RUWQY_;6CSZ?_ &;Y/F[?G\_=C#!NFT>E9GACQ,WAN6X86HN%G"@@OM(Q
MGO@^M8%%:+#TU!P2T9#K3<E-O5'5^(O&SZ]IHLA8+;KO#EC+O/'X"L/1=4;1
MM7@U!(A*8B?D)QG*D=?QJA151HPC'D2T%*K.4N9O4[G4OB,U_IMS:+I8C,\3
M1ES/NP&&#QM'K7#4444Z4*:M!6"I5E4=Y,Z'P_XPO] 3R%5;BT)SY3DC:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !115BRLI]0O8K2V0O-*VU1_7Z4-I*[&E?1%_P[H4VOZFML
MA*0K\TTF/NK_ (GM7L21PZ?9Q6EJ@2.-=JJ.PJIHND6_AW24MH\-(>9),<NW
MK]*E9BS$GJ:\+%8CVLM-D>QAZ'LHZ[L2BBBN4Z HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ='_K4_WA6C6='_K4_P!X5HT 8?C'
M_D4M0_W!_P"A"O%J]I\8_P#(I:A_N#_T(5XM7L9=_#?J>7COC7H%%%%=YQ!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z9\//\ D6+_ /Z[
MM_Z M>9UZ9\//^18O_\ KNW_ * M<F-_A?<=6$_B'F=%%%=9RA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %==\.?\ D9G_ .O9_P":UR-==\.?^1F?_KV?^:UAB?X,O0VP
M_P#%B9_C3_D;M0_WE_\ 0%K!K>\:?\C=J'^\O_H"U@U='^''T1-7^)+U8445
MUOP]TZ&]U]YIT5UMH_,4-_?R #^'/Z4ZDU3@Y/H*G!SDHKJ5K#P-KE]$)/LZ
M6Z$ CSVVD_@,D?B*W] \":II>N6M[//9M%$Q+!'8D\$<94>M,\:>+-1L]8DT
MVPF,"1*N]PHW,Q&>OI@CTK(\*:QJEQXGL89]2O)8F<AD>=F!^4]037&W7G2<
MVTDT=25&%112;=S7^)X_?:8>^V3_ -EK,^'7_(SG_KW?^8K3^)_^MTS_ '9/
M_9:S/AU_R,Y_Z]W_ )BE#_<_D_S'/_>OFB;XDS2-K]O"6)C2W#*OH2QS_(?E
M7&5U_P 2/^1EB_Z]E_\ 0FKD*Z<-_!B<^(_BR/7/&AW^")F;EL1'/ON6N(\!
MVRW'BNW+C(B1I!]0,#]37;^,O^1%E_W8O_0EKBO %PL/BN%&!_?1O&".QQG^
ME<>'O]6G;S_(ZJUOK$;^1I?$R[=M4L[//[N.'S>O4L2/Y+^M<-7<?$RV*:M9
M77\,D!C QW5B3_Z$*X>NO"6]C&QS8F_M7<]A\*7$USX)ADGD:1Q'(NYCDX!(
M'Z"O'J]A\*6\MKX)@CGC:-S'(VUA@X)8C]*\>K'"6]I4MW_S-<3?DA?M_D%%
M%%=QQG4Z!XXOM'C2VG7[5:+PJL<,@] ?3V/Z5WEKJ>@>+[8V[*DQP28)EPZ^
MX_/J#7C53V4\]M?036N[STD!C"C)+9X&.]<E;"0G[T=&=-+$RC[LM4;_ (N\
M*G0)TGMV9[&8X4MU1NNT^O?'T/ISUWPXM!#X?EN2J[YYS\PZE5  !_'=^=6_
M'@#>$+DL!N#1D>QW#_Z]5_AU<K+X;:$'YX9F!'H#@C^9KDG5E4PMWWL=4*<8
M8BR['F6I7C:CJ=S>.6)FD9QN.2 3P/P&!596*L&4D,#D$=15C4;1K#4KFT<,
M##(R?,.2 >#^(YJNJEF"J"6)P .IKU8VY5;8\UWOKN>P:RPU?P!+<2*-TEHL
MY'HP :O.O!W_ "-NG_[Y_P#037H>M?\ $G^'TD$A)9+1+?CN2 O]:\\\'?\
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M](8V=A.CG Z*&!)/L!7?*WLWVL<4;\Z[W.[^)G_('L_^OC_V4UYC7IWQ,_Y
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M;8G\S6#XW4+XPOP/5#^:*:Z#X8)F;4W]%C'Y[O\ "N=\:2"3Q=J# YPRK^2
M?TK&G_O<O3_(UG_NT?7_ #,&BBBNXXPHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#V&/\ Y)N?^P4?_15>/5[#'_R3<_\ 8*/_ **KQZN#
M _;]3LQ?V?0****[SC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 4 L0 "2> !7K/@WPTNB6/VR
M[0"^F7G/_+-?[OU]:P_ ?ACS676+V/Y%.;=&'WC_ '_P[?G7=7$V]MJGY1^M
M>5C<3?\ =Q^9Z6$H6_>2^0R60R/D].PIE%%>:=X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #H_]:G^\*T:SH_]:G^\*T:
M,/QC_P BEJ'^X/\ T(5XM7M/C'_D4M0_W!_Z$*\6KV,N_AOU/+QWQKT"BBBN
M\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *],^'G_(L7__
M %W;_P! 6O,Z],^'G_(L7_\ UW;_ - 6N3&_PON.K"?Q#S.BBBNLY0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC_R*6H?[@_\ 0A7BU>QEW\-^IY>.^->@4445WG$%%%% !1110 4444 %%%%
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M/**]#_X5?_U&/_);_P"SH_X5?_U&/_);_P"SH^NT/YOP8?5*W;\CSRBO0_\
MA5__ %&/_);_ .SH_P"%7_\ 48_\EO\ [.CZ[0_F_!A]4K=OR//**]#_ .%7
M_P#48_\ );_[.C_A5_\ U&/_ "6_^SH^NT/YOP8?5*W;\CSRBO0_^%7_ /48
M_P#);_[.C_A5_P#U&/\ R6_^SH^NT/YOP8?5*W;\CSRBO0_^%7_]1C_R6_\
MLZ/^%7_]1C_R6_\ LZ/KM#^;\&'U2MV_(\\HKT/_ (5?_P!1C_R6_P#LZ/\
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MX5?_ -1C_P EO_LZ/KM#^;\&'U2MV_(\\HKT/_A5_P#U&/\ R6_^SH_X5?\
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MC_R6_P#LZ/KM#^;\&'U2MV_(\\HKT/\ X5?_ -1C_P EO_LZ/^%7_P#48_\
M);_[.CZ[0_F_!A]4K=OR//**]#_X5?\ ]1C_ ,EO_LZ/^%7_ /48_P#);_[.
MCZ[0_F_!A]4K=OR//**]#_X5?_U&/_);_P"SH_X5?_U&/_);_P"SH^NT/YOP
M8?5*W;\CSRBO0_\ A5__ %&/_);_ .SH_P"%7_\ 48_\EO\ [.CZ[0_F_!A]
M4K=OR//**]#_ .%7_P#48_\ );_[.C_A5_\ U&/_ "6_^SH^NT/YOP8?5*W;
M\CSRBO0_^%7_ /48_P#);_[.C_A5_P#U&/\ R6_^SH^NT/YOP8?5*W;\CSRB
MO0_^%7_]1C_R6_\ LZ/^%7_]1C_R6_\ LZ/KM#^;\&'U2MV_(\\HKT/_ (5?
M_P!1C_R6_P#LZ/\ A5__ %&/_);_ .SH^NT/YOP8?5*W;\CSRBO0_P#A5_\
MU&/_ "6_^SH_X5?_ -1C_P EO_LZ/KM#^;\&'U2MV_(\\HKT/_A5_P#U&/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Z9\//^18O_P#KNW_H"UYG
M7IGP\_Y%B_\ ^N[?^@+7)C?X7W'5A/XAYG11176<H4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !77?#G_D9G_Z]G_FM<C77?#G_ )&9_P#KV?\ FM88G^#+T-L/_%B9_C3_
M )&[4/\ >7_T!:P:WO&G_(W:A_O+_P"@+6#5T?X<?1$U?XDO5A1116AF%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G1YDG]]OSIM%
M#O,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G1YDG]]OSIM
M% #O,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G1YDG]]OS
MIM% #O,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G1YDG]]
MOSIM% #O,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G1YDG
M]]OSIM% #O,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G1Y
MDG]]OSIM% #O,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G
M1YDG]]OSIM% #O,D_OM^=!=R,%F(]S3:* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ='_ *U/]X5H
MUG1_ZU/]X5HT 8?C'_D4M0_W!_Z$*\6KVGQC_P BEJ'^X/\ T(5XM7L9=_#?
MJ>7COC7H%%%%=YQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5Z9\//^18O_ /KNW_H"UYG7IGP\_P"18O\ _KNW_H"UR8W^%]QU83^(>9T4
M45UG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5UWPY_Y&9_\ KV?^:UR-==\.?^1F?_KV
M?^:UAB?X,O0VP_\ %B9_C3_D;M0_WE_] 6L&M[QI_P C=J'^\O\ Z M8-71_
MAQ]$35_B2]6%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'LFB_P#(!T[_ *]8_P#T$5>JCHO_ " =
M._Z]8_\ T$5>KYJ?Q,]^'PH****DH**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ='_
M *U/]X5HUG1_ZU/]X5HT 8?C'_D4M0_W!_Z$*\6KVGQC_P BEJ'^X/\ T(5X
MM7L9=_#?J>7COC7H%%%%=YQ!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Z9\//^18O_ /KNW_H"UYG7IGP\_P"18O\ _KNW_H"UR8W^%]QU
M83^(>9T445UG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5UWPY_Y&9_\ KV?^:UR-==\.
M?^1F?_KV?^:UAB?X,O0VP_\ %B9_C3_D;M0_WE_] 6L&M[QI_P C=J'^\O\
MZ M8-71_AQ]$35_B2]6%%%%:&84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'LFB_P#(!T[_ *]8_P#T$5>J
MCHO_ " =._Z]8_\ T$5>KYJ?Q,]^'PH****DH**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ='_ *U/]X5HUG1_ZU/]X5HT 8?C'_D4M0_W!_Z$*\6KVGQC_P BEJ'^
MX/\ T(5XM7L9=_#?J>7COC7H%%%%=YQ!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5Z9\//^18O_ /KNW_H"UYG7IGP\_P"18O\ _KNW_H"U
MR8W^%]QU83^(>9T445UG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5UWPY_Y&9_\ KV?^
M:UR-==\.?^1F?_KV?^:UAB?X,O0VP_\ %B9_C3_D;M0_WE_] 6L&M[QI_P C
M=J'^\O\ Z M8-71_AQ]$35_B2]6%%%%:&84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'LFB_P#(!T[_ *]8
M_P#T$5>JCHO_ " =._Z]8_\ T$5>KYJ?Q,]^'PH****DH**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ='_ *U/]X5HUG1_ZU/]X5HT 8?C'_D4M0_W!_Z$*\6KVGQC
M_P BEJ'^X/\ T(5XM7L9=_#?J>7COC7H%%%%=YQ!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5Z9\//^18O_ /KNW_H"UYG7IGP\_P"18O\
M_KNW_H"UR8W^%]QU83^(>9T445UG*%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5UWPY_Y&
M9_\ KV?^:UR-==\.?^1F?_KV?^:UAB?X,O0VP_\ %B9_C3_D;M0_WE_] 6L&
MM[QI_P C=J'^\O\ Z M8-71_AQ]$35_B2]6%%%%:&84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'LFB_P#(
M!T[_ *]8_P#T$5>JCHO_ " =._Z]8_\ T$5>KYJ?Q,]^'PH****DH**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ='_ *U/]X5HUG1_ZU/]X5HT 8?C'_D4M0_W!_Z$
M*\6KVGQC_P BEJ'^X/\ T(5XM7L9=_#?J>7COC7H%%%%=YQ!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5Z9\//^18O_ /KNW_H"UYG7IGP\
M_P"18O\ _KNW_H"UR8W^%]QU83^(>9T445UG*%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5UWPY_Y&9_\ KV?^:UR-==\.?^1F?_KV?^:UAB?X,O0VP_\ %B9_C3_D;M0_
MWE_] 6L&M[QI_P C=J'^\O\ Z M8-71_AQ]$35_B2]6%%%%:&84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'LFB_P#(!T[_ *]8_P#T$5>JCHO_ " =._Z]8_\ T$5>KYJ?Q,]^'PH****D
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ='_ *U/]X5HUG1_ZU/]X5HT 8?C'_D4
MM0_W!_Z$*\6KVGQC_P BEJ'^X/\ T(5XM7L9=_#?J>7COC7H%%%%=YQ!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z9\//^18O_ /KNW_H"
MUYG7IGP\_P"18O\ _KNW_H"UR8W^%]QU83^(>9T445UG*%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5UWPY_Y&9_\ KV?^:UR-==\.?^1F?_KV?^:UAB?X,O0VP_\ %B9_
MC3_D;M0_WE_] 6L&M[QI_P C=J'^\O\ Z M8-71_AQ]$35_B2]6%%%%:&844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'LFB_P#(!T[_ *]8_P#T$5>JCHO_ " =._Z]8_\ T$5>KYJ?Q,]^
M'PH****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD/Z_XT?\(EH'_0,A_7_&C^T:?9A]1GW1XI17M?\ PB6@?] R']?\:/\ A$M
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M _Z!D/Z_XT?\(EH'_0,A_7_&C^T:?9A]1GW1XI17M?\ PB6@?] R']?\:/\
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MC_A$M _Z!D/Z_P"-']HT^S#ZC/NCQ2BO:_\ A$M _P"@9#^O^-'_  B6@?\
M0,A_7_&C^T:?9A]1GW1XI17M?_"):!_T#(?U_P :/^$2T#_H&0_K_C1_:-/L
MP^HS[H\4HKVO_A$M _Z!D/Z_XT?\(EH'_0,A_7_&C^T:?9A]1GW1XI17M?\
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MO_A$M _Z!D/Z_P"-'_"):!_T#(?U_P :/[1I]F'U&?='BE%>U_\ "):!_P!
MR']?\:/^$2T#_H&0_K_C1_:-/LP^HS[H\4HKVO\ X1+0/^@9#^O^-'_"):!_
MT#(?U_QH_M&GV8?49]T>*45[7_PB6@?] R']?\:/^$2T#_H&0_K_ (T?VC3[
M,/J,^Z/%**]K_P"$2T#_ *!D/Z_XT?\ "):!_P! R']?\:/[1I]F'U&?='BE
M%>U_\(EH'_0,A_7_ !H_X1+0/^@9#^O^-']HT^S#ZC/NCQ2BO:_^$2T#_H&0
M_K_C1_PB6@?] R']?\:/[1I]F'U&?='BE%>U_P#"):!_T#(?U_QH_P"$2T#_
M *!D/Z_XT?VC3[,/J,^Z/%**]K_X1+0/^@9#^O\ C1_PB6@?] R']?\ &C^T
M:?9A]1GW1XI17M?_  B6@?\ 0,A_7_&C_A$M _Z!D/Z_XT?VC3[,/J,^Z(-%
M_P"0#IW_ %ZQ_P#H(J]5R*TMX(4BBB58T4*JCL!P!3_(C_N"O)D[ML].*LDB
MA15_R(_[@H\B/^X*0RA15_R(_P"X*/(C_N"@"A15_P B/^X*/(C_ +@H H45
M?\B/^X*/(C_N"@"A15_R(_[@H\B/^X* *%%7_(C_ +@H\B/^X* *%%7_ "(_
M[@H\B/\ N"@"A15_R(_[@H\B/^X* *%%7_(C_N"CR(_[@H H45?\B/\ N"CR
M(_[@H H45?\ (C_N"CR(_P"X* *%%7_(C_N"CR(_[@H H45?\B/^X*/(C_N"
M@"A15_R(_P"X*/(C_N"@"A15_P B/^X*/(C_ +@H H45?\B/^X*/(C_N"@"A
M15_R(_[@H\B/^X* *%%7_(C_ +@H\B/^X* *%%7_ "(_[@H\B/\ N"@"A15_
MR(_[@H\B/^X* *%%7_(C_N"CR(_[@H H45?\B/\ N"CR(_[@H H45?\ (C_N
M"CR(_P"X* *%%7_(C_N"CR(_[@H H45?\B/^X*/(C_N"@"A15_R(_P"X*/(C
M_N"@"A15_P B/^X*/(C_ +@H H45?\B/^X*/(C_N"@"A15_R(_[@H\B/^X*
M*%%7_(C_ +@H\B/^X* *%%7_ "(_[@H\B/\ N"@"A15_R(_[@H\B/^X* *%%
M7_(C_N"CR(_[@H H45?\B/\ N"CR(_[@H H45?\ (C_N"CR(_P"X* *%%7_(
MC_N"CR(_[@H H45?\B/^X*/(C_N"@"A15_R(_P"X*/(C_N"@"A15_P B/^X*
M/(C_ +@H H45?\B/^X*/(C_N"@"A15_R(_[@H\B/^X* *%%7_(C_ +@H\B/^
MX* *%%7_ "(_[@H\B/\ N"@"A15_R(_[@H\B/^X* *%%7_(C_N"CR(_[@H H
M45?\B/\ N"CR(_[@H H45?\ (C_N"CR(_P"X* *%%7_(C_N"CR(_[@H H45?
M\B/^X*/(C_N"@"A15_R(_P"X*/(C_N"@"A15_P B/^X*/(C_ +@H H45?\B/
M^X*/(C_N"@"A15_R(_[@H\B/^X* *%%7_(C_ +@H\B/^X* *%%7_ "(_[@H\
MB/\ N"@"A15_R(_[@H\B/^X* *%%7_(C_N"CR(_[@H H45?\B/\ N"CR(_[@
MH H45?\ (C_N"CR(_P"X* *%%7_(C_N"CR(_[@H H45?\B/^X*/(C_N"@"A1
M5_R(_P"X*/(C_N"@"A15_P B/^X*/(C_ +@H H45?\B/^X*/(C_N"@"A15_R
M(_[@H\B/^X* *%%7_(C_ +@H\B/^X* *%%7_ "(_[@H\B/\ N"@"A15_R(_[
M@H\B/^X* *%%7_(C_N"CR(_[@H H45?\B/\ N"CR(_[@H H45?\ (C_N"CR(
M_P"X* *%%7_(C_N"CR(_[@H H45?\B/^X*/(C_N"@"A15_R(_P"X*/(C_N"@
M"A15_P B/^X*/(C_ +@H H45?\B/^X*/(C_N"@"A15_R(_[@H\B/^X* *%%7
M_(C_ +@H\B/^X* *%%7_ "(_[@H\B/\ N"@"A15_R(_[@H\B/^X* *%%7_(C
M_N"CR(_[@H H45?\B/\ N"CR(_[@H H45?\ (C_N"CR(_P"X* *%%7_(C_N"
MCR(_[@H H45?\B/^X*/(C_N"@"A15_R(_P"X*/(C_N"@"A15_P B/^X*/(C_
M +@H H45?\B/^X*/(C_N"@"A15_R(_[@H\B/^X* *%%7_(C_ +@H\B/^X* *
M%%7_ "(_[@H\B/\ N"@"A15_R(_[@H\B/^X* *%%7_(C_N"CR(_[@H H45?\
MB/\ N"CR(_[@H H45?\ (C_N"CR(_P"X* *%%7_(C_N"CR(_[@H H45?\B/^
MX*/(C_N"@"A15_R(_P"X*/(C_N"@"A15_P B/^X*/(C_ +@H H45?\B/^X*/
M(C_N"@"A15_R(_[@H\B/^X* *%%7_(C_ +@H\B/^X* *%%7_ "(_[@H\B/\
MN"@"A15_R(_[@H\B/^X* *%%7_(C_N"CR(_[@H H45?\B/\ N"CR(_[@H H4
M5?\ (C_N"CR(_P"X* *%%7_(C_N"CR(_[@H H45?\B/^X*/(C_N"@"A15_R(
M_P"X*/(C_N"@"A15_P B/^X*/(C_ +@H H45?\B/^X*/(C_N"@"A15_R(_[@
MH\B/^X* *%%7_(C_ +@H\B/^X* *%%7_ "(_[@H\B/\ N"@"A15_R(_[@H\B
M/^X* *%%7_(C_N"CR(_[@H H45?\B/\ N"CR(_[@H H45?\ (C_N"CR(_P"X
M* *%%7_(C_N"CR(_[@H H45?\B/^X*/(C_N"@"A15_R(_P"X*/(C_N"@"A15
M_P B/^X*/(C_ +@H H45?\B/^X*/(C_N"@"A15_R(_[@H\B/^X* *%%7_(C_
M +@H\B/^X* *%%7_ "(_[@H\B/\ N"@"A15_R(_[@H\B/^X* *%%7_(C_N"C
MR(_[@H H45?\B/\ N"CR(_[@H I1_P"M3_>%:-,$,8((49%/H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img205696091_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" />#A,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HK-G\1:):W!M[C6-/AG4X,<ETBL#Z8)S6@CK(BNC!D8 JRG((]10 Z
MBBB@ HHHH **** "BBB@ HHHH ***YG4/B#X6TN]EL[S5E2XB8HZ+#(^TCJ"
M54B@#IJ*SM&UW3/$%HUUI=VES"K;6*@@@XS@@@$=:T: "BBB@ HHHH ****
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MVFIVW^JN(PX&<[3T*GW!!'X4 7Z**J:AJEAI-N;C4+R"UBY^:5PN?89ZGV%
M%NBN2D^)O@Z)]K:RI/\ LP2L/S"U?T[QKX:U618[/6;5Y&&51V\MC] V#GVH
M WJ*** "BLJ3Q-H$4QADUS34E4[2C7<88'TQFM)IHD@:=Y$6%5WF0L H7&<Y
M],=Z 'T5REQ\2O"%K.T,FM1LRG!,44DB_@RJ0?P-;VFZQIVLP&;3;V"ZC'#&
M)PVT^A'4?C0!=HIDTT5O"TT\B11(,L[L%"CW)KF)_B3X0M[@P/K41<'!,<;N
MO_?2J1^M '5452TW5M/UBW-QIU[!=1 X+1.#M/H?0_6KM !137=8T9W8*B@E
MF8X 'J:Y^]\>>%K!ML^N6A(&2(6,N/\ OC//'2@#HJ*Y*/XF^#I7VKK*@_[4
M$JC\RM='8ZC9:G )["[@N8C_ !PR!A^E %JO$?C=+,=>TV$N_D"V+*N?EW%B
M"?K@"O;JQ/$NG>'-0M(U\1K9^2I/EO<2B,J<<[6R".@S@]AZ4 ?/O@26:'QS
MHQ@=U9KE%;:>JDX8?3&:^G:Y+PUHW@BROS-X>_LZ2["D;H;OSW4'TRQ(_#WK
MK: "BLJ3Q-H$4QADUS34E4[2C7<88'TQFM)IHD@:=Y$6%5WF0L H7&<Y],=Z
M 'T5RMS\2?"%K*T4FM1,RD@F*-Y!^:J0:V-)\0:3KJ,^F:A!=;.65&^9?JIY
M'XB@#2HHHH **** /%?C3KHGU&ST.(G;;KY\W/!=AA1CU"Y.?]NLOX0:-_:'
MB\WSIF&PB,F2N1O;Y5'Y;B/]VN3\2ZH=9\3:CJ!8LL\[%"3GY <*/P4 5['\
M&=-^R^$Y[Y@P:\N#C(P"J<#'KSN_SF@#T>O"?%?Q-\36_BC4;2PO$M+:UG>!
M(UA1\[&*[B64G)Q7NU?+'BS_ )'+7/\ L(7'_HQJ -^T^+'BVWG62:^BND!R
M8Y;= "/3*@']:]XT/6;77]'MM3LVS#.N<'JC=U/N#D5\L364T%G;73*?)N V
MQ\<$J<$9]1P?^!"O1_@_XH%AJ<F@W4H6"\.^ MT67'3.>-P'Y@>M 'N%>0?$
MCQ[X@T/Q0=.TN[2VACA1B1$CEB<GG<#_ )%>OU\]?%W_ )'V?_KA%_*@#O/A
M7XPUCQ++J4&K7"W!@6-HW$:H1DMD': #V_*L?XD>._$6A^*VT_3+U;:W2%&P
M(4<L3R22P/Z5#\#O^0AK'_7*/^;5W'B;X<Z+XIU0:A>2WD,_EB,_9W4!@,X)
MRIYYH \?_P"%I>,O^@S_ .2L/_Q%'_"TO&7_ $&?_)6'_P"(KT?_ (4IX;_Y
M_=5_[^Q__&Z\:\0Z?%I/B+4=/@9VAMKAXD:0@L0#@9P!S0!O?\+2\9?]!G_R
M5A_^(H_X6EXR_P"@S_Y*P_\ Q%7/AOX*TWQA_:?]H3W<7V7RMGV=U7.[?G.5
M/]T5W?\ PI3PW_S^ZK_W]C_^-T ;OP[UV^\0^$8;W49!)<B5XVD"A=V#P<#@
M=<<>E>077Q7\73W4LL.HI;Q,Q*0I;QL$'IEE)/XFO=?#WA^R\,Z1'IM@93"C
M%BTK;F8D\DX 'Y 5\JT =A_PM+QE_P!!G_R5A_\ B*?'\5?&$9RVII)[-;1_
MT45U?PS\%>'O$'A9[S5-/^T7 N7C#^=(GR@*0,*P'<UU%W\(_"5R,16UQ:\8
MS#<,?Q^?=0!QVD?&R_CE1-8TZ":'@-);91QZG!)!/7CY?PKU70?$6E^)+$7>
MF7*RJ,;T/#QD]F7MW]CCC-> ^,_ 6H>$)4D=_M5A*<)<JN,'^ZP['^?YUD^'
M/$-[X9UB+4+)R"IQ)'G"RIGE3]?TZT ?5->>?&'1_P"T/"27Z+F6PE#D@9.Q
MOE;]=I_"NZTZ_M]4TZVO[5]\%Q&)$/?!'?W]13=3L8]3TJ[L95#)<0M$0?<8
MH ^9/"NMOX>\36.I*<)%(!*.>8SPP_(G'OBOJ56#*&4@J1D$'@BOD26)X9GB
MD&'1BK#.<$=:^D_AWJKZOX&TV:0DRQ(8').2=AV@_B #0!U-%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !4<\\5K;RW$\BQPQ(7=V. J@9)/X5)7-
M?$'_ )$+6/\ KA_44 53\4?!H)!UD<>EM,?_ &2D_P"%I>#?^@S_ .2LW_Q%
M?.%=18_#OQ5J5C#>VFE>9;SH'C?[1$-P/0X+9H ]M@^)'A"Y.$UJ(?\ 72-T
M_P#0E%=#9ZA9:C%YMC>6]U'TWP2!Q^8-?,^I>"_$FDPO->Z/<QPQ\O(H#JH]
M25R ..M9>GZE>Z5=K=Z?=2VTZ]'B8J<>A]1QT/% 'UK17GWP]^(H\3?\2S4@
MD>J(N59!A9U Y..S=R.G<>@]!H R-<\3Z-X;6)M6ODMO-)"+M9V;'4X4$X]Z
MR%^)_@UV"C61D^MO*!^JUYM\:_\ D<K/_L'I_P"C)*\WH ^N;2[MK^UCNK2>
M.>"0922-@RL/K4U>*?![Q4UM?2>'KN;]Q/F2UW'[LG=1]1SCU'O7M= &=K.N
MZ9X?M%NM4NTMH6;:I8$DG&<  $GI6=I/CKPUKE^ECIVIK-<OG;&8I$+8!)QN
M4=@:XSXW_P#()TG_ *[O_P"@BO/?AU_R4#1_^NI_] :@#Z7HHHH J:EJ=EH]
MC)>ZA<);VT>-SMVR<#IUKFO^%I>#?^@S_P"2LW_Q%<9\;=8W3:=HL;#" W,H
M]SE4_P#9_P Q7D= 'U;HWB#2O$%N\^E7L=RB$!]H(*D],@@$?E6E7@/P@UG^
MS_%YL7?$-_$8\%L#>OS*?RW ?[U>_4 %%%% !1110!YW\5/%NK>&(=+32IEA
M>Z,N]S&KGY=N, @C^+]*Y+P9\1_$VH>+-/L;^^2YMKB7RW1H$7&0>05 K2^.
M?_,!_P"WC_VG7!> O^1[T;_KY6@#Z<HHHH *AO+J.RLI[N7/EP1M(^T9.%&3
MC\JFJMJ%H+_3;JS+E!<0O$6 SMW C/ZT >+W'QLUIKIC;:;IZ6^[Y5E#L^/<
MA@,_A7J7@[Q,OBOP]'J0@,$@<Q2QYR XQG!].0:\4G^$_B^&X,2:?%.@.!+'
M<H%/O\Q!_2O8_ /ANX\+>%X[&[D1[AY&FD"<A"<#:#WX H Z>BBB@ HHHH *
M*** "BBB@ KYWOOBGXO:]F\K4DA0.P6-+:,A1D\?,I/ZU]$5\BW7_'W-_P!=
M&_G0!](?#W7K[Q'X4COM19&N/->,LB[=P'0D=,\UF_$+X@R^$);:SLK2.:[F
M0R%IL[$7) X!!)R#W'3WI/A!_P B(G_7S)_2J/Q0\#:KXEN[/4-*6.9XHC#)
M SA#C)(()X/4YR1V_  H>$OBW?:MK]KINJV-LJ73B-)+8,I5CTR&)R,_3K7K
M5>(^"_ACXAM?$UE?ZI EG;VLHF.94=G*\@ *3W]:]NH **** "BBB@ HHHH
M**** "BBB@ HHHH CGGBM;>6XGD6.&)"[NQP%4#))_"N4/Q1\&@D'61QZ6TQ
M_P#9*M?$'_D0M8_ZX?U%?,M 'T?_ ,+2\&_]!G_R5F_^(J:#XD>$+DX36HA_
MUTC=/_0E%>)6/P[\5:E8PWMII7F6\Z!XW^T1#<#T."V:JZEX+\2:3"\U[H]S
M'#'R\B@.JCU)7( XZT ?3%GJ%EJ,7FV-Y;W4?3?!(''Y@U9KY*T_4KW2KM;O
M3[J6VG7H\3%3CT/J..AXKW3X>_$4>)O^)9J02/5$7*L@PLZ@<G'9NY'3N/0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .-^)GB+4?#7AF&[TR1(YY;I82[(&V@HYR
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M_DG&K?\ ;'_T<E 'D'_"TO&7_09_\E8?_B*/^%I>,O\ H,_^2L/_ ,17'U]
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M6=V"A1[DT /HK-MO$6B7LZP6FL:?/,WW8XKI&8_0 YJQJ&I66E6INM0NX;:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB#^RKAR+34&"+Z+-T4_C]W\1Z4 =1\;_ /D$Z3_UW?\ ]!%>>_#K_DH&C_\
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M#W"@'YOKD#CO7B:LR,&1BK#H0<&O0O!'POG\1VHU'5)9;.P;_5*@'F3#U&>
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MK0H?LEEKD,4:3>9Y$[#@R C*D^N-I'KR/3CRC2+QM/UJQO$;:T%PD@/IA@:
M/J#Q"2OAK52"019S$$?[AKY2KZM\1?\ (L:M_P!><W_H!KY2H ^E?AN2?A]I
M!))_=L.?]]J\]^-Y/]M:4,G MV./^!5Z%\-O^2>Z1_US?_T-J\\^-_\ R&]+
M_P"O9O\ T*@#B_#GBF[\,1:@U@H%S=Q")93_ ,LAG)8#N?2J%MINK:S))-:V
M5[?/G,CQ1/*<^Y -7?!VB0^(O%EAI5Q(\<,[,79.N%4L0/KMQGMFOIJQL+33
M+..TLK>."WC&%1!@#_$^] 'R4RLCLCJ593@J1@@U[%\'O%<\[2^'KR4R+''Y
MEH6.2H'5/ISD>F#69\:M)@M-9T_488T1[R-UEVC&YD*_,??# ?A7.?#.8P_$
M/26 )W-(A&<=8V'_ ->@#Z0=UC1G=@J*"69C@ >IKYL\<^,[KQ9JSX<IIL#D
M6T(X!'3>P_O$?ET^OM?Q(OC8> =5=20TL8A&#C.]@I_0FOFJ@"S9:=?:E(8[
M&RN+IQR5@B9R/P JS9WNJ^&M3+Q>?:7295XY%*Y'0JRGMUKZ,\%:#!X>\+65
MK&B"9XUEN'4<O(PR>>^.@]@*/&/AG3O$FB3QW<*^?%&S03@8>-@,\'T/<=_K
MB@#YAKZ/^%O_ "3C2?\ MM_Z.>OG"OH_X6_\DXTG_MM_Z.>@#S[XVD_\)+IX
MR<"SSC_@;5C_  G)'Q!L@"1F.4'W^0UK_&W_ )&?3_\ KS'_ *&U8_PH_P"2
MA6/_ %SE_P#0&H ^BJ^022Q))))Y)-?7U?(% '1ZYXNU#7-,TW206BL;*WBA
M6!#_ *QU4*6;U.1P.WYDY-UH^IV-NEQ=Z=>6\$F-DDL#(K9]"1@UZS\(/"VG
MOIQ\0W"":[\UHX0X^6+&.1_M'U[5ZA?V-MJ=A/97<2RV\R%'1AG(_P >XH ^
M5-,U.\T?4(;^PG:&YA;*NO\ (^H/<5]0^'=8CU_P_9:I&H47$89E!SM8<,/P
M8$?A7RQ<PFVNIH"03&Y0D=\'%>]_!Z4R>!@IS^[NI%'/T/\ 6@"K\5_&=SH5
MK!I&FRO#>W2^9),APT<>2/E/8D@\]L'UX\>T/P_JGB:_:UTV S2A=[LS !1Z
MDFNH^,"2+X[8N"%:VC*9[CD<?B#74? YX/LFLH"/M&^(L.Y7#8_7- '%^(/A
MGXA\.Z>]].MO<V\?,C6KLVP>I! ./>N0CC>618XT9W<A551DDGH *^JO$DT$
M'AC59;DKY(M)=^[H1M/'OGIBOE.@#V#X/Z%K&F:OJ-Q?Z?<VD#0!!]HB,99M
MP(P&&3P#7K]5M.,ITRT,^[SC"GF;Q@[MHSGWS5F@ KC_ (I?\DXU;_MC_P"C
MDKL*X_XI?\DXU;_MC_Z.2@#YPKZM\._\BQI/_7G#_P"@"OE*OJWP[_R+&D_]
M></_ * * -*O/OC!I"7W@[[>%'G6$JN&[[&(5@/Q*G_@->@US/Q#V_\ " ZQ
MNQCR1U]=PQ^M 'S."5(()!'((KZL\/:@=6\.:;?NP:2XMHWD(Z;RHW?KFOE*
MOIOX?@CP%HP((_T<'GZF@#FOB=X]DT%/[&TMPNH31[I9E/,"'H!Z,?T&#W!'
MB,<=WJ=\L<:S75U.V !EW=C^I-7/$>JOK?B/4-2<G]_,S*"V<+T49]@ /PKU
M7X*Z) FF7FMR)FXDE-O$2/NHH!)!]R<'_=H \_F^'/BZ"U^TOHDQ3&<(Z._3
M/W 2WX8KG(IKBQNEEADEM[B)N&1BCHP]QR#7US7A7QFT:.Q\1VNI1*%6_B.\
M#NZ8!/Y,OY4 =Q\-/&\GB>QDL;]E_M*U4$L.#,G3=CU!P#]1ZU>^*)(^'.K$
M$C_5#C_KJE>.?#.^>Q\?Z:5)VS,T+@=PRG'ZX/X5[%\4O^2<:M_VQ_\ 1R4
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MJ,XR5(/7\*]]E^+GA..R6=;BYED/6W2W;>/J3A?_ !Z@#&^-ZDZ-I3X^47#
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M\<_^8#_V\?\ M.N"\!?\CWHW_7RM 'TY7E7QO_Y!.D_]=W_]!%>JUY5\;_\
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MQI/_ &V_]'/71ZQ_R!+_ /Z]I/\ T$USGPM_Y)QI/_;;_P!'/71ZQ_R!+_\
MZ]I/_030!\FU]*_#;_DGND?]<W_]#:OFJOI7X;?\D]TC_KF__H;4 <)\2?B-
M?Q:I/H>BSO;1P'9<7$9P[MW53U4#ID<Y'IU\_P!#\-:WXKNI1IUN]PR8,LLC
M@*N>F6)Z^W6H?$L<T7BG5DG5A*+R7=NZYWGFO6O@SJ]@OA^YTQYXH[P71D$;
M. TBLJ@$#OR,?EZT <K)\&O$<5NTSW>E@*A8KYLF1@9Q]RO.Z^E?&GC+3/#6
ME3I+*DM](A2*U1LL21U;^Z.<Y/X5\U4 ?2OPV_Y)[I'_ %S?_P!#:N"^./\
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M <'L.@*T ;?C7Q%_PD_PST2^D8-=+=F&YP,8D5#GVY!#<?WJYKX=?\E T?\
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MQAHTK$!5O8=Q(Z#>,T ?4]4M8_Y E_\ ]>TG_H)J[5+6/^0)?_\ 7M)_Z":
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M"@#$^%O_ "4?2?\ MM_Z)>OH^OGGX20"7Q];OC/E0RO]/EV_^S5]#4 %%%%
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MM(^(OAC6ITM[?41%.YPL<Z&,GZ$\?K5[QC'-+X,UE(%9I&LY,!>I&TY'Y9H
M\+\7?$/5_$MU+'%/+::;G$=M&VW</5R/O'VZ#]:@\/\ P]\0^)+5+NTMHXK1
MR0L]P^U3CJ0.21[@5RU?3O@G5[#4_"FF"TGB9XK6..2)7!:-E4*01VY'\J /
M%?$7PSUGPSH\FIWMS8201LJE89'+9)P.J ?K7(VO_'W#_P!=%_G7L'Q8\9:9
M/I)T"RE2ZN)'5Y7C;*1@'(&>Y/IVKQ^U_P"/N'_KHO\ .@#ZZKYP^*7_ "4?
M5O\ MC_Z)2OH^OG#XI?\E'U;_MC_ .B4H Z+X(?\AO5/^O9?_0J]MKQ+X(?\
MAO5/^O9?_0J]MH ^>OB[_P C[/\ ]<(OY5I_!+_D9]0_Z\S_ .AK69\7?^1]
MG_ZX1?RK3^"7_(SZA_UYG_T-: -7XY*YAT-P#Y8:<,>V3LQ_(UY]X%D6/QSH
MK.P -TBY/J>!^IKU[XOZ3)J'@X742EGL9A*P S\A^4_ED'Z UX'#-);SQSQ,
M5DC8.C#L0<@T ?7E<K\2?^2>ZO\ ]<T_]#6L;1?BYX?N=)C?59WM+Y5Q)'Y+
M.'8=U*@C!]\8S^-<'X_^)$GB4?V=IGFP:6.7W</.??'11V'XGL  >?U]3+:O
M>^"Q:1XWSZ=Y:Y]6CP/YU\LU]9:/_P @2P_Z]H__ $$4 ?/O_"K?&7_0&_\
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M_P"*7_).-6_[8_\ HY*["N/^*7_).-6_[8_^CDH ^<*^K?#O_(L:3_UYP_\
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M0!Z1\#O^/36O^ND/\GK=^+__ "(C_P#7S'_6L+X'?\>FM?\ 72'^3UN_%_\
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MWOBTK;11FTTU"#Y ;)D;U<]_8?SKGM!T.\\1ZQ!IEBH,LIY9ONHHZLQ]!_\
M6ZF@#V/X+Z:UMX8NK]P1]LN,)D<%$&,C_@18?A7I54M(TNWT72+73;4$0V\8
M1<]3ZD_4Y/XU=H ^;OB>ZR?$75F4Y ,2_B(D!_45T_P/B8ZKJTH'R+ BD^Y8
MD?R-<+XPNTO?&.L7$9!1KN0*1W . ?TKU#X(63QZ1JM\1A9YTB4^NQ23_P"A
MT >J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7F/Q3\&ZWXCOK"ZTFV2X6*)HW3S51@<YS\Q Q^->G44 >2?#/P)KV@^(Y
M-1U6U6VB6W:-1YJ.68D?W2<# ->MT44 17-O%=VLMM<1B2&9#'(AZ,I&"/RK
MP76?A'XBM-0D32X%OK0L3')YR(P'HP8CGZ>G:O?Z* /#O!OPT\1VGBJPO=2M
M%M+6VE$S.9D<L5Y  4GJ<5[C110 4444 %9NO:+;>(=$N=,NLB.=<!@,E&'(
M8?0UI44 ?->K_#GQ1I-P\9TR:[C!^66T4RAAZX'(_$"J]AX#\4:C<I#'HMY#
MN."]Q$8E7W);'^>E?3E% $%G;_9+&WMMV_R8UCW8QG QG%>4>+O@_)+<R7OA
MQXU5VW-92':%_P!P],>QQCU[5Z]10!\OW/@CQ1:.4DT&_8@X_=0F0?FN138/
M!7B>Y?:F@Z@#_P!-+=D'YL!7U%10!XMX"^''B#3_ !+9:KJ4$=I!;L7VM(&=
M\J0,!2<=>Y'2O::** /G.;X5>,(I61-,251T=+F, _3+ _I7L7P]T&^\.>%(
M['451;CS7D*HV[:#T!/3/%=510 5QOQ,\.ZCXE\,PVFF1I)/%=+,49PNX!'&
M 3QG+#K7944 ?/>E?"[Q:NJVKSZ<D$22JS2/<1D  CLK$_I7T)110!P_Q/\
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M'5'U6%87NC%L02*Y^7=G)!(_B_2O1*** "OG2X^%/B^&XDCCTU)T5B%E2XC
M<>H!8'\Q7T710!\X?\*M\9?] ;_R:A_^+J2'X4^,)&P^FQQ#U>YC(_1C7T71
M0!XOI'P2NWE5]9U.&*+.3': LQ'IN8  _@:]6T/0--\.:>++3+80Q9W,<Y9V
M]6)ZFM*B@ JEJ^H)I6CWFH2%0MM"\OS'@D#('XGBKM>??%[6QIOA(:>A_?ZB
M^P>R*0S'_P!!'XT >!R2-+(TCL6=R68GN37TE\-]+.E>!-.C>,)+.IN)/?><
MJ3_P':/PKP/PMHC^(O$EEIBAMDLF967^%!RQ_('\<5]2HBQHJ(H5% "JHP /
M04 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YKX@_\B%K'_7#^
MHKI:BN;:"\MI+:YB26&52KQN,A@>QH ^1:ZBQ^(GBK3;&&RM-5\NW@0)&GV>
M([0.@R5S7L__  JWP;_T!O\ R:F_^+H_X5;X-_Z W_DU-_\ %T >':GXU\2:
MPC1WVL7+QMPT:$1JWU50 :S-.TN_U>Z6UT^TEN9C_#&N<>Y]![FOHRW^'/A&
MU=6CT2!BIR/-9Y!USR&)S^-=#:65K80""SMH;:$'(CAC"+GZ"@#B?A[\/4\+
MQG4-0,<VJ2H  !D6X[JI[D]S^ XR3WM%% 'A'QK_ .1RL_\ L'I_Z,DJ7X)?
M\C/J'_7F?_0UKU?6_"&@^(YXY]5T];B6-=BOYCH0N2<94C(R3^=/T/PKHGAL
MRG2;!+=I<;VWL[$#MEB3CVH V*Y7XA>&_P#A)?"D\,2;KVW_ ']M@<E@.5_X
M$,CZX]*ZJB@#Y!(*D@@@C@@UU'PX4M\0=("@D^:QX'8(U>Y:EX!\+ZO>R7E[
MI,;W$AR[I(\>X^I"L 3[U-HW@OP]X?NVNM,TU()RNWS#([D#VW$X_"@#(^*>
MM_V/X+N(DSYU^?LR8Z $98G_ (""/Q%?/$,,EQ/'!$I:21@B*.Y)P!7U3K?A
M[2O$5JEMJMFMS%&V] 692IZ<%2#69I_P]\*Z7>Q7EII"+/$P9&:61]I!R" S
M$9!'6@#8T;38]'T6RTZ/E;:%8\^I Y/XG)J]110!!>VD5_87%G."8;B)HG Z
M[6&#^AKY0U"RETW4;FQG&)K>5HG'NIP:^MJYO4_ /AC6+Z2]OM*22XE.7=99
M$W'&,D*P':@#C?@IK/G:=?Z-(_S0.)X@<YVMPP^@(!_X%7JU8NB>$="\.2R2
MZ38+;R2KM=_,=R1UQEB:VJ "BBB@#R#XY_\ ,!_[>/\ VG7EVEZ-?:RUTEA"
M9I+: W#HOWB@90<#N?F!Q]:^F];\-:/XCBBCU:R6Y6(DQDLRE<XS@J0><#\J
MBT3PCH7AR6272;!;>25=KOYCN2.N,L30!\[Z-XR\0>'X#!IFIRPPGGRRJNH^
M@8$#\*R[_4;S5+MKJ_N9;B=L R2-DX':OH?7/AIX9UR=[B2T>TN'.6EM&V%C
MZE2"N??&>:H6/P@\+V=PLL@O+L*<[+B8;3]=JK0!PGPF\*3ZGKL>MW$96QLF
M+(6'^ME[ ?[O4GU '>O<;[_D'W/_ %R;^1J2""&U@2"WBCAAC&U(XU"JH] !
MTI[*&4JP!4C!!'!% 'R#7T1\)?\ DG]I_P!=9?\ T,U:E^&7@Z:5I&T90S')
M"3RJ/P ; _"NDT_3[32K"*QL8%@MH@0D:]!DY/ZDF@#RGXY_\P'_ +>/_:=<
M%X"_Y'O1O^OE:^A];\-Z1XBBCBU:R2Y6+.PEF4KG&<%2",X'Y51TSP%X8T:^
M2]L=*2.XC.4=I'?:?4!F(!H Z.O*OC?_ ,@G2?\ KN__ *"*]5K-UG0=+\06
MJVVJV:7,2MN4,2"IZ<$$$4 ?-_@K_D=]$_Z_(O\ T(5]/RQ)-$\4BAD=2K*>
MX/45SNF^ /"^DWT5[9:2B7$3;D=Y7?:?4!F(S72T ?+WBWPQ=>%=<FLID<VY
M8M;3,.)$SP<COZBJVB>)=8\.R2/I-]);&3&\ !E;'3*L"._I7TWJVBZ;KMF;
M34[.*YAZ@..5/JI'(/N#7%R_!GPQ)-O6;48E_P">:3+M_52?UH \:U#6==\5
M7T,=[=7%].S;88@.-Q[*HX!/L*JZMI=SHNIS:?>!1<0X$@5L@$@'&?;-?27A
M[P7H7AGY]/LQ]H(P;B4[Y#]">G7MC-,U3P%X9UK4)+Z_TM9;F3&]UED3=CCD
M*P&?>@#%^$'_ "(B?]?,G]*Y7XX_\A#1_P#KE)_-:]:TK2;#1-/2QTVV6WMD
M)(123R>I).23]:K:WX9T;Q&D:ZM8I<^5G8Q9E9<]<%2#CVH ^?OAU_R4#1_^
MNI_] :OI>N>TCP-X;T*_6^T[3%AN5!"R&5W*Y&#C<QQP2*Z&@#Y KZ"^$'_(
MB)_U\R?TK1F^&?@^>5I7T5 S=0DTB#\ & %=!IFEV.C6*66G6R6]NA)")ZGJ
M2>I- %RODO5/^0M>_P#7=_\ T(U]:5RUW\./"5[=27,^CIYLC%F*32("3ST5
M@* ,;X-?\B1)_P!?DG_H*URWQE\/+;ZE#KR7$8%R!%)"[_,648!4=QC&?3\:
M]>TK2+#1+%;+3;5+>W#%MB9Y)ZDD\D_6OF_QQKDVO^++ZXD=C%'(T,"G^&-2
M0/IGK^- &/8ZG?Z8[O87US:.XPS6\K1EAZ'!K27QEXF10HU_4L#UN6)_4UZI
M\&=&LH]!FUCRU>]EF:+S".40 ?*/3)Y/X>E>CSV-G=!A<6D$N_AO,C#9^N:
M/G?3/B;XJTZ56.I-=1@@M'<J'# =L_>'X&O;?!GBZV\7Z0;J./R;B)MD\&[.
MP]B#W!']?2O#?B+::98^-KZWTI(HX$V[XXONI)CY@.PY[#ITXQBNI^"!F_MO
M5 K$0&V4NO8MN^4_EN_.@#VRBBB@#FOB#_R(6L?]</ZBOF6OKJYMH+RVDMKF
M))895*O&XR&![&N4_P"%6^#?^@-_Y-3?_%T >,6/Q$\5:;8PV5IJOEV\"!(T
M^SQ':!T&2N:JZGXU\2:PC1WVL7+QMPT:$1JWU50 :]Q_X5;X-_Z W_DU-_\
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M1410J* %51@ >@J.[M+>_M);6ZA2:"52KQN,AA0!\C5]6^'?^18TG_KSA_\
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M0YV2;0V,@J>"".A-?3FN>&-&\2+$NK6*7/E$E&W,C+GJ,J0<>U8W_"K?!O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S
M=?T2V\1:)<Z7=Y$<R\.O5&!R&'T(%>=67P5^Q:C!=IXBD!AE61=EKM8$'(PV
M\X/OBO5Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M(\;_  [7QC?V]W_:KVC0Q>5L\D2*1DG/WA@\_H*[>B@#C?!/P]M?!TUS<_;&
MO+N9!&)#'Y81,Y( R>I _(5V5%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>"_$/X?ZG8:U=:IIUM)=V-T[S,(8RQA).6!
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MB!_W><_B<>U>B444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F:-PH 6B
MDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C
M<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %
MHI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-P
MHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@
M!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3
M<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-P
MH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6B
MDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C
M<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %
MHI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-P
MHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:* <T4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (: !CI0:!TH 7 ]*,#THHH ,#THP
M/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,
M#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#TH
MHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*
M,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M# ]*,#THHH ,#TI,#TI:0T ''I1QZ4E%(5Q<#TI<#TI**8PP/2CCTHHH%<,#
MTHP/2BB@8N!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I112 ,#THP/2B
MBF 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z4
M8'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444
M&!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z
M444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>
ME&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%%
M !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z4F!Z4M% " 8I:
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BD)P,FL;5=>M[%""X!I-I:L3=C9R!W%,>9$&2PKS*_\ &K[V\J3BL&X\
M8:A(Y"R'%<\L3%&;JI'K%UX@M;0X<C\ZRY_'>G0, W?WKRBXU>[N#F23-4))
M&D;<QR:PEBY=#-UGT/?].UJVU) T1X-:5>&:!X@FL)50OA17K>BZU!?VR_.-
MU=-*LIK7<UA/F-BBBBMS0**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $- Z4&@=* %HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *0T4AH 6BH9)TB7+&LNYUZVB)!<4$.:1M4?C7+MXF@SPXJ2#Q+
M;LV"XHN+VD>YTE%48-4MY@,,*MK(KCB@I-,?11104+1110 4444 %%)12 6B
MD%+0 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
M"<&C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=
M[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=[4 +1
M2;O:C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C=[4 +12;O:C
M=[4 +12;O:C=[4 +13=U&Z@!U%-W4;J '44W=[4;J '44W=[4;J '44W=1NH
M =13=U+N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM2;O:@!U%-W
M4N[VH 6BF[J-WM0 ZBF[J-U #J*;NHW4 .HIN[VHW4 .HI-WM1N]J %HI-WM
M1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J
M%HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-W
MM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J
M %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM1N]J %HI-WM0#0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I7G7C9CY<@[5Z+7!^
M-K8FUD;%8UU[A%38\I;M3[;FYC!Z;A3&/./2A&VNK>AS7E(XSWGP\8UTF+D
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHK.MM7M;C 612?K6@K!N15G4I)[#J***!A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2CK24HZT .HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC6MVA!P":]NT._2YL8QNRV*[\+4NN5G32E=6-:BBBNLV"BBB@ HHHH ****
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M.*Y)2.N*L65X4"GTT"G5F6@HHHH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 -/6DI3UI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK9=I'2M/(-<\I.3-H120!0.U.I!2U!H@%+24M PHHHH **** "BBB@ HHHH
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MS7+:?K@+!'-='!,)D# UK&2DM#NHUX55>+)LTM-I15&PM%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %*.M)2CK0 ZBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRV#2<L<"B*-W(P.*UK2P&,N.:ZL/@YU7Y%1IN14@L&?!8<5-<6\<$6<<UK!
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M9GI=074RQP-DXXI(;R-X@V1TKE?$NN+;QLH;M7-L:SJ)(Y#Q??JSD YYK/\
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M;+?_ )[)^='VRW_Y[)^=%T!/14'VRW_Y[)^='VRW_P">R?G1= 3T5!]LM_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4D5P6GW45Q?8=QC->F:,UND"A7!HCJ1A_>=S=4844M-5PP&#3JL[K"5%<DK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX>N-T.":37X<QLU9VA2[7"Y[US+W:AY"_=8KR9V><BE%-7[HIPKI/7%HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ-.>S-"C-1I.D@X-25MOL;IIZAFG4VG4#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I1UI*4=: '4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !0>!144\GEQ,?:@#B/&NL;;1X
M5;FO*68L=Q.2:ZCQ;<F2^D&>]<L:\JO/FD<=1W8E%%%8$!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 +7HO@K5"&C@+<5YS6]X8NC!J2<]Z
MUHRY9%P=F>Z@Y&12U3TZ?S[=6SVJY7K)W.P****8!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO<Z7P7:Y)9AWKOQPH%<YX7M/)A!(ZBNDKZS#0Y:21T1V$IU-'6G5T%!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5'4WV6S'VJ]6/K\OEVA/M4R=D)['C?B*7?J4GUK'J_JS^9J,IJA7CR
M=Y,XGN%%%%2(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M]I<GEWR-5&IK9MDZFFMP1[EX9E\VQ!SVK<KE_!4F_3OPKJ*]BF[Q1VQV"BBB
MK*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJUS?0VH
M_>-BB]@+-&:P+GQ19Q9 <5B7OC2!0=D@S6;JQ74ES2.X:144DL!^-9-YX@MK
M,'<0<>]>8ZEXRO)&(BD./K6#<:O>7&?,D)S7//%+H92K=CTN[^(5K$VU16_H
MWB"#5(E*D9->#EBQ))R36OHFLSZ==(/,/EUG#%2YO>)C5=]3WNBL#0]=BOX5
M^8$XK?KOC)25T="=PHHHIC"BBB@ HHHH **** "N \<-AG%=_7 ^-T)+FL:_
MP$5/A/+'ZGZTL7^M7ZTDG4_6EB_UJ_6O*ZG&>R^#A_Q+D^E=77)^#F_XER?2
MNLKUZ7P([8;!1116A04444 %%%% !1110 4444 %%%% !1110 4444 %%-=U
MC4LQP*RKW7[2U4Y<9^M)M+<3=C4DD6-"S$ "N:U/QE:6&Y3R17)^(/&#L2MO
M)Q[&N'N;N:[8M*V<UR5<3;2)C.K;8[#5/&IN2WE,P%<Y<:Y=RY_>M^=9>:.:
MXY592W,7-L?)-),<R,6-1TN.,U=M-+N+Q@(UZ^U0DV3N3:' 9]110,\U[9H=
MM]GLP,8XKC_#'A=[>1)94YKT)$"*% Z5Z.&IN*NSII1MN.HHHKJ-@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#0.
ME!H'2@!:*** "BBB@ HHHH #24II*!!4-T,VSCVJ:F2C=&1ZT >0^((F6Z<G
MUJKH,H2^7/K71>,+%HD9P.M<5I\K170.>]0]SRJ_\4]OTN0/;@CTJ_7/^%[G
MSK,9/:N@%4>G!^Z@I*=24RT8NNV(NK208R<5X+XETZ33;IWVG!-?2$B!T(-<
M=XD\+0Z@C'RP3]*4E<YZ])31X=;ZB"H!&#5Z.\!'6KNL>#[JUD8QQD**YF>"
MZM6(<$8K!P/ KX'70Z!;D>M*]P'4C-<R+]DX8FI(]1![U#B<3P<D]C4MW"WF
M3ZUU=I*&0$5Y\;S#[@:Z?1;]7C )YHL3BJ,N0ZR)ZIZJ<PU)&^0"*COE,D5"
M/(@N66IS3GFD[4EQ^[D.:K/<;N%ZUI%'M4(.:T(;R<1N*WM$O P49KFY;.:8
MY(.*O:8S02!3VHJ+0O&8;]V=N9L]Z Y-9\4I9,YJPDH'4US7/F)TW%EG<:7.
M:@\Y?6CSA5)DI2N4B@_M)3[UZ)I%XL%D26' KSJX<(_F#M2)KTN/+5_:MX2L
M?5Y=B/9PU-S7]3:^E,:-T-5;:WVP@MUJK9QO+)YC]ZU7^2+%3-W.''XIU*ED
M<]J6!)6<%!JYJ;_O35)#4(*/PE:\CRM/TD[;E1[U+.NY:K6+;+T#WIW-*BO3
M9W4+?**LHPK/MY R#'I4X>B,K,^?>DC7@D6K>5(K$CF([U.MT1WKH5:QU0K*
MPS4;=7?.*VO"?R38K%FEWBM7PS)BX-/F3/I<HJJYWPY%%,C.4I^:H^G3N1S2
M".,DUYIXUUG;&41N:[+7]16U@89P<5XWJ]^+N[8.<C-)R2.+%5N5614T^![R
M[#GG)KV'PKIPBME)6O/O#:VXG7.*]5T^]MH8@JD#BDC/"1UNS7Q@8HJ!;V)^
MC"I@P;D51Z8M+29I-U(!QI*0'-+0 M%%%, HHHH I:BI:W8#TKRCQ%"RW63Z
MUZ_,F]2*X#Q7I^'W 5=/<B>Q+X-(#K]*[TUYAX=O1;7 4G%>CVDZSPA@:=1:
MA'8L"EH HK,H0THHQ2'@9H&<KXKN-D#CVKQVY;S+I\^M>H>,)?E85Y:RDW#'
MWKLH+4X\0] ,>5XIGDFK('%+BO3CJCS[V9@ZE:DC(%8.XI)BNVGA$D9R*Y34
M(!%(2!46Y6:WYD:NE39(&:Z!3D"N-TJ<^>!FNP@.Y!7JX=W1Y6(C9EJ)PIK3
ML[E4/-8W2I%D(Z5K."DCD-N\NE,1*]:CM->^SVCQ.W)K):9F&":R+XNK97I7
ME5L+U1Z>$KM:,M7DXGF9AW-(@&VLV&8D\U8$IK*"MH=4W?4N<4A0-5993GFI
MEF&.M:F8R4;*LV>GF]; ZU3F?<173>%%#W2@USUY6.BBKLYO4=+GL9L\X%5X
M[LOQZ5ZWK6@1W-DSA,G%>4W]BUA.P88YK3"XK6S,\3AKZH/,/K32YJ)9E(I2
MP(XKU565CS?8M,<7I/,Q4>['6H9;A1WK*55&L:3)92KBJ#$H^<\4->*.]027
M<9&<UQU6GJ=5*+V+BW(Z9J5"9'4#O7/2WP5N#6KHE_&\ZB0]ZXYS=CLC3U/6
M/!&G'S4<BO4T38H ]*XWPC<6K6\>PC=BNTSGI7FU&V]3N@E86@4M%06%%%-=
MMJ$TA&'X@G\NW?GM7B^INTU^PSGYJ]*\6ZB$1ESVKSJQA-]J! YYKNI1]VYS
MSE=V.Y\'V>$C?%>C1C"@5SOAVP^SVJ9&.*Z,5RU7=FT%9"T4HHJ"PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &'J:Y#7X9GE8HI(]JZ]NM1/#&_P!Y0:PQ%%5H<K-:53V<N8\P
M,=RC<QM^5.&_N#7H4^F0R]$ K.FT!6!Q7B5,G:UBSTHYBNJ..W8I&E"C)-='
M)X<.20:Y7Q3$=+@SGK7/'*:TIJ-C?Z[3M>XY+Z%GV[QFK2L#R#Q7G-A//->[
M@QP37<VDI$(!ZT9EE;P;23N7A\3[4T-U02N!2&;BJD\I/2O*4;;G0Y$5Q* #
MS6'=SMDD'I6C,":R[I:ZJ5C";=C9\,WDDDVTY-=FL+N,D'%<GX(M/-N^E>D7
MJI:VHX&<5[5'#7ASMG%+$6ER(XZZ4K,14.VK-RWF3%JBQ7F59+F=CU:<7RJY
M 5J)U^4U;*U&RYXI*0VB_P"'0?-KOXO]2OTKD/#MO\V<5V*\(!7T6!5J9X&-
M=Z@HI:;2UVG&(Q '-4KR_CMHF.X;@*BU6_%K"QKAKO4GNYCACC-<.+QBH1\R
M92L:\^M23N1SBH0[2'))JA"*O1FOE<1B:M5^\S!MLG48J3%,4\4^N(D0]*KR
M]*L'I5>4\4X[DF9=' -5;&W\^]0XXS5JX4R$JHK<\/Z2?OL*]? 474FC6"NS
MIM/@$-NF/2KE-1=J >E.KZQ*RL= WO3J**8!1110 4444 %(:6B@!M%.Q1B@
M!O'I1@>E.Q1B@!HX[44[%% #<4HH-5[J86\18^E -V)S)&OWF JO=W$/V=OG
M'3UK@M7\5-'<M$I_6L\:[-,N"QK.;T:/,K9E3IMQ.GEEC+GYA33)'_>%<VEX
M['J:E\YSW-?/3R^<I-W/(GF$+W-MGC /S"LZXN#GBJX9SW-+CUK:CERB[R=S
MEJYDWI%#X[QXSD9I)KZ1Q]XTP@8J%Z].*Y59'&\56EHV5YG9NI-9TY S5Z6L
MVZ? -4BH7>YF7+9?BNE\+:L^GR $<&N:"&68?6MR&WP@(X-85JWLVK'O8!<G
MO'K5EJ,%S$K>8-Q'K5X$'D5Y):W\]FX.XD5V6D>(%F 5SBMZ.*C/0]J%92.J
MHJ*.995RK9I]=1L.HI*,T 074HBA8D]J\]UB_:>=DSP#74>(+WR8R :\_FFW
MSLV>IKDQ$^B/"S2L_@0\&G9J /3@]<9X=B8&I$N9(V^4G-5]^!6EI-B;JX5L
M<9JH1;>AK0I.I-*)U7AN666+,@/XUT8JK9VJV\2A1CBK(KTXJRL?7TH<D%$=
M110:HU"BFG Y)XJ":]@B',@% KDYSZ4R1T"D.0!6%>^)[>W! <'\:Y;4O&>[
M*H?UK*=2,495*\(+4T?$PMARC+FN021BY':JD^IRWEP 7)!-=/::*9K8.!R1
M7!4C[5MQ1X]6/MY-Q1BN"YPO)K9L?#K21";:<U:TW0V:[PZG -=U:VB00!-H
MJZ&'NO>-L+A+IN1Q"VDD!V[3BK$8(ZBNLFL8Y/X15-])!Z5,\&^A-7+I7]UF
M(2,5!(P]:VVT<GO43:(3WK+ZI,P^H5#GI6JI(U=2= )[U7G\/$+Q5_5IHU6#
MJ(Y&9QZU56?;)UK:O]&EB!(!-<W<K)$^"I%3[-Q6I+I2CN=_X<U#*JFZNR4Y
M4&O)_#UX4N47/>O4+23S(5/M7?AY-QL>GA)WA8LT4VE%=!UBT444 %%%% !1
M110 4444 %%%% !1110 4HZTE*.M #J*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF/&,WE6/X5T]<9
MX^?98#FLZKM!DS^$\FNWWW+MZU7I[G<Y-,KR&<04444@"BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*3-&:!BT444 %%%%( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N/\>1^98"NPKG/%D/FV7X5G55X,F>QXE*NV1A4=6KY-EW(OI56O(>Y
MQ!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M37)4Q+EHC&55LDEF>60LY)S4><]J2I8H9)6 12:YMS(CP: ,G&*Z"S\+W-T
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M.>'+L2640+=JZ($&N1JQU)W'"C- Z44BA:*2EH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-;0H^T@8KK_#^J%)51FJ)Q-(L]#HJ&WG$R @U-6)J@%+2"EH&%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AH'2@T#I0
MM%%% !1110 4Q_N&GTU_N&@&<'XL/[LUR&AG&J@^]=CXO3$1KB]);R[\'WK-
M[GC5OXR/7].8"W!]JY;QEJ8BB8!NU;VGS;M.W#TKS7QK<.TA&:M['?4E:F<:
M4?4M0(&3\U>O>$-(%O:1DKS7G_@^R$M_N<9YKVO38%BMU"C'%*)EA;/4M@;0
M *=2T51WB$#TJO/:)*""HJP:!2$SE-4\.)."0*XV_P##\MLQ9 :]=*@]15:>
MSAE0@H*9E*%]CQJ*[N+*7G<,5T^E>*",*S5>UGPT)-S(F*XVZT6XMG)4D4KF
M>L3U&SUF*91\XK4CN$D'#"O'+2ZN+0_,YXKI-/\ $NSAFZ47'"KW/0]P]:7<
M*XD^,(E;&:OVGB2.XP0:+FSJ(ZD45EIJJ$=:7^U$]: YT:=,9PM9QU1,=:H7
MFL*JG!IASHT;VZC\I@6'2O+/$T89W9>>:W+R_EN&(4FJ+Z;+=#Y@3FM(3Y65
M&JXL\\=9-V,&M#3=+EN)E.P]:[2#P@TL@.VNITKPTEK@L@KIEB6XV.EU^:-B
M/PQI/V9%++78*H P*CAA2) %&,5+7&]3G8M%%%( HHHH **** "FGK3J3O2
MR]7E\NU?Z5XCXEF,EYC/>O9/$#[+9_I7B6L-YU_@?WJF1Y^*O>QV/@RS#;21
MU%:?BKPVMU;NP3G'I3_!D&V&,^U=W-;I+%M9<\4TM#3#0]T^7-0TZ72[S[I
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MI1L!QNKT*3M#4XIJ\]#WS2CFUC^E:%9^F*4M8_I6A7!/<[8[!1BBBI&%%%%
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M=.#_ (T?ZZ'/B_X+_KJ<9!/);7$<\+;9(V#*V,X(^M:__"7Z[_S_ '_D)/\
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MOIU54.WUKU?PSX=2TA#.N#[UO1I.;+A#F8_P]X:AM(E=XQG%=2B+&NU1@4H
M4 #H*6O3C%15D=:26P44450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!#0.E!H'2@!:*** "BBB@ I&Z4M%
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M"BL4;!1113 **** "BBB@ HHHH *XGXA?\P[_MK_ .R5VU<3\0O^8=_VU_\
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M"<9KKM T&'2X-JJ!Q7H5\3"4;QW.:G2:>IM0KL@1?05(O6DIR]:\PZQ]%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% ##$C=5!I!#&.B"I** (S#&?X!^5'D1?W%_*I** (
M_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I*
M* (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_
M*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?
MW%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'
MD1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+
M^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B_N+^5'D1?W%_*I** (_(B
M_N+^5'D1?W%_*I** (_(B_N+^5*(8QT04^B@ Z4444 %%%% #70.I4]Z\X\8
M^'OEDN56O2:J:A9K>VK1, <BLZD%-6)E'F1\[LI1MI&"*!71>+=+_LV^V[<
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MZ7\I2L-(T_3-QL[9(F88+9))'ID\U=HHK)R<G=FJ22L@HHHI#"BBB@ HHHH
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M33&IZJ*>>.M02W"1CJ,TFTEJ)M+<CELHY!R!6#J>F0!&.>:OW.J[00*Y^^U
MR9RV*X:^(II66K."OB*:5D<_=PB)FQ7-ZD^6 K=O[U%!PP-<Z^^\N $!//:N
MK*,+4G651JR1Q1DV=EX$4BX!KU%:XCPAI;6R+(RXR*[<5Z&-FI578]>@K0U%
MILB>8FT]Z=0.M<AL>7^,+$V]\)%7@5M>#=1$B;&/(XK3\3:<+FV=\9(%>?:=
M?-I-RV3@ U[%/_:,/R]4<$_W57FZ'L)D10"2.:4,&Z5YC?\ CDJ$5375>'->
M74HU7/.*\Z>&G"/,T=4:T9.R.EI*7O1BN<U$V@]0*,#M2XHQ3 2G+UHQ0.M
M#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'::ZV[@@\UZ-H6OE$5<\4(VP<]#TH&EK.L=0CN$!+#-:"L#TJCT4[CJ**3-
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M36*3'D"HTTN-#G K3G(Y3C[71)"H)4U-)HLJ\[37:I J#@"G-$K#H*CF'RG
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MQ.*>Z(H;6WM_]1!%%_N(%_E4M%%)N^XTK!1110 4444 %%%% !1110 4444
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M$@[BIA6%X;O?M%@@SSBMVOEIQY96/<B[JX4445(PI1UI*4=: '4444 %%%%
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MP]3GB==.5T34445T&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1117HG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>:ND>8^!6WH6GJUTI([UC33;U-).RT)]&\+LRAG%=9:Z!#$!E!^5:MK;K%&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY XKR?Q5XB:=W2-SUK0\5:\Q9DC>O/[B1IG+-WKGE.QLHE=Y&E.7.35>5-W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ-FM[:M$PR#7C7BC1GL;T[$
M^6O<*YOQ+HZ7=K)(%!;%85Z?/$SJ1NCP^GQ2-&X93@BK-_9R6UPP92%SZ53K
MRVFF<NQV^@^,Y[4+ QPHKO\ 3_$=O<H"\@S]:\*!P>"15NVU">W88=L?6NBG
MB)1T9I&HT?0"WUNPR)!5>]U6WMH6/F#.*\?@\43Q+@EC5>]U^>Z0C<16[Q2L
M6ZRL6_%&LM=WCJIRM<R:5W9VW,<FFUPRDY.Y@W=DUM$\TJHJYR:]K\+Z5';:
M=%(1\Q%>>>#-+-W<[F3C/<5[!:PB"W6,=J[<+3^T;T8]2:BBBNTW"BBB@ HH
MHH **** "BBB@ HHI&8*I)H \Y^($V),9[5YHQR3]:[?Q_<>9>A%-</TXKRJ
M[O-G'4?O#XEW2 5Z_P""H\6"FO);)-]P!BO9_",.S3@2.U:85>\716IT>,C%
M>>_$2TVV@=17H=<_XJT_[?8E<9P*[*T>:#1O-7B>&=:2KE]:M;7;Q%2,=.*K
M>4W]QORKR6K'$,HJ3RG_ +C?E1Y+_P!QORH CHI64J<$$?6DI %&*.IJY!I\
MTWW5/Y4TK@5,&C!]*UXM!N9& VL*OKX3N&('S<U2IR?0KE9S.T^E&T^E=K'X
M$G< [VYJ]%\-IG4$SL/QJU0J/H/V<CSP@CK25Z2/AFW>8G\:D'PU4?\ +2G]
M7J=A^RD>:A">BFG+;RL>(S7J47P^2/JP-7H?!<49YP:M8:8U29Y,FEW;KD1'
M\J:VGW*]8FKW"#0((H]I1?RJ.;PW!)T5:OZHRO8GB!MI5ZQFHRC#JI%>R3>#
MHI.P%49? "29PP%0\+,GV3/)\4F/:O1;WX<O&C21R'CTKBM1TN:PE*LK$ ]<
M5C.E*&Z(<&MR@/I71:!XCGTZ5(\G9GK7.4H.*F,G%W0DVCWK1M9COX02PSBM
MFO#- U^6PN$1B=I.,U[/IU['=VD;JX)(KTZ-7G1U4Y\R+E%%%;F@4444 %%%
M% !1110 4444 -D_U;?0UX;XM8_VQ*/>O<G_ -6WTKP[Q;_R&)?K7)B_A1C6
MV.?[BN@\-#-TO^]7/CJ*Z#PS_P ?2_[U<5/XC".Y[78_\><?TJQ5>Q_X\X_I
M5BO76QVH****8!1110 4444 %%%% !1110 4444 %%%% !1110 AH'2@T#I0
M M%%%  :2EI* *NH_P#'HWTKQ#QO_KVKV_4?^/1OI7B/C;F<T G8XRRG\F<<
M]Z[>RN!<6P7/:N!,+;\BNDT*X;S5C->1C8+='=0G?0V8U^SWBN.,&O3_  QJ
M GA"D]!7F=_\H+#TK:\':F1)M+=Z>"J-JQ.)B>K@YI:BMWWPJWK4M>JCC#-&
M:**8!FEI*6@ HHHH **** "C%%% "44&DH$+4$]NDRD,H-3T4 <?J_@^WOMQ
M*#GVKS3Q#\-$+,T:'\!7O9 /457EM8I?O(#2L%CY1O/!5W;.=D3<>U4T\/W^
M_;Y+?E7U3<:!;3?\LE_*J@\)VH;/E+^5%D2Z:9\[67@VZN&&^%ORKO/#_P .
M4(#2)@_2O6H-"MH<8B7\JT(K6*(85 *+"]G$YK2?"EO9JN%'%=-#;)"@"J*E
MP!TI,T[%I)"U0U*?RH6Y[5>)P*YO7[G:I&:3'8Y&]F,URPSWJ$G"XI I:=C4
M@C+-BL7JS6.QMZ%;AV5C7;J@6WP/2N=T&TVQ UTA_P!7CVK5*QG.6IP?B./Y
MF-<]IJA;P'WKJO$L>$)KE+$XNA]:Y9OWS:'PGINDMF$?2M,5D:(=T K8QBNI
M/0Q88JCJ*;H&J]5>[&832>H(\LUTB&YQTYJ_H+X=3FLOQ:2E\/K5O0Y/N<UR
MM6D;K5'IUGS;J:F(!&#5;3VW6JU8/6NN.Q@SFO$>B1WENY*CI7SEXVTDZ;.[
MJ,<U]73Q"2%@:\5^)^@[X&95JA7/%+6;>@!J9EP=RFJ4T36DFWTIT=V2<$4P
M.J\/^))]-G4;CC->\>%/%B7T$:,XSCUKYF'.&'%=)X9\1R:;=KECC- SZPBD
M61-P-/S7(>%/$$>H6:$N,D>M=:,$ @TA#Z*!10 4444 %%%% #<<U7NY!'"V
M3VJSWKGO$=\+>%AGM0!P?BR[\TLH/>N/5-RUI:C<-<W+#.>:B@MBS 4 :NC6
M!>/?CI53Q-^[3%=IH5AMTYG(Z"N)\82#S"H[4 4?!\6[5 ?>O=]*7;;*/:O$
MO Z;M1'UKW*Q7;"![4 6J:_,;?2G4C#Y#0!YEXMBP7;WKE=*)6\4^]=SXN@_
M=,:XVPB"MN]Z\^K_ !#IA\)ZKH4F^ ?2M2XM4GC(8"L#PN^Z*NFKNCL8,\I\
M8^&Q&CSQIS["N"LKN6UG$;\<U]"ZEIR7\!0@<BO&_%WA\Z?=-(HX'-<F)H*2
MN;4:EF286ZAW=3BHM-OY-/O,\@9K.T341(3&QZ<5KW-F'3>M>13DZ4[';.*F
MCT_0M6%W;+EN36[G(XKQ_0]:>RN5B8\ UZEIE^EY"&##I7NT:BFCSJD.5E^B
MBC%;F-@I"N1BG44,I'/ZWX?BU*%@RCI7B7BSP2UK+))%&?RKZ-P".:RM1T:*
M_C*L@YJHR:(E&Y\C36<]O)AD(J-IY(Z^A=6^&4=T6=0!7%:E\,7A8X!-=*G%
MHSY&>5F]>J,UW(6.*]+;X=RDXVFGV_PPDFD (/Y5G[2ST*4#S.VCGN'&%)KM
M_#OA:XOY4+QG&?2O1=%^$XBVNW:O1-'\,0::H&Q<CVHE58_9HS?"OAN/3X$8
MH,X]*[(*%& *1(U08 Q3ZQ;;+2$Q3J**0PHHHH **** "C%%% "4E.I#2&-9
M@HS7'^)M9$,3QAN<5OZK>K;6['<.E>2^(-0:[O.&XS4R=D5%7,.\>2ZG8G)&
M:I2PX'2MV*$!,D5G78(<X6N.4FS91L1:7:EKI3CO7L/A>V58!\HKS32$ 921
M7J7AMAY(K:B[F=0Z90 HXI:%Z4M=)D4M13?:LOM7SU\2;3R[HG%?1MPFZ,BO
M#OBA; 3YQ0!Q?@BW2:\VN!UKU:^\"V]_I>\(,D>E>5>#V\G4!]:^E-#VRZ3'
MD9R* /F/Q)X&FL9&:*(X'M7$36T]NY5U(Q7V7J7AVWU"-E*+S[5YGXE^%BLK
MR1CWXH ^?1]:O6MR]NP=6/%:'B'P[/I$K8C8@'TK#CD8+\RXH ]'\,^.9[.9
M$9SC/<U[CX?\70ZA"@:09QZU\F1LV\,IQ73:1XIFTEU^<D?6@#ZXCN$E4%3F
MI17DGA'Q^EX$C=P/J:]/L[^&YC#+(#^- %VBDW ]#2T %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRC^E6:JZ<<V,7TJU7L+8[D%%%%, HHHH **** "BBB@ HHHH **** "BBB@
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M4+92&!.*^1XY#!)YB=17JW@#Q0Z%(I'ZG'6D(]_!R,TM5;&X6XMD8'.15J@
MHHHH **** (9Y/+0L:\X\8ZCN;:K5W6KR^5:.WH*\>UZ\\^=AGH: *4.&DR:
MV-,MQ+=!<5BVQ&178^'+0O<JQ'% '6PP"WTE^,?+7CWBIR]TPSWKVC5/W.FN
M!_=KQ'76\R]8>] &YX!@)OE.*]J@3:@'M7E/@. +<(U>M)]T4 +2'[II:.U
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MYYM52&0G:8V/Z5[A52BXVN3&2E>P444=JDH**!R.F** "BBB@ HHHH ****
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MTP6(C1;@K^G^1Z&$QE&51*3MZER#)P36A$:SX#P*T(J^"J'TD2VAJ8=*@6I
MQ["N>US2X\TQC3MCM_":L0Z=)-VK>GA:M3X41*K".[,Z0G' J!;>2X?:%-=1
M;Z&V<M6K:Z5%"<E17KX;)ZC:<SCJXU)6B9.D:&(PLC#\ZZ:-!&H %(%"\ <4
M_-?2T:,*4>6)YDYN;NQ:*,T9K8@**,T9H **,TE "&@J",&@T4 9M]H\-XA&
MP9/M7"ZYX4DMMSQ9_"O3,U'-"DZD.,U$H)HVI5Y4WH>"RI-!-M=6X]16[I3+
M/A20*[?5_"\5PK-&@!KA;O3Y](G+C. :X*^$C/XCN;IXA::,Z6/3F(RN34ZZ
M9(>QJMX?\10N5BE'/O7=6_D3QAU K"&549:G!4IRINS.3&DR'L::^ER*.AKM
M/*C_ +HI#%$?X:U_LJA;8SN>>7$$L'\)JA)+(.JG\J]*FL()?X!65?:$DJ'8
MN*Y*N3I:P'<\^EN*R+ZX9<%2>M=#JFCR6CLQZ5SUY#E1GUKSO9NC.S&>H^"K
MKS-(0,<G%=1BO-_".I);0I&S 5U\WB*VB ^<?G7U6'DYTTS-R2-?O2USC>*[
M8?Q#\Z;_ ,)?;9QD?G71R,CVD.YTM%8</B:VD(^8?G6G!?PW'W7%)Q:*4XO8
MM44F:,TBAK!6&"*P]7T"*_C;"C)K=-)GM2:3W&FUL>,ZUX2ELI2Z*2/:LZU1
MXVVNA&/45[A<6<,Z'S%!KS_Q5:VUB"R  T14KV1YF,P-.K%RO9F+$5P.:L@K
MZUR#:ULE([4'7&/0FNF-&;Z'RU3!34K([(,@'WA3@Z?WA^=<7_;+MW-*-3E/
M\1JUA9LS>#EU9V9D3^\*C=E(ZBN3749<_>-6X-3/0FF\+-(EX64=4:LRYJ#H
M::+H..M1-+SUKS<5A(U(M-:GM9/FM?!5E=^Z61TI3TJ**3=Q3G<**^7E3DI\
MB/UVAB85:*JK8WM!=([E68@<UT6K^*8K"+"L#Q7FKZBT)^0XK)O[Z>Y;YG)%
M?9Y7E\HTDZA\)G.:1G6:I'1:EXY>9F"L16!-K=U=D[)&.?>L2:-B373^#M%-
M]+\PR*]1QITU>QXL9U*KM<R)'O&Y=FQ[U$$E/5C7J&K^%$CM R@ XKA;FT,,
MQ3'2MJ$Z=38RQ%.K2^(RQ"YZFK-L\EM('4D8J<14OE9KI]DGNCE59K8Z;1?%
M\EO*L<C$CWKTBQUF*\LR^\9Q7B(AP<CK6G9ZM/:Q%-YQ7%B,"I:Q.[#9@XZ3
M-[Q9J1F<JK<9KAY$WG)K2GNC<L2QS55EKNI4E""B<=6LZDW(SVB]JEL;'[7<
M",#O4KK5_066&_5F'&:SK-1@V:4;SDD=79>&'MK'SER"!5"YO9+0'S,\>M>A
MZ;>6]Q9B,XY%<?XLL$WMY>,'TKYV4FY-GTL(I12,FW9-5A=@ "*R+BU:*1@0
M>M:.BAK;<,<5:U(QS+\HP:]/ 8NSY)GE9AA+KVD#FRE-9*LNF&Q3=M>YRH\2
M]BFT7>FYQP:N%:@DCP<U-K%J1L>'9ME]&/>O9;)]UNGTKP[1GVZ@GUKVG1WW
MVR_2O$S./O)GN9=*\6C2I:2EKRCU I/7Z4M)ZT ><^,L[W-<$C=:]&\9VY,3
MN!VKS)&VN0?6OILNG>E8^?Q\?WA.QJ%C4C-D5 QKN9Q11'N*RJ0>AKU#P7J?
MF!8RW2O+7-;GA74C;7HRU>=C:?/39W82IR3/=@0W(I:IZ;/]HM%?/45<KYQJ
MVA[R=PHHHH&%8^O:<-0M6R.@K8J.9=T3+ZTXR<9)H4E=69\[:S$UIJ$B$8 -
M4C.-G6N]\6^&Y)9FD1>2?2N5B\*W4N!@_E7T-'%1<+MGCU<.^;0Q))<C@U4E
M,K*0JD_A7<VO@&ZD()S^5=-IWP^VX,BY_"LJF-@BX8:3.0\$"X6Y3,; 9]*]
MUM<_9DSZ"LC3/#EM8@8B&16XHV@ =!7D5ZGM)7/1I0Y%8<*6D%+6)J%%%% !
M1110 4HZTE*.M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M J087I112&'6C%%% !1110 4444 %%%% !2CK24HZT .HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(MFD D<U6%7OCH_$=8****](Z@HHHH **** "BBHIKB.!=TC "@!TK!8F).
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M_B-8%X96"]C7@EI(UOJV#Q\U 'UKX6OA<6$7.>*Z2O.?A_=^99PC/85Z-VH
M**3-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ,M0^497"CK5MUK3T&P2>['F=,UC5DH1N=-"'M)*)T'AKPVLL*R2)4?B+0A
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MR/:MJ*WCA7"@5)16+DWN:J*6PG>C%+12&%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!Z+12#H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*?O5O?#69_M4*X.,T ?1<9S&I]J?44'^H3Z5+0 4444 %%%% !1110 4444
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MYG!6WAZ[=P6'%=-8:!"B#S5Y^E;ZQJ@P *<17-<]&AEM"CLKE>&SA@&$%3$
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M7/&K0Y)M!13<G-.JS(*4=:2E'6@!U%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0T#I0:!TH 6BBB@ HHHH
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MK6KL3!78_P ,\S+]:]@T_P#X]4^E>0>&1^^7ZUZ_8?\ 'JGTJ:&Q516+5%%
MK<R%J*?F,_2I::R[@128SRKQ&-NHL3TS5;3I%:Z3'K7:ZUX?2[9GQR:S-/\
M#0BG#$=#7+.GS2N:1G96.NTT8MT^E: JO;1>7$J^@JS75%61FW<****8AII
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** *FI<:?+_NUX;KIS>/\ [U>Z:@-U
MC*/:O#_$<1CNV..K5QXO9&%8Q>YKI_!N/[6B^M<Q6SX:O%M-31W/ -<=-VDC
M&.Y[ROW12%U7JP'XURUQXRLXX0-PSBN-UOQE)/D6TA'T->E.O&*.IU$CTR[U
M>"VS\ZG'O7.ZAXWA@5E7&:\OEUF^F^].:IR3R2???-<LL6WL8NL^AU]_XT>=
MCL)K&G\07$O1V%8E+DUSNK)F;FV69K^XE/S2-CZU6+$G.>:,9[TZ.-G<*O)-
M1>Y(VK=E82WDH5%./I6MIGA>ZO)%;:<5Z;HGAJ"TB5I(QNQZ5O2H2F]32%-R
M.9T#P41MFD''O7?6>G0VL8 1<CVJVD:QKM08%.KT(4HP6ATQ@D%%%%:%!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKV2/B-?I7D?@F/-RC&O75^X/I6-;61Z. 5J8M+24M8G:%%%% !1110 4444
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M&KL:0W)M&3$Z?6O0XO\ 4K]*X#2/]>GUKT"+_5+]*BAL.KN/HHHKI,@H-%%
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MVBG.>*]W#U5.)P5(69H32".,L:\U\:>(!!E U=OK=X+>R<YYQ7A/B:[>^NF
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M_P!$C^E6:ZXNZ,&%%%%4(2L#Q2F[3W^E;]8WB1=VGM]* /F_75VZW_P*O6/
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MOS!=QPYZFO6D.84)[BOKL'4YZ:/-JQM(?FJEY?QVL9+&HM0U".VC/S &O/\
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MG[&M=H.@KVJ'\-'R>-?[YA2CK24HZUL<@ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRQ!0:RY1ASBF@GO6<-RI%J)\MN:K W3.$49!JG#&TK;0*ZS1-%+%785L26M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3Y2U;'C+76U.^:VC8E<]JZ3P!H/EQQS,GO43_>5+(Z*5Z%!M]3T;2;"*UMD
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M)2CK0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $- Z4&@=*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#0.E!H'2@!:*0T9H 6BD
MS2T )WJEJ2YM)/I5VJVH<V<GTH \,\3<7;?6MCP3.#=(M9'BD?Z4_P!:N^!_
M^0@GUH ]KA_U8^E25'#_ *M?I4E  :2EHH$)BC%+10,S]4C#0'Z5YAK3B.X9
M?>O5[M-\1'M7E_B2V*W3'%95(WU-(2L:'A:?&!GO7H<!S$*\J\/S^5*JD]Z]
M/LW#0*?:E38IEJDHS16R1FA111T%5+B]C@&6-#=BMRV2!WJI=7J0(236%>ZZ
M!D1MS6-->W-T".2#6%2M&)4:;98U;4[>Y)3&37+SZ#]K8NB]:V8;'>^Z05I;
MXK>/ Q7%.LJFAT1ARGG-]83Z>2>0!4%GJXWA')KL;^T_M!RH&0:Y^\\*S0DR
M1QGCFLY87F5T:*K8LF*.XCR ,U0:.>TDWH2!55;JXLGVRY %:,5W%=( 2":X
M[3HLU]VHC:T;Q9]F98Y7->@:?K$-_;Y4CI7D$VG GS$'-7=/U2[L$*@D"O0H
MXQ-69S5*#3T.N\2$-T(K!MEY%9E]K[S8#M5S3;R.7;SS5N:E+0E1:1Z%H0_T
M<5O#I6+H0!M@16U7=#8PD%%%'-60%)2TA% T,E^X:X+6O^/MOK7>R_<-<'K0
M_P!*;ZUA67NFE/XAFF?ZU?K79QS+#;@D]J\^BNOL[9SC%76UR25-BM7/0FHH
MTJP<F:&K^(T4M&AYKGL3WTF_)P:>ME]IF+N.M7D,5HNT<5A7Q#D[(J%.VXZV
MM%@CW.!FJ]Q<;SL3-)+<RSN%CY!K6TS1S(0\BU%&A*;NRY5%%613T_1YIW#L
M.#786%@EO& 5YJQ:VJP( !TJSBO4A344<DI-B  #BBBEK4D!2TE+0 4444 %
M%%% !1110 4444 %%%% !1110 4444 13Q+-$489!KRSQYX32XA>2.,9 )Z5
MZL3S5'4;1;N!E89R*!'QC?P/9:D\9! !IZ29&1UKUSQOX%"-)<11\GGI7D]Q
M:O9SE'&,&@#I?#7B*33;A%+D#-?0'A7Q)%J5J%#@G%?+B %@P[5VWA7Q,^F'
M#/@?6DQGJGC"=2C\UQ=A(K2@>]-N_$::GE-^2:=I<0-RN.A->;43]H=,/A/5
M/":@0\5U=<[X<B"0#Z5T5>C'8YGN%%%%4 4&B@T )7-:^^%85TM<EXD8@FHJ
M?"5'<Y.(_OS]:ZWP^N)0:Y"#F?\ &NVT!>5KCP_Q&]78Z6BEHKO.82B@T4"%
M%<YXDAWPL<=JZ,5EZM%YEN_TI/8:/%;U0MVP;UJ5M%%U:[HU&XU8U:WVWC''
M>K5C?)#"$)%<UDWJ;7:6ARF^32KQ8I#WKLK">.[@]\5ROB"+[3<^:G.*-(U)
MK9@KG%>5C*.MT=M&I=69K:A%+:.9%.!FKWA^[\^Y57/.>]/=H[^ 9P>*S(UD
MT^[WKP :SPM51=F%:+:T/9=-B581C'2M"N,\.>(%G15=^:[!'#H&'>OH*;36
MAYS5F/I"P7DTM07+;(B:MDGG7CR\_P!("@UR$"^9*A]370>,")KK/O69IT >
M1!CO7F3=ZECJBK0N>E^'+0+8H^.U=$O:LW1%VZ<@]JTAUKOBK(YV[L=1116A
M(4AI:0T ,D.(F^E>7^*/FE<>]>FW#$0O]*\P\0-NN'!]:YZSM$TAN8&C1$Z@
MHQWKU_1X]D"_2O-=#MP;U6QWKU2P4+"/I66&+JERBBBNTP"BBB@ H/2BB@#S
M;QU%NCD/M7E6DDQZC_P*O8/&RY@D^E>.V[&/4A_O4 >^^&&W6<?TKH)7"+DF
MN.\+WR1V2;SVJ+Q%XH2!&5'Y^M #/%/B)+6-T#\XKRFXOI=2N&Y)&:GU749M
M2N#DD@FFVT$=N,G@F@!#M@C!(YJSI5E)J%VH4$@FI;6P>_F"@9&:]&\->'$M
M520I@B@#0\/Z"ME"I9>:Z=5"J *5%"J!Z4N* %%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 T]:2E/6DH **** "@_=-%!Z&@#C/%QQ :XJW;FNS\8\6Y-<+;O\
MU?-YHO?.V@]#;A:KL;5F0MTJ]&XQ7@31V)EQ6J5(WD("C-4UD.[ K7L71"":
MVPN%567O.R(J5.5:$D>B"[QYJ\5O6>FPVB *HXJ.*^C"@9%7$GC<<-7U^$HT
M*4>6!YU24I.[)./2EI 0>E+7:C(6FNBR+M(&#3J0TP..\3>&X[B-G1>?:O,9
M9+C1;WY,@ U[W,@DA8$=17E7C+3%C+N!UK>E*_NL\G'T5#]['<Z7PMXI2]B2
M)W&[%=B&##*]*^>M$O'TZ_#;CC->W:#J4=Y8H=V6(J:D.5W.C!XGVL;/<V0:
M=313JR.X**** "D/-+330 AJMJ5Q]ELVESC JT .:XKQEK?DVSP TUJS.K-4
MX.3.&\3ZM)>7C*"2N<5CV\0!Y[U5DN6DE+=>:L6TA:09KJ7NQ/E:TI5JFIK0
MV^1G%6EAQVI8<*@J3>*\*KFE2,G%(]:EDM.4;MC53%/  I-PI"P]:JEG$E\:
M,JV01:]QDPQ2$46\3ROM49J[)ITZKG8:]>AC*==7B>%B<LKT-6M#.85"]6)%
M9#AABJ[5TG%&_4KR53FZ5;DJE,W6I9TTT9]R>#6=D;\5<NGZU15<OFN7$VY=
M3Z3(_:*NN78Z#P[>&#4(^>]>Y:-<_:;523VKY[LG\FY5_0U[3X+O?/LADUPT
M)=#[#'PTYCK#2449"\FNH\D6@5"UY;H?F<"A+RV;[L@HN@LSCO'5QLT]QFO"
MYV\R5C[U[/X_D5K)]IS7BH^^?K7)6W/8P"]T]&\!0993CO7LT?$*CVKR;P!C
M8OUKUE2HC7)K6A\)RXYWJ#A6'XFOOL=BY!QD5M]LUPOQ#NC%8'!K23LCDI1Y
MII'A?B.[:YU:5B2<FLV&,NV!3KY_,O&;U-7-%B$MX >E>9-W9]11BHP-*PTT
M[0[+6H(PBX%:)C2*':OI5+&6K91LCEE4<Y'3>$XR;A..,UT/CW38YM.1MHR!
M5+P9:[G5L=ZZ'QIM73\'TK>"]P\^O+]\K'SGJ$?E7#*.QK. &\&MK5TW7<F/
M6L7&'Q7+(]6EN>D> -7^SWT:,V!FO?+.X6Y@5U.>*^4M'O#:72N#CFO?_!.N
M1W5DB,_S5KAJGV6<>98>_P"\B=MBDZ4[L#337:>*0W5M'=0,CJ#D8KQ?QUX,
M$+//#'R>>*]MS@UEZW8)>6CAE!XJ*D%)&U"JZ<KH^4Y4:"4QMP14L,<DYVQ@
MDUJ>*[06VK2@#H34GA-$EU! W3->9*%I6/I(5&X<R*BZ)?OR(F_*K,/AC492
M/W3?E7O>D>';6>S5RHZ>E:T&@VT)&$'Y5TQPMSS9YDT[6/G>;PE>10-)+&PQ
M[5S4D)2X,??.*^A?&TD%G92(% )%>'V5HVH:P<+D%ZBK34-$;X6M*K>4MCT/
MX9:65FWLO''45[1& B;0 ,>U<EX/T@65HC;<9%==WKJHQY8GE8RISU6UL+UH
MQ2T5L<H4444 )32,C!IU)0!SVO>&X-3A.5&:\LUGPA<6DC&&,X'M7N9^E07%
ME%<J0R#FL:E&,SIHXF=(^<0+G3IM[ @CVK5A\<W\*>6I.*]/U?P/;W:LXQGZ
M5P^H>!Y+<DQH3^%<CHSI_">E'$TZZM,PY_$5U>_?8\U4\QG.2QJS-H5Y$V!"
M:1-+O!UB-83E)O4ZZ<(I:#4-3J<U+!I5VS8\HUOZ=X9FF8;T(K+EE+8W<X05
MY,Q(+9YF 09-=7HGAIYG5Y4./I71:5X5C@(=AS]*ZB"V2!0JJ*[*.$ZS/.Q.
M9*W+3*UAI<5I& H%:.!3:=7H)):(\24G)W88HQ113$%(0IX(%+2&@"-K>-NJ
MK^50MI\+GE5_*K5'>E9#4FBJNG0*<[5_*K"QH@P%'Y4ZBBP-MBT4"BF(,444
M4 %%%% !2CK24HZT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!#0.E!H'2@!&..M9&HZO%99W.!6E=/L@+>E>.>.=3F%P55B* .U'C"'>1Y@
M_.M.T\26\V 95_.OG?[7<AR?-/YU8MM>N+:09D;CWH ^F(;V"4 JX-)>D-9O
MCGBO$M+\=M#M#,378VOCB*XM&!/:@#CO%:$7+\=ZL^"/^0@GUK/\0ZE'=RDK
MCDUH^"2#J"4 >U0?ZL?2I*B@_P!6OTJ2@!:*2B@!:*!10 UQE37G_BB+#.V*
M] /0UR'BJWS:2,!VJ9;#1Y_977EWBX/>O5M#NO.@09[5XY"I6Y)/8UZ-X7O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO115VDQ0!6%A;C^$5(EM&G0"I,4M @''2BBB@ I:2EH ****!A1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4:B<3W>&99D#*<BIATJG86QM;<1DDG%6QTKC9]6MA:***!A2&EHH 2B@BC%
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MH **** "BBB@ HHHH **** "E'6DI1UH =1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "&@=*#0.E "T444 %%%% !1110 4444 %%%% !1110
M4444 !I*6DQ0(**,48H *6DQ2T %%%% PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#1U
MHHH$%%%% PHHHH$'%)@>E+12&,*+Z4FQ1VI^#28-,=Q0 .U%*!1B@0448HI
MPHHI: $HHHI@%%&*,4 %%%% "4M%%(8E!I:*8B%XDD&"M49M'MY<YC7\JT\4
MG-%DPN<U<>&()0<1K^59<O@Q">%'Y5W5&T5FZ:97,SSYO!7I4;^#W4<&O1-@
MH,:'M4NA%C51H\P;PM*K=33AX:E]37I1MXS_  BC[-%_=%9O"097MY'G*>$Y
M'/)-6X_!V[[W-=Z(8QT%*$45<</&.PG4;.1M?",,3 E ?PK<MM(@@ Q&O'M6
MGBEK;8ANXQ(U08 I]&*6F(2EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)4G?0^FP&$Y%S2)FY-**;BG"L3U0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 0U%);0RC#H#^%2T4 8E[X<L[D']TN3[5S%]\/8;
M@DJJC\*]"YI.:EQ3-(U9QV9Y%<_#'TQ6?)\,GKVPJ#UI!%&>H%0Z,398RHNI
MX8?AE+GI3X_AC)NY%>X^1%_=%'DQCHHI>QB/Z[4/);+X9;&!8"NRTGP?;6(!
M:-21[5U(4#I2Y-6J<48SKSGNR.&".!0J+BI**6K,A*6D'6EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "E'6DI1UH =1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "&@=*#0.E "T49HS0 449HS0 449HS0 449H
MS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 4
M49HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS
M0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 44
M9HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0
M 449HS0 4E+FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- "44
MN:,T %%&:,T %%&:,T %)2YHS0 E%+FC- !28I<T9H ,449HS0 449HS0 8H
MHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F
M@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &GK24IZTE
M !1110 4444 %%%% !1110 4444 !I*4TE #)$$BD&N3U?2V60R@<5UU0W,"
MSQ%2*YL5AXUX<K+A)Q9P,;<XJR&J]?:4T660<5F E6PW6OB\5A)T)6DM#OA-
M26A8%+FHPU2)&TGW:Y(P<G9%WMN:.FP;Y.<5T<:!$P*XRWN9K67D\5MVVL*<
M!S7U&55:-&'(]&<=92D[FU1G'6J\5]#+T(S2W-RD<1.:]U3BU>YS6,?7+T("
M@/6LS1X?,FW8[U6U2Y%S<A5.:W-"M"BAF%>+%O$8OR1T?! W%C!@"GTK"U+2
MF.745T(X&*1E#C!KUZM&-569@I6.$:ZFMF\OGBIK2.6ZG!.>:Z.;1X)'+%>:
MGMK"*#!5>:XHX*5[2>A?,AUG;"&, BJ.LZ2M]$V%YK8HKTH+E5D8SBIJTCQK
M6/"]U#<X4<$UM^'?!TD;+).N17H4]E#<,&D4$BID41KM4# K5U&T<5/ 4X3Y
MD16EM';0A$&,59IHZTZLSN6@4444#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 48HHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4=:2E'6@!U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %&*** #%&*** #%&*** #%&
M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*
M** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #
M%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&**
M* #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%
M&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&
M*** #%&*** #%&*** #%&*** #%&*** #%)BEHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IZTE*
M>M)0 4444 %%%% !1110 4444 %%%% !28I:* $Q24ZDH BEB652I'%8&H:2
M 2T8KHS32H88-<]?#PK1M)%1DX['#_995D (KH=.L0$!8=:O-8QLV[ JRB!%
M %>?ALKA1J.3-9UG)6,VZTF-P2!S6'<Z;+$25!KL*9)$L@P0*Z:^ I5=4K,B
M-1HX<2W5OR :CFO[R<%<&NPDTR)^H%1KHT2MG KB_L^NM%+0OVL>QSNEZ6\T
M@>05V,$"PQ@ 4V&W6$8 JQ7I87#1H1MU,YS<A,48I:*ZB!,48I:* $Q1BEHH
M 3%&*6B@!,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4HZTE*.M #J*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,48I:* $Q1
MBEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q2;:=10 W91LIU%
M#=E&RG44 -V>]&VG44 -V"C;3J* &[:7%+10 F*,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M
M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%
M+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8H
MQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F
M*,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img205696091_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &0!)$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "DYI:Y;XH>,(_A[\-O%7B>4!H]%TJZU!ES
MC=Y4328_';C\: /*?@G^UOI?Q6MOBEJ^L6%CX*\)>"/$,V@CQ!J6K)]FO/+;
M:TK,Z1K"/FBXW-_K ,],^I:3\6/!6O>)SX<TOQAX?U'Q (1<G2;74X);L1$
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M4L%ABV_*2HD.,9KY7_X33X1ZA^P_X_\ &'B]=$\7?'WQMK%PS+<!9]4TYO/
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M^&-<@AU?3=2GT]-/O[NU6XU!81EKFUCCF=I;<CD28' )QQ7SCK7PA\%?"/\
MX*'_  5T+P;X7TSP[H^K>$-2M-1L;&W"0WT:138$Z])6(499LLV!N)P*\[_9
M5L?"/AGP_P#M1:;X<L?#NE?&C3M=\1Q^%K2.W@BUJ"%;=A''9+@2A%*L L?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KF/B%X;NO&'@K5=$L_[%$M]&("OB+2FU.P>,L/,26V$L7FJR;EQYB@
M$@G(!4]/3=H[<4 >!R_ ?QU/IN@:?+JGPBDL/#\J3Z/:M\,)S%ILB?<>W3^U
M\1,O8H 1VJ]'\)?B;#XLD\4IXE^%J>)I;464FM+\-[H7CVX8,(3-_;&\Q[@#
MMSC('%>X44 >!Z+\#/'WAOQ!JNO:1J_PCTK7-6W?VAJ=C\,;B&YO-S;F\Z5=
M7#29/)W$\\UE:/\ LP^(_#Z6B:6/@KIJ6=ZNI6RV?PHEB$%TH %P@75AME
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M\+MXP7Q:?#FD_P#"5+!]E77/L,7VX0_\\A/MW[.3\N<<UT%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJDNI6]O<1P2W$,<TGW(VD 9N<< G)YJW0 4444 %%%% !1110 4444 %%%%
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M^1/+H5])+&RVMG<I(SRPE#)N1LA#&OS%B:^L=HH50N: /DOXT:/<Z+_P4%^
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M+%%#$H5(T48"J!P  ,8J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M],!G WMZ90 4444 %%%% !7Y_P#_  15_P"36?%/_8YW7_I#8U^@%?G_ /\
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M-_<//]CN([-)[>2/>Q*![>.59%&59U1^&,AD /9Z*** "BBB@ HHHH ****
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MFS5C\#75]\2M(U&>TMM.\.>%+.2VT2VMY ?.EFB1))64+B-8HU,2+G)\R4D
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MJ&EPS3.%X4,S*2P'8-G':N[%8R6*Y;PC&W\J2^\ZL1BGB;<T4K=E8^$_V$/
MO[3"_LT^'9-!\0Z/HGAN:6>72K/7$87"V[2$A@/(8A'?>RY/(8$<$5]T_!K2
M_B'I'AJZB^)&JZ7J^LM=LT,VEJ1&L&Q J'Y$^;<'/3N.:[Z.&.)%6-51%4*J
MJ   .@&.@J0J.N:*F,E4H*@X1TZJ*YOO'/%2G15%QCIUMK]X^O!_VE+J'X9Z
MQX*^,3%X;3PM>-IFO21(6SHM\T<4Y=1RRPSK:7&0"0L,F!R:]XJ*2))D*.H=
M",%6YR/2N XCYI^.7B7Q#X*^'O@4IJT/@V'Q5XC"^(]>OA(J::D]M<2Q1R2Q
M/&\:^<EK;"7>N %4G+5Y5X@\166F^,?"5OXA^+]G?:[8_#'Q.6\4:7?)I\EU
MY=_8O;L&9V; 6!SO#?O?L\C?,A=:^ZI8([B)HY8UDC889) "K#T-0S:/87$@
M>6RMY'"[ S1*2%Y&,XZ<T ?%^N?M#>)H[GP]JGAKQE#XAUS5?@OJ>O67AF![
M>5)]9A^QO'.D48\R61@;H>7DY$$@4##UN_%OQ5X#M/V<_$VJ:9\4QXPT6>]T
M2Y%[JVL174-N[7L))2; V%Q&SF(G";20J*<5]9QZ/8PR1R1V<$<D8PCI$H*C
MG@$#@<G\S1)I=G+"8GM('B+F0QM$I7<3][&.O)Y]Z /EC3O&7B?Q1^TMJB3_
M !/TOPU!HWB"WM[3PC-'*\VJZ3+:1E&C3S@DHEDDE<3B-BC1,I;:C*/5_&4D
MU]^TA\-M-NTW:-%HFMZI#NY4ZA')80Q'IPRP7-WCOAW(^Z:]6^QPB19!$@D5
M=BN%&X+Z ]AP*P_&7@FT\96]CYMS=:=?Z?<K=V.HV+JL]K* 5++N5E(9&9&5
ME965B"#0!\;_  [^-EU=^)OA^5^+9\0ZAJ_COQ3X8DBN-5M?)N;2)-0:Q/E(
MNP,9([';(%.?.51E9%4^U>#]$^.4'BC2GU[5?-T5;A#=Q_VE8ONBS\PVIID;
M'([!U/O7N*:#IL;(4T^U0HVY=L*_*?4<<=ORJY@<<?Y]* / O!^M+JO[3EW=
MZ-XOT_QYHE[H,^]+;RI&\-F.>W$<"2P?*4N"\K%9?WA:VR&*J0O3_ V9X]:^
M*VF1[AH^F^,98M-3RRJ*DMA975P$X^8?:[B[R?7<.U>E7&F+_9]W;6<G]F23
MJX6XM8TW1NPP) &4J6'!^92..01Q5/P?X/T[P/H$&D:8LGD1M)+)+,^^6XFD
M=I)9I&/WG=W=V;N6- &W13=Q].:-U #J*** "BBDH 6BDYI: "BBF[N: '44
M44 %%%% !1110 4444 %%%% !1110 44U6W<]J-U #J*** "BBB@ HHHH **
M** "BBB@ HHHH **** "OFCXK?M/_P#"L_C)JOAWQ)XM\'> /"\>BR-8W6MF
M9]0N+QHU>.Y6(E$DMD)>/8CL[NC#*<5]+U\M?'C3?BSX^^)5WI'AZS^%EGX8
MT>&VFM)/'NGRWUU=32*QDFBVD+&BX"#^+*,2<$4 >G?LR_%N^^.7P5T'QGJ-
MI';7%^]RB26]O)!#=1QW$D4=U''*2\:2I&L@1B2 ^-S8#'U>O.O@7+XN;P#"
MGCK4M#U?Q'%=7$4UQX;4BPV+(PC6)6^883:"#R&!KT6@!GF8Z\&C<?3/TJGK
M5I=7VEW%O9WC:=<RKL6[1%=XL]64,"NX#.-P(SC((XKYF\=^,/$/[._C?QK?
MZ9KFJ>*_">E^ K[Q+J&F:[=M=&ROX9!]C"3']XJW 6Z!3)4?9R5VXP0#ZEWG
MG'-&\\XYKY&^)'Q'\5?LM^%_"?B[4_$&H>,9=8T74VUFQU20&*348-*FU".6
MW50!;INM)83&F%VRJ<%E)/6Z3J'B?X4>,?@ZNL>*=2\2_P#"<&;2]<BU!P\:
MW_V)[N.XMD  @0&WEC\M?EVRJ<;E)(!]'U^?_P#P15_Y-9\4_P#8YW7_ *0V
M-?7WBG]H;X6^!]=N=$\1_$KP?H&LVNW[1IVJ:]:VUQ#N4.N^-Y RY5E89'(8
M&OD'_@BK_P FL^*?^QSNO_2&QH ^VOB%H.J>*/!^I:9HNLOX=U2XCV0:I'$)
M6@;<#N"D@'@'OWKX6_;/^!7Q.\,_LP^/]5UOXQ7WB/2[>R1I]+DTP(MPOGQ@
M*6\TX )!S@]*_0S:/PJ.XMHKJ%X9XTFB<8:.10RGZ@USSHPJ34WNO-GJ8;,\
M3A*$Z%)KEEO>,6^VC:NODS^6;[+-_P \9,_[AK]B/V(O@7\3/%7[+/@/5=#^
M,-[X:TJYM[AH-*CTT2K;@74RD!C*,Y(+=!UQ[U^@/_")Z)_T!]/_ / 5/\*O
M06L-K$D,,20PH,+'&H50/0 <552G&K'EE^=B,%CZ^7S=2A:[5M4G^#31S_PZ
M\/ZOX6\&Z=I6NZY)XDU6W5EGU22(1-.2Q()4$XX('4]*Z<=.>:0J.O2EK2*4
M4DCBJU)5:CJ2W;OVW/CK3=5\+V?QN^,7B+7;GQ[IJCQ1I]]81:7IFL?9;Y+3
M3;!&_<10F.8&:WECR020ORG&TUSGQAOK=O&7Q<U9-.\;2:G;W?A>_P!)5=.U
M2<6\\4RM<FU5$:/Y(_OB+*X9QSN;/W3MHVU1F?(=Y9^#?%_[5T.J3>&]4LX-
M%O;>>&^_L*^:76M5FC2-',YB\M+.UC(.TL TN6('D@OC?!_6IK7X@:WXD7P=
MXB\)>'M2\(ZB]Q97&FZM<7#7D5TK$W;RQ 276QW'[O>#RJ22J 1]J;?<T;1U
M[T ? .C^'7A^#W@T3>$_$$TVK?!-_#KP0Z+>>8=6M([=5@E41@Q2*Z/L>3:&
MV$JQ %=2VAVND^-==\8ZU\//$TU[??"?38XDM+&YBU W437R7<(N( S6\_E2
M6P.&#D%=H8C%?:VT?C2;1U[T ?GY/'J&C^%_$$$FC>*-$TF'XH>&-6T[3_#N
MF:S%:KIYAL'O/+7RDD>$*MVSAD \U=VQ7*5O:/>:;H/BS29]/TGQ3:MI/Q5F
M@L=FC:IY=OI,MLXE"@Q[1:M/(Y)QLSANBJ1]R^6*7;0!\3ZQ>WMMXO\ BC9O
M9>+]5\%+\2;"[UF&2SU.>6;27TV-9A;?+OFMUU%/GBAW((5D 4QD XO_  CF
MKR>"1HZZ'XQ\-?#P?$75)=2:/17NY9K":.9K.7[-*DDDEJ)3%N!C.P[#@",E
M?O':*-@SF@#S_P"%-G;> /@YH]M)J7B#6;#1[%E%]KEHYU*>",MM9XEC#LVP
M#:NS>0%RNXUX2_@#6M7\$?&:/PF?$.M^&]2?3]:TJ/78I8=1N]0B<RWEM&]R
MJ2/"T<%I'&93A6>1 0B*!];;!2[1Z4 >/_"V1_%_Q>\=^.;;3[ZRT&_TG1]%
MM7U/3Y[&>XFM9+^:5_*G1)-@^WQH&*C)C<#A:^<-2EM+;QMXNNI+3QK<7B?%
MVUEM;M[#5Y3'I<]I;1W8B<(0+8M'=IA3L"J@&%\JON[RU/49^M&T4 ?"K7VG
M6W@W0K62#Q5:^'M*^+-W;II8MM1@$NFS?:I41(-H>XAQ\RJJN!C"CM5+QII7
MBC2=&^'UEX2L]8L$?QIKM_X9CO=+O7%EITVEWD$"3%HF:T22XN-B&4?NEF1M
MA5"H^Q_B!\*=#^)D_A^;69-31]"U!=4L?[/U*>T"W"@A681,N\ %AM;(PS<<
MFNQVB@#QWX>W&GZK^SAN^'.@:AX3>31IA8:/JEI-:W5G=M"2(Y5D^8NLA&YP
M2"02&/6O(O$":#<:?^RBEO;ZX_A9('AN;+2;:^DLA8R:-+"BW20 I@3&V0"7
MD;W& IDKZ^\L5C^'O!^D^%&U+^R;8V<>HW;WUQ DKF+SWQYCHA)6/><LP0 ,
MS,Y!9F) /EKX2> ?&'Q,^$/A271?$FJ>&(M,6\T]K/6!K%E<;$NYC#E%N+=B
M! 80"RL< #/%>@Z]\/\ 1=*\ Z9X:^(=SKGB#6FDN9].U;P_'JTUY;2'8NZ&
MY5YI(9 )%"[I " V!M5P/?=HI-@Z4 >'>-(=:M_!'P6L_$$WVCQXNN:.)9HR
M@9[I('.H,N.,&W6\SMXVL1T->YUC-X1TN3Q9'XDDMVEUB*T-C%/)*[+#"7WL
M(T)VH6.W<R@,P1 Q(10-F@ HHHH **** "BBB@ HHHH **** "BL?Q-XPT/P
M7IZW_B#6=/T*Q9Q&+K4KI+>(L02%W.0,X!.,]JYFW^/WPRNYHH8/B+X3FGE8
M)'%'KEJS.Q.  !)R<\<4 =]13032YH 6N<^(7_(@^)?^P9=?^BF_*NAS7Q-_
MP4K_ &U;S]FGPGIOA3PW8V]WXI\46LX,]X"T5E:XV,^T$;G8L0O8;6)STH Z
M3_@E>P_X8?\  ('7SM2[_P#3_<?KT_#%?6]?D7_P2G_;8OM"USP]\!=?L;>3
M0+M[@:-J,*D36]P[/.T4O.'1R7P0 0S '(Y7]=* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-HI:* /%/
M'7[&?P0^(VO/K?B+X9:!>ZK*_F374=N;=YG)Y:3RROF,3W;)KT3P'\.?"OPP
MT--'\(^'=,\-:4K;A::7:I!&6Z%F"@;F/=CR:\"^/\?C_P (_%NU\6:3X#\3
M_$S1IM/?3HM+T?7HK6SMD>*594EM7V_O))&B(N 7(52N$VC?Z%^RKHGC70?@
M[8V?C]6M?$!N[N<:7)J#:A)IEM).\EO9O<L2TS11.B;B2< #)QF@#V*BBF-(
M%!.1CU- #Z*Y#P?\7/!7Q U*]T[PSXMT3Q#?V2B2YM=,U"*XDB0_==E1B0I[
M-T/0'@U9T3XE^%/$GB/4?#^D^)-)U+7=.W"\TVUO(Y+B#:0&WH&R,$@'T) -
M '345S&E?$WPEKGBG4/#.G>)M(OO$>GY^UZ3;WL;W,&-N[?&#N&-Z9R.-ZYZ
MC/3T ?*G[ __ #<9_P!EE\1_^V]?45[?0V%K+<W,T=O;1*7DEE8*J*!DDD\
M <YKY=_8%_YN-_[++XC_ /;>OJ#4=,M]6L;BSNHQ+;7$;12QMT=&!!!]L$_G
M2>Q4;<RYMCR_Q?\ M)_#W1_"6MW^G^/_  K<:A:V4\]O"VK0,'E1&95P) 3E
M@!@$=:_*'_A\?\=%/S:?X4ST_P"0=+_\=K]0?&7[('PSOO!^N6VE^!]*_M.:
MQGCM3L*XE:-@G.>/F(YK\>V_X)>_M/LV3\,\G_L/Z9_\DUC2=;7VMOD>GCEE
MZY?J#F][\Z2^ZS9^F/[#O[<D'QN^$.H:_P#%'Q'X4\-^((=9FLX+5;I+/?;+
M# ZR;))"3EI)!N''R^QKZN\,^,M!\;6$MYX?UNPURSCE\E[C3KE)XU< $J64
MD!L,IQUP17Q/^P+^PS_P@OP5U'3_ (R^ K*'Q3)K<\\"7%Q#=,+0PP*GSPR,
M@^=9>,Y_.OL_P+\-_#?PTTN73?#&DV^C6,LQN'AM5VJTA55+'WPJC\!1'VW.
M^:W+^(ZJRY86+I2G[;2]U'E^3O?\#IJ^;?C)\9M=^'OQL@T&[^(?A?P9X5NO
M#TVKPR:OHS3S"6*>.-T#_:8PPPY; 7(QWKZ2KQ?Q=X)^(+?&U?&6@6GA>\TJ
M+07T5+75;^XAE8O-'*[MLMW4 &/:!W!SQTK<\DN7'QTTCX<V>D:+XVUG^UO&
M-QH\VL-#X?T.\E-W;1.JO-'!&LK+_K$/EEF(^;DA2U2>+OVG/ W@W0['6[J;
M5K_1+S3K758=2TG1KN]MS;W+;;=B\4; &0\*I^8Y''-<OXB^&GQ1USQUX1\4
M2_\ "'FXTCP_K6ES6\<]U#'YE[)"T03]TV4B6TMU+$@N7D8*@"K7,:3\"_BK
MI/AOX0:)(_A#5=+\ Z'!:KI\]_=1076IP((+>]?%N2ZQ0IO6+@"25FR3'&P
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M-!M;FXEVJ$7?(\99L*JJ,G@*!T%?('_!%7_DUGQ3_P!CG=?^D-C7Z 5^?_\
MP15_Y-9\4_\ 8YW7_I#8T ??C-MYX ]32&1>NY?SKEOBIX B^*/@#6/"TVJ7
M^C1:E$(FO],D$=Q#A@V4;L>/3N:^./B)^P'H7P[\"Z_XGN?BK\4-0ATBRFO6
MM+/4%>>?8A81HHC.68X4>YKW<OP>7XBFY8O$^RE?1<CE==[IHSE*:^%7/I.;
M]J+P=%^TM#\$C<$^*I-(.J>9O7R@X.X6V,[O-,0,V,8V '/->O&1>S#\Z_FB
M?PS\3&\4GQ!_8/BS^U/-\T7IL[GS\] =^W.<<=:_6CX9_L$:'\3/A]X=\56_
MQ3^*&G1ZQ8Q7GV*\U )-;LR@M&X,8^93D=.<<<5>#P>6UN;ZSBG3L]/<<KKO
MH]!2E-6Y8W/O56##@@BG5R/PG^'<7PI^'^D>%(=5U#6XM-C:-;_59?,N9MSL
MV7; R1NQTZ 5U]>'5A"%24:<N:*;L]KKH[=+FBOU/*+SXU:MJ_B#Q'I_@GP;
M-XNMO#<_V+5+S^T8K1#=B,2/:VP<'S941X]V[RXPT@7?N5PO,^(/VNM'T30?
M!'C*+1YK[X;>),)/XA28K-I+?O!(;FU*96.)HPLK[\H=^5PA-5_!.F^,?@/K
MGQ TFT\#ZCXUTC7?$-[XCT:_T>ZLXUC-XRRS6UV)YHVC*SM,5=%<&,C^(;3G
M^ _ACK/PU\,_"SP5J_ABZ\41-<:I=^(;RQ\B33K5[]KF6>)Q-(DCQ"2Z91B-
MB44%AGBLQGI]W\6I]'\;^*K#5],L],\)>']$AUVX\2R:EN'D2>=UA$?RA?LT
MY)WGY54C.[ R_#/QG\3>)=%T?7Q\-]3M/#^LSV:V,DMY$;R.WN)547%S;#F%
M51PY56D<9PZIABOF6@?LT^)(])^,_P --0U-G\#:QX6M- \)ZS.QFN+6V?\
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M_3A<5];5XIY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M) )!ZD9K[MT/POHWAF&6+1]*L=)BD;<\=C;)"K'U(4#)KXH_X*_?\D!^'O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*5X/_P#!]:__ !RNC\=> ]"^)GA+4_#'B;3TU70M2C\F[LY'95E3(."5((Y
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M=94>WT!'TJ2@ HHHH **** "OS__ ."*O_)K/BG_ +'.Z_\ 2&QK] *_/_\
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MV2XT"QN!]IL[&)I9O.8,2KX,C[L,6Z87 ('IU,NQ%&C[>JN5/9-V;]%N=]3
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MMW4E5>.WERTS*<.NT9W 8YKZ_P!;\>>'O#2;]6US3M-3^]=W21#\V(K\:O\
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MA>./#HNET76(FFMEO8A',H5V1@RY./F1NY'2NTV<DYK.R)/A#XE?\$B/AO\
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MIC?;8<7#1/\ *X0X8AN.*\AL?@/^TCJ5C;7EC^U]#=V=S&LT%Q!\.=*>.5&
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M=NB\W\CV8X&-&G[7&2Y;[1^T_ET7FS\';*UN;N]AMK6&2>\ED"1Q1*6=F)P
M!U)-?TR_!NWUVT^$?@BW\4AAXGBT.Q35=V,_;!;IYV<<9W[J^$M#_P""2OBW
MPSXZ?QEI7[0"V'B9G,HU&W\$P*\;GJZ#[5A'/=E )R>>37Z'Z'9W&G:+86EY
M>-J%W!!'%+>.NUIW50&D(R<$D$XR>O6O#;/'OI8NW-U'9V\MQ-(D,,2%Y))&
MVJJCDDGL .:_/#_A]I\+/^A%\8?]\VO_ ,>K[(_:$\?>'O _PE\63:_J]II:
M3Z5=P0K<2 -+(T+ (B]6)R. #7\TY0@D8Z=:A23;5S25*I&"G*+2>S[^A_2A
M^S;^T+H7[3GPLLO'/AVTN;"QN+B:V-I>M&9XGB<J0X1F )&& ST93WKU(M7Y
M6_\ !,N[^-W_  SS>6_PYM?#/]@?V_=-)<ZSYGG&?R8-R_*WW<;<';G.:^L?
M^$0_:FU!E:;Q=X,TQ<$XMH7D.?0AHB/R-<DL2XRY5"3^1]#0R2-:C&M/%TH7
M5[.3O\TD['YV?\%"/'WP8U+XA_$!O">H^/8?BM!KAM+WSYXTT=6A;RIQ$%;>
M.4X]\U]6?L ?&?\ 9T\(:?XY/@KQ!XKTU2EG-J4GCVZA"L5$H06Y5N3\SY'4
M_+Z5^5O[1UKJ=C^T!\1[;7+Q-0UJ'Q%J$=]>1H%6><7$@=PH  #-DX &,]*^
MOO\ @D'\*?"GQ/\ 'GCIO%.D0ZRNF65M+;0W))C#-(P)9,[6X X8$>U=$G)P
MO3W\SR*$,-'$<F+DW36[CN_2Y]_:M^VQ;>)+J33?A;X-UKQ]J"G!N8H&@LX\
M]"SL,C_@2J/>OS;_ ."B_@'XU>-_BY8^)?%O@JX,D>@1LSZ#92SVEI;K+.VR
M650R[U^=F^<@ @\ XK]M=)T#3M!LX[/3;&WL+2(;8X+:)8T0>@4# KYU_; U
MGXZ7&D7GA/X6?"_3_&VAZ]HMS9:AJ5SK%O9R6DDJO$55)94W?(P;TSQFL:=*
MJI<]2=_+H>EC<=@9TO88+#*"_FDW*;_)+T2/RR_X)O\ PC\1:E^U-\-M=U'P
M=J5WX1DDNW.I3Z;(]D<6LX5O,*[,"0  Y^\!WK]X8H(X5"QJ$5>@ X%?%?["
M=C^T1\+-!\(_#'QY\)K#P_X(TBTN(V\1+KEK<3ER[R(IBBF8\L^W@=.:^V-O
MO75;J>!S2:Y6]!,#ZT$4X+13)/C+]JS]C+XM_M*:OXCT]/C;'I'PYU26WE@\
M*S:&DRP>6D9_UH97.9$+]?XL5ZU^S1\(_BI\*5UJ#XC_ !6_X65:SQ6T6F0_
MV5'9?80GF;^5/S[@T?7^Y7N6P<FC:* '4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%<WX_\47G@_PC?ZKI^DMKNH0^7';:8DZPFYFDD6../S&!
M"Y9P,D8% 'Q_^UA\*!X^^-EUJG_"A/%GQ(%KIMM9#5M'\7KHUL&!>1@(]Z%F
MQ(@9^1\B@8(->V?L8^'8/#?P3@MH?"E]X(,FJ7SOH.H:I_:4UJ5G:/#7&YBS
M$1AF#'*L67HHJ#X@?L\>*?BMKZ^()OBYXY^'LDUK"C>'_"FIQK:6[A!O^9XB
M9&WEOG 4$ ?**[WX)_#W2?A;X/E\,Z9K>J>))K2]FDU#5-:NC<7ES=S$32/*
M^ "3YB\*  ,#KF@#T*BBB@!-M&T=>]+10 W:,YIU%% 'RK^P+_S<;_V6;Q'_
M .V]?55?*O[ O_-QO_99O$?_ +;U]54 %%%% !1110 44G-&Z@!:*;N_"C<?
M;% $-Y9Q:A9SVTP+0S1F-P#@E2,'FORI^.7["OP?\$?MD? GX?Z1H%U;^&/%
M<=^VJVK:E<.\QBB+)M<ON3!'8C-?I?\ %KQ9=^!?A7XS\2V"0R7VCZ+>:C;I
M.I:-I(8'D4, 02N5&<$''<5^$_CC_@H9\3?'_P 8O WQ)U*UT)/$'@]9TT](
M;1U@;S5*MYBF0EN#Q@B@#]T?A#\(O#'P+\ :=X,\'V<EAX?T]I6MX)IWG8&6
M1I'R[DL<N[=>F<5VU?+O[!G[46K?M'? \>*/&<VD6.O#5;BR\FQS$K1J(V4E
M6=CD[SWQQ7TRM]"_"S(Q^M3S+H:.G-:N++-<S\2/A[H_Q5\!Z[X0UY)I-&UJ
MU>SNUMY/+<QMUPW8^]=$LZ-C# UQ/QH^,.A? ?X9:YX[\2K=-HFD)&]PEC$)
M)F\R5(D"J2 27D4<D=:HS>FY^9>B_L"_":^_X*!:]\(Y;35CX.L_!ZZU#&-0
M83BY,L*Y,F,D8D;BOU2\$^#=-^'_ (+T#PMI"R)I.B:?;Z;9K,^]Q##&L<>Y
MCU(5!SW/-?DYH_\ P4.^&%C^WCKGQEDLO$?_  BM[X370XH191?:Q<"6%B2G
MG8"8C;G=GIQ7W1-^WY\,[SPCHFKZ%)J&OZAK-ND]KHEC;;[M2W 24 E4<'@K
MN)] >*QJ5H48\U1V1WX/ 8K,*OL<+3<I>7YOHEYL^D\Y[U_.A\1OVV_C1\6-
M<\*:OXH\8_VE?^%=275M&D&EV<0M+I65EDPD*A\&-/E<,..G6OU_6/\ :"_:
M .7>'X/>%I/X4S+J4B'WX*'_ +]D>AK\L/C!_P $\_B9\%?$W@'0]?NM!EN_
M&NLIH>F-8W<CHL[O&BF0M&I"YD7G!. >*FC6]M>T7;I?0ZLPRU9:XQG5C*;O
M=1?-R^3:TOZ-VL?9?[%G[3/[3G[27@77K:VO],U6XAOQ'+XJU2UM[9;)#&"(
M4BAC4,V06R4?[V#CBOI[PM^Q;I>H:E%KOQ-\0ZC\1=>'(6_E9;2+G.$BST]B
M=O\ LUSO_!.?]EGQA^RM\._%.A>,I],FO-2U1;N Z7.\J^6(E7YBR+@Y!]:^
MJ]4UBPT.U>ZU&]@L+:,9>:XD$:*/<DU+P<:U2\KR?1?Y(ZZ&>8S#4%AL$E3?
M645[\O66_P!UCX<_X*!?L<_!VS^!?Q)^)MMX*AM/&MIIT#P:A;7ES$D9C,,*
M!;=91" (U"XV8[]>:[_]AS]E/X5_#KX9_#?XE^'O"XT_QKK'A*PEO=4_M"ZE
M\U[BUADF/E/*8UW/S\JC'08'%?"__!4?]LS7O'GQ&U#X8^$=>V?#[3X8!>2:
M7.&CU>=D61BTB_>B3>J;,[=Z$G)"[7_\$\_CU\;/BU>CX):3XW-CI%KI[75M
MJ%[$9[BPM82B&")\$A,.H521M"J%*C@^E2H<U14JDN3O?H>+&#JUN6K*S>[?
MZGZO?$?XT>#?A/8&X\2Z[:Z>^TF.UW;YY>WRQ+ECSQG&!ZU^77_!3CX@:[^T
M1X-\(^(M(\-ZAH_@[P_/=%+K4Y4A?46F$(#Q1$@N(Q&>8R^!(2=HK]!OAK^Q
M[X)\&7PUC6$G\:>(W;S)=3UUO.)?NPC/RCGG+;F]Z[+XN_L\_#OX[:=IECX\
M\,6_B&TTMVEM(9998Q"S !B/+9<Y '7/2O3KRR^A3=.BG4F_M/1+T7^?W';6
M>"HTW3HISD_M/1+T7^9^"7[&?PTNOBA^TGX TM7L8K*/6+6YO)-0D1(6ACE5
MWC"OQ([A=JQX.XL 1C)']%=K8V]E EO;0K;PQ@*J1J%50.@ '&*_-W_@EC^S
M7\-?%GP_U3QWJOA6WO?%F@>-;N'3=3:>8/;+#';O$ H?:=I=C\P/6OTKV^]>
M-S.W+?0\GFE;EOH<E\5/ACH?QB^'^M^#/$<<\FBZQ"(+I;:4Q2%0RMPPZ'*B
MOS(\#?\ !/\ ^$NO?MU?$CX5W=GJQ\):%X=M-3LXUU!A,)I/L^[=)C)'[QN/
MI7Z<?%/Q%XC\)_#[6]6\)>'/^$N\1VL(>RT7[0+?[4^X KYAX7Y23^%?GIX7
MU?\ :B\,_M0>,?C*O[.$D]SXCT>WTAM(;Q!;*D C\G#B3.6)\KIM'WNO%0+T
M/TC\*^&;'P=X7T?0-.5UT[2K.&QMED;<PBC0(H)[G"CGO6M63X5U'4=6\,Z1
M>ZMIXTC5;FSAFO-/\P2?9IF0%XMPX;:Q*Y[XK6I@%<]XR\?>&?AUI*ZKXK\1
M:5X8TMI5@%[K-[%:0&0@D)OD8+N(!.,YX-=#7)?$OX3^$?C%X=70?&N@VGB/
M1UG6Z6SO0602J&"OP1R S?G0!\+_ +"_QL^'/A[X]?M/W&J^/?#&F6^N^-3/
MI4UYK-O$NH1M-=8>W+.!*IWKRF?O+ZBOT5KP6S_8/^ &GW<%U;?"S08;B!UD
MBD6)LJRD$'[WJ*]ZH ;M'X4;1S3J* &A /YTZBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** &^6*\R^)'[2WPL^#^MQ:/XS\=:+X<U66(7"V5
M[=!9?+)(#E>H!*G!/7!Q7IGF=_\ ]=?+GQ2\)_$[3_C1XDU;P1\(_ WB_3-4
ML[*2;5O$=[Y,[S(KQ[!F-CA55>,@<J1R6) /?/AU\2O#?Q8\+P^(O">JP:UH
M4TLD4-];',4IC<H^TXY 8$9]JZJO-?@''XBC^'ZCQ7X;TGPEKOVZZ-QI6ARB
M2TB_>MM*, ,[EVL>!R3Q7I5 !1110 4444 %?G__ ,$5?^36?%/_ &.=U_Z0
MV-?H!7Y__P#!%7_DUGQ3_P!CG=?^D-C0!^@%%%% !1110 44SS./>L#4?B'X
M8TGQ!;:#>^(](L]=N<>1I<]]$EU+GIMB+;FS["@#HJ*B:;:NYN![UP_CCXZ>
M!/ATK_V_XHTVPF4;OLS3!YR/41+ES^ K:E1JUY<M*+D_)7-:=&I6?+3BV_([
MRO*?VHOB?K7P;^ GB_QIX??0XM7T>WCG@/B(R?8C^^16#^6RL6*LP55.2Y4<
MYP?.;S]M6+Q1.]I\-O ?B'QO,K;?M4=N8+49Z$R$,1_P)5^M>"?MK:;\:_B%
M^S#XRU'Q_<^'_ ?A"RCANI=-@62XN)W6=!#&YC$G60H,@@ X)  )'J2RG$4:
M;J8AJ%NC:N_1;GHRRRO2ASUK1\FU?[CY[TO_ (+,?&S5-2MK0^'_ (<VGG2+
M']HN+"_$:9.-S$79( ]<=*_7*V\?:/9Z/93ZSKFCV=T]NCSXNT6+>5&XH2WW
M<DX.>E?S(:;;Q76I6T,UY#8P22JC74RNR1*3@N512Q '. I/H*_?KX>?L)_!
M_3_!GAY7TNYUPI8P?Z9<WEPGG_(I\PH' 7/7;CC-<6%CAI-O$R:72R3_ #:.
M3#QP[;^L2:7DKGJVI?M&?#+2U?S_ !YX?+(<,D6H12,#Z84DY]JY+4OVUO@_
MI;%'\5K<."1BVM)Y02#@\JA'ZUO:;^RS\*=)V^3X'TB7'_/U!Y_?_;W5U>F?
M"SP9H:J-/\*:+8[<8^S6$4>,=,87M7H7RF*VJ2_\!7^9W<V61Z3E]R_S/SX_
M;^_X**?9?AG9Z#\)=3U#3]2U>XDBO=;6%H)+>W5?NPL<,KN6&&&" K8QD5\)
M_L^?M!?$Y_B-H_A0>/\ Q(VC^*M2M]-U*W:^EG$B33(KNJL3A^>JX)Y!R"0?
MM[_@MIJQTOP7\*-!MK>&*SN[[4+N0J,,&AC@10 #C!%PQ/'8=._YL_ 7Q8O@
M;XW> ?$<FSR](UZQOV#J6&V*='/ ()X'8UYU2M3IUE5P\>5+57UV.+F7MU+"
MIKMU/Z+/A5\&?"OP:T%=+\-::+<,!Y]U)AKBX8?Q2/CGJ<#@#)P .*YK]J?X
M^K^S/\%M:^(#:&?$9TV2",:<+O[*)/-E6/)EV/MQNS]TYP!QG->;7'[:&L^-
M#Y?PT^%WB+Q,K$JM_>1BVM<^H?YACZE:\$_;8\+_ +27Q._9U\03:YI>FP:6
M9K5F\,^'K9[J]F/GH%)VB0X7AB5<=#QBO+J9A]:J\[;G)]=?S/H<3D..IPGB
M,PJ1@[7M*2YGZ15W]]CD?^'Y6<?\64 _[FO_ .XJ^B=!_:J^)?[2'AW2_P#A
M4W@AM%CO[2*6[U[6WW6UG(Z*7CB;;B3821NVG.,^7S7XS_\ #.?Q6_Z)KXLS
M_P!@6X_^(K^@_P#9ATFYT/\ 9M^%%A?6DUAJ%KX3TJ&YM;B)HY895LX@Z.I&
M58,""#R"*=:G*HE&,G%=;?UH>3E^,H8&;JU**J2Z<U[)]VNOH]#S;PE^Q/HN
MH3RZS\4-8O/B+XBN(VCE:^F9;:)6SE4C!Z#)ZG'HJU\0M_P1-\<L58_$KP]E
M>G_$OF_7UK]=_+%+M]Z*-"%!6@OZ]2,?FF+S.HJF*G>VRV2\DEHEZ'@W[%_[
M-\O[+/P1MO!5Y?VVJZD;ZXO[N^M$=(IGD("D*W3$:1KQ_=KW?%.V^]!7/?%;
MGEGYX_MJ?L[?M!_M!7WB7POX>\"?#B'P9/J$-U9:ZN8-8F" '][(9"IRQ;/R
M<@"OHS]E#0_BOH]MXA7XI>"? ?A&;%LFFMX)@,9N5 D\WSR9&R0?+QC'WFZ]
MOH+:,Y[T;/>@7H+1M'UI:*!C=M.HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\\^/?AU_%GPC\1:4NCW?B)+J*-9=)T^X6WN+
MR,2HTD44K.@1V0, VY<$@YKT.DV@'/>@#Y3TO_@G?\$]3TNSNY/#WBC3WN(4
MF:SNO%%_YT#,H.QPEPR[E)P=K$9'!(YKVOX*_!G0_@/X3N?#'AO[0NB?;I+N
MVANKAYY8O,"%E,CDL_SAB"3T(':N,^+7[4#?#CQS)X6T?X8^.OB%?VUI%=WD
M_AC34FM[42EA$C.\BC>0C' Z#'TKMO@[\3+SXJ>%9M9OO"FL>#)EO)+7^R->
MB$5[&%52&D0$A=VXD8)^4J>^  =_1110 4444 %%%% 'RK^P+_S<;_V6;Q'_
M .V]?55?*O[ O_-QO_99O$?_ +;U]54 %%)2;CZ4 .HINZC=2N W-)YFT<BO
MY]/&'[>'Q_LO%NN6\'Q3UV*"&^G2...1 %42, !\OI7U?^P/^T%^TO\ ';2_
M&6EZ;K\'B%K>:U$FM^(V5O[.WK*,1@#)+;<\JP&SH,\Q4E[.'-:_H=N#POUR
MM&BIQA?K)V2^9^I^L:Y8:#8RWFI7MOI]K$NY[BYD$:*/4L3@5X'XP_;>\&V&
MH/HW@VRU+XA:]RJ6N@V[21Y]Y,<CIR@;&:R-)_8K_P"$LO(M3^+'C;6/'=\C
M;Q9><8+*/U"HIR/JI7KTKW_P?\/?#?@#3EL?#VB66D6P'*VD"IN]V(ZGW.37
M%?%5=K07GJ_\CZ/DR++_ (Y2Q,UT7N0^]^\_DD?*?Q \._M)?M!> ?%%JT6E
M_#_2;W3+J&+1XW62]O=\+!86=CM3>3M+%HR,\BOR@\4_L3_&?P?\1O"_@36/
M!GV/Q3XH$S:1I_\ :ED_VD1@L_[Q9BB8 _C9<]J_H9\2>)-.\)Z#J6L:K<+:
MZ=IUM)>7$S=$BC4N[?@ :_"3XU?\%#O&_P 2OVCO#/Q0TW3]-TH^$)IET'3Y
M(3*HAD+!A.2V79E."05 _A"UU4:+HIWDW?JSQLPQ[QSC:C&G%;**M][W;\V?
M='[&O_!.RTT?X*FT^+WAFYTCQ@=1G?R[?55D_P!'(3RSF&1H\\-[U[6W_!/O
MX?0,3INM>*-&^<2#[#J"KM88Y&Y#SQUK ^$O_!2?X:^//A?HFOZS+<:1K\\6
MW4-)M[6:403J2&"R;=I5L;EYSA@#SQ72+^WAX4U$[=%\(^,-<9L;6L]-5E//
M_73/Z<UZ4.'JV,2JQH7OUV/=P68<04J,8X6I)0V6UOQ(&_8E:Q7_ (E'Q9\>
M6.'RO_$SSC_OD+S7S[^W;^SWXR\ _LI^.-7O/BYX@\2Z1:_93+I.IEI5G#WL
M"*&8R'[K,K="/DQ@5]"O^UEXXU%@-%^!OBNY#8VM?(]JIR?[QB(KRW]J+XC?
M'OXA?L^>/--M_A!#IEC<:4YN9KB\AN98H1AI66)B"6"*V,*6# $#.*I\-5,,
MG5E&,;?WU^7-N=>(S+/*E&<<34BTUK=4[_?:Y^)>\G':OWZ_X)[_  ^\*>'O
MV6?AYX@MM(LK;6-1TL3W>H&,&:1B[YRYYP/3./:OP'5<MM SDX&.37[C_ ']
MC:_\7?!?P/+\2O%_B>:1M)M7/AR.4VMO9J8U*PO&<D%5P&P%.[.:6'P^&K2;
MQ$^5+RN?)8.27-&=5PB][7U\CZ-\8?M'?#3P&'75O&&F)*APUO;R?:)01V*1
MAF'XBOP"_:,_:"\7_M ?%?5?%?B+4[PD74C:=8-,WEZ9!OS'%$N<)M &2.2V
M6))))_??P;^R[\,/ NQ]-\'Z:\Z8*W%[']JE4CN'E+$?ABOS2^-__!+OX[_%
MSXH>(O%2P^ =._M*\EFV6-W-;K*"[%9'C$14.PQN*XR<D\DDZ8KZFDEAN9]W
M*WX)&6(^JJRP]WW;M^AZ=^PG\0?VA_VF/@N;>#QQ9Z;I&@W;:6^N7D)N-1N?
MD60*68-O*+(HW95L;>3R:^F=,_8=T'5;B.^\>>*O$/CO41][[=>O'#_P$*2X
M_P"^ZT_V'/@[XR^!/P+@\'>-+3P_9WUE?S-:Q^'6=H3;LJ$-([C<\ID\W)/8
MJ.@ KZ'VUO3S7%4::I4&H)=4DF_GN;T\RQ%&FJ=)J*75)7^_<^,/VE/^"7_P
MV^/%KI=QX?N&^'FN6$7V<7FGVJW$-Q%DD":$LI9U).'#@XX.0%V]O^QW^PQX
M0_9"L=0N-/O9_$?BS4HQ!>:]=PK$WDAMPABC!/EID*2-S%BHR<!0/I;R_>EV
MX[UY,I2J2<YN[?<\Z4I3DY2=VQ-M>*?M,? +Q-\>-+T2T\-?%7Q)\+)=/GDE
MFN?#LLJ->!E "/LECX7!(SGK7MN*38/4TB#X?^!/_!.'Q%\!_%NB:CI/Q_\
M%TFA6.J+JEWX;A22VLM0?<I<3(MP5.]54$LIR ,U]Q4W:*=0 FT4FP4ZB@!N
MT4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#$\4>$;+Q='IB7TU]$NGZA!J4/V*\EMBTL+;D5_+8;XR?O1ME6
M'!!KR;XI_LB^$/C!XZN?%&MZSXKM;B:VAM_LNC:]<65NI3</,V1L!N8,H/L@
M/<U[I7R;\>OBAXF^%?Q@N[[6='^)_B3PA?Z1+I^G:;X#TE;BU5G1 \KRQL)4
MO!('"EMJ"-E*9;?M />_A%\+=+^#?@N+PQHUU?WFGP7$]Q'+JETUS/F21I"'
MD;+-@L<$\XX[5V]>4_LR:AXYU/X)^'[SXC6=UI_B>9KAVM=09&NX[?SY/LRW
M!157SO)\K<0!ENH!R!ZM0 4444 %,WG\:Y+XO_$!/A3\*?&'C.6W^U+H&D76
MIBW)QYS11,ZQY[;BH&?>O)-#USQA\+_%OPBC\2>*KOQ1'XZ\[3=7@NX8EBMM
M2%F]Y'-:B- 8XAY$\/E$MPT1SN5F< ^BZ_/_ /X(J_\ )K/BG_L<[K_TAL:L
M_P#!03_@H9XD_9<\<>'_  UX!7PAKE_+;22ZQ::L);BXLG_=M$K)#/&8MR/O
M <98,I''7X;_ &!?VZ/%/[/.J^'?AM;VWAB'P3K_ (LM[G5]5UI)5FM(IS;V
M\\BS"9(T5(H@^74@').1P =C]VZ*\I;]K#X)KU^,/@$?7Q/9#_VK6/XJ_;8^
M!'@_0[C5K[XN>$+BVA*AH]+U6+4+@[F"C;!;F25N2,[5.!DG !- MMSVZBOE
M3_AZ)^S-T'Q*Y_[ .I__ "-6Q\8?V[/AS\/-!CN-"UO3?%U]<H&@_L^^C-HH
M)P&EN,E$&>V2W3@9S77AL)7QD_9T8W?Y>KZ'30PU7$RY*4;O\O7L>K_&WQI+
M\._A'XR\1VDUO#J>G:1=W-B+E@J/<K"QA3GKN<*H'<G%?S7>(O$6L>)_$5_K
M>LZA<ZAK%W.T]Q>W4K/+)(QR6+$DDYK]:?&WCCPUXZ\ ^*O'_P 1_C)X%U[Q
M!I6CWFH:#X!TWQ':R6GVJ.!WAAD2*;=*S.%7;&VYN!O.<5^:_B/X[:;XG\8/
MXCO/A9X)CO)'626VLX;RWM)'&,$P1W(0?=&0H .22"22>C%X>AADJ=.ISS7Q
M6^%>2?7U^XZ,5AZ6'48QGS2ZVV^3ZGZD?LB_"WXH?M(_L^>#_$7Q!^*?B*VT
MFX@D@M]/M/W$\]O$[1(\DO\ 'N"<%U8L,-DYS7TSX(_8_P#A9X'=)H?#4.K7
M:\FYU<FZ9F_O;6^0'W"BO(/V//VV/"_C+]GW0=4\=:YX9\,ZW'+-9C2=-7[-
M%!!&Y6$"'<VQ0@4#MQVKU2]_;9^#NGD[_&$,@#;#Y%I/+SZ_)&>/?I6,\]K1
M@J'MU",>B:7WVLW\SV:>'SRO1BJ%&I[/IRQ=FO5+4]LM;"WL85BMX8[>-1A4
MC4* /0"DNK6&^@:&XA2:%N&25=RMSW!ZU\[WG_!0#X16_P#JM5OKKYL?N]/F
M&1Z_,HX_7VKY9_X*"?MK^"?BA^SCKGA7PQ+K%OJMQ>6S"1XUA4QI*'.3OW8.
MT$<>E>/];HSDESW;^9SU<@S:%.5>K0DHI7;>FGS/T@/A+0^^C6!SU_T6/_"M
M',<*8&$5> !@!0*_ER'B#5,@G4KS'_7=_P#&OUG^$OB*S^(WPM\%V_Q$_:F\
M)>'-&CT6RB_L+3/$EG!>*@MT&RY=W5A*/XU</\V?I5UJDJ:7+&[9Q9?A*&*D
M_K%=4HQZM-M^B6[^X^W?B+^TE\._A:LBZ[XFLTO$ZV%N_GW'XQIE@/<@"O(7
M_:@^)'Q481_"OX97?V&3&S7/$G[BWP>K!00&'^ZY/M4'PY7]D3X9LDVG_$'X
M<7U^O/V[4_$]C<S;O[P+2D*?]T"O74_:J^!L:[5^,7P_5?3_ (2BQ_\ CM<W
ML\35^.7*O+?[W_D>W]<R7 ?[M0=:?\U1VC\H1_61^8'_  5(^&WQ1T70OA_X
MA^(GBBUUX7%U>VZ064>RVL'*0LJIPI;>$;G9QY7).:^-/V?=&EU[XZ?#S3K>
M-+FXNO$-A D#8_>%KA!@YXP<]S7[X^*?CM^S;XYM8;;Q)\1?A9X@MX)/-BAU
M36]-N4C?!&Y5=R <$C-8.E^/OV2]'OK:_P!/\1_!FQOK5UF@NK>_TF*2)U.5
M96# JP(R".>*[:=-4X\B/G,7BIXRNZ\DHM](JR5NR1]$QV\=NNR- B^BC%/"
MA1[5Y;_PU=\$/^BR?#__ ,*BQ_\ CM'_  U=\$/^BQ_#_P#\*BQ_^.U:5M$<
M6KU9ZK1MKRO_ (:P^"'_ $63X?\ _A46/_QVC_AK#X(?]%D^'_\ X5%C_P#'
M:8'JM%>5?\-8?!#_ *+)\/\ _P *BQ_^.T?\-8?!#_HLGP__ /"HL?\ X[0!
MZK17E7_#6'P0_P"BR?#_ /\ "HL?_CM'_#6'P0_Z+)\/_P#PJ+'_ ..T >JT
M5Y5_PUA\$/\ HLGP_P#_  J+'_X[1_PUA\$/^BR?#_\ \*BQ_P#CM 'JM%>5
M?\-8?!#_ *+)\/\ _P *BQ_^.T?\-8?!#_HLGP__ /"HL?\ X[0!ZK17E7_#
M6'P0_P"BR?#_ /\ "HL?_CM'_#6'P0_Z+)\/_P#PJ+'_ ..T >JT5Y5_PUA\
M$/\ HLGP_P#_  J+'_X[3?\ AK'X);<_\+B^'_U_X2BQ_P#CM 'J]%>5?\-8
M?!#_ *+)\/\ _P *BQ_^.T?\-8?!#_HLGP__ /"HL?\ X[0!ZK17E7_#6'P0
M_P"BR?#_ /\ "HL?_CM'_#6'P0_Z+)\/_P#PJ+'_ ..T >JT5Y5_PUA\$/\
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MXU?!SP1H/P?;Q=X4\0>&_$ >^AM6AT^ZN$U"UWJYW2VLJJ53Y"N[D9(P37]
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MCO)#%;OJE[';B5E&Y@I<C. "3Z#DX% '3T5'',LB*ZLK(P!# \>M24 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M,'QT^%OQ$A^,$'C[X<>'?!_BW6'L!I\R^)[ZXMYK. QRIY*JNZ-[>1G\QEVH
M^Y.6<$>7W/[*_P /]4^$OPLM_"7B+6-)U#Q-%=76HWUEH8V6>GFZN'F6WMXS
MRD";RJ @# X '%>,_M3?"WQ?KGQECU_0/"OCO6]6NM.MK+1=9\*^*XM)L=,D
MC:9E-W$P).UYG<NR2JROLV_*0VO\./!/B6T\>V^HOX#U#3?$.H>/M3U6_P#$
MD[VH\O3#$\8CE9)GDQ(D=LJ0X(P8G_Y9Y4 ^M:*** "LSQ)JS:#X=U34UC\]
MK.UEN!'_ ']B%L?CBM.F21++&R.H=&&&5AD$'J* /BOPM9KX'^#_ , /BQ:[
MG\>>+=7T ^(]8X$^KQZN52:*X;!+Q1/=*\2'B/R45-HR#YQ_P5S_ &F=7^%=
MOX)\)>"/&NK>%_%TKMJU[#I,LUN[63!XHF:50%(,D<@V!LC9D@ @GZJ\)?LU
M2^'[CPGI5[XG_M/P+X,O3?\ AO018>7/;2!)8X$N+GS6$\<"3%8@(XR-B%S(
MRYKS;_@HE^R)XN_:Z\(>#]*\(:EH>FW6CW\US.^MRS1JR/&% 0QQ2'.1R"!V
MYH _'+X=_M/?$SP'K4\UA\0O%.FVNHZHVK:E'8ZI*GVRYD93+-(-V'D?:-S,
M"3@9S7Z3>#OC)^SG:ZVGBKXM_%&_\<^*20VV_P##FJBQM^^V.(VH# '^\ /1
M :^0/@S_ ,$P_B=\9KCQB=)\0^$[1/"/BB\\+7YO;JZ!DN;79YCQ!;<[HSY@
MVEBI.#D"OU;\0?L%_"#7%D\G0[C297R/.L;R4%?HKLRC'TKKIX_%86FX89I7
MWZ/T3['TN4XC!TX5*6)J2IWM9QBGZWNT[>AYYXX_X*;? 6Q\"ZW'X.^(UC#X
MF2PF72$U#P_J@M1<^6?)$@6VSLW;<X[9KXX/_!5KXQ+XB&F_\)?\,#9>3YO]
ML#1-6^RAL_ZK;Y?G;O?R]O\ M5[%^V-^PWHGP?\ V=?'/B;P]XMU:&TL;:-Y
MM/N]C+<YF1-I9-@YW=U.<=.:_(O<"<UQ1FYJ[5G\F>?CZ&%H5%]5K>UB^MG%
M_-,_4;PW^V;\-_C9XPT36_CSX]L=+TG1((FM_#VFZ9?36]Y=[1YDSB.)\(6!
MPKG.T@$8W;OJ^/\ X*>?LQ6\*QQ_$G:BC: -!U,8_P#):OGO]BOX(_'3QA^S
M%X&U;PA\=/\ A%O#MQ%<?9=(&BPS_9@MU,KKYA.6RZLWXXXQ7L*_L[_M7V]Q
MOA_:(LG122AET6+D=BRF,C\#FO?P>183DYWCJ:E+5\W/?T^%K[B,RS>MCW3@
MZ?+3@K1BMEW?JWJV?*_Q,_X*L?$?2?%E\?"'C#X=:WX<GU66&P_XDFK+<6UF
M9&\J6X\V.,$A-NX)N;.<*:]Y_9Y_X*A>!?\ A%]2/QG^)?AG^WOMF+/_ (1?
M0-8\G[-L7[YDML[M^_IVQ7YX?MP?%_X@^,_BK<>#O&?Q C\>IX-NIK2WO;73
MXK.%;@[!/M6.--V'0)N;/*<<'G[F_9I_X*2?$G7OAM9ZQXI^%FI>--%TTKI]
M]XD\+@R3++&BDO/ <X9E*L6W(I). .@FCE-?%XB>&PTHSE'LTK^G-:_YGDN:
M2NSZ _X>C?LQ?]%,_P#*!JG_ ,C4?\/1OV8O^BF?^4#5/_D:ND^&/[>WP6^*
M+1P6GC"WT+47X-AX@'V&16_N[G^1F]E8U[[;7T-Y#'-!-'/%( RR1L&5E/<$
M=JX\7@,7@9<F*I2@_--%1E&6L6?+W_#T;]F+_HIG_E U3_Y&H_X>C?LQ?]%,
M_P#*!JG_ ,C5]3JY-)YGMQ]*X"CY9_X>C?LQ?]%,_P#*!JG_ ,C4?\/1OV8O
M^BF?^4#5/_D:OJF@T ?*W_#T;]F+_HIG_E U3_Y&H_X>C?LQ?]%,_P#*!JG_
M ,C5]544 ?*G_#T7]F3_ **7_P"4#5/_ )&I?^'HW[,7_13/_*!JG_R-61\-
M/@+XZ\/_ /!2OXK_ !4O]#^S^ M<\-0Z?IVJ_:X&\^=8]-5D\H.95YMYN60#
MY.O(S]@T ?*O_#T;]F+_ **9_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-7T_
MJ6J6NCV4EW?7,-G:QX+SW$@2-,G&2Q.!U%<YX5^*_A3QK;WT^D:U;S)8S74-
MPLX:W>,VTS0SL5D"ML21&7S -A(X)H \#_X>C?LQ?]%,_P#*!JG_ ,C4?\/1
MOV8O^BF?^4#5/_D:O?/#GQ8\)^+=<U'1]*UNWNM2L+A;66 ADWR&WCN,1%@!
M,/*EC<M&64!ADUUU 'RK_P /1OV8O^BF?^4#5/\ Y&H_X>C?LQ?]%,_\H&J?
M_(U?55% 'RK_ ,/1OV8O^BF?^4#5/_D:C_AZ-^S%_P!%,_\ *!JG_P C5]54
M4 ?*O_#T;]F+_HIG_E U3_Y&H_X>C?LQ?]%,_P#*!JG_ ,C5]544 ?*O_#T;
M]F+_ **9_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-7U510!\J_\ #T;]F+_H
MIG_E U3_ .1J/^'HW[,7_13/_*!JG_R-7U510!\J#_@J-^S+D_\ %R__ "@Z
MIG_TFI?^'HW[,7_13/\ R@:I_P#(U9'[:WP'\<_%KX]?LR^(_"FA_P!K:+X/
M\3-J&N7/VNWA^R0&ZT^3?MDD5I/D@E.$#'Y>F2,_8- 'RK_P]&_9B_Z*9_Y0
M-4_^1J/^'HW[,7_13/\ R@:I_P#(U?55% 'RK_P]&_9B_P"BF?\ E U3_P"1
MJ/\ AZ-^S%_T4S_R@:I_\C5]544 ?*O_  ]&_9B_Z*9_Y0-4_P#D:C_AZ-^S
M%_T4S_R@:I_\C5]544 ?*O\ P]&_9B_Z*9_Y0-4_^1J/^'HW[,7_ $4S_P H
M&J?_ "-7U510!\J_\/1OV8O^BF?^4#5/_D:C_AZ-^S%_T4S_ ,H&J?\ R-7U
M510!\J_\/1OV8O\ HIG_ )0-4_\ D:C_ (>C?LQ?]%,_\H&J?_(U?55% 'RK
M_P /1OV8O^BF?^4#5/\ Y&H_X>C?LQ?]%,_\H&J?_(U?55% 'RG_ ,/1_P!F
M3_HI?_E!U/\ ^1J^K*^??V\OA;XG^,_[*/CGP=X-TS^V/$FI&Q^RV?VB*#S/
M+O[>5_GE94&$C<\L,XXYP*^@J "BBB@ HHHH **** "O@?\ :VNKW4/C9K+V
M'A/]GZ^72[*R@OKSXK6\MWJ26['(O!&@/E6227*Q--C <MN8*IV_>P?)QWKY
M?^,EA\9_%7Q@UB#X;^"?A-]DLM)CTZXUKXA074UYJ%M<9>2&+[.O%N&0JT;G
M#,N<<4 =7^Q7<Q7?[/>BRQ#P<&-]J*RCP#&T>B[UO9E/V56 ^3@'*C:3DC(.
M3[O7EW[.NC^)?#OPMLM(\6V/A33-9L+BXMWT_P #Q>3I%O&)6\M+=" R@*5R
M& .XM7J- !1110 4444 %?G_ /\ !%7_ )-9\4_]CG=?^D-C7Z 5^?\ _P $
M5?\ DUGQ3_V.=U_Z0V- 'Z 5A^+O WASX@:,VD>*-!TWQ+I3.LC6.L6<=W 6
M4Y5BDBE<@]#CBMRB@#RG_AD_X(_]$=\ ?^$O8_\ QJO3K6Q@L;6&UMHD@MX4
M$<44:A51 ,!0!P    /:I\>]%+U 3:*7%+13 ;L I-M/I*0";:X_XM?";PY\
M;O .I>#?%MK->Z!J!C-S;PW,D!?9(LB@LA!QN13COBNQHH ^1E_X)6?LY*<C
MPA?*?4:Q<C_V>OJO1M'MM T>QTRT$GV6R@CMH?.E:5]B*%7<[DLS8 RS$D]2
M2:OTE #=G?%&T9Z4[%%/4#\^?^"K7P7U[XU7GP;\-^$[33FUS5]5O;1)+H+%
M)(R6QE13,>B!4G.T\$LO2OAOP#_P3N^*DGB#Q-<ZM!I=II/@S43:>(F;4%WP
MHMM%<R,@XW*89E8-T//7&*_9[XE? ;3?B=XU\+>)[WQ%X@TN^\,RFXTV'2YX
M8X8YF5T>0J\3%F9)"AR<8 P >:7QM^S[X8\>:UJE_?2ZG:PZU;Q6FN:?87C0
MVNL0QA@D=R@&2-KLA*E2Z81RR *-Z5>K1J1JTY6E'5/LQ6333/D+X1?#O]IG
MX*_"?P7XI\"^(H?B+HNHZ+8ZA>>"?$F4N+.26!)'BMY6;@(68 ;UQ@?(U=K<
M?M_1^)O"NK^&8+&#X3_&=$1+/2_B"DD.G&4NH8&<!?EV[\;@F2!C(K[0C@2&
M-4C4(BC:JJ,!1Z#T%>%_MDVGPTTWX#>*_%/Q+\-6'B'3-%LWE@BND(F,SD)%
M''*OSQ,\CHFY2,;O05]3_;&%S!VS:A>7_/RG:,_^WE\,ON3\S#V<H:TW\NA\
ME^%/VFOVO?&GQZ\3?"+2Y?A9-XJ\/Z='JEU(8KDVKPNL##RY Q+$"YBSQC)/
M/%?HUH;7_P#8NG_VKY/]J?9X_M7V;/E>;M&_;GG;NSCVK^:+X9_$O6?AS\0+
M/Q%H^NZIX:G\PQS7FCS&.X6!R!(J_, ?E[$XX%?L[H'[)/Q%\4:%I^L:5^U1
MXRO=+U&WCO+6ZC1BLT4BAD=3YW0J0?QKS,-@L#B%*57%*G9Z7C)W7?W4RY2E
M'97/L[?BOS"^)GQ*_;2^%/Q7^'GP^UKXI^ 'UOQQ-+!ITMK9(T$+(4'[XM9J
MRABX"[5;)!'%=)\>/@O\8/V>_!*^+]0_:=\2ZA8PW4<,L+)#;,%8,25^TZ@B
MS. IQ$I+N>%%?EW\0?CSX\^)7CS3/&&O>*-2U/Q#I0B^P:E-)MFM?+?S$,>/
MNX<EACN<T8S 8/#PC.ABHU+]%&2^?O)!&4I;QL?T-_ ?2?B-HOPTL+7XJZQI
M6O>-EDF:ZOM%4K;.AD8Q!08H^0FT'Y1R.]>A@U^3/[(?B7XX?M:6URNG?'W5
M-#U"TMFGN8+B*TD96$H0*L8N?/9"I#>:8E3)* DBOI.\_9]_:(\-6,;7O[4*
M6L&\1HUUH4+,[DY"J68LS'!PHR3T&:ZUE.!<4_K\+OHU/](LGVDOY6>;?\%'
M/"OQ/^"OAGQ!\6?#WQY\6:=9WNJV]M:^%+65H;>V$BE2(W$OHA;&WN?K7U=^
MS+\%?%?P@T_5Y/%7Q7UWXI'5EMI;9];0C[#M$A81YD?._P P9QC_ %8K\;OV
MU/CIXL\9:GI?@V]^+L_Q3\-6T-OJZ7!TO^SXA<2Q$I^[*AR5BD'WL8,C+@8.
M?J+]A7QU\?\ ]H3X<R:5X4^/&GZ#<^&!'8_V'J6CVMQ<I:JBB*4.T19T_@R2
M3E.>H)X89?1J5Y45B8**^T^91?II?\"W-I7L?J[N]Z^<_P!JSXT?&GX/*=5^
M'?PRTOQKX4L-+FU'6-4O]7AM#9>5N9@$:16<"-=WR@^G7BN$NO@I^V"L.;?X
M_:#++G[LOA^V0?F+8_RKY-_;Q^+WQ]^"_@=? ?C/XL^'?$,OBBWDM;S3=#LH
MTNDM0%WM,PB4QB3>% &-P+XX!KIK9/3I4I58XRE*W1.5WZ7BOS%&HY.W*SZ^
M_9#_ &GOCA^T5<Z#K^N?"C1]!^&.K07$D7B2SUB.5R\9= OD&3S.9$*G*#IG
MI7UW7X<?L._M)_%+2M#?X;^'OB=I/@W2K25)M/@UK3&O!))<7*1&&(QPR.,S
M3(V,8&]V. ":^\+?P;^V=JT*W6C_ !:^'&IZ<_\ J[J.'(?!PV-MHR\,&'WC
MTJ<-D]/$TE4>,I0OTE*2?SM%_F$JCB[<K/>?VBO"-AXR^%/BCP%965M-K?CF
MUGL(5:(/MD>,1F]DS_#;KY;[B>J1(OS,BGCOACX=L=;^-'Q\TWQ(!JME;6.B
M^'HO[0/F>9I8TTRMG.<AYKB[W'^(KSG;7S1XV_8G_:S^('BRX\1ZM\5M"35)
MHD@+:;K^IV,:Q+G:BQP0(@&23P.2Q)Y)->=_M.:3^T#^S7X,TZ^UW7? \.G7
M6B_\(W*GAW4I+>YN]/MU_=P.DABEGVB1\/#ND02.2R!B3USR*C!76.I/R3?_
M ,B3[1O[+.HU;]H?]JKX*_LJ>$?B1 W@F[\ 0:%I$=O)JD=Q/JLHD@AB$DOS
M!6+2$MNW<@@G-?9O[,=]\>-2MM6O/C./"'V:XAMI='_X1;S=W(<R^=O]C%C'
M^UGM7XY?M0?M:?$SXJ>!M"^'_B74= C\/VHAOX]/\/+#L0(K1PQR>4S;"BDG
MR205)7<H9<#ZZ_8U_;Z^,>N?"VTTJU^%0^).G^$K>WTRXO-&OBFH+&$(B:2'
M$CN2B8W!0'*-SD&O+CE=2MB7A:$XR??F23\DW97-.=6YC]2Z:6Q7R)IO_!3+
MX<6%Y%I_CGP_XN^'.I-]^'7M'? ]2-FYR!ZE!7%_M2>./ WQQ\(7_C;P3^TY
MJG@I_#6AWET-$\+ZZ;)]0=%:1=\/F(Y<L @^4DY ZUIBLCS/!KFKX>2CWM=?
M>KK\28U82=DS[NWGGBGU^>7_  3/\$^)_B7X-\+?&#5_CMXZ\57-O/?V.I^$
M=2U>>ZL$F'F1HDBR2')$4D$PR#@LO2OT-KPS4**** "BBB@ HHHH **** /!
M_P!KS0?%&H_!GQ7%X4\/Z1KD&I6,D'B*WO;IH+RXTP(PEBLWV,HG\MI=A?"(
M[;L,20>;^">LZ7\3?C]XEUE;61M";X=^&FT"UOUSLL+UKV68%&SRYB@5_7RE
M!SM&/5?$WP/TWQ5XFU;5;SQ#XGCLM7M4L]1T*#5G73KB-05_U6"8BRG:QB9-
MPZYJ?QA\$]"\6:C8:A#=ZIX;U"SL6TI;KP_=FT>2R8J3;/@$% 5!4@!TRVQE
MW-D Y']C&ZNKO]G#PJMR28[66_L;(L<YLH+ZXAM"#D[A]GCAPV>1SWKVZLOP
MUX9TOP=X>TW0M%LHM-TC3;>.TM+. 82*)%"JH^@ ZUJ4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"_[5EU\/&^
M/U[:_$;4_BE<JNAV4VG:=X-^W"SM$:6X$CL+88+R,GWF))\HC "+N]T_9";P
MDWPKN#X*'B)M _M2<1_\)69?M^_;'O$GF_O,;LXW\[>G&*\N_:7_ .$^U#XN
M:C;:'XV\>^&+>QT6#4;?3/"'A]+B&]M$D(NW%RR.'NEWG9;'!(C0+EIJ]1_8
MYU"\U3X'VEY?7OBG599M2U!UU#QA9I:7]U%]ID\N4Q  JC*%VAAD#C@ 4 >Z
M4444 %%%% "%0:3:/PZ4ZB@#Y4_8%_YN-_[++XC_ /;>OJNOE7]@7_FXW_LL
MWB/_ -MZ^JJ .1^*GPRT;XQ?#GQ%X*U]9/[(URSDLKAK?9YL888$D9=64.IP
MRDJ<,H.*^+O^'+/P1/\ S-7C_P#\&%C_ /(=??\ 2;?>@/0XWX1_"O1/@K\-
M?#_@?PZ)AHVB6PMH'N"GFR<EFDD**JEV9F9B%&2Q.*[#:.E.VT8I:@?FQ\2O
M^".Y\?\ CSQ!XAB^*]GH]OJ>JW.HPZ?#X-BQ;K+*[K$66Y3S H;;DC!QG%?3
M_P"QI^R;_P ,E^"]?T*3Q+:^*I]5U 7IO8-%CTTHHC5!&521]V"&8$GC?C%?
M0^P9SDY^M&P4[L#S'XF_LT?"_P","RMXL\%:3JES(,-?"'R;K_O_ ![9!_WU
M7@-U_P $_M6^',S7GP3^+OB;P"X/F+I-[-]MTYF]/+X&/=UD/6OLW;2;!WYK
MWL)GV98./LZ=9N'\LO>C]TKHRE3C+4^+_P#A;/[5WP3(C\9?#G2?BQH\/W]4
M\)3&*[(]3%MRQ[X6(#MFO)?&/_!6*TM_V@OAWI%MHVJ>%O!T4CV_B^UUVU2.
MXBDF(1&P-Q58>)2006#,"HP*_1_4FNET^Y-C'#)>^6Q@2X9EC:3!VAF4$A<X
MR0"<=J_'[QG_ ,$B?V@O'WB[6?$FM>,_ -WJVK7DM_=3-J%Z-TLCEG( L\#D
M]!].U/&9CAL=35\+&G4O\4+I6Z^[=J_FK!&#CUN?KOX?\4Z/XLTV/4-$U:QU
MBPD^Y=6%PD\3?1D)!_.M/=^5? GPC_X)DW_@_P"'.DR/X]U+P'\3K97BN=6\
M&:G/-872AR8V=)$BDW;2H*A@N0<=>.M^R_M@_!'_ %%UX;^-NB1\!)@+'4=@
M_P"^%SQU)D/L:[%E&"Q2_P!BQD>;^6HG!_)ZQ?WHCVDHOWD?:5<)\9/C-X?^
M!/@6\\6^*$U+^Q[4[9&TS3I[UU^5FW.(E(C3"G,DA5 < MEE!^>-'_X*0>'/
M#^H0Z5\5_ WBGX5:HQVEM3L7GM21U*NJAV'?(CQCO6K^U9\8O _Q6_8T^+$_
MA'Q7I/B '0)F:.QND>5.GWX\[E/^\ :\_%Y+F.!7-7HM1[K6/_@2NOQ+C4A+
M9GO/C#XI:1X+L-%EGBO=1O\ 7)1!I>DZ?#YMW>2>6TI5%R% 5$=F9F5%"Y+=
M*T? OCS2?B)H(U;1Y9'A6>:TFAN(S%-;7$,C1RPRQMRCHZD$'ZC((-?.^L?$
M;P\W[:?P:\*SZK;G5;7P;JCK8LP#1SW)M&CZXRS16EP=HR0%R0 X)[;]F]GN
M/%'QMU>%U.B:AXXF^PR1D%)&AL;.VN67'&/M$$R$_P!Z-N :\6S-3T+XM?#^
M/XI_#O6O"DEU#8IJ<2QM<3Z?;WZH ZL<P7"/$_W<?.IY.>H%?/?[,_[#@^ ^
MF^,X9=;M9I-?AU"P"-IUI>LD,MP[6\C3R6R.V(B@>W8-"7#$#FOHCQ-\6?!/
M@L.?$'B_0M#V]?[2U*&WQ_WVPQS7Q!^V!_P4]T+X9^-_AYIWPUUNR\3V,>HB
M^\3RV&V5'LA\GV5'(V[W#.^0<J8X^S$'H>&KQI^UE3:CWL[?>)23=DST_P#9
MK_8/7X!_%_6/&0UZUNX6N6^R1+IUGNFA>UC1B-MM']B;SO-.RV;8R%%;.VOK
M^LGP_P"(M.\6:!INMZ/=Q:AI>HV\=W:74+92:)U#(X/H00?QK4W<US;#'45Y
M%^TA^T9IG[.'@*[\2:EH^I:JJ6UQ+#]FM9C:B6--R1W%Q''(+<2,0BNRD%C[
M&JL'[4WAV7X1+\1&T3Q*N@&<0&8:'=,-A3=]K"B/S#:#G]_LQ@9QTH ]GHKQ
M_P#9I_:.T[]I/P%;>(].T74-)#6\$DWGP2FT,LBDO%;W#QQBX\M@5=E4 -Q7
MH7C;Q?#X%\+ZAKMSI^IZI;V2"22UT>RDO+IP6 ^2% 6?&<G Z GM0!O45\__
M  '_ &PM"^/&E^([S2/#^M.FBO?,\MC87-Q!-'!,R1HDC0QYN)459!;@%E#@
M$YJ+X)_MF>'OC=\1M?\ ".EZ!KD%QIMWY'VA].N0L*BVCE8WGF0H+5_,:2$1
ML6+-$Q!P10!]"T5Y%^TA^T7IO[./@&[\2:EH^I:LJVUQ+#]FM9C:B6--R1W%
MQ''(+<2,0BNRD%C[&JL'[4OAV;X1CXB-HGB5= ,X@,PT2Z8;"FXW841^8;0<
M_O\ 9C SCI0![/6)XI\50^%=-2ZDM+O4)991!;V>GP^;//(02$49 !PK$EB%
M 4DD 5YU^S3^T=IW[2?@.V\1Z?HNH:2&MX))C/!*;0RR*2\5O</'&+CRV!5V
M50 W%>A^+_%VB^ _#M[KWB&_M]+TFQ3S)KJY<*J]@!ZLQ( 4<DD #)H X32_
MVE/!=YX6\5ZY=S:AHC^%[I+'6=)U2RDCO[6Y<1F&(0KN,K2^;$(_*WB4R*%)
M/%=+X%^*>E^/;W5]-@M;_2-=T@Q&_P!'U: 0W4"2J6BDP"RLC@-AT9ERCKD,
MC*ORUX\U+PWK2P>,+37M+UC4K[Q_X9U[Q+9:;>P78TC38IDMK19GB9E41R*L
MSL6(W>?M+(@%>QZ3OU#]M#Q'-9!7L]-\"V-GJ,T>,?:);ZYEMXF/7<L:RO@]
M!,I_BS0![K1110 4444 %%%% !1110 4444 %%%% !5>\OH=/M)KJXD6&VA1
MI))&. J@9)-6*I:EJ-GH^G7-]J%S#96-O&TL]S<2*D<4:C+,[L0 H ))/&*
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MC2T\9VFAQ3+%9W]O)IJ"2*!(V'F(Z -<2;]@VRD84D!P%5:^[<4;12 _+O\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\
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M#M_9:C<6NHV>A0^39-<H0#-$G\ D3RY-O)4N5)8@L0#T6BBB@ HHHH ****
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M?O-\$?V?_!?[/OAU=)\)::+=I+>W@N]0D5!<7WDIL228HJH7V]6"KFN@\?\
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M    =;M%+MH 6BBB@ HIFX^GUS1N/I0 ^BF;_;-/H ^5?V!?^;C?^RS>(_\
MVWKZJKY5_8%_YN-_[+-XC_\ ;>OJJ@ HHHH **** "BBB@ HHHH **** "BB
MB@ KC/BU\/X_BG\.]:\*274-BFIQ+&UQ/I]O?J@#JQS!<(\3_=Q\ZGDYZ@5V
M=)M^OYT ?)/[,_[#9^ ^F^,XI-:M9I/$$.H6"H^GVEZR02W#M [3R6R.^(BF
M^W8&$ON('-5_V:_V#U^ ?Q?UCQD->M;N%KEOLD2Z=9[IH7M8T8C;;1_8F\[S
M3LMFV,A16SMKZ]VCZ4;10 ZBBB@ I*6B@#X@_;"_X)SZM^UW\3X?%-[\5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4TG5EM;S15@$;1MJ%M*7%Q:3E5 $8W!VD/R;68K]54FT?6EH **** "BBB@
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M0C*,@,*X/(R5]< 'U=1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img205696091_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" );!1(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M="^&.LZ)XPU3Q$FK6<DVI1RQRQF)L*'(/'T(% 'G7PZM+>7PG\0O,A1PD;!
MPR%^]T'05Z%^S_-))\.0CN66.Y<*#V&:BT#X3ZQH&E:]8Q:S:R#6$VNS1']V
M3G)'YUTOPW\%7?@71YM,FOHKJ%I#(C(A4@GKF@#R[PS<:GXO\?\ C)396EY<
M2Q&!/MDF!;QY(^0;3WP>W2O7OA_HFJ^'/!]II&KW*7%Q;;E$B,3\N20.?0''
MX5B3?#6:Q\?OXK\/:I]BEN,B[MY$WI(#UQZ= ?PKO;6 V\(1I&D<DEG;J2:
M)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)XPOY
M]+\&:U?6S%9X+*5XV'\+!#@_@:\G\'>-- \)>$+>RM-"U+699(]^IW5C:^;&
M)&Y8._0X':O7O$VF2:SX6U738B!+=6LD2$]-Q4@?K7FGP_\ B!X7\,^"H-$U
MJ8:7J.GAHKBWFB(:5@3\RX'S9H 35[KP]IGP3UN_\'RR"RORQ*^8V8G<[64
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^<OVE?^0YH/\ U[2_^A"OH#1O^0'I_P#U[1_^@BOG_P#:5_Y#
MF@_]>TO_ *$*^@-&_P"0'I__ %[1_P#H(H NT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$L.HX$\,:,"H'W=I(_G0!0\!Z5I?B_P3=W6L01WUUJ%Q,+N24!G4AB H/\(
M P!]:K_%[38='^"-WIUN\CPV_P!GC1I6W,0)%')J8?#;7=$UR\NO"7B<Z;87
MTOG36DL(D5&/4H#D?Y]JT_&?@K5/$O@Q?#L.J1D2%6N;JY4[W8,&R .!DCIV
MZ4 5?'%_<PVGA338;E+:&_NTCFDD7<A41L0K#(R"<=^U2V_@.\@\76'B!]1L
MK:2W7RGCLK3R1.A_A;YB#[5?U[P6_BOP9%HVL7*1WD)1XKJU!_=R+T89]L_G
M57PUX0\1VES _B3Q.^J06A!MX!'M!8=&=NK$4 =1X@FEMO#>J3VX)FCM)7C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "HIK:"=XGEB1VB;?&Q'*GU%2T4 %%%% !1110 5%]F@^TFY\I//
M*[?,QSCTS4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\Y?M*_P#(<T'_ *]I?_0A7T!HW_(#T_\
MZ]H__017S_\ M*_\AS0?^O:7_P!"%?0&C?\ (#T__KVC_P#010!=HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBO-]9\1>*;;6+N&UA8VZ2E8SY.<C
M/K6%?$1H).2;]#FQ.*CAXJ4DW?L>D45Y3_PE/C'_ )X-_P!^#7.^-/B+XHT3
M0)?.?R);D&*)O*VG..2/<5SPS"G.2BHO7R.6GFE.I-0C&5WY'7>'/BI;:Y\3
M=3\-#RQ:H"MG*#DR.OW^>X/)'TKTJO@S3=3NM*U6WU*TE*7,$@D1AZ@U](:1
MX\\4ZQI<%_:IYD4JYRL.>>];XC$1H).2;OV.G%8N.'2<DW?LCV.BO*?^$I\8
M_P#/!O\ OP:WO"6M^(-0UAH=3B*P")F!,6WYLC'/YUC3S"G4DHI/7R.>EFE*
MI-047KY'<4445W'I!7-^*?$&JZ2([?0]!GUB_==_EJZQ1HO3+.W'X#FNDJCJ
M\^HVVFR2:591WMX,!(99O*4\\DM@]* .?\#^-7\5I?VU[IDNFZKIT@CNK5SN
M"DYQ@]QP:??>*[RX\0W>B>'K&&\NK&-9+R2XF,<<>[.$! )+X&<8QR.:P_AO
MX@GO=<U[3=:TH6'B))!-<[3E94Z*5]AGCZTSX4DS:CXPN9&+3-J[HS'J0%7%
M '8^&?$5MXFTD7MNCQ2([13P28WPR*<,IQZ$5LUYI\,BJ^+_ !['"V81JQ.!
MT#G.[]<UUWC*VFN?"6I""^N;*1(&D$MN0&X!..0>#0!NT5XKJ-K,_P #K'Q"
M^HWO]KVELMQ!<K.RE3G.",X8?[P-:?B^&>R\.Z!XH@O[M=6^U6PDE$IVR([!
M60I]W'/IGWH ]7HKS7XSB\C\%Q7UIJ=W:/'<Q*R0.%5PQYSQGZ8-1^/]/E\)
MP6GB[2[VZ%Y!=PI>!YF9+J-V"D%"=J]>P% &QJ_B/6]/^)&AZ(4M!IFHK*P9
M<M(=@&0<@ ?>'3-=M7EGC_6+;2/B!X-U:\)6WAMKN1\#)Z1_XUT/A[PSIU[>
M+XKDEEFN;PK<0K'=R&&($# 5=V#[Y&,YXH Z^7S!$YB"F3:=@<X!/;)]*\\T
M[QGXOU3Q/JN@0Z)HJ7.FA#*\E_*$<-G&W$1/;N!7HU>1:7=ZO:?&'Q>=)TF+
M4&:.W\P27@@V<-C&5;- '<6&H^*DUJVM-7TG34M)U?\ TBRNI)=C 9PP9%ZU
MTM<[X=U+6[[4=136=.2P\ID$,23B8%2H).[ SSGM7*W5G>'XU1VK:S?M9W.G
M23-;F0!%^91M7 &!SUZ^] 'IE%>;^#&DTOXF>*?#\$\[:;%'#<0PRRM)Y3,#
MNP6).#CIFJ/C_1=$TJV%K8VUY=^)-7E9+1?M\XPS'F0A7 "KR>F.* /5J*X&
M[\,:IH7PWCT?2=5*70=6N[Z[G.=I.9"&.<<<"N=TO4;'3?BOHUCX;N;UM)OK
M60SB65Y(IF .&4N2<_3 H ]@K U?7+E=7@T32(HY=0D3S9G<_);19P&;N22#
M@>QSBM^O/OAU<?VIX@\7ZI)DRMJ/V8$]D1%P/IDD_C0!Z H(4!CDXY.,9I:\
MRU>"]'QKTBR&KWWV.[L9II(-XVC&1M4 ="/7)]#3O#).B?%/7?#MK/<#3#91
MW:QRS-)Y3DD':6R<>V: /2Z*\PN-:\/K<RJWQ3U2)@Y!C#V^%.>G^H[5H>'=
M5T6XUZVBM?B%J&JSMNVV<K0%9?E/7;$IXZ\$=* ':]XO\70:W<6GASP<=5M+
M?"/<O=+"#)C) #=0 1S5KPGXE\1>(TUBUU/18]%O;,B)?WPF =D# G'!QD=#
M76W,R6EI+.V D:%SVZ"L7P=;LF@)>2A_.U!VO&WC#*)"653_ +H('X4 /T#7
MY-1N+O3-0@%MJUD1Y\2G*NI^[(A[J<'W'>MVO.O$MXVE_&3PB8!SJ5O<VT_/
M55"L/U'ZUZ+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MSE^TK_R'-!_Z]I?_ $(5] :-_P @/3_^O:/_ -!%?/\ ^TK_ ,AS0?\ KVE_
M]"%?0&C?\@/3_P#KVC_]!% %VBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNVWE541L>">N>U8]U:>)F^+4.LIX<=]*AMFLQ.+N$,VYE._:6SCY>G6O1:*
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MXXZOX2\47NC3^&X&\A_DD-RPWJ1D'[OH: /;:*^=?^&EK_\ Z%JV_P# IO\
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M-?2TO^J?_=-?-/P;_P"2TZI];G_T(T ?3%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5YKK/Q4DTK6;NP&E"06\ICWF7&[!Z]*]*JE+HVES
M2M++IUH\C'+,T*DD^YQ73A:E&$FZT.9>MC?#SI0;=6/,CS3_ (7)+_T!E_[_
M '_UJ\O^+6M1^,$M=4331;75LOER.'W;TZCL.A)YKZ8_L'2/^@79?]^%_P *
MBNO#.B7EI-;3:59F.5"C 0J.#^%=53$8*4&HTFGWN=$ZV$<6HT[/U/A7K7NW
MPW\6Q^!_#0M(])$MQ._FS2F3!/' Z=!_4UD^#?A5-_PMZYTK4(C)I^E/Y[LR
MX$JY_=^W)P<>@-?1_P#8.C_] NR_[\+_ (5S86I0@VZT.;YV,,/.C!MU8\QY
MO_PN27_H#+_W^_\ K5O>$/B"_BC66L&T\0!83)O$F[H0,=/>NJ_L'2/^@79?
M]^%_PJ6VTRPLY?,MK*WAD(QNCB"G'ID"NBKB,%*#4*5GWN;U*V%<&H4[/U+=
M%%%>:< 5G:O>KI5E)J"Z=<WLR (([2(/*P)Z#IQWK1KGM8\5C1-9@LI]'U6>
MWFCW_;+2U:=$;.-K! 2#^% ',?#+6](UO5?$5W%9RV&M37 :]M)5PR 9"_4\
MG)I/AX#=>//&^HRG=,UW'!GT1$& /SK;T'17D\::KXIDM6M5NX([>%'X=U7D
MNR_PYXP.OK65#;3^!_&^M:DUG>W6D:P$E0VD#3-#.HPRE%!.",'.,4 0_#\?
M9/B#XXL8C_HYO%N-OH[#+8_$UVOB)K]- O9-,N8K>ZCB9UDDCW@8!/3(KGO
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DO^J?\
MW37S3\'&4?&O4QD98W./?YC7LOQ2\6KX0\$7=TC 7=Q_H]LI[LP.3^ S^E?+
M7AK5=5\':_I7B;RI1%(Y<.>DZ;B'&?P- 'VS15;3[ZWU/3[>^M)!);W$8DC<
M=U(R#5F@ HHHH **** "BBO)?&_QL3P;XKNM$;1GN3 J'S1+MSN4-TQ[T >M
M45X'_P -*Q?]"Z__ '_'^%=)X&^-2>,_$\6C+HS6QD1G\PR[L8]L4 >L4444
M %%%% !1110 4444 %%%>4_%GPGXU\1:CI\OA:[E@ABC99@EZ8,DD8X!&>]
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M",0-O2OI&Q\,:%IET+JQTBRMIP"!)%"JL ?<5\]6'_)TC_\ 82F_]%M7TW0
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M9ZXI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /G+]I7_D.:#_U[2_\ H0KZ T;_ ) >G_\
M7M'_ .@BOG_]I7_D.:#_ ->TO_H0KZ T;_D!Z?\ ]>T?_H(H NT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 17$ZV\)D;\!63!#)J%P99"=F<D_T%
M;$D22IM<9%*B+&@5  !VH 208A8#^Z:^:O@W_P EIU3ZW/\ Z$:^EI?]4_\
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M4MO_ ,>T7^X/Y4 24444 %%%% !1110 4444 %5KW4++38A+?7<%M&QVAYI
M@)],FK->0?M$QRR^"-/$2.Q^WKD*"3C8_I0!S/[1.K:;J=EH L-0M;HI)-O$
M$ROMR$QG!XKTOP%XDT*V\!:'#/K.GQRI9QAD>Y0%3M'!!-?'TL,T6/.CD3/3
M>I&?SIZ6UTZ!DAF93T(4D4 ?>ZNKH'1@RD9!!R#2U0T,,-"L _WO(3/Y5?H
M**** "BBB@ HHHH *\&^(OP8U-]=E\1^#Y-D[OYKVR/Y;H_=D;CZ^N37O-%
M'R]*?C3J<3Z5)'JX3&UFV>7D?]=.,_G7H_PH^$;>$9FUK6WCFU:1<1QCYA #
MUY[M[UZU10 4444 %%%% !7/ZQH.JWVLP:AI_B2[TY(X_+>V2))(WYSG# X/
M;-=!10!EZ3HD.F2W%TTKW-]=;?M%U( &DVYP,#@ 9/ XK/U/PF;C7#K6EZE-
MIFH20B">2)%=9D!)&58$9&3@]>:Z2B@#)\/^'[/PYIQM+3>YDD::::0Y>61C
MEF8^I)J;7-/N-4T>YL;6]:RDG0IYZHKE0>#@-QTK0HH \_A^&]U!X!;PA'XB
MN/L1W)YA@0MY;')3D>I//6GZC\/+W4?!MGX;D\27"V]L5S(MO'N<(04!XXP0
M/KBN]HH \X^)UK-9_".XM+N[:ZE01QM.RA"_S=<#@'%:MOX+DO%TT:IK5S?Z
M;9[)8+.2-%4LO*%V R^..IYQDUM:]X6T7Q-'%'K%BEVD1)17)P#5[3M.M=)L
M(K&RB$5M$-J(#G:* .8\1>";K7O$^EZTFNSVATPEK:!(4*J2,,3D<Y''/3M3
M;;P-=V'C"\U^PUV:V%[M^T6BP(8WP ,].#QUZUV=% !7.:QX0M]0U:/6;*ZF
MTS5XT\L7=N 2R?W64_*P^HKHZ* .3D\%/JE[#/XBU>?58;=Q)#:-&D<*N.A8
M*!O_ .!9K4\1Z1=ZUH\FGV>I/IXE!1Y(XE<E2,$#<.*V** ,W0=.NM)TF&RN
M[]KYH5"+*T:H=H  &%&.U4[#PGI^F>*[_7[-/*GOX@EPBCY68$'=]>.?6MZB
M@#G_ !1X/T[Q3%;M<F6WO;5]]K>6[;986]CZ>W2H[;P[JQA%OJ?B6ZOK?&'3
MR(XC(/=D (_"NDHH 8D:Q1".-0BJ,* .!7#OX!U5O&7_  D__"4W O!%Y"I]
MFCV"+.=F,>YYZUW=% !1110!S4/AS5H[JYW^*+V2RGD+_9S%'E >JA\;@/3G
M(K>M[.WM;)+.&%%MT38(\<;?2IZ* .(_X5S#]B?1QJUV/#S2F0Z: N.3DIO^
M]MSSC-=%K6DW&H:6EIIVI3:5)&RM'-;HIVA?X=I&".V*U:* ,BQT66.XBNM2
MOY-0N8@1&SHJ*F>I"J ,^_7KZUKT44 <=K^GSZ3XML_%MI&TL2P&TU"*--SF
M(G(< <G:P&?;-,\1^%9?&=YI6JV?B&2VM[-A/;+#$CJ7_O$D<\<8KM.M(JJB
MA54*HZ #% '$ZKX%O]3\6Z?XA_X2*:*XL4V0HMO&5P1\V<COS].U=N.@R<FB
MB@ KF-8\'_;/$$6OZ7J,NEZH(_)EEBC5Q/'_ '75@0?8]173T4 8FB^'DTF[
MN]1NKR6]U&Z"K-=3 +\BYVJ%'"@9/3UK&N(1XP\7:?/&A;2-&D,OG'[L]QT
M7U"8!STSD=J[3K2*JHNU5"@=@,4 +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\Y?M*_
M\AS0?^O:7_T(5] :-_R ]/\ ^O:/_P!!%?/_ .TK_P AS0?^O:7_ -"%?0&C
M?\@/3_\ KVC_ /010!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LCK&A
M=SA1UK'\^>^O (R54= .P]:U+JW^TQ;-V*+>V2VCVH.>Y]: )0, #.:6BB@!
MLO\ JG_W37S3\&_^2TZI];G_ -"-?0-UXFT"W::";7-,BF3*M&]W&K*?0@GB
MOG3X2ZE867Q?U*ZN[VV@MV-QMEEE54.6.,$G% 'U%15&QUK2M4=DT_4[.[=!
MEEMYUD*CU.":O4 %%%% #)88YEVR*&%+'&D2!$&%':G44 5WO($F\IGPU6 <
MC(JE>:>EP2ZG;)^AKF_$?B-_!GAZ^U*Z4E($/EHW1G/W0#[F@#Q2P9?^&HG.
M1C^TYA_XXU?3E?#BW.MI>+XO*RD_;0WVH]&EY;&?H#7V-X4\36?B;PQ8ZM#,
M@\^,%U+ %7'##';D4 ;M%,26.0D(ZL1Z'-/Z4 %%5C?VJD@S#BG17<$S;8WR
MWI@B@">B@\#-46U6W4X&YO<"@"]152#48;B41J&#'ID5;H **S7U90Q"Q,1Z
MUS/COQTGA?PE>WYCQ.R^5;@G[TAZ?U- 'S]\:=7@U#XH7KVKK(EL$B+#H651
MN'X'(_"OJC0M4MM9T*RU&S??;W$*NA]L5\-/%=7=RDD@=Y;MRRNW61BV"?SS
M7N_P \:K#%=>%K]R"A,UJ3_X\O\ (_G0![_1445Q#-_JY%8^F>:EH **** "
MBBB@ HHHH *CF@AN%"S1)(H.0'4$?K4E5=2U&TTG3KC4+Z98;6W0O)(QX %
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M@D8Z=>:VM%UBRU_1[75=/E$MK<H'1OZ'T(/!H OT444 %%%% !1110 4444
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M*^@J* /-?AI\*&^'NIWMXVL+??:81%M%MY>WD'.=QSTKTJBB@ HHHH ****
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MWO\ 4[]=NHZK<-=3(>L:]$3ZA0H/N#0!U%%%% !1110 4444 %%%% !1110
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M,EA_R=(__82F_P#1;5]-U\R6'_)TC_\ 82F_]%M7TW0 4444 %%%% !1110
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MXMZ[IOB'XA7&HZ7<K<6C1Q 2*" 2% -?1FG?%7P9=R6ME!K43SR[8T3:>6/
M'2D!V]!( ))P!45Q+Y%O)+M+;%)VCJ:X>6[UKQ#*8HE*19^ZO"CZF@#N8IX9
MP3#*D@!P=C X_*L[7M,GU2S2&"81X;+ G 84S0=%.D0R;Y?,EDQNQT&/2MB@
M#G],\*6EGMDN,3RCU'RC\*Z     8 HHH **** "N.USX7>$O$6K2ZGJ6FF6
MZE WN)&7./85V-% 'S#\<?!&@^#HM#.B69MS<F<2Y<MNV[,=?]XUVWP^^%'@
M_7/ NEZE?Z:TEU/%ND?S6&3D]A65^TS_ *GPU_O7/_M.O2?A/_R3'1/^N)_F
M: -?PSX0T7PA;36^BVOV>.9@T@+%B2.G7ZUNT44 %%%% !1110 56>_MD=D:
M3#*<'Y35FJ4FF122,Y9LL<GI0!/#=0SL5C?)';&*X+XQ^,/^$5\$S1P2;;^_
M!@@P>5!'S-^ -=S!9PVA:0,>!R2> *^8O&%_+\4_B]%I=O,$T^"3[-&Y8 +&
MI^=_SS^&* .*&BZOX>TK1_%B$HDT^Z%L$%64Y&?8XKZ\\'>*+3Q7X;LM2MW&
M^6,>8G=7'##\_P"=8WB3P;HFL^"Y] M[B%%6$+:CS%^1E^[^HQ^->3? ?Q$=
M%\4WGA;4'VB=CY.6X65>"!ZY&/RH ^DJACNH99#&C[F'L:F(R,&JT%C';S&1
M"V<8P: +-%%% !7F'QF\)6VI^&FUZ&Q@EO\ 3&%PVY1^]B7[RL>XP.E>GTR:
M*.>%X94#QNI5E(R"#U% &/IVKZ9<^#(=5MXT_LTVGFK&%XV!<[<?IBL[P/X?
MTWPYX?:\BMH;>6\+74\@4+\K$LH/H N./K7 >%/M>G:I??#&82M'#?"XBF/7
M['DOG_OH(N/1C7JOB:SGO/"VI6EH,326SI&!ZXXH YG4_B7!ING)K/V S:*6
M7-Q'<1F38QP)/+W;MO(XQGVK/^)EQ9RQ>$M5B42AM4B*2QIN8J48X&.?2LSP
M3X@\!WO@FT&J)9V][9P+#=V\X(;>HP3M[YQQ6G\0;FU6T\'%0ELAU6)DB8A=
MJ[&_Q'YT =&/%\D'C"TT'4-,EM?MT;26LQ=6#;>JD \&HQXN@?XAKX:?29X[
MD0-(MW)MVL@Q]W!SBL'QG/$OQ8\%YEC&#+U8#J.*+Z:(?'S35,L8/]F2#!89
MSD<4 =5?^)91JT^E:18/?WEO&)+C#A4B!SM4DGEC@\#\<9%)H>OIXH\/W,\V
MFW-E+&SPS6UTF"K+D'GH1[BN,T+Q%:^&/BCXJTO79ELQ?RQW=G/,<+*NT*0#
M[8_G7H46K:?J-C=R65S%+%&I#2(1MR5SUZ=Z .(^#=Q#9_#$W$[B.&*XG=V/
M15!R35[5/B9!I%I!JMS8$Z-*ZK]H2XC9U5ONN4#9VGZ9]JY7P5;S:A\!=5M;
M)@URS7&T YZ'./TJ]X4\1?#_ %'P;9SWJ6<5S!"L5Q;3 [Q(HP1M[Y(R/K0!
MZK%*DT22QL&1P&5@>"#6/XB\-6OB>&"SU!Y&L%8O+;HY42GC:&QU YX[UB:U
MIOC.\N(9?#VJV>FV/DKBWGMR[*<>H(K5.K-X6\*0W/B:_ADNHUVRRH-@E<DX
M"@_A0!PB>$[3P=\7M#'AE7MX+^"3[;:*Q,>U0<-CM[>]>N5Q&EZ[H$.HG4[S
M5[6?5M0=+>.*)]_E@G"1(/J>3W.3QTKMZ /)_&%]K/\ PMCPO$MA&ZQ"9K=3
M*,/G )/IT%=3-?6.@:K''9Z.K^(M842S00;1]T<N[' VCU[UA>+)X1\8_""F
M:,$139!8<=*+^X.C?'.RN[U\66IZ<;>WE8_(CJ<[<]B<4 ='I'C);S7;O0-0
ML9;'6+>+SU@9@PGC_O(0>1GCFLNR^(]SJL>JKIWAG4)KO3IQ%+:LR*^#C+9)
MQ^&<U!K%J-4^,>@S6+J3I]I,]Y(G.%8J$4GW^8X]J7X>SPR>+?&H25&8ZD",
M,#D>6M 'H2DE02,$CIZ5Y+\2=6M(_$L2>)/#.H:AX=M805FACW(DK'YF8=P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPAM8F,%O*L]Q+CY8U4@\GW.!^- 'VA2*JH,*H4>@&*4<# HH **** "BBB@
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MG_Q3I^IV]]#K=FD\,BR+(-V00:^CJ* &H&$:AR"^!DCN:=110 4444 %%%%
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MCZ?=:I:ZG/:QO>V@98)B/FC##!Q]:O44 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !5>[L;2_C$=Y:P7$8.0LT8< ^N#5BFR2QPH7E=40=68X H
M^?OVB],L-/LM -E8VUL7DGW&&%4W8"=<#FO3/ .@Z-<> =#EFTBPDD:SC+.]
MLA+':.2<<UXO\?\ Q;:ZYXBL](LI(YH=-5B\J'(,CXR,]\!1^=>H_ [Q3'KW
M@:&P=Q]LTW]RZY&2G\) ],8'X4 G<]-5510JJ%4#  & *6BB@ HHHH ****
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M4KV0R7-S(9'8G/)[?0=*IT ??BS1-$LJR(8V&5;/!'UIRLKKN5@P]0<U\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'H<#-9>EZY#J
M$KVLL;VM_%_K+6; ;ZKV9?<?CBM2O._$?C[P))J1TV]U1HKR!]@O+=3FW<'^
M_C'!Z@Y'J#0!RNJR>%-0U2ZG\4^,]4T_6(I&_P!%622(6WH$4 AAC!R,YS7J
M'@VXNKKPK9RW<TL[_,J33*5>6,,0CL#SEE"DY]:RPUB+JW;Q'I]A=JZK]FU?
MR%99/0-D':>F.<'G&*[%=NT;<;<<8Z8H 6BBB@ HHHH **** "BBB@ HHHH
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MKZ T;_D!Z?\ ]>T?_H(KY_\ VE?^0YH/_7M+_P"A"OH#1O\ D!Z?_P!>T?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!\Y?M*_P#(<T'_ *]I?_0A7T!HW_(#T_\ Z]H__017
MS_\ M*_\AS0?^O:7_P!"%?0&C?\ (#T__KVC_P#010!=HHHH **** "BBB@
MHHHH *\O^/KPI\,W$IP6NXUCXZMAOZ UZA7F/QOTJ]UOP:;2U@+K"_VK<!GE
M01CVX8T ?)U%%.C1I9%C099B% ]2: /J;P[IKZAX8T:>&X!M9+53&,?=&2"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYE4BO.53EJ<\%;MU.+GY9\\%;\3W;X6:!X9\3^&(-9>)[BZWF.>&5\K&XYP
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M\1:-I]RUM>:G:P3+@M')( 1GD<5IU\Q?'G3-'MO&-Q?/J;R:E<QQG['&G^J
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MY[;G%(74=6 _&O$SX2^),Y"RW5WCU?40<?\ CU+_ ,(!XYG8":\? Z%KO/\
M6E]9GTILK^Q,*OBQ</EK^I[298QUD0?\"%(;B$=9H_\ OH5XR/A;XIG;,VH1
M@CH6F9J4?!W6I26EU*T#?[6X_P!*/;UNE/\ $/[)RY?%BU\HW_4]@?4;)&*M
M=P CL7%5VU_2$8JVHVP(ZCS!7EB?!C4,?O-5ML_[*M5A/@O)L'F:LN[_ &4X
MH]M7?V/Q'_9V4K?%7](L]#/BWP^"0=7M,CK^\%>&_'?QTFJ_8-!T:_CFLW'F
MW!B;[S9PJD^G>NW7X+VVT;M6EW=\1BO*OC#X ;P=>:=J%I)-<VDPVO*Z@!9!
MR%X]1FM*<ZS?OQLCDQF'RVG3OAZKE*_:VG7H=SX$\$?#>WL+.UOI8-5U>Y W
MF1FP&(^ZH&,#ZYK#^,?PKTWPUIB>)/#J-:112*L\ <D)DX5E)Y'/O72?#[3/
M!>KPV&LV6MLEW 0TEK/(JLK@<@@\D>XJK\=?'^D3>'&\-:==Q7=U<2(TS0MN
M6-5(."1QDD=*NDZC7[Q'+CH8.,E]4DVK:W[G>_"GQ-<>*_ 5G?7C!KJ,F"5O
M[Q7')^M=K7GOP6T*YT'X<VD=Y$8I[F1K@JW!"MC&1VXKT*M3A"BBB@ HHHH
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MV-QM)P;@ \?CVK;TSX27ETXGUO4"A;EDC.YS_P "/%>A# 4J:YL5/E\EJ_\
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M*H Y#_AI#PO_ - G6/\ OB+_ .+H_P"&D/"__0)UC_OB+_XNNO\ ^%0^ O\
MH6[;_OY)_P#%5X+J_AO1[?\ :"C\/Q6$::2;ZWB-L&;;M9$+#.<\DGO0!Z7_
M ,-(>%_^@3K'_?$7_P 71_PTAX7_ .@3K'_?$7_Q==?_ ,*A\!?]"W;?]_)/
M_BJY"^L?@AIM]-9W=M81W$+;)$+RY4_]]4 '_#2'A?\ Z!.L?]\1?_%T?\-(
M>%_^@3K'_?$7_P 75?'P(_YY:?\ ]]R_XT8^!'_/+3_^^Y?\: +'_#2'A?\
MZ!.L?]\1?_%T?\-(>%_^@3K'_?$7_P 772:9\,_AMK&G0:A8:%:S6LZ[HY%D
MDPPSC^][5;_X5#X"_P"A;MO^_DG_ ,50!R'_  TAX7_Z!.L?]\1?_%T?\-(>
M%_\ H$ZQ_P!\1?\ Q==?_P *A\!?]"W;?]_)/_BJ/^%0^ O^A;MO^_DG_P 5
M0!R'_#2'A?\ Z!.L?]\1?_%T?\-(>%_^@3K'_?$7_P 777_\*A\!?]"W;?\
M?R3_ .*H_P"%0^ O^A;MO^_DG_Q5 '(?\-(>%_\ H$ZQ_P!\1?\ Q='_  TA
MX7_Z!.L?]\1?_%UU_P#PJ'P%_P!"W;?]_)/_ (JC_A4/@+_H6[;_ +^2?_%4
M <A_PTAX7_Z!.L?]\1?_ !='_#2'A?\ Z!.L?]\1?_%UU_\ PJ'P%_T+=M_W
M\D_^*H_X5#X"_P"A;MO^_DG_ ,50!R'_  TAX7_Z!.L?]\1?_%T?\-(>%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1A8LXP,>M=Q7DG[//_)/IO\ K\?^0KUN@ HHHH **** "BBB@ HHHH ****
M"N?\<>'Y_%7@S4M$MIHX9KM%59) 2JX8-SCZ5T%% '#?"SP-=^ ?#MWIMY=P
M74DUV9P\(( !15QS_NUW-%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<;W$HZ,Y)R?IV'TH IZBGC/POX%T[Q[_ ,)3>7%W*8IKJSG5?*V.1\H7'!Y
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MD^5RV0IZD;B?ZU%X+1IOVB_$SQ."L2RE\'_: Q^9% 'N=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\Y?M*_P#(
M<T'_ *]I?_0A7T!HW_(#T_\ Z]H__017S_\ M*_\AS0?^O:7_P!"%?0&C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH **** $894@'&1U]*XH?#L+XBFUZ/Q!J::C*OEM("F-G9<8QBNVHH Y1/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4456OM1L=
M+@\_4+VWM(<A?,N)5C7/IDD"@"6>:*VMY)YG5(HE+N['A5 R2:\S/Q@GN5DO
M-)\&:QJ&D(3F_0;5*CJ0,'/YUWUOJ>B>((;BUM;_ $_48V0K-%%,DH*D8(8
MG@YQS5#7M;T3P-X:,DHAM;:)/+MK6)0-Y[(BC^E $^C^*M(USPTNOVETO]GE
M&=W?CR]OW@WIC%<,?C0@C.I#PKJ__".A@/[5*X7&<9VXZ9]ZP+[3M0\/? +6
M)[R(V]UJLSW$D!X,2RO]T^^,<5ZO%I]JG@D:>L2BU^P&+R\<;=F,4 /U#Q1I
M.F^&6\0SW(_LX1"42+R6!Z #N?:N*MOC"J7=JVL>%]4TK2[MPEOJ$XRC$G@D
M8&!WSFN&1_MGPI\'Z7.-]L=;\D@G^%7; _6O6?B;:0W7PUUZ.:,,J6;R*,=&
M49!_ @4 =8K!E#*<@C((I:Y[PGJ1?P%IFHWDG LEEE?D\!<D_D*Y[_A=_P /
MO^@XW_@'-_\ $4 >:?M*_P#(<T'_ *]I?_0A7T!HW_(#T_\ Z]H__017S%\;
M_&.A>,=4TB?0KTW4=O Z2DQ.FTE@1]X#/X5].Z-_R ]/_P"O:/\ ]!% %VBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img205696091_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &E!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\"?LDZU+
M^T%^V;\>O$GCI!J&H>"[Y=$\.Z3>C?'I=OY\\;R11MPLC"%,N!G+MS@U]]UX
MY??LTZ!:_&*[^*'A74;[PAXOU&W%KJSV'EO::K&""#<0.I!=<##J5;CDG)H
MX+]L#X6Z'X=^ /QX\4:?;BVN=9\)-!=6ZY\DO )F255Z*Y\P@D#G:I/3->9_
ML:?M">)-!U3X'_!W5])TE]$UOX=6^LZ;J%C)+]IA\M2NV8-\IW"-C\HX) R<
M9KZ<^(/P0B^(_P -_&/A+5/$>J,?%-K]BO;_ #&7BAY!2&+;Y<8VEN0I))R2
M3@UY]X!_8MTGX?\ Q%^'?C"W\6ZO>7?@CP\/#-A;7$$ CELP' \TJ@)?Y_O
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M?_$W0OB?I]_>:#)?,EA=FQNH=2TNZTZX@F"(Y1X;F..0?+(ASMQ\U?'7P=^
M7B^Y7]H/2/B%\(KZ;P]\0/%/]M65M>:U81G[.]QN/SV]Q(T=Q$")5 PI*8WB
MOH+]E?POX^\'^#]:TWQK>:Q=:?'JDG_".Q^)KFWNM8M]/V)A+N>W=XY&$GF;
M2'9MFW)!^50#VZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HIGF<XI=WX4 .HIN[VHW>E #J*;N_*G4 %%%% !1110 4444
M%%%% !1110 4F*6B@!-M&VEHH 3;]?SHVBEHH :%"].*-HIU% ";0*-M+10
MW:/I2[:6B@!,4;?QI:* $VCZ4;:6B@!-N:,4M% !1110 F*3:*=10 FWWHVT
MM% ";11BEHH 3;2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4)M:>:%UB^^X*.DPD V[06SA2: /T*W'CCZT;C^-?/?[0OP/^+WQ.\2Z9?\
MP^^-US\---MK);>YT^'24O%N)@[,9MS.N."JX_V:\V_X)_\ C;XBZMX_^._@
M_P"(?CBZ\=S^#M9M=+M;ZXMTA''V@2,J*. Q1>"3]T4 ?9]%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% #=@H"@=R:=10 W:*-H[<4ZB@!NT4ZBB@#X8_X)/?\
MD[^,'_90M0_]$P5]SU\,?\$G_P#DG?Q@_P"RA:A_Z)@K[FS^% "T4QI N22
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M R\RMMC8[0Y ^Z3V)K\U_@?JGC+1OBYX1N?A^;C_ (3-=2A&EI:Y+23%P A
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MW5= NO"VHZA:I<7&BWQS/9NPR8WX'S#Z#Z5TU !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q5^PK_R<Q^UW_P!C
M?!_.ZK[5KXJ_85_Y.8_:[_[&^#^=U0!]JT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-W'B@ W
M4;L=:\D^(OCSPSXBFTCPY!\3M.\,IJ\\ML9=+U&$:A=,A"M! _S"(AF 9Q\P
M.U1M+9'.V_[#OPML;L:A9IXHL]<#;QK4/BW4_MF_.=YD-P<G//((]J />_,J
M2N>\'Z7JF@Z:=.U357US[,VV#49PJW$L>!CS@H52XY&Y0 P . :Z&@ HHHH
M**** "BBB@#X8_X)/_\ )._B_P#]E"U#_P!$P5]QF3;RQ&*^&_\ @E#_ ,D\
M^+W_ &4+4/\ T3!7V/XL\)Q^*K*.VDOKNQ".'#6<FQCP1@GTYK*K*48MPC=K
MI>WXF%:52,'*E'FDME>U_F>:_M7_ +3FG_LJ_"U/&U_HEQXA@;4(;#[':3K$
MX,BNV[<P(P-G3'>OCVT_X+;>%KR[A@7X7:P&D=4S_:D1ZD#ILYKL?^"F'P+U
MF^_9NBA\,P^(_%FI_P!MVI_L^W22[8)LEW/L0$\9'/O7Y5:7^S7\6UU.S+_#
M'Q@J"9,M_8=T,#<.?N5G0J5:D+U8<LNU[_B9X:I6JT^:M3Y9=KW_ !/Z2TN%
MD13G!(Z&G[B>G2O,[?X*P^3'GQ%K?  .;H@UZ5%%Y<:KDM@8R>M9X>K7J7]M
M3Y;>=S+"5L55YOK%+DMMJG?[MA)YFAAD<1M*54L(T'S-CL,GK7G7@GX[:=X^
MTK3M5TOP_P"(#I5]>R6"7DMFBI'+'-) _F 2%E42Q,N[!'0]"#7HES,MO;R2
MLK.J*698U+,<#H .2?:OF']F_3]2\(>#_#ZZCIGCFVU4Z[JS-HTEH\=DL=UJ
M%R\<DN5VJHCD63.[()(Z\5VGH'U$)"6/'%-6X63.UE;!P<'I7QI\//">L^&_
M$7@*[7PAXFM$M_&7B:6^E-C,2NESBZ-LKDG_ %;,]L57G:0#P5-7K/PU>W'@
MKQMXG7X;:NOBW6M+^R:?X8M[633HM,TM)D"VQFC*^9<.K&:78V7*>4K!5#$
M^D_B5\2K'X7^&[?6]0L[V^LYK^TT\_8$5VC:XF6&-V!8?)O= 2,D YP<&NK\
MT;L#!]N]?&NH>#O%6G?"GXD:./#VNWOG^/\ 2M1TNW@TT1J]F)=/FFDAA5L1
MQJ8KABIP01R-S5H:UX!\1Z;XJO(K?PGJMR(_BW8^)()[2$>4NG2VL2RRHQ8#
M =9!(HY!.<'(H ^J-#\5:3XEBNY=*U"WOXK2ZDLIY('W+'-&VV1"?56!!'8@
MUI[N<<"OC[P_\,=3T'21H3> KB&UN?B%K]U=W45GYL,-I,UX]K-]G#!+B-DE
MC12X*0LX;;E!CD='^'_BZ;PMX;@\1>$O$U]J4/P<OM&O3<6\LQ.JB2#[/&S9
M*F8".4J^>,CYN10!]U75TUO:SRQPM=21H2(8BH9V R$&X@9/3D@<BN;\:?$*
M#P#\-=6\9:MIE\+72M-DU.[T^W6-[E(XXS)(H&_8S*H;.&YVG&:^8_#OAOQ)
M_9?C"WNO#'B)1J7PITZWN UK*/M6L1QW"RH3G+7'[R(%NI_O';QF>*/ ?C#Q
M!\)[[2-<\(:UK@O/A+%I.AP" L]CK*6TR74<JELQRR,;;;*>"(V7<,X8 ^S=
M+U:+5]-LKZ$%8KN%)XUD&&VLH(R/7D50\6>,-/\ !NGPW5\9':XN$M+6VMTW
MS74[_<BC7/+'!/H "20 2/F&Q\%>(]4^)=E%XB\/>,HT,^BZGH&IZ4UM%;64
M<-K$LUI<RG+P8E6?S(P2LJRX&2<#U'XU6MU;_%[X)Z[*2/#MAK5[;WK<E(Y[
MFQFBMI&[ ;R8PQ_BF4=Z .KD^-&B6_Q$L/!UQ::M;7U^SP6M]+ITHL)KA(S*
M]NMQC:9!&K-Z?(PR2" _1_C5X8U[Q5%H5I<RM-<75U8VEVT+"VN[FV!^TPQ2
M=&>/:^?]Q\;MC8X[Q7H^N>,/C)X2UGP_<>(M)/AW49+;5+34( NDW=DT,@>2
M,,OS2ES&$DC.0-X/!(/G/@'X1^*+&X^%7A&ZTN[MH_ _BW6-<OM8< 6UU;2_
M;OL_EMGYVD^VIN7JNQ\]L@'UAO\ 7Y?K1OY(R#7SM\=O"D^M?&[PS?'PWJFL
M:.GA#7K._DM;62:W:27[-]FB8 X+G9<;>,C/49%>2:#X<\1Z9X*G&LZ!K^G^
M9\%/LFL7=]%+&CZO#&Q(ED)R9@-Y#G)QT/2@#ZZ^)_Q(L?A3X#UCQ9J5I>7U
MAI40FN(=/17F"Y )"LRCC=D\YP#Q5[Q;XRLO!FB2ZOJ"3'3[<JUW-"F_[+$>
MLS@'.Q>K$9P,GH#7Q5JG@SQ%XK^"EYJGAKPYKJV>I?"ZRTJZL%MF,FJZHS0/
M#*D9/[QHHQ,&E/#"91N.WCVSPGJ#Z'\,?B4/&_AN2VUVUMKG^U==;3S!#XBB
M,)\N:,D9W,A5##_ X95&W:2 ?0<,ZSQK(CJ\;C<K*<@KZ@CKZ_C4M>?_  #T
M'5_"WP/\ :-KY<ZW8:#8VUZ)/O"9+=%=3ZD$$>^*] H **** "BBB@ HHHH
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M4E\RYN=BA?,E;NQQDGU- '24444 %%%% !1110 4444 %%%% !1110 4444
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M!M(G\PRE5_U:L,M@ C.: /T""C%.I%^Z*6@ HHHH **** "BBB@#X8_X)/\
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M "BBB@ HHHH **** "BBB@#XB_X*@*%T/X&8 _Y*-IO;V>OML1@9XZU\2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M G/% '>4444 %%%% !7Q5^PK_P G,?M=_P#8WP?SNJ^U:^*OV%?^3F/VN_\
ML;X/YW5 'VK1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4M6O'TW2[N\2WEO'@A>46\ R\NU2=BCN3
MT'UKX>\*_"OXAZUKFE?$_2_@1\)](O+O;JMK)>:Y=2W5EYBAMXB\D0+.%/)7
M;ROWAC-?;>OQS3:'J"6\DT,[6\BI+;@&5&*D!D!(&X'& 2.:_-WP9X'^$D6A
M:/)J?[/_ ,?+[7MD4ESKUU'J*Q3W&0QNI,WFP*S?O#E" "<J<4 ?IH*6DI:
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M_C?\4/$_AOQYK$<6L?#R'P1I=A:RZGHGC"Y*7EZ2TC.;< X4.I1%9U<-)&5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*\32I%X=U5Y+YM,C6TF9KV
M,9:W4(<R #J5ZX]J_/6Y^('P^E;1_P#A$/VC?C)\0/$1U"R:W\/1F;_B9?Z1
M'E#NLD4*1DDE@,#!XK['^+WA;XL>)-5LO^$ \:>'_"^D?9F2]AUC0SJ+32$_
M*5Q+& NTD$'/0>M>'Z9XN^*.K>-Y/!EC^TS\+=0\3V[[)M!M-"C2[^4_.@ N
MF*OC(/RDKZ<4 ?9%%%% !1110 4444 %%%% 'PQ_P2?_ .2=_&#_ +*%J'_H
MF"ON>OAC_@D__P D[^,'_90M0_\ 1,%?<] !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^9'_!5'XU^.[WP#
MX@\$WGPIU'3_  ;::S9/;^-I+L&VN650X41[."6++][^$U]B_LO_ !F\=?%K
M1]3;QI\*=1^&0T]+9;,ZA=B?[>KJVYE^1=NW:N>OWQ7QG_P5Z_:@\)WGA-O@
MIIPFU'Q1#>6VHZA/"5^SV(52RQ,>K2,KAMH' ()/.*]-\+_\%7OACJ7P]T*/
M0/#GBCQ'XYGB6VC\'Z;9&6X\U0%YE'RE#V*AF_V!TI!Z'W:7->5?&K]J;X8?
ML^VC2>-O%MCIEWMW1Z9&_G7LOIM@3+X/J0![U\A>*/%7[47[0#>1K&K6?P'\
M-W1&S1-!/VS7YD/0.X.8C[[HB.ZFNU^!W_!.?P9X7ODUS6=/FU3578R27^N3
M?:[R1CU8DC8I]PN?>O*J9A!3]E13G/RV7J]D>)6S2FJCH8:/M)]ELO5[(YO4
MOVX/C7^T1?/I7P"^&,FB:9+POBKQ:HSMS_K$A!V#ZYD'M70^"/\ @G"WCC6+
M?Q5^T+X[UCXK:ZI#II<ET\.G0'.=H1<''LNQ?]FOLO0?"^F>&;-;73K6.VB4
M8^48)]R>YK6*UUTXU9>]5?R6W_!.VC&M+WJ[U[+;_@F-X1\$>'_ .AV^C>&M
M%L=!TFW&(K/3K=((E_X"H S[]:^0?^"CGBKXS6?PS\;Z-X9\"Z3JWPRN/#C/
MJWB"XOUCNK4Y?S0D1D!;:H0C"G.X^E?;5>'?MO\ _)HOQ<//_(N7??\ Z9FN
ML[CQG_@G1XL^,^H?#7P1H_BCP)I&C_#.W\-1MI/B"UOUDNKL@H(M\0D.W<A=
MC\HQ@>M?:VVO$?V(U_XQ'^$1R?\ D6[/_P!%BO;Z "DQFEHH ^(_^"H#%=!^
M!O4?\7&TWG_@,E?;/J?SXKX?^-7_  3Y^(/QL\63ZCJG[0>M+I4.MOK6D:3-
MI8DCTN3>S1",B8?ZL-M!Q7T3^SO\*?&'PE\,ZGIWC/XDZC\3K^ZO/M$.H:E;
MB%K>/8J^4HWMD9!;/^U0!ZU1110 W:.N*6J.LZU9>'='OM5U.YCLM.L8'N;F
MYF;:D,2*6=V/8  D_2O%?^&[OV?_ /HK/AG'_7W_ /6H ]XVBEK)\+^*M*\:
M^']/UW0KZ'5-&U"%;BTO;=MT<T;#(93W!%:U !7SG^SE_P G$?M-?]C'IG_I
MJMZ^C*^<_P!G+_DXC]IK_L8],_\ 35;T =G^T/\ !.7XZZ%X4TV+6$T8Z'XG
MT[Q"TCV_GB86KES%C<N-V?O<X]#7&_%#]ES7-7^*&K?$'X=^-;;P?K>O64-C
MX@T_5M&CU;3M36'B"1X6=-LJ# W!L8'3KGZ)V"EVB@#Y3^&_[#Q^'-E\$K:+
MQA]O_P"%=ZIJFJ3O)IPC_M%[U7#(H$G[H*7X^]D#M7L/Q?\ V<_ OQVETN3Q
MC87]Z^FK(ML;/5[RQVARI;<()4W_ '1][..<=37I6T?A3J .&\*?"S2OAK\.
M)?!_@J6ZT*V2.<6=S<7$NH2VTLA8^;FX=V?:[;@K''&.G%>5^"/V:?&*_%ZP
M^)7Q%^(]OXQ\2:+I=QI6AQV.AIIUM:";_63.@D<R.0,8W  =!7T7M%+MH ^7
M/@W^S1\5/AK\5O''C75?BGHNL2>,DC;5;>U\,?9SY\%LT-M)&QG8*$+!F7!W
M;<<5N?$S]FWQ5\9_A)X)\"^-O'T>KPV6J6]]XIO(]*6 Z_##(9%M_+1PL*GY
M,X#9* X%?0VWW/YT;10!6N(9([&2*R\J&98R(?,4F-&Q\N0"/E!QP"./2OF?
M7OV-[^^\.:+=6?C*.3X@Q:E?:IK'B+5=,^U0ZI/>6<EG-N@$J[%CAE"PJ'Q&
ML:KA@6S]0[11M% '-_#?P7;_  V^'OACPG9SS75IH6FV^F0W%Q_K)$AB6,,W
MN0H)]ZZ:F[13J "BBB@ HHJM>RW$=G.]M''+<*A,<<C;%9L< G!QSWH ^7OC
M3:^)?B%^T!!H^D:7\-M#;PMI]MJ5IXF\<:2-3OII)7D^6Q7S(S&D9B&]]V07
M3 YS7:?!?1?!MQ-8ZKJ.A^#--\<:/>7NF)<>&W06TDDC;YI;9.JF3.6!!=3Y
MBEF )/!_%+Q!^RSXH\937OQ?TOPYI/C..W2VEM_&UGY$XC0L5"-(-DBY=L/&
M6!R.3Q6K\%?A[^S_ *_XMTSQ)\)OAYHSC37:5?%NFZ8UI;PL49=D,Q5?.8AR
M"$RH4G)!P" ?3M%%% !1110 5\5?L*_\G,?M=_\ 8WP?SNJ^U:^*OV%?^3F/
MVN_^QO@_G=4 ?:M%%% !1110 4444 1-<(G#,JGK@G%'VB+_ )Z)_P!]5\^?
M'[]A'X8_M)>-H?%7C#^V_P"U8K..Q7^SM1,$?EHSLORA3SEVY^E>:?\ #H_X
M#>GBK_P=-_\ $T ?9WVF,'!D4'L,]:/M$7_/1/\ OJORG_:F_8$^%GPA^(WP
M+T30#KZV/C'Q2FD:H+C4R[&W)3A#M^4_,>:^BO\ AT?\!O3Q5_X.F_\ B: /
ML[[1%_ST3_OJG>9D CD'GBOB_P#X='_ ;T\5?^#IO_B:^QM'TJ#1-)LM.MBY
MM[2!+>/S&W-M10HR>YP.M %VBBB@ HHHH **** /Q/\ !/\ R4;XR?\ 8Z:C
M_P"CY*[6N*\$_P#)1OC)_P!CIJ/_ */DKM:_GKB/_D:5O7]$?RSQ;_R.L1ZK
M\D%%%%?,GR 4444 %%%% !7L7_!+/_DL7[1/_7UI?_MW7CM>Q?\ !+/_ )+%
M^T3_ -?6E_\ MW7Z/P5_O=7_  _JC]7\._\ ?ZW^']4?HQ2TE+7[(?OP4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% 'PQ_P2?\ ^2=_&#_LH6H?^B8*^YZ^&/\ @D__ ,D[^,'_ &4+4/\
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MKXVGN]6ABC !,D10LT@0')9L%@3P.* /M6BBB@ HHKYD^&_[3/B#XO?'C7=
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M_P"D[UVM? /_  5&_:O\<_L\VOA_0O"TOAZ32_%.FWMM?6M_"\UX 0$,B!6
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M_P"VA\9_B/K'AC5?$?CBXU/4/#-\-1TB=K2VC-K<#'[P;(P&/RC[V1Q77?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 4-8LY[_2;ZVMKAK.YF@DCBN%ZQ,5
M(5Q[@D&OCK3?!TVGPZ7X#\-_LT_\(UXBM9(O-\<WALC8V3*P9[^.]1S<SR\%
M@"JR,QP^!NKZ_P#$<GD^'M3?[=_9:K:RM]NV[OLX"']YCOMZ_A7YS>#[?X1:
MMX7T:_OO"'Q^\2:E-##)-XCVZRUG?2Y'^E9:41^4[?/RFT*W(Q0!^EU%(*6@
M!K-M4G&<5\Z:W8Z1^T-X^\!:[I'AC7=%U#P[>737^LZQHT^F316LEK/!+9@S
M(IE\QY$.%W*NS=G.,_1E)M% 'P[IOP;\1>)OV?\ X2_ Z_TB^L]6\+^)+7^V
M[[R'2VCL+&>65+F.8C8_GJL(102=TC;@-C873?@WXA\0_L^_"OX&7FD7UMJW
MAGQ/:C6+XP.EM'IME<RRK=1S$;'\Z-(E502VZ4@@;&(^X=HH6,*N!G% 'Q%H
M?PC\27_P%^%GP1N-'OK?6?"_BNU?5+YH'6U73;*\DG2Z28C8_G1I$JJ"6#2D
M%1L;'H'Q^_8A7X\?$*7Q6?BMXY\(^9;Q6_\ 9N@:AY5L-@(W!<=3GFOIW8,D
M^O-+M% 'P;_P2'TU=&^$GQ0T\3R7*VOCJ\@$\QR\FVWMUW-[G&3[FOO.OAC_
M ()/_P#)._C!_P!E"U ?^08*^YZ "BBB@ HHHH **** "BBB@ HHHH ****
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M=\/ZC\:/'#95;;048V,+9(W27&""H/.4!7'\2UQDG[*_QI_:9==3_:-^(O\
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M"O\ >ZO^']4?J_AW_O\ 6_P_JC]&*6DI:_9#]^"BBB@ HHHH **** "BBB@
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M*GS(=,R1IMGSD*L?&['T /<&OH^WM8;2".""-(88UVI'&H55 &  !T%>M[3
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MS^(O^1@U3_KZE_\ 0S6?6AXB_P"1@U3_ *^I?_0S6?0 4444 %%%% !1110
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M+/"#_#OX=)<^&?$ATV/2UE2#PYJ=V(8Y3+'B!OG"2E6C,;E7C8$G&1YG\/\
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M HHHH **** "BBB@ HHHH **** "OBK]A7_DYC]KO_L;X/YW5?:M?%7["O\
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M_P 4M!\-?#1=0\->(_$VGO8VVEVMC(NFVK:?"E]?6MO,Z1K*'21!]W]Y('Y
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MQ&.FJF(E=K3I^AHHJ.B.8^'/@/PIX6\,Z5_PCF@6>E6IM(C&8[5(9638,;\
M9;&,YKLMHXH$:KC P!3JY9U)U'S3;;\QV2T0FWC%>*_M(?L]ZQ\>[30K?2?B
M=XH^&HTV2:263PS<-";SS @ EVLN=NPXSG&\^M>UTW:*S&?&WP"_X)WW/[/G
MBS1-2T?XU>,[G0M.O&NY?#32^587;,I#"2-7VG)P2<'D#TK[*HV_A2T )BBE
MHH **** $VT;1UQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !113-Q7J* 'U\5?L*_\ )S'[7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWPX_Z$SXE?\ A*R__%4?\/+OAQ_T)GQ*_P#"5E_^*KZVHH ^2?\ AY=\./\
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MOAQ_T)GQ*_\ "5E_^*KZVHH ^2?^'EWPX_Z$SXE?^$K+_P#%4?\ #R[X<?\
M0F?$K_PE9?\ XJOK:B@#Y)_X>7?#C_H3/B5_X2LO_P 51_P\N^''_0F?$K_P
ME9?_ (JOK:B@#Y)_X>7?#C_H3/B5_P"$K+_\51_P\N^''_0F?$K_ ,)67_XJ
MOK:B@#Y)_P"'EWPX_P"A,^)7_A*R_P#Q55-4_P""H7PLT6QEO=1\,?$'3K.'
M!DN+OPT\<:9( RQ? R2!SW(K[!KPW]M/X1Z_\=/V9_&?@;PL+4ZYJRVHM_MD
MWE1?)=PR-N;!Q\J-VYZ4 >M>$_%%GXR\+:-X@T\2?V?JUE#?VWG)L?RI4#KN
M'8[6&1VK8KD?A-X<O/!_PK\&Z#J0C&H:7HUE8W/DOO3S8X$1\-CD94X/>NNH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@_5O
M$'B/4/V:/%G[0,?BS7+?QI8:Y>WEC;)JDHTV"QMM4:V6P-H&\ET>&,[F9"Y=
MR=P.!7WA7S[=?LC6=PVI:#_PE^JI\,M1U@Z[<^"U@A\IKAK@7+Q"XV^:MNTX
M\PQ ]R P4[: $_:$_:A\3?!/Q-IFEZ)\%O&7Q(MKRQ6[?4/#ML\D-NQ=E\IR
MJ-A@%#<D<,*^-OV?OCY\3?@S\5/C/XLNOV:_B5J4/C[6H]5@MH=+F5K15\WY
M')B^8_O1T]*_4K:*7;0!\5?\/"/'W_1J?Q3_ / "7_XS1_P\(\??]&I_%/\
M\ )?_C-?:U% 'Q3_ ,/"/'W_ $:G\4__   E_P#C-'_#PCQ]_P!&I_%/_P
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MI_%/_P  )?\ XS7VM10!\4_\/"/'W_1J?Q3_ / "7_XS1_P\(\??]&I_%/\
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ME^&DEC.D,5KXDA:*2Z#*6WH"JG QCH>M>P4W;_\ JIU !1110 4444 %%%%
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M%/%<!\+OCL?BE8Z=JD/@7Q1X>\/:AIZZG;ZWK:V4=J\+(KH3Y=R[J65@W*
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MD8K&RQR 8R&Q@T ?0WQ)^+GA_P"%OP\N?&6J2SW6E1I&T$.G1^=<7KR$+%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I-H-+10 W8*-@IU% ";:38..O'O3J* &[10L87-.HH *
M*** "BBB@ HHHH **** $*@\4;:6B@!NWW-&P4ZB@!H7'O\ 6G444 %%%% !
M1110 4444 -V#^M&P?KFG44 -VCWI=M+10 W:*-M.HH 3;SFDVCZ4ZB@!NT4
MN*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+F
MUAO+>2"XBCG@D7:\<JAE8=P0>"*GJGJ4-U<6-Q'9W"V=TR$13R1^8J-V8KD9
M^F10!\D?L4?"CP?XZ_97NM(USPWIM]87>O:Y!(IMU5@@U"X5=KJ-RE0 %8$$
M8&,8%9_[,/QM\;6OP2TC3;N>WU:/3?%.J^%U\6:]<[R;6U9OLK&)662ZFD.(
M@(\G",S9P<^J_#?]F?7?AI\-9_!&F?$N_M])N+F[N9+ZSTR"'4%:XE>67RYB
M65#ND;#;,KD8/ J[)^RGX?T5?ADO@O5;[P4G@(W,=BEDD=PL\%RH6Y603!LR
M/C=YOW@Q8\Y- '&6_P"U?XEU3X,?#3XGPZ+I.F>&M8U=-)\3_;&FD?25:[:U
M%PA&W,?FJ 0P!7S%)^ZU=;X^^/\ K'@+1?&WB2ZL;2;PGH^L6VD0:A!:SS-;
MJ2BW5W<(A):*!W*D1@$[&Z=:YVZ^&>@_!7X&R?!F:'Q%X[M?$T>JVVFQMIQF
M13,7E,,T\2;80&E)$LI'0D'Y<#U#P[\)KCPO\*?"WA'2_$5]IUUHL4'F:D@$
MTEY*BGS6G#@^8)79F?/)+$@@X- &M\*?'#_$3PC%KJW>CZC97$T@L]0T*[%S
M:W< .%E5OX2>0R')4@C)QFNSK@?A#\(=(^#^DZU:Z5L\W6M5FUJ^,,"P0_:9
M517,4*\1IB-?E'?))))-=]0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %-VBG44 )M%)M%.HH ;M%+M%+10 FT4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img205696091_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *P! T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDTH((R.E9L<\FIRGRP4LT;ECUD/M[5I4 %%%% !1110 4444 %%%% !1110
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MP*I:EHUAJT)2Y@5B1Q(!AA^->>^*=/U6S"3ZA>^:)9"JH&/ ]^U>GQ?ZE/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\3QM+X;OE7KY>?R(/\
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M10 4444 %%%% !1110 45FZYI[:CIKQQ.T<Z?/$ZG!#"N L/'>JZ;,;>_07
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M:F2+YHP68*>H!QFJ=Q?Q00EPRNW 50W)-203M*A+IL8'!%*P%A=L:A4 51T
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MW4 /<ED9<XR,9J..?> CC$BC!'K[T%\"HB=^#T(.0: )6.14)&.A(I2U1.]
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ME3BNAPUY\.?].NYM(UR\TN"\8M<6\*AE<GKC)XK1?P%HS^$T\/"-UMXV\Q9
M?G$G]_/K7444>TEW#V<>QQ.G_#T1ZI:7VKZW=ZM]B;=;1SJ%6,CH>.N*DU7P
M"MWKTNL:7K%UI-U.,3F!0PD_ ]*[*BCVDKWN'LXVM8Y3PCX(C\)WVJ72:C->
M-?E"_FK@J5W<YSSG=75T45,I.3NRHQ459!1112&%%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#%!&(X8TCC'144 #\!3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^(7_'A8_P#7
M>NQKCOB%_P >%C_UWK6A_$1SXO\ @R.NA_U$?^Z/Y4^F0_ZB/_='\J?61NM@
MHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %9M^ODW<-P/NO\ NW_F/ZUI5#=P?:+62+N1D?4<BHG&\=#2E+EE
MKL5ATI&IEM(9;=&/7&#]:D;I6>ZN;-6=AM%%%(84444 %0Q)Y>J1LO)E!W ]
M@/3TJ:F6O[_4-Z<I"I!/8D]J75#6B;\C4HHHKI.,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HKQG4M>U>/4[E$U.[55D8 "9@ ,_6JO\ PD.M
M?]!6]_[_ +?XUUK"2:W/->903MRL]PHKP_\ X2'6O^@K>_\ ?]O\:/\ A(=:
M_P"@K>_]_P!O\:?U.7<7]IP_E9[A17A__"0ZU_T%;W_O^W^-'_"0ZU_T%;W_
M +_M_C1]3EW#^TX?RL]PHKP__A(=:_Z"M[_W_;_&C_A(=:_Z"M[_ -_V_P :
M/J<NX?VG#^5GN%%>'_\ "0ZU_P!!6]_[_M_C1_PD.M?]!6]_[_M_C1]3EW#^
MTX?RL]PHKP__ (2'6O\ H*WO_?\ ;_&C_A(=:_Z"M[_W_;_&CZG+N']IP_E9
M[A17A_\ PD.M?]!6]_[_ +?XT?\ "0ZU_P!!6]_[_M_C1]3EW#^TX?RL]PHK
MP_\ X2'6O^@K>_\ ?]O\:/\ A(=:_P"@K>_]_P!O\:/J<NX?VG#^5GN%%>'_
M /"0ZU_T%;W_ +_M_C1_PD.M?]!6]_[_ +?XT?4Y=P_M.'\K/<**\/\ ^$AU
MK_H*WO\ W_;_ !H_X2'6O^@K>_\ ?]O\:/J<NX?VG#^5GN%%>'_\)#K7_05O
M?^_[?XT?\)#K7_05O?\ O^W^-'U.7</[3A_*SW"BO#_^$AUK_H*WO_?]O\:/
M^$AUK_H*WO\ W_;_ !H^IR[A_:</Y6>X45X?_P )#K7_ $%;W_O^W^-'_"0Z
MU_T%;W_O^W^-'U.7</[3A_*SW"BO#_\ A(=:_P"@K>_]_P!O\:/^$AUK_H*W
MO_?]O\:/J<NX?VG#^5GN%%>'_P#"0ZU_T%;W_O\ M_C1_P )#K7_ $%;W_O^
MW^-'U.7</[3A_*SW"BO#_P#A(=:_Z"M[_P!_V_QH_P"$AUK_ *"M[_W_ &_Q
MH^IR[A_:</Y6>X45X?\ \)#K7_05O?\ O^W^-'_"0ZU_T%;W_O\ M_C1]3EW
M#^TX?RL]PHKP_P#X2'6O^@K>_P#?]O\ &C_A(=:_Z"M[_P!_V_QH^IR[A_:<
M/Y6>X45X?_PD.M?]!6]_[_M_C1_PD.M?]!6]_P"_[?XT?4Y=P_M.'\K/<**\
M/_X2'6O^@K>_]_V_QH_X2'6O^@K>_P#?]O\ &CZG+N']IP_E9[A17A__  D.
MM?\ 05O?^_[?XT?\)#K7_05O?^_[?XT?4Y=P_M.'\K/<**\/_P"$AUK_ *"M
M[_W_ &_QH_X2'6O^@K>_]_V_QH^IR[A_:</Y6>X45X?_ ,)#K7_05O?^_P"W
M^-'_  D.M?\ 05O?^_[?XT?4Y=P_M.'\K/<**\/_ .$AUK_H*WO_ '_;_&C_
M (2'6O\ H*WO_?\ ;_&CZG+N']IP_E9[A17A_P#PD.M?]!6]_P"_[?XUZOX5
MN)KKPY:33RO+(R\NYR3^-95:#IJ[9OA\9&M+E2L;-%%%8'8%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?$+_CPL?^N]=C7'?$
M+_CPL?\ KO6M#^(CGQ?\&1UT/^HC_P!T?RI],A_U$?\ NC^5/K(W6P4444#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBF32K#$TC= /SH;L-*[LC.A_P!9< # $I _2ICTJ*W0I%\WWF)9OJ:E
MKGCL=4MQE%*124"(9QN\I-[(&D"EEZU,;&Z7[ERC+VWQ\_F#_2H;H'[.Q499
M?F%:L<BRQK(ARK#(-$8J3:83G*,4T41IKR'_ $BY++_=C78#]>2?Y5=CC2%
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M:T/XB.?%_P &1UT/^HC_ -T?RI],A_U$?^Z/Y4^LC=;!1110,**** "BBB@
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M^@BO0O!W_(K67^Z?YUVUOX,3RL+_ +U/Y_F;M%%%<1ZH4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0O^/"Q_Z[UV-<=\0O\
MCPL?^N]:T/XB.?%_P9'70_ZB/_='\J?3(?\ 41_[H_E3ZR-UL%%%% PHHHH
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MT>YA4I\NJV'T4459F%%%% !1110 4444 %%%% !1110 4444 >$ZK_R%KO\
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M !IV8KHMT54_M33_ /G^M?\ O\O^-64D25 \;JZ-R&4Y!I6'<=1110 4444
M%%%% !1110 45#-=VUL0)[B*(GD!W"Y_.GQ313H'AD21#_$C C]* 'T56DU"
MRBD,<EW;HXZJT@!'X9JP"& (((/0B@!:*** "BBB@ HHHH \@\=?\C7<_P"Z
MG_H(KT+P=_R*UE_NG^=>>^.O^1KN?]U/_017H7@[_D5K+_=/\Z[:W\&)Y6%_
MWJ?S_,W:***XCU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *X[XA?\ 'A8_]=Z[&N.^(7_'A8_]=ZUH?Q$<^+_@R.NA_P!1'_NC
M^5/ID/\ J(_]T?RI]9&ZV"BBB@84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5G2O]HO&'_+.'@>[=_P O\:O32"*%Y"<!036=:(4M4W??
M8;F_WCR?U-95'JD;TE9.1-1112*"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!I&#4=H_V6]\G_EE/DK[..H_$<_A4K56NA^X+C[T9#C\.?Y9%0]-5T+C
MK[KZFQ134;>BMZC-.KI.,**** "BBB@ HHHH **** "BBB@ HHHH \)U7_D+
M7?\ UU;^=>X6G_'G#_N#^5>'ZK_R%KO_ *ZM_.O<+3_CSA_W!_*NW%_#$\K+
MOCG_ %W)J***XCU0HHHH **** *]]?6VFV4UY=RK%;PJ6=V["OGGQK\5M4UZ
MXEM=+E>RTX$@;#B20>I/;Z"NE^.7B21&M/#]O(55E\^X /7G"C]"?RK%^$/@
MJ#7;Z35]0B$EI:L!&C='?_ 5VT81A#VDSBK3E.?LX'+:1X#\4>(E^T6NG2M&
M_/G3ML!]^>36E<_"+QA;PF06,4V/X8IAG]<5],JJHH55"J.  , 4M2\9.^B*
M6$A;5GRWX9A\4Z5XKLM,MI+RPN)IE78X(7&>20>"*^HP,  G)]:C>V@DG29X
M4:6/.QRO(_&I:RK5?:-.UC6E2]FFKA7C?QP\2>7!;:! _P SD33X/0=A_6O7
MKNYBLK.:ZG8)#"C2.Q[ #)KY5U"74/'7C.>2!"\]U(?+7/"J.GX 5>%A>7,]
MD1B9VCRK=GNWPH\2_P!O^#X89GS=V/[B3GDJ/NG\L#\#7=5\S_"OQ"WAWQBE
MO<,4M[S]Q*&XVMG@G\<C\:^F*G$4^2?DRL//GAZ!7S-\6+NY7XCZM$+B41J8
ML('.!^Z3M7TS7S!\6?\ DIFK_P#;'_T4E:8/XWZ$8OX%ZF78^"O$NK6B7MII
M4\\$HRL@(PP_$TQY/$_A6[3S'O["4'Y=Q8*?Z&OHSX:_\DZT3_K@?_0C4OCS
M1[36/"&H1W4:DQQ-)&Y'*,.AK3ZU[_+):&?U;W.:+U.3^&?Q-D\1S?V1K&P7
MX7,4R\"8=P1V->HU\B>$[B:U\6:5+!GS!<H!CT)P?T-?7=8XFFH2TZFN&J.<
M=>AQ/Q6TR]U;P/-:V%N]Q.9XV")UP#S7@O\ P@7BK_H"77Y#_&OK"BE2Q$J<
M>5(=7#JI*[9\>:IH>IZ(\::E92VS2@E!(/O =:DTOPWK&M0O-INGS7,:-M9H
MQP#UQ7IOQ\_Y"6B?]<9?YK6U\!O^1:U3_K\'_H KL=9JE[2QR*BG5]G<\G_X
M0+Q5_P! 2Z_(?XU]'^!K2XL/!&D6MU$T4\5N%=&ZJ<FNAHKBJUW45FCLI4%3
M=TPHHHK W"BBB@ HHHH **** /"?CW_R&M'_ .O=_P#T*NW^#?\ R3NU_P"N
MLO\ Z&:XCX]_\AK1_P#KW?\ ]"KM_@W_ ,D[M?\ KK+_ .AFNR?^[Q..'^\2
M/%_B9_R4;6O^NP_] 6OIG1O^0+9?]<5_E7S-\3/^2C:U_P!=A_Z M?3.C?\
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M 4444 %%%% %'4>3;KCK)G\J*2_YNK0=PS']*6L7\3.E? OZZA1110 4444
M%%%% !112$T +FBF4X'M2N.PM%%%,04444 %%)G-+0 AZ4VG'I3:3&B33/\
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M?SKW"T_X\X?]P?RKMQ?PQ/*R[XY_UW)J***XCU0HHHH **** "BBB@ HHHH
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MALN06YW2'_/ZU]#4L3)*U-="L-%N]1]0HHHKD.H**** "BBB@ HHHH ****
M/(/'7_(UW/\ NI_Z"*]"\'?\BM9?[I_G7GOCK_D:[G_=3_T$5Z%X._Y%:R_W
M3_.NVM_!B>5A?]ZG\_S-VBBBN(]4**** "BBB@ HHHH **** "BBB@ HHHH
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M7^9HHM"?[1E7MY*G]327Q(;^%FC11170<@4444 %%%% !1110 4444 %%%%
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MKQ%JNG:AIXT>*2:T!)G2- QDQR%R02,^HHO&0*%4YQSG/6I=#U5;>Y<2KO#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R#QU_R-=S_NI_Z"*]
M"\'?\BM9?[I_G7GOCK_D:[G_ '4_]!%>A>#O^16LO]T_SKMK?P8GE87_ 'J?
MS_,W:***XCU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"/^_*?_$UZ-_PB&@?] R+\V_QH_P"$0T#_ *!D7YM_C1[>C_+^"#ZIBO\
MGY^+/.?^$X\0_P#/^/\ ORG_ ,31_P )QXA_Y_Q_WY3_ .)KT;_A$- _Z!D7
MYM_C1_PB&@?] R+\V_QH]O1_E_!!]4Q7_/S\6><_\)QXA_Y_Q_WY3_XFC_A.
M/$/_ #_C_ORG_P 37HW_  B&@?\ 0,B_-O\ &C_A$- _Z!D7YM_C1[>C_+^"
M#ZIBO^?GXL\Y_P"$X\0_\_X_[\I_\31_PG'B'_G_ !_WY3_XFO1O^$0T#_H&
M1?FW^-'_  B&@?\ 0,B_-O\ &CV]'^7\$'U3%?\ /S\6><_\)QXA_P"?\?\
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MXA_Y_P ?]^4_^)H_X3CQ#_S_ (_[\I_\37HW_"(:!_T#(OS;_&C_ (1#0/\
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M#(OS;_&C_A$- _Z!D7YM_C1[>C_+^"#ZIBO^?GXL\Y_X3CQ#_P _X_[\I_\
M$T?\)QXA_P"?\?\ ?E/_ (FO1O\ A$- _P"@9%^;?XT?\(AH'_0,B_-O\:/;
MT?Y?P0?5,5_S\_%GG/\ PG'B'_G_ !_WY3_XFC_A./$/_/\ C_ORG_Q->C?\
M(AH'_0,B_-O\:/\ A$- _P"@9%^;?XT>WH_R_@@^J8K_ )^?BSSG_A./$/\
MS_C_ +\I_P#$T?\ "<>(?^?\?]^4_P#B:]&_X1#0/^@9%^;?XT?\(AH'_0,B
M_-O\:/;T?Y?P0?5,5_S\_%GG/_"<>(?^?\?]^4_^)H_X3CQ#_P _X_[\I_\
M$UZ-_P (AH'_ $#(OS;_ !H_X1#0/^@9%^;?XT>WH_R_@@^J8K_GY^+/.?\
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M6^QTE%5M/O[?5+"&]M'WP2C*-@C/.._TJS33OJ0TT[/<****!!1110 4444
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MPK(-W/\ .B+4I6[&DZ=2$%4:TE>WRW+UE:&21IIF+,W3)S@5-/"@278H&TX
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M%JU?'.G7!!ZQ-C\JA@Z#Z5I+XS*'\-D]0GK4IZ&HJ&$0HHHI%#6ICN(T9ST
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MPBO[=76.X4/AA@^G(JY6"MNC63G\,NGX!1113)"BBB@ HHHH **** "BBB@
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(WVEDSG!]LT5%)*\0H.DYVJW2\OP.ZHIL:+'$B)]U0 /I3J#,**** "BBB@
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MWNT.1(@)]CWKIKT>1)HXL)B?:RDG\O0N4445S'<%%%% !1110 4444 %%%%
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M[3_Q[_&KOA[QC=^*?&^@P7-M#"+>X:53'GD^6R\Y/O7F%=9\-?\ D?\ 2_\
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MC@D<?_7JC+(50[<X'>O1?L,!B\N1/,&,?/7'>);OP_X>U"V@N7DB:8%F506
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MEZO3[BOK<DO<2CZ(9##'!$L42!$48"@<"GT45VI6T1R[A1110 4444 %%%%
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M1D%D+!1G@9)/H*W;.9(JP0/(&1D)P2"<<5!<P&W*LJ_(N!L4<FNB+I':AI2
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M]Z[OPEXIM?%NC"_MD:-E8I)$QY1J\F\$?$6Q\*^ WM)+"]FN!*[(PB_<DD#
M+9_I7:?#'26\,>&9[S5YH+5[^;SMLDH 4=AG..]75II)Z6[$4JC;6M^Y<\2^
M(/&6F:G=C2]!M;K384#K/([ D;06Z'L<C\*P=#\?>-_$%FE[8^&[&2U9]A<.
MW;KW]Z]!O[RUO= U&2TN89T%O("T3A@#M/&17'_!^6.#X=K+-(D<:SR%G=L
M#CJ34Q:Y&^75%M/G2YM&>A(6**6&&(Y'H:=6/J'B?2;'2KO4!>V]PEK&9'6&
M57./P-<WHNO^-]9^RZDNCZ9#I-R0RQO*_GA#T;/3I[5DH-JYHYI.QWE<MXQ\
M4W'AN;1T@MXI1?77D.9"?E&.HQ7/WWCW7;W4M23PY9:<]IIIQ,]Y*0TQ'4(
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MNR@@BMH$@@C6.*-0JJHX J2NQ4H)6L?.SQ^)E)R4VK^;.)_X51X2_P"?*?\
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MP2<$_C_.O4Z*2JM*R6@W23=V]1%)9 64J2.0>U+1161J%%%% !1110 4444
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M]7U'1O"-O:VP>73IH&N1YBC8%"ANIYZ'I7H5%%1*3:L7&*3N@HHHJ2@HHHH
M**** "BBB@ HHHH **** "BBB@ HHKC/&E[X@AO;*#2H)A;[D=YXCWW$%6]L
M8-3*7*KFM&E[6?+=+U.SKC/&'C"\\-ZC#!%9-+%) S*^TG,G9:O:CXI6Q3,:
M>:Y !#<!6Q_]:L4^)KF^($R1@J<I@<#ZU4J<I1T=A4:M.G.\X\R['<64TEQ8
M6\\L9BDDB5V0]5) )'X5/7,VGBEF;;<Q+_O*>*S?%=]K<W]GOH;RR[9 \L<!
MQN'8$^E*=X*X4H*K44;I7[['<456T^2YFTZVDO(A%<M&IEC'16QR*LTT0U9V
M"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444R4LL3L@RP4D#U-
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M[WJ(ETT:F54Z!L<@?C5FE>^HFK.P4444""BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img205696091_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(O\ "OO?^1[)_:%K_P _,/\ WV*/[0M?^?F'_OL5YA_PRG\(O^B?Z+_WX/\
MC1_PRG\(O^B?Z+_WX/\ C7!S5OY5][_R'S8C^5?>_P#Y$]/_ +0M?^?F'_OL
M5GZUXRT'PW;I/JVMZ;ID,C;$DO;N.%6;&< L1DXK@/\ AE/X1?\ 1/\ 1?\
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M:MX0TW4(]*\<7FGV2SQEA;VZP6[+$G/"@LQQ_M&O9_\ AE/X1?\ 1/\ 1?\
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M%Z[MHSCM6<,2Z$TL:THMM:;V]-+_ #:.5XVKA6OK=ES2:6O3[MC]1?[3L_\
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MV?'[PO\ !7P+K^N7VIZ7=:GING2W\&B2:G%;W%[L!(2,,2?F((!"GGL:P?\
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M[_ABSX&_]$QT#_P'/^-;8J&6^WG["<E&[M[J>E]+-R3^_44>>RNCV+^T[/\
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MG1QU.M/D2:?IZ_Y%4,RI5ZBII--^3[O_ "/>:***]$]4**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ__ ""[O_KDW\JN
M53U?_D%W?_7)OY4 7**** "BBB@ HHHH **** "BBB@ JOJ'_'C<_P#7-OY&
MK%5]0_X\;G_KFW\C0!);_P#'O%_NC^525';_ /'O%_NC^524 %%%% !1110
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M$?OG_P#)CY7W/%/^%S?$_P#Z('KW_A0:5_\ 'Z/^%S?$_P#Z('KW_A0:5_\
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MRN2W'3CC->I_\,O_  C_ .B<>&__  71_P"%(W[+WPC88/PW\-'_ 'M-C/\
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M7_Q^C_A<WQ/_ .B!Z]_X4&E?_'Z]KHH^LTO^?$?OG_\ )ARON>*?\+F^)_\
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M<U.=5-Q=KO2^G^=SV*BO(O\ AK#X7_\ 0P77_@FOO_C%'_#6'PO_ .A@NO\
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MGJ__ ""[O_KDW\JN53U?_D%W?_7)OY4 7**** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %?(7QJ_:H^'7A/]J#P+:7^K3?\
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M5UY-^U!^SKH/[47PAU3P-KDK61F9+FQU*.,/)8W29V2JI(SP64C(RKL,C.0
M6_V8-0T_5/V;?A9<Z4RMI[>%]-$6U@VT"UC4J<=U(*GT(->G5^5GP[_9S_;M
M_9GTN3P;\/?$&BZKX3BG=K0M<VDT,(9LED6Z021@DEB@RN2QP2<G[=_8_P#A
MG\4_AK\.M57XP^,O^$R\9:QJTFIR2QS-+%9QM%$BV\9*J  8V;:BJ@+D =R
M>[4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\JZ&N=^':A? NA*!@"TC 'X5T5 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7C_ ,./^3C/C'_U[Z'_ .D\U>HZ_J$VD:#J5];V
MKWUQ:VTD\=K']Z9E4L$'N2,?C7YB? #]LSXD:I^T=<WDNBQ^(9/%<\5O?:'I
MUNL<RK"CB/R69AM,8+9WM@@')'4>;BL1"C4I*?5_HU^IY&-Q=/#U:,9WU?;R
M:_4_4JBOD']JKXX?$ZW^$/BI=.^&&O>%M+^Q*9/$L^L6L4]BWF+EECAD=B.@
MR&S\QXK;\,_'3XS_ /" Z7M^!>H7[?8(=E^WB.U'GIY(_?'/S!CP<'GD\YK3
MZY34W"SV[/\ R-7CZ2J.G:6BO\,O\CZCHKXF_8\^./Q1F^&.G+=_#O7?'&DF
MZN]WB--9MY+AV\QL1B*=U)"GY<EAP,BOH+_A<GBO_HC?C#_P(TW_ .2J=+%0
MJP4[-7\G_D51QM.M351)J_D_\CU>BO*/^%R>*_\ HC?C#_P(TW_Y*KYV_;&^
M.7Q2A^'KK;?#W7? FDC4K3R_$#:U;I.S9_U1C@=B QR,[B,#FBKBH4H.=GIY
M/_(*V-IT:;J--V\G_D?<%%?BC#\=_B=_8.M_\57XD=/L\.ZY_MB7-O\ Z3PX
M^;/S'Y./Y5^F'P_^-GQ)N/#]K_;GP4\01D6\/D7%CJUC<^>NP9=M\L94G@XY
MZURX;,J>(;7*U\F_R1Q8/-J>+;7*U\F_R1[]17Q1^V-\</BA#\(]<6S^'6O>
M!](#VO\ Q4\FLV\=Q WG)E?*@=FPQ^3(;^+FO7_!/QL^)-QI,?\ ;OP1\06[
MB./R9+#5K&Y$J[>6;?+&5/3CGK72L9!U'3L]/)^?D=D<=3E5=*ST2^S+S\O+
MYGO%%>4?\+D\5_\ 1&_&'_@1IO\ \E4?\+D\5_\ 1&_&'_@1IO\ \E5O[>'G
M]S_R.CZQ3\_N?^1ZO5#6_P#D&R?[R?\ H8KS?_A<GBO_ *(WXP_\"--_^2JJ
MZI\8/%,MBZM\'?%ZC*\_:-._O#_IZH]M#S^Y_P"0?6*?G]S_ ,CV&BO*/^%R
M>*O^B.>,/_ C3?\ Y*H_X7)XK_Z(WXP_\"--_P#DJCV\//[G_D'UBGY_<_\
M(]7JCHO_ ""X/H?YFO,+WXS>,TLYVM/@OXKFN@A,4<UYIT:,^. S"Y)49[X/
MTKYJ\+?'+XQ1?M,>(%A^&>IWUROAZWW>#V\01+%:KO7%T&/[O+'C &>:QJ8N
M%.VCU?9_Y'/5QU.DXJS=W;X9?Y'WE145K))-;1/+%Y,K(&>/.=A(Y&>^*EKM
M/1"BBB@ HHHH **** "BBB@#D;CXL>%+6YU"WFU=8I[%XXYXWAD#;G=HT"#;
M\Y9E8#9G[I]*T])\:Z'KEU<V^GZG!=SV]RUG+'$262502RD>P!YZ<&L7Q/\
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M;RZUJVU 7%W:+#.D@DA43R$/E, [.<XW+DFOT'C4K&JEBQ P6/?WH =1110
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M%%% !1110 4444 <Y??\E TC_L'7?_HR"NCKG+[_ )*!I'_8.N__ $9!71T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 53U?_ )!=W_UR;^57*IZO_P @N[_ZY-_*@"Y1110
M4444 %%%% !1110 4444 %5]0_X\;G_KFW\C5BJ^H?\ 'C<_]<V_D: )+?\
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MK]4-;_Y!LG^\G_H8H OT444 %4=%_P"07!]#_,U>JCHO_(+@^A_F: +U%%%
M!1110 4444 %%%% !1110 4444 <Y??\E TC_L'7?_HR"NCKG+[_ )*!I'_8
M.N__ $9!71T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 50UO\ Y!LG^\G_ *&*OU0UO_D&R?[R?^AB@"_1110 51T7_D%P
M?0_S-7JHZ+_R"X/H?YF@"]1110 4444 %%%% !1110 4444 %%%% '.7W_)0
M-(_[!UW_ .C(*Z.N<OO^2@:1_P!@Z[_]&05T= !1110 4444 %%%% !1110
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M?&:X\>)9_!;3-,;PCXHO/#,IFGE?[1);A"95P_"G?T//%?:"J(U55&%48 H
M=5;4M2M=(L+B]O9X[6TMT,DLTK85% R235FLOQ-HJ>(]!O-,D6V>.Y38ZWEL
MMQ$RY&0T;$!@1Q@T 4+CXC>&+.$RW&N65N@B28F:4(0K[2I(/3(=3CKA@>XK
M>M[J&ZWF&190C;&*'(##J/UKRZU_9WT"&7%Q/-J5HBNT5O?J)@DSPPQ-(2W+
M$);Q[0> <]>@ZWP;X%_X0^[UETU:]O[2_F66&SN6!CLP <K'[$GGZ#ZD L?#
MW_D1]#_Z](_Y5T-<K\/]/@;P3HA*MDVJ?\M&]/K70?V;;_W7_P"_C?XT 6J*
MJ_V;;_W7_P"_C?XT?V;;_P!U_P#OXW^- %JBJO\ 9MO_ '7_ ._C?XT?V;;_
M -U_^_C?XT 6J*J_V;;_ -U_^_C?XT?V;;_W7_[^-_C0!:HJK_9MO_=?_OXW
M^-']FV_]U_\ OXW^- %JBJO]FV_]U_\ OXW^-']FV_\ =?\ [^-_C0!:HJK_
M &;;_P!U_P#OXW^-']FV_P#=?_OXW^- %JBJO]FV_P#=?_OXW^-']FV_]U_^
M_C?XT 6J*J_V;;_W7_[^-_C1_9MO_=?_ +^-_C0!:HJK_9MO_=?_ +^-_C1_
M9MO_ '7_ ._C?XT 6J*J_P!FV_\ =?\ [^-_C1_9MO\ W7_[^-_C0!:HJK_9
MMO\ W7_[^-_C1_9MO_=?_OXW^- %JBJO]FV_]U_^_C?XT?V;;_W7_P"_C?XT
M 6J*J_V;;_W7_P"_C?XT?V;;_P!U_P#OXW^- %JBJO\ 9MO_ '7_ ._C?XT?
MV;;_ -U_^_C?XT 6J*J_V;;_ -U_^_C?XT?V;;_W7_[^-_C0!:HJK_9MO_=?
M_OXW^-']FV_]U_\ OXW^- %JBJO]FV_]U_\ OXW^-']FV_\ =?\ [^-_C0!:
MHJK_ &;;_P!U_P#OXW^-']FV_P#=?_OXW^- %JBJO]FV_P#=?_OXW^-']FV_
M]U_^_C?XT 6J*J_V;;_W7_[^-_C1_9MO_=?_ +^-_C0!:HJK_9MO_=?_ +^-
M_C1_9MO_ '7_ ._C?XT 6J*J_P!FV_\ =?\ [^-_C1_9MO\ W7_[^-_C0!:H
MJK_9MO\ W7_[^-_C1_9MO_=?_OXW^- %JBJO]FV_]U_^_C?XT?V;;_W7_P"_
MC?XT 6J*J_V;;_W7_P"_C?XT?V;;_P!U_P#OXW^- %JBJO\ 9MO_ '7_ ._C
M?XT?V;;_ -U_^_C?XT 6J*J_V;;_ -U_^_C?XT?V;;_W7_[^-_C0!:HJK_9M
MO_=?_OXW^-']FV_]U_\ OXW^- %JJ&M_\@V3_>3_ -#%2_V;;_W7_P"_C?XU
M1UK3H%TV3Y6^\G_+1O[X]Z -BBJO]FP?W7_[^-_C1_9MO_=?_OXW^- %JJ.B
M_P#(+@^A_F:D_LV#^Z__ '\;_&J6C:= =,@^5NA_Y:-ZGWH UZ*J_P!FV_\
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M '7_ ._C?XT 6J*J_P!FV_\ =?\ [^-_C1_9MO\ W7_[^-_C0!:HJK_9MO\
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M_9MO_=?_ +^-_C1_9MO_ '7_ ._C?XT 6J*J_P!FV_\ =?\ [^-_C1_9MO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %4-;_ .0;)_O)_P"ABK]4-;_Y!LG^
M\G_H8H OT444 %4=%_Y!<'T/\S5ZJ.B_\@N#Z'^9H O4444 %%%% !1110 4
M444 %%%% !1110!SE]_R4#2/^P==_P#HR"NCKG+[_DH&D?\ 8.N__1D%='0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5/5_^07=_]<F_E5RJ>K_\@N[_ .N3?RH N4444 %%
M%% !1110 4444 %%%% !5?4/^/&Y_P"N;?R-6*KZA_QXW/\ US;^1H DM_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:W_R#9/]Y/\
MT,5?JAK?_(-D_P!Y/_0Q0!?HHHH *HZ+_P @N#Z'^9J]5'1?^07!]#_,T 7J
M*** "BBB@ HHHH **** "BBB@ HHHH YR^_Y*!I'_8.N_P#T9!71USE]_P E
M TC_ +!UW_Z,@KHZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH\@\C*_*0"N,"OU3C8O&C,NQB 2OI[5^4OQ%\&_&#XR:;JGQIM-+^)G@W6=
MO='T+X<>$Y4G-U\K(+JYO8BI?8PWDRL0&P0Q88%?JS#O\I/,QYFT;L=,]Z '
MT444 %%%% '/?#W_ )$?0_\ KTC_ )5T-<]\/?\ D1]#_P"O2/\ E70T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !5#6_^0;)_O)_Z&*OU0UO_ )!LG^\G_H8H
M OT444 %4=%_Y!<'T/\ ,U>JCHO_ ""X/H?YF@"]1110 4444 %%%% !1110
M 4444 %%%% '.7W_ "4#2/\ L'7?_HR"NCKG+[_DH&D?]@Z[_P#1D%='0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJAK?_(-D_P!Y/_0Q0!?HHHH *HZ+_P @N#Z'^9J]5'1?^07!]#_,T 7J***
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8M/<>'B_V.XM[N#S82 Y)#C:P/0<C@8R0#Z0HHHH **** .>^'O_ "(^A_\
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M OQK\6M#TA?AYXH\2ZM9VUNNC:-%%<:9I U*."&!+<1X9WB+2ME26>;&/E4
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]7_ .07=_\
M7)OY5<JGJ_\ R"[O_KDW\J +E%%% !1110 4444 %%%% !1110 57U#_ (\;
MG_KFW\C5BJ^H?\>-S_US;^1H DM_^/>+_='\JDJ.W_X]XO\ ='\JDH ****
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M* .>^'O_ "(^A_\ 7I'_ "KH:Y[X>_\ (CZ'_P!>D?\ *NAH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *S&:ZNM0N8H[GR(X0F (PV<@DG)K3K/L_\
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M2!Y'9(VD(1>K95&(8?*<=:["^O$U#PZMU$&$4\<<JAA@X8J1D>O- &M1110
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M_D:C^U/'7_0O:'_X.9?_ )&J?:+S^YD^T79_<SKZ*Y#^U/'7_0O:'_X.9?\
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MII>CZ7=V0 VS76I20R$XY!40L!S[TF[$RERJ[.BHKD/[4\=?]"]H?_@YE_\
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M%/8@UZY^T7XNU;P+\'-?UO0[H6.IVQMEBN&\O"![F*-SF0%%^5V^9@0.IZ4
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MIWS:C=WFIRK)++,T<<9/RJJ@;8D    Q6QH_2]_Z^I/YUH5GZ/TO?^OJ3^=
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M  '^'>O-IQO_  9HUR-.MX[6T1K1 D4,;;HD"@8VHWS*"/E.2,9K=_MS6/\
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MMS6/^A:N?_ J#_XN@#?HK _MS6/^A:N?_ J#_P"+H_MS6/\ H6KG_P "H/\
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M_0M7/_@5!_\ %T ;]%<^OB#5G+ >&[GY3@_Z5!_\72_VYK'_ $+5S_X%0?\
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M*.^L?$6G:M;6+7\$-M/;R)'*B,I=XBI^8@$?(>_I5C^W-8_Z%NY_\"H/_BZ
M-^BL#^W-8_Z%JY_\"H/_ (NC^W-8_P"A:N?_  *@_P#BZ -^BL#^W-8_Z%JY
M_P# J#_XNC^W-8_Z%JY_\"H/_BZ -74]-M-:TV[T^_MX[NQNX7@GMYEW)+&R
ME65AW!!((]ZR;OX?^&K^7P[+<Z%83R^'7WZ1)) I:P;R_+S"<93Y/EX[4O\
M;FL?]"U<_P#@5!_\70=>U<?\RW<_^!4'_P 70!0\*?"7P9X%UB[U7P_X9TW2
M-1NE9);BU@"-M9M[*O\ <4M\Q5< GDBMVP\.Z9I>K:IJEI806VHZHT;WMU&@
M$EP8T"(7/?:H"CV%4?[<UC_H6KG_ ,"H/_BZ/[<UC_H6KG_P*@_^+H H:O\
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M/[<UC_H6KG_P*@_^+H_MS6/^A:N?_ J#_P"+H WZ*YZ3Q!JT:[F\-W(&0/\
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M";;L+K"K2$ G 'KQ6EX$^(ND?$2SNYM+^UPRV<JQ7-IJ%K);7$)9%D0M&X!
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MVZGC\0V]K=6EPEC-Y0CN7:.V,K%?W9D=&50W.1SBO2Z^?-,_9%M=+O/"TO\
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MU!(]0D#_ &5?)CB$2>P$0Y^GI0!Z-1110 4444 %>:?\-#>"C_:[_:KU[;3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7Q,C!8FEMV6.,,,#<I&$QG)R#I3CSS47U?\ 6]OS0CT#^WF_Z!M][?NUY_\
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M5[;0;+1SJ86ZN]#*M'>S)!_JFWR3^>I=U<"V4;>: /KW^W6_Z!E__P!^E_\
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MK'$4HT:KIQES)=?ZO^;&G=7,K^W6_P"@9J'_ 'Z7_P"*H_MUO^@9J'_?I?\
MXJM6BN<9E?VZW_0,U#_OTO\ \51_;K?] S4/^_2__%5JT4 97]O-_P! R_\
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MRF-@FUF^4'=C!/'K517,T@)?[<;_ *!E_P#]^E_^*H_MUO\ H&:A_P!^E_\
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M]Q_T$[G_ +YB_P#B* +]<_\ $#5AH7@O5[\ZW:^'/)@)&K7L7FPVA. )&4D
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M YZ5\MWW[1WQ&TK0?".JKJFF:G;WS22006ZVKW6H(=0BABCN(UD_=-Y$F3Y
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MPQ&</;12N"(7:,['D905/("YYS7JDF@B:X2>2[DDG16C65H82RJV-R@[,@'
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MBLU%J3E?1V,U%J;E?1VT^\OT50_L^X_Z"=S_ -\Q?_$4?V?<?]!.Y_[YB_\
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MW'_03N?^^8O_ (BNP[R_15#^S[C_ *"=S_WS%_\ $4?V?<?]!.Y_[YB_^(H
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M[/N/^@G<_P#?,7_Q%']GW'_03N?^^8O_ (BNP[R_15#^S[C_ *"=S_WS%_\
M$4?V?<?]!.Y_[YB_^(H =K5X-/T:_NFN8[-8+>24W,REDBVJ3O8 C(&,D9[5
M\KVGQU\47/@GQK"GQ&T.36-)U%$TK5OLMLD.J1M8FX2))"_D*SL"V"2RH-IR
MQ!KZF_LZ<]=2N2/]V+_XBLG_ (5_I']EOIGV:V_LUY/.:S^PVWDM)G.\IY>"
MV><XS7-6ISJ-<LK?><E>E4J-<DK;]_\ ,/AIXED\9?#OPSKTSK)-J6FV]W(Z
M0M"K,\:L2$;E1DG@\BNEK/739U4*NHW"J!@ )$ /_'*7^S[C_H)W/_?,7_Q%
M=$4TDF=,4U%)LOT50_L^X_Z"=S_WS%_\11_9]Q_T$[G_ +YB_P#B*91?KG/B
M)K']@^"=6OO[=M/#)BBXU>^A$L-J2P4.RD@$#/<@>O%:G]GW'_03N?\ OF+_
M .(IEQH[W4$D,]]--#(I1XY(XF5E(P004Y%3)732)DFXM(^.]4_:@\<V7A&.
M3_A(-,M[_38-<N'NY+.)TU2>SN8D@LU8-L8O'+EFAZG[N,&OL^PN'NK&WGEB
M:"22-7:)NJ$@$J?ITK$_X073?L=E:>3#]EL7$EI!]CM]ENPZ-&OEX4C)Y&*T
M_P"S[C_H)W/_ 'S%_P#$5ST:4Z;?/*^QR8>C4I-NI/FV_ OT50_L^X_Z"=S_
M -\Q?_$4?V?<?]!.Y_[YB_\ B*ZCM+]%4/[/N/\ H)W/_?,7_P 11_9]Q_T$
M[G_OF+_XB@#C/COXT'P_^&]]K;>)8/"D=O+$'U"6T%U(5+@&*&,D!I7^ZN<@
M$Y(P*\%N/CYX_P!-G^'[ZOK^D0VDUI9/K*Z-]DN[BYFN;UH8UCB,F64*H#F'
M=M8N1D+7U'J?A>#6K;[/J,O]H6^X-Y-U;PRID=#AD(S56+P+ID#V#QPP1O8;
MA9LME;@VV[[WE_N_DSWQBN.K1J5)7C*R."M0JU)\T9V7S.CHJA_9]Q_T$[G_
M +YB_P#B*/[/N/\ H)W/_?,7_P 178=Y?HJA_9]Q_P!!.Y_[YB_^(H_L^X_Z
M"=S_ -\Q?_$4 7Z\<_:<^(U]\-_!UC>:;XIM/#E_<W)M[6"6UCGFU"<HWE0Q
MF5E2-=^&>1N%0'D'!KU3^S[C_H)W/_?,7_Q%4-6\'V6OQQIJFS4DC)*+>6L$
MH4GK@-&<5E4C*<'&+LS&M&52FXP=FSRW2_B%XW7XR?#[0M5O-#DT+7/#MQ?2
M+I*M(9KF*.V+R"0\>7OE?8%SE<$DY 'N%8\?AN*%K9HYVC:UC,4#+!"#$A !
M5/D^5>!P..!5G^S[C_H)W/\ WS%_\113BXWN[A2A*%^9WN_T1?HJA_9]Q_T$
M[G_OF+_XBC^S[C_H)W/_ 'S%_P#$5J;%^BJ']GW'_03N?^^8O_B*/[/N/^@G
M<_\ ?,7_ ,10!YM\=/&GBOP3?>!I=#FTZWTC4/$5CIFHFXC:2YD6:8)LC'W5
M!&[+')Z8'>L/P?\ %/5;[]HB_P#"S^*=.\0:#<65Y/!;V=L@DL9X+A(V@<HQ
M92JMRTN-[-\F,$5[!<:']L6,7%W+.(W61!+%"VUP<AAE.".QJ"V\*V]G?W-]
M;R>1>W6//N8K>!99L=-["/+8]ZYI4YN?,I::''*C4=3F4]+K3^NYMT50_L^X
M_P"@G<_]\Q?_ !%']GW'_03N?^^8O_B*Z3L+]%4/[/N/^@G<_P#?,7_Q%']G
MW'_03N?^^8O_ (B@"_7G/[0'B34O!WPOU/7-*UPZ#=6)219%L4NVN68[$MU1
MV !>1T ;/%=O_9]Q_P!!.Y_[YB_^(J*ZT/[=#Y5S=R7,60WES10NN0<@X*=0
M0#^%1.+E%Q3L9U(N<'%.S95\"VFO6/A#28?%%_#J?B%8%-]=6T(AB:4\L%4=
M ,X'KC/>MZJ']GW'_03N?^^8O_B*/[/N/^@G<_\ ?,7_ ,15)65BXKE21?HJ
MA_9]Q_T$[G_OF+_XBC^S[C_H)W/_ 'S%_P#$4QE^BJ']GW'_ $$[G_OF+_XB
MC^S[C_H)W/\ WS%_\10!Y3^T]\1M0^&_A&PN]*\4V?AW4KJ=K>TMY[6.:74+
M@QGRH4,KJD2!\-)(W 0'D$BO4O"]U=WWAK2;F_DM9KZ:TADN)+%MUNTA0%C&
M>Z$YP?3%5-6\'67B!(TU0)J21Y*+>6L$H7/7&Z,XS5R'2)+:&.&&_GBAC4(D
M<<<2JJ@8  "< "L8QDJCDWHS",)*K*;>CMH:5%4/[/N/^@G<_P#?,7_Q%']G
MW'_03N?^^8O_ (BMC<OT50_L^X_Z"=S_ -\Q?_$4?V?<?]!.Y_[YB_\ B* +
M]?.'[2GQN\4?#7Q=#9:+?6>GP6NB_P!KQV]S;K(VL3_;8H/L:$G(.QRWR?-E
ME/0<_0']GW'_ $$[G_OF+_XBJE[X7@U*:UFO)?M<UI)YMO)/;P.T+_WD)C^4
M^XK&M"52'+"5F<^(ISJTW&$N5]RS>'.I:82,'<_'_ #6C5&+32MQ'-+=S7#1
MYV+($ !(P3\JCM5ZMCH"BBB@ HHHH **** "BBB@ HHKS/Q_XL\1:/XHN+/3
M"WV#^SK69W6V\SR-U\D4\P.#DI SOM.?N9P: /3**^=]/\>?%C7K5X8[>#1]
M1V2NWVJS+)';HL#13C .7F+2KLYQM( !4FO5_ ?C*^\27FO65_I5Y87>F7*Q
M%IHPL,@89'E-_$ !R3_>!Z$4 =C17CZ^/_B-8Z;I"Z+\/?\ A+K.33X)6U23
M7H+1GD9<NI1U)X/?OFF_\+,^+G_1%X__  K+7_XW6#K1B[-/[G_D<TL1"+LT
M_P#P&7^1[%17CO\ PLSXN?\ 1%X__"LM?_C='_"S/BY_T1>/_P *RU_^-TO;
MP[/_ ,!E_D+ZS#M+_P !E_D>Q45X[_PLSXN?]$7C_P#"LM?_ (W1_P +,^+G
M_1%X_P#PK+7_ .-T>WAV?_@,O\@^LP[2_P# 9?Y'L5%>._\ "S/BY_T1>/\
M\*RU_P#C='_"S/BY_P!$7C_\*RU_^-T>WAV?_@,O\@^LP[2_\!E_D>Q45X[_
M ,+,^+G_ $1>/_PK+7_XW1_PLSXN?]$7C_\ "LM?_C='MX=G_P" R_R#ZS#M
M+_P&7^1[%17CO_"S/BY_T1>/_P *RU_^-T?\+,^+G_1%X_\ PK+7_P"-T>WA
MV?\ X#+_ "#ZS#M+_P !E_D>Q45X[_PLSXN?]$7C_P#"LM?_ (W1_P +,^+G
M_1%X_P#PK+7_ .-T>WAV?_@,O\@^LP[2_P# 9?Y'L5%>._\ "S/BY_T1>/\
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M#(?_ "0<R_I,]WHKPC_A;GQP_P"B 1_^%K9__&Z/^%N?'#_H@$?_ (6MG_\
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M:74"3JC=5#*&P?SKSJ^$J8=*4FFGI=24MO1OOU+4DRW1117$4%%%% !1110
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MX_\ PK+7_P"-URGAW]HSXJ>,EU*70?@:+^VT^_N-,GDD\76L)%Q Y250&CY
M8$9Z&MZ%L1/V<-'_ 'O=7WRLAQQ%.4N76_FFOS1]&T5X1_PMSXX?]$ C_P#"
MUL__ (W1_P +<^.'_1 (_P#PM;/_ .-UZ7U"M_-#_P &0_\ DC;F7])GN]%>
M$?\ "W/CA_T0"/\ \+6S_P#C='_"W/CA_P!$ C_\+6S_ /C='U"M_-#_ ,&0
M_P#D@YE_29[O17A'_"W/CA_T0"/_ ,+6S_\ C='_  MSXX?]$ C_ /"UL_\
MXW1]0K?S0_\ !D/_ )(.9?TF>[T5X1_PMSXX?]$ C_\ "UL__C='_"W/CA_T
M0"/_ ,+6S_\ C='U"M_-#_P9#_Y(.9?TF>[T5X1_PMSXX?\ 1 (__"UL_P#X
MW67IG[0WQ5UK5-1TW3O@QIE_J.FLJ7UG;>/K"26U9@2HD41Y0G!Z^E+ZC5_F
MA_X,A_\ )"]I%:,^BZ*\(_X6Y\</^B 1_P#A:V?_ ,;H_P"%N?'#_H@$?_A:
MV?\ \;I_4*W\T/\ P9#_ .2'S+^DSW>BO"/^%N?'#_H@$?\ X6MG_P#&Z/\
MA;GQP_Z(!'_X6MG_ /&Z/J%;^:'_ (,A_P#)!S+^DSW>BO"/^%N?'#_H@$?_
M (6MG_\ &Z/^%N?'#_H@$?\ X6MG_P#&Z/J%;^:'_@R'_P D',OZ3/=Z*\(_
MX6Y\</\ H@$?_A:V?_QNC_A;GQP_Z(!'_P"%K9__ !NCZA6_FA_X,A_\D',O
MZ3/=Z*\(_P"%N?'#_H@$?_A:V?\ \;H_X6Y\</\ H@$?_A:V?_QNCZA6_FA_
MX,A_\D',OZ3/=Z*\%F^+GQT\F3R?@# )=IV&3QK:%=V.,XCZ9KY"\=^/OVAI
M?VV?AK=W_P .O#MKXXCT"]33M#BUS=:7,!$N^1Y-V%9?FP.^T5W87)ZF(<DZ
MD%9-_'%[*_26GKT)E42Z'Z;T5\_:7\6OC\FGP+J?P$LI;\+^^>S\9VJ1%O50
MR$@?4FK7_"W/CA_T0"/_ ,+6S_\ C=<3R^K?XH?^#(?_ "17,OZ3/=Z*_,7]
MLSX@?'O4/%7P@?Q1\.M#\-+%XPADT."UUX3M>7&X>7!.RD!5(P"V .O2OJ_P
M[\6/VBX;%EU[X$:5<WN\[7TSQA;Q1;,# (=6.<Y[XZ5W5LFJ4J%.LJD'S7TY
MXK9VT?-9_H2JB;:L?1=%>$?\+<^.'_1 (_\ PM;/_P"-T?\ "W/CA_T0"/\
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M 4444 %%%% &9XFUK_A'/#>K:M]G>[^P6DMU]GC^])L0MM'N<8_&OS4_9_\
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M 7)#+"#N X8XQCD<]7%?5YPIU:FC_K\SBJXJ.%K0A6J+WO*WX^I^A=%>/?\
M#7GP@_Z':U_\!Y__ (W1_P ->?"#_H=K7_P'G_\ C=='UBC_ #K[T=OUO#_\
M_(_>CV&BOBSXM?\ !0+0;'QMX(M_!^IWIT1-6:/Q TNCN?/M!@?N"ZY))SC;
MSR*]DT7]M#X0ZUIT=V?%#:<7)'V>_L9XI5P<<KL.,]1[&LHXRA*3BIK3S,89
MAAIRE%36GFOP/;Z*\>_X:\^$'_0[6O\ X#S_ /QNC_AKSX0?]#M:_P#@//\
M_&ZU^L4?YU]Z-OK>'_Y^1^]'L-%>/?\ #7GP@_Z':U_\!Y__ (W1_P ->?"#
M_H=K7_P'G_\ C='UBC_.OO0?6\/_ ,_(_>CV&BO'O^&O/A!_T.UK_P" \_\
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MM765R?B;_D=O!O\ UVNO_2=JZR@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /)?VJK'QMJ7P'\4VWP^:=?$KPKY8M&VW#1;U\U8CUWE-P&.?3G
M%?"_[#O@_P"/&D^/M4E\/V]QH6DM!)]O/BVUN?L,LI(Q^[W(S2YR=RG@9W=<
M5^H5%>=6P:K5HUG)JW8\K$9>L1B(8AS:Y>B/&_L/[0'_ $&?AS_X++__ ./T
M?8?V@/\ H,_#G_P67_\ \?KV2BNGV*_F?WG5]77\TOO9XW]A_: _Z#/PY_\
M!9?_ /Q^C[#^T!_T&?AS_P""R_\ _C]>R44>Q7\S^\/JZ_FE][/&_L/[0'_0
M9^'/_@LO_P#X_1]A_: _Z#/PY_\ !9?_ /Q^O9**/8K^9_>'U=?S2^]GC?V'
M]H#_ *#/PY_\%E__ /'Z/L/[0'_09^'/_@LO_P#X_7LE%'L5_,_O#ZNOYI?>
MSP[6=!_:(U.P>WM?%G@'2)F((NK72+IW7!R0!)*R\].17QSI>O?%GX.^-OCG
MXI3QCHMKJ&EZA9?VQ)=::%369&)"K;!AA<*6R!7Z;U\0?\%#/V=?B)\7=:\,
MZWX1LY-?TVPMGMIM*AF59(92^[SE5B VX84XY&P=J\W'4)1I^UIN3DO-^AY.
M98:<*7MJ3DY1Z7?56_"_Z'VMINH6^JV%O>6D\5U;3H'CF@<.C@]U8<$>XJS7
MQ]^RY^S1\7/ 'PIMM/U#XDWW@F62XDN%T*TL;.^6V5L<&256PQ()*J=HSZDU
MZY_PJ'XF_P#1<]8_\)_3?_C5=U.O4E!2E2:;]/\ ,]&EB*LZ<92HM-_X?\T>
MRURMQ\4/#=I\2+3P'+J!7Q3=6+:E#8^3(=UN&*E]^W:.5/!.?:N N/@U\2[J
MWEA?XZZVJR*4+1Z%IR, 1C(819!]QR*^>M3_ &6?B&/VH-&C7XB^-KFR_P"$
M?D+>-C&IDMV\Q_\ 1 _W0#]['7YJBK7JQMRTWJUV_1D5L37AR\E)ZM+6WZ,^
M[J*\4L?@K\2M/LX;:/X[:[)'$H16N-$T^60@=V=HR6/N3FIO^%0_$W_HN>L?
M^$_IO_QJMO:S_P"?;_\ )?\ ,Z/;5/\ GT_OC_\ )'LM%>-?\*A^)O\ T7/6
M/_"?TW_XU1_PJ'XF_P#1<]8_\)_3?_C5/VL_^?;_ /)?\P]M4_Y]/_R7_P"2
M/9:*\:_X5#\3?^BYZQ_X3^F__&J/^%0_$W_HN>L?^$_IO_QJCVL_^?;_ /)?
M\P]M4_Y]/_R7_P"2/9:QKOP7H-_XHL?$ESHUC/X@L86M[75)(%:X@C;.Y$D(
MRH.3D ]S7F?_  J'XF_]%SUC_P )_3?_ (U1_P *A^)O_1<]8_\ "?TW_P"-
M4XUZD?A@U\U_F'MJG_/I_P#DO_R1[+17@GBKP;XU\#Z#=ZUKW[0M]I&EVJ[I
M;N[T/3$C3L.3%U)X ZFH_@7^T=I_B+]FQO&VMZW%XBU70;&:XUU=/2,7"&,N
M1F(;0K,B@CH#4+$+GY)KE=KZVZ>C9*Q4>?V=1<KLWK;9>C9[)XD\$^'_ !A-
MILNNZ+8:O)IEP+NR>]MUE-M,.DD>X':P]1S6W7$_!SXM:/\ &[P#8>+]"@O+
M?3+QY4C2^C5)<QR,C9 8CJI[UYI\1/VUO WPSUCQ9INJZ?KDL_AJ[M;.\:VM
MHV5GN$9XRA,@R,*<YQ^-:SQ,(TXRG/W>GYERQ-&G!59223V?RO\ D?0-%>%:
M?^V%X,U+X?\ A+QA%8:R-+\3:X- LD:W3S5N"S*"XWX"90\@D^U=EK?QOT+0
M?C1X?^&5Q;7[:_K=E)?VTT<2FW$:"0G<V[(/[MN@/:I5>E)74NWX[#CB:,DF
MI=OQV^\]#K%\3>"M \:+8#7M%L=9&GW*WEH+ZW67[/.OW94W [6'8CFN<T_X
MRZ+J7QFU3X9Q6]Z->T[3$U::9HE^SF%F50 V[.[+CC'KS7>UO3J:\T'JC:,X
MU+\KO;0\X_:3_P"3=OBC_P!BOJ?_ *2R5>^!/_)#_AY_V+NG?^DT=4?VD_\
MDW;XH_\ 8KZG_P"DLE7O@3_R0_X>?]B[IW_I-'7I_P#, O\ '^@?:.YHHHKS
M"PHHHH **** ,[_F8/\ MU_]GK1K._YF#_MU_P#9ZT: "BBB@ HHHH ****
M"BBB@ JA)_R'H/\ KVD_]"2K]4)/^0]!_P!>TG_H24 7Z*** "BBB@ HHHH
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M?$/AJRT2SL].U56S]J@BA6-)#Z$A>1V.1QBN[H **** "BBB@ HHHH ****
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M9N/*SS,7@YXF=.<:CCRN^G7^OF>3_P#"??&7_HDND?\ A6I_\CT?\)]\9?\
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M(HX\85EXRW?!K](M)M;F'3K(:A)%<ZFD")<7$4>T22!1O91V!.3BH\#_ (2
MG S]EZXY^_6C7BX_,'CG"\%'E26B2V5NB6G9=#2,.4****\HT"F)&D>=B*FX
MY.T8R:?10 C*&4@C(/!!J)K2!MH,,9"C R@X^E344 ,6-$9F5%5F^\0,$_6G
MT44 ,>-)-I=%8J<C<,X-4?+2/7(0B*@-O(3M&,G>G-:-4)/^0]!_U[2?^A)0
M!?HHHH **** "BBB@ HHHH **** "BBJ6M:Q:>'],GU"^=X[6  NT<3RMR0!
MA4!8G)' !H NT5Q'_"ZO!7V'[:==B6T^RQ7C3-%(JI%(VV,ME?E+'HIPV 3C
M'-=A:WT%\KM;RK*B.4++R-PZ@'O^% &)\._^1%T'_KRB_P#01715SOP[_P"1
M%T'_ *\HO_01714 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52_YC(_Z]
M_P#V:KM4O^8R/^O?_P!FH NT444 4=)_U,__ %\2_P#H9J]5'2?]3/\ ]?$O
M_H9J]0 4444 %%%% !1110 4444 %%<;J'Q>\):7J&J65WJIM[G3(_-N4DM9
MAA=ZQC8=F)"795PFXDG%:6E^/O#^M7UY966IQ7%Y9S)!/;J&WQR."54@C.?E
M;/IM;.,&@"GXF_Y';P;_ -=KK_TG:NLKD_$W_([>#?\ KM=?^D[5UE !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!G?\S!_VZ_\ L]:-9W_,P?\ ;K_[/6C0 444
M4 %%%% !1110 4444 %4)/\ D/0?]>TG_H25?JA)_P AZ#_KVD_]"2@"_111
M0 4444 %%%% !117RK^T=^SUXBU;7O$OQ#E_:1\8_#'PK!;+<3Z?I\I2RL8X
MHE5W'SC[Q4L0!DECC- 'U517Y")\9/AH+I4'[=_Q1D7>!N_L?4=IY_W<X_"O
MUWM\&WB(<R#:,,W4\=: )*JZI:2:AIMW:Q7$EG)-$T:W$6-\1((#+GN,Y'TJ
MU10!P4WP=T6YO7FFAMY(ETY=,@C-JF5A7RR/,8_ZTJ8E*;ONY;'4UI^#/ ,7
M@N^UN:#4KV[MM2G66.TN9-T=J "-L8[ YY^@^IZJB@#G?AW_ ,B+H'_7E%_Z
M"*Z*N=^'?_(BZ#_UY1?^@BNBH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JE_S&1_U[_^S5=JE_S&1_U[_P#LU %VBBB@"CI/^IG_ .OB7_T,U>JCI/\
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M %%%% !1110 4444 %%%% !1110 52_YC(_Z]_\ V:KM4O\ F,C_ *]__9J
M+M%%% %'2?\ 4S_]?$O_ *&:O51TG_4S_P#7Q+_Z&:O4 %%%% !1110 4444
M %%%% !1110!R?B;_D=O!O\ UVNO_2=JZRN3\3?\CMX-_P"NUU_Z3M764 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &=_S,'_;K_P"SUHUG?\S!_P!NO_L]:- !
M1110 4444 %%%% !1110 50D_P"0]!_U[2?^A)5^J$G_ "'H/^O:3_T)* +]
M%%% !1110 4444 %>/?M>?#/4?C%^SGXU\':1I*:WJFJ6T<=M9R7PLP9%FC=
M7\TJP&PKOP00VW:>M>PUY/\ M4:3\/-<^ OBJR^*NH2:5X"E2 :E>0LZO&!<
M1F,@HK-_K!&. >O/% 'SYX7\7_MT:)H>G:=>_#GX<:I-:Q+"]])J)B>;;QN*
M),%!QUV@#/0#I7VS'O\ +3> 'P-VWIGO7XG?&CX<_L8Z+X9T^X^%/B?6/&GC
M;^U;);7PVQNWCU2-IT66!F\J,QY1F(97#;E &<XK]KX%"P1@*4 4 *>W'2@"
M2BBB@ HHHH YWX=_\B+H/_7E%_Z"*Z*N=^'?_(BZ#_UY1?\ H(KHJ "BBB@
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M?:KS_GQ/_?U:/M5Y_P ^)_[^K5VB@"E]JO/^?$_]_5H^U7G_ #XG_OZM7:*
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MMK1+B_.E:J\4>V*-(D6.(+]YMJJ!GEC[T 4E^(G[;^X;OA5\-0N>?^)M+_\
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M.U=97)^)O^1V\&_]=KK_ -)VKK* "BBB@ HHHH **** "BBB@ HHHH ****
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M1?\ H(KHJYWX=_\ (BZ#_P!>47_H(KHJ "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %4O^8R/^O?\ ]FJ[5+_F,C_KW_\ 9J +M%%% %'2
M?]3/_P!?$O\ Z&:O51TG_4S_ /7Q+_Z&:O4 %%%% !1110 4444 %%%% !11
M10!R?B;_ )';P;_UVNO_ $G:NLKD_$W_ ".W@W_KM=?^D[5UE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE_S&1_U[_\ LU7:I?\
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M5PBI.S=O6_Z7 ZBBO/O^$1^(/_10K7_PGX__ ([1_P (C\0?^BA6O_A/Q_\
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MM8;=IW\R5H8PID;^\V!R?<U9HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUM0S)<1)+$ZR1NH970Y# \@@]Q0!0_XF_P#TY?\ C]'_ !-_^G+_ ,?K2HH
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MFF^/H-,2XM3X3BT"/Q!J'B:9YA%%%+,88$B586#L9!ALLI4G&"P('9P?M!>
MKC5M/TU=<=;J^FM[:(2V-S&BS7"[H(9':,+%*XQMCD*L<KQR,@'HE%>+>./V
MN/AYX/\ #NL:G!J4NN2Z:5!M;&VE)N%^U):N\+E-LJI)( S1E@.AY(SUT'QR
M\#W'BH^'(]>C.K"5[?RS!*(_.2+S7@\TIY?G+'\QBW;P <KP: .[HKS3P]^T
MC\-O%6DWNIZ;XH@ET^STR369;F6":%#9)]^X0N@WQC(^9,CD>M>BV=U%?6D%
MS V^&9%D1B",J1D'!Y'![T 34444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5CZ;_P C#K7_ &Q_] -;%8^F_P#(PZU_VQ_] - &Q7D_PI^
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M27\T0RX Q@(Q]JT?B'^TMX+\ _#N[\6B^;68$\/-XGM+.QC8RWEB#&!*F1@
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M_2K@1.DT0CB?<,@1L3\V ,DGU'8B@#1^'?\ R(N@_P#7E%_Z"*Z*N=^'>?\
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MB<$%5PC!@,U]+T4 ?.</[)!AT,:?'KUG;*VF:;8NEKIOEP^9;:L^HR2*GF'
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M;>[@LX7@NY$=5-O L"NI"@[FCC3=SC*Y &3GH/\ A(6_Z!.I?]^5_P#BJ/\
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MG><[CG@9K-7]D'Q)JG@^?P]K/C?3Y;:W\ W/@/3I++2&C98G: I=3;IFW.!
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M^($#VVK(F@-X8UB]33H-/\Z;[5;K RRD[LR8\PA8UVYR<DY& #M?^%6^%_\
MH%+_ -_I/_BJ/^%6^%_^@4O_ '^D_P#BJ\R_90\>>(O&6C^(8/$>LQZY<64M
MHT=S;W$-W$!+;)(ZBXBCC1CYA<^7MS&"H+,"#7O% '*?\*M\+_\ 0*7_ +_2
M?_%4?\*M\+_] I?^_P!)_P#%5U=% '*?\*M\+_\ 0*7_ +_2?_%4?\*M\+_]
M I?^_P!)_P#%5U=<5\9O$UIX/^&VLZO?^)'\)6=NL9EU:&%)98U,B@I$K@J9
M'SL7(.&<'!QB@":/X4^&EFE9M,4HQ&T>?+QQ_O5)_P *M\+_ /0*7_O])_\
M%5\V:C\?/'^AQ_"_3E34;NQO]=MO[2UZ"P345GM9KUXH=/:>W!A%PL>PS.N
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M I?^_P!)_P#%4?\ "K?"_P#T"E_[_2?_ !5=710!RG_"K?"__0*7_O\ 2?\
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MP#*T99]SG[Q8$ *RB@#T;_A5OA?_ *!2_P#?Z3_XJC_A5OA?_H%+_P!_I/\
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MI_#7P98^'-2DM;[4="9EB>VN(%;4FE<;&5E=UCC&1]TD%G"@ ^@_^%6^%_\
MH%+_ -_I/_BJ/^%6^%_^@4O_ '^D_P#BJY7]G3Q%JOBCP;?ZAJ&LMK-E)J$A
MTMKJ>WFOHK38A1;HP ()2V]]N-RJZ*WS UZK0!RG_"K?"_\ T"E_[_2?_%4?
M\*M\+_\ 0*7_ +_2?_%5U=% '*?\*M\+_P#0*7_O])_\51_PJWPO_P! I?\
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MH;F&.XA;[T<J!E/U!J:B@"M:Z;9V5NEO;VL$$$;;DBBC"JISG( & <U9HHH
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M',I4J1(H88/4<]C4M% %:PTVSTN$Q65I!9Q,VXI;QA%)]< =>*LT44 %%%%
M!1110!6;3+-I[>8VD!FM@P@D,:[H@1@A3CY<CKBK-%% !1110 4444 5UL+9
M+U[Q;:%;MT$;7 0>8R@Y"ENI&>U31QI&"$54!)8[1C)/4TZB@ HHHH ****
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M &C17FNL?'#PWX?\?6_@K4O$>CV?B:=%=+*7S0!N1W4-)MV(S+%(P5F!(0D
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M3A@.&!Z$5U&=6]++\W_PHG"5.3A-6:Z,-S1HK.SJWI9?F_\ A1G5O2R_-_\
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M%.I3G2DX5$TUT>@KWV-&BL[.K>EE^;_X49U;TLOS?_"LQFC16=G5O2R_-_\
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M.,,"""177YU;TLOS?_"B=.=.3A-6:Z,-]C1HK.SJWI9?F_\ A1G5O2R_-_\
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M]T<N*JJC2<Y*Z1]/PQ""&.-22$4*">O I],BW^4GF !\#<!TSWI]9G4%%%%
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M?\_=_P#^!DG^-:E% &7_ ,(_%_S]W_\ X&2?XT?\(_%_S]W_ /X&2?XUJ44
M9?\ PC\7_/W?_P#@9)_C1_PC\7_/W?\ _@9)_C6I10!E_P#"/Q?\_=__ .!D
MG^-'_"/Q?\_=_P#^!DG^-:E% &7_ ,(_%_S]W_\ X&2?XT?\(_%_S]W_ /X&
M2?XUJ44 9?\ PC\7_/W?_P#@9)_C1_PC\7_/W?\ _@9)_C6I10!E_P#"/Q?\
M_=__ .!DG^-'_"/Q?\_=_P#^!DG^-:E% &7_ ,(_%_S]W_\ X&2?XT?\(_%_
MS]W_ /X&2?XUJ44 9?\ PC\7_/W?_P#@9)_C1_PC\7_/W?\ _@9)_C6I10!E
M_P#"/Q?\_=__ .!DG^-'_"/Q?\_=_P#^!DG^-:E% &7_ ,(_%_S]W_\ X&2?
MXT?\(_%_S]W_ /X&2?XUJ44 9?\ PC\7_/W?_P#@9)_C1_PC\7_/W?\ _@9)
M_C6I10!E_P#"/Q?\_=__ .!DG^-'_"/Q?\_=_P#^!DG^-:E% &7_ ,(_%_S]
MW_\ X&2?XT?\(_%_S]W_ /X&2?XUJ44 9?\ PC\7_/W?_P#@9)_C1_PC\7_/
MW?\ _@9)_C6I10!E_P#"/Q?\_=__ .!DG^-'_"/Q?\_=_P#^!DG^-:E% &7_
M ,(_%_S]W_\ X&2?XT?\(_%_S]W_ /X&2?XUJ44 9?\ PC\7_/W?_P#@9)_C
M1_PC\7_/W?\ _@9)_C6I10!E_P#"/Q?\_=__ .!DG^-'_"/Q?\_=_P#^!DG^
M-:E% &7_ ,(_%_S]W_\ X&2?XT?\(_%_S]W_ /X&2?XUJ44 9?\ PC\7_/W?
M_P#@9)_C1_PC\7_/W?\ _@9)_C6I10!E_P#"/Q?\_=__ .!DG^-'_"/Q?\_=
M_P#^!DG^-:E% &7_ ,(_%_S]W_\ X&2?XT?\(_%_S]W_ /X&2?XUJ44 9?\
MPC\7_/W?_P#@9)_C1_PC\7_/W?\ _@9)_C6I10!E_P#"/Q?\_=__ .!DG^-'
M_"/Q?\_=_P#^!DG^-:E% &7_ ,(_%_S]W_\ X&2?XT?\(_%_S]W_ /X&2?XU
MJ44 9?\ PC\7_/W?_P#@9)_C1_PC\7_/W?\ _@9)_C6I10!E_P#"/Q?\_=__
M .!DG^-'_"/Q?\_=_P#^!DG^-:E% $-K:QV=ND,>[8O]YBQ.3DDD]234U%%
M!1110!2U#28-1EAED::.6(,J20RM&P#8R,@]#M'Y5!_PC\7_ #]W_P#X&2?X
MUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W
M?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_
M #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44
M 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\
M@9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W
M_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_
M  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_
MC1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X
M&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\
M7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_P
MC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?X
MUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W
M?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_
M #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44
M 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\
M@9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W
M_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_
M  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_
MC1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X
M&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\
M7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_P
MC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?X
MUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W
M?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_
M #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44
M 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\
M@9)_C1_PC\7_ #]W_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C1_PC\7_ #]W
M_P#X&2?XUJ44 9?_  C\7_/W?_\ @9)_C4EKHL%K<+-YMQ,Z@A?/G>0+GJ0"
'>M:%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img205696091_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205696091_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &\!0 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBVW^?(,S@&(;@5^Y-,\&:#HLUI/I^BZ=83V=DNFVTMK:1QM!:@@K;H0/EB!
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M1FC- ']/OPY^&^C_  N\.OH^C?:'CFO+C4;FYO)3+/<W4\K2SS2-P-SN['@
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M1D4P%HI-U&Z@!:**2E<!:*:&]:7=3 6BDW4W?0(?13=U&Z@8ZBF;_P Z=NH
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M^'VGPL_Z$7QA_P!\VO\ \>K\;,T9H _9+_A]C\*_^A%\8?\ ?-K_ /'J1?\
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MY"5IC_KNO^->5?'_ /:3T#X+^ ]8U>WOM)UC7;2*.6#0WU%(I;@-(J9 &6P
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MXT?\)%I7_03M/^_Z_P"->>?\,J_"'_HG/AW_ , (_P#"C_AE7X0_]$Y\._\
M@!'_ (4[UNR^_P#X 7Q'\J^]_P"1Z'_PD6E?]!.T_P"_Z_XT?\)%I7_03M/^
M_P"O^->>?\,J_"'_ *)SX=_\ (_\*/\ AE7X0_\ 1.?#O_@!'_A1>MV7W_\
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M K^AW_@GC_R9=\*O^P8W_H^6OYXJ_H=_X)X_\F7?"K_L&-_Z/EH ^BZ^%?\
M@LE_R:/:?]C-9?\ HJXK[JKX5_X+)?\ )H]I_P!C-9?^BKB@#\0:*** "BBB
M@ HHHH MZ3_R%+/_ *[)_P"A"OZG:_EBTG_D*6?_ %V3_P!"%?U.T %?D!_P
M6Z_Y*I\-/^P+<?\ H\5^O]?D!_P6Z_Y*I\-/^P+<?^CQ0!^:U%%% !1110 4
M444 ?4'_  3,_P"3X_AA_P!=K[_T@N:_H(K^??\ X)F?\GQ_##_KM??^D%S7
M]!% !7\]G_!2'_D]KXI?]?MO_P"DD%?T)U_/9_P4A_Y/:^*7_7[;_P#I)!0!
M\U4444 %%%% !1110!^FG_!#_P#Y'[XI_P#8,LO_ $;)7ZZ5^1?_  0__P"1
M^^*?_8,LO_1LE?KI0 4444 %%%% !5#68;Z;2[M-+N;>SU)HF%M<7=NUQ%')
MCY6>-71G4'!*AU)Z;A5^H;BW2X@DBER8G4JP!()!Z\CD?A0!\R>.OV7]2U?1
MTU_X@?M,?$[29-,M&:_U#P_K%GX;TR-02SR&**#"*,_>ED=@ ,N:/@C\.9+>
MWM[WX4_M.ZW\1=(M=3#ZM!XFU"Q\5V\R&/#0">(13V[XV,N)MH(R8VW'/G7B
MCQ]%)I[^!;37/%WCSX>:K=>?INKS:!?/K&CR6LJW*26UQ=VY@URWC>#?L4R7
M!C1B!=+DK[E^R_X/O8=%N_'.K?%H?&34O$=O;Q1>(;73;73K3[) TQCCCAM\
MC<KS3!F9BV<+A=N* /=**** "N4\=?\ 'UX7_P"PS#_Z+EKJZY3QU_Q]>%_^
MPS#_ .BY: .KHHHH 8RAO<>E<_X>^'OA?PCJ-]?Z'X=TG1[Z^;?=7%A8QP23
MGU=E4%O7GOS7148IJ4HII/1BL@Q[T8]Z.?6CGUI#$V^]+CWHY]:.?6@ Q[T8
M]Z.?6CGUH ,>]&/>CGUHY]: #'O1CWHY]:.?6@ Q[T8]Z.?6CGUH 3&*P/&'
M@/P]\0]'72O$ND6FMZ<LT=RMM>1B1!(C;D?![@]#7048H3E%WB!5U!3]AN.<
M$1-_(UXW^Q5_R:G\,>W_ !)8?ZU[+J'_ !XW/_7)OY&O&_V*O^34_AA_V!8?
MZUW1_P!TG_BC^4B?M(]NHI*6N$H**** &[<]>13J0#%+0 4W;SG//TIU% #=
MOO3J** &[:=110 4444 %%%% !1110 4444 %%%% #=E.HHH *HW7_(4L?I)
M_(5>JC=?\A2Q^DG\A0!>HHHH 8J\]:?110 4W;3J* &[:=110 4444 %%%%
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M_H0K^IVOY8M)_P"0I9_]=D_]"%?U.T %?D!_P6Z_Y*I\-/\ L"W'_H\5^O\
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MLL?%GX#?$?3=>L?@7_8D&GZ?+'-J5GHF@R:3&LDJL$=HVABWLRQ$;@#]S'%
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M% !1110 4444 %4;K_D*6/TD_D*O51NO^0I8_23^0H O4444 %%%% !1110
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MFG44 -V9ZG(^E&WWYIU% 'E'PS7/QI^,8S_R^Z9_Z;XJ]7KRGX9_\EJ^,?\
MU^Z7_P"F^*O5J /PK_X*\?\ )Y&I?]@:P_\ 0&KXKK[4_P""O'_)Y&I?]@:P
M_P#0&KXKH **** "BBB@ K[U_P"",7_)UVM_]BE>?^E5I7P57WK_ ,$8O^3K
MM;_[%*\_]*K2@#]LZ*** /YE_P!H3_DOGQ+_ .QFU/\ ]*I*\_KT#]H3_DOG
MQ+_[&;4__2J2O/Z "BBB@ HHHH *_8G_ ((C_P#)%_B%_P!C!'_Z3)7X[5^Q
M/_!$?_DB_P 0O^Q@C_\ 29* /T?KRG]K'_DUGXR?]B9K/_I#-7JU>4_M8_\
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M)HZ[MNE%;^)+U!;!2TE+68PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /PK_P""O'_)Y&I?]@:P_P#0&KXKK[4_X*\?\GD:E_V!K#_T!J^*Z "BBB@
MHHHH *^]?^",7_)UVM_]BE>?^E5I7P57WK_P1B_Y.NUO_L4KS_TJM* /VSHH
MHH _F7_:$_Y+Y\2_^QFU/_TJDKS^O0/VA/\ DOGQ+_[&;4__ $JDKS^@ HHH
MH **** "OV)_X(C_ /)%_B%_V,$?_I,E?CM7[$_\$1_^2+_$+_L8(_\ TF2@
M#]'Z\I_:Q_Y-9^,G_8F:S_Z0S5ZM7E/[6/\ R:S\9/\ L3-9_P#2&:@#^:VB
MBB@ HHHH **** "OZ'?^">/_ "9=\*O^P8W_ */EK^>*OZ'?^">/_)EWPJ_[
M!C?^CY: /HNOA7_@LE_R:/:?]C-9?^BKBONJOA7_ (+)?\FCVG_8S67_ **N
M* /Q!HHHH ]D\'_M)WG@'P7<:;H/AC2]/\1W&D-H,OB1)9VF:S:Y%PP\EI#$
M)2RJOF!?NC[NX[ZV/%W[6$OCFZ']L>!=!N=-FU+5=?O].WS^7=ZM?PI'+=DE
MR5V&-'2-?E!!SD&O Z* /9O$/[3VM>(OA=-X0ET738+J[TC3= O]<C,OVBZT
M^PD\RTA*EMBE2L09E4%A!'T.XMXS110!;TG_ )"EG_UV3_T(5_4[7\L6D_\
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M (*0_P#)[7Q2_P"OVW_])(*_H3K^>S_@I#_R>U\4O^OVW_\ 22"@#YJHHHH
M<).O&11YGMCZ4VB@!=PXXI*** /TT_X(?_\ (_?%/_L&67_HV2OUTK\B_P#@
MA_\ \C]\4_\ L&67_HV2OUTH **** "BBB@ HHHH ^=_C9X@^,?@3XN66O\
MPZ^'FI?$_1+G118WFCRZ_9Z596LXF9UGC>:8L92IVN#!@KY>)00R5V/P/^(?
MQ,\>+K'_  L;X2-\+FM?*^Q#_A)+76!>[M^_F  QE-J?>'._CH:\'_;4\6?!
M_P /_$+1H/B#^T#\2OA'JSZ6KP:5X)U*\@MKB'S9,32)#;3+OW!ER2"0@X.
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MVLK2%((((QA8XU 55 [   5<HH \H^&:@_&KXQ_]?NE_^F^/_&O5Z\I^&?\
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M\=>"_$OBR^\1Z?X9T+0[FTLYKB^M[F=IIKA9W18U@B<\+;2LQ.  !SS6A9?
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M*3LME#E!R0N!@8KPR@ K^AW_ ()X_P#)EWPJ_P"P8W_H^6OYXJ_H=_X)X_\
M)EWPJ_[!C?\ H^6@#Z+KX5_X+)?\FCVG_8S67_HJXK[JKX5_X+)?\FCVG_8S
M67_HJXH _$&BBB@ HHHH **** +>D_\ (4L_^NR?^A"OZG:_EBTG_D*6?_79
M/_0A7]3M !7Y ?\ !;K_ )*I\-/^P+<?^CQ7Z_U^0'_!;K_DJGPT_P"P+<?^
MCQ0!^:U%%% !1110 4444 ?4'_!,S_D^/X8?]=K[_P!(+FOZ"*_GW_X)F?\
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M;\T_^*H M455^UR_\^<WYI_\51]KE_Y\YOS3_P"*H M455^UR_\ /G-^:?\
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M_1_PR+X?_P"AJ^*'_A<W_P#\?H]GA_\ GX_N_P""&I] [A1N%?/W_#(OA_\
MZ&KXH?\ A<W_ /\ 'Z/^&1?#_P#T-7Q0_P#"YO\ _P"/T>SP_P#S\?W?\$-3
MM_B#\>-%^'/Q+^'_ (*O[.]N-1\9SW-O936X0Q0-#&'8RY8$ @\8!Z=J](#J
MR[@00>AKX'^)G_!-7P]JOQ8^']_H&GZQ/X:%U=R^*9M0\02O=NK(#$T3,Q;=
MOW;B""1BO;M)_8O\(:'I\-CINN_$C3[*!=L5M:^-+V*.-?[JJLP 'TKNKT,!
M&E3=*J^9K73K=_WM-+$KFN[H^C-PHW"OG[_AD7P__P!#5\4/_"YO_P#X_1_P
MR+X?_P"AJ^*'_A<W_P#\?KA]GA_^?C^[_@E:GT#N%&X5\_?\,B^'_P#H:OBA
M_P"%S?\ _P ?H_X9%\/_ /0U?%#_ ,+F_P#_ (_1[/#_ //Q_=_P0U/H'<*-
MPKY^_P"&1?#_ /T-7Q0_\+F__P#C]'_#(OA__H:OBA_X7-__ /'Z/9X?_GX_
MN_X(:GT#N%&X5\_?\,B^'_\ H:OBA_X7-_\ _'Z/^&1?#_\ T-7Q0_\ "YO_
M /X_1[/#_P#/Q_=_P0U/?9)TC!); KSOX!_'71?VA? "^+-#LKW3[%KN>S\G
M4 @EW1.49L(S#!(XYSZ@5YAXB_89\!>+K2.VU[4?B!K=M&_F)#J/B^\G17P1
MN >8@'!//N:\F_9E_P""=.F>"_!L-UXT3Q!I'C>.[NL77AKQ+-;JMNS?NP#&
MZX)7 /KW]*[:=# ?5YRE5?/=6T];_:]/0F\K['WAN%&X5\_?\,B^'_\ H:OB
MA_X7-_\ _'Z/^&1?#_\ T-7Q0_\ "YO_ /X_7%[/#_\ /Q_=_P $K4^@=PHW
M"OG[_AD7P_\ ]#5\4/\ PN;_ /\ C]'_  R+X?\ ^AJ^*'_A<W__ ,?H]GA_
M^?C^[_@AJ>_>8O4G\:\K\%_'C1/B!\9_&W@.RL[RWU/P2;=;VXN @@G^T1[T
M\HAB3@#!R!SZUQ6I_L7^$-;T^>QU+7OB3J%E.NR:VNO&E[)'(O\ =93-@CV-
M>)?"S_@G1HGA7X]>,M4UG2]2'A$7-C=>%C;Z[(;@-"NZ;S\,"P\S& Q/'%=V
M'H8"5.HZM5\R6FG6Z\R6Y75D??=%5?M4O_/G-^:?_%4?:Y?^?.;\T_\ BJ\4
MT+5%5?M<O_/G-^:?_%4?:Y?^?.;\T_\ BJ +5%5?M<O_ #YS?FG_ ,51]KE_
MY\YOS3_XJ@"U157[7+_SYS?FG_Q5'VN7_GSF_-/_ (J@"U157[7+_P ^<WYI
M_P#%4?:Y?^?.;\T_^*H M455^UR_\^<WYI_\51]KE_Y\YOS3_P"*H M455^U
MR_\ /G-^:?\ Q5'VN7_GSF_-/_BJ +5%5?M<O_/G-^:?_%4?:Y?^?.;\T_\
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M5I0!^V=%%% '\R_[0G_)?/B7_P!C-J?_ *525Y_7H'[0G_)?/B7_ -C-J?\
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M^+O&'Q$^(/A>V\":IX@M=/TZ'PO;ZJFIM;16AG_?2SQJL9>0W!X7.%1 3G(
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MN(W&TD YQNX'/7/H>SWHV^] 'B/P%T34M!^*7Q?M=6\077B6]6_TTM?WEO!
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M_P!*K2O@JOO7_@C%_P G7:W_ -BE>?\ I5:4 ?MG1110!_,O^T)_R7SXE_\
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M110 4444 6])_P"0I9_]=D_]"%?U.U_+%I/_ "%+/_KLG_H0K^IV@ K\@/\
M@MU_R53X:?\ 8%N/_1XK]?Z_(#_@MU_R53X:?]@6X_\ 1XH _-:BBB@ HHHH
M **** /J#_@F9_R?'\,/^NU]_P"D%S7]!%?S[_\ !,S_ )/C^&'_ %VOO_2"
MYK^@B@ K^>S_ (*0_P#)[7Q2_P"OVW_])(*_H3K^>S_@I#_R>U\4O^OVW_\
M22"@#YJHHHH **** "BBB@#]-/\ @A__ ,C]\4_^P99?^C9*_72OR+_X(?\
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M,P_^BY:ZNN4\=?\ 'UX7_P"PS#_Z+EH ZNBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ JC=?\A2Q^DG\A5ZJ-U_R%+'Z2?R%
M%ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVI_P5X_Y/(U+_L#6'_H#5\5T %+N]J2B@!=WM29HHH *^]?^",7_ "==K?\
MV*5Y_P"E5I7P57WK_P $8O\ DZ[6_P#L4KS_ -*K2@#]LZ*** /YE_VA/^2^
M?$O_ +&;4_\ TJDKS^O0/VA/^2^?$O\ [&;4_P#TJDKS^@ HHHH **** "OV
M)_X(C_\ )%_B%_V,$?\ Z3)7X[5^Q/\ P1'_ .2+_$+_ +&"/_TF2@#]'Z\I
M_:Q_Y-9^,G_8F:S_ .D,U>K5Y3^UC_R:S\9/^Q,UG_TAFH _FMHHHH ****
M"BBB@ K^AW_@GC_R9=\*O^P8W_H^6OYXJ_H=_P"">/\ R9=\*O\ L&-_Z/EH
M ^BZ^%?^"R7_ ":/:?\ 8S67_HJXK[JKX5_X+)?\FCVG_8S67_HJXH _$&BB
MB@ HHHH **** +>D_P#(4L_^NR?^A"OZG:_EBTG_ )"EG_UV3_T(5_4[0 5^
M0'_!;K_DJGPT_P"P+<?^CQ7Z_P!?D!_P6Z_Y*I\-/^P+<?\ H\4 ?FM1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M['L?^?*W_P"_*_X4 ?EK17ZE?V/8_P#/E;_]^5_PH_L>Q_Y\K?\ [\K_ (4
M?*O_  3,'_&<7PPY_P"6U]_Z07-?T$5^>?[,.FVD/QT\+/';0QN'G(94 /\
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MZOI^DVMI>+I=NEO:B:.%5<0QHJJD88':JJ !@ "@#KJ*** "BBB@#RGX9_\
M):OC'_U^Z7_Z;XJ]6KRGX9_\EJ^,?_7[I?\ Z;XJ]6H _"O_ (*\?\GD:E_V
M!K#_ - :OBNOM3_@KQ_R>1J7_8&L/_0&KXKH **** "BBB@ K[U_X(Q?\G7:
MW_V*5Y_Z56E?!5?>O_!&+_DZ[6_^Q2O/_2JTH _;.BBB@#^9?]H3_DOGQ+_[
M&;4__2J2O/Z] _:$_P"2^?$O_L9M3_\ 2J2O/Z "BBB@ HHHH *_8G_@B/\
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M3)$-O)->B>$?B1?Z[\9?'O@VYAM39Z%8:5?VUQ;JP?\ TH7 >*7+$%U:WW#
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MJTKX*K[U_P"",7_)UVM_]BE>?^E5I0!^V=%%% '\R_[0G_)?/B7_ -C-J?\
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MW$BQW$(4,\[L0 8CQDUR7_#%/@?_ *"OB#_P(@_^,T ?%6*,5]J_\,4^!_\
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M*;NZ4GF=\<4 /HI-WXT4 +13/,XR>.:?0 4444 %%%% !1110 4444 %%%%
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MJ7[%VG7>EZ9:Q>(9&DMKF66:>YMV+W"/!;P@N8Y4)D06PV.20 [#:>M 'O\
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M0KYWG'+S-(74;3\@5,KG!%>84 2VG_'W#_OK_.OU.K\L;3_C[A_WU_G7ZG4
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MYQSDY)S* /IG]A__ )&#Q1_UZP_^AM7UU7R+^P__ ,C!XH_Z]8?_ $-J^NJ
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M;X>T2+PYH.F:3!(\D-A;16L;R?>940*"?<@5I4 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *;M]\4ZB@!GE].>!2[ >O-.HH \H^&:Y^
M-7QC_P"OW2__ $WQ5ZO7E/PS_P"2U?&/_K]TO_TWQ5ZM0!^4/_!1K]F#_A:W
M[2U]KW_"2_V7OTRTB^S_ &#SL;5;G=YJ]?I7R_\ \,+_ /4[?^4G_P"WU^BO
M[7G_ "62Y_Z\H/\ T$UXK0!\J?\ #"__ %.W_E)_^WT?\,+_ /4[?^4G_P"W
MU]5T4 ?*G_#"_P#U.W_E)_\ M]'_  PO_P!3M_Y2?_M]?5=% 'RI_P ,+_\
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M]]?YU^IU !7Q_P#MN_\ (U>&_P#KRD_]&5]@5\?_ +;O_(U>&_\ KRD_]&4
M?-E+D]:2B@#7N/&&O7=U8W,^MZE-<6  M)I+N1GMP.@C).4QVQBHI_$NKW7V
MXS:K>S&^=)+LR7#M]H9"2C29/SD9X)SC/%9M% %_5M>U3Q!)%)JFI7FI21)Y
M<;7D[RE%[*-Q. .U4*** /3_ -F7_DN/A?\ WY__ $GDK]!*_/O]F7_DN/A?
M_?G_ /2>2OT$H *_/;]I#_DMGBG_ *[1_P#HE*_0FOSV_:0_Y+9XI_Z[1_\
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MGH"D#^W--R>G^EQ_XUH_8;;_ )]X?^^!_A4$FEVLES%.88\QJR@;!@YQG^5
M%;_A,M _Z#FF_P#@7'_C1_PF6@?]!S3?_ N/_&K_ -CMO^?:+_O@4[[#;?\
M/O%_WP* ,[_A,M _Z#FF_P#@7'_C5.X\7Z$VI6;#6]-(59,_Z7'Z#WK=^PVW
M_/O%_P!\"D^P6W_/O%_WP* ,_P#X3+0/^@YIO_@7'_C1_P )EH'_ $'--_\
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M5Y%?6]B-3OCI,&I+(+B+3S</]G602_./DQ@/\P4J#SQ7I-,\OD$&GT %%%%
M!1110!Y-^T?IFLZMX%L+72I;J&T;5;?^U6M+::X?[%\V_P#=0LLDB[O+W*A!
M*[LY&0=WX*#58_A5X:36K2XL=22U"20W3RM*%5B$9O-+.&90K%7)92VTDD5W
M6SW]Z7;0 M%%% !1110 5X[\4=(U:/XI>&=9MY_$<VB1:/J\-_:Z0SF./]S&
M8V1%'-PQR$).<CY1US[%3=M 'B_[+]G-!X3U:YDM=6T:&]OO/M]!U:.Z#Z;'
MY2*(_,N0&D=B#)(4)02.P7."S>U4W;3J "BBB@ HHHH \%^,V@>*U\1^*]1T
M&3Q!>B[\%WEM;V]G.5@M[D31;/)50,3%2[=2[8PI&!C:_9GTW5=)\!ZC::F;
MQX8]7N/L$UW:W%H);8[2IBM[AFEAC#%E"NQ)*ELX85Z]M_"A4V]Z '4444 %
M%%% !7RS>-XND^)7CN^\"Z/KUGK,:36,7]O&Z2'4Y'GBWW222J;=(K= XMXU
MYD);.%^]]34W;[T >9_LXVOB&Q^#/ANT\46NI6>MVT<D,RZQ=?:;M@LCA7ED
MP-S, "?K7IU)M_"DW>U #J*;N].:-V>WM0 ZBF[^M.H ^0]:T359/&6O/:Z7
MXR/@NZNK1M?M9HKT7'R7<HEVD.YN X:-O]&P%@C"D<\>_? ^VUBU^%N@1:ZM
MY'J"Q/\ N]0)-RL/FN8%E+?-O$1C!W'=G.>:[S9R32>7VSQVH ?1110 4444
M ,DSY;8!)QT'6OB;6?#_ (GNKB_M]+B\5V/@2XO(;B\&H:9J5Q=0W M;A?*>
M!9O-G;S_ "7>:%Q$6:+ PA:OMNF^70!SWP];49/ ?AQM7M9;#5FTZW-W;3S&
M9XIO+7>K.269@<\DY/>NDINWKS3J "BBB@ K,\13:C;:#J4VD6L5]JL=M(UI
M:W$OE1S3!3L1GP=H+8&<'&<XK3I-M 'Q-<:;X]_X0N[TGQQHWB\^);[Q%=R6
M^LP375Y:V"O!;LUYY=FO*Q,62WB(QNR"<!FK[1LU*VL(,CR$(,O(,,W'4\=:
MG*"C;[T .HHHH **** .=\?W7B&S\&ZO-X3L;;4?$JV[?V?;7LWE0O-T4NV#
MP,Y]\8XSFOC:3PW\51H?ABWU2U\61:MIVHZH\<UQ)->3W\QU1'C'FP%8[=C#
MYFR64-"(BP"@"ONDKNHV^AH =1110 4444 %>?\ QUTZ[U?X3^(;*QNM2L9K
MB%(FN-)M&NKF.-I%$A2)71F^3?D*P;&<9. ?0*;L% 'R+:0?%J35/A=%8>&K
MV#P3I>O9>2PN9+.2\A:6X03WEM,6ECB$1CD$98_.^3M 51]>4SR^<@X-/H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JU]8I?V
MDUN[,J3(T;,IY ((./?FK-% '@LW[&W@_P#X5[X0\)VFM^(],B\,Z1<^'X-4
ML[N%+RYTZY5%N+:9C"4*R"-/F1$="N49"23[-:^%]*L]%L=(BT^W_LRQBC@M
MK5XPZ1(B[$ !ST7CZ5J44 >1?"?3[;3_ (Q_&&&U@CMHEOM-(2% B\V$9/ ]
MR:]=KRGX9_\ ):OC'_U^Z7_Z;XJ]6H ^%OVO/^2R7/\ UY0?^@FO%:]J_:\_
MY+)<_P#7E!_Z":\5H LZ7?/I.I6E]"D;RVTJS(LT8="RL& 93P1QR#UKV+Q!
MXHT?Q1\3O!VLZOJ5K?P6F@6UQ?M*XVS744#R&%_5FD 4K[]#7BE'^3Z4 =[X
M0U:XA\4:?XQNM;TTZE-J[1SP7[OO&]<O,X0$B,[RNY>0>@XIOQ4U32[L>&K#
M3O*(TS3?LLH@G$Z*YGE<()1C>0L@R1P"3C%<)^?H.>/RH_\ U4 %>]?L9?\
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M4444 %%%% !1110!Z?\ LR_\EQ\+_P"_/_Z3R5^@E?GW^S+_ ,EQ\+_[\_\
MZ3R5^@E !7Y[?M(?\EL\4_\ 7:/_ -$I7Z$U^>W[2'_);/%/_7:/_P!$I0!Y
MK1110 4444 %%%% 'TS^P_\ \C!XH_Z]8?\ T-J^NJ^1?V'_ /D8/%'_ %ZP
M_P#H;5]=4 %%%% !1110 4444 %%-W>U+0 M%)10 M%)FC=0 M%-W>U+GVI
M+1244P%HI** %HI-WM1D^E "T4E% "T4E% "T4GX49H 6BDHH 6BDHH 6BDH
MH 6BDW>U&[VH 6BDHH 6BDHH 6BDH_"@!:\,_;&U7QQH_P %9W^'=]=:;XKG
MU.QMK:ZM(!,RAYT#94JWR$9W'' )->Y4A7.: /@+P+^U)\9+.R\2^(M9TBZ@
MLM:OUOM-AU[2;B2'2+=K226"R"6ZB0R3.B)N)(0DY!)4-U'Q"_:<^-+^%_%D
MVF>$[?PW+'!J:6.[3;BZO+*2TM[.?=)SLDW^?/& J_>BR-W('VIMYSWHV^YH
M ^;?@-\4OB%J_P 3;_1?$<<>J>&M1N]>N-/U(64T$MLEK=V\<*%F^0Q2)<,R
M# 8"/[S<X^E:;M&<]Z6@!:*3-&?:@!:*2B@!:*2B@!:*3\*,T +1244 +124
M4 +1244 +13=U&[VH =1244 +1244 +12;J,GTH 6BDHH 6BDHH 6BDHH 6B
MDS[4F[_.: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !17+>./BAX4^&=O;7'BOQ!I^@0W+,L3WTZQAMHW.W/147EF/RJ.
M6('-=,LJR(KH0ZL,AE.010!Y9\,_^2U?&/\ Z_=+_P#3?%7JU>4?#-O^+T_&
M/WO=,_\ 3?%7J] 'PM^UY_R62Y_Z\H/_ $$UXK7M7[77_)9+G_KR@_\ 037B
MO^>] !11_GO1_GO0 44?Y[T?Y[T %>]?L9?\E8O?^P3-_P"C8:\%_P ]Z]Y_
M8R_Y*M>G_J$S?^C8O\* /MJBBB@#\S/B%_R/WB7_ +"=S_Z-:N?KH/B%_P C
M]XE/_43NO_1KXKG_ //>@ HH_P ]Z/\ />@ HH_SWH_SWH *^P_V)?\ D2_$
M/_807_T6M?'G^>]?8?[$I_XHOQ#_ -A!?_12T ?2%<G\6/\ DEOC+_L#7G_H
MAZZRN3^+&?\ A5OC+C_F#7G_ *(>@#\V**/\]Z/\]Z "BC_/>C_/>@ HH_SW
MH_SWH *_0[]GG_DB_A3_ *]3_P"AM7YX_P">]?H;^SRV/@QX5'_3J1U_Z:-0
M!Z-7A7[9'_)(X?\ L)P_^@25[K7A7[9'/PDA_P"PG#_Z!)0!\0T4?Y[T?Y[T
M %%'^>]'^>] !11_GO1_GO0!+:?\?</^^O\ .OU.K\L;3_CZA_WU['UK]3J
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M_P"@K?\ _?4?_P 11_8<O_05O_\ OJ/_ .(K5HJ1F5_8<O\ T%;_ /[ZC_\
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M,7=7+U%%%<Y04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;3+/3R@-QOB<!KN[O68Q(GSNAVR#RP,N ;O_  [_ +O_ **IJ'_@FMO\:/\
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M_C1_:UE_S^6__?U?\:D^PVW_ #PB_P"^!_A1]AMO^>$7_? _PK0T(_[6LO\
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M_P"^!41BHWL9Q@H7MU=R/^UK'_G\M_\ OZO^-']K67_/Y;_]_5_QJ3[#;?\
M/"+_ +X'^%'V&V_YX1?]\#_"K-"/^UK+_G\M_P#OZO\ C1_:UE_S^6__ ']7
M_&I/L-M_SPB_[X'^%'V&V_YX1?\ ? H A.J61S_IEO\ ]_5_QKY\^&/PUUCP
MS\<-4UR^@L;/3$EUB7^UH[N-I-36]NH)H8RH^8>2L3)\_J-O!-?1']GV_P#S
MPC_[X%-&FVXS^XB'_ !64Z:FTWT,)TE4:D^@G]K6/_/Y;_\ ?U?\:/[6LO\
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ML07'M^%/HHH **** "BBB@ HHHH *AFM8IV0R(KE&WH64':W8C/0\G\ZFHH
M**** "BBB@ HHHH **** "HOLT7G&;RU$I7:9,?,0.0,^G)_.I:* "BBB@!-
MWM1N]J_-S5O^"B/Q+TWX!>(=232/#\WQ'M]99[.%8)/L@T06\TYNW3S-VX-:
MW$/+ %P,9XS]8+^U;H=KKCV4^AZU-I-GK%CX;U+Q-!'#]@M=4N4B:. J9?.(
MW7$"%Q&5#3)S@,5 /<Z3?7SUX7_;)TOQA>6]K8^#/$,#:@FMII-Q=-:K#J%Q
MI;E9X%99F,9;!*M*J*<'GBO(?"7[?'BE=0TK5O$W@2Z?PO)\-+7QQJ,>B?9V
MFM-]Y+%).#)<KN@$2!EC ,O!R,\4 ?<M%>'G]K;PH?C_ !_":/3M2DUES OV
MS=;I'F:U:Y1EA:43O&$4*TJ1%%=E5B.2/<* (Y(5D1D8!E88*D<$?_JJJVB6
M#3QS&RMS-'MVR>2NX;?NX..,<=/2KU% !1110 4444 %%%% !1110!%+:QS!
M1(BR!6#C<H.".A'O0MK%'(\B1HDDF-[JH!; P,GOBI:* "BBB@ HHHH ****
M "BBB@"G_9%E]K^U"U@%SG/G>4N_/3.[&:FAM8K=-D4:Q)DG:BA1DG).!WS4
MU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SI=_
ML&_"R^LW@F@U1G?PW<>%3<"[42?8IKIKI^=G^L#NX#8X5B,=ZZZX_9>\%W7B
M9M58ZFMK-JEKKEWHJWA^P7>H6Z1I!=21XSO40Q':K!&,:LRDC->NT4 >2>%?
MV8?!OA"3PVUD=0?^P;O5KRU6:X!#/J+.UR'PH)&7.W&,>IKFM,_8E\ Z;HNH
M:6;W7KNUO/!__"#'[3>HS1:6)9)5C0B,893(0&.> ,YY)^@** /)M7_9G\(Z
M]\0-&\6ZA-JUY=:1=PZC:6-Q>F2TBNH8?)CF1&!:(A<$I&R(S ,RL>:]9HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img224024147_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224024147_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! <X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%2>Z"HF['K6AZW9>(=(@U.PDWP3#.#PR-W5AV(_SQ6+\2O\ DG>L_P#7)?\
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MJ^&),K9WW[RUZXX!9,$_[)93[KBMYVE%P7V?Z9G&Z:D^IZ[7C>C_ /)PE_\
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MLX/#MO()+D2B:XVG(C !PI]SG/X>]:T(\U1$5':+.@\ _$NU\3(FGZB4MM7
MP!T2X]U]&]5_$=\;?C#P5IOC"P\NY40WD8_<72KED]CZK[?EBOF"W262YB2
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MNVV[+GR5EV8()^5N#D9'XU<HK-.Q1Y3\*M.UI[.6ZCU[981ZA*LUE]C0^<P
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MDGBDU"YU/5$B</'#J%X\T:,.^T\'TYR*ZJBA3DE9,'%,****D84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>onct-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-07T13:27:51.1179+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.oncternal.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:onct="http://www.oncternal.com/20231231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" id="Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical">
        <link:definition>100070 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>995465 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestments1" id="DisclosureShorttermInvestments1">
        <link:definition>995475 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions">
        <link:definition>995485 - Disclosure - Commitments, Contingencies and Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements" id="DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements">
        <link:definition>995495 - Disclosure - License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>995505 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValue" id="DisclosureFairValue">
        <link:definition>995515 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>995525 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995535 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995545 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995555 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>995565 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables" id="DisclosureShorttermInvestmentsTables">
        <link:definition>995575 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables" id="DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables">
        <link:definition>995585 - Disclosure - Commitments, Contingencies and Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueTables" id="DisclosureFairValueTables">
        <link:definition>995595 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>995605 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995615 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995625 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
        <link:definition>995635 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails" id="DisclosureBalanceSheetDetailsPrepaidAndOtherDetails">
        <link:definition>995645 - Disclosure - Balance Sheet Details - Prepaid and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
        <link:definition>995655 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails" id="DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails">
        <link:definition>995665 - Disclosure - Short-term Investments - Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" id="DisclosureShorttermInvestmentsAdditionalInformationDetails">
        <link:definition>995675 - Disclosure - Short-term Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995685 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>995695 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails" id="DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails">
        <link:definition>995705 - Disclosure - License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995715 - Disclosure - Fair Value - Schedule of Companys Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails" id="DisclosureStockholdersEquityAtmProgramDetails">
        <link:definition>995725 - Disclosure - Stockholders' Equity - ATM Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" id="Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails">
        <link:definition>995735 - Disclosure - Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" id="Role_DisclosureStockholdersEquityEquityIncentivePlansDetails">
        <link:definition>995745 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>995755 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails" id="DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>995765 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" id="Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails">
        <link:definition>995775 - Disclosure - Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
        <link:definition>995785 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
        <link:definition>995795 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
        <link:definition>995805 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
        <link:definition>995815 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>995825 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="onct-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="onct-20231231.xsd#DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="onct-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="onct-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails" xlink:href="onct-20231231.xsd#DisclosureBalanceSheetDetailsPrepaidAndOtherDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:href="onct-20231231.xsd#Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="onct-20231231.xsd#DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:href="onct-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:href="onct-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:href="onct-20231231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="onct-20231231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:href="onct-20231231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails" xlink:href="onct-20231231.xsd#DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:href="onct-20231231.xsd#DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="onct-20231231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails" xlink:href="onct-20231231.xsd#DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="onct-20231231.xsd#DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails" xlink:href="onct-20231231.xsd#DisclosureStockholdersEquityAtmProgramDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails" xlink:href="onct-20231231.xsd#DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="onct-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="onct-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="onct-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:href="onct-20231231.xsd#Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="onct-20231231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="onct-20231231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestments1" xlink:href="onct-20231231.xsd#DisclosureShorttermInvestments1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:href="onct-20231231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements" xlink:href="onct-20231231.xsd#DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDebt" xlink:href="onct-20231231.xsd#Role_DisclosureDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValue" xlink:href="onct-20231231.xsd#DisclosureFairValue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="onct-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="onct-20231231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="onct-20231231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="onct-20231231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:href="onct-20231231.xsd#DisclosureShorttermInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables" xlink:href="onct-20231231.xsd#DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueTables" xlink:href="onct-20231231.xsd#DisclosureFairValueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="onct-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:href="onct-20231231.xsd#Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AnnualBaseRent" xlink:label="onct_AnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:label="onct_AnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MDAndersonCancerCenterMember" xlink:label="onct_MDAndersonCancerCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxesLineItems" xlink:label="onct_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_EquityIncentivePlanMember" xlink:label="onct_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UpfrontLicenseFeesPaid" xlink:label="onct_UpfrontLicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantForfeitedPricePerShare" xlink:label="onct_WarrantForfeitedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:label="onct_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsExpired" xlink:label="onct_WarrantsExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RepricedStockOptionsMember" xlink:label="onct_RepricedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidClinicalTrialsExpense" xlink:label="onct_PrepaidClinicalTrialsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidResearchAndDevelopmentExpense" xlink:label="onct_PrepaidResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PatentCostsPolicyTextBlock" xlink:label="onct_PatentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:label="onct_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="us-gaap_GeneralInsuranceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_GeorgetownUniversityMember" xlink:label="onct_GeorgetownUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsCancelled" xlink:label="onct_WarrantsCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsMember" xlink:label="us-gaap_AssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockOptionsOutstandingForFutureIssuance" xlink:label="onct_CommonStockOptionsOutstandingForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SubawardPaymentsReceived" xlink:label="onct_SubawardPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" xlink:label="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:label="onct_PeriodForCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantExpiredPricePerShare" xlink:label="onct_WarrantExpiredPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTerm" xlink:label="onct_ResearchAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" xlink:label="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExerciseOfWarrants" xlink:label="onct_ExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_LicenseAgreementMember" xlink:label="onct_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NonRule10B51ArrModifiedFlag" xlink:label="onct_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsIssued" xlink:label="onct_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmountReceivable" xlink:label="onct_ResearchAgreementResearchFundingAmountReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenPlanMember" xlink:label="onct_TwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrivateOncternalMember" xlink:label="onct_PrivateOncternalMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OtherReceivablesNetCurrentIncludingGrant" xlink:label="onct_OtherReceivablesNetCurrentIncludingGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock" xlink:label="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OfficeSpaceMember" xlink:label="onct_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAndDevelopmentGrants" xlink:label="onct_ResearchAndDevelopmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PercentageOfNetSales" xlink:label="onct_PercentageOfNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantExercisedPricePerShare" xlink:label="onct_WarrantExercisedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsIssuedPricePerShare" xlink:label="onct_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:label="onct_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AtTheMarketEquityOfferingProgramMember" xlink:label="onct_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NoncashLeaseExpense" xlink:label="onct_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyFiveMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxesTable" xlink:label="onct_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandFifteenPlanMember" xlink:label="onct_TwoThousandFifteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:label="onct_IncomeTaxReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ReagentsMember" xlink:label="onct_ReagentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RentExpense" xlink:label="onct_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NationalInstituteOfHealthGrantAwardsMember" xlink:label="onct_NationalInstituteOfHealthGrantAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_GoingConcernPolicyTextBlock" xlink:label="onct_GoingConcernPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:label="onct_ExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ContingentValueRightsAgreementMember" xlink:label="onct_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommitmentsAndContingenciesTable" xlink:label="onct_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="us-gaap_ValuationAllowanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CashlessExerciseOfWarrants" xlink:label="onct_CashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" xlink:label="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WeightedAverageContractualTermOutstanding" xlink:label="onct_WeightedAverageContractualTermOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdvanceLicensedAssets" xlink:label="onct_AdvanceLicensedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:label="onct_ChiefFinancialOfficerSonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:label="onct_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:label="onct_ExerciseOfCashlessWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_Rule10B51ArrModifiedFlag" xlink:label="onct_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MaturitySecuritiesDebtMaturitiesPeriod1" xlink:label="onct_MaturitySecuritiesDebtMaturitiesPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedClinicalTrials" xlink:label="onct_AccruedClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:label="onct_RelatedQualifyingSubawardCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedClinicalTrials1" xlink:label="onct_AccruedClinicalTrials1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RemainderOfLeaseTermBaseRent" xlink:label="onct_RemainderOfLeaseTermBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockWarrantsMember" xlink:label="onct_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AwardPaymentsReceived" xlink:label="onct_AwardPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NasdaqListingAndReverseStockSplitPolicyTextBlock" xlink:label="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:label="onct_ResearchAgreementResearchFundingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceCommissions" xlink:label="us-gaap_InsuranceCommissions"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining weighted-average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contractual term outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and exercisable, Aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value, options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Market Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The California Institute for Regenerative Medicine ("CIRM") Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Regenerative Medicine Award [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California Institute for Regenerative Medicine Award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Cancer Center.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M D Anderson Cancer Center [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Cancer Center</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to non-vested stock option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change In Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fees paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement two thousand twenty three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 incentive award plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of California San Diego.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of California San Diego [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of California San Diego School of Medicine</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease liability, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, net of current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones to be received under research subaward agreements throughout award project period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones to be received under research subaward agreements throughout award project period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantForfeitedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Exercised Price Per Share Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantForfeitedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Forfeited Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantForfeitedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant forfeited price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement two thousand twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Warrants Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee to be paid and payment made.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee To Be Paid And Payment Made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee to be paid and payment made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of option grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RepricedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repriced Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RepricedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repriced Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RepricedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repriced Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period from closing during which percentage of net proceeds payment would be payable under the CVR.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Which Payment Of Percentage Of Net Proceeds Would Be Payable Under C V R</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period from closing during which payment of percentage of net proceeds would be payable under the CVR</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice for default in payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice For Default In Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice for default in payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for issuance under the Inducement Plan and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock shares provided for issuance of stock awards to its employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Investment Holdings [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan and inducement plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan And Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 incentive award plan and inducement plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less current portion of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrepaidClinicalTrialsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical trials expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrepaidClinicalTrialsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Trials Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrepaidClinicalTrialsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Aggregate Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for cash (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Number of Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Number of Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days in written notice of termination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days In Written Notice Of Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice of termination, period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrepaidResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrepaidResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrepaidResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term nonvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General Insurance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premiums</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Georgetown University.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Georgetown University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Georgetown University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of restricted stock units, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of restricted stock units, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Warrants Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants cancelled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital vesting related to unvested share liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting related to repurchase liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockOptionsOutstandingForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options outstanding for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockOptionsOutstandingForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Outstanding for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockOptionsOutstandingForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subaward payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subaward Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subaward payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares of common stock a participant may receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents at carrying value and short term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents at Carrying Value and Short Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; authorized shares - 120,000 at December 31, 2023 and 60,000 at 2022; issued and outstanding shares - 2,948 and 2,829 at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for cumulative change in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period For Cumulative Change In Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for cumulative change in ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantExpiredPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Exercised Price Per Share Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantExpiredPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant expired price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantExpiredPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Expired Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining weighted-average period, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining contractual term, Option vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of common stock for tax withholding obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State rate change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock transaction price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforward expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Plan And Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan And Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Plan and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental fair value of vested options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, available-for-sale, accrued interest writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company's SARD and SARM technology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Proceeds Entitled To Receive During Period Specified After Closing From Grant Sale Or Transfer Of Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net proceeds entitled to be received per CVR</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Which Grant Sale Or Transfer Of Rights To Company Sard Or Sarm Technology Could Trigger Payment Under Cvr Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Rule10b5-1 Arr Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Rule 10b5-1 Arr Modified [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Rule 10b5-1 Arr Modified.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmountReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmountReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmountReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research amount received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 4)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Or Part Noncash Gain Loss Of Forgiveness Of Payroll Protection Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on forgiveness of payroll protection program loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on forgiveness of payroll protection program loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted units expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Worldwide sales milestones based on achievement of tiered revenue levels.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones Based On Achievement Of Tiered Revenue Levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Worldwide sales milestones based on achievement of tiered revenue levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice in fails to pay amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice To Pay Failure Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice, to pay failure amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options forfeited or repurchased in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited or Repurchased In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units, Forfeited/Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of restricted stock units, Forfeited/Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Maturities of Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, Contingencies and Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock And Warrants Net Of Issuance Costs Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and warrants net of issuance costs shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance cost (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrivateOncternalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Oncternal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrivateOncternalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Oncternal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PrivateOncternalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Oncternal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OtherReceivablesNetCurrentIncludingGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other receivables net current including grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OtherReceivablesNetCurrentIncludingGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables, Net, Current, Including Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OtherReceivablesNetCurrentIncludingGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant and other receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accounts prepaid and other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Prepaid and other [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid and Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants awarded to researchers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_PercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant weighted-average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of restricted stock units (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Exercised Price Per Share Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercised price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercised Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential regulatory milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Regulatory Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential regulatory milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Exercised Price Per Share Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative changes in ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity offering program member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-The-Market Equity Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term, Options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement two thousand twenty five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock And Warrants Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and warrants net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance cost of $375</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from payroll protection loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patent costs as general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Determine Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ReagentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reagents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ReagentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reagents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ReagentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regents of the University of California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Components of Net Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NationalInstituteOfHealthGrantAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NationalInstituteOfHealthGrantAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institute Of Health Grant Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NationalInstituteOfHealthGrantAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The national institute of health (&#8220;nih") grant awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Going Concern [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discounts on short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid and other expense total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Value Rights Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price, Forfeited/ Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Liability, Current and Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Compensation Liability, Current and Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand fifteen plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and 2015 plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards non expire portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Non Expire Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards non expire portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business basis of presentation and summary of significant accounting policies line items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnbilledContractsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Contracts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnbilledContractsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled grant receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock unit awards unvested and outstanding for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Unit Awards Unvested And Outstanding For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock unit awards unvested and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant activity table text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Activity Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Warrant Activity And Changes In Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WeightedAverageContractualTermOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average contractual term outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WeightedAverageContractualTermOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Contractual Term Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_WeightedAverageContractualTermOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contractual term outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration risk credit risk policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average grant date fair value nonvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average grant date fair value nonvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, fully offset by valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance licensed assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Licensed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance licensed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, authorized shares 5,000 at December 31, 2023 and 2022; issued and outstanding shares none</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief financial officer, son.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer Son [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased for settlement of minimum statutory tax withholdings (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased for settlement of minimum statutory tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State rate change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Cashless Warrant Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cashless exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Companys Assets Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement two thousand twenty two member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Two Thousand Twenty Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount agreed to be provided in contingency funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Agreed To Be Provided In Contingency Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount agreed to be provided in contingency funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum period of written notice to terminate agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Period Of Written Notice To Terminate Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum period in days of written notice to terminate license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10B5-1 Arr Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b5-1 Arr Modified [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b5-1 Arr Modified.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research amount payable quarterly</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges on short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment Losses, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MaturitySecuritiesDebtMaturitiesPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MaturitySecuritiesDebtMaturitiesPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity securities debt maturities period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_MaturitySecuritiesDebtMaturitiesPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity Securities Debt Maturities Period 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trials.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options and common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised And Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Tennessee Research Foundation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of Tennessee Research Foundation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of Tennessee Research Foundation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related qualifying subaward costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Qualifying Subaward Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related qualifying subaward costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedClinicalTrials1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Clinical Trials 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedClinicalTrials1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trials1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AccruedClinicalTrials1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to subawardees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RemainderOfLeaseTermBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remainder of the lease term base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RemainderOfLeaseTermBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remainder Of Lease Term Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_RemainderOfLeaseTermBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of the lease term base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Pharmaceutical United States of America Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Pharmaceutical United States Of America Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Pharmaceutical (USA) Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options outstanding and fully vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AwardPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AwardPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_AwardPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nasdaq Listing and Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nasdaq Listing and Reverse Stock Split [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nasdaq listing and reverse stock split.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental fair value of unvested options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of restricted stock units, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate research agreement budget</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business basis of presentation and summary of significant accounting policies table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance commissions</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AnnualBaseRent" xlink:to="onct_AnnualBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AnnualLicenseMaintenanceFees" xlink:to="onct_AnnualLicenseMaintenanceFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MDAndersonCancerCenterMember" xlink:to="onct_MDAndersonCancerCenterMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_EquityIncentivePlanMember" xlink:to="onct_EquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UpfrontLicenseFeesPaid" xlink:to="onct_UpfrontLicenseFeesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfCaliforniaSanDiegoMember" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantForfeitedPricePerShare" xlink:to="onct_WarrantForfeitedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedResearchAndDevelopmentExpenses" xlink:to="onct_AccruedResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantsExpired" xlink:to="onct_WarrantsExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RepricedStockOptionsMember" xlink:to="onct_RepricedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PrepaidClinicalTrialsExpense" xlink:to="onct_PrepaidClinicalTrialsExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PrepaidResearchAndDevelopmentExpense" xlink:to="onct_PrepaidResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PatentCostsPolicyTextBlock" xlink:to="onct_PatentCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GeorgetownUniversityMember" xlink:to="onct_GeorgetownUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantsCancelled" xlink:to="onct_WarrantsCancelled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsMember" xlink:to="us-gaap_AssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockOptionsOutstandingForFutureIssuance" xlink:to="onct_CommonStockOptionsOutstandingForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SubawardPaymentsReceived" xlink:to="onct_SubawardPaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" xlink:to="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodForCumulativeChangeInOwnership" xlink:to="onct_PeriodForCumulativeChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantExpiredPricePerShare" xlink:to="onct_WarrantExpiredPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTerm" xlink:to="onct_ResearchAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" xlink:to="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfWarrants" xlink:to="onct_ExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseAgreementMember" xlink:to="onct_LicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NonRule10B51ArrModifiedFlag" xlink:to="onct_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantsIssued" xlink:to="onct_WarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmountReceivable" xlink:to="onct_ResearchAgreementResearchFundingAmountReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenPlanMember" xlink:to="onct_TwoThousandNineteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" xlink:to="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PrivateOncternalMember" xlink:to="onct_PrivateOncternalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OtherReceivablesNetCurrentIncludingGrant" xlink:to="onct_OtherReceivablesNetCurrentIncludingGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock" xlink:to="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OfficeSpaceMember" xlink:to="onct_OfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAndDevelopmentGrants" xlink:to="onct_ResearchAndDevelopmentGrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PercentageOfNetSales" xlink:to="onct_PercentageOfNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantExercisedPricePerShare" xlink:to="onct_WarrantExercisedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantsIssuedPricePerShare" xlink:to="onct_WarrantsIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CumulativeChangeInOwnershipPercentage" xlink:to="onct_CumulativeChangeInOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AtTheMarketEquityOfferingProgramMember" xlink:to="onct_AtTheMarketEquityOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NoncashLeaseExpense" xlink:to="onct_NoncashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTwoThousandTwentyFiveMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxesTable" xlink:to="onct_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandFifteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:to="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxReconciliationPermanentItems" xlink:to="onct_IncomeTaxReconciliationPermanentItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ReagentsMember" xlink:to="onct_ReagentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsReservedForFutureIssuance" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RentExpense" xlink:to="onct_RentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NationalInstituteOfHealthGrantAwardsMember" xlink:to="onct_NationalInstituteOfHealthGrantAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GoingConcernPolicyTextBlock" xlink:to="onct_GoingConcernPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExclusiveLicenseAgreementMember" xlink:to="onct_ExclusiveLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ContingentValueRightsAgreementMember" xlink:to="onct_ContingentValueRightsAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_ValuationAllowanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CashlessExerciseOfWarrants" xlink:to="onct_CashlessExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OperatingLossCarryforwardsNonExpirePortion" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledContractsReceivable" xlink:to="us-gaap_UnbilledContractsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" xlink:to="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ScheduleOfWarrantActivityTableTextBlock" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WeightedAverageContractualTermOutstanding" xlink:to="onct_WeightedAverageContractualTermOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdvanceLicensedAssets" xlink:to="onct_AdvanceLicensedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ChiefFinancialOfficerSonMember" xlink:to="onct_ChiefFinancialOfficerSonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OperatingLossCarryforwardsExpirationYear" xlink:to="onct_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfCashlessWarrantShares" xlink:to="onct_ExerciseOfCashlessWarrantShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_Rule10B51ArrModifiedFlag" xlink:to="onct_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmountPayable" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MaturitySecuritiesDebtMaturitiesPeriod1" xlink:to="onct_MaturitySecuritiesDebtMaturitiesPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedClinicalTrials" xlink:to="onct_AccruedClinicalTrials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfTennesseeResearchFoundationMember" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RelatedQualifyingSubawardCosts" xlink:to="onct_RelatedQualifyingSubawardCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedClinicalTrials1" xlink:to="onct_AccruedClinicalTrials1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RemainderOfLeaseTermBaseRent" xlink:to="onct_RemainderOfLeaseTermBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsMember" xlink:to="onct_CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AwardPaymentsReceived" xlink:to="onct_AwardPaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock" xlink:to="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmount" xlink:to="onct_ResearchAgreementResearchFundingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissions" xlink:to="us-gaap_InsuranceCommissions_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CashlessExerciseOfWarrants" xlink:label="onct_CashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NoncashLeaseExpense" xlink:label="onct_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_CashlessExerciseOfWarrants" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NoncashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:label="onct_ExerciseOfCashlessWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_17"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_Rule10B51ArrModifiedFlag" xlink:label="onct_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NonRule10B51ArrModifiedFlag" xlink:label="onct_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="onct_Rule10B51ArrModifiedFlag" order="13.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="onct_NonRule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestments1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_GoingConcernPolicyTextBlock" xlink:label="onct_GoingConcernPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NasdaqListingAndReverseStockSplitPolicyTextBlock" xlink:label="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PatentCostsPolicyTextBlock" xlink:label="onct_PatentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_GoingConcernPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_PatentCostsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock" xlink:label="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AtTheMarketEquityOfferingProgramMember" xlink:label="onct_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" xlink:label="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AtTheMarketEquityOfferingProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockWarrantsMember" xlink:label="onct_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidResearchAndDevelopmentExpense" xlink:label="onct_PrepaidResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidClinicalTrialsExpense" xlink:label="onct_PrepaidClinicalTrialsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OtherReceivablesNetCurrentIncludingGrant" xlink:label="onct_OtherReceivablesNetCurrentIncludingGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onct_PrepaidResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onct_PrepaidClinicalTrialsExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidInsurance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onct_OtherReceivablesNetCurrentIncludingGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:label="onct_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedClinicalTrials" xlink:label="onct_AccruedClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedClinicalTrials" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MaturitySecuritiesDebtMaturitiesPeriod1" xlink:label="onct_MaturitySecuritiesDebtMaturitiesPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="onct_MaturitySecuritiesDebtMaturitiesPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:label="onct_ChiefFinancialOfficerSonMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:label="onct_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RentExpense" xlink:label="onct_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommitmentsAndContingenciesTable" xlink:label="onct_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OfficeSpaceMember" xlink:label="onct_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AnnualBaseRent" xlink:label="onct_AnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RemainderOfLeaseTermBaseRent" xlink:label="onct_RemainderOfLeaseTermBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="us-gaap_GeneralInsuranceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceCommissions" xlink:label="us-gaap_InsuranceCommissions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_ChiefFinancialOfficerSonMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="onct_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_AnnualBaseRent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RemainderOfLeaseTermBaseRent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceCommissions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:label="onct_ExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_GeorgetownUniversityMember" xlink:label="onct_GeorgetownUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NationalInstituteOfHealthGrantAwardsMember" xlink:label="onct_NationalInstituteOfHealthGrantAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MDAndersonCancerCenterMember" xlink:label="onct_MDAndersonCancerCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ReagentsMember" xlink:label="onct_ReagentsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyFiveMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_LicenseAgreementMember" xlink:label="onct_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ContingentValueRightsAgreementMember" xlink:label="onct_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UpfrontLicenseFeesPaid" xlink:label="onct_UpfrontLicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:label="onct_AnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdvanceLicensedAssets" xlink:label="onct_AdvanceLicensedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTerm" xlink:label="onct_ResearchAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:label="onct_ResearchAgreementResearchFundingAmount"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmountReceivable" xlink:label="onct_ResearchAgreementResearchFundingAmountReceivable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAndDevelopmentGrants" xlink:label="onct_ResearchAndDevelopmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SubawardPaymentsReceived" xlink:label="onct_SubawardPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:label="onct_RelatedQualifyingSubawardCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedClinicalTrials1" xlink:label="onct_AccruedClinicalTrials1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AwardPaymentsReceived" xlink:label="onct_AwardPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PercentageOfNetSales" xlink:label="onct_PercentageOfNetSales"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_NationalInstituteOfHealthGrantAwardsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyThreeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyFourMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyFiveMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_LicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ContingentValueRightsAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountReceivable" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AccruedClinicalTrials1" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AwardPaymentsReceived" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_UnbilledContractsReceivable" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetSales" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AtTheMarketEquityOfferingProgramMember" xlink:label="onct_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AtTheMarketEquityOfferingProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsIssued" xlink:label="onct_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExerciseOfWarrants" xlink:label="onct_ExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsCancelled" xlink:label="onct_WarrantsCancelled"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsExpired" xlink:label="onct_WarrantsExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantsIssuedPricePerShare" xlink:label="onct_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantExercisedPricePerShare" xlink:label="onct_WarrantExercisedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantForfeitedPricePerShare" xlink:label="onct_WarrantForfeitedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WarrantExpiredPricePerShare" xlink:label="onct_WarrantExpiredPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantsIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ExerciseOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantsCancelled" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantsExpired" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantsIssuedPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantExercisedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantForfeitedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantExpiredPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrivateOncternalMember" xlink:label="onct_PrivateOncternalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandFifteenPlanMember" xlink:label="onct_TwoThousandFifteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenPlanMember" xlink:label="onct_TwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RepricedStockOptionsMember" xlink:label="onct_RepricedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="onct_RepricedStockOptionsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_EquityIncentivePlanMember" xlink:label="onct_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WeightedAverageContractualTermOutstanding" xlink:label="onct_WeightedAverageContractualTermOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_WeightedAverageContractualTermOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" xlink:label="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_EquityIncentivePlanMember" xlink:label="onct_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockOptionsOutstandingForFutureIssuance" xlink:label="onct_CommonStockOptionsOutstandingForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" xlink:label="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember_2"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" xlink:label="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsOutstandingForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:label="onct_IncomeTaxReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="onct_IncomeTaxReconciliationPermanentItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="us-gaap_ValuationAllowanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsMember" xlink:label="us-gaap_AssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxesLineItems" xlink:label="onct_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxesTable" xlink:label="onct_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:label="onct_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:label="onct_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:label="onct_PeriodForCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="onct_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesTable" xlink:to="onct_IncomeTaxesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_CumulativeChangeInOwnershipPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_PeriodForCumulativeChangeInOwnership" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:label="onct_ExerciseOfCashlessWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" xlink:label="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AtTheMarketEquityOfferingProgramMember" xlink:label="onct_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" xlink:label="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockWarrantsMember" xlink:label="onct_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidResearchAndDevelopmentExpense" xlink:label="onct_PrepaidResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidClinicalTrialsExpense" xlink:label="onct_PrepaidClinicalTrialsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OtherReceivablesNetCurrentIncludingGrant" xlink:label="onct_OtherReceivablesNetCurrentIncludingGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onct_PrepaidResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onct_PrepaidClinicalTrialsExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_RelatedPartyTransactionLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidInsurance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onct_OtherReceivablesNetCurrentIncludingGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MaturitySecuritiesDebtMaturitiesPeriod1" xlink:label="onct_MaturitySecuritiesDebtMaturitiesPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="onct_MaturitySecuritiesDebtMaturitiesPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:label="onct_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommitmentsAndContingenciesTable" xlink:label="onct_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:label="onct_ChiefFinancialOfficerSonMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RentExpense" xlink:label="onct_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OfficeSpaceMember" xlink:label="onct_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AnnualBaseRent" xlink:label="onct_AnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RemainderOfLeaseTermBaseRent" xlink:label="onct_RemainderOfLeaseTermBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="us-gaap_GeneralInsuranceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceCommissions" xlink:label="us-gaap_InsuranceCommissions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_ChiefFinancialOfficerSonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_AnnualBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RemainderOfLeaseTermBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceCommissions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:label="onct_ExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_GeorgetownUniversityMember" xlink:label="onct_GeorgetownUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NationalInstituteOfHealthGrantAwardsMember" xlink:label="onct_NationalInstituteOfHealthGrantAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MDAndersonCancerCenterMember" xlink:label="onct_MDAndersonCancerCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ReagentsMember" xlink:label="onct_ReagentsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTwoThousandTwentyFiveMember" xlink:label="onct_ResearchAgreementTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_LicenseAgreementMember" xlink:label="onct_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ContingentValueRightsAgreementMember" xlink:label="onct_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_UpfrontLicenseFeesPaid" xlink:label="onct_UpfrontLicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:label="onct_AnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AdvanceLicensedAssets" xlink:label="onct_AdvanceLicensedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementTerm" xlink:label="onct_ResearchAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:label="onct_ResearchAgreementResearchFundingAmount"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmountReceivable" xlink:label="onct_ResearchAgreementResearchFundingAmountReceivable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ResearchAndDevelopmentGrants" xlink:label="onct_ResearchAndDevelopmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SubawardPaymentsReceived" xlink:label="onct_SubawardPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:label="onct_RelatedQualifyingSubawardCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedClinicalTrials1" xlink:label="onct_AccruedClinicalTrials1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AwardPaymentsReceived" xlink:label="onct_AwardPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PercentageOfNetSales" xlink:label="onct_PercentageOfNetSales"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_NationalInstituteOfHealthGrantAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ResearchAgreementTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_LicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="onct_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AccruedClinicalTrials1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AwardPaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_UnbilledContractsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AtTheMarketEquityOfferingProgramMember" xlink:label="onct_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrivateOncternalMember" xlink:label="onct_PrivateOncternalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RepricedStockOptionsMember" xlink:label="onct_RepricedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandFifteenPlanMember" xlink:label="onct_TwoThousandFifteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_TwoThousandNineteenPlanMember" xlink:label="onct_TwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="onct_RepricedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_EquityIncentivePlanMember" xlink:label="onct_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_WeightedAverageContractualTermOutstanding" xlink:label="onct_WeightedAverageContractualTermOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_WeightedAverageContractualTermOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" xlink:label="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_EquityIncentivePlanMember" xlink:label="onct_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CommonStockOptionsOutstandingForFutureIssuance" xlink:label="onct_CommonStockOptionsOutstandingForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" xlink:label="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsOutstandingForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="us-gaap_ValuationAllowanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsMember" xlink:label="us-gaap_AssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_ValuationAllowanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxesLineItems" xlink:label="onct_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxesTable" xlink:label="onct_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:label="onct_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:label="onct_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:label="onct_PeriodForCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_CumulativeChangeInOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_PeriodForCumulativeChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_NoncashLeaseExpense" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_NoncashLeaseExpense" xlink:label="onct_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="onct_PrepaidResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="onct_PrepaidClinicalTrialsExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidInsurance" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_AccountsReceivableNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="onct_OtherReceivablesNetCurrentIncludingGrant" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidResearchAndDevelopmentExpense" xlink:label="onct_PrepaidResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_PrepaidClinicalTrialsExpense" xlink:label="onct_PrepaidClinicalTrialsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_OtherReceivablesNetCurrentIncludingGrant" xlink:label="onct_OtherReceivablesNetCurrentIncludingGrant"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedClinicalTrials" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:label="onct_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_AccruedClinicalTrials" xlink:label="onct_AccruedClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="onct_IncomeTaxReconciliationPermanentItems" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:label="onct_IncomeTaxReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="onct-20231231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" name="PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" name="ClassOfWarrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" name="DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_NationalInstituteOfHealthGrantAwardsMember" name="NationalInstituteOfHealthGrantAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ResearchAgreementTwoThousandTwentyFourMember" name="ResearchAgreementTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_AccruedClinicalTrials1" name="AccruedClinicalTrials1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" name="RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="onct_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ResearchAgreementTwoThousandTwentyFiveMember" name="ResearchAgreementTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_AtTheMarketEquityOfferingProgramMember" name="AtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" name="NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" name="TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" name="LicenseMaintenanceFeeToBePaidAndPaymentMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_WarrantExercisedPricePerShare" name="WarrantExercisedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_AccruedClinicalTrials" name="AccruedClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_ResearchAgreementTwoThousandTwentyTwoMember" name="ResearchAgreementTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" name="CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_UniversityOfTennesseeResearchFoundationMember" name="UniversityOfTennesseeResearchFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_PeriodForCumulativeChangeInOwnership" name="PeriodForCumulativeChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock" name="ScheduleOfAccountsPrepaidAndOtherTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_CommonStockOptionsOutstandingForFutureIssuance" name="CommonStockOptionsOutstandingForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="onct_WarrantForfeitedPricePerShare" name="WarrantForfeitedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="onct_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_RelatedQualifyingSubawardCosts" name="RelatedQualifyingSubawardCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" name="ProceedsFromStockOptionsExercisedAndWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_AdvanceLicensedAssets" name="AdvanceLicensedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_ExerciseOfWarrants" name="ExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_ExerciseOfCashlessWarrantShares" name="ExerciseOfCashlessWarrantShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_OtherReceivablesNetCurrentIncludingGrant" name="OtherReceivablesNetCurrentIncludingGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_ResearchAgreementResearchFundingAmountReceivable" name="ResearchAgreementResearchFundingAmountReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" name="TwoThousandNineteenAndTwoThousandFifteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_WarrantsIssued" name="WarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_OperatingLossCarryforwardsNonExpirePortion" name="OperatingLossCarryforwardsNonExpirePortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_CommonStockWarrantsReservedForFutureIssuance" name="CommonStockWarrantsReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" name="AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_RemainderOfLeaseTermBaseRent" name="RemainderOfLeaseTermBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" name="NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_PrivateOncternalMember" name="PrivateOncternalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_TwoThousandNineteenPlanMember" name="TwoThousandNineteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_AwardPaymentsReceived" name="AwardPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_RentExpense" name="RentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_ResearchAgreementResearchFundingAmount" name="ResearchAgreementResearchFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" name="SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_SubawardPaymentsReceived" name="SubawardPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_UpfrontLicenseFeesPaid" name="UpfrontLicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_CollaborativeArrangementPotentialMilestonePayments" name="CollaborativeArrangementPotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="onct_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ReagentsMember" name="ReagentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ResearchAndDevelopmentGrants" name="ResearchAndDevelopmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_WarrantsCancelled" name="WarrantsCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" name="MinimumPeriodOfWrittenNoticeToTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" name="CaliforniaInstituteForRegenerativeMedicineAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" name="ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ResearchAgreementTwoThousandTwentyThreeMember" name="ResearchAgreementTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_NasdaqListingAndReverseStockSplitPolicyTextBlock" name="NasdaqListingAndReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_AmountAgreedToBeProvidedInContingencyFunds" name="AmountAgreedToBeProvidedInContingencyFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" name="PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_RepricedStockOptionsMember" name="RepricedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ContingentValueRightsAgreementMember" name="ContingentValueRightsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" name="PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_ResearchAgreementTerm" name="ResearchAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_UniversityOfCaliforniaSanDiegoMember" name="UniversityOfCaliforniaSanDiegoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_GeorgetownUniversityMember" name="GeorgetownUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_MaturitySecuritiesDebtMaturitiesPeriod1" name="MaturitySecuritiesDebtMaturitiesPeriod1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_PrepaidClinicalTrialsExpense" name="PrepaidClinicalTrialsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_NumberOfDaysInWrittenNoticeOfTermination" name="NumberOfDaysInWrittenNoticeOfTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" name="NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_WarrantsExpired" name="WarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" name="CollaborativeArrangementPotentialRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" name="InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_WeightedAverageContractualTermOutstanding" name="WeightedAverageContractualTermOutstanding" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_ConcentrationRiskCreditRiskPolicyTextBlock" name="ConcentrationRiskCreditRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_PrepaidResearchAndDevelopmentExpense" name="PrepaidResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_AnnualBaseRent" name="AnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" name="SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="onct_PercentageOfNetSales" name="PercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_ResearchAgreementResearchFundingAmountPayable" name="ResearchAgreementResearchFundingAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="onct_TwoThousandFifteenPlanMember" name="TwoThousandFifteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_ChiefFinancialOfficerSonMember" name="ChiefFinancialOfficerSonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="onct_WarrantExpiredPricePerShare" name="WarrantExpiredPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_WarrantsIssuedPricePerShare" name="WarrantsIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="onct_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117178848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oncternal Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001260990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,959,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1715807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12230 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">434-1113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#8217;s 2024 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116895136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,697<span></span>
</td>
<td class="nump">$ 37,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">27,558<span></span>
</td>
<td class="nump">26,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">3,566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,059<span></span>
</td>
<td class="nump">67,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,729<span></span>
</td>
<td class="nump">68,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">4,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease, current</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,198<span></span>
</td>
<td class="nump">7,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease, net of current</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">7,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, authorized shares 5,000 at December 31, 2023 and 2022; issued and outstanding shares none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares - 120,000 at December 31, 2023 and 60,000 at 2022; issued and outstanding shares - 2,948 and 2,829 at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">227,825<span></span>
</td>
<td class="nump">219,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(197,779)<span></span>
</td>
<td class="num">(158,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">30,052<span></span>
</td>
<td class="nump">60,969<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 36,729<span></span>
</td>
<td class="nump">$ 68,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117823472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,948,000<span></span>
</td>
<td class="nump">2,874,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,948,000<span></span>
</td>
<td class="nump">2,874,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501114783760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="nump">$ 785,000<span></span>
</td>
<td class="nump">$ 1,490,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">29,753,000<span></span>
</td>
<td class="nump">32,980,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,746,000<span></span>
</td>
<td class="nump">13,457,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">42,499,000<span></span>
</td>
<td class="nump">46,437,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,714,000)<span></span>
</td>
<td class="num">(44,947,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,235,000<span></span>
</td>
<td class="nump">777,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,479,000)<span></span>
</td>
<td class="num">(44,170,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on available-for-sale securities, net</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (39,485,000)<span></span>
</td>
<td class="num">$ (44,161,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (13.43)<span></span>
</td>
<td class="num">$ (16.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (13.43)<span></span>
</td>
<td class="num">$ (16.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116851008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (39,479)<span></span>
</td>
<td class="num">$ (44,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discounts on short-term investments</a></td>
<td class="num">(1,633)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">2,624<span></span>
</td>
<td class="num">(2,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,769)<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(801)<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Deferred compensation</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,164)<span></span>
</td>
<td class="num">(36,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(64,349)<span></span>
</td>
<td class="num">(26,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of available-for-sale securities</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">651<span></span>
</td>
<td class="num">(26,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">9,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchases of common stock for tax withholding obligations</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">9,579<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(30,445)<span></span>
</td>
<td class="num">(53,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">37,142<span></span>
</td>
<td class="nump">90,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">6,697<span></span>
</td>
<td class="nump">37,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117960976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 88,120<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 202,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (114,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, net of issuance cost of $375</a></td>
<td class="nump">9,582<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Shares repurchased for settlement of minimum statutory tax withholdings</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(44,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,170)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 60,969<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">219,257<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(158,300)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">2,874,000<span></span>
</td>
<td class="nump">2,874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, net of issuance cost of $375</a></td>
<td class="nump">$ 1,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Shares repurchased for settlement of minimum statutory tax withholdings</a></td>
<td class="num">(156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares repurchased for settlement of minimum statutory tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(39,479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,479)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 30,052<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 227,825<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (197,779)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">2,948,000<span></span>
</td>
<td class="nump">2,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants net of issuance costs shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116460384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock, issuance cost</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501121767552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (39,479)<span></span>
</td>
<td class="num">$ (44,170)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501208378944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_Rule10B51ArrModifiedFlag', window );">Rule 10B5-1 Arr Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_NonRule10B51ArrModifiedFlag', window );">Non Rule10b5-1 Arr Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Rule 10b5-1 Arr Modified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_Rule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b5-1 Arr Modified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_Rule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501120231824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oncternal Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Oncternal,&#8221; or the &#8220;combined company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers and ONCT-808, a CAR T (chimeric antigen receptor T-cells) product candidate that targets ROR1, and zilovertamab, a humanized monoclonal antibody that binds to ROR1. Oncternal&#8217;s program activities previously included ONCT-216, an investigational small molecule designed to inhibit the E26 Transformation Specific (&#8220;ETS&#8221;) family of oncoproteins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, cash equivalents, and short-term investments, no debt and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">197.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. From its inception, the Company has incurred recurring operating losses and negative cash flows from operations. The Company has concluded that the balance of cash, cash equivalents and short-term investments will not be sufficient to fund its planned expenditures and meet its obligations for the twelve months following the financial statement issuance date without raising additional funding or making changes to its operating plans or programs to reduce expenses. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for twelve months following the issuance date of these consolidated financial statements. The consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">          </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of its pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had capacity to issue up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock under its at-the-market (&#8220;ATM&#8221;) equity offering program. Through December 31, 2023, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">457,342</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the ATM program. There can be no assurance that the Company will be able to sell any additional shares of its common stock under the ATM program and no assurance regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM program may be at prices that result in additional dilution to existing stockholders of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq Listing and Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2023, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that because the closing bid price for the Company&#8217;s common stock had closed below $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Requirement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 8, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company regained compliance with the Nasdaq listing rules. Each of the Company&#8217;s shareholders received one new share of common stock for every 20 shares such shareholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#8217;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock was not adjusted as a result of the Reverse Stock Split. The Reverse Split also affected the Company&#8217;s outstanding common stock options and warrants, and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data, common stock options and warrants included in these consolidated financial statements, including the exercise price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of accruals for research and development costs. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist of Level 1 financial instruments in the fair value hierarchy (see Note 6 &#8211; Fair Value) and include cash in readily available checking accounts, money market accounts and commercial paper.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consist of U.S. treasury notes and bills, certificates of deposit, commercial paper and U.S. government sponsored enterprise securities with maturities of less than one year from the balance sheet date and are debt securities considered to be Level 1 and Level 2 financial instruments in the fair value hierarchy (see Note 6 &#8211; Fair Value).  The Company determines the appropriate classification of marketable securities at the time of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">purchase and reevaluates such designation at each balance sheet date.  The Company has classified all of its marketable securities at December 31, 2023 and 2022 as &#8220;available-for-sale&#8221; pursuant to ASC 320 Investments &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company records available-for-sale securities at fair value as determined by prices for identical or similar securities, with the unrealized gains and losses included as a separate component of other accumulated comprehensive income (loss).  In accordance with policy, the Company does not invest in or hold equity securities in its investment portfolio.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adjusts the cost of available-for-sale debt securities for amortization of premiums or accretion of discounts to maturity.  The Company includes interest and dividends on securities classified as available-for-sale in interest income.  Such amortization and accretion are included in interest income.  The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realized gains or losses on available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company records unrealized gains and losses on available-for-sale marketable securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders&#8217; equity on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in short-term investments in the accompanying consolidated balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which the Company determines the accrued interest will not be collected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates short-term investments for other-than-temporary impairment at the balance sheet date.  Factors considered in determining whether a loss is other-than temporary include how significant the decline in value is as a percentage of the original cost, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company&#8217;s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized loss positions until their amortized cost basis has been recovered.  As of December 31, 2023 and 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment charges on short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company obtains the fair value of its available-for-sale marketable securities from a professional pricing service. The fair values of available-for-sale marketable securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank. The service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service or mathematical calculations. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, credit spreads, current market and contractual prices for the underlying instruments or debt, as well as other relevant economic measures.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred compensation represents the accrual of retention bonuses for certain executives and certain other members of senior management.  The retention bonuses were entered into in connection with the waiver of annual cash performance bonuses of such personnel for the year ended December 31, 2023 and a temporary reduction of the chief executive officer&#8217;s salary from April 2023 through December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, which include clinical trial accruals, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as an exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop its own assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, and accrued compensation. The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has short-term investments that are measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented (see Note 6).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue from certain grant awards or a research subaward (the &#8220;Grant Awards&#8221;) (see Note 5), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment in the United States.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:52.33%;"></td>
          <td style="width:1.88%;"></td>
          <td style="width:1%;"></td>
          <td style="width:19.956%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.88%;"></td>
          <td style="width:1%;"></td>
          <td style="width:19.956%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425,785</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,454</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">737,151</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646,760</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Statements (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net loss. This update is effective for the Company and was adopted on January 1, 2023, which did not have a material impact on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Standards Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting &#8211; Improvements to Reportable Segment Disclosures (Topic 280), which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. Topic 280 includes amendments which a) introduce a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker&#8239;(CODM), b) extend &#8239;certain annual disclosures to interim periods, c) clarify single reportable segment entities must apply ASC 280 in its entirety, d) permit more than one measure of segment profit or loss to be reported under certain conditions, and e) require disclosure of the title and position of the CODM.  This update is effective for all public entities beginning after December 15, 2023. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Tax &#8211; Improvements to Income Tax Disclosures, which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. The standard requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This update is effective for all public entities beginning after December 15, 2024. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117103328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance Sheet Details</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid and other consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.429%;"></td>
        <td style="width:2.681%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.605%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.681%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.605%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">478</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party receivable (see Note 4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant and other receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.991%;"></td>
        <td style="width:2.959%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.415999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.915%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">868</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legal fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,579</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116921104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term Investments</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests in available-for-sale marketable securities consisting of money market funds, commercial paper, certificates of deposit, U.S. Treasury securities and U.S. government sponsored enterprise securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available-for-sale marketable securities with original maturities of more than three months from the date of purchase as of December 31, 2023 have been classified as short-term investments and are measured at a fair value on a recurring basis, and were as follows (in thousands):</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.606%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:14.743%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.862%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.461%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.502%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">Maturity (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,840</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,844</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available-for-sale marketable securities with original maturities of more than three months from the date of purchase as of December 31, 2022 have been classified as short-term investments and are measured at a fair value on a recurring basis, and were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.606%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:14.743%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.862%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.461%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.502%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,681</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ee1e1737-1e34-4355-a0d8-679b3a702be0;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,573</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined there were no other-than-temporary declines in the value of any available-for-sale securities as of December 31, 2023. All the Company&#8217;s available-for-sale marketable securities mature within one year. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for credit losses as of December 31, 2023 and 2022. During the years ended December 31, 2023, and 2022, the Company recognized an unrealized loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an unrealized gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in the accompanying consolidated statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0942af95-94b2-4cac-8c0c-f1444938ea88;"><span style="-sec-ix-hidden:F_cdb93c50-11db-48e2-b68f-a8c32248923f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest receivable</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on available-for-sale securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">116,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at December 31, 2023 and 2022, respectively. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t written off any accrued interest receivable in any of the periods presented in these consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501119991296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingencies and Related Party Transactions</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments, Contingencies and Related Party Transactions</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022. From May 2019 through April 2022, the Company leased office space in San Diego, California. In April 2022, the Company entered into a sublease agreement for office space in San Diego, California which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cb4bed05-8324-4d04-8ccd-d2135d259695;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;San Diego Lease&#8221;). In May 2023, the Company entered into a lease agreement for the same office space which expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Base rent under such lease is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">145,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> annually and the monthly rent expense will be recognized on a straight-line basis over the effective term of the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. As of December 31, 2023, the Company has recognized a net operating lease right-of-use asset and a lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that matures in September 2025, which has a weighted average remaining lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. As of December 31, 2022, the Company&#8217;s lease had a weighted average remaining lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.52%;"></td>
        <td style="width:3.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:32.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">318</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, long-term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;) entered into a Materials Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During 2023, the Company sold $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of materials to SPH USA which was recorded as an offset to ONCT-216 operating expenses. As of December 31, 2023 and 2022, the Company had amounts receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, from SPH USA related to license agreement. SPH USA is the Company&#8217;s largest stockholder and an affiliate of one of the Company&#8217;s directors.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117103328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License, Collaboration, Grants, Research Subaward and CVR Agreements</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2015, and as amended and restated in March 2022 and August 2022, the Company and UTRF entered into a license agreement (the &#8220;DAARI License Agreement&#8221;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader technologies owned or controlled by UTRF, including all improvements thereto, which is now known as the dual action androgen receptor inhibitor, or DAARI program. Under the DAARI License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the DAARI program to advance one or more lead compounds into clinical development.  The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expenses under this agreement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2016, and as amended and restated in August 2018, and as amended thereafter through January 2024, the Company entered into a license agreement (as amended and restated, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was paid and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,355</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued, (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain annual patent costs, (iv) certain development and regulatory milestones aggregating from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in license maintenance fees as research and development expense for each of the years ended December 31, 2023 and 2022, and (ii) approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in patent costs as general and administrative expense for each of the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> anniversary of the first commercial sale of a licensed product. The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. The Company may terminate the agreement at any time upon at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; written notice.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> agreement that expires on December 31, 2025, the Regents will receive payments aggregating $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with quarterly payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">131,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2023, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">137,813</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2024 and 2025. The Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development expense under this agreement in each of the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Award</span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">            </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2017, and as amended and restated in December 2020, CIRM awarded an $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million grant to researchers at UC San Diego to advance the Company&#8217;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. This study is known as CIRM-0001, or Cirmtuzumab and Ibrutinib for Relapsed Lymphoma or Leukemia (the &#8220;CIRLL study&#8221;). The Company: (i) conducted this study in collaboration with UC San Diego, (ii) received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in development milestones under research subaward agreements during the award project period from October 1, 2017 through March 31, 2022, (iii) was committed to and met certain co-funding requirements, and (iv) was required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. As of December 31, 2023, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The National Institutes of Health (&#8220;NIH&#8221;) Grant Awards</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NIH has awarded the Company three research and development grants for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to support preclinical activities for the Company&#8217;s ONCT-534 and ONCT-216 programs, including $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payable to subawardees. Under the terms of the grant awards, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and the Company is required to provide periodic progress performance reports. During the years ended December 31, 2023 and 2022, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in award payments from the NIH. During the years ended December 31, 2023 and 2022, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in NIH grant revenue and had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in unbilled receivables as of December 31, 2023 and 2022, respectively, which has been included in prepaid and other assets.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SPH USA, a Related Party</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License and Development Agreement (&#8220;LDA&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2018, and as amended in August 2020, the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country/region-by-country/region or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) either party in the event the other party declares insolvency or bankruptcy. There has been no significant activity under this agreement for the years ended December 31, 2023 and 2022. See Note 4.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the GTx merger agreement entered into in June 2019 (the &#8220;Merger&#8221;), the Company, a representative of holders of the CVRs, and Computershare, Inc. as rights agent entered into the CVR Agreement. Pursuant to the CVR Agreement, the Company&#8217;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#8217;s common stock held immediately prior to the Merger.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i) 50% of certain net proceeds received by the Company during the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year period after the closing of the Merger (the &#8220;CVR Term&#8221;) from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10-year period); and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net sales of products by Parent or its affiliates during the CVR Term incorporating the DAARI technology. As of December 31, 2023, no transactions or net sales relating to the DAARI technology had occurred.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501119906816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and December 31, 2022, the following fair value hierarchy tables presents the Company&#8217;s financial assets measured at fair value on a recurring basis (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.28%;"></td>
        <td style="width:2.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.040000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,844</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.28%;"></td>
        <td style="width:2.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.040000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of short-term investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its money market funds, treasury notes and treasury bills as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices for identical assets in active markets without any valuation adjustment.  The Company classifies its commercial paper and U.S. government sponsored enterprise securities as Level 2 assets under the fair value hierarchy, as these assets have been valued using information obtained through a third-party pricing service at each balance sheet date, using observable market inputs that may include trade information, broker or dealer quotes, bids, offers, or a combination of these data sources. The Company does not hold any short-term investments classified as Level 3, which are securities valued using unobservable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The Company did not transfer any investment securities between the classification levels during the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501224683760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC, pursuant to which the Company is able to offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company has no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. During the years ended December 31, 2023 and 2022, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55,274</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">402,068</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of warrant activity and changes in warrants outstanding is presented below:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.54%;"></td>
        <td style="width:1.032%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.51%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.241%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.032%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.427%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares Underlying Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,746</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">772.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.94</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued / Exercised / Forfeited / Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.94</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, all warrants met the criteria for classification in stockholders&#8217; equity.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contemporaneous with the Merger closing: (i) Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (&#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">97,708</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, and (b) an annual increase on the first day of each calendar year beginning January 1, 2020, and ending on and including January 1, 2029, equal to the lesser of (A) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as is determined by the Board, are reserved for issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2015, Oncternal adopted the 2015 Plan which provided for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the options issued under the 2015 Plan expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan was terminated as to new grant awards in June 2019.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the stock options issued under the 2019 Plan expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period. Certain stock option grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of non-statutory stock options to certain new hires who satisfy the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of the 2019 Plan. As amended in May 2021 and December 2021, the Company has reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for the issuance of common stock under the Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.19%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.382000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.481%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83.25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173,794</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,487</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">279,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value per share of option grants for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at December 31, 2023 of the option exercise and the exercise price of that stock option. There were no stock options exercised during the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Company repriced certain stock options held by employees and consultants. The repricing action was taken by the Company's board of directors to align the stock options with current market conditions and to retain key employees. The board of directors determined that the original exercise prices of the stock options were no longer reflective of the current market value of the Company's common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the repricing, the exercise prices of the stock options were adjusted to reflect the fair value of the Company's common stock as of October 2, 2023. The vesting schedules and other terms of the stock options were unchanged. The repricing was implemented through an amendment to the existing stock option agreements, which was approved by the board of directors. The repriced stock options are subject to terms such that any exercises prior to a premium end date shall use the original exercise price prior to the repricing amendment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the repriced stock options was determined using the Black-Scholes option-pricing model.  The incremental fair value of vested stock options resulted in a one-time charge to stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  The incremental fair value of unvested options of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be recognized over the remaining vesting period of the stock options.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Awards</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit awards (&#8220;RSUs&#8221;) are rights to receive shares of the Company&#8217;s common stock upon satisfaction of specific vesting conditions. The Company began issuing RSUs in the first quarter of 2022. The RSUs generally vest over an 18 month to two-year period. RSUs activity under the 2019 Plan is summarized as follows:</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.02%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.860000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Restricted Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/ Repurchased</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Units expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value per share of RSU grants for the years ended December 31, 2023 and 2022 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The total fair value of shares vested during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The total fair value of shares vested during the year ended December 31, 2022 was nominal.</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.227%;"></td>
        <td style="width:1.546%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.588%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.607999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The expected volatility assumption is based on a blend of volatilities of the Company&#8217;s share price and a peer group of similar companies whose share prices are publicly available. The volatility of the Company&#8217;s shares price was measured using the closing share price beginning June 10, 2019, the date of the closing of the Merger, through the current period.  The peer group was developed based on companies in the life sciences industry with comparable characteristics to the Company including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term represents the period of time that options are expected to be outstanding. Due to limited historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs represent rights to receive shares of common stock contingent upon satisfaction of specific vesting conditions. The stock-based compensation expense for these awards was determined using the closing price on the grant date applied to the total number of shares that were anticipated to fully vest.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the unrecognized compensation cost related to non-vested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.9</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the unrecognized compensation cost related to non-vested restricted stock units was nominal, which is expected to be recognized in the first quarter of 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.232%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.503%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock unit awards unvested and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock available for issuance under Inducement Plan and 2019 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">832,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">708,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501120696912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.848%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,910</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,660</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,501</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company's deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of the Company's deferred tax assets, management considers all available evidence, both positive and negative.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#8220;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#8221; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2023. Accordingly, a valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">66.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been recorded to offset this deferred tax asset. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company had federal and state net operating loss (NOL) carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">119.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Of the federal and state net operating losses at December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">93.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne, respectively, do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, unless previously utilized. At December 31, 2023, the Company also had federal and state research and development credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal research and development credit carryforwards will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2034</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unless previously utilized. The state research and development credits do not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating losses and credits may be subject to substantial annual limitations due to federal and state ownership change limitations provided by the Internal Revenue Code Section 382 and 383 and similar state provisions. Such annual limitations could result in the expiration of the net operating losses and credits before their utilization. The Company has not performed a Section 382 analysis to determine whether ownership changes will impact the use of net operating loss carryforwards and credits carryforwards and limit their ability to offset future taxable income. For financial statement purposes, the Company has included the federal and state net operating losses and credits in the schedule of deferred tax assets offset with a full valuation allowance. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by historical ownership changes will not impact the Company&#8217;s effective tax rate in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be recognized. At December 31, 2023 and 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#8217;s 2014 through 2023 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized interest or penalties in its consolidated statements of operations since inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501115571744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, cash equivalents, and short-term investments, no debt and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">197.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. From its inception, the Company has incurred recurring operating losses and negative cash flows from operations. The Company has concluded that the balance of cash, cash equivalents and short-term investments will not be sufficient to fund its planned expenditures and meet its obligations for the twelve months following the financial statement issuance date without raising additional funding or making changes to its operating plans or programs to reduce expenses. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for twelve months following the issuance date of these consolidated financial statements. The consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">          </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of its pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had capacity to issue up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock under its at-the-market (&#8220;ATM&#8221;) equity offering program. Through December 31, 2023, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">457,342</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the ATM program. There can be no assurance that the Company will be able to sell any additional shares of its common stock under the ATM program and no assurance regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM program may be at prices that result in additional dilution to existing stockholders of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_NasdaqListingAndReverseStockSplitPolicyTextBlock', window );">Nasdaq Listing and Reverse Stock Split</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq Listing and Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2023, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that because the closing bid price for the Company&#8217;s common stock had closed below $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Requirement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 8, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company regained compliance with the Nasdaq listing rules. Each of the Company&#8217;s shareholders received one new share of common stock for every 20 shares such shareholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#8217;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock was not adjusted as a result of the Reverse Stock Split. The Reverse Split also affected the Company&#8217;s outstanding common stock options and warrants, and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data, common stock options and warrants included in these consolidated financial statements, including the exercise price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of accruals for research and development costs. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist of Level 1 financial instruments in the fair value hierarchy (see Note 6 &#8211; Fair Value) and include cash in readily available checking accounts, money market accounts and commercial paper.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consist of U.S. treasury notes and bills, certificates of deposit, commercial paper and U.S. government sponsored enterprise securities with maturities of less than one year from the balance sheet date and are debt securities considered to be Level 1 and Level 2 financial instruments in the fair value hierarchy (see Note 6 &#8211; Fair Value).  The Company determines the appropriate classification of marketable securities at the time of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">purchase and reevaluates such designation at each balance sheet date.  The Company has classified all of its marketable securities at December 31, 2023 and 2022 as &#8220;available-for-sale&#8221; pursuant to ASC 320 Investments &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company records available-for-sale securities at fair value as determined by prices for identical or similar securities, with the unrealized gains and losses included as a separate component of other accumulated comprehensive income (loss).  In accordance with policy, the Company does not invest in or hold equity securities in its investment portfolio.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adjusts the cost of available-for-sale debt securities for amortization of premiums or accretion of discounts to maturity.  The Company includes interest and dividends on securities classified as available-for-sale in interest income.  Such amortization and accretion are included in interest income.  The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realized gains or losses on available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company records unrealized gains and losses on available-for-sale marketable securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders&#8217; equity on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in short-term investments in the accompanying consolidated balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which the Company determines the accrued interest will not be collected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates short-term investments for other-than-temporary impairment at the balance sheet date.  Factors considered in determining whether a loss is other-than temporary include how significant the decline in value is as a percentage of the original cost, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company&#8217;s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized loss positions until their amortized cost basis has been recovered.  As of December 31, 2023 and 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment charges on short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company obtains the fair value of its available-for-sale marketable securities from a professional pricing service. The fair values of available-for-sale marketable securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank. The service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service or mathematical calculations. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, credit spreads, current market and contractual prices for the underlying instruments or debt, as well as other relevant economic measures.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Deferred Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred compensation represents the accrual of retention bonuses for certain executives and certain other members of senior management.  The retention bonuses were entered into in connection with the waiver of annual cash performance bonuses of such personnel for the year ended December 31, 2023 and a temporary reduction of the chief executive officer&#8217;s salary from April 2023 through December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accruals</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, which include clinical trial accruals, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as an exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop its own assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, and accrued compensation. The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has short-term investments that are measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented (see Note 6).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue from certain grant awards or a research subaward (the &#8220;Grant Awards&#8221;) (see Note 5), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment in the United States.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:52.33%;"></td>
          <td style="width:1.88%;"></td>
          <td style="width:1%;"></td>
          <td style="width:19.956%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.88%;"></td>
          <td style="width:1%;"></td>
          <td style="width:19.956%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425,785</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,454</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">737,151</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646,760</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Statements (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net loss. This update is effective for the Company and was adopted on January 1, 2023, which did not have a material impact on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Standards Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting &#8211; Improvements to Reportable Segment Disclosures (Topic 280), which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. Topic 280 includes amendments which a) introduce a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker&#8239;(CODM), b) extend &#8239;certain annual disclosures to interim periods, c) clarify single reportable segment entities must apply ASC 280 in its entirety, d) permit more than one measure of segment profit or loss to be reported under certain conditions, and e) require disclosure of the title and position of the CODM.  This update is effective for all public entities beginning after December 15, 2023. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Tax &#8211; Improvements to Income Tax Disclosures, which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. The standard requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This update is effective for all public entities beginning after December 15, 2024. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk credit risk policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ConcentrationRiskCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NasdaqListingAndReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nasdaq listing and reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NasdaqListingAndReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent costs policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501224683760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:52.33%;"></td>
          <td style="width:1.88%;"></td>
          <td style="width:1%;"></td>
          <td style="width:19.956%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.88%;"></td>
          <td style="width:1%;"></td>
          <td style="width:19.956%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425,785</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,454</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">737,151</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646,760</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501118765024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock', window );">Schedule of Prepaid and Other</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid and other consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.429%;"></td>
        <td style="width:2.681%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.605%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.681%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.605%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">478</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party receivable (see Note 4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant and other receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.991%;"></td>
        <td style="width:2.959%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.415999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.915%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">868</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legal fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,579</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accounts prepaid and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501120660768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.606%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:14.743%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.862%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.461%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.502%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">Maturity (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,840</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,844</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.606%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:14.743%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.862%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.461%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.502%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,681</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ee1e1737-1e34-4355-a0d8-679b3a702be0;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,573</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501118616992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Lease Liabilities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.52%;"></td>
        <td style="width:3.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:32.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">318</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, long-term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501119125216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Companys Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and December 31, 2022, the following fair value hierarchy tables presents the Company&#8217;s financial assets measured at fair value on a recurring basis (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.28%;"></td>
        <td style="width:2.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.040000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,844</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.28%;"></td>
        <td style="width:2.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.040000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other Observable Inputs (Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Short term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial Paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government Agency</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501114784336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ScheduleOfWarrantActivityTableTextBlock', window );">Summary Of Warrant Activity And Changes In Warrants Outstanding</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of warrant activity and changes in warrants outstanding is presented below:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.54%;"></td>
        <td style="width:1.032%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.51%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.241%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.032%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.427%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares Underlying Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,746</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">772.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.94</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued / Exercised / Forfeited / Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance Outstanding - December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.94</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.19%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.382000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.481%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83.25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173,794</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,487</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">279,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.02%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.860000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Restricted Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/ Repurchased</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Units expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value per share of RSU grants for the years ended December 31, 2023 and 2022 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The total fair value of shares vested during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The total fair value of shares vested during the year ended December 31, 2022 was nominal.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.227%;"></td>
        <td style="width:1.546%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.588%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.607999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.232%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.503%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">548,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">425,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock unit awards unvested and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock available for issuance under Inducement Plan and 2019 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">832,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">708,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117950128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.848%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,910</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,660</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Significant Components of Net Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,958</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,501</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116392512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 04, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (197,779,000)<span></span>
</td>
<td class="num">$ (197,779,000)<span></span>
</td>
<td class="num">$ (158,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,300,000<span></span>
</td>
<td class="nump">34,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock transaction price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment charges on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457,342<span></span>
</td>
<td class="nump">55,274<span></span>
</td>
<td class="nump">402,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse Stock Split description</a></td>
<td class="text">1-for-20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents at carrying value and short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business basis of presentation and summary of significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-8A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501208365056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">737,151<span></span>
</td>
<td class="nump">646,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">170,521<span></span>
</td>
<td class="nump">170,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">548,073<span></span>
</td>
<td class="nump">425,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">18,557<span></span>
</td>
<td class="nump">50,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117143408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Prepaid and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_PrepaidResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_PrepaidClinicalTrialsExpense', window );">Clinical trials</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_OtherReceivablesNetCurrentIncludingGrant', window );">Grant and other receivable</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid and other expense total</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">3,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Related party receivable</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OtherReceivablesNetCurrentIncludingGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other receivables net current including grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OtherReceivablesNetCurrentIncludingGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PrepaidClinicalTrialsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical trials expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PrepaidClinicalTrialsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PrepaidResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PrepaidResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117142704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_AccruedResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_AccruedClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal fees</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="nump">2,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,877<span></span>
</td>
<td class="nump">$ 4,678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116990432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis (Details) - Short term investments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 27,555<span></span>
</td>
<td class="nump">$ 26,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">27,558<span></span>
</td>
<td class="nump">26,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">23,840<span></span>
</td>
<td class="nump">21,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 23,844<span></span>
</td>
<td class="nump">$ 21,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury debt securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_MaturitySecuritiesDebtMaturitiesPeriod1', window );">Maturity (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,738<span></span>
</td>
<td class="nump">$ 2,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,737<span></span>
</td>
<td class="nump">$ 2,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_MaturitySecuritiesDebtMaturitiesPeriod1', window );">Maturity (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 977<span></span>
</td>
<td class="nump">$ 1,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 977<span></span>
</td>
<td class="nump">$ 1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_MaturitySecuritiesDebtMaturitiesPeriod1', window );">Maturity (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MaturitySecuritiesDebtMaturitiesPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity securities debt maturities period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MaturitySecuritiesDebtMaturitiesPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116364224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Short-Term Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Assets<span></span>
</td>
<td class="text">Assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Marketable securities credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable on available-for-sale securities</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Debt securities, available-for-sale, accrued interest writeoff</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483580/946-220-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116401440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember', window );">Shanghai Pharmaceutical (USA) Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">San Diego, California | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_RentExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">Jul. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_AnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116869248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">$ (87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, long-term</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501113959040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,746,000<span></span>
</td>
<td class="nump">$ 13,457,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,000<span></span>
</td>
<td class="nump">1,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_NationalInstituteOfHealthGrantAwardsMember', window );">The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAndDevelopmentGrants', window );">Grants awarded to researchers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_AccruedClinicalTrials1', window );">Payable to subawardees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_AwardPaymentsReceived', window );">Award payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_ReagentsMember', window );">Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_NumberOfDaysInWrittenNoticeOfTermination', window );">Written notice of termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_UpfrontLicenseFeesPaid', window );">Upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_AnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels', window );">Worldwide sales milestones based on achievement of tiered revenue levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember', window );">University of California San Diego School of Medicine | The California Institute for Regenerative Medicine ("CIRM") Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAndDevelopmentGrants', window );">Grants awarded to researchers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod', window );">Development milestones to be received under research subaward agreements throughout award project period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyTwoMember', window );">Research Agreement 2022 | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAgreementTerm', window );">Research agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountReceivable', window );">Research amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyThreeMember', window );">Research Agreement 2023 | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyFourMember', window );">Research Agreement 2024 | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyFiveMember', window );">Research Agreement 2025 | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_LicenseAgreementMember', window );">License Agreement | University of Tennessee Research Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ContingentValueRightsAgreementMember', window );">CVR Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR', window );">Period from closing during which payment of percentage of net proceeds would be payable under the CVR</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement', window );">Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_AdvanceLicensedAssets', window );">Advance licensed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdvanceLicensedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance licensed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdvanceLicensedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AwardPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Award payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AwardPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, potential regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestones to be received under research subaward agreements throughout award project period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysInWrittenNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days in written notice of termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysInWrittenNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from closing during which percentage of net proceeds payment would be payable under the CVR.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAndDevelopmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAndDevelopmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Worldwide sales milestones based on achievement of tiered revenue levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_UpfrontLicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_UpfrontLicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_NationalInstituteOfHealthGrantAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_NationalInstituteOfHealthGrantAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_ReagentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_ReagentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=onct_ResearchAgreementTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=onct_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=onct_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=onct_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117937904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Companys Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">$ 27,558<span></span>
</td>
<td class="nump">$ 26,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">23,844<span></span>
</td>
<td class="nump">21,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">10,912<span></span>
</td>
<td class="nump">21,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Government Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">10,912<span></span>
</td>
<td class="nump">21,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">16,646<span></span>
</td>
<td class="nump">4,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | U.S. Government Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | U.S. Treasury debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">12,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | U.S. Government Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | U.S. Treasury debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501121478736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - ATM Program (Details) - ATM Program - Common Stock - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="nump">457,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,274<span></span>
</td>
<td class="nump">402,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of shares</a></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501208347008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">170,521<span></span>
</td>
<td class="nump">211,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WarrantsIssued', window );">Number of Shares Underlying Warrants Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ExerciseOfWarrants', window );">Number of Shares Underlying Warrants Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WarrantsCancelled', window );">Number of Shares Underlying Warrants Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WarrantsExpired', window );">Number of Shares Underlying Warrants Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">170,521<span></span>
</td>
<td class="nump">170,521<span></span>
</td>
<td class="nump">211,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WarrantsIssuedPricePerShare', window );">Warrant Exercised Price Per Share Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WarrantExercisedPricePerShare', window );">Warrant Exercised Price Per Share Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WarrantForfeitedPricePerShare', window );">Warrant Exercised Price Per Share Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WarrantExpiredPricePerShare', window );">Warrant Exercised Price Per Share Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">772.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant weighted-average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ClassOfWarrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercised price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantExpiredPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expired price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantExpiredPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantForfeitedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant forfeited price per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantForfeitedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantsIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued price per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantsIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501113935200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Incentive Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance', window );">Percentage of annual increase in shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,060<span></span>
</td>
<td class="nump">708,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 7,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=onct_RepricedStockOptionsMember', window );">Repriced Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Incremental fair value of unvested options</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember', window );">2019 incentive award plan and inducement plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember', window );">2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember', window );">2019 and 2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.33<span></span>
</td>
<td class="nump">$ 25.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenPlanMember', window );">2019 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=onct_RepricedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=onct_RepricedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117199568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Details) - Equity incentive plan<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance | shares</a></td>
<td class="nump">425,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted | shares</a></td>
<td class="nump">173,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, cancelled | shares</a></td>
<td class="num">(51,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance | shares</a></td>
<td class="nump">548,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options vested and expected to vest | shares</a></td>
<td class="nump">548,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber', window );">Number of options, vested and exercisable | shares</a></td>
<td class="nump">279,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 83.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">16.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled | $ / shares</a></td>
<td class="nump">69.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">56.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options vested and expected to vest | $ / shares</a></td>
<td class="nump">56.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and exercisable | $ / shares</a></td>
<td class="nump">$ 74.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_WeightedAverageContractualTermOutstanding', window );">Weighted average contractual term outstanding, ending balance</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Options vested and expected to vest</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm', window );">Remaining weighted-average period, vested and exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 155,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, options vested and expected to vest | $</a></td>
<td class="nump">155,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue', window );">Vested and exercisable, Aggregate intrinsic value | $</a></td>
<td class="nump">$ 68,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WeightedAverageContractualTermOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average contractual term outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WeightedAverageContractualTermOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116980256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Unit<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock units, Beginning balance</a></td>
<td class="nump">50,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stock units, Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted stock units, Vested</a></td>
<td class="num">(30,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod', window );">Number of restricted stock units, Forfeited/Repurchased</a></td>
<td class="num">(1,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock units, Ending balance</a></td>
<td class="nump">18,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of restricted units expected to vest</a></td>
<td class="nump">18,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term nonvested</a></td>
<td class="text">1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Options vested and expected to vest</a></td>
<td class="text">1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value nonvested | $ / shares</a></td>
<td class="nump">$ 32.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, vested | $ / shares</a></td>
<td class="nump">35.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/ Repurchased | $ / shares</a></td>
<td class="nump">32.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value nonvested | $ / shares</a></td>
<td class="nump">28.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options vested and expected to vest | $ / shares</a></td>
<td class="nump">$ 28.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options forfeited or repurchased in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116462880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.60%<span></span>
</td>
<td class="nump">100.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501117968560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 7,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,064<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,436<span></span>
</td>
<td class="nump">$ 3,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501120690464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-Based Compensation Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock option</a></td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted-average period</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501116445904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CommonStockWarrantsReservedForFutureIssuance', window );">Common stock warrants</a></td>
<td class="nump">170,521<span></span>
</td>
<td class="nump">170,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_CommonStockOptionsOutstandingForFutureIssuance', window );">Common stock options outstanding</a></td>
<td class="nump">548,073<span></span>
</td>
<td class="nump">425,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance', window );">Restricted stock unit awards unvested and outstanding</a></td>
<td class="nump">18,557<span></span>
</td>
<td class="nump">50,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance under the Inducement Plan and 2019 Plan</a></td>
<td class="nump">832,060<span></span>
</td>
<td class="nump">708,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember', window );">Inducement Plan and 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance under the Inducement Plan and 2019 Plan</a></td>
<td class="nump">94,909<span></span>
</td>
<td class="nump">61,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockOptionsOutstandingForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock options outstanding for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockOptionsOutstandingForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockWarrantsReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockWarrantsReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock unit awards unvested and outstanding for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501113273584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes</a></td>
<td class="num">$ (8,290)<span></span>
</td>
<td class="num">$ (9,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(2,820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit carryforwards</a></td>
<td class="num">(2,910)<span></span>
</td>
<td class="num">(4,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">State rate change</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">196<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">8,660<span></span>
</td>
<td class="nump">16,057<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501113126384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 29,997<span></span>
</td>
<td class="nump">$ 27,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">10,958<span></span>
</td>
<td class="nump">7,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">22,501<span></span>
</td>
<td class="nump">19,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">66,628<span></span>
</td>
<td class="nump">57,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(66,561)<span></span>
</td>
<td class="num">(57,899)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember', window );">Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140501113813728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, fully offset by valuation allowance</a></td>
<td class="nump">$ 66,561,000<span></span>
</td>
<td class="nump">$ 57,899,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change In Valuation Allowance</a></td>
<td class="nump">8,700,000<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">10,958,000<span></span>
</td>
<td class="nump">7,804,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">119,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsNonExpirePortion', window );">Operating loss carryforwards non expire portion</a></td>
<td class="nump">$ 93,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text"> 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear', window );">Research and development credit carryforward expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 70,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsNonExpirePortion', window );">Operating loss carryforwards non expire portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OperatingLossCarryforwardsNonExpirePortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards non expire portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OperatingLossCarryforwardsNonExpirePortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M553PCUPR-*8TA7DVOS"NQ646:KKY8BYK3>L4^<"O\H%O]O+5 C2.J8BRP\M
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MZ8Q#1!+UB%D_*+ZIIK07KG#FJVY3',M!: '\?\6Y.CSH#[2#_N(_4$L#!!0
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MUP+J]QUC\OE!?Z#]-\3Z/U!+ P04    " "-@F=8?YYHR-\%  !<)0  &
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MRM((\&9)0QJU"Z#SA5)VZ[@+NK&?_0%02P,$%     @ C8)G6/?Q17U+ @
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ML?'B\LGL_.+L$$W '\ 1C9^S;HKG<)(L2,C&X$1@2@BVDD)"2"BY)(#CADU
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M&_X1K:NVP0/T_;*F2%%_P03A3__\^+]02P,$%     @ C8)G6-GN[VX8 P
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MVBG0_E9130?!.1B?M^7?4$L#!!0    ( (V"9U@HM5;!)04   P.   9
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M)J,VF.KM44V<+OQ]?Z$=O1[\,*7G&AIFH/5$:[>;L('Z 3C["U!+ P04
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MF)@6-W4'\]T)#E\3P&JA<#9Z!!/8+;6Z-M20#,0>*[-E"U@X(5JV]G"(>>_
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M3XZ$!N(M.E'.(,PUZF7]&=G (+F$T="IQ"?LO#)+X1<0*(*JW>H*SK9F"[\
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M&,8 2D!_U;NH++Q["^Y2A:X +,M'6*EF/>D[Y"*H9(<'+"C2!, [$LDO,-?
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MK,<![MGTT'6L]6;O.*H\6*__NI6(<9-\-?IA/'$&*A*]L9AIR1.'C8LB9-S
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M.38\^)E?CI\\866,66N<X3VEKAD?Q&'HF.*&(&13XU?A>UNXNF13C2S46!L
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MI9YJ,2TX/SW?)35-$@H("<$>ZS)9NR^IO6X[B&GP;U/$M(R_S#7)P(1,S;^
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MW6OPF9F](*X2=^2:WDR*"$S78;N)TTWH:EOMJ$>&846/$AIO0/L[3>??3WR
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MO=*H[ 0:GTMIMHXM4+_[HS]02P,$%     @ C8)G6!'O$LVJ @  X 4  !D
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M\</([PYO-,1<,!%RE@*K%&8-A0U4>XKI)CAH7%N-<,4%@<I"$T=]/6D]2T-
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MHRBA? D0(J>>&-T3NZ1'$:^A.".C." THJ,C>*,^T9'#&_UGHN2:ZZ*6NE5
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M7IE8GLN50K ^DGEV(RYVMDZ:KY46:*6%NFAM:;?[+[;W ^<R6C=NM-)\K;1
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M7%'!D83MS+L.KY9A;!-<Q!\4#NKD&=E2[H2XMXO/V<P++"-@0+2%P.;C 9;
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MI32_3H6T0$4IR=X<>8B(/#>M-(<+N>]BW OYVFX-!-:J?MQ4/WX3]AX/*=A
M8"W!TD:P=&A[I\]\&Z9!$IW;^U_#6GPG#=])+]]EY>2-=3+ZYOZ-=9+L17EM
M@P8":Q5\V11\^28<?3FD8 .!M00+@Z<;3C"TIVO$4[<FHTF0QF>F[H@;14DZ
M2;I='9[<RL)>SC>@M*3$7G@J;W_G5'<R[<5Y;:.&0FM7'3U5';T)<]<TAA)M
M(+2V:$\WN+#WOO._[!T_/XPG29*>N_MY6!*,DM&9N?V3Z2,'N7-#F4)N&J@N
MQLUN,_A=NW'G;']A!T(WU3S!5-/D5RQWE"O$8&L@@XO4<)+5@%8MM"C<C',G
MM)F8W./>#+4@;8!YOQ5&I7IAOZ 9D^?_ %!+ P04    " "-@F=8,>UJV"@#
M  #="@  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RU5FUOVC 0_BM6
M5DVMM#5OD$ '2"O5MDJKADJ[?:CVP20'L>K$F6V@_?>SG30+)&2=Q+Z 7^X>
M/_?8=[G1EO%'D0!(])323(RM1,K\PK9%E$"*Q3G+(5,[2\93+-64KVR1<\"Q
M<4JI[3E.8*>89-9D9-9F?#)B:TE)!C..Q#I-,7^^!,JV8\NU7A9NR2J1>L&>
MC'*\@CG(^WS&U<RN4&*20B8(RQ"'Y=CZZ%Y,7>-@++X3V(K:&.E0%HP]ZLEU
M/+8<S0@H1%)#8/6W@2E0JI$4CU\EJ%6=J1WKXQ?T3R9X%<P""Y@R^H/$,AE;
M PO%L,1K*F_9]@N4 ?4U7L2H,+]H6]B&H86BM9 L+9T5@Y1DQ3]^*H6H.;B]
M PY>Z>"]UL$O'7P3:,',A'6%)9Z,.-LBKJT5FAX8;8RWBH9D^AKGDJM=HOSD
MY!)3G$6 YN;-7('$A KT'LTXY)C$"&<Q^B83X.BTW#Q3N_?S*W1Z<H9.$,G0
M7<+60MF)D2T5(XUK1^7IE\7IWH'3KR Z1[[[#GF.Y[>X3U_O[NVZVTJ'2@RO
M$L,S>/X!O%N@6$*,9IC+9W3'<29P\=H>OBI3="TA%3_;PBQP>^VX.A4O1(XC
M&%LJUP3P#5B3MV_<P/G0%O21P'8D\"L)_"YT)8$ S*/$7'P,&Y7GN<I:V19T
M@10:)%TN-A/?5=>PJ<?2M'$JBQV"O8I@KY/@5"V0"%,D.<&T]<T5 /W:F=ZP
MM\>KQ29P@W9J_8I:OY/:=2;67&=3&ZE^X\!>.-@CU;0)@F$[IZ#B%'1R*G(W
M+[,9GE3Y%]"J6M X?+#/KVGB.GX[O[#B%W;R^ZP$D^:Q,<.40P1D@Q>T5<2P
M*>+0WR/9M'%K0N^0'%0D!YTDZ\6PH%D*B223F+8Q'319#)S]1]@T\OO!@4<X
MK+@._Y+ ]1KV< /I GAKS>K$^=>:=22PG9!=Y\]'S/E/A;L$/I(*QT+;E:'V
M+7=?=?>YD:$[E4JH>F5V_>'> VTQVB_?=JWWT(W?#>8KD@E$8:E\G/-0/6]>
M]%+%1++<M",+)E5S8X:)ZC^!:P.UOV1,ODQTAU-UM)/?4$L#!!0    ( (V"
M9U@FJ&+,T0(  !8(   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;*V6
M76_:,!2&_XJ555,K;<T7)*&#2"UHVJ1.0Z7=+J9=F.1 K#IQ9AMH__V.DS2C
M)*!>[(;$]CGO>5X[MAGOA'Q4&8 F3SDOU,3*M"ZO;%LE&>1478H2"AQ9"9E3
MC4VYME4I@:954LYMSW$".Z>LL.)QU3>7\5AL-&<%S"51FSRG\OD&N-A-+-=Z
MZ;ACZTR;#CL>EW0-"] /Y5QBRVY54I9#H9@HB(35Q+IVKZ:1B:\"?C#8J;UW
M8IPLA7@TC:_IQ'(,$'!(M%&@^-C"%#@W0HCQI]&TVI(F<?_]1?USY1V]+*F"
MJ> _6:JSB159)(45W7!])W9?H/$S-'J)X*KZ);LZ-AQ9)-DH+?(F&0ER5M1/
M^M3,PUZ".SB2X#4)WEL3_";!KXS69)6M&=4T'DNQ(])$HYIYJ>:FRD8WK#"K
MN- 21QGFZ?B&<EHD0!;5)S,#31E7Y".Y3A*Y@93<,KIDG&D&BIPWPQ<X_K"8
MD?.S"W)&6$'N,[%1M$C5V-;(9)3MI*E_4]?WCM2?07))?/<#\1S/[TF?OCW=
M>YUNXTRTT^&UT^%5>OX1O3E]IDN.7M%-/0<4I^/7]5)IB5_<[SZ#M>*@7]'L
MPBM5T@0F%FXS!7(+5OS^G1LXG_KL_B>Q5^;]UKQ_2CV^0T4JDZPRG\(6MWB)
M&U;WF:Z5PDK)G!3;V!T$8WN[[Z4;,PJ]-N85XJ!%')Q$G&('2R@G6C)<F3ZR
M6F"X5]5SW.@ K1L4!5$_VK!%&YY$NX4U<JT >JF&G8*N/SB ZHLY A6T4,'I
M^1(YGO>*FB.S#ROHEAR&HP.N;I 7C-Q^L+ %"T^"?=<9R#ZBL%/,.<#I1HSZ
M6:*6)3K)<B\TKAQM3CS^[\3KXXLZ'[4?A>$!8C=H$(2'2VGOG=KFQOQ&Y9H5
MBG!889IS&:)%6=]"=4.+LCK(ET+CM5"]9GAQ@S0!.+X20K\TS-W0_A6(_P)0
M2P,$%     @ C8)G6#&4$HM.!0  I1X  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S N>&ULO5E1;^HV%/XK5G8UM=)M@QT@T %2H;M=I5NI*K=W#],>7# 0
MW21FMH%VVH^?G:0Q"8Y+NK"7-@[G?/[.L7/.EWBPH^P'7Q$BP$L4QGSHK(18
M7[DNGZU(A/DE79-8_K*@+,)"#MG2Y6M&\#QQBD(7M5I=-\)![(P&R;T'-AK0
MC0B#F#PPP#=1A-GKF(1T-W2@\W;C,5BNA+KAC@9KO"13(I[6#TR.W!QE'D0D
MY@&- 2.+H7,-KR9>6SDD%M\#LN-[UT"%\DSI#S6XFP^=EF)$0C(3"@++?ULR
M(6&HD"2/OS)0)Y]3.>Y?OZ%_28*7P3QC3B8T_#V8B]70Z3E@3A9X$XI'NON-
M9 %U%-Z,ACSY"W:9;<L!LPT7-,J<)8,HB-/_^"5+Q)X#[%8XH,P!E1W:%0Y>
MYN E@:;,DK!NL,"C :,[P)2U1%,726X2;QE-$*MEG HF?PVDGQA-5Y2)"T%8
M!.[B+>%"+I'@X ),Y8:9;T("Z )4&.%X#C CX)Y@OF%$#@3 X L.&/B.PXUT
ME<L$'LELPU@0+\$8\X"#LQLB<!#R<S6) @8)<%"8_6EZ \X^G8-/\C[XMJ(;
M+B?C U?(D!5Q=Y:%-T[#0Q7A003N:2Q6'/P:S\F\".#*7.4)0V\)&R,KX@V9
M70(/?@:HA3P#H<GQ[LA"Q\O7STOPO$J\9P&F*L6!" C_#*ZW,KGX.207\AF_
MF&*Y@G]\E4[@3I"(_VE*83I#VSR#JB-7?(UG9.C(0L$)VQ)G]/-/L-OZQ11^
M0V"%9+3S9+1MZ*/K2&ZGX&^Y$R>4"U.HJ;^?^*L*MQTAO]/I#-SM?@P&JV['
M]W*K KE.3JYC)7?+*.?@*9;%-DPXWLHB:]S2*4YG;_IVB>"A1=],KIN3Z]8C
M]U6.B9%=]V#N"UBB=VC2,M/S<WJ^?6$+FYJK33U7&Y_G&]_$U#^@H1:[5R)K
ML.IV>LA,N)<3[ED)/UU.+\$WEA3&UV.X6N'J/H,-@14B[^>1]T]>D/I-)J,A
ML$(R8$NWU]9_+$D90&$#>KUVJ[1-36:PVX/F?0KW^C]LJ"QE0+:Z9##Q*P@B
M31 U59HR)'/AR1C:3(H,=0N&UJ;VP>J4@?JE=3](J<%,KGNO@K1NE=#>*ZT5
M"OP#[O%+$&TB(W,K<MWGLRFT8AYT5X:=D]<K:.W\M1/2$%HQ(5H)0+L4N,="
MY>(5G$GI_4HPX^?&F.TH,'$UAE??L1B)%@W0KAHF-(H(FP4X! ]X34QLQG:(
MVDO7$%HQ8"TZ8._T>[E1)=(46C$A6HM :W<_IOOV#6\$7EDCFJSZ7M=<@Y$6
M!\@N#H[OO>BP^Y<[FWTN<ZJ![8582PA44T)4=VAT*! .WAX,-A4M&FD1@>PB
MXF,M.@,M;0Z_S-=@5;TYM*I =E51KE[VGFP'J_O8-H56#%UK$]0^>1U#C8J4
MIM"*"=$B!=F_'1S9D]]!J>[)'W L1J+5!;*W]T1VWM(M8;'ZU@>NER2>O1J#
ML0+57L"&T(IA:RF"_-/OZ$:E2E-HQ81HJ8+L'TC>[\P9P'Y9[?L'M??0"/8[
M5;57ZP9DUPTU&G/__<9\:%+Q=<G3RL&KJ1RJ6Z[WOG2PFA09:E'@V47!QSIN
M!FI?=(.17/2*-V)/:P3/KA',I<G>=NV0M;^=-X163,#>4<+_<);0[&'"*72(
MIW6(9_]&<F3;?0>ENNU^P#&-Q-T[\),B<9F<@W(PHYM8I$=9^=W\K/4Z.6$L
MW1_#JTEZ8JIAT@/<>\R6LN:!D"PD9.O2E]6!I6>BZ4#0=7*L^$R%H%%RN2)X
M3I@RD+\O*!5O S5!?C(]^A=02P,$%     @ C8)G6':43R [ P  2PD  !D
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M-(ZBF0IKK9?@F=:+D0F$!Y )0(T>*"V"TBB4QJ"T&$KC*)JI]=;\"=X<2"8
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M *6%*%I;Y=K*HE8395&]Y#/O"6)1OC)07*2]"D-MK!?R<AWRQ)GH*_\^-)$
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M _W]*L_5\P?3P7X7[.)?4$L#!!0    ( (V"9UC98]%,>P0  +X0   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;*687W.C-A# OXJ&9MJ[F<0@S!\[
MM3T3)W?3F^FUF;C)/73Z(,,:,P'$2;(=S_3#5Q(82 PX[KT8)*3=WZZTNY(G
M.\J>^1I H)<TR?C46 N17YLF#]:0$CZ@.63RRXJRE C99)')<P8DU)/2Q+0M
MRS-3$F?&;*+[[MEL0C<BB3.X9XAOTI2P_1P2NIL:V#AT/,316J@.<S;)200+
M$(_Y/9,MLY(2QBED/*898K":&C?X>F[K"7K$4PP[WGA'RI0EI<^J\26<&I8B
M@@0"H400^=C"+22)DB0YOI="C4JGFMA\/TC_K(V7QBP)AUN:?(M#L9X:(P.%
ML"*;1#S0W6]0&N0J>0%-N/Y%NW*L9:!@PP5-R\F2((VSXDE>2D<T)CA=$^QR
M@JVY"T6:\HX(,ILPND-,C9;2U(LV5<^6<'&F5F4AF/P:RWEBMA T>%[3) 3&
M?T&?OF]BL4=7:%$L$J(KI$>@/W/MQ!OE1#7DPQT($B?\HQQ<SHJS #+E8Y0G
M)$,7R$1\31AP^04]9K'@EXV.O]9TPTD6RLZ+5^V)*:1=BLX,2AOFA0UVAPW8
M1E]I)M8<?<I""%\+,*5#*J_8!Z_,[5Z)=Q ,T!!?(MNRA^AQ<8<^7'QL6E0\
M>C0-*_\/M:9AE_^5(#27^RI$MS25P<9)X6G&2!:!# "!YGO4''=/]KK[9D=8
MB/[^78I$7P2D_)\VWQ7ZG7;]*NBO>4X"F!HRJCFP+1BSGW_"GO5KCW5.99W3
M)WWVQR9= E.[B.K](Q=["5&<97$6R6"2VR0 ]&^K-POX0KRKQ:L$LYTYMNM[
MWL3<MF"Y%99[+E8DO2VD;_M@W",8[ _]L=,.XU4PWKDP@?)+DIS \8YPKESL
MC/QV'+_"\<_%@2Q\[WKY1TRN,[+\83O3J&(:G<>$ML#5:LE\@> EEQE>-@35
MW;U\H[/XQA7?^%R?O0($%L2<+)-^WXV/V&Q_C$<=VPM;=8:W>NF^Z<JD8+;
M9*4] ,D\S>( VD.RSG6M^;C0.&ZPCH8#V^U ;10C_&.H=9B> "RKGMT,5F_@
MC#L([9K0_C'"9NR>8+2/&;WQP.IBK$L*[LWIIQD/[7<P#H\976_@X@[&NC#@
M_LIPDO%]D7Z"WCF/OJX?N+^ G*3O#/\3P.Y17/E.]XZH2PSNKS%'O($\+S%Y
M(MZ0! E@*9('=BZ(3O1O$WXK:+\^'^V!,(X<E!8',]M!(=GW'9AP7:!P?X4Z
M&'-U,(:!NGXHXK=F79;GUMYMU&I?/\+_L:\N=KB_VCU4YNS>6IH#BVG8M;U:
M#>G7=3 $%X8@[Z09=4W$_47QX/E7.^LFBAA$1,@#JURI6%[N O1$DHT.C5;^
M0HG?S..NZSFC]I"PZZIH]U?%FB2N2+:*Y-VIIPVW5.J^%[>NC'9_97QJ7?&F
M0]^8T4F(CQSJC1S\%M!L7"E38)&^.',98)M,%+?+JK>ZG-\45])Z>'&S_TJ8
M/%]PE,!*3K4&OO0.*R[+14/07%]0EU3(ZZY^70.1-U(U0'Y?42H.#:6@^LMB
M]A]02P,$%     @ C8)G6":%"9[; P  ,PT  !D   !X;"]W;W)K<VAE971S
M+W-H965T-# N>&ULK9=M;^,V#(#_"N$->P':^"U.TBX)T+2W[8#=5K2[NP_#
M/B@V$QNU)9\D)PVP'S]*3AQO<9(6O2^))8OD0XHBY?%:R">5(FIX+G*N)DZJ
M=7GMNBI.L6"J)TKD]&8A9,$T#>725:5$EEBA(G<#SQNX!<NX,QW;N7LY'8M*
MYQG'>PFJ*@HF-S/,Q7KB^,YNXB%;IMI,N--QR9;XB/IC>2]IY#9:DJQ KC+!
M0>)BXMSXUS-_8 3LBD\9KE7K&8PK<R&>S.!],G$\0X0YQMJH8/2WPEO,<Z.)
M.+YLE3J-32/8?MYI_]DZ3\[,F<);D7_.$IU.G)$#"2Y8E>L'L?X5MPY%1E\L
M<F5_8;U=ZSD05TJ+8BM,!$7&ZW_VO U$2R ,C@@$6X' <M>&+.4=TVPZEF(-
MTJPF;>;!NFJE"2[C9E<>M:2W&<GIZ:,6\5,J\@2E^A[>?:DRO8%+>*PW"<0"
M'E!IF<4:$["+X2//--R8:)JU/]RA9EFN?B2I[J4J91(59!S^3$6E&$_4V-7$
M;@C<>,LYJSF#(YQ^ !\$UZF"=SS!Y+\*7'*Z\3S8>3X+3FJ\P[@'H7\!@1>$
M\"VX.]#Z[X2%L(EM:"V$QV)K%%W.*&<2N!4%'23%;"K>2,GX$BFY-<PWT%YW
MSS9V^F;-9 )__48JX;W&0OW=%;/:?K_;OCG0UZID,4X<.K$*Y0J=Z7??^ /O
MIQ/>]1OO^J>T3W^OBCE*DR%RO^W*;GM%VZXN8(;+C/.,+^G<Y(S'V.5";22R
M1DP)64TCKQ^.QNZJ@RUJV*(WLOU".Z#_GT<U471 Y'73#!J:P1MI/M%\-\S@
M .8R]*)PV$TT;(B&;R2BDK? C*;=!RPK&:<F.[L AX> ?MCO=_.-&K[1&_FH
M"IQ)K-$!F#^*HB.!NVK KEX/9I$ GTNT0RU@12^[F*Y>P^1[^QKNG:3Z;'L/
M)I=LA9)Z*<&9AFP"%%/1E-3Z*I:#1ED %WQU--O.V/&A,#48!I"PS:D*Z;?:
MC_^UT"_@C]*43P6U T"=Y$51/X/P<J^"O5?!Z[Q:FG)#^C7"@F425BRO<+\7
M\$^K 76Z4-L;M#(G#'I'JJ2_;U#^R0[Q0LX+>"EE;<T/VIA1+QH<X=RW&O]T
MK]EQPHX3GU'&F4(HZ0QBNUQ!JUZ=!^YW  <]_QCPOO_XIQO0UT^ Z) T&/7"
MX CIOC?YIYO3V="*\X?N/'W-<'4&WFW=8PN42WM;5U0(*J[K*VTSVWP1W-3W
MX/WR^G/B Y-T^5"0XX)$O=Z0XB?K&WH]T**TM^*YT'3'MH\I?=6@- OH_4((
MO1L8 \UWTO1?4$L#!!0    ( (V"9UAYO_R%TP(  &P'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;*U576_:,!3]*U>9M'722CZ ;.H@$M#NXZ$:
M*FKW,.W!)!=BX<2I;:#\^UT[D-$NH#[L!6SGGN-SCWVO!UNI5CI'-/!4B%(/
MO=R8ZLKW=9ICP71'5EC2EX54!3,T54M?5PI9YD"%\*,@B/V"\=)+!FYMJI*!
M7!O!2YPJT.NB8&HW1B&W0R_T#@MW?)D;N^ G@XHM<8;FOIHJFOD-2\8++#67
M)2A<#+U1>#6);;P+>."XU4=CL)G,I5S9R?=LZ 56$ I,C65@]+?!"0IAB4C&
MXY[3:[:TP./Q@?V+RYURF3.-$RE^\LSD0^^3!QDNV%J8.[G]AOM\^I8OE4*[
M7]CN8P,/TK4VLMB#24'!R_J?/>U]. *$\0E M =$+P!1]P2@NP=T7:*U,I?6
M-3,L&2BY!66CB<T.G#<.3=GPTI[BS"CZR@EGDIF1Z2J7(D.EW\'-XYJ;'5S"
MC&Y+MA8(<@$C34=<6=,UW&O,P$BXT8:3APA?&%?PP,3:A3HV^.&"X:MBI=%P
M<8V&<:'?#WQ#@NVV?KH7-Z[%12?$A1'<RM+D&F[*#+/G!#YEVJ0;'=(=1V<9
MKS'M0#?\ %$0=5L$35X/C\[(Z3;N=QU?]Y3[.5-X.6;6U2G;4748&"GR;8EN
M_&LTUT;15?_=9E[-W6OGMN5_I2N6XM"C^M:H-N@E;]^$<?"Y+?'_1/;,AEYC
M0^\<>W+']>IRH1"!EP:)WX"BR]66<TT4UH;:%K5)@D[0"P?^YCB;]C![9IL6
MG?U&9_^LSINGBKH/G=5&"F:XH%IIT]C_=_.P0UWUA<838?UVC7&C,7Z=1C*R
M@ M>P@Z9:J^^\TQQC6R[+*\"0@B%K5Z((6,[W79/_*/&5:!:NGZN(97KTM1%
MW:PV3\;(=<H7ZV-Z2NK._Y>F?H=NF5IRZEP"%T09=#Z2[:KN[?7$R,JUQ[DT
MU&S=,*?G$)4-H.\+*<UA8C=H'MCD#U!+ P04    " "-@F=8B-H*.BT#  #/
M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6S-5EUOVC 4_2M65FVM
MM#:?A+8#I/*QK=*J(5BWAVD/)KD0JTZ<V@;:_?K93D@!!;1*>>A+8COW'I]S
M<N/<SIKQ!Y$ 2/24TDQTK43*_-JV191 BL4%RR%33^:,IUBJ*5_8(N> 8Y.4
M4MMSG-!.,<FL7L>LC7FOPY:2D@S&'(EEFF+^W ?*UEW+M38+$[)(I%ZP>YT<
M+V *\CX?<S6S*Y28I) )PC+$8=ZU;MSK@>OH!!/QD\!:;(V1EC)C[$%/;N.N
MY6A&0"&2&@*KVPH&0*E&4CP>2U"KVE,G;H\WZ)^->"5FA@4,&/U%8IETK4L+
MQ3#'2RHG;/T52D$MC1<Q*LP5K<M8QT+14DB6ELF*04JRXHZ?2B.V$MSP0()7
M)GC["<&!!+],\(W0@IF1-<02]SJ<K1'7T0I-#XPW)ENI(9E^C5/)U5.B\F1O
M*EGTD# : Q<?T.AQ2>0S.D?3!',X[RM_8C1@J2H:@8WMHR<]!G0Z!(D)%6<J
M^'XZ1*<G9^@$D0S]2-A2X"P6'5LJ?GH7.RJY] LNW@$NKH?N6"83@499#/$N
M@*V$5>J\C;J^=Q1Q"-$%\MV/R',\OX;0X/_3O2-T_,ILW^#Y!_!&:4[9,P":
M E^1" J;48W--Y2RJ!A^GZ,)1&R1D;\J:@R<,!TLI$"_OZD-T*V$5/RIL[M@
M$]2ST0?$M<AQ!%U+G0!"40*K]_Z=&SJ?ZJQJ"&S'N* R+CB&7E3I^<SX%&W[
M!$4YUHDO$-L&41]FJUZ[Y3@=>[4MJB8H\-TJ:(=LJR+;.DIVHN1C'B5(?07J
M1%FIHS)7!Y^L(WD4Z;5OJ"&P'=%A)3I\4Z4=-FE<0V [QK4KX]J-EW:!V-JJ
MVL )@[W2K@MJM>I+^[(B>WF4[!?(@&-J*AO'ZG=$A.18_XCK:![%>NT[:@AL
M1_95)?OJ317W59/&-02V8YSKO+073N/E74)NG\I^X(=[]5T7Y;?#O0*WMUJC
M%/C"=(Q"45EFLN@CJM6J*[TQO=C>>E]WJZ;E>H$I6MT[S!<D$XC"7$$Z%VWU
MS?&B>RPFDN6F 9LQJ=HY,TQ4QPU<!ZCG<\;D9J(WJ'KXWC]02P,$%     @
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M@PC*YB7&(\C8WG1U-3P9M1)U[A>*H1YMI6VFKO6V.VO6C.J_\&;A/3"=<VE
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MM[%.G&C:LN9%\8WM;%9<Z3[)/I:ZE05A#/3W@G-U>#$_Z)KC]#]02P,$%
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M%\#P4R1K@.]#(?13(>N@NKZ<_ ]02P,$%     @ C8)G6*P9F!M$ P  RA0
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MK(SF7"Q=N .!22$*%6A3IB9=&R+53P>W70\JN-;)N2R4S>TRN.]Q/7P'6/7
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ML_'V^LORNMECYX)S@)^([[]02P,$%     @ C8)G6&7AF;6W 0  91P  !,
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MK<OFD,^ZOXO33U!+ 0(4 Q0    ( (V"9U@'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ C8)G6$KG
M5+GO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ C8)G6)E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "-@F=8+VN<V<X(  "7
M-@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ C8)G6!R.-9M8!0  W!4  !@              ("!$A$
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (V"9UASA"JI
MV@(  -L)   8              " @: 6  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "-@F=8L;3L+% $  #T#P  &
M@(&P&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ C8)G
M6.4O#[7:!0  DA@  !@              ("!-AX  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( (V"9UA_GFC(WP4  %PE   8
M      " @48D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "-@F=8D@Z) H8"   "!@  &               @(%;*@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ C8)G6/?Q17U+ @  I 4  !@
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M970Q,BYX;6Q02P$"% ,4    " "-@F=8CMF:R5<&  !Y#P  &0
M    @('U7   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M (V"9UC<)XJ:8PX  #,H   9              " @8-C  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ C8)G6!6/VQ\C!0  50T  !D
M             ("!'7(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "-@F=8D@;A$,@/  #:+@  &0              @(%W=P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (V"9U@E0M;\M0D
M -4:   9              " @7:'  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ C8)G6'?.G$$P(0  36P  !D              ("!
M8I$  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "-@F=8
M?A5L-$X#  #R!@  &0              @(')L@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (V"9UC'F=]\/0,  (H'   9
M      " @4ZV  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ C8)G6!V\&.4\ P   P@  !D              ("!PKD  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "-@F=8$>\2S:H"  #@!0
M&0              @($UO0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( (V"9UAQPE>@BP,  .H(   9              " @1;   !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ C8)G6#HH;%B2
M!@  B!$  !D              ("!V,,  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "-@F=8(7+#"T0$   Y"@  &0
M@(&AR@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( (V"
M9UC>45S7-P4  $L?   9              " @1S/  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ C8)G6*HH5MJ[ P  ,@\  !D
M         ("!BM0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " "-@F=8,>UJV"@#  #="@  &0              @(%\V   >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (V"9U@FJ&+,T0(  !8(
M   9              " @=O;  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ C8)G6#&4$HM.!0  I1X  !D              ("!X]X
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "-@F=8=I1/
M(#L#  !+"0  &0              @(%HY   >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( (V"9UB7KJQ?P@0  "0:   9
M  " @=KG  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MC8)G6 L?F#T' P  Y@D  !D              ("!T^P  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "-@F=8':6/GX(,  #%C   &0
M            @($1\   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( (V"9UAKR:A8)@8  ,XR   9              " @<K\  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ C8)G6.AP"- A P
MHPH  !D              ("!)P,! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "-@F=8%4;3=CP$   7%   &0              @(%_
M!@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( (V"9UC"
ML$70Q 8  !$[   9              " @?(* 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ C8)G6-ECT4Q[!   OA   !D
M     ("![1$! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (V"9U@@(.H<(@,  *$*   9              "
M@?0C 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ C8)G
M6)]C#I>C P  * L  !D              ("!32<! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " "-@F=80(6Q\?4#  !,#P  &0
M        @($G*P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( (V"9U@ -:F)500  ,H4   9              " @5,O 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ C8)G6*P9F!M$ P  RA0
M  T              ( !WS,! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "-
M@F=8EXJ[',     3 @  "P              @ %.-P$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " "-@F=8I2??71H$  #&'P  #P              @ $W. $
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ C8)G6+DCVC>R 0  5!P  !H
M             ( !?CP! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ C8)G6&7AF;6W 0  91P  !,              ( !:#X! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     #< -P#X#@  4$ !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>150</ContextCount>
  <ElementCount>295</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestments1</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Commitments, Contingencies and Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements</Role>
      <ShortName>License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestments1</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Commitments, Contingencies and Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Balance Sheet Details - Prepaid and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails</Role>
      <ShortName>Balance Sheet Details - Prepaid and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Short-term Investments - Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails</Role>
      <ShortName>Short-term Investments - Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Short-term Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-term Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails</Role>
      <ShortName>License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Fair Value - Schedule of Companys Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Companys Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Stockholders' Equity - ATM Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails</Role>
      <ShortName>Stockholders' Equity - ATM Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="onct-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="onct-20231231.htm">onct-20231231.htm</File>
    <File>onct-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img205696091_0.jpg</File>
    <File>img205696091_1.jpg</File>
    <File>img205696091_2.jpg</File>
    <File>img205696091_3.jpg</File>
    <File>img205696091_4.jpg</File>
    <File>img205696091_5.jpg</File>
    <File>img205696091_6.jpg</File>
    <File>img205696091_7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="445">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "onct-20231231.htm": {
   "nsprefix": "onct",
   "nsuri": "http://www.oncternal.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "onct-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "onct-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 235,
   "keyCustom": 60,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 23,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2023": 6,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 150,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 588,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 445,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100050 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_ecb1ed7c-4185-403a-a988-00ae5ff973fd",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecb1ed7c-4185-403a-a988-00ae5ff973fd",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical",
     "longName": "100070 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_ed1bd376-c8fc-43e3-8746-8f969b50e374",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ed1bd376-c8fc-43e3-8746-8f969b50e374",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "longName": "995465 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestments1",
     "longName": "995475 - Disclosure - Short-term Investments",
     "shortName": "Short-term Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions",
     "longName": "995485 - Disclosure - Commitments, Contingencies and Related Party Transactions",
     "shortName": "Commitments, Contingencies and Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements",
     "longName": "995495 - Disclosure - License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements",
     "shortName": "License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValue",
     "longName": "995515 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "995525 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995535 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995545 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995555 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "longName": "995565 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "onct:ScheduleOfAccountsPrepaidAndOtherTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "onct:ScheduleOfAccountsPrepaidAndOtherTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables",
     "longName": "995575 - Disclosure - Short-term Investments (Tables)",
     "shortName": "Short-term Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables",
     "longName": "995585 - Disclosure - Commitments, Contingencies and Related Party Transactions (Tables)",
     "shortName": "Commitments, Contingencies and Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueTables",
     "longName": "995595 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "longName": "995605 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995615 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995625 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24db6605-9fb8-4748-a200-1daa7520b56f",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "onct:NasdaqListingAndReverseStockSplitPolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
     "longName": "995635 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails",
     "longName": "995645 - Disclosure - Balance Sheet Details - Prepaid and Other (Details)",
     "shortName": "Balance Sheet Details - Prepaid and Other (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "onct:PrepaidResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "onct:ScheduleOfAccountsPrepaidAndOtherTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "onct:PrepaidResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "onct:ScheduleOfAccountsPrepaidAndOtherTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
     "longName": "995655 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Details - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails",
     "longName": "995665 - Disclosure - Short-term Investments - Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis (Details)",
     "shortName": "Short-term Investments - Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_8bff7594-8784-4e75-992e-1abf18d3a26a",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8bff7594-8784-4e75-992e-1abf18d3a26a",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
     "longName": "995675 - Disclosure - Short-term Investments - Additional Information (Details)",
     "shortName": "Short-term Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995685 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "shortName": "Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:OperatingLeaseLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_caa34144-abe4-4bd3-99a2-59f166c310aa",
      "name": "us-gaap:ProceedsFromCollaborators",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "995695 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails",
     "longName": "995705 - Disclosure - License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements (Details)",
     "shortName": "License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_39371a89-6f01-47df-bc36-a1e47990e15b",
      "name": "onct:ResearchAndDevelopmentGrants",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995715 - Disclosure - Fair Value - Schedule of Companys Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value - Schedule of Companys Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_559906c9-0c59-49e6-96f8-3366e04dca58",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_559906c9-0c59-49e6-96f8-3366e04dca58",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
     "longName": "995725 - Disclosure - Stockholders' Equity - ATM Program (Details)",
     "shortName": "Stockholders' Equity - ATM Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_cbe31993-74d8-4712-92b5-682ceee9fb09",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "onct:GoingConcernPolicyTextBlock",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_060e4155-636b-4f25-aae8-2486660150ed",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails",
     "longName": "995735 - Disclosure - Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "shortName": "Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_98e40839-86be-43a6-9e04-8e2e7abd9e58",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "onct:WarrantsIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "onct:WarrantsExpired",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails",
     "longName": "995745 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)",
     "shortName": "Stockholders' Equity - Equity Incentive Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "longName": "995755 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
     "longName": "995765 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details)",
     "shortName": "Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e420a3e6-0b0a-450b-a468-f2a3164e557e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e420a3e6-0b0a-450b-a468-f2a3164e557e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails",
     "longName": "995775 - Disclosure - Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "shortName": "Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails",
     "longName": "995785 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)",
     "shortName": "Stockholders' Equity - Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_97f0b34a-98a0-4cbd-85a6-33dc53e598fe",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
     "longName": "995795 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "shortName": "Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
     "longName": "995805 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails",
     "longName": "995815 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "shortName": "Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails",
     "longName": "995825 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_186f5f62-cf61-4bb2-96bc-ba6c3544943d",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88c0a536-1858-45ff-bae1-c4b868dccb47",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "onct-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r675"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r626",
      "r680",
      "r869"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discounts on short-term investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "onct_AccruedClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AccruedClinicalTrials",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trials.",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "onct_AccruedClinicalTrials1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AccruedClinicalTrials1",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trials 1.",
        "label": "Accrued Clinical Trials1",
        "terseLabel": "Payable to subawardees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "onct_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r74",
      "r131",
      "r500",
      "r515",
      "r516"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r23",
      "r405",
      "r408",
      "r437",
      "r511",
      "r512",
      "r783",
      "r784",
      "r785",
      "r789",
      "r790",
      "r791"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r675",
      "r873"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r530",
      "r789",
      "r790",
      "r791",
      "r854",
      "r874"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.",
        "label": "Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash",
        "terseLabel": "Exercise of warrants for cash"
       }
      }
     },
     "auth_ref": []
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.",
        "label": "Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash Shares",
        "terseLabel": "Exercise of warrants for cash (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r327"
     ]
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital vesting related to unvested share liability.",
        "label": "Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability",
        "terseLabel": "Vesting related to repurchase liability"
       }
      }
     },
     "auth_ref": []
    },
    "onct_AdvanceLicensedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AdvanceLicensedAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance licensed assets.",
        "label": "Advance Licensed Assets",
        "terseLabel": "Advance licensed assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r710",
      "r720",
      "r746"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r713",
      "r723",
      "r749"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r714",
      "r724",
      "r741",
      "r750",
      "r754",
      "r762"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r367"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "onct_AmountAgreedToBeProvidedInContingencyFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AmountAgreedToBeProvidedInContingencyFunds",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount agreed to be provided in contingency funds.",
        "label": "Amount Agreed To Be Provided In Contingency Funds",
        "terseLabel": "Amount agreed to be provided in contingency funds"
       }
      }
     },
     "auth_ref": []
    },
    "onct_AnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AnnualBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual base rent",
        "label": "Annual Base Rent",
        "documentation": "Annual base rent."
       }
      }
     },
     "auth_ref": []
    },
    "onct_AnnualLicenseMaintenanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AnnualLicenseMaintenanceFees",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fees.",
        "label": "Annual License Maintenance Fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r127",
      "r155",
      "r186",
      "r199",
      "r203",
      "r244",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r398",
      "r402",
      "r424",
      "r496",
      "r569",
      "r675",
      "r687",
      "r816",
      "r817",
      "r859"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r133",
      "r155",
      "r244",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r398",
      "r402",
      "r424",
      "r675",
      "r816",
      "r817",
      "r859"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Member]",
        "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": []
    },
    "onct_AtTheMarketEquityOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AtTheMarketEquityOfferingProgramMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market equity offering program member.",
        "label": "At-The-Market Equity Offering Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r693",
      "r706"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r693",
      "r706"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r693",
      "r706"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r252",
      "r495"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale debt securities",
        "verboseLabel": "Fair Market Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r252",
      "r491",
      "r794"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "onct_AwardPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "AwardPaymentsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award payments received.",
        "label": "Award Payments Received",
        "terseLabel": "Award payments received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r84",
      "r85"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "auth_ref": []
    },
    "onct_CaliforniaInstituteForRegenerativeMedicineAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CaliforniaInstituteForRegenerativeMedicineAwardMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The California Institute for Regenerative Medicine (\"CIRM\") Award",
        "label": "California Institute For Regenerative Medicine Award [Member]",
        "documentation": "California Institute for Regenerative Medicine Award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r125",
      "r644"
     ]
    },
    "onct_CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents at carrying value and short term investments.",
        "label": "Cash and Cash Equivalents at Carrying Value and Short Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r81",
      "r152"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r81"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "onct_CashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants.",
        "label": "Cashless Exercise Of Warrants",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "onct_ChiefFinancialOfficerSonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ChiefFinancialOfficerSonMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief financial officer, son.",
        "label": "Chief Financial Officer Son [Member]",
        "terseLabel": "Agent"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r185",
      "r299",
      "r300",
      "r301",
      "r303",
      "r306",
      "r311",
      "r313",
      "r522",
      "r523",
      "r524",
      "r525",
      "r662",
      "r769",
      "r787"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted-Average Exercise Price",
        "periodStartLabel": "Weighted-Average Exercise Price",
        "terseLabel": "Warrant exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "periodEndLabel": "Options outstanding, Number of Warrant",
        "periodStartLabel": "Options outstanding, Number of Warrant",
        "terseLabel": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "onct_ClassOfWarrantWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ClassOfWarrantWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant weighted-average remaining contractual term.",
        "label": "Class Of Warrant Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration, Grants, Research Subaward Agreement and CVR Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r114",
      "r119"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "onct_CollaborativeArrangementPotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CollaborativeArrangementPotentialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential milestone payments.",
        "label": "Collaborative Arrangement Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CollaborativeArrangementPotentialRegulatoryMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential regulatory milestone payments.",
        "label": "Collaborative Arrangement Potential Regulatory Milestone Payments",
        "terseLabel": "Potential regulatory milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r62",
      "r497",
      "r555"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Maturities of Lease Liabilities",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingencies and Related Party Transactions",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r269",
      "r270",
      "r627",
      "r814"
     ]
    },
    "onct_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onct_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for issuance under the Inducement Plan and 2019 Plan",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Number of common stock shares provided for issuance of stock awards to its employees",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r678",
      "r679",
      "r681",
      "r682",
      "r683",
      "r684",
      "r789",
      "r790",
      "r854",
      "r872",
      "r874"
     ]
    },
    "onct_CommonStockOptionsOutstandingForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CommonStockOptionsOutstandingForFutureIssuance",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options outstanding for future issuance.",
        "label": "Common Stock Options Outstanding for Future Issuance",
        "terseLabel": "Common stock options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r556"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r556",
      "r575",
      "r874",
      "r875"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; authorized shares - 120,000 at December 31, 2023 and 60,000 at 2022; issued and outstanding shares - 2,948 and 2,829 at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r499",
      "r675"
     ]
    },
    "onct_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "onct_CommonStockWarrantsReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CommonStockWarrantsReservedForFutureIssuance",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants reserved for future issuance.",
        "label": "Common Stock Warrants Reserved For Future Issuance",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r137",
      "r139",
      "r145",
      "r492",
      "r506"
     ]
    },
    "onct_ConcentrationRiskCreditRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ConcentrationRiskCreditRiskPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk credit risk policy.",
        "label": "Concentration Risk Credit Risk Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r398",
      "r399",
      "r402",
      "r403",
      "r442",
      "r637",
      "r815",
      "r818",
      "r819"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r398",
      "r399",
      "r402",
      "r403",
      "r442",
      "r637",
      "r815",
      "r818",
      "r819"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r650"
     ]
    },
    "onct_ContingentValueRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ContingentValueRightsAgreementMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights Agreement.",
        "label": "Contingent Value Rights Agreement [Member]",
        "terseLabel": "CVR Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r285",
      "r301",
      "r441",
      "r647",
      "r649"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "onct_CumulativeChangeInOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "CumulativeChangeInOwnershipPercentage",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative change in ownership percentage.",
        "label": "Cumulative Change In Ownership Percentage",
        "terseLabel": "Cumulative changes in ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r153",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r297"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivable on available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r252",
      "r253",
      "r254"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, accrued interest writeoff",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities credit losses",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r252",
      "r259",
      "r260"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Short-term Investments and are Measured at a Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "totalLabel": "Deferred Compensation Liability, Current and Noncurrent, Total",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "terseLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r103",
      "r384"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "terseLabel": "Deferred grant revenue",
        "totalLabel": "Deferred Revenue, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Domain]",
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards",
        "verboseLabel": "Research and development credit carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r853"
     ]
    },
    "onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research expiration year.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year",
        "terseLabel": "Research and development credit carryforward expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred tax assets, fully offset by valuation allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "onct_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business basis of presentation and summary of significant accounting policies line items.",
        "label": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business basis of presentation and summary of significant accounting policies table.",
        "label": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones to be received under research subaward agreements throughout award project period.",
        "label": "Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period",
        "terseLabel": "Development milestones to be received under research subaward agreements throughout award project period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r693",
      "r706"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r693",
      "r706",
      "r742"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r175",
      "r177",
      "r179",
      "r180",
      "r181",
      "r183",
      "r413",
      "r414",
      "r493",
      "r507",
      "r653"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r177",
      "r179",
      "r180",
      "r181",
      "r183",
      "r413",
      "r414",
      "r493",
      "r507",
      "r653"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock option",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Common Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r121",
      "r141",
      "r142",
      "r143",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r184",
      "r245",
      "r246",
      "r315",
      "r360",
      "r361",
      "r362",
      "r389",
      "r390",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r437",
      "r511",
      "r512",
      "r513",
      "r530",
      "r598"
     ]
    },
    "onct_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plan.",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "Equity incentive plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Aggregate cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r710",
      "r720",
      "r746"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r707",
      "r717",
      "r743"
     ]
    },
    "onct_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive license agreement.",
        "label": "Exclusive License Agreement [Member]",
        "terseLabel": "Exclusive License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "onct_ExerciseOfCashlessWarrantShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ExerciseOfCashlessWarrantShares",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants",
        "label": "Exercise Of Cashless Warrant Shares",
        "verboseLabel": "Cashless exercise of warrants",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ExerciseOfWarrants",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares Underlying Warrants Exercised",
        "documentation": "Exercise of warrants.",
        "label": "Exercise Of Warrants",
        "terseLabel": "Number of Shares Underlying Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r420"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r420"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Companys Assets Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r100"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r417",
      "r447",
      "r448",
      "r449",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r419",
      "r421"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r317",
      "r322",
      "r417",
      "r447",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r317",
      "r322",
      "r417",
      "r448",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r417",
      "r449",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r447",
      "r448",
      "r449",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r421"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r12"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r256",
      "r257",
      "r258",
      "r296",
      "r311",
      "r410",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r505",
      "r658",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r477",
      "r478"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r750"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "Patent costs as general and administrative expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r580"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Insurance Expense",
        "terseLabel": "Insurance premiums",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "onct_GeorgetownUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "GeorgetownUniversityMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Georgetown University.",
        "label": "Georgetown University [Member]",
        "terseLabel": "Georgetown University"
       }
      }
     },
     "auth_ref": []
    },
    "onct_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going Concern [Policy Text Block]",
        "label": "Going Concern [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r693",
      "r706"
     ]
    },
    "us-gaap_ImpairmentOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges on short-term investments",
        "label": "Other than Temporary Impairment Losses, Investments",
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r583"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r583"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r370",
      "r379",
      "r381",
      "r387",
      "r391",
      "r393",
      "r394",
      "r395",
      "r527"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest and penalties",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes",
        "terseLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r118",
      "r173",
      "r174",
      "r190",
      "r377",
      "r392",
      "r509"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r373",
      "r374",
      "r381",
      "r382",
      "r386",
      "r388",
      "r521"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State rate change",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r378"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income taxes",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other, net",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "onct_IncomeTaxReconciliationPermanentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "IncomeTaxReconciliationPermanentItems",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State rate change",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credit carryforwards",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "onct_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onct_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Increase (Decrease) in Deferred Compensation",
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred grant revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Change in lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r786"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r714",
      "r724",
      "r741",
      "r750",
      "r754",
      "r762"
     ]
    },
    "onct_InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Plan And Two Thousand Nineteen Incentive Award Plan [Member]",
        "label": "Inducement Plan And Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "Inducement Plan and 2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r766"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r766"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r766"
     ]
    },
    "us-gaap_InsuranceCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Commissions",
        "terseLabel": "Insurance commissions",
        "documentation": "The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r189"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-term Investments",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r517",
      "r518",
      "r519",
      "r520",
      "r607",
      "r608"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r535",
      "r536",
      "r539",
      "r543",
      "r604",
      "r606",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r679"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r535",
      "r536",
      "r539",
      "r543",
      "r604",
      "r606",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r679"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total short-term investments",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestments1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r108",
      "r109",
      "r120",
      "r209",
      "r211",
      "r422",
      "r423"
     ]
    },
    "onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock And Warrants Net Of Issuance Costs",
        "documentation": "Issuance of common stock and warrants net of issuance costs.",
        "terseLabel": "Issuance of common stock, net of issuance cost of $375"
       }
      }
     },
     "auth_ref": []
    },
    "onct_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock And Warrants Net Of Issuance Costs Shares",
        "documentation": "Issuance of common stock and warrants net of issuance costs shares.",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "terseLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r155",
      "r244",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r399",
      "r402",
      "r403",
      "r424",
      "r554",
      "r654",
      "r687",
      "r816",
      "r859",
      "r860"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r104",
      "r502",
      "r675",
      "r788",
      "r811",
      "r855"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r124",
      "r155",
      "r244",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r399",
      "r402",
      "r403",
      "r424",
      "r675",
      "r816",
      "r859",
      "r860"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "onct_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "onct_LicenseMaintenanceFeeToBePaidAndPaymentMade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "LicenseMaintenanceFeeToBePaidAndPaymentMade",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee to be paid and payment made.",
        "label": "License Maintenance Fee To Be Paid And Payment Made",
        "terseLabel": "Annual license maintenance fee to be paid and payment made"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "verboseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "onct_MDAndersonCancerCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "MDAndersonCancerCenterMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Cancer Center.",
        "label": "M D Anderson Cancer Center [Member]",
        "terseLabel": "MD Anderson Cancer Center"
       }
      }
     },
     "auth_ref": []
    },
    "onct_MaturitySecuritiesDebtMaturitiesPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "MaturitySecuritiesDebtMaturitiesPeriod1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity (in years)",
        "documentation": "Maturity securities debt maturities period.",
        "label": "Maturity Securities Debt Maturities Period 1"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r324",
      "r474",
      "r510",
      "r544",
      "r545",
      "r605",
      "r609",
      "r611",
      "r612",
      "r617",
      "r638",
      "r639",
      "r657",
      "r662",
      "r667",
      "r676",
      "r820",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r324",
      "r474",
      "r510",
      "r544",
      "r545",
      "r605",
      "r609",
      "r611",
      "r612",
      "r617",
      "r638",
      "r639",
      "r657",
      "r662",
      "r667",
      "r676",
      "r820",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "MinimumPeriodOfWrittenNoticeToTerminateAgreement",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period of written notice to terminate agreement.",
        "label": "Minimum Period Of Written Notice To Terminate Agreement",
        "terseLabel": "Minimum period in days of written notice to terminate license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "onct_NasdaqListingAndReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NasdaqListingAndReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nasdaq Listing and Reverse Stock Split",
        "label": "Nasdaq Listing and Reverse Stock Split [Policy Text Block]",
        "documentation": "Nasdaq listing and reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "onct_NationalInstituteOfHealthGrantAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NationalInstituteOfHealthGrantAwardsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The National Institute of Health (\u201cNIH\u201d) Grant Awards",
        "label": "National Institute Of Health Grant Awards [Member]",
        "documentation": "The national institute of health (\u201cnih\") grant awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r83",
      "r107",
      "r122",
      "r136",
      "r138",
      "r143",
      "r155",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r178",
      "r186",
      "r198",
      "r202",
      "r204",
      "r244",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r414",
      "r424",
      "r504",
      "r577",
      "r596",
      "r597",
      "r655",
      "r685",
      "r816"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Rentable Area",
        "terseLabel": "Rentable area",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.",
        "label": "Non Cash Or Part Noncash Gain Loss Of Forgiveness Of Payroll Protection Loan",
        "terseLabel": "Gain on forgiveness of payroll protection program loan",
        "negatedLabel": "Gain on forgiveness of payroll protection program loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r741",
      "r750"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "onct_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Rule10b5-1 Arr Modified",
        "label": "Non-Rule 10b5-1 Arr Modified [Flag]",
        "documentation": "Non-Rule 10b5-1 Arr Modified."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "onct_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice for default in payment.",
        "label": "Number Of Days After Receipt Of Notice For Default In Payment",
        "terseLabel": "Days after receipt of notice for default in payment"
       }
      }
     },
     "auth_ref": []
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice in fails to pay amount.",
        "label": "Number Of Days After Receipt Of Notice To Pay Failure Amount",
        "terseLabel": "Days after receipt of notice, to pay failure amount"
       }
      }
     },
     "auth_ref": []
    },
    "onct_NumberOfDaysInWrittenNoticeOfTermination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "NumberOfDaysInWrittenNoticeOfTermination",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days in written notice of termination.",
        "label": "Number Of Days In Written Notice Of Termination",
        "terseLabel": "Written notice of termination, period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "onct_OfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "OfficeSpaceMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r198",
      "r202",
      "r204",
      "r655"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liability",
        "verboseLabel": "Total Lease liability",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less current portion of lease liability",
        "verboseLabel": "Less current portion of lease liability",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability, long-term",
        "totalLabel": "Lease liability, long-term",
        "terseLabel": "Lease, net of current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r674"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "onct_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "onct_OperatingLossCarryforwardsNonExpirePortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "OperatingLossCarryforwardsNonExpirePortion",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards non expire portion.",
        "label": "Operating Loss Carryforwards Non Expire Portion",
        "terseLabel": "Operating loss carryforwards non expire portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r243"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r243"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r812"
     ]
    },
    "onct_OtherReceivablesNetCurrentIncludingGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "OtherReceivablesNetCurrentIncludingGrant",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivables net current including grant.",
        "label": "Other Receivables, Net, Current, Including Grant",
        "terseLabel": "Grant and other receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r712",
      "r722",
      "r748"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r715",
      "r725",
      "r751"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r715",
      "r725",
      "r751"
     ]
    },
    "onct_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs policy.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Common stock, issuance cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Repurchases of common stock for tax withholding obligations",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of available-for-sale securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r147",
      "r210"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company's SARD and SARM technology.",
        "label": "Percentage Of Net Proceeds Entitled To Receive During Period Specified After Closing From Grant Sale Or Transfer Of Rights",
        "terseLabel": "Percentage of net proceeds entitled to be received per CVR"
       }
      }
     },
     "auth_ref": []
    },
    "onct_PercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PercentageOfNetSales",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net sales.",
        "label": "Percentage Of Net Sales",
        "terseLabel": "Percentage of net sales"
       }
      }
     },
     "auth_ref": []
    },
    "onct_PeriodForCumulativeChangeInOwnership": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PeriodForCumulativeChangeInOwnership",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for cumulative change in ownership.",
        "label": "Period For Cumulative Change In Ownership",
        "terseLabel": "Period for cumulative change in ownership"
       }
      }
     },
     "auth_ref": []
    },
    "onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement.",
        "label": "Period Which Grant Sale Or Transfer Of Rights To Company Sard Or Sarm Technology Could Trigger Payment Under Cvr Agreement",
        "terseLabel": "Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from closing during which percentage of net proceeds payment would be payable under the CVR.",
        "label": "Period Which Payment Of Percentage Of Net Proceeds Would Be Payable Under C V R",
        "terseLabel": "Period from closing during which payment of percentage of net proceeds would be payable under the CVR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r299"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r556"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r299"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r556",
      "r575",
      "r874",
      "r875"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, authorized shares 5,000 at December 31, 2023 and 2022; issued and outstanding shares none",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r498",
      "r675"
     ]
    },
    "onct_PrepaidClinicalTrialsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PrepaidClinicalTrialsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid clinical trials expense.",
        "label": "Prepaid Clinical Trials Expense",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "totalLabel": "Prepaid and other expense total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r261",
      "r262",
      "r645"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r659",
      "r812"
     ]
    },
    "onct_PrepaidResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PrepaidResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development expense.",
        "label": "Prepaid Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "onct_PrivateOncternalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "PrivateOncternalMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Oncternal.",
        "label": "Private Oncternal [Member]",
        "terseLabel": "Private Oncternal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaborators",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from payroll protection loan",
        "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r522"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of available-for-sale securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r795"
     ]
    },
    "onct_ProceedsFromStockOptionsExercisedAndWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of stock options and common stock warrants.",
        "label": "Proceeds From Stock Options Exercised And Warrant Exercises",
        "terseLabel": "Proceeds from exercise of common stock options and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r136",
      "r138",
      "r150",
      "r155",
      "r165",
      "r173",
      "r174",
      "r186",
      "r198",
      "r202",
      "r204",
      "r244",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r397",
      "r400",
      "r401",
      "r414",
      "r424",
      "r494",
      "r503",
      "r529",
      "r577",
      "r596",
      "r597",
      "r655",
      "r671",
      "r672",
      "r686",
      "r785",
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r316",
      "r324",
      "r354",
      "r355",
      "r356",
      "r450",
      "r474",
      "r510",
      "r544",
      "r545",
      "r605",
      "r609",
      "r611",
      "r612",
      "r617",
      "r638",
      "r639",
      "r657",
      "r662",
      "r667",
      "r676",
      "r679",
      "r813",
      "r820",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r316",
      "r324",
      "r354",
      "r355",
      "r356",
      "r450",
      "r474",
      "r510",
      "r544",
      "r545",
      "r605",
      "r609",
      "r611",
      "r612",
      "r617",
      "r638",
      "r639",
      "r657",
      "r662",
      "r667",
      "r676",
      "r679",
      "r813",
      "r820",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "onct_ReagentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ReagentsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reagents.",
        "label": "Reagents [Member]",
        "terseLabel": "Regents of the University of California"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r707",
      "r717",
      "r743"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r438",
      "r439",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r574",
      "r576",
      "r603"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r438",
      "r439",
      "r440",
      "r441",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r574",
      "r576",
      "r603"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r438",
      "r439",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r574",
      "r576",
      "r603",
      "r858"
     ]
    },
    "onct_RelatedQualifyingSubawardCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "RelatedQualifyingSubawardCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related qualifying subaward costs.",
        "label": "Related Qualifying Subaward Costs",
        "terseLabel": "Related qualifying subaward costs"
       }
      }
     },
     "auth_ref": []
    },
    "onct_RemainderOfLeaseTermBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "RemainderOfLeaseTermBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remainder of the lease term base rent.",
        "label": "Remainder Of Lease Term Base Rent",
        "terseLabel": "Remainder of the lease term base rent"
       }
      }
     },
     "auth_ref": []
    },
    "onct_RentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "RentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent expense.",
        "label": "Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "auth_ref": []
    },
    "onct_RepricedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "RepricedStockOptionsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repriced Stock Options",
        "label": "Repriced Stock Options [Member]",
        "documentation": "Repriced Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r285",
      "r301",
      "r441",
      "r648",
      "r649"
     ]
    },
    "onct_ResearchAgreementResearchFundingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementResearchFundingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount.",
        "label": "Research Agreement Research Funding Amount",
        "terseLabel": "Aggregate research agreement budget"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ResearchAgreementResearchFundingAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementResearchFundingAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount payable.",
        "label": "Research Agreement Research Funding Amount Payable",
        "terseLabel": "Research amount payable quarterly"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ResearchAgreementResearchFundingAmountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementResearchFundingAmountReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount receivable.",
        "label": "Research Agreement Research Funding Amount Receivable",
        "terseLabel": "Research amount received"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ResearchAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementTerm",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement term.",
        "label": "Research Agreement Term",
        "terseLabel": "Research agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ResearchAgreementTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Agreement 2025",
        "label": "Research Agreement Two Thousand Twenty Five [Member]",
        "documentation": "Research agreement two thousand twenty five."
       }
      }
     },
     "auth_ref": []
    },
    "onct_ResearchAgreementTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement two thousand twenty four.",
        "label": "Research Agreement Two Thousand Twenty Four [Member]",
        "terseLabel": "Research Agreement 2024"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ResearchAgreementTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement two thousand twenty three.",
        "label": "Research Agreement Two Thousand Twenty Three [Member]",
        "terseLabel": "Research Agreement 2023"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ResearchAgreementTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAgreementTwoThousandTwentyTwoMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement two thousand twenty two member.",
        "label": "Research Agreement Two Thousand Twenty Two Member",
        "terseLabel": "Research Agreement 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense",
        "verboseLabel": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r369",
      "r867"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses and Accruals",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "onct_ResearchAndDevelopmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ResearchAndDevelopmentGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grants.",
        "label": "Research And Development Grants",
        "terseLabel": "Grants awarded to researchers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r708",
      "r718",
      "r744"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r709",
      "r719",
      "r745"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r716",
      "r726",
      "r752"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Shares repurchased for settlement of minimum statutory tax withholdings (in shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "onct_RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock unit awards unvested and outstanding for future issuance.",
        "label": "Restricted Stock Unit Awards Unvested And Outstanding For Future Issuance",
        "terseLabel": "Restricted stock unit awards unvested and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Shares repurchased for settlement of minimum statutory tax withholdings",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r94",
      "r501",
      "r514",
      "r516",
      "r526",
      "r557",
      "r675"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r245",
      "r246",
      "r360",
      "r361",
      "r362",
      "r389",
      "r390",
      "r404",
      "r406",
      "r407",
      "r409",
      "r412",
      "r511",
      "r513",
      "r530",
      "r874"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r641",
      "r651"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Grant revenue",
        "totalLabel": "Revenues, Total",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r155",
      "r187",
      "r188",
      "r197",
      "r200",
      "r201",
      "r205",
      "r206",
      "r208",
      "r244",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r424",
      "r494",
      "r816"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r674"
     ]
    },
    "onct_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10B5-1 Arr Modified",
        "label": "Rule 10b5-1 Arr Modified [Flag]",
        "documentation": "Rule 10b5-1 Arr Modified."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of shares",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock transaction price per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "SalesMilestonesBasedOnAchievementOfTieredRevenueLevels",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Worldwide sales milestones based on achievement of tiered revenue levels.",
        "label": "Sales Milestones Based On Achievement Of Tiered Revenue Levels",
        "terseLabel": "Worldwide sales milestones based on achievement of tiered revenue levels"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ScheduleOfAccountsPrepaidAndOtherTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ScheduleOfAccountsPrepaidAndOtherTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accounts prepaid and other.",
        "label": "Schedule of Accounts Prepaid and other [Table Text Block]",
        "terseLabel": "Schedule of Prepaid and Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Significant Components of Net Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income [Table]",
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r505"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsPrepaidAndOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r92",
      "r93",
      "r94",
      "r128",
      "r129",
      "r130",
      "r185",
      "r299",
      "r300",
      "r301",
      "r303",
      "r306",
      "r311",
      "r313",
      "r522",
      "r523",
      "r524",
      "r525",
      "r662",
      "r769",
      "r787"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Common Stock Reserved for Future Issuance",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r67",
      "r68",
      "r92",
      "r93",
      "r94"
     ]
    },
    "onct_ScheduleOfWarrantActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of warrant activity table text block.",
        "label": "Schedule Of Warrant Activity Table [Text Block]",
        "terseLabel": "Summary Of Warrant Activity And Changes In Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r534",
      "r538",
      "r540",
      "r606",
      "r610",
      "r614",
      "r618",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r642",
      "r663",
      "r679",
      "r821",
      "r871"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r206",
      "r656"
     ]
    },
    "onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shanghai Pharmaceutical United States of America Inc.",
        "label": "Shanghai Pharmaceutical United States Of America Inc [Member]",
        "terseLabel": "Shanghai Pharmaceutical (USA) Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Options vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited or repurchased in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited or Repurchased In Period",
        "terseLabel": "Number of restricted stock units, Forfeited/Repurchased",
        "negatedLabel": "Number of restricted stock units, Forfeited/Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of restricted stock units, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Number of restricted stock units, Beginning balance",
        "periodEndLabel": "Number of restricted stock units, Ending balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average grant date fair value nonvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value nonvested",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-average remaining contractual term nonvested",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Number of restricted stock units, Vested",
        "negatedLabel": "Number of restricted stock units, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock reserved for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Maximum number of shares of common stock a participant may receive",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of option grants",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, ending balance",
        "periodStartLabel": "Number of options, beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, exercised",
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Vested",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Intrinsic Value",
        "terseLabel": "Vested and exercisable, Aggregate intrinsic value",
        "verboseLabel": "Aggregate intrinsic value, options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number",
        "terseLabel": "Number of options, vested and exercisable",
        "verboseLabel": "Number of options outstanding and fully vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining weighted-average period, vested and exercisable",
        "verboseLabel": "Weighted average remaining contractual term, Option vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of restricted units expected to vest",
        "verboseLabel": "Number of options vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, cancelled",
        "verboseLabel": "Weighted average exercise price, Forfeited/ Repurchased",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r332",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r363",
      "r364",
      "r365",
      "r366"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental fair value of unvested options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Options expiration term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Remaining weighted-average period",
        "terseLabel": "Weighted average contractual term outstanding, ending balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Options vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental fair value of vested options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value, vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.",
        "label": "Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance",
        "terseLabel": "Percentage of annual increase in shares reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Investments, Total",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r781"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short term investments",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622",
      "r643"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r21",
      "r121",
      "r141",
      "r142",
      "r143",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r184",
      "r245",
      "r246",
      "r315",
      "r360",
      "r361",
      "r362",
      "r389",
      "r390",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r437",
      "r511",
      "r512",
      "r513",
      "r530",
      "r598"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r534",
      "r538",
      "r540",
      "r606",
      "r610",
      "r614",
      "r618",
      "r625",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r642",
      "r663",
      "r679",
      "r821",
      "r871"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r184",
      "r476",
      "r517",
      "r531",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r579",
      "r580",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r680"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r184",
      "r476",
      "r517",
      "r531",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r579",
      "r580",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r680"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r711",
      "r721",
      "r747"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r94",
      "r522",
      "r598",
      "r623"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in Shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options for cash (in shares)",
        "negatedLabel": "Number of options, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r94",
      "r338"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Aggregate offering price",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r94",
      "r530",
      "r598",
      "r623",
      "r686"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options for cash",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r21",
      "r94"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r86",
      "r558",
      "r575",
      "r599",
      "r600",
      "r675",
      "r687",
      "r788",
      "r811",
      "r855",
      "r874"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r154",
      "r298",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r315",
      "r411",
      "r601",
      "r602",
      "r624"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split description",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "onct_SubawardPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "SubawardPaymentsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subaward payments received.",
        "label": "Subaward Payments Received",
        "terseLabel": "Subaward payments received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r443"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r443"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r443"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureStockholdersEquityAtmProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Investment Holdings [Line Items]",
        "terseLabel": "Short-Term Investments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r578",
      "r679"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r857"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r296",
      "r311",
      "r410",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r505",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "onct_TwoThousandFifteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "TwoThousandFifteenPlanMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen plan.",
        "label": "Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2015 plan"
       }
      }
     },
     "auth_ref": []
    },
    "onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "TwoThousandNineteenAndTwoThousandFifteenPlanMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand fifteen plan.",
        "label": "Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2019 and 2015 plan"
       }
      }
     },
     "auth_ref": []
    },
    "onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan and inducement plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan And Inducement Plan [Member]",
        "terseLabel": "2019 incentive award plan and inducement plan"
       }
      }
     },
     "auth_ref": []
    },
    "onct_TwoThousandNineteenIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 incentive award plan"
       }
      }
     },
     "auth_ref": []
    },
    "onct_TwoThousandNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "TwoThousandNineteenPlanMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 plan",
        "label": "Two Thousand Nineteen Plan [Member]",
        "documentation": "Two thousand nineteen plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r664",
      "r868"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfCompanysAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShorttermInvestmentsAndAreMeasuredAtAFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury debt securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r664",
      "r666",
      "r868"
     ]
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled grant receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "onct_UniversityOfCaliforniaSanDiegoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "UniversityOfCaliforniaSanDiegoMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California San Diego.",
        "label": "University Of California San Diego [Member]",
        "terseLabel": "University of California San Diego School of Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "onct_UniversityOfTennesseeResearchFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "UniversityOfTennesseeResearchFoundationMember",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Tennessee Research Foundation.",
        "label": "University Of Tennessee Research Foundation [Member]",
        "terseLabel": "University of Tennessee Research Foundation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r380"
     ]
    },
    "onct_UpfrontLicenseFeesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "UpfrontLicenseFeesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/DisclosureLicenseCollaborationGrantsResearchSubawardAgreementAndCvrAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fees paid.",
        "label": "Upfront License Fees Paid",
        "terseLabel": "Upfront license fees paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r113",
      "r115",
      "r116",
      "r117"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Change In Valuation Allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceLineItems",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceTable",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Table]",
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "onct_WarrantExercisedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WarrantExercisedPricePerShare",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Exercised Price Per Share Exercised",
        "documentation": "Warrant exercised price per share.",
        "label": "Warrant Exercised Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "onct_WarrantExpiredPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WarrantExpiredPricePerShare",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Exercised Price Per Share Expired",
        "documentation": "Warrant expired price per share.",
        "label": "Warrant Expired Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "onct_WarrantForfeitedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WarrantForfeitedPricePerShare",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Exercised Price Per Share Forfeited",
        "label": "Warrant Forfeited Price Per Share",
        "documentation": "Warrant forfeited price per share"
       }
      }
     },
     "auth_ref": []
    },
    "onct_WarrantsCancelled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WarrantsCancelled",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Underlying Warrants Forfeited",
        "documentation": "Warrants cancelled.",
        "label": "Warrants Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "onct_WarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WarrantsExpired",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares Underlying Warrants Expired",
        "documentation": "Warrants expired.",
        "label": "Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "onct_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Underlying Warrants Issued",
        "documentation": "Warrants issued.",
        "label": "Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "onct_WarrantsIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WarrantsIssuedPricePerShare",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Exercised Price Per Share Issued",
        "label": "Warrants Issued Price Per Share",
        "documentation": "Warrants issued price per share"
       }
      }
     },
     "auth_ref": []
    },
    "onct_WeightedAverageContractualTermOutstanding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncternal.com/20231231",
     "localname": "WeightedAverageContractualTermOutstanding",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average contractual term outstanding",
        "label": "Weighted Average Contractual Term Outstanding",
        "terseLabel": "Weighted average contractual term outstanding, ending balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r181"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.oncternal.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r181"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-8A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3D"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0000950170-24-027984-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-027984-xbrl.zip
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MH=N,!02@[BD!8'USBP!$ZRP</T8<DZ"[BHBV^7;G8PB BBD41ZZ+S3QRT2
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M*/KCIC:"S2GR@M1TL4*;UG[680!60+ 8:^MOW;.F<_P4Y62'7&&ZYAC5@QU
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M8&S)=PDF(_%S)5KS^Q.)O_XO)#[W:]43 L#S-A._B5BDM'@S27- +[EQ9$\
M,EFK.EH0FY<>P#;X?I2]=/7^(8?-C"L61#W;N2A*51>7')-NR5BEA22NA:
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M\1-+!4#$BU?N.2$@B-[>"#:1^@SQVK+0C'0>.8.A[%XQ1$[M!1O=L5]-75%
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M^N"\-6';IRV(/[9^>1E=-TOK2>JOZ&VQ[_)VHGYS*4PHWY^7G[=YH2=R0N^
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M=ZB=)JC6K5XU>KTEI2I@8:#KDL&;-SW$W8R8:#!8_Z"5W9? Y7K"R!HO"XT
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MS#J>YS#=>9G-]^8N?TS=[<BI0?7V2\ #&N(5LFO8V^<-S\O7CFIHKC?>0;9
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M+Z\I\L@*XD%%=X9'MHM&EJ<8D)F:&NS7*@_2CUQ2*">+%=&+_Z3.]6A9PHP
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MAG>Q)V>^&,R*?UI$0"PHX8Z[,,8&A^0#F0ZHI3KH)YZ?GW^YZWC:32->=Q)
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MB)M.<2BB)H4O3M-K1\<$+Y7M*37@#M%O_EZ%2!J-4@FVJ_+4Q](^BS;QA?F
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M_ FSM,<S@E[R-;^U:ND/C-?8A_+$MU#1E/HT'V5[R#KT7D<;XV3?L@L9F?C
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M1;/[!\HWK2_FI$5<%,69L<HY](O:?#' TBN_C5Z9)IICZF=S=W5DQY&O#OF
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MSGK4^X9-_,F*5N:XP3%2SLY"_*3@%VZ* KY35:"G,1KJ330E#!=4TTR;K)<
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M6:+^@@$FL0NX.6@]Z"JD1U0< ]3 ,4" 2X$P2"[(XJAAS54:E3<-/;JP##Y
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M.7?YK!770]/62<I C^_7CJIH:9=)\HIOD%J&7-%K168>;J7Y?-0KO/H<7\&
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MO/ #0GR0-9BOMN%!5CC_A_]JY_?OW31_JV#I>7]I_NVD_D\J/^1?35GT/S$
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MPTS 4::A;5*Z:.V+6\HGS0*0<D4"'$!!_!>Z='+/C[-H3I'LZ:G+!ZV)ZO'
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M&(LEVQ7(TQ3M[KN\1\Q3D?^LP&,\BUDKB%.;N8A\K:(FL!49:R:#<8EK5PP
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M(?$6 K14#OL?Y.GVX>_=KMYLJ=DX"KVX+=?9(E;<$U,HO40=0:79G56+GLR
M@+CN2'_H)V$^S7J_*V^/0(7O%^KI>^HJ"?Q\"V#DFDK7_>2HX\DY)U8,S_63
M0)20=5WN" [DMCTVGUI[)-!T,/$ ^[7H9S,(+3+WN.Z]_OC+IP*E)OTQM PD
M/"2]V]<(\LI/$/2M=WR":Z*.PP+ZWKY3#[%D!M 6$!_S-!FL;-^[_^Z;!Z.P
M)DT9*Z4'#L !9=-3KG_N(ZIV-.YP+*D9C!49]1.&YG<4.H6KS+.^4;S?"% >
M R!884O*3=F0R1+Q>2%6U;9?.]_FRY-48T/XO>27IOLFCV'MB^>\3)I7U3C
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MPM.]V*$MH-^J^X3!5='0DUA\ +J(?X+_6DH0;Z_4^,\L5(0_PL@2 &SR>00
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M'=*G4]*RP?)QS/YU6K\A\>]]ATAXZJ;X1.#"R4EB=%'KY$2IJY-;!->QG@R
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MR[I(X1[W>!>M][B]EF <V-BVK^W>VZ<[=-1GQNHH!C!_Y22L#QL3D" T6(B
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M;OENK$/KO5^)&D8&UR'+ZD>2E@9HL=G$4K_@Q=NS<'&%GM"^G%MVGKG8DZK
M6F==VDF__3Y'V*:K5J[&B YT<K\_^ Y24^%A"4]RU<S<HS->!UTF)<LZ?X,*
M'?&YO-H>[./#8!NF*;N\'F;OB^_FC"4)'><96^&DV!"!JG'<#59*K:E#_XB
M^DQNBE,%)V<2YJ4^K6KDMP$\X(V7;K^MA#6V4&%O>@8K#N4S*F)[;$Q2N.#"
MP#>11K*77F[?3< YI[KW3O& < A*:!MT<H8'?"4_HJ;?.H,A+IW'AE;28!NW
M8]Z'*_2>PG31O 3TLT\@;[:0B]LEM>[Q^3.!OT[S+R/6+],1&@K#=:X+M= -
M5BIQ*')5+KG'Z-2S?:BO]-YX.@<;JCKBL+S3(A-YW^+7PJ>IT_2R'A8COG5Q
M/OVPP'A:KSWC-F%PW2PL]G9UK>==,TZNQ&+.0?NC*\??@5:)DS.;^8P2KL\1
M\H(J0V#&W+JKMH-)7,M7OU\5/^[Q M'B@!8OTB/,1U=%9P\H/*_OQO0KB*UM
M,'_O:RC6>>5?Q+\][#AW0+^<SMP;U[209ZOJET>$AKBN4E T9YXP"P[2QG3>
MO;Z7DY-_!-V!K&A,0T:>;^ NA=%PQ\>N+*\\4R?9OG0:YQ@5U"A8M,*_AS*,
MM_"M5",$;;@9/]/)*\1HUB<Q=\8[2,F=;3"LMW$?QLM1QU?6R,!85GA$'0?V
M'!>G.W9.L. )G/ "J^[5&!IER[B2%85C .-?(E.([0M;)QUJS5 UM$OH<-XK
MB[XCV2V<C$BC.^?#Z_/2/]>MGF5Z3:QX4"DUG)4M2B,A4<'6RZL*GC&U,46J
MB;*&9U RV2XJ\E7%2[$K/0'6#"T>$O;<]P0D[)!I#CD.^YGSP>*';VQXIASR
M,&*S(>\I[VY<50?YA.;00J@M=EM,D2I RH5<QJXIJ>%3W05YN60V!S9Z8ROO
M+7@E./AV;2(U$=? ]8NX6/9AKXB:T#@S\6"Z%$0 3T9WT1J!3[%R?,I)Q7UM
M<#$I5'C4VCPFQPW;]%5),]-+JK9HG8%T+-$L(WU&1TY^4GCGK9CQ]/#P-7"5
MF@Q1+7GE!7I0YQ%<<(J_H8U1[=(I19&8<L-:%?5@YK9G<O^NNLT3OR90Q]28
M9#F[:O #J]FAU)>WLOTB;Z<-X<3'D65X &OW=;@Z%RR/X\'U@%F5C:3'KXU5
MBNXA##Y<PILFC)TGTMF;?AI7:_^K9/:!8&T\("6Z'-(*Q,59;.-(\( ^'($K
M6Q7@7*V*N]O/[P767XS^ ?0K"<"W77<<&^\":>R#8X>U_CKOU8:W% _X87*$
M:V['O0'/*9$3/N4&X '/2/Y2EA*[#4$QM. !50=XP$<6D?8#R5"5;LC53!/H
M/=BC%:6P2<A:3!\>\#0&=$S_&:LT]1&9%/Y[K);GR"E*W-6#(GB8F<GD9$AF
MV"I^O-;V_*XH'C!]E_KRFD!?,#N"\; OMM('H)N:+[2BCE1;@ B1GEUMT3)2
MK&6>\^$9W9FHW"WKO) LM>S.XEID1UY;S)#2)7AR3CP@A)H?<E-]->OTX%\%
MJB:%H6UL<9:'"'"=!L?Z*%&&_L_O :!TOQ!QT]!;!,PO$W%YWG[,J<;37M=9
MZM-6\%%]QLYBRY4Z7V S*9I_^+"NA]XQ2SZ,I/3( 9:[LYD?A6(*97)&E5Q+
MYGV6EZ-U,IX%(0O$Q7<)X02."5+TM:]8^]?CPE(A2\XX"4AG$]+]\@H/'M V
MC@5#<(RZ,7C QD\MPMP;0/YH#;*%!&+/G6W/MG5Q0K!\9FPU9P89=O 8=,,9
M'JC;V6$/(5+V8J@=0D^'JYG_V-I5#=ZQU7PQ.SD<T\;:5NZ;S'4T9_7_L??>
M84U^V[IH%!4%!%&1(A"4)EVJE)"(2!>0WHF BH" ]$[H2 U%>I,F4@/2>^^]
M2R?T4$,/(82#Z^R[U_JMN^_>^SSGW'ON\YS]Q_PCR9=D?M^<<XQWC#G'^UII
M2Q )Q:EXR8D#]J!"$RZP%^)*EGOXC_$SMJ.KTPLK'F3H-+S<1<Z%PY_J&L'#
M]O_;&R#*_2W72T!\":PE&X67N(KQLOYSQ^W_CV#\^M=6-(B<])UIIUE(L@T\
M%QH*2(YL"_Q%AH!9_RS85 \3KNY];R L&J42OCV)1K3D3+H_GPY;[9U6AO1_
MXHTL);P9F"Z,(ZRW]7R"#D @J]-V'/LFFHOC>$,[6BLA+<KIS8AL5H?7]SJN
MYX6^^P(XRNO+V^C:I-9^Y\-W&T%*G:(A-)]?LJW \V,Q:O@4K)E1W]H&)"X+
M4W.?ML$/5(.6!/O>P.9V,._<: XL[5IU$8$?U,<L@SEHF8)M0[^0$>XC= /X
M8BR?'F^[Q!27LYE/I/0%/\NH"?_R/Y;5P1(CZ>IXG1]11S'I?$R49/3N-?I*
M#6ZI+M&&&Y&ZZ2^02<XHQYZ /3(:8L;P3YQ-9<<^%M<W?MHU8A#]RO29UO0G
MU9YBZ?ZDGV"OMRE]MM6![//[2RPO9Y>IOUQC%>?73X/F6UF_W[EPH8.JYKBY
M2<&V^LY^!9\V4N#81AP^O:\:850$8ZZ_DN8E":2]7D^9H]&I*BN(?-#,5=X6
M\<:?.:A'E#ZO:3%XJW4IW<"0E<L=M%$K&Q[\K"CZ7[I_#+OESC.,DT**B6ON
M[EZP5AWR%=?<?&SP[8MZ&O*XP$++G^I0V417_8.F?@DH([@R;ZHHK<!PBC'N
M"O$])7&-*)"&R>?JYCC8?QQ/";-\T*K;^74E02")I?JYU_O6//\!FZ@VTB\P
M]A"=(0=ELKG"HOQ/)R._=M_*OFL=NR<+27%J)*XSR\#8*=?_&L]QLV/*4(_N
M-55KHCJ3$%D>*?5\YHQ0W ?GOA>HX&NV?$# JUH[!7]YFY" ( UFOJ*1#Y+T
MA=?.HNQSV6EQ\Z<FOAG!',6K_\8LG;R:I07N4"</.MPI+W,-!T^$^GTY<3G"
MD=)\58'%=:Y(>U3-GUFZ]+.H=0GH]QG'F#<]\WM6F9._M?$4PYE%ZP" L2^C
M1G-I(M7"^]@E6I3XYJY6N.;+_^@0U0[TGVL7TW!_1"V5MO"-:7]S*MY0KE \
MJ%XYH^42<.O)E9WA'?K?G3/Z'VW_[RN/&@91-J?=[Z:IU4>51/&7K[K#B^Y-
M:'"HY>S7TKSZMNE.M)XRK)O*,,3C+I@/3O%\,*!!0B/44RQ^&[*>K8/N]#OF
M>62H:)GCPF[T\D".GT*CNXGVNAW&,<^!(7U@WD=]9;7;\@T[1^TX^(&SK]PH
MM_5JFG(LAW.BEG:V[8SZ^V5V,:T[\BG:ZEJ^54K)J%HY[2OT/.3U=Q.P >):
MW%%N']'_D3RQP=620./$?FM[^3LX\" W>?GVH=P4!55U@W:ADF?PSC'"WQ4?
MF#7XLY\K=*BI-DN;R;C)29B=XVMNCB8%Q>*NR&C,"S..J[FE>^]_*NWW7V*J
M_Y&8:A$".?#589!&)UTX>.PBS]#5CY$@QY$=G%"D6L^/M X"B2'SQ:4M5<^^
MUZ:,:X#B;$JD)6ZJ'RC0-_CD4+!)?ZNFF-)V;A_7'^C:;'CB_KH!751HF8.J
M.!GI&CHK?>SWD8#)GX!$G-0SHYH,8P"^@F)I7!SXBZN;:)\$+J68G+NU80-^
M@%<.TGA"W7U7]<]WKO_BH!&FD4]4"_]1;N- .Q-:)E[:M/"0ITYRB6GD6,]-
MUF]C7G(FDV= I'FVT^<:SF9+O[&##K@-YH"_E6ISVK_%BD]DH6A4#-POHGS3
M&*<PSF6]> G0L63OR10>(+7!'"'4,8%+EP B3%*+H48V*OIM\.O8VWVD!:1?
MFDJHSK-.-V^^WS@G>?-!";PU_'M8XV2,F0:ND2?DSG^C@1JC<)&9,4U<+^W<
M,-3$QCP5+DJR;GQ"YYB:(!@([-B*SR"?<_:@04K3%G9+U#;VJ$<.?IZ4O'K>
M@^C&ULR?6TY)GRL>QQLS>&X*K0#<XICNB6L[L93"D XH[O;WP[LGI(&V#\ZT
MV /%Y>;3P+7SG0IQG$_V#LS*B[X8<F#\"YSS^"VY>RWHFAL&R?;)1VTV%Y0(
ME82+Y!N\_W@NGJ\!!D*6SUV0Q/%%QH"=Q?OA.;Y=&Q*()_N=@90M>-;4%I:/
M%1_N-VFO;(O#AWP@1'LM$V$7<%8. U).*3:]Z4,[UK'C+10W[BYZJ15//O.P
M-L:]E/$S)RFR>H6!-CE5=+_*D:(?UK(?W=.)8]Q:,]GS0(1>",%TM^QGID"$
MZ(-I*+E^P@=_"E7FCD79,V-:7!O)X0:9D3;Q?KY<](5GF$/G&[X7A^TN8\C!
MOCFPAV%ER9RJ>T79F?WT)&BA'2PP7J?#YU$CI?#I=YGC/LG3-+799"<PIL,B
M!?']:"OMMON;XJI0U/* W]TEV18%^NW%?,1G./3G6IU8FZCD!IBA?F2N\K&+
M?#[,Q347)T&!0EI(:V5E]DQ*#K:I1I7+<+_'ILY=A4[=Y'!\\SW8!AL4,HG8
M!(N@CQ:(1F6"S]+>TK@_I[K!#?[R$!@?5O?N=,=00L7++Y/ZD,/<D,\F&L[1
M$.B&]L%R*-/>SA)^H3GR*@%_HG$).)'4\N1'E4HLZ5G*F.YR<[58$6#&DGT\
M_6"1ABZF+C8Y\ZTN9AQ2-L2!89-YD2/UE4K[I_Z@#UF/R<@[[Q84@)USC!E9
MS[L9.B#//>O-;<A3V#?K-,8+>M*?C65L=$_MPHDSZO/QY#S^Z)+(8S<9Z"[,
MC V8WF^7RC=61TP8F":+7DU6-3CSO6 S9OI^-_J\\RS<XQ>$1+.X@ZU;FA=F
M\PU=1&ZE"G59IW!Z,R%(]VA]A\9R>^)7I(_)9ZL_16=;!CRMC>1F-*2YCHGC
MO[K-7,BB1JC\DF[92M"-G7:XDG+41+="B*T?[[#EZK1D[?(6?;\'M"RP!7_;
M,E9G0@H+-:"S)0;8WT8I[[[ $2.ZEV%W9NETYUF,&*?['AI]4/V^3E?UV9/Z
M! B&SA3^R+3['%9M')-Y-WGENK3%5#D,Z&S:XDJ, C\Z6*MZJ\E[FT6 R>/$
M[A0^E.J\5(=HT6UO\%X*H5/:?)1XF[HR R!W4QY-1DT]B-3'",O3CV29O#^1
M_ITKK1]A6ZM7RCZ]N=2#Y.9BC;TSNMO](.;#,BUYUU)]*](Z3)"'W .A/$ZE
MR%5SY_XR@/^Z30 !7,F<^JC1?_Z)8R-EA>;(&]O?U><B@\I5;=?.[";G<T+:
M/&^@;Z4(N()*YO3E?'JM\!8],@0\0]=0:?I$@P\TA;_:LELGC9J\$6>5=A^P
MB!L[V/OZ2 CK%%ZN9Z%^YW:D/GNREPX%?+,S^+A>"R\;"CNY[7L)D)!'UVNI
M54\(ZJ5(;^>F(GL;AKW$ XMIM7+_W:FHN\2F'!M5/FV^IL[^ZIANQW[;Y:8;
MO'GN@S7NA5U&7_*4D-9P9D0T_*?E0CR"M"@3>0GXFHX>#$;6U5C&1DD/#30K
MW,N)> G<8<=3%X5^X+&0RF[8Z"36FAI7W'9%M,*(@'>5B_J_7,7R6?%/S&YW
M^XO<C=RJ\C3(;\<IYM,YM=4$9"<7'-Y/VR6EO 307:\W[6B\;_]X\ Y49P,;
MF.9DFW&OX4V('RN);0_A7!?.HLV"Y"$KFWRYQL<CP?8!(MYLQ3DNY<\85H\'
M&[HQ7I#ZX)4W,N?<W\DN )-QSHV*27+[5CD6?);MK34V7BKAZO"FT3K6I1#$
MG2TYF%7#YP_RBM<L,S2.!DAO"S.<NWZLM]W2Q'@L]PIGC16]\[$G!'Z*ZXJ%
M?%Z_>Q:IQOU9Z*F&B%YHK3T[J'SCI^&(P>"MC/HLC#72(-22"1M3MOF]Y#JN
MNK-8,GIT2Y\5[F!-:JXU48*QZA!S<R:/E;M_[=ZWY'LV8\OS-6;&,3JV'=QS
MT\]S T]L:J..1&C^Q$4F,_BKN+6K]N<E8'(!W\71 ]+YPZA6?0DPNO.'/43+
M!EW9H<L::-][KJB+*DQ8N]\QKU=E5'G#_?LRU=Z6 2W^"4;#P8:K;:E'+MMV
M=\>$C;-M)?K =3(J6U0XH3>R[)QQQ,9?]QZ<3]')].OT]*"; T5YF3+G0;%Z
MV"V%!],-@9@@3DW8W;W,FB<)F>',=$[@U4[H#QA15V GE/3HIIE]/..A+--%
M;%<FO>@'+[S'5G^=Q7+M N5 9)F"M1'Q;C# 5J[C!>^NZ]&BZ7Y>5&YP_JVE
M9:JMGQDH)*J;S:"A\\]6[D^7MHFX6Q,'Q/XWXK.T +3V(EN&%_NO.L]-D+C*
M1\M]YV+,T\LUBSZPF\8PHK/=>E/D7ENMV%TA<4H#$UH;]XI3,=M:6,VB+>]O
MK$,'GS-OV=JL>;-!9_J,7^YC^>2Y;W"6?!54Y2_4J/D=RR>E_CYRX(5([2/J
MXQ6;/<-QF^\XSNKX><&)>.]JWG98B3+NQ@N@1/":N\-R"NEZ:SYR\*Z>S,F+
M)UF1QKQ/ 3/%^5ZVLMVLQZQ/6BG9HU3\@"G8!YSL/Y*2XV+"$8MKZ70+OJLE
M8J!>A0"2ZF[VA>=,;BFM> )#UGS4KPUL^UJ*L#7?M&9HK$&M%TA(_'8S?4<Y
MCG+I''[;O-\V\FQBE+OWJUU8DSW#"2-.QO58H7<AT% T@*/WO/:3E8;C;JIU
M:4^R*2'3K<XET<7C@C0AFKJ<GMD/O\=MEYYUO"C+G$6[<DS#D$",U@\R4<M7
M$RNL_?"*!-C^&.B"8P!GD_O)-;66-I6^5,'B6>'$TT?D5$XW@SZ3&=]2!FDI
M<LKG<TASSTT-JI%M+SLQ;SA"_YV3:!.(EL$'9O2/Z\?2-&N$4*!/C-9<:4P/
M(@]\M_1/PP7%%$T[=,/3C7B2+/A9.J>UA*4(?7W':'J2F4JB8LHJSV@&;)RU
M.[ +N$'-?R_?-]I Y3SX$KT7L/OY6.\24#IP&L:.B-J+>>8KHB$^-AD[_Z:2
MLK3/RS]*^@N9_H/$YT-1;>J6G[8IUBFE$Y75):]FEDN;Q[5_<L-%F_2B:-P5
M)(N6"=\9R.!\6OG<A?OV!R*R_K"JQ=1Z"/L!^V+3J[>A9S'E8KS1H<DN!D?B
ME4C*($K5$1;T\6%!E![;\X+D/;]C0]=%O!_I^)2SD^0EP,])JGHTPM<J6OX$
M,_#ZLQ/ ;O8]W%VK?UHHWR9]2R@Q)?=BI\Z[:8" =-/C:Q=$]U03@T#*C"1:
M5\ASDT@U]*^ +WZ?5W?,G@S8Z#O/<DD)H?)S/4T-'Y 3$BM.(;K.#JY6HLLE
M@"FO%U^M#]OHYE@//N&YA3ELK5%NQ=CWSDP&'S EO#%4J-@9Z'O^DA$3J&:0
M$,HL:B8%A1Z*?.$/-7_!:DE&=Q5RU"V!O= 07.3OQJWIK4N 9%0##&&(;@RO
M@_QPYZ?1&%_FPDI\297U[S;N6_UB4YG2FHMX4D1"RTP3HQ]3= GHVVE7XO,7
M2.W" I$07/2Y,G:+!Q]@\:<W@88@]$D(4OCH0NFXL.AIS  )-]);Y :%VA:\
MY>J;EN[,EX!432#FVA\];?VC=5&*O!>W=K$\:N81_N9OY<UTG(Y KX)/0OJA
M2,DI?:8O4W&??G/WLFF4AC]W# 6Z3X9,IDN7YKNU(]2""YF5)J(\O:4>:JX]
M^:^ZVG]IQ-/@:*<B\PJLPS>W]80*N!1=]PE!(A;Z>G@'Q),N\6,JM, DCC&!
M]M@$[W'3#D*"HP6)9-')8Y\+<I1U$Q:H'!,?BRLOBFD9, 7(<,*N0<7CC>L+
MJAE_B?<] DYUINJ5^*VL#$M1K-,UJPS>>/$61$DNPZGT?+@K/2:P2MQ<_AG!
M0)T$.K7EU!TKL& <?[C2'1L$/X2.N6G%6M"0YJ3KQPL^UOIZXIDW]T6"UE'P
MJ%W"Y8/%3SW!^M4ZNY8Y5:DNA Q9_%A.UC$TJ%6/0,FU4]J]6LIU\BOXOB3+
MV=%C.%O-1:+M'_44O9\XNV.*-=W4R)^?)B&F8Y;,E7'%-JUNOD-P&\-^6D7V
MWEG7DTT7C2_';.ZRV5=&0,+K/T@9_7<1C:%+P)5/74F;ADWJP([XH:!_?L?0
MR@QW<PMOZFF T]IP(6R#GCVC:;QP@%Y<LX@KRESBP7V["\77(/!>Y;V3EF1(
MF6%/&2[K)87Q-$EW]HDBAS1"]CE^4(5MD@TC;>S;:] N(0C1(23$D7<*LZO#
M.(A5)^]K'3JH@RV(X"S&/*DV7M"0^3'JE;VOJHF8!7U^_O8>X(:C,&!YOBYN
MR3.'/F<YOY64Q+&G ND]L-3H=@F@9_*D6$5R[D=_F5$;:ILS,LYI\%<F=28V
MV <9>GR[0Y';14E)HD'EZW/K&BN::G'2U!H-1F:JV16UT\8_CA4S7@0::YL>
M_+0$<\MD81241^TO1%*Q\S>#LN*]J1A,& AB+S@2JC!)2UM!5Q"D//&YW!/&
MH(?/CE!I@X+#/$7JT:ME6L>;[QKR;U0C6.PG+P$WRF^_<RH97ZR.(,E3( ]Q
MJK!=6!^I6U =Y;%W0W&6$SM55BG7P7&'?T8M%WVZI)2?:U&!%2KNMJT$%-CY
M$6TV/1@09EBF8]_K2'E*;:\G;F ,- LP(JC:-'G71K 5< D8"I/BE')UB*'!
M+N0Z/%/-E1O/S(:+HA'>@E!*"3M!O]@2&8(;'ZL<#=I"%XV4E?B/*?;H[PY;
MN8LAQ;C8=Y9<%@]?"##%B*7$OXL@>R6FY86QZ$AL]+^/%%C_VBER<^0#Y_?P
M15/?P0UQC@7W!P4&%GCRDK$]]\8RY37K@TGB@ZZ>YV O39&TBLIZ*SW4*<TJ
MO@?KKCFY!YK4PD@NW974;:P//GRCO<O-%$/0R\# ?Y__P&&M*NTA1D85'39V
MS_RN%=Z54L:[EZVYF=;+5GAGON;"=*GSZ[9#_ZL!BE\'WZNCF.;NL)J7$(#.
MM:B7E"G,/=EK@I=5G;O]A:0C?XR_=<4[3 5HYR/,K-1B&\>WSWALK8F=Q53W
MW2=Y40=7D.7+#^F4'GB2<,<U\3"))6N2!6<U=0/(VT^&FE_E"XD?J69%SA*,
MT8]O0 D:)[=@NZVX^5]X05C7LNDEX-V?9$Z4JG90G5[V*!X@>D_[@U;N.D4M
M<N&V!?A9?%&*9?PWY"Z3F(EDZ&*:83))JI0&>A?.^A4D\2&[8T:Q+?XC?M,[
M%N)U8W)(=S[_ASL('47%Y17,*6EY_1+P.$*9%<T4O3<[;ERB^F-<U/S N-5H
M_/7ZBT^9?KZ+[CM$26&NPJL,5MH["C_%T0HD^%>E@@C?Q($TJU'4Y-M-=E^6
MYPWZ@1MW&/ N1_U&ANXR^P:KK?(.+D8WHAB]7['[_G[W?GF!I18>"+N/..;2
M%0?J1[*8!7#M"OE;MF+T" @9TY=SW/?]\+5*H%VYF9RCL,QC>7@D"V+LX(YQ
MU!U#-I7,2*K\S% *1I_;VV8Q6XW4=2(/C6?:'NW?= %V5;.#]SM[.@\8(?('
M[+NM$QJYN9GA]:SR5B0[QV3^-;M)Z0KYBN*^$@_!=AFR[2W+XI/4.'.$?P/]
MU7.#ECTMS([#X91NS^$W\#P(95?L;9UF6(:,F0-5U!TC#7MQJG<VAA;+T&#H
M5+10-!+!:B]I,F=)\E,&_7W#9M-6O'8R08;Z:Z&SA,5"ADRZ%O&KF!S6'*O5
MCQA:)%\#@^I\P"#!X8*AQQ*$R'S^4=T]\^?N8?@BYP/CZ(W?M.>T-"@<9-_"
ML'0L S^18OTYI>F;@'E1R&SN6W"5R("8J> 66' X?9_2=Z^PY0XS.?5._+6(
MS1?<=U"I?M@'&L>ATO0984[VW2</.4:M@DME!A+IP^R6[GY<4"C]-.'23?2>
MZ5E+K$@3ZW?Q_!E/6LQC-;1_/Z[&[R2JL.5ISM1<?.B#Y%690F?/R+RYC<3"
MAFQC)#>#99=LEP@5 _S5'6"8FVDKE&9SGJ-FC'',OTK/7EJ9G:\NRBY5.=LB
M_MQ0IM?*L/Z4O^F<VP$6\KV1'$28YURK6EI57%4:QN"7>6?.FU5DF<AB "2!
M[M5'KX4)Y3J(AU:@8TB?1(;<;7LFS"X6>3:9[BZ[WX% &BCU+"@]6F7QJW4I
MB149$)=R::C?!T+W'\6P)#E/]%HRLMD\U.;RC>"36V8 MI0V%R@S65I!AT8I
MCCW-#'&=+/_ "K,QS=/<;_JV4N?X\4_[59M(:BB?Q#' "P+"+L%]7=^\:&"N
M;DA0P;??YLWG_K+]Y3$:@'<8P:GN#^1\7YA!B:K[$#J_'ADL>[3Z%6#J?:KD
MO,NABPDNJBS.S-S](.TOJ#"C,5.28'-EIXU-+!%23/'".ES!U]ULJ2X![(>#
M]S#6JNB.[YSESV(,XEQ%A58=!OC(D NWRCGQ3,Z_!MY'F!^\R6OZEJ Q7A\N
M;7/T-&$92-V_3%D<Y2:\LU+Q-9-J-F+;)NK:AC J^KCP68'ZQQCIQ*?YK3V4
M/Q)->:_<IEG7_U.F^[_X(O^'^2*)_F'6;#7<P[R"/W1J8.8ZO-O[X3%%4^=^
M\3JX=29U/ ;MVZJRZ=I7TSYFCM:^]T23NJ\S K;(F):K-EW?/<<8EA49HR+!
MV?<%0-?OC,%]SN3YH#A3O?FN./*;1Q9>2NSNXS<CF>2_S4XF>CNQ/WVBPU>.
M66?'JXV"[=D$Y)Z2^Q1]]SV;#,14+@UDN[DQ-WCSEA5+EBD6NT2['9[*?*<"
MUW\145!^C,GHL1;B<KU(HFH;I=::W&V0L99O$;$T*S(3XS<S04D=M!O0-R\-
M^D^#"TT%L 9UCC0^128'TK^3P_LRO=-4L$<( ,(,/=DAIH.,XB%_S;7VFK/T
M97:LVL5<78RXR "9.$=[_E!31YU(NE9V@8T)'9OM0)I!2W!Y#JJRIG!Z^K=N
MKYV8O>RWZ/ $L&]J3O#.9SR9<\;FS2@U$_-.O$X_+R>XEB)PR^!OFU$]G0)L
M2C"BZB85@YV]%N##Z5<CKRN<WL-N/*#KQ&.)]<7[RTZ<R*P=;D2\"22C_:D1
MMTGV--@A=PQ#UV*?0Q:D'=Q0CXC(WYH^.(25'%Z0R7">0WG&T#RAT ,0&?8(
M?E9N\8\2H[_ O+ N-&1K!+(VCO@'DL:)G// ;L^/7RX!'F>EHW57".FI8_65
M'_VS0/2T>C6.>4(@*TJ3D&T@!!]B?F:>PX9AWM3\L-_&D8X6C*G(7#;@GCB@
M2"2,6P_#"CV,3%.)$"YRS2FMJQK=,ZHKB\FH\F_MV!J711FFR%9+9->"-@2I
M609S&I$/T.L7Q%@M_+5._$-8"RMR$$MYA, 1P'$<+3#D)TPOWA=XQG75?W*#
MM%8(C;-O&Y@U=E!]##QL58%@4&81./-]1LC^_500J=YLS-;<WRNU-O@QE=MO
M)2.S,4J<[-]7,*S@6 ?^E9-#4]A5L(1R)79N1A"A&?/83@;&Y-H9YL[U76:Q
M7U-;P.(V<S#!4[F[-8QLAM*WJ7?T&YL6SN"PF4;\6!&E"L9[*4RW1>_QG$;J
MM%$0N5'8"[(W>;[!NPVWKJ).-_S<)> DVTD]737\OGEFPT*B,%*7PN;Y%\V%
M U/8,NR,_!B!/8*M0I]/CLZ_N 1$ G6O;)$,7@.I2]@Z2.X<?,W&\E.QWO.>
M0=L9"JS'L(_L^D^JTTRN7"K5Z.B*=+A?CBH[.Y:VG&+C!800I'R#>3E:N?J=
M<#A;/.\EH.$;V4257J]8"GA70:&+R6>)/S!<JI4':9@B.K;I3KJ>)GHU#SGN
MJ4@I6%J*K[;H33<S'8JTR-Q_]!%[K;M0B/]I1FTMF9\G6WU(7ZR8'OC+HR4K
MV>,S L^ZL<J__=F;_7K_UFL1D6\DP*VVWM@)H%ZZFUTF+%^S_$QG_4BC4%*Q
M?J1H>@(_H6<VF2>?16O?=4SK0*NA.R<P/ARB^*DE&"4P>,TY37MTN:%D9%K!
MS*YD^M.H(RE_P#L;=6[0BP+=+;-,A9P^0<J.KEM4%=*VMQ?A[HOOUM-_:IA5
MC$35'+*-)LJ5'?/]1$A"?0U9G@?RF_6TP?+YA9"7@/#EXZ*'J%,3%4N07M=I
MR).OK32[EHN+7H1JD=/?.$9S/>4,6U.H6V9[)CE4# H#6Q 4"]SKOX*'96\\
M#O(:7.236>)XC7NTST!-F:AS<K_[:HZH@PQN;*^$:)OW&TBEVDG9U^QYU4DA
M-U82#]KJ\\B3OCYV]5 2(:B0I>C7+$[^B*"T__!,GG1$DXA]+2X;:J'KYRCJ
M4*MLQ^*8$2%*$B6W2%9HL>EY?5\(;L1\?!([/"/-M_NKXUS:)HHB:.]UWBN>
MF'*;/#N+!"Y2V^"Y(1"PR#GF$K!D\+[_]OEHEZ,T9%$F]X1:<.Q%,_Q^GA6E
MK@EP-R@-@KUI"E)\!M:1TZ]ZFR_HW':8QZ&@,R2H3#9;V)#_@;DLE*_VZY/
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MR.&T\+39"Q@57F@SN\B^_PEP];5% B6=G)CZ^@S9V62,9L&F\?BS6N;&*]@
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M%-QDF5.=SDO:_!.J!@&VSC_SA\"DEX N-&QK1'FM?$,S=QM5?2)L)IEJ+CX
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MZ$Y,/2-2RQ=2?DRV4[MQ:&)^":B1IE5@P(?@]O?TX?[N(G9+88YT8( &6;_
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M_%0R2]^YA<I=N,*:)*(CZ7/%V4=5V::9#IO*;-= /S"-F2Y%LNVF$'K!G)-
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MX45ZO2O/[NMW"7S5WFSB9M^'SEM+%4%56-8'NA,EM>/XW:3W@G?L,)JC+ 0
M?$0/CR?"@5IB+*<PJH%O[!,AP-@  8 )GL)W)\_ML(+NY+BKT:Z,H=/*)0D
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M$B/@-V8J?##M^K*/M:7'T17XT4U*M?(U_L;:NS%F+QPVQ1H)@.H!=!P6WT8
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M_1KTR:KC!ZD!2%^3OB9]_7_]ZQLLPB=H8B2.Z P^,U9H!;0K-ZC$/A;"0@D
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M:/Q0ULG_*HX9#6F"OPO++HHFYW>JQ43 7!?N8<-I5SL& =FJ+H&&MAR1E=T
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M3X-#BE5B3>>H4BG,4S-?40V_ NP;*$:D>FAFR=H5:AE+U+"JRY"/O/4!MMT
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M]X4_I IIWQ!N71UT;V'P6:N8.PX<%&>SG28X5=ESAY#'2#:;X 59F?KI'>#
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MTL@G/XB',AY*);SJ?.9I%!7\,7UBFMW8Z?\JV"&/8KG0..'/1,NCTF)+;&\
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M[WV)YF]?X:FC_C<?Z;FO>F"UY1",X7AS _CS^"DG\#A&]K?T]?H_^J+LMFX
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M\JH_8)F"C*9!U@PUDD P5GXX>%_;43$-":"LKC]?0 +.[T#1H<Y#D*6'=DB
MFN95FNK\A+J_D4I&69@^FRA^Z)@=^%-'(7]M!C&GC4[D,GZPPAYG##L2@-7T
M2$W"YF)5L&T'Y99N2JOV/SW>Y"BKC+-?4,*YB *$H6V&V*^4XA)RC[ 3*0
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M;Z: $0H-?W:[<BTE;,7]G:AX_?H1#2.0M0<H)/W4B\"'O#<&']U!S;8-^DC
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M9G"DB-399^UK$)S587W#&\/\8P8>&IP%5O&0@T45X$H^ZQYN7U -<*[?PTU
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M2("M]&54R4^=,3)P3L'A\#;P*32.%A;.'@B=;%2.&9ABA:8P6L&]E]7T4+[
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M!9Z!"?-IKS)\HT*2LL.;9\BCFR9\?(K")MZJ$./(\GGL<,/;!HI @PA:!B1
M>X(%W?Q;@^"D%"3#P=/8,WM#5C9JQ=[/B(!$Y)<&;!'[2O! WNA+6X[A?[PY
M$GR:<\[4-Y!U42H Z:J=<]'&HE(#&X5WNMO#BY?,"T)>T'W= )-L.,O-^7(X
MK0Q9G_5_"*?0M0Q#:VA]07Q$IA2CV!JY$*@J\LBD,#:%S($5O@[#GO5BV.A/
M!I=F;G5D*?(G]:3V94 R-=:M')1&!IZO9LXWN>"\@BF(GZB*%3CKS=L:?AFC
MP?2TIR&SDSLCV<_-%]"7W1#O?J 2EJ7_T+KG8AXU-N)#(B9_ [[IE[!&.(X\
M.(Z^T&/>_8.)Y"4AR]G.54MO9T/*\)8)#_0$5NC2)XAX:_+%5"VX?02RTW^,
M!+#=0KD&B_]2M^D3%)PNQ2=?W 1>$F@(:#0!X>%62,#[-"0@-:\MSP/]Y%*J
M2W/\"(7*U3W,_UI,V_]*0GO.^!P09@]0RH=Q-4FD*E\6;P/J8AUZX26:.Y<N
MQC@-KD2'[VS\QQ!"/!7"0'LD +*W?39J8\%Y,I&U#"QP4)Z21 +L@+'K6D]4
M3\/.,*->42T=;=%'R&@8SOS9#L!_-?&"CW,0>P4D/7]O7?V)&8Z:_1]'I2#F
M4%.^IWV9D_0O294ZSQ"DQ_PU=JVU5V$6ASY_;M?R7ZL#'?+^(6NGDJ6^\2(H
MGVX?ARW5#Y2__*?G^/XS^D,F?>@OB?9?FY& 6QI>8Y"%YMY? I-'3G_^R%@8
MO+>XYIL'%W/\6K![>S-T3:4OSF7V0R2FY?:J ?7]L5UW,.,(%H'<58".K X=
M,3W5B WTWGH=HW5]:;U\2+8<M7*H,OJ4KM6032YA6E/=G21V-O_:EXJXU4NN
MZU*LH@C<V4HXJ-N@4,$SLI*&<W%LS3[258_<*;&MV?B";]UZT=#N9L,+VEV&
MYQ=6%<0M^O;8.Q.=S:YZ0_LOB#VCG0/P]8-6*OU "B\8-'ZLF);8"&0$9;6-
MVH[6/0J24/7)"E#-C?9MPES^UGX^^E2(((/;4DC(^K'5:GBTU1"_4IYAA<:]
M,"*F;;V8?.5 6MDIUM6 E9J)GAU5TG;3+R;%S?-#EWPN#'<9GO3)IR[6_LA3
M& J+:H-FK'@OFE"KBC&<>:^P$$Y2FP1]L=L<#7VW.2^-!3/5<H'8]U"=A?&,
MO4\^?=Y)<G@7=/.SQ0";D4!@$HW$.R&NJ1-2\,-UE:18&[:I)J,7-LJ9H0KM
M;1C$JX+C4(I4OXD@"G:SSJ$?!88*%5S/"[V_QV4D11:RS5K<Z"NE\6E7"[%T
M^=:VJ'9,D#]W%1#8@V<1%B8@!;EE;Z5B5CJFYJ!5V9+O)W>P"LP0'&RL(]];
MZG"RLR9Y_5ZF,/UM[DQ30-+EN5)$OUJ]8HZIIL&6]:7VP_K'E2/VO2UBA1WD
M!4FN+??,IIIN";>R!7W!3.[)L9=N%FDZ#^?W4QDQ)]0C%^9E/M=%?/CZI&#X
M-H-KSP11U:#52:*T6GU_*0[1YVJO+>)/2, [],!F1];0Y"4C4LU[]G9-ED^W
ME]OUA7]P='VZ:5KSI%5Z==#O( Z4J$4;S1!?5#&B/<OF7CD$:VL!0:6B3N(]
M(^@HB^>J+;F<,*TIX!?Z]HKV)C72.NP'Z3*@Q)Y5@+EC7%MJ%<&3UN0252+>
M8JO5*VU1O=*6W6+U[Q9%NM/+HD#BR8#%=?DZH(;*N/%AAYT%_NV1KI0,\R^)
M/RS"CSA^R,AFTTB,JV6]JZH;:!-9=*IVZGT@^;1TOYLH\!9LC#4\J-G<2/HF
M+)0=M/ZX^@.A7'#,)ZE6<E+TX]W!@4H_AMH =?"'DX=E83G;A*N%1JX$_<[2
MS$./*Q]-:664V^@Y6_1J"+/(*YXVU=W^]-V0;L),EY+O%F;3Y0(OVAH/PF:%
M7?'>[>U.^@J*UEX\:#=1^D62]_X]N:]U P5X R<S=@],0?AN/J32:M90_E2_
MF4 :<;+LQ@(16;4N%$(-=6V[DF\0VG+9S1I7>4WQT@Z"/#%NG'+X+DSZF,)E
M7#AJ<AC?=);U+9$](0,V%AGD*^#G5D5/#0^;QF6-@4;97?3?["MZ,3*I8VZY
MT7K&&VJS'#)!N3F6K&6A+Q0D5-EY.1(YCZKTL[@\G'E2P),V]]KLPU>45VV:
M<'N8;RGO#]9G&!E2L QR$%0YF)ILX_'8-I>(XL8R"WX$.N^!V@SR]3Q6-6O"
M/XYP%XKL"+>#AJB&CV9A2EZ3VR>S!A=WI$'=ZA?EH8&5/<:=:P6;,@HF=D6!
M#(6)VT,H6YY\0Y%3,;K#SN%F-3&^&Z,;*[.C?H'#)?ZFK,+[N1;QM*QGNAHC
MZ6)EV\+*B1I<E:&1$4OWE>?\:N<V8Y[R*^@)-.?@2]1;5;_'3$,+/^;P%I)S
M-U\Z^!JQ+:A3!/.&&+KD3)!*Q&3=N8/9S_V>U46$('X>C O$V7AS0&_\KN%=
MA W16M-Z^%E<0VHJNW;.!5<N_7#XWP98<VT"(^"E>I,M9@,DWZUU08!8M/>
M POJ6<,W7TEX<K#$EJ9'LO+\MPH-?!VZP_46!TD"]T;)9PI<.F;Y+77Z-ZUR
M]H/]E#02GVYSW7LB]4+ON^V2Z0G1FL#92<]>_MZD?5*KX;)HJA)?8@]@[I@C
M6,B:0280_*&<V49WM>>4+]BGXL1N8'U6M]I]4;NC^D>((%L%<=O -\<G6>)Q
M63=O]C%(#H6'"Z"_'H"S+)#?&AF/-3F^'8TMX]XNY<!_.0<ALUZ -NU=B'Z-
MW^:*+N;'36S19?!WNUQ<_[=0&QR^NG>EL;G0>\\,:'M6VUQIRX:T_=]\#9'
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M&>]8),#YG<O<)$%<=W_I%](8/&+5!=+_5.QY5[R)7*O!]7MR+:!K 5T+Z%I
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MIDS[@6X(L!Y3+J*3?T"@W,L"5^ %J#04_A/3/G2PJYI]4,I_7]ENV7B$+0W
M -)YN%W4??R=BR"I[P^+2E:<$O S/E@Z&1M(]$9LM<7Y<?4[$YU2 3M_07U1
MM$/GI6@HOI).LZHYGQO?].M?N^T!WJ.$3=0CV\RB\(TFKQHO^Q^51@+LBN;O
M.? X&/Q* OXE8XKZI)0R%<0#GMN^4$D.9#!F,4.^%<;)56 MLR3-IF9C"6RC
MJ@(T%*C^QM@$M'DZ"?#8$UJI@"I=#H[.$5#/P_#J;!YR8CT+2PS0'+"*&'KO
M]2'3NN"7@J^YQ(@=YSUVDU 0Z!1?G2"%JWHCTS)786/1Q'"F9\+G"!_\17B
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MR'@_<3 Q2AFA<!Y1-2LY+V?/>\"A]XV4LA1_E:4@T&3?E _)C5;RO8UN8<4
MH\&^"G\-@+E'<N<E-%AXJGGR60ZS'#W[4[HO96I W"_FT[)!:M6'.+)][' "
M3W WF>W3R1->&4FR%\/[TYLN/+>+@LARXW$RR".?(JN7]PVU:LMBF![3V;/K
M95E_-\[Y[ ?J[SR529R']3?3IDA"::PFGK,J4;F/2OXLNU' >$M%&BC-[HE
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MB+)A1R6#2[7EA8++%O^JW]GL [=H&1/BW9@RT"QXLDS/_SN,^3\S)2F$P>R
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M6>9O*Q11#8E='4J9<DPY%6GWOLCWHI$0KEA[M29S Y0^PK4Q<[TI9!M:+]*
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M*D ,1]6PR@_E%'.5>MB'I! JD%D%[J;"Y;X7^E=^9CN0\GZ*SYES1"ID3,2
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M*MCVBQUABL2TBB#S]N27?_%V%0' \R 302NJ7SQ$\US1TH[S%T7;6@$'V]I
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M#^2;JMU.N(G#OMQ"V>>IF!K)[WWNI=9O[;9QL'.=LHUJ[(K=L2VC&, G/-8
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M;9WY\T^6"ZM./$YI"+='GB=""O#Q1M!9-1^A3:;^OB\Y$U&*'$&LLR/UET,
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MR*5GV08"]36,MX1RE]66-0!#])^+YUX6AN63+9&GC7^H.4 C4EZ%Z85H\)Z
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MY/R<4PZN$%/4MK7!,^2+A_17UI@7"+UKUXW;7P#<:_W/!PI1+M_P.'M=EJ0
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M"/'K-_>/F*;'+HJZS7C@!\G"U/UHA-J9/KA\9&*D-PM?CP>D-&'(WU@&82[
M+M7Q?"#*IWU1#3///U5Y*])13M!<,MUXP/V8 >6&G7DPO7C?4@4=CGHNKE$?
M>IS@ZQS6(]]O?4<.=IW/R/RHUPZXJOUI$T;?7#R]GL0,'J)3IE/X8K"<9NZ?
M;*KX6F!Z/'5=55@@AKZNK#EYS7?XWG1&693 .I7 MHU'<CTSL(.26]9:ZYEN
M2(U0#U(/$%ZRTO9#(]]K2F*5OP!<$  .F/\<-/[O!E[/'\^6>@T9QM.]$RE&
M>A Z9FXD 0\)=_5,T0/[2KN]<F@32*P,B*VJYA]0Q/"?AYY +_W^PN@F7?\O
MP..%?H&K;V\6$;:3?=L.7V6@<HH3JR2B/T/:_)C18D_5>Y9,,57=W:_ZV]LR
M'IB_I$Y[RIL$&#J0O OSTOG]5C_]W>##U2L1<9,=WN!9;C<_;?)I163T(\D(
MB:*0F>31;"CX\GZ*%!1#8(UA;-G\/Y%3[^X.XB3-Q4#O[R#FNTB)Z"HD]Q!\
MM%R*%,H7\],^;V&*V(\S-7#[A&]$)$W,T)9PZ&Z@^J[\X1WWQK7I:T.J=S$2
M48YTF-\U,,>$)2(NG9^:1'H<"CF19N(RBLM^L]X37IA<?70:(_YD*G"4'M]$
MY>6R$B9ZS>2;6I$ Q1/HWC1?%*H<%"K,&H.B]J?(W^^&=N5-XG#PFFXTN.'M
M.TZ05?_<;1+S1OS<FPO\0_#2O1+S[G;44P[P.U=AHWOI270J.2BO;JH2XGM%
M>,SWE_4T!7'?F!IRH+MX=85^;"N?A5(>*XA(2/QZ8 :XF8-[NM7)>,8 3X#*
M-3ZFVEZXIJ/T/<H)/335T)1\6$XH78HB^0'@@L[Q.VYD\G]M;&(#[23;6V5J
M\9_^^GGM!6#D(;KI2LJEX/'#JG$HX/0V-\1P6(BHM>AM60Y.VR9] ,#9WI+Z
MP>6\"R>00YCO,J8M=[ 4X9X?)'K2\^;A12RMSW$#::96LYJT,'HD]3??":3K
M$3CJ=WPSXS_G(1GR06P<QR-;PF9_6C7LF72^)AF)6PJFV#P5O]QM,GW@Z>'&
M?FE$"A*SQB,=F,1 .-__6DZ)$+_O$AVS?'-4Y5\%?@ZR5=S;WOO"#H>NY<:=
MA8>#D<6#=<<\RH%F_J#"J;_AL\!DVS1%6[P>7ERQ;(889;J];DD5./4+X>$=
MQ$0X^PV=ONFAVQ!SOU6 J+O>-L;T-O[4-PM0VTQ,P)O%NL#Z0[3]@3_P!_[
M'_@#?^ /_($_\ ?^G<@H<,E#ST]V^:/X[UH$N?_E+R/X W_@]P!-'DI<"AFF
M$L 83^F%&'-^$,Y__5(%3\GPI20F58KKOJ(LC?']G=U_E%AB[H]O3D.9"7O0
MIF/PE)CSS-?]-(/W90D 9O]\&73_#Q\N\J%F)%0I]U_) OX_+M]1I=1KH*)
M#7]']^X?^&\(:1<>"+GN OR+1L@ZF6I1!;X7OQNFJXIO(H8RUCG;+P!9Y]77
M0F2UD^BK4H4M]@C""785S<SRQ$-B\/.&>D$W">&1W $_#QPT[V\(YN:YX^/'
MELE :44RN>4!QNHT3A.<%9O);S]$#!MG$_CD0PUU-V"8D8S5J1J=!"#X7NLL
M\=7(>>S<C%(M;,%=7_W=IWPHF[MD_G]L?1T*+EH11O!T$-'?H_\2IA1L46Q+
M+;-IC6LJV[+]%FFE7*4>VY'K! )'FJ+R)AZS*H@J.XV%(*.C%^5;IC5US.8X
M=M!P6!<'JP3S"F>H90DT-.K_IWS7TE1 ST_0^NW5R-J_VVK#/_ '_C8(.5XW
MDC:^RL/YX:X'[1]7S\+L\^E'P-5+U;[3,XNZ&U%QSVVU=+#&N1HG G>0K"TB
M=&F%QU](+PM(CR0?Y*!#[!8)OFVAX_ :[PO4P$ \S%5?J2-F"$:>J;Z"=)*G
MRP/6$T&LVDI'N-U%7F:/&SK>0Y+UC?.3O';GJU4Y%;8\2V-@WM*J!6M\CF"1
M:\Q17N@"XLGI221];3:=M2!CA]N:;A2<+N!#DAADIL! U=Y3^O7@3'Y>^#XC
MQ5/M^9W@_T"8"?6>@-T+&0#'W\)P9+2S8T:Q+2QE:E9(2?J@\>![467JW 97
MTRAUMIT\[6!>""X]6Y)U,E^*-G:P@V>Y .RMWIZB"_.LT_PB$?TF].N*OZGO
MML_4X)T=OX5A>0BP88+PR%K&'LD%;,M83J6?=36<>./:1+_3>L34[4B+X2JW
MB]FEN^?ZQJE##)9-]-XG/HFL0U&4+%A^D)6EG:A(C4#G<\1<.8>3:R.8$;9&
M'D4X;R?.>:Y4(5CEK7_ZNII-V"9>:;MQ^9-RS(ON\D]%0MK+WV[%Y,C?/A"D
MGUO_<($@F1)5.!6N:+F#S%QD:W*N:S=;3N^(L,QK\9<6A\*PF2E@MJN;946S
MGD"E$XTX=":7*G6M,S?I/JD*38=T^KC)Y=X.?6W<"[3K/E^'G^R^CQ95050T
MV1/D%;IR.TYEA[0W>"=0OQ69%0I04NX3M:[5DA[D0EAM[^1>"-Q]X67XGMWG
M*B[9,R63H$>HK9]L%#6>?*QUM9U3VOI<P)?2P(!A6SC&@6(V1IH/!1A/*2I+
MAMQ+]5=_J_#P'_@#?RWT QF:G]I-3-@O5['UIQNQ6VKXZWF:Y ]EUHHV:66-
M>1B6:6<E]44=*H6ZHLTBV\./QSG&$+AVFQJSJ(Z#B%?3%T;^@L3?++RG6]Z@
MV^;CII/[04\JIGMF-&,_SRGQ@RRDF4E0ZRY5&7&EB9X]9R(LDO7@@]7=2XTG
M9\01A37-WKH?K5LJ01V05FG3I1?8R6"A*KOXDM7:%!K(&$(Y<84BE6;8LH*0
M)D+#IRI:<:%$ZYGBXZD3XVU6H9>)^OUJ(D^RXW5.K]HYN=)HY]90'SX !=DN
MAAJL58;5C/FK!9=&WSZ_K85TX8$R#+()2@)P_9CS6V-#_IUL[ '?XS_9QH9_
MBZ2IWVS4A^H8[>?]9+V-2U,4T O&VY)]L/QF0N#T148JR#9+_HY!H&:ME"?+
M9K[#_Z/A1GL86J<:V^YM=W2UO(7)26B#N],>MGF1PD:1R;E!SM<2E\'2W139
MIVX^A!FO*F092LU[!"LEGEPG,9OYS$ME^<V!!QP.&,@SJ#@66@N=P1XJ32 A
M4B&@^=7ER;'"N!NDXK0KXO4W4*)@Y<GHA/!Q9:PSUIY0%(/'3@?JZ@J-)(&.
M'K^=W4-9$M0JK#FJ6&%[9F[5YU3U!TJX2NE$FN-8M2&X;C<+87E)Q)8Q-E2I
MGY&9M(\(RO;L>(6TM):_GVO-[%0WFZ, R#Z=KD4RA'C*NP>;=$%?BU'4$,ON
MM.<?KQJ1]P3)X<HV"%IAJH'$-M5GD_PU&8_G(JI\PAQKRY<7B(NN"[Y<B6N+
MDU,UY :\7GR[_,S=1*=L3?N]7KLJ-CS0]UWL5JA!^"KR!LSC;@@#AW&,L#"[
MFLRG;Y3FRUJ#(8K IW(\R2U]^S^)LS^P-TP:7>N@;[,UA \+I@.PLBW0&BP/
MQ,,/'FX4GY:G"DI]!P$K?,#Z*;5%_AC=^[I.#G3-6I7H6!4'CV%[/I9<[B6*
M,8G0@XLW^()6(/?O\XTM&QYF$V0@;'<KCICOSV/(5@3'2.J1$[8S)TD[Z,^_
MRIHB..^Y!)9P_\D'Q,NZ#N7([@=DNUGL8QMLZ79VK/"5+U[#REEZBL1N*X2C
M75!'/9-.L[M#Z_Z?(H.A=&BJ*X^_<4Y/:TU+WM/Z%__9J7Y_,5@>=1=X-]RS
MFLR.TI4C26Q9QA-[ 7\-U"G%ML78U5E O9;3U=^]@8 G>2G*K+:W9FL0I:R
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MW!C4U=&1S()39FP:Y3$"DOOZ,9! V X?A*F6Y92Q:Z@>Y<11-<M+A0?W9XH
MJC<M5N"/^12-IVZ;$%$U[(MC)ULJ9):^;:BN]OSQ4V="*C^]NA >;_9O2JA_
M!UCD#94TY^]MY_\'/)O_#P -#$Q4,'L,8=R4"C%7FS(BT')5=P6Z9YOB2),+
M$EISH#X06NQ*=9C2'GJR+<]1M?^4HR!5:F:ZW>M&@O-8:@EX0C:]TZ]>Y!-8
MU>9,?6CL4UKXRH!T,]0D/K0!(^Y8T+T;.. -_P7 HK"?"H# DNL34P3$QAYK
M4-N38&CA^3G(<]-<E2Q4>^78;9J0T#N[H/NV@5JN:Q>.R+2#A/I\BE9:FK(3
M8MS!3HQ$J>.&-75L98L?;L@NG!\<+!7K?VX%9>E5190&A'SA=^$UT,IEKY*A
MS#@9[DYYJFS@1WBP:K>WOC5?Y#>T8OQ%[5Y':)/\M:O!PH.G0R7W[VGNO]R!
MJ-8Q4[* !]!7.0P'ZWJ!98&-";SX,5A?5VP&I.])2$3HH=+6L!)3S2.D4QS+
M1LH%<%-/7)#A)2]LO_X7@.SC-<ZL\3 0N1(OF5_C<+G'*=F#-:NHV_\23>4S
MWU!I,=J8>'#87V*X,G#0Y*$FQ<Q8)M!N3;GJNSY_K*H+NV)N;:YZ8W1&X656
M=0P)GFW7I:_T$LJ+&J.;=0(R,T@7]?FF0S=BCTGGPBQ^ 9Q-/)?G4DLAZBPT
M0XRACQKHG:_=MOI<,/P7:O:=.^?P&GP$(DIL6E5LX/Y5T<E6U-/%/>_)R>XM
M6FUYC?H4394'%L&PS=<@_^V/!WCVA\?D#C(+Z3[]Y[M68Q!%DPR=U,1!0]FK
M%<EOWRL61(6**_D'/QV!(1M&VAP;YB(+M?LUOE[E8A5*==.]VO%:RLTR:=L!
M%4.B5D7U[L2Z^^!^.1_@V'6TLG*FMXB;JW$!7#V#2OF]/>/J%HM@-\)B\N3!
M5=F$_1F'W-S%+7(%X^"""_,@<YJ/0VI$3B^=9>]3'P<__VK>3(W4'CI!<P'!
M!R5I%V;:_.S&?E5US:R%&.!3._-> ?LSW]T ><T!)L8VYTCA*/[1H 72#1V#
MD\D:2DAC3F++D.:JGAA7]PV)0NIG2%<<@PQV7.I+6:@@/-V.DDW]^8)HX=;8
M>X($=+0&X02M6;+G!/4I]3C_FC!28LX/QI9E(, Q9&'.0\^'V<%9$5K,J$J\
M.E:S^=$56%7 9FP+E[O]S\D>$$W=]VV*X3K0+#)9FEDMS7]U4/[-I(417( /
M/@^S17&7LR=NUA%DS$IFS\9E>_\IF<\Z"6K^5TK5\""<21-Y;05(]KPG9F,R
M #8,-[6ALE8I&H[ED-[78]3P!^&Y$:R$?RO;G5VUB.TO5U/'!3]F(SVRHN07
MVA6I:YQQ*HB;PJ1DX?34V=8Y-_:SYTP,PU5T]O@Z,03/>25 3G,+@I#'\XXP
M*B)S\O-BPUD]A1 \A=M,7N8K S.JPC (]U,%ULI0: --^1'V4)9>=71:I)WQ
M1*+;'"D43@+MQ&51&G<:[QWQ)STAU$MB=S>,I02E2:3,Q/1F=&SHB:AZ?D<V
MG^"ZJ'INIA)>7#/Y,1\7G<;E)V 9'O)A,9=N)\B$+>7E/>(1@5DH1<^%N=UT
M06F:AMG<C>MS&')L1(PW#S5V$ON,R-728BYZ_)](^&B1[_V0]<VW;U)Q;__I
M:07$#KVS.2^]&MQ(<T>?O.#V>.M)F%OQ;K?>BIYLFU@CE]KGIP<\@+<*FWJ\
M:%Z5=$*HA+GYT[:G_XLF>=L3@S,CP6P%RL/*-/2,IA=C+PQEVM=!$OPE,6<0
MV-[LI">-'0#7$/_P,Z9=E0^@ !4V%S@O-\$'A]!NC\-%DANEV1B1Q[Z\+4,E
M+>7N ACIO#8B<*V";QF9?I\QFD1I_&2_RN=<CJ_Q$\S] CS$$.YU7 (6B4UH
M<TW;7OT";!!,2Q[8DT<7ACQ7I&3+[5C 4)"&Y&MK+M]@-4=J@9*%^;/QFXOA
MPP*NQMH'Q,^H'A5''[[=2JOL:!5\4[\90!3A0_(TP7;,;3&P&?N!NPD%_J.$
M%\!*R\)ZD=*%,%V?6H?I&3M9S>K?S47WA\W]SP%-1/\7()Y4/'7C9N@70.4-
MW-^KWM6":;I=0D^H/?G06+ SG##FYV7;AO-W;-G+2L[+21]-]_*^RRK#-\^X
MXW:;>GX6B:<R\'#2FA:)=X36A^^@-[\M>(SKLQM3O]LP^SE17.D*MGEG5!2U
MX>MU03@163*&+YS8*NJ4XC>;W&^1D7(SJ[M#$9'GPVN<:!6WDKF-T))[G!<Z
MWXXMU7PKGA^;<WD$XYALJ<<40G;@L!]7CL.T6FM*9 E !M5_ SV/HGO,N=DD
M/>Z"KC( 6$!'KAB\A\IH*];:<.JZD_?_I'L@+'EGT>"+YION[6#*!%OI;('D
M;T<!M=4:U[@W.RQ8],]<]3LHH^>O])M(" K5\5A@RR%+3U&@_H:HPGI.1?'9
M/R=3;%JB,#I*%X<!UJ@=:#TYG!SUQHK?%RC%8?#%/*())[>,\MB7\ST[%=83
M7G7S<*>4!ZZP:1".( )]1E1*+'OP018:N&EC#'0K/<LM.C^5.A$83@O4BW@I
MRT?%(E4A+/NGQQHS]2^3")JBPD(T=4H(MO&<16.3&?E.G_WJV%:O&F145#GP
MZ_AP(3*4-57(0V@%H@&[.K&EWYK/B=@H;J,IDG97G?+PZL@281%=*+/S<S.2
M[F)>UXAY3^5H,$:-ON1+??"]REG[5(%=21[<56]!4@K[3%T.M5X=HS+Y;><4
M8'M>NT_W!4*M]JT4:I4PEI\1O4T8(?\+9A;ZL/SD#@("#H*0M" VTRS#&@39
MF4.E<^/M0NT:YZ$YVZ"HD8/LAH-W%91(Z)","C>(%*7/+[MYZ2'A-M7C%E2S
MAH/YL59 0(5P6[JZN?&YADD_U4IG*K]08?H/Y0 V.OF:33!/_2,:,Y&Y-X],
M"-ID)OR6SF!HK2T3N(Q PINIV?-7=]I+E=0!S>)S3J7[;\X.Q%/],O;S\J%J
MM@ @[L?CJ*"+,CMN&#NQZ!LD1JHK_>/!XO;.'HU<Q3;R(6.R&W?0=$%74 7S
M/E@=J0X(M_&9W/VD=Y:=&F.%W99V)[:Y=U4^PG4(#BOQR1_>EZ,G%;\\#]B)
M""@>5"H(8@T0Z"5.XRDU[R%4PE*6$M*_26)[^\[JL:PJV&*#B^A'A;G"+P#<
M3P:_<I!4#4(JVSO]K 7(P< A]>I?&L&_N6?0";2L@XB@*C.6J9J*C$'4TWFP
MKR1R)C7ZAHC(]W5Z/]8'OR%$YML=Z6.&R+?\=>4>JT2ITOMY+D2QOY(6[<Z%
MN\(68G1Y:)(O$8*Y1CD;4>SVF</G5/H+GNSDB4/:^!;OV\ZLOL1XM?1I4#%T
MX67OE-+3=4@,HE=TDC XJI$B%VWRKDW['+S@O;G9?B9I1;BSD)I@X/GLJSRS
M077"S]<6O5P$P?0.>'[(W@T*3WD]<J*B K$W< Z-ZJXXY)/NX#$PIAC;N/U
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M2P!TY%P??#4_-,W)FI+_A+MJ/[6AU*3->6KZ<' U4:MF%6_WN3$ZWLW\4Y"
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MPWG,YWJ-HE4W"D=.,I=Q>"4]1PFZ"D:_^HO:\)L:6:'FX>M<D/O6BWF[AQR
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M<UJZZKK:&6T26![8C56Y&GR^)6H.Y7:^Z%A$G.1XB(!]EF'U^^-_DJ\YG=@
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M@1K,">#>5@:E >B7ZF,DDBU4<M+NRU>NE\E.74/>=.%R6ES&E(LR1771*WI
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MQYJHW00G/0?]71(6^\V\]*V)?@)+ZL:6/L@; 9*1ITK*,01[FKP+?E[%M(A
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MQY&_II8COO>4+W0MXA"9'RMLYNY8@_XA 5PS]*RU\PI-KK]7^?*HON%B6,_
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MJ;KGB3(_;>8Y<7VMY_K;-[= [$;Z6S<_.=^M"<:C*IYG5SBQW",-<?O63$[
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MF9BF9R)+[ZDI<]G]!\4X0_+CA[<6WRYF[P!OT N-61'FIR1W@/J.WVSNW^\
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MW^T-8<PL*3XCR9"G>Z]9SX-D:,3;$\&)S_<,#[*0J_T1>@PSKJ3DN>>]KZN
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M'\<K^WR#L"$J/4!P'+R*@B20" KRH_D_F7GZ'W1S^W^'9?U]"G9XSN]YY%K
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MAG#'R2G)/P#]0J5%!P[9$Y/NF]/@JUNF?$#\!.@/0"AE?.L=CVJK\NAI?\?
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M!:G2:6N9&=6'921 %[C[[48H[ZX72ST87I])3A!U98S0RQDM-?VB-UF@89[
M]*QH5"V*W!FLZ2JA*3OY(K:(0T.#,P)T4CEI'PLB!Q2*JK9F%:TS\WS_+)&S
M:_=@VYN^&#BC5IA[#DSURN71>8;94'"Q0O)99'GB:B%W5SO[3:SF\I+W/8/;
MG]_)%>6_U0_FO#=UP%^JH-#&-+XVSS,V W,GFZ\1\)@XOCMHOXBW>?I87>4
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M.?X5L:E>X2Z(8?SUZ+I2P=0<QWBM<VN< ;+KU G8;5%-&^'2"9GZ<=$Q-_1
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M_=6FCY(99#KQKX?=Z3R>Y&?%_@THWX?H&CTG5Y1% 0;J1R=>>P,'%VPM"7K
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MY?AQN4G9G.? +24IK4]Y1(P O56I13K[2O4;3^=( ^[ATD6,7>W'M_IS6S/
MJJ HU"VF\:@W'4(&[\=(\>3>CGRRU-9::23;[V<$N0D92,"=Q=K]<RE(FK>L
MP]ECO)8]5EW+C<QM=+SU5J-!>:23(U;/G7UAS,N#I)S9]^N?\,6H;C<OIW/9
ME(E$#1)2:"[ /*(>[6BDUV030N+6]W;0/Y?T54QI#,?*FOR,@L$6Z+/,>Q=?
MQ:)8XRZO)L-]Z@Y@?!!:!V97,3*+C_ET1Q4@_LZ*BXKV. X,N]: #++#"9_7
M5,N_EV$GX"&Q?^G)=81=<RU$]U+(:S/DNQY_*8X=!W[2WQ'/V'Y6=*_?JP-9
MG!XA^&*DEH3B'ZA#Y\-VPJX>!#9N05#9D72[,#.=;;W<$GQ^]UENX!9"%AGI
M6K"EXXM6R'1K/FL2PJZ;/P88@+[A_+S"?TE0GV.[@CUEP.T>QM;EC4)4T<@W
MA51<:O$%FZC8"OJO:?BP?GT*+0I$2U)?=,/SVI[7Z ;76>NZ=/[#%]\?&I>K
MLT>^GEQ/DP]V+W/,K[31X')_49%DT6^&I(N@U/6P4Z9]^G"DCE'589+=NKJ+
M!ZI_F?G<SB#Q]7+UDWE+?P](6<&%[_;O0$5QV3%OI IRYY2T3@<Y<SHGUJE>
M1DO"S)1T1H/UMYL?U*7S]E&=82#"!\UP-R>]4U7Y)43Q+&EZ=C[%_'&^+I<T
M^M+$P,G M=+HE,:DF@J6VJ&V9-79D_39;6EZ>>T6_@6$.@X<266DT[_3O+WO
MKM=;U&T;(Q$DA3&2X"+ -?T0;'V(WMX8-7N31M+>--(2]!*&5Q-L,8?QV4YG
M>*@S^DJ.>KV0?%L&20NVB 77CTA;9^M;O7U;M>[D &(*^T1:5@U%%D@$2$B-
M%&%=-2NKBPEG%]H-8FR_?UGUG4R^2%ZGOPX[5I+ :ONYPVPYJ_SEWE28Q%22
M%S9Y0&G\!9IT5"KBW6V,;3?U1D_/9^_SE$;//T$!@).9Y KGJH=/!L / D!^
M-E*)[\'!#Q'Z^6\_]*Z+VP\GS0QA@[ "JA'TOJ/CH6Y,# G&\9X%"?(0>KH\
MC1 W]0>?IH"BD>-&\\&&!55*KW*0[()*]CO+258:WR=C%=V'NNY"%B[\7HJT
ME6B(!D#UHQ*_>8GD4V_+M_.)S/_WW,IB'PO@JJ+E2T7C(D>&3GJJ+04'^Z#)
MH9/?%LW;(Q4MM9!!N;"SNS_N:LHFU95XH[T]H!]<?C0 )S8=4R9RE)HAX\\A
MF:UUI6R\2=R@&&N?>F\W[;?D[T#?D(N]X7>%>2#;!",L0R1Q+P7DC7N%B\;C
M.HI>+/-)/R98Z8O&+GC#YU[_GO4/- V I'@_F03:CX,P*BF[N4@F?4A=16RI
M./5J)F3.'LX (S'2<RP%OQPIK(J-+;3%/_I*6^B&PMVIIM9TF4BG?: L,E+^
M:_D#&;K&07B5;DUOMT^"IGX@@;&-:-RGW65B5*L L;=*-KY%^2[/3#)8#_('
M<-_QPT"41 =R4[A1#3DU/BZB+%_AU0I3>?<@R!6)4]8G)F@T?C;!,2+PJ\XP
M, V&WT*'P"9*MK_'@_VA9"]3ZBNE;(]GVA=Y7!1IL61]C-8+3[X NS0DH@8T
MO*[2_'"&DVGSBYKR9_BGCU6X^GPN2NQDS=M@B@-$CG:>,> PLW:;S?.A"H*+
MTH'Q)]%"%=1?3BVX^C1(A)P^)=.$V!)IS'RN94H\!(^HL(THZ+FIQV9;LQ'D
M-C:A1A[L?S=O'&R[$>) @VVDKPS&;'LPY:QNVDIJN(OZ^_I6!I=?JS;0R=^\
MBE5?.+KHG^Z):$^LS6^WJQR84IS?]O5<$'+6JO+4QZ@1DCM,M\/S9GWJ::KK
M3=L'Z-33)MJ8F-7)>N'G71]S'4P,\.EM&][HF#E/I0105'D(':3QM15H>^8Y
MS:6>7G,8#W9\3;,)GDG]6=BA7#B+/ FNVZ[9GP%20])RQ;JT2[Y,G(O#2;HF
ME(/@1I"Q'I<.9/4H[M$,Q_?F=B6S0H[ZX&BD4E:[WR=?IGYDW;Y9D9_X3BU3
M94Y\(DQEC(]Q,T_T5DRI$4=[;KRP"T("8TS#SV#!,%D_V\$>F#+16-CQB)-6
MA;#)C]84*0OUN9CQ,NE:GAJS=0']MAMA<'F9ZYBJU.0[SO3A]J/"<F]A!8=8
MV!MDQ*'E"SAT?(;NTO</H,VF1FU1X9^$RBR=Z,K$7!S@/RR@]G_0R)%M,\+S
M<"']7O-&+YT*,:\H*AK(J0BWQY/(8(3*2@!+\N\-^4 3[Q)?-S:2LNUHYB;[
M32_.^4-*EP0C2_/\ZH3>=*TFY_;IV69'O_EPN?3";*XT@W2WM\#,OM$5VCU3
M#M]#+Y24Q3^)IO^WMKO68X&KVQ]F&JU?G?6?X1V.X#8:"5L('LF]]+^N9I[2
MZ&8P^QJO<,A;5Z>(ERY=^8Z/DD>"*!9>Z%[$&.>@P!-2_].7U!X\GO))+E>)
M'I^:>%OVAO\-NXEG43&3[50J.'?C,C8/^_7TNXLQW>^4J0.2%5I(U'QC.%B*
MP<$H?2$( KTV5S .1'RY^X0*0;1TC2_?5EU<R?=SC/(Z;Q"\W#.],)H7D^1N
MXG61H_QZ@1?]AS22>G37OZ6QOQZ]WN;_IJ>PC;78(G B;:C^#,A7*GW6[SDQ
MSZ@VQU,*6"49H'2=^M2Q06C@P(^><-YVZ1?;)JY)CTM\3Z8 $K/<]9,+A235
M5BI/?[4PM?)^%^HAP><A/I29B#['($-K0TT#P*.M8QOADYJP%V/:BN[_"=6I
M=1X0^P+@/ V3$S%"<HW<M\;TWKJ_6Z .6V;Y97&2LZBF^/R\2.E7Y:N!3Y,3
M.Q/ZO[9,;UE_\5<JBC!^#%A<KGQ7Q0=U8[WQV$ (C2?#W)6ZSB%)1D5MX3U=
MRV?@B89Z:RYQ"#3Z&]PU\@MB=3)Q;KK#=.0-T\TA%(,^W0,WQ_H ^CZ)EV3<
M'WHDP+^5,M]TE]2]](I:'\^6DR[#/P#7NC-M$0J$OB+ZX1;R&UR32U#/R"T;
MUOCQI+@1R&R[G3A/<JG)]AL\YBQ#1 \;>JM/04$0@!:/N6\K4%#78]Z@S\S'
M#]@DXMZ"*Y"0=.73@ZD:55MC08E7)KH$)*CA'*PF3UI[9RB?=3<(S+GR_;P_
MC<,K\373&%8MF[A>>O;B$>GO'KDEHN#KI*V_W6M7!1 ]8ML>NV;R>1SH<-*C
MO^G_T#:/,:CAC4!6;HPJ+^1#T*;;^5?ZFIHG)=%@:YI''(!;NB-T9$#1:E)M
M%'>!-NEY+XA2T>WG#&M:$GQK*U]^FYM36\MM<'V$@ZP%;;\53YXUZ3W1T[F/
M"L7&GN=T\&=:H (DRH9&S4<YYEK0>V^_?ZA28T1SF<F#$OS2SM-SDV)%^-R'
M7K"JD\3IZ[TF@9.M$%&V$S916P3+VP@L[RQ4;.V[18/7M:A-Z9L,J]WZ ^X?
M >(*NF-4+SM^/UUXH.6;;*5C  U+SFR*;E+H[C/@B5$]<9 @Z&6>:.*<N_=%
M*Y_=M1DSBW>F@\[IDRL!R[]\4&>JTED?=%2F3AT$?3U#3>P:6'7B? O#\O@(
M L#=P]7J=6=XC</*[QW!,B5Q"XJSN]<3T!K*^!'UZ'$,>G <N@.[TF=\ &>B
MPAOG/7T0*S5)6*)2]W'0]]0)"#4P$C] V+RE0+L90JR]H]Y>[']EWG[[HJRS
M@6%R"&UYXU'.<(Y/\N=QUM7[:-,4(+)4W-@KNE'E\-AMO.#TZ9:0VGR":']+
M<$N"LN&M?BM[7_2/%]\%MU0:2(-U)RRJ;CLVEW+I3Q;4SA9- [4,OOH53SF*
M8PL2S(^1&1Y^="U$]]=]5/C0W=Q%TYS5E@M"+:5VP8KH=XO2USH1;UR5N]5"
MYFH@ 2RP&.<=Q<$/UE6O!(M_%5>7?^J**@&9VNOQ]J<_AJ=HU"G_I+R'1XPX
M3>Q/D[LJX\G19*.\*%^8RY(ILA=,7Z,)*C;04K!7Z"Q$P?$.DAJ45A+]6NAM
M]>]P[G[: @*=8<4G__#4_I__U=1<40!=L8][]5&\)JBW5H]]\O%RE*$B/:B*
M*XM&EO-(Q/^HXVS]YZ3PG+)1]WJE@)7(;,7#9HC&RB# <D(XO5>YU]KP)$%G
MIB>^6@0F5\95KZ# W%/"*&DJ<=RC-%&.3BI%/BJU,PZ^_\%D,O]"R^0^W8N#
M?I_VS_?T")"J UX5#0:W%V$RDOO"%:+I4IC<>;-/JN]1Z#HYLAVP&R7I[*0>
MEM85/!)1+T'W99M'1$WOG_I(M\B$Y3]U%?/DN3QC<ED!F^O%@ONM+JU9FS!M
MU0AW7I>91B_M&B&$'./V<E^!L'%3<K[;3!UXZZ>R)M+\K"ORQ&1\U!(]<5=C
M4UYTK?8.UDX2:?]8'L#%673K^KN,AJ_3>U%MOEE7X.)H2D,QE9?-J\4#HDX&
M%7!GUSE>LZH\^FY0*"./Z+553: >0!SC@V4H=8Q+*K+]@L@FST6O5%%\."^O
M,Z,9'&EBB@W<Y(Y243)31=L$(>>!-P/ATP]I\)*UW[QM>#:1\](!GF7&/>_)
MDT[FIDZ<&*XG/>CB_=*2>-KIRDR=GFD89)RR68CN&-8\ 2I<S6)#UBO3U6BA
M9.E,44C.G&T .]WI'F$SB:<*^[M\GY^!I6TP[6Q"7 !C?J*?>)?V2)T-7$F=
MAY511"UZ@$/_I1 \%%C[1&<Y$2:2-!!*'2-V=!-9 9;$RR/DK82^C!VE^8^?
MVGS$*;8GIMF@+C?:'H7]T+;ND+7?SMO'6D!P@_Z'&5D56T+^L\OUS]P02HM\
MKWP5R;?//D6_I.O ^AAA&8<YB/.IZ=K*<6LELVWZ8=YX^J,_@+!$WO@2=^!>
M*WKE%]*V?"N!\5N+_0IG*C]/)A\T0W\4GXW1;?_*@@HX:U L4NL\TEMZ%F+=
MY'L?+9D18-/+JD%H_%FM45V(A,SO4>:*$5[T>_(D5"*0&!P9MX6@</XFU(RC
MH-@N-]Q._O'ITOH9[I3K3EG2?0W5CJ_#/61,S2[O?#PR*TTU!"KJ6#'#BKX\
M'&5KU?-+BM19CYX 5&0 60K:<,\;IO']]T*&&L%#M=._CF"YAP;E?P"^XA9_
M&_G?(D;U8RN-<3FYVGN/W,9@1LSOG0:O>C%6?P!>+C=!V,+6#;EW.MHWNQ(W
M59_;M5_9#IO9?RMWT8/Y9E+L?5CXFO@'4/_^791F!N'HXP,M]X5##N:1_!7;
MGSROM\^E]U&G;8<&D4T6J7\ \[%_ *I&TK0YM2W-K'[8PJOUPIW3QIZK)"VV
MOB*\?,IW,;*;DNTEN?F9A2%]"5EF\3\ _:+B<]NRW_83PA';SUOT3<E!J&VK
M0Z:"QDZ9BIB?GYC7]*P/DZLH?M4=,!5MORM%*G[,.X]G&2JJB1#BQKAMP4._
M<"+!(80-4)?+<=5AT7-A.UQ+?DU=QH@97R.>.CB7IUU140Q?RV4QU"BW?/K5
MO?+;?<;F)4L&<*:6A:FI=Y+OXQ!I!:<<NH#1!-?@GXY:"]J_%7V\L2#41EAG
M?FB[A*S*OH>[MJ+/AO=_1%QW="(^\2POBZ!XV\2H^Q23I*9+6YZPI6HLA!MD
M&6=^&G-6^*.& +/]C6_GM]W$@"!XY<CE]XI,/<4<M%+#( XC*0'RYK#@)LYW
M]I.UL2A$=TV$T7(^ 6T<XJ[).%1CA(C7]"JG5\+EV:UKS,=RV.C?X]_="FIM
M7?@\=N(BCHK_J3,4)XKQ6&6]T;<79XO8S[G1)_5R>7I$DJ8<-33YC581P^F#
MD\T]EKJEII$/5'A,_2D_YSVICB!I@S)-_M\@H!^905TU3IVLG6E_LF>\M*B@
M+H0^-R&!OG L =M[A[=:<U$/?L9+TQ:]T.SZ?(Q-E1; ABT_^@/XBMQ^5!%Z
MU2$'BKD6GOT#Z(7\PA1;/]S58I5%_ &$N!DRFCE=KR=)"V&Z%K:-;R[QA<S0
M:K,;W#O00Z5JK4OK;TD4@@F;_,\W^N6:T2'17RTU8O)]Y<)^D3%((?2:F:HV
MPZU(W"/?ZHOK:[<L5V2(Y27%CE$1X<KA;47OG4&NMCFU/V?+$EYP1F+(P5W2
M;DLI#YKZ;%U.\>8E\/P0KW/<0^Y5@S&PI$X]IW:]K*GK4!UL<3V-O72E_2N%
MGUV&<FS<9* )=>S@?<IM*'B3QSP7XI=6'JR8]QE)B)ZH&'-]YM;N!M5HTI!P
M=)FO:%\J-E_J%6JOK2@=<V*[%NB"NIB8_%BONX1JVC?7^=RYQ5E9&2#=[4S;
M[GW8.M3+PL/EZ01]@(=0N\]3/W>@4X;2P,SX=@8C,\#I55%F+3C[MEF22_N+
MU/&$%+?MXJ4E#8ZI\IQT;8Q>4L= )0=+X4,%Z$@UM35:HX%%):^T9_^^L^0H
MO49MJK=Z3+[[E6?X.N4 ..^#!HK[?!&6__S.*IZMI\TB][$MDYR7V9KLI E=
MP8R_397'#5?5/5_/:!&3FYZ5=)7AHI7'%L.Y=R<*\MEM D(?5QE5W@&'=.(T
M+0I"9Q:O]/Q\5.8UU^JIM,N5,+:Z/LFV3=Z8%+@[[,D^0=V[^_;T'R,SDJ;W
M!R&GHIR%MP>3VG54'865).0^Y*P687O3[PVK*$)^O*4.U0^[BWOCH^\Z WS4
M^4G#RHV>H;ASI$2Y0Y:N22% DJ?Y-LGW,7\A>AZK'<48IJ_**S@Q9QPWQ'05
M,Y.1(I/+P-)NWK4A?B"_KAI2W*!L5/AC )EUF(%=<#+L7J[C"8?D+[U^5P6[
M$]QP&Z<MZA>BM?Y$=IS#H&PPMNX4(SJ(D_]G.U8][O;'[U>Z6U+,^0 ?KG#1
M0W1#[59]P[M[ %XB<^\,]I/4<A'TU&'>>SA1OQF)2<6Z#"\4HI]5?*:DC>*Q
M [OU/Z2NS4$!GH\4SVT=F;*0$IF*SFB8\ 4,/'UYV&*9J&O8^J(V^C4!0P!X
MI(NXJ(#F9=H>,/++D;5._B.W*\VDM?<#$KAN7+PA":6D>0% 0%X-W@*ZK[!"
M!+3H\3=>2@[_=4&](;%<XNW5EF!WC'U837#4[SL^GN;E G26P$M/_F(\J?P2
M[7N$^,I,15)VKJ_.I=%^\F+/_;?OR#:'[.O9@!T51[9W]>/+)!!&?G56"8)*
MEB//7&+2:"%=&!_24"HKZFV\C./AG2K[$YP.\RDV!I[/%</?QW'7OB6S[;B;
MTU@"_Q28,AE?J9W!:J]=+@5^:ON]_8U\47FTAD_+1?)K\3MITDJN<[=*::QH
M&K:R-ZZ/IDX7]MIB#@1+O+[RA]T=F+[SMFKCP;97"H-9"5%Y0X._X!NZLR*K
MTI0FA"]]2^-*@^A9YJ.Y5PW/'UHRB1?:RCY*T4E4<\9U]YL.2_/1I%HFT/[$
MJXTZ+%6]!P7"U03S<9)W3JWV$'EPS7"G@I82%(C/3</X4V_@Z$BU%\^!>BW(
M8=8/1J8US]7GJ4KELB:]Q-R3UN%+B&J,B6M_.2'VPZ3"AF'<MLI06\(%0:0N
M?8F-6S3(_XLVWZ?I)O.P2Y.L'4A#XWBF+B':TF\.8WRW6JT\2AJJLG3R^WZO
M#/.>KKVA!;O.3'"__X$Z)CPB676_4_!AF:\GP^URLDZ-+PF2(Z/JEJME,>V9
MIN.&\,N[N-[C?630.39I8X?Y8?H$S!IOIYF872^YHB,\G;*E*"IH%C>2!F9M
MSQ.MI%*_._L^!'TBQVA2NDSD>Z?0A[$)$_^= 1;AC==[_)24T)(0$6VJ47?"
MX%WGUU@H)9IJ;M\1=:NQ49]0>ORV4FTLB, 5.2+]<,DU'CO"+S((V33'%+6M
M9JM4>\TS5%S+IM.PI1FL*=Y6H DB#\K'9R8TU.UP6+W^)_N01PFNJCWQ_C^L
M3/9_TDP._AMU[QG55-2M"P>1(AT%I*-T"*"4"$BQTGL)@0!1.B3T7E5 6J1(
ME]!["4FDA XJ':2WT*7W*E5 O?K><\YWRCO.]]W[_;CC_EAC[&2/[.RU]UIK
M/L]<<SX3N7/32<Q$O)MQ&$QM^4A:,UE!27-\J8//,_"2.RG^_2E_O*\LA@,^
M-F->HRR!D&BR+=]Q UF-!=XJ14<NB,(B8$2Y6SK%WX![=Q%3QZ(F(#:PTY0,
M3H5:3V8J4ZK0R\H2*8C-U_W7[!NR#LI,"9U"WYC)CK8@Q.R5:OU(P04DXAN5
M6>U$G7A QDFM,'*GB>Y\C*ENV-PE9(8UA*# %</RS&.*;E5E)%.OU8/YPC!Y
M.S/WOY1S\Z(IU'FFG?=&/KMK0DXL5!!+%PW!G,^3>(FHR. $DBPF PBID3%%
M[H9&[S^JK:HS0SZ>BQWU58!!R\_V*4Y<B&F/K?^G"@?/X84=V713\P7J)(Z]
M:*-KI"E/+\(%(Z+3R?CJKH5,,F+RZ@[Z07BO7S>.Q2""M#GB<X+SZ(-UO/R]
M=@8?F6_,DZ)-'<ENB69>_I!V\@<+2TV39^7;G:/68T8V:!8JB&I;"<[V(+FG
MKF)E'7DH../XAH Y9S*?^(!QQ<U7&,**$4H,D#RO_WVWBH%UO)5^GV\.V4TR
M T.<%[/CLDB?S!D6TOY*6$-KN/,<?H3^1O_"O)%8?,9L7)P^-K(7K*]P<WN)
ML5J"@;C0[E&[S(<#8'_FNPI;6?[T8+.X6P^L=JW]@;X_:#7';OJN^SQ%!.>E
MUGYH+HB=:H)WY8*(SUN4-_K-PAT\]+<US78VLSL,.&/'KV?QUKDLNPS47XVL
MC)PFT-@B'M2[Z]R47C<AW):8532/*JD_R7>I*W5W<3-[,H'W-+WEY\M M3!A
M84:U G%:,%4X8_L UH^32F!GG-KT%ZVK'<W7?!D,E>I.M+90@0?Y;YH8[SSY
MUU"$\."1T,>;?_I>K7M-WS9I3)IVM5,'?^U.XR<-\)_.E\<O?:!*EZ98#C3'
M?J5L ,:;78=VC)KMS;NA4G:@*L-,A%+7G!!9M&738&O#D2PX?GMXM\C$DDJH
ME)^_7$N)W\$A4K"P(.<?!DY52504($4!A0HR)^D//R8GX8@1Y0.XMLA'MJ0+
M<*#7=@W.H,%D$RUEAPJITXYF5O*0OA:)"H26X6$P*HW%,&:8/^M;<VPSXOD;
MF$D><3?C,JOC9:3L)BQW(=/<*"AVUK/D796,PR?_OF;?SH&#W WAESUN])W"
M:\U6IV&(R"[HVBX61CJY,BYE!0O])'%S;SQ%J[7A'C6\Y7E9M#^8ND<"+&!4
M&[39<2.,8D"L[S0 6%T7S=&:5M(@VF@3H?Y]YM$M+<=<S;>O0"_ AQE9)B_N
M'Y^@%<!Z:HSRT&[S R6_V%(FB4G,]IP#CD_6\<AD^JW%;I7Q5X]N%-XT[1<;
M+[SB)V+STXT'3K<V7SPX][X/4CW_)7RAT_KNG>&%T7L%"N=U S5E.,LZ_5W>
M<6FK4@:\W&I-3#V6TG ,M=MM!/)H?Y@HWP&N PT*=6KX8-7''_+DT=5#'S_A
M/2DK)9X=7,7ZH0O\XH)-_9FR,)X%L2<Q4C-C(]I?GP:QM>[TLG1XI31<%R=*
MXDJ&3\^4Z[TA@U>9'R)5@(FR<RY*X:829:$RQSA&0N+E(SU@]$O"4"VBX:8"
MNJW)R_;5[ Z9?V^U<XQ0HZ1BYZ8SM]0^OCDI=RP+'VSA.K%?G752]W2V4XZ0
MZ'.# Z7&&;7HPB#RA=MVK9F4Q<B0BCKPK+B?+V;2AA> &&M26%*=9S3A0AUO
M3.BKL"^,RL&%FVX[/ PI  ?W>[(8"]GGH0!_ U3^&6&9A@K+VM!CM0"VV[=;
M)\:_^W7X?HOT"L_R9FLD6"Q3OT!4 KUP]UI>2SRU)]+\P;)O^I _@U!+V45:
MWQC8E!NT/=[$5ERJ.HO,,I3+Y$Q<[+:L)5J^'K]IAHOU%%R*\+0G&X*4YNTJ
M_8&-S*8_)C!=<%:CZR?RK//;.V=9)CN(7*-;S^J\L%:0FH @I6Z.;8A:_1RS
M/J*KO2L%HN*E ([YR6:,H S3U[Z!,Q_&\S77:G*ZP7C<:'@A>N;9;[T\V(,Y
MZAB'PW!!+#%0;X7G)\4TR;!Y+]3]SV,G&_FHUF$U#<VGPTH,5(6OG06BPN4@
MR;[YRO;F*Y2PUL_TR'7\KJASCD4M/\JZQ^S'KPN>:N3J/D,^ZCB.;K-HPHC-
M%1@\INL77E.TUV>3FTFE;+),/-$2?$"*NCD@T"7#N(AR?#G;E0V]N/<EH8LS
M];9V2$UY\XA#H(I]/CQ879@+WQ6;E[CK=H%<KAAW[P<U@#T"F#F4;+98C^GN
M_@AW4Q5SY:)/)]4.@(3WW+E->X+3/)RH$2L(PG3X:;ZMCD8TO#49U.^;JLA@
MZGAX*O&Y!BBIX2YV?PY8DF;YX/EAAB&XP;H#R-@$NI=<^OS1-.-Q;<3:D8CE
M!<6/=RHRXU9=9^C->Y3B#_2"2%Z>/$ ^]!=D8.T;0@<&[YH%0$+.OP\I >]S
M;'_;(WUIL0L3/62=#1/@V,X+/8N&;V ]?A$U"Y5Q)W8B-C18Y+L-+R%]\PSO
M9[:0<[*X/'DY5X$J@ZQQWV1,3SXP'YZ*9X (?0S%6)XCOPV,%G*.5QK?@W9.
MX)DMJ[TL'^HQ[%%O!*XO:=QU\%V)+?J8>=5]^L>>0H?GS:13MXT?^&LFWB?2
M"I!BC=9Y4-O,DY7P@"P7)/(@AGM%B+29J>WSD5F.%=<FA/^ KUWCNPJ2+RJ\
M#QZ]F\O84FM_T,JJ/U(9T\MPX-;O[7\OW!0<8Q,0?Y/SB\3K3+<4SEL-R$4-
M'(" L5>6 THIWZ$#9K6(XH*3-6ZP77:;OK[NH/O>1E([8#^0=I2QUJYHRCCN
MV-0X3[$L_U$V-'I+]P(9Z#/\29GQB_!H=OO QLA;10;3/!26V=5AG.3=/P,N
M8.?JKVQ#KT8=J K.K%FN+L;+A(HF2K0$\F4Y()]/1SI'',HMDMQYO'MK:W2X
MZV1S$^;MPJVMXVE8C-VI \#N+>)#8;NE8Z*C/[GIC]XH7OP&1/X"?POK^)J>
MX+C8O@BNSXF3+[V3I>&PG'5;B->1Q=@;Q,&XY>S7R%F?MU6QS>IN5D3\<XKN
M-:51C)]B,$8M[UN4,I2LM3<K?RP >0(T+;GG-!'@9Z0ZDR^$NW7KR4A*NN1D
M&P1LA5T9TU/RX+C[OQOB4ESZ&]"5E*U>KSLG=@GAS$N<1'BTX\O?=0UBE)R[
MKN&;M"SU5].9UZHPEI\9OW]H%I8*8'#I?7>ZH0U4%OQ<-B0&0 ^+^E79&>I9
M*DPNH-)\XI:DVAGOLQLICFC8&B"MH]P/?P/HT6[PO;?$)KN:"D!_X^FQ^>@!
MP[NBP^-0.%J,F ZHQ0MA(0.MSR-RN^'#501-$6+6LP._RNQ&W2/T0H97U-00
M4'C4.'SAC1G%F#*$19\<YWQ+'Z)"_,XT]@\P!T<^%A+_@]-NIOR+I+Y@X9\/
M2 ,M7J)!AC?"LORJ!-FR5,@VW1W6CJS=5:O0#K_)ILY,$N<<M;)J"+Q;3QL1
M,2XOP'"9I@PLE]V#2Y_A,K*<(CW6WGU$:7XW?]:J<XLC9T+GBF?4I7,4-LBK
M)[,*CZ[Y2)49^AUG%'?3TM#/1 PE_WVT[14T'#Z$9*QQI'(S9^Q[>54&5%Q6
MS2C^4*)E6P$Z='=VW/Z"9TWE"3?#.RCQ678FM%Z:D&.87Q1IR:HD<SUAF4.I
MCM^'HYG6+O-!A0@KD1U%?2"(3,#:?DL072/!C+(#4!$,"C<6#>4H7J46D -L
M63 KNJ$ RV9',?IG\_'+5N)8EQ2Y&^P:K L4"4@]&%+EPU2;;]8=6U&S*';4
M;J#F)TD(6ZQ6X(0"M/0DS;E:M[^ZM<FP79]QJ0[K8SQ\,+O&UH+?3!E<>\PV
MW833D'-6\O?^H%9EL O[9:IH;_RC:2);5"-E(R>90Y6A*XN7Y8BI6;+;Z>XQ
MP5/OB'4PVRCVCNOG"=)\W-YUH9QE7&RA$OPK]#AEGPUP&[1^V^BSF21-,L[+
MA[=/S<K$PWI=BDL2V?G3$BI*U?@&@'$AFTD=?[]4B55699SVE?@<E6!>S6'B
MZ5?&,\*M%5]R6BIX?*'WY.0?HUS%ZC@O48IHK07H8+1[4.SLT,(^(1_%R+Q@
MV_#IIG%!2O2E7X??B$G/:6:)7S\@@ 2_ J$/838<7SM%A76BMBJ=.SQ/83RQ
MYF4Z4D1#2"B2Y6TO.4@40/I7%.R:GH82@(_Y[P#Z<,@;2I4SEJ1+JM49YN*J
M)HY;-8%P4H98N@*PV.B)>(S,3H^KYL+*>< M3OS UCSYI52;LQNL'E4<9%LK
MJ"V;5\3?&-?05Z:G_9!3YW;8*#$_MFVQ;HR@X6;!2Z-*QF@L21Q"CN/$RC%E
M9L3QNV68IRDK,/'^HH=85B,?+3#\_'7L@I4EH!\AE:&)G=[L)6B' &ZD39*B
M1S!TL*C ;<\2F$^KG ]Y)R>H7[+L6_7H4B_)IJX<H](!='Y+RIB]I* E*LU-
M?PY)WV)]6U7_(Q8X^V457[QOZ'_KX?B=70]3L\,;C=Y?L$ZXM?B07 &0D7F?
M'^C3H@(C#J>\VMT?<#-?/=HYGEX[?VQXN GD5GK'9RY4&;UX8_>&C1%W<[K*
MJ$55E>&D!%FA2</'D$V*),8.*H_HFJ$]W^?+N4<!4VJW+)*0=N\1XX$JBX\;
M"V)\3W&/ZJONJX+#97'PMXM0:94THYM%.WV3[?%TX$C,G&0[A$DLIX*[JJE)
MW^_E1$(N"U!*$UZWXW\6T:2?6E;* T!@U?)M9MF0/[X/[)G*$@/I@)C0SAC&
MDJ?:;C!EGGL)R0O^4FZE:-7C[4SU^3E*%M)7^#XX3 HY98H0ZFKV:\$M.>RI
M3:_08CPVSB"CCB3I(/'/)>C^5!&#E'@5\_+S$=//W1&X0O=W+CXE9D&==^,*
MO1INA_ W"'^G'6B^I7Z0V8PLM;X>!W=O;TU8?:,<7;3/$WWP*?0&D+?L->OQ
M)9"W.I*[A+DT/T3&\+JNN#XD6[^\3*X*2Z=G]'1DQ#*E4N1O^NG_34Q>,T5<
MQ(;VF<X?!ES5.<TCTK@, [ZQ$5954 HB*=O<#'!<>*,-[+Q2RE/,=AT,K48=
M53"4_XCO-V+RD;W8OA+"-I=OWG!)!74;UAQ)W1)Y-P:1YUW:L[EMY['QSC2L
M+MA$V[=T.^3 )?+Y8>2*BS.BR8@F-^(9#"];VKFQ$XT-RT,*]_Z-J)"X>BQ9
MJ'&,HQX+%TO?ANUBQ'8?Z.W"N##*-P^"M\UD\!6#QGW8["_],4I_WCCK1A.W
M6PENHMXA4+57+HL ]R"_,!R'=J^17(!1)Q-=\'^V(\EN%_T;,)Y=Z,?^&[#-
MM0VK7WYT8K<)4WETT75!2$>>QT(;XW'SC-N<9+\!<88X@1=-P EYVM\ 3K0&
M]6&8Z-=Y\8C ZY>0.#,JS>7YYL'V^WXUCD'H=B_!/I]*6O\F_8GE<KRP%\[P
M/,CM5V29EI_E :+F /P;D,BMDE54V=8[RI]>'9O=E5)DS/AF%Z8AO.O-&=Z\
M;5)I.B=?ZXI?G,YX!3[NV1C'"C_P$:Z<6!599MQL(:YK)_* V9BGANY/D(%M
MNT#)9 [Q6M,J'TM[0S7 %BTU]H8_>D8GLD]G7'[L9&?ZIZJ8]VR4*,XX_08H
M)![E[]9\.YIZ]% LPMU?F+9FYO6@]=7&I5/MU:G.P+N<>@5&LAFG3^N5KSR#
M:F9^!0BL*PV992%#_^5'BE,N_[A(WH:8CM)SL;O."4)7#DO/%9@-B,;T,H;_
MWST*%N<IY]/&%08#0-=C[.U.@G&55[^=D=$[?N?N(RVC7>S>UXI^W6)))DLM
M\L9(SJ*F\+V!!WO<(?Y48R&W%>@(5CF^FO,DMNRL6SP'\O  H\.V7O75,J<L
MO5.'U^MIQ:(9NR/<"$+J%]?8.C2]KS;Y3VIH:S?.<I"#U6O4LQ;N.^(2IV$$
MVM4[][_^BQ$=O^F]^1L@0OA>9JPC?GFK33FB1%I#NC3W8"!O]^CQYR#@G-$T
M"3/]O57M[U9<W_M?"^-#S;MV(!Z=/ ?)P\2>6C^,DFM#T@Y;)'] T'X./SNN
M2B;SSU56C3X.*PFK'I4TW:!94"> \^W%'>H$Q4W357(*,3SJXCY*@KP,>DKP
M?ZM5^R\>A[_50*ZQXKP;E^[X@T,U>5QE"\BBSR=ZKLX<V2$<Q:V4'..[,,'A
MB:6I;QSH;JQ33&8/+&,"Y&*ERLITE,YD] P6OXCQ<^91?7<$LX;T17I,8WQM
M?^R>N!;&$I67#-:7+^?NE?@ '$Y4M.MNM19PCOLWTKPL+,A[0R%DGW.]\-]E
MR@O]^8)<S.*6LF'L^!(7_16H?B7-H#"@8M/L$U*JL*DB<;6'.UAR5<X(@0A7
M7LZ Z!3#FM-%XK.*2GVK5((43SX($8-(LSUYP<KRR%[UKDP8C=C&V3T:^/TM
MJ+^2)'6[(>NWB-8UU=L*YSC9$:]ZJ<NP.YEYS0(:AYK20]>3L*K[8":$.MRM
M2I9+8FVJM_(]"6V@L06Z<-RB.ED#C0/]F<GQ=HBA88D<G"?OJ,H8WN,B(S=J
M>NQK>A&5,OR=[/MEV?X;807(C1GK;>C(XDXG'#7%U6R@W?&2'"A=WR\S_WR>
MLU8 $D<<,WX<%[XT99NM?OCZ^B:UFQM[80"A:?.C'U.O^#0^MBN(>>HV+8 @
MA_GFI_>1M,9YG2Z7ET!6/I=69$.:5U >^P%8Q>\M+;&GB(>NE-'@'4C;><?]
M1%$;!P\AU!EITQB&9TY?#\W%(H1N(_&#!?RS1] +WC??< K;JOP%&E4JA>WN
MH9LZ)2]E8UXEB_KD)^?RL;W_">QILG-JV#Q?:K;_7M1TV3&17MLBS%_-KL-=
M7R7<\=ZSL++))JC<'Z+B8K=.IB],=C"Z9Z>+&/2LCPU3U!><XMLWRL\R?8$2
M.31.%#DU8!1V!3X=^6%^O]VVGC7S@7.&;6S5LT/#PSJ3=.+Y9@'-<8O&*->%
M#$C8[/V!8T=+W$:+J).B:_F5'0=B*/=%NK('.*Q&81G#.+#QZNX[O3#MP\1]
M<_*[X4H^/!E>#$G5_WP?=>0C?F:_:D:<##63W'H7M)XE/%;G2?I&)M/Y$(N]
M(=#\TBR:XA-PWUU+KW'S,?UF3\-*$&*ZZ2[-S',9'/MPJM?D!:'^'"9O7'J:
M0_/>D_$=3J5EKB6Y*@LH9ZAU(#V2.&E_T.S= SOIE",H5OZ,71%SE33/^IA]
M*.ZV;[:Z]W[T:_.3?C_\<M^.UVAR?*&+:RI]K,,WAX0O;5U9^,AP<]G6CSS;
MT.&!U/C@>-2R;K* !Z(TO_%@$*E9'J]Z1<@SG>7MIL@@!)MVGDK^Z-5AG#M_
MW7$].68 .)8;J6\D"]=W4^!/ IN:)M5%TTVAGS8,N-G_W672ZPX>"]5G=18D
MCCR\%Y&R)NUEACK,IK.OA&I./05NUD99FQ<0P\P/R325J'KS"QVTMFST['T3
MZFJ3Z,=8]XY?,.FX.,>C/;'7]B2<C6DZRXUG/V0(@>;  1&BL@%=9;AHL<C+
MSM1?-[=Q!F;/;P=\7JOFOAL!7=6M;\R,36LR\6QC :5YH6=G$^NRX"&[9!C5
MD3R<'K0S0=)+^X6YK;<C09;BVCIH>%L?6'_MHY%$N2IVBT[Y5HG:"KGR\;9>
M3ZE6[===@_T?KO#$F*.7AI:E'< PH9K^?>KGMF-Y I>M+:D'NY]2K6YSA/F^
M#JY60?FN"OJ"CIG2;R<[L"[GX+@UC^]6N".AZ@F==;WT,*=#8DU)TP0TZKBA
M9T)JM3DX*?H0:I J@GT^/AZ79I$TN26GPPS:R:(Y9 <ZEGP'O,)W^*9_J7SF
M?9275;]4W^TL5MWSI@U [2-G&-53SG+<]#"S*9+<3>U!J<O-U0S:SJ8'@YU5
M[6_8#]4"EH'OWDY+&@>9HP(\_6'U2Y-.BRYB>MD8OW#<TB6ZUMJ(E[4[P;3Y
MR1]6OH:OSJ;4\N!.>3:(1Y KLZ7UZJ=T4%*R92J[>B<FPE(7?P/(.NEAS[]@
M'M'ZPN1XJ7H?"<]\&KL[BAD@9V9,5O])7_A0P817UV3ST$E.&0@T($B=Y[O,
MBRFYMMPY#*VJY'D%_O)MBW!;KL6;Y0PK9"C'0UPW+F_!KCUO@%PO.CQ92F",
M!4:][QY0>X^RC@;[KU6<QJ3D>-LMD2QH&__R$HUK?Y><1!9(=4% F<U^Y 7?
M B:^G\18N=O&'_\*7D8'%.KQM@G,-[[3TI]?)5(A QVV9)?KV"Y$L<7Y'W.0
M+8G47.I-'FXAGM(6$H=O:N-DAP+]J!=T1\1TFGU24@_-E2GJ9',H/?7M%(3L
M_ZF<6;^\2>YKF_F?>20=!>O N 7G[5]</^'KB"F<R,*GZH3I1>+VY>O^ 7'^
MWW==GM8/.ZMW4W[N.G,/_G*J&-X<R,^GY:[AT=-A,<LEY2U1-A=>[%>DM3:M
M.9RU7.)2L@\6Q$XD&MEQ.\GEC\D_6C(&)7W/(,>.V>0/4BE KH#>3=!Y/R=G
MGK\N$J=Z8V_0U@5G.:H3E2I\K5O1A(ZKX=LZZKNXKXOMC_R*K44WSF'WKQ[J
M2$$LS\?_%0T8AVTU=?\172(M'AZ&+1=_P/(5.)\MOD'\!X1=E)-L^LE2L[>Q
M$;B-:H+D5TBE==X13/'1M2U%7XY)1_6X1I[H,/B.)4XMMY]^0*:$NB ^ZPDN
M"QV.YECRUT7?<.SB4Z56Z3V5<NF"+R=!_=/YL]IF4%&Q0AIC$B#!'.<V/D>*
M@;JD$EY.>!_N2_G7!&V$OUM%1AKDTC+ (?@FG20L=]'\\;PQ4+P'Q]YDD'%)
M*#GG^O7DZPNU%*WYKC2DN?9 ]/"D/J3&]1] P395:OY8E[A2;NR>%[L=29@U
MPK_5Y.GL G)A#S2#KK\1E<Y2ZEY1+B0+S$*S;PH\%>KXO(48D,*XV_,;IL6!
MAN#^0QJN>O7<16 &J[Z>#';MJ+WEQZ\L3%C#L;GJN6MUP^6S&D)L XIX6UFH
M08HLCI8%59WQ\DF>G5^L6C$%CN5SZ3-(OV%2T3X_\9$FW&R4HPQ\070+52AI
MAZS<K5L ?S7G6[L;N=1X_]P_.3/OS=>/H[ MM_=NJ-U=*;1U#24O7*>NV'AS
MTSE_=:WZOO@+TY!683J"JXIXJ2\,F* I'GQ<_N! :> JQ T6*5/8[R(/DMT:
M'J4"J]JG]6RV,",<_?(?03<L/X;<N?^&M1:E7J(?+:4Z4.@P-A<#N'<-::8'
M32-U\- JL,*[VQ,C#^7K/D03A&G4,#@&,V+_QPK;UQ5) CMEY]&*M??,JO7N
M,;*IDAC4-9*[4C]/D,S"^P9>WT(WQTE*+;$:\R_A;3&9O5WW^1L1]VY]H:[,
M);X#(;YYAHY'GAY,VCPQX:*-6X*?K'K&8O?;0QPC!Q238\1RO7BL52?+X"$%
MV,163-J2\)6F45U:RU&B;KT 1A7.7^!:WVM:V12J(%P^)SQS:+BVX8#ZW)\6
M\I&_<9!B^\%A>_Q[8@B1S&QGI !J*O1NA[M1N[!SU[2U;&"9TIC]69V=VI#$
MQU(/V!\\G)EO$PL!;:1(._C1V8#P#\ORAD[*AI,%;*']H@^2C(JX1]VT"W*H
M?EKXF-P_Q<F'>-9,1'P@G244SBNM/X5,UYF;MB56=QIW21'YF"),TPU$U'."
MI^O2$5,W]\/O$$,E@HJ&J3RL8Y/CA5Y("]ZW)QZ3HGYB$TGJ/#Y\K<":]3L;
MY==WEN16R"VIWP &80L; 2FB&3U#$;P,#C )__GO9 U4[0']+ 5;\.;^'>](
MDTFWIXVWO$78_4<YC9>Y))%+)Z_99DP3RF8)C"7GTPY1]*JO'VZ$,Q5$"T2]
MU3%N&!,9H^O0\B#X3+1G-B)Z!0Y)<X%V :^\:$\QVUX>/P@JIW8/SV+5/]0I
MB/C+$TK>9K8QM(\M\U(ACS[5SGV"/,I4E&M\XU$WX7*W8$#-L'CR-(9IC7_:
MAR*[G;6LS7J1*P,2;[+MX[U'<Q2'@382"AN>EK<3E*BJIGK$(IYV*DOMWGID
MT)2RY2W2?F3BQ%6"+@CG'64APGEU\-E4K O5G$BV#+:  5Z@;462X?:[-C;;
M,"\[LC3/-S1+S9_:O/,X%"5CQU=L)59CXC=?0B0=9X"Q),3<F?/(0QU#G->U
MV:?@<'=@WY7!XJF:1F=3 *24$Z_^JT,L]R6$EV!TBVYCX"=-H!*)T8,M7[EV
M<"1/X?U"KRSN8:V,L) #+0_>EPN$\9$,>(>ZP." Q-MZ$Z(74.3SW@5P@M!;
M _B2YH!O=,3+;5C8 HZR')G87<_AA^6[5I ;A_$?##DACT%UTH*6U^B3[NYE
M9=&HZU<]/!>UJ%6B+V$^+JVTWR(JP)$%#1J+JT#-](>NV:9$_PN/$_RSD#X<
M(B[Y7UA[_T\V8/JA=FSJ1#&<>A*;D,9K^5PX8*Q7OK<5OM4UZ)^<;S+79/T2
MK)B\"1,_.)W,6KS9-/7%:%J9'"=<SLYG%:NW:M/_X$)#(TFPG8I0??X:K/%5
M9E36$?(V-!:!.\AJ<,)>ZYYD+.(L!E:)990/6N>A3<Q%YQJZBV71H$V,=LY?
MVPI\D?&L2-5C -@.4GM+L+XDE/JV_+3")\@?(;_?,/4L#]H>[%#?ZP+9E4QO
M-'&'X1F[,!XY;N9=(2+,\R)OW8SU(0F2(8T*ZCWJ,R6*R;;QAL)OA! $%?M_
M@L")NGW;:?E:DE=N_0:4O_[SFF.*R-_Z([^;Q)K'-?O5X2)7T?6L/Q=AN(6X
M\Q/H]^3+UF:[+\!?X44I;,L4IIE!QY:F EP[A(CSD-F.H+M=AY!&=4E*6CV8
MRK*<#M_4X1A!65@ZIE\80R/9#+>_34U3?%N&I;QF6Z<VJ>UAW18P1&Q@_>'L
M!<6\==UH1)_B&K7O.M(Q,/V'-?/*^,P+)BTJ.?D!\6WCZ9HB%W<-:]06QD@R
MJGRM(#IQ(IM]Y+E[+&13[R2OGDJC#=)"?&WU\*3PUV3+;T!VZM56&,./;+>Y
MU-^ FGN?UE=_ QX^^M>#7"7VP3KS_Y]GP!.X\4HQ]E^@['^<R>0K1HI9$@>6
MOV:=K#GL2HW90;SMR>?'&*%8TU5*9ZZ>U^@24XR$=J5(6C$NFQ2K\"B_,D .
M6Q:] UL'='R*Q#B+5\<-X+J"&#*9(2%*:/.VF(3Q<WF#(!9 ]^N'TS(MJV5=
M#4 T#;G4UO=^8*<CMB4P Y+KX%_-&DT4'PP:IJC(ZHQ'V<8PZ$%3_IGF'$_0
MZ#%.Y! _L,QMVZSV:SD(V!EH(?[P+3KKI#_*.RH9DMO+.6[9094:?X>K7?B3
M&_2"BEMC3.!R?%W)/*/'/&LX=[K@H2.OX,#T6%F#ZXP%W2D:O--APH'^&W<4
M_=]-IF>/-Y_D>.:0_",LGE]H+.E-<6DGSO9S[/CBKWN4).O$[(1Z.-?AUC?U
M@T\<Q*>5*A@M)4\S:6'C_C5^A5*K?LRW]%'4X/ :VV?^!LI&I]/&) ^8_):,
M8<5L?O^MX2:^TJA=0Z:U1OJS)SCF@Y:<TUJA6^Q4A(]03?Y@507T>*&BM>O
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MF:"G#_3?#>+]LJ->,0&!/<QG2V\4@[B@S0CWTQT.XT,HY]V#G8OGF,C)-T%
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MT$W&W*]DPO1$E5>1CM9_>Y*TIO_KXKVOIWI;FIFVX#M=<GC5=ZU7WLBN3.;
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MN3<9CY%^.V;JF1"Z',^XI(X0#._/G^H?M.%9HM92!LO@GCD:*U#RIXE,T$B
MR+GIM0NY2I:GV@EI0D/F>2PF79CUO?6>'Z5Y=:G]+^A;2$\#),[U[FC!W,L1
M.4<7N:\1T6Z<^QGK ZO-YPIY,^2'X.&W#O/ AS5A)\#E+#NY1YU"@WD_%;PX
M@@(VVTHTED.E9%6R*R_6%D@K<7R^5%.M(^$:E@L^T== >RG0+GVO5VO9D6C!
M07N+NZ\,(H$M-M#+!*%^\C15UT5MF_IGY94EDPS[BE@OG^GN;@2>6Q*5IRN6
M4*O R;A6NE:26J<#;$P>FQ-L Y7NXH*)V@J5QFT.K+;1GDW\\]C5$^T7N=PW
M_%!+V, X.F-;Q)AD4_+SE,>'T5+3M.*?)/"C[B&.]GS D"VHT$5'=$FA)H)Q
M$.SPY 9_L@VG\,TJ?L8_@.!%OW0V(N%E1&GCB]O&$55N22W)H(!:$H,[:*]3
M<A'"1G7DG"*)#,TFA&>JFSZIAY2_BB6<(O]GEU?4#_&HK1=;6K^_6<]"1MH^
MO\F/FO>QT'!_.OG4\+1_1;:J]O+7Q;IG^CQZ'R2O1B>^OZUG>'YT7BRR8HC@
M#-[ARS81UYM,@?;M2^5F,3(.\O!'ES#RZX166U9:3;1 1D,#N^]!QW%LNQ$9
MO!ZA= [Q=1;3+44DQSB..DYU/>F86\'@-*=#[6$:'=Z[@O?Q1= DOG'C.#<U
M%0E52.>UHE;/_N RB=#)!(9.HS."QKP4>.5+N@BPHYMY7O\(9T81L!0I*.W!
M$.&2PNNN<*M"HEA>*7Y=467 4RI/X!L<$]W.4F8;8!>$?OV0.<YBAC1V3EY]
M=)DMD'%$GL.28S0_ZQ%S[!RE.#B-293=A/M;HB;-R]%DRW;H]S8*<#(KB;RS
MJ6.75O6-H:>3*A3B<R?D9-WEL4&M5F8>PK-O"GFR1%"J9IOL7[LB]'*S,=S5
M]T<QI=(CF8/+7TUQ!8Z&;(NZ,\M:_BN,D%1/OODR!;.P^<J54))R(6OC:P!"
M#&KX6,A0JB<^8124D^2.PR2>L%8 .V&&OSZ7BV$?+(4(C6HVU2M$B*/%\SRD
MU^L-5-"D*A-?2?AJZ=6^CP:TT#[V ZN8UI\0(P,Y4+$:O?RG/%_%"ZB@=[>R
MBHETMC)9:W@=IW*ZRS\V[.D4+V.4 M1MW)\\63!Z%XE8%<)1&DT_C'_FE2^J
MV\D:B3CZ23:Y.300-5%[T93-RQL)>9+=*U$2];PZ(GG20X3Y2'M_WX*T[W$*
MXD@B7/Q6E=L5547A)R@F%85G4V1U!Z7[A7@S*=HRAET3WW;_ =S*E[B=^/;K
MUX./\-08L$!CN8F*D_V35>U(@1*Q7+.)%OK ?*,.>CGY%Q/UN%M@W:S$_:_5
ML#[,2Z6<,8M,CG0S8_*5%Q;O:Q;MQW'O=EL;4 ,N$[6Z]:-3XH2W<QIW?R?+
M!TSB@(O+0D8+KHAQ'_-;!LD%"/SPL]<< <8:6CJ03]Z-:MDZ:@!3S_CV+7'X
M%N,L 6DR69;4#4(0!G3:V(/3<)Q[6:&LZD.L%^EUDC_N=?PR6#&S.GCRSIG9
M0EX.;XJA.Z;*9$2&HY\X7L/9#>M)?FV<0BF34+#'S7U:4^J'NM*K32]<HT_V
MP6 &)>^XL&%Z@EA4YK'!2+7G;H-I'-N1*KMQ@RFJD=*?J@5'BTOM1/6AO&_,
MKI=1>-ZW[BSUUE3CD[]B7KE<7&U6Z1\?QG?=^@,8?2BCI5608)7$:M*%'53?
MU'L%MR/S&;F>20N+U5)Z.QKV[PO7_^>ULOR7D,E))%1&T;WIA_HHN=-.\S4V
M1WAYTUGYI #75L&ANI5Z4J!>B]JO'6_7FO[(2'_H>],3(='-CGI%4AG.VKYU
MDLYK45?1?"S7KJ9?A"10:"1.)ZB(("++!OGX&ECYH[:@*FFR1*GH]+H;T6.K
M*HW_.O#A7UTS*(:(_4*NQ',^AOV29K1.IP4B1U").O!'[FZI[.'L58NNV*#I
M4C9W@.4 &EK-4V.2HUZ6$$: S-9)90V#IYR,7$<6H\+ X^O55,5K72Q8ZV'-
M5X^"N7+A8\CBHK'RO]Q'F_[9N%JB]B@.9T6;?0*+H ]\Z+WOTU[DP0/)%*R7
M9TK8(J9RXN@G8.>RGU82$LT3_X;86\2/=3SSNJ*P/G@G(K+%[8H&XI36_R_Z
MGI-5&4$\S0;@NH8OU/\:\_':E8XS'DC0BU.4)+C-1U('LW(317C.UQ:OSQ78
M,^NMCS0B<U*J(Q#%&G+WAO7^  +G#YX,+V1 9(R#_.U>1P>V(Y8S<8_-*?J-
MBFA+PKS!2.2T>X/_!!IG;.L>0*WU^I\RT"O<$**,I2=5 4#_]]GQV/R;] !L
MZ%^J&R"AGLV7TA0 O=W("Y](K/>'Q-[HWZ#FBRM&SV*V 5M 7QT4[</MU^M9
MHG%@M^@H ?EJT&5;T/6#D5"Y'M_DK6!DR5H+;ZEVF9BQ![<+KRQPNRBLR-.5
M]GJ/Z1UW*M'-%Q^&-K_-S7\W2P0IM>XINCF)+W%35?BTVY-1YZ5O4]]EE&VN
MQ*VP4FQU(K<^]DQLOA0>L O+_V%QK\;%N"NIZP[6AYR]I\ K6L]T4)X+ _QG
M?^/?X2\O]%V;" 2)Y:NY8W/@?5#O<E1 @%5-Y%<5T$,HN,]&A=G-E$ 1@"]E
MTZ<(1KEPY()=Q@$=?$!(O]R03]Q^3M@,]@7E)AQ@:V&YKEQ]'^:0&UZ1O0'[
MYBEX#R<ZLO 'H"X#7<X/MT:)/ZZ,4ZQ#W+ \43W$B0\2:&X=X5Z%_E;YS95Z
M")2WD$;"AN/P%N ?RR/M99X[(0LMFSX;X_:$YSN'.*X]^:H#VH6Z5_$!K[+G
MO(Z-<G"PH93W@',(TBH1N?6A;%.<,6!+$9_^K89':12=F5XN*+9#;7#K\&1!
M$M)7_[CT>77:&WY_$RV3YI7)V'8M&,/"-$MWTA0?P.34*W>?N@PQM<MW%'^S
M3_[]UNSY'T#Q3 #G7^7_[!VH1DH$$K G$\Q,Y3FC&J N?G4R-YH?A=?!-R*I
MK+ES]*N!I*SUKGM!@2;J-1:O'EI*<1$EA9,)5/^&XR^(YUV8)F1W&A:P7G&E
M 2$*6U!ZV][LZ9#8!13@;$BCFN89*:DD.'JL@*:A>F)ZK8.NV,FXX]='(4!:
MI7#?::2N(5SO5R'<8M^M(B1$=+XVIK5Z2)FMC0$):!\19BE[K>[2JUNN=O!T
M-$>N[35J]5#B066<NL0 J=><Q-WG1< IGJU9UWP[JJ'-71P3QOZC*(ZNBXKN
MVB&.Z>6RC9$OHLZDW2' :0L&SL[:>F5Y/GQM*YDFU.ZS(E. &Q':U!,A5?W.
M1&62B>N:-04U<VP^,6AQ^AY.;!1B/H=3J6&IEE'9QU%-T1Y126V@B@=&$S,R
M^XO?T>W HFS'RU]NP50S->KGQ'9@&--)[/TU54J@EI6F%[66L84B\8+A4^%;
MK5ZZCK\\,N_-U'6WN,_84K3;[&V<2F*617>,A(>6!U;113C*KQ5ZOCR+449;
M$]()'XJ2Q0I6FM\IY6452UJC[R.*\W9Y;)J3B>6,BMD_O7"R%>P'QL8\3_1>
ML202?A+I*#TG)8J!UGU! 61QK+'38F-;N4#1Y,@Y'R43 ]!V/Q#OCN/?#=@9
M!S_D!*XYB48_4T3[4-!=K<4$80L9(3(5+6AB%M]5O/@/6>2_"B$"4O&Z+BIL
M<LJ9 LD8YX?E?,DC2V>]OY(7P_90JQ>*6!!)L+!CC$K^4LARU;KR)OQF=!A7
MK\9;TDF+FR1>>>6+?7.*8@4;S2C:\'BY.KBHW/9F;E?'T*"0>:"P:2WA=6B1
M;&8@/SV 6+J&:F"EYD&Q\,BTS8<XK$%UGUK1F6Z_:?Q*V,:ZWE)]V: GCQ%
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MJLY'56L.1='<[_;YHET]>]VWY-$;CT0;L=YC^/6Q**/^8*.QGQ*4TC9#@[B
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MM95$'E$W[,J$/)=X^8QIX^/N]RR^MPK>A*+W*J4D8]\A85;CH48L.YJDP]+
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MS$.QQCG+:GMQF<<DGI8A;_:?=K0)P"EK-!C&MFIXB9U\*+R$S:P%D38]:Q=
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M&,89A 9YSC#3DA_MM\D"92K;)Q59 A^YE1"?098YVIZ3Q0 GS5UN%M&" W]
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ME[9V2(7)8G8\[/VM166Q7ESB*[-TZ]3".LP.UL@^G)(+TB3SS<CV[![?0YY
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MUPT&N&;PX=<9L>6'1AG>H!$%M56I)/6 E+>HP(\)X%_;^8WTK.<.WEGUWTU
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M3[O\L_*PX?[_&TL/_[M$<XCI20)A0IF9I33F:2C=%3!5\%IS\*>8Y[02"L(
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M.&/L;>;+AU(-[/L8[ # '17JB0L>15& WV_6"<@HY7>O/M^E)W9%,1+L",
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MQ5O>EP=>]<KYRXU53D_99-5L*U2]QG@Z0[^%!7ZR261W[)C\H:X8)COJSQ4
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MD/UIP+0#FO/-^)W8I7>$)5<%2\L?@.9.$Z)^<//'ZNV_ \&_GL3Z)\&N YS
MK_UPL#F*CC[O2WSB4^IN%GG<A=R ST TR\AGWK(IOXI[JZYI.5#,;AYOU@[$
MW*>Q'LSA'C(@;Y^"=?RUFD%J!MFQ-VC71K\7"IE@M_P0( N#&PMOM;VAP'K)
M!-?&?6JI]F]UF#8%%"R1<!F%^GX\Z5VBP539!9KN57J)OT#!<D%&$&\[K[=%
M-4V2TO0T/)IOHD:U@\M7C*Y=57?+X-([Y5=% 3B$.:Z$OP2-!P;*?:WOL9RM
M*E<>RQ<[_;B7$WL55689.='197%$[)CAX_YXCI,U/C(OR&#VVR"^U[N_H+RG
MXG8='[H48"J!BWEQ[7&E7")1]JBSJ/S5B,^/Z[A81-]$V"/OF0JK'Y"5;]8F
M_@-92">#(\WAY#++;UB73V]"V,]J,U>:Y$$< JO&:'7A?N14^_VEF27S],#O
M%]@1MN[S<[V2@K&)5@LU5DJ3=WB]9 YM2*!<C6N5HK:=D"A/HW%MN 1$N&'9
M1COO7]^M_^# _WD<J/%/3E')B"A ,+BT4LR-[])B%EOAXR0X$:XDU3MOTT1J
M5&*2D]4AI*VD_<[\ X"U+;WX?DV0%*Z,XSJSWS8U]_P#J'Y<JJM*5E):%'$=
M):&O22%UIM.C^AR]P3H9=\ 2MDL\F Q]& +-_I8^@YUDAUCPAAG<!;%RWLJ_
MPW)H&TLVK-Y>W7/RW;0J8[%#9:1'M7P6+2.<52DT JS3<C;1Y* T;^Y()LN2
MEK5K$DV_&ESI%YQZEX\$/&BE>N@V8F\0XN-[;2W2TAQ[!\WJE@5V,UQ<R^PW
M\#[9>H"TV^I .K)Q'+:JP:Q7FE(H@'T*@V6Q#Y\.!HV<15T&":92JCE5)RVS
M8_8\]A\TL%>P4+7\&*,>N2ZIS;**&;6T?>;K7#539Y>\HA0N9<XJO\^W&!5A
M =E9^7@^E$KIW/>7]@ Z LW["O>F%RJ2L&Q]^8[/DJ'@+=;GM72_.LV3T6M,
M+N_R):Z" XR(8GLW*_BH3X56F2!.8#TZY1MMO5&RZB"JST' UV'X]ID;1!^#
M]F2;]A/(1JGH=1,7SNA"^E,OZYY2NRU5MB>:;E!?&?%4$TUV8BIS9D.4L;3D
MXV;D2U+7ZGXG87'H@LXS^-,?@)X']JE52%GF[[L8ITOBY;03^Q!=,]\Y7@6U
MN[>?LPKT(WSD-T 1Q]010A,U[*\+J[\E,3<X!^%"F+[H=@E2Y34^=GG5EDP(
MHH4D-'A90GOE%7D*#>>2&QLL>>>7'*OGX1Z*3-+I\T.*T2FI2.M'X\-12@DF
M6E%E!T-H3:"#V>1I4+GGGAQXQM*2O_T)<*,&-EMS#< A,@J:B@8S>^L9Q $H
M4$*E6%TR?=W_<?<+@Q'C"(,6"U5[_4 >DWZ<K<XJ"R /O=-[8N['IMD6@8[Q
M%F(X3OI)_ZQ2R>$F67G):Q8.Y+22QY)Q$G^OR=>@;5LC+\2Y3Z97(BM@.Q2\
M\A>%HDS7:*<_<0*/^6#H"N.E'.A0'-F3'H+_(O!8:CN6]AL7[)%356"WG]#/
MZ=M/>1H*0B;=?VIA\LR>ZY:[>%%X-V\9!!&8SF,?J3 1E00*-/K\_$:_>7.G
MTI?Z6FP-V+\^^%NUC"G_,3/A]X']6+:$ZL.SX^^\1(B$\FO[9,3]_OD+B3VZ
M7#%&ID:^_@-@W6^@7$>FT!^S$6>VG4N+VD:?"A6,JT8#1P/3.8YJ!Q!;?<]V
MQH.R#D]+SEF5(&?J"V\]8.@&$S]D*Y@MR9*(/5^4& @FV(>F=M],@Y,,=MS\
MLV*%.PU$CNU2+W"#W8$'2Q=]WIW<"?NR*@@?E'22+O85* >*3BS&CL]IE1)?
M8RLT18M?,R\YX@.?'XZU6/B,ADPN%'>%.UU%#2<Y3!Y<X &L8S06FI^CG1L;
ME+,-XB$,B;Y8ZE4E^17*7*#-=]Q[=@4JCMTMX092; [QU:7Z^R!I N60:QRF
M47?35JG]#T"'FL[[YOW7(EQF-E<3KV%V5<Y>EZMR/KQS:.NPL&.Y@VH0"WX<
M*TH^4[Q*\-6?K??5G"OG/L?>);6MU"3['PR8: (+[^JXN- !)#7BWFS;/EY)
MP4 YS[:;:!_>/\6+'U.X-WN&(?/J&PSNMD04/S0L*.;8G3X-/%?MTCNQN3'/
M1G0-P)N_-7Z;4OHL1JS2&R6$F_Q7X2LX+4(!3CPX-%OEZ0E!D/1'P2D_J3LB
M^X=>\5U"D^=J4TRY#HVO=GY[VF0U<(I[";W6(M!\2/.%SU^W_;RB77,E*H+%
MY/OE)PHELQ4^0M*G!W)XX>;.;--F=UV6RC,;+3>]I;7TZV5S:AS-'Y?^LF/C
MM?>\F/I2*]T*FPIC'8%2PMN0[R\CTC"G'G2!7J(6?,(OA2@T>BZI/ZN79F.V
MB>H5Y&AFD8AM?=0_MG'_[D9K"B.8GADI_=^V6>@7I(V#60&K2G O,IS(0@MN
MK%_).@,NVO:3>!)4=#$Z2Z_A?JNZEN"HOB!RZBYA>V5\YK47K%1G49T\D0A.
M/7B'#;G]D!LS1Q-M\>Q0D4?$?!W&J%U$TQY4W>=AM?UVEINZ&)4,VNJ.2(,R
M!LY[$L^^Z4D+:V==S34US6CC6YW(2KT9;#J-D+R%V:H3FZ"B4TB=I$@^EHU9
M;4[*O9V/.&%Q:![W>/XHG"YD_@-?= 2'9A TL:$OL2V"U%0*^E'SU>O4_$$(
MQVAV]Z*P_DRZH%<;<":&5K(#M(EE/#[=/9I+EK)=*-@Q6;0L7,CB*2N1MQE-
MY!2<[1_S<6#UDS:KYFW^YVJ5,+UTPZ3J-41CJ=>YM4RVW+MJU1M(U'%6T]J<
M$F 25J]0;[ZT-LK6>]F0G9U8D-[29S_72[;989&^7I+99(OH:X@N8<&5'O1^
MATV@$1C,I[DU)Z#+TP&$I6>%B,%*NTA+J<['/EY2:?IDIOL,\9'9._(,SY)[
MRHA*)\;'K)+85$V\5P:M*8-FNQ%HWP33)I"K@/-G/=NR%YZ&QB_;>0^>@I$:
M\M'J9W::#G)/43CBA)?6+[VO%O*M%BTBF2.DTESI\7SO0'!N6A?0>_N2"(1W
M(K.9W&V,2C[\*L*U^"O0WUB\ [[V_=!VO1C^JXRHJUR]V2;XU=WB%UV(T<O#
MT!]W,^#2_)]^T(9*;RCTZ&JRT'S$%7^\%6%,6&_E>OVN\+[HFX,/0JTT4LG'
MQ/X1Y7YD]Z:')$3E;._W@S38Q_.<:51*YW/"1VN?F7?W?4\]R-2RS)+/]L:/
MJ5,07ST ]G:_D"3SBB1O)(SK^E!R0(4<A"L>WSE@M\;N /GB.DUS?&.K[XDG
M4E>1-STSJ"QM^3EO&S(7!N'+P8S$2.Y'&':^D#Q^,T4<N757=.EJ:5!&@-.4
M"2J1#D0GO7]C"/92/"$")B"-XJC>-J_-PF:Z)EN9^Z1-!AI*NC,E2]G0I_C.
M;$RF-29&F+>S(%N(M8NM7*QN-@^N3C2]O*!7:>\*K0G=K-!>ATLF]]>'L[W'
M8FUD;3ZFP/KZN8!#O,32EFU. /'W6!BKU!/'CJ^CR^Y/H&9YH'51SJ-9&U!D
M,O++3R:<MI]#W-@)I!F1_RPG*(OS#Z ]?LXNHU3QK?2D33E*P\^-8XHVN6#-
MKOWQ@"WMS?HQVM"\0+S;*-VS7?_K0<[+F9PB(FJZ;,95VX-;WPW-G?DEFJZ8
MOQW@VW1]D@'+ S7<FFTHN!$UE<?T,-M8=4'*UJ'0Q?)2Q]R=_4-%*_^/KSP>
M@S4]RTE:I@]\OZ!#%M.6YZSVB(/)>6@L5:3;]3MJWZ&//)N4/F\8*%I^7_2X
M;JM)H7O/56(?/I6:V2QQ,0K:>LRF2YF;&<=,KAD8ABY&L+[O7KM=46V@\= C
M&BO2E-FH3+^<E05QVVOWFH(V:)$+? (,$+QMZ2<HT44R\PY0F\76BH$L071B
MY9@%X6V'<Y\HL';P7UXQTHF)K'[\ )_9BYBEJ65Y$\S7$:?NV[?2)6*D(O9M
M-YZC*?LRH2(:W!NUE5I2"LXK3CK?>VER%=SVKO'.$IX>C_P47J^4PQL1?])[
M^->LLEQ"Z2L".?6]'SD;+<.3$[=_"I:R&RCL3(IO'@.)AU_L1\Q/6$;U6>ME
MHH.8GJB[,.FW<]B!H]8%SA2VNX6=P72&Y>![K!9S,DK%UI<!,8ZO8TYYZM8S
M&V5]HH!KPSJB>8YD5 9^P8(Q>4Y0] T5]+B++3"9G"/V@=X.=Z,.LT@%;E#.
ML%YIS] !._0(^[2TS^4.-:7SDID+<8LO*^Z87U#0_TXQL\DC-1WUO&O,#3'A
MO,C N2K\NG%C/DV>Q0L1@G8P1,/4N:K5E]J'\$+D;6T1+2476@%UCZY1E)E:
M.$[B/Y5H/84)T^0&P']8(?[_-_Z3G>"=5:P#0J$=8C6_!$%/[H4WE09N)OO)
M1[^WL!.B('"*QP9Q/OFY:SC9FW7RA 5Z@L_]/>W-GB_]V\]NSK:Y,=51:W4Q
M7.55S/EU59&E"=M4DD=R()YQXJ?_IWW:WFE[Y&H<3O0.TVRXW"&P\/;]@>#Z
MI91_$*G^IT:E=H P*-G ^1M?9 4_(,2<:V=@HJ2BX \ TJ67_A>^](3(G M,
M5.F\T.#-WT()M/NH4XI/TW=7JD-G==[Y5V;U:.=_M@D*2(A<[+#6:#TI4,LC
MKJ966J<;V=LF+8>\JZ*053.A&Y!J7#+C-%=+)Z8%80>N<8OCGN_:2C%6!1,-
MB^**J4:33R ZJ<LQR.0IPNMR[^H<1\P0>,C)ZWWYK[2G;/E4S2"[5MXJYI"T
MSW/2WP($,9,T[#2)J#$W-3LV<Q/&H<# #R/>0H;5H@3&WB;M(MHIB3[PY%)E
M'W)F*^7]<V0!8;(XBMP<&D8K*[8A51V6."*E15WXR@<VX3*NRZ!>A*.D%J<2
M1A+X[(<_;RP*':6FWDYZ(7*RZN3WU%NK_QWX5"FUI$H#A\PE*LG3?>"W!^0C
M-K"Q9IK=Q?$;D-;80>"W2^)2&KSP/5"E<EFXT-'A R=QK,VH7 )"ZV5K .=;
MKE)\:J5KE=PU<9QEABFWO]<XS7W3D\YE#H%\,-AS4DTU*__\63]2R (M6VDH
MHJ]1?_2[.6U.I!Z +$FQC![XPI4;)/[2^<VZ-R4L.23N#R!QNES_#D;>22VO
MIC53\%N?SOW"!_V@(3/CG!<LE5K5XK]Y;1Y8Q6?7.96'-=(?HK0ZH^@[0</]
MU;(72<)$ =Y#5I6WD9^E.MJ(*YK<<CA>LR[&!<8;2$G=373*J$N"Z][<ZVH1
MPB0$7*XWFR$G>5KINM_KEB4MS'!?$$R;K:5!(,,!1T09/NTE9?BFE3$G$@6L
MW$O>7:7*+]^6FF^V,Z3S5_!/?AMNY6,C_7;!:DRA X6YA9+Q2/4YM)'VO*<!
M,!U@[6\V084%WT2A/FVZKZR@A!&O>4ST4<* S 83\_^A7M0I2S,UM8M@P32^
MYCAKNVLRT4XS\)PY)&@M2V[T*B&,=[;E5XAZ@FF3W\QUWHEP%4T-/EJ(6C+B
MG;>61777<4#X>F/:6E(@^Q%HM"197U=/(0WES^+>?[Q_0';/RS9^.4E3L#51
MZ@9AXTE0. .IJ4$PB[3.]_$=^*,<#OFF&V9Y&?+P^IK89![(L;VKY_D]BR23
MD0"20B84<<UKK,.-I9I%KL'%Q. *9TQ6 S>,CI^9%I1V+ C!-9_B[O=)NBV8
M**.2-T7=>\9V%]NP5[\AA](OW!:5=R=#I0-ZD_;A#< 2I,F6'[.)KDT9^82)
MKFKTOL7!9"C]:>5.[OZ$!L6S6+VL4U:EL<=-UZ7R@]=3I8P:G( 3R.ENE]?F
M3IC1^@;^R#0XT&EP])68G4 #[2M$]]0]3L&%.^#)T9E7W,#:IP5AG;?X0\S[
M529]M*8,I?2F9@6N_;1K*OOLYZ[#*U 7JE$P5":E$$FJV,:TF/*$_@9OKH@?
MW-A:S-7DM_M%.&WU^TJ6VX*W_@2..^16A3L!U^NM:4I.;F.MQN^O3[H#_.5&
M_)\</W[V"E)*Y)PJX43K6WAQO)$E:)0\%B76Y<ZG6;3K>O-,KK'LV^+_2MO]
MRDV%WL[0/9_%;.T4WQ[R>L[-$?1O0M?RJ_8YU(ELM0\V]&J)"[)Q1)L 'P #
MB_;"J3$=FK7]%W]KDG <3%CH4'4P^[".ZA*:C93T:'UZ:)M2HUMWZQ+Z"L'H
MWN:!]9H.HZLLUE=-N=CQ6NP0&8N+G6A^0-^3;69SUMQ-;>GPR4*P*-5TVB7.
M1%=M6Y5&4SH$XYK!A]!](D21=)P8@EU3(:Y(-64$&Q7B[8_=JV]G\,1<11V'
MJ1O)^(-V53G,.05"D!;FRM4"NR:8WZ;#AG3/K/I'9^S[; ,8:,DR5&\M:>J<
MY& 8G%I?6QBO@L70]J*G5>0YK*<=--T)C-6M%-^,R0/-U#^SZNR.=034JM>*
M 2JPHJ;7NBOZ18@ ?M'_;ZRL_AO"4OPKA;P6)1[-<I4&#1LUPAT[M/L\7]\;
MO8KX.AT=/0Y<=O0B;5I0(=[??P2)DD>,$:(2'1NYC2D#F70Y7#+Z@%;FO(5E
M_2)>\/T&XX*W!XA W*+81H% L6.?C<(9]^$M?53(FZS9,AU:)$R8I'F%=86V
MSX@*/X-PE 5@+CSEJ[OXS3"EE.V&34H3Q)"@WJUKU>2=\;JZ-NS/BQ]'";2?
M])M>-05]<F=SO1=6/1RJ?_\-B#YXNP#/.S2"^&K:Y!.)8>2;5T;BCV+JCN9+
M'@T 5M[RH=ZX[B/EO ; 1-/;$"4E&?Y)C%.']2/!.''YE3*<??=E*F;$/ ]9
MOF\;BLY-J2D'RU7>%9[*;$@B?V,HG4EF>^#!P[A(7,T3;4,FD(P#1X(;VWNM
MV(.AZ0AC%K$A+MALHD?EJF-SLN;@$PU7GW21-<]]3R\H!'!5S^P6I1]?Z&K-
MH?=^'8O=6*GZA)N=%.24=)V&PBK@:6]OA4"GCWA/J>G6CWN-30T%"2K.9^5:
MG% R+02A-.="C&K29BSVIYQ)EBX5,BOOEJE3"#J^7;F$_5YR5ZZ?J67OL=N,
M0K#YT;O4 @NXV<E("+.+B-Z'04C69GY@BK[X+5];2B^# ,)@;3]HU@_$WT[P
M&^"#IGV+[9F$/1H.3PT#U0$Y!T8=Y<-*QZX8RU+W5%3)2H;?H(-8(XN^S4S!
MU?A<LJ]8&%:A6D:BAW8L*HH9,Z/:S-+$A6B,*(#KD)J-L4]U>ZUW+(/"5S&G
M7>2/79/L!2OQ8&50]5'ND*;?G7T,RGU"H59\HVQ\WR'BIL\V?+%^A9) :1*#
M<#.#62-I WB:[T#<8#^_>K6VEBLZIPA$L_V8^'R;?PIWR)Y)EX+@;>ML6HO%
MS>F.V[U<T"\0P V5SGVXP<O<\>; NE=-T?+K@YL[&7"8I$)^+S3O;4\^-B0[
M7DFL#E;/\QN]"B-D?+9A%@DF@7E(F_ZL-5S= 8N4F7RJ&38=AW%7&+4BVJ;3
MOKVPD*FXR3K7TAZ4:QV@QZNH]1YZH]STJW*(4;MU,]E5@N=CICL)O"CB44P!
MAW^]Q?VXXZ LRO 1]R_2]"KB:WC[=P(;]OFPKM*A=3B%.2YF+HOS](?C'#=X
M8TC;9VN[NG_ /2-H/!+C>[W3LY.@]?Y"'50P[HI!]MIUB2$+%6=6D&EMN1?1
MHIJ$IE<_[3'OC\];D[BR$F\H@Z 0(N]$PQ^ J*4#-HBJ/(Q_?2C+3@OI,I0E
M(U<QX8?PJ9=YL=ABOUCG%&N?A8T< RHI*'[Y62&/@U;N\!7A?(X;%:"/EU\P
MZ);-EX]ZTOEDSSJ0&-$.<D!;>>J<R$BKMKX%-APLK7[F,K+G-T^"19.II1/P
MDQ,O3Z?KT1>4PR2?ZK"G\NYT@Q&[6@AKS!-Z4EO%"C/Z];+=$6,YJ,>>4#;8
M5I :8B'D%Q($54%,C;SP6)<]A);ZVG"^X,L@<CT(5:W]2KCN,.!CR7G+NVD[
M!;;7R3O$7O/CFM(TP_+GA[<1^S/3^;!!IT]/Q;8M+^U[[EGKFX91&E4BWEIV
M#T\ M"OQR@W'IPK^;]8O*$C-CQF^3;@9:EE:GLRP+DR;),?FLU_9-&EQ3GK,
M$IBXDVW[R"#54*[Z-]51;=##KW?7-M/@7Z)"E7VJ;.]-DFOYC(1LH,L'GCFC
MJLC(T4+RG2ZL=B"MJ#"T)+$!=(4ZW+?2Q1E7_S$8]9\M&S1%F0&9IN.JUU-@
MR/?,D;3AOYDOA2A4# 06C;X[=*$A"I2=+XCX=6MI\^8R6"6X7G)E_$GB/\<'
M@WAM)*U]%,51945945:W3\9"?+@"M;!SF4[NMO-_)>GU8$( YJB___#?[!C_
M1V#:_RPWCFN;!L= //\Q*8&O3JIH&L^)E#*9*.XP9?'! +ZCK*V6T)&1%D>R
MWJ %/R[R]V(KE1_/<1IF1WRU[A*]+T0 )]_>78V \K9F\7=G&$U)(X<$%8NY
MZ1$C/[3Z>W)8 0T7C%+/DGP[&:9(D\9:/N&@+*@V.VN6,*UH"[TTV:E;;)R;
M8[SJTXF&#)/H2W%\WKV?FCX>X7=(4YR2+?!G28"0U-;$"^9#967-P+7G,J]N
MV);^ 40M/C[\W4"VNQ@<C*+KOK'2'ON;*>A%U^6G4#=AKA=G!?0PY(<!+TM.
M[HZF$$%3+2_;$,%$=[9BR+/-.#%W\TI!3);TP/P(ZX>^,)?SUG;2YIH="/C,
MA4T46A#/^39W!8$>80&#7G^_%U0-,5N.2"6]&+JS-KFT(!VN/>*CCW%,:S#L
M9-NZI:) 9/NXWJ)H)U ZV1 2[]5R U1>?W0I1G,?+-Z#K-!KLL^?\+4J2Y4N
MYFE35!81,@\MPL[-\E&31T T [HQ?Y6\MZM=;X4<D)\94O*OOH2[_?*E);S2
M9+8A.F6F=RC@BY7+@6) 5+^4C25S";F$F5!Y\V3M"JPK1@R;TR"B>EY3H;E0
MO6(:B/=OF5QIOB*)VL2'"E\I227T0:^SL*G7:^=H/Y<%?*[>#B)C)^W]OF'\
MV1QL^)AFM,M?"O[%S&7+-\1W\ &BZ;1X'_(;_>2;^]:+(9FR/X!NV8 _ *6Y
MK]67#='[=AKGU:%'(II9C%*HQ]^TQ=[_Q=PO:"/."'^YKV/KVL2UOX]8(%^9
M'QN/^'7HI,AC7_T$2^74L4XT'-4=L&41DCDZ/OI9)-L.]N^LQ\*A5F6! <4Z
MZ*YG17WN5+<(Z6"U<% 9L_FC9R9UI=@HR)9X@<4[P+:>BX2UY8=_>A-OH83*
M_A^K-P.E8\.2/H##3NO#VY_>^EU)LQ5>3:&H<T^_=GP*/"4#YE:ZF#Q^.+A#
M!PB-/I=W/9#1H:=J_75K02#1:R3@.=_13:>@NPF",U"V\Z"&H$:=4E7EW02F
M$&</S>H=9(+N4T!?G^WD6?6<,-6%7!4)5L)4 7F*:26-PVFQ06F]>O1F=>:9
M6;$N)8&- A:,7> I-:SU*-4$Z(/F&XU!)^FSJ4-1>I9WN!W+F0Z6L7M2V@TE
M0X+<J/3V)KWC> B-]*M+S-[I'\#-.1LA<E4C4MM="YW-3':#53@4-2WR16_/
M_K4#O!(GVY<.N,.E-V'-V*0T?!S\8!$//^KZ&:Q]BN>5DRW^QZV4)N54[C=Z
M1'M%)F_ 0!/(GA[7KXMK>\5H[OVH-MG@V<)N%FDP0(?2&Y,2/UP#N3TV463!
M**Q67]4YS1UQ;6'$\[*1 )Z*MO-!%?-=0#U.*"(A^[YG7%*H92S*FK>(61&-
ME;YXW30H!<6E@Y"A #*@=)/GG  % )&(%"CT:J"M!'^\,U@,]@]?D#5"SJ%#
M'1P[N QJ]0-5^^6J6 52&\=I\>!.*BH0L=@(S8X6]*%X/,[3V?3T+1/J6#1
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M06 R(BE"-M-IK>9^S>RXK809F3J7\XN@YS)9Q@.HD\7T?DRL:GCWG-KH8UX
MT)HB@+9$V4<+IE+^+(-^8FH2,)T#+-8.IMWF]AE9!WJ?>A/?G6U,YI1MVWK]
MK41-[A/7O)DTQ8JE\>#6]+?BYQ([[79P+OOXPTF)%/ I- $*L$0=@?.@P/G
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M=5\V*WLZG[NMFOC^;J?<_I\>V.#WBL"S'$U,#LSE^DLR[R<_@.W9Q[:M02&
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MZQLF?-U#6<[=TK6L+\VVGW_VV5S=1^#C.U_@*8:3]!!G%@VC.0.P62Q$L3,
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MDG/OW[4BO*T"<MF^)5X4 @8MVSP:5O7ZUNE*56JIOC56WUA4"Q)U'U,#)<%
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M-D1ANYPL,K?0VF*!8%4GSKWJQ8=/&3O;PC=+8MM'\V2_OFAC* @< 9"#+F<
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M?AA/NRC6#GIGHMT8/P+JG8LNG9=7\+,S$7;UFI=XP674]6F(9G5/;Q\6;\]
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MB#81]4?CBK[[?D88^W@U9VQ?G1U I_<PRG%_Y0\6%T>4K(0__$Z6("B@HX[
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M[7,#"^LP?2!9&1$5!N,/.W=$GT1LHK\O,-T]W'7NTU99XRC?\5^G$LA[/%,
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M[&,&W7K@E/.$TK \( >>C0:QW#HG&Q5X%XKB>9/KE"I_A=PL]^P"6]O7^<[
MKD?'.C-HY#R,"7D9\70:H^2Z)$"R4PVR+\8M2ON>VMZQO5_X*$=[_F&>7=L7
M*3$3^<^I49J7/L6=_@"_;].7S3R/V_.9D< #066[3T[42?DZ=#5#YX=8X&Y;
MHP];7-Y?[5;H3TRM,HUC-VFXB+RBK'60W'F^F+ 5\"LP]X?OJL&AG+-D44I_
M<*PJC.\/]W 1S%C>H[DYX)*D3NUK92^#S[>$R/UQJ"K_>-Z;:V$0*&FL>&&C
MDV ."[._U.9LRGYB/-5XT>DQHGP?D2U]WV',YO93_IEA<6>1&SC8JX++IWFA
M[DJQE.L3",U@_#Z N!TOG! ]EJ/1,>Y=+)5*:*M(OR1D;*T:')\)E-/XA:BL
M[,<@P:1\W.\QA&%9P@GW!3/!AV*7JM<,%D6^?WFE<[=HU4Y N2"ZE;&(<Z#B
M4Z$+C8](1O+Z4ACD-@'5H\M#ZCUNGPYU">6&>YL3]F**-G1_+(E]APUGW>_$
M#2\8BW@-"T">?4S+7 JX)/'\QA@1O8-[<LYTA[6LHMJ-B]T*F(GJ.1BGK("/
MMN_M7='QRN"?3O3JGQ\P+R2_O5P2\K"1V:YX8BX,\N^'(-)D(U+XB1(9?"*?
M.4YV(/F$BM4=AYA@56V2>HS.7?6?7?F]M-:VY\]OR+77_G7H[>0EF^(30M09
M*0*D2(.I-7C_+_>[\_WN98D48N*09'8M#=TO2S37IU^3F3"+.94<]<2G89 +
M9T#$1X0*L7"@,Q(B2@@(;Y>NA&<]B(%%/LC>P<.D):#!Y6_YG<#JF^:[AYJH
M*N_<AT14U(Z7K^G-@V[TRZ&UELZ)E4S'&RT"2S+7[MYA]_D1-/-P-04UG>7R
M#E0 401Q;+8.1JJ".1#2:-(RSD[?2\%OY(6G!_F$7NEMZ)CT'QL=$76!D(53
M+"_Y=[<NFUKHK/<-,:XQ)(<=:1V7E4@VKG +:LX0'>F8Q(@UIWF.SX$:/L][
M<<3.9EN^59+T$>$_D7R\_<WEO#KS(]1.H_</4QA(;= QLF$5XM+X$4CD/"(L
MW[O^A?:K-IM+?XJ[\,:Z'::2)OZH>?0R3?[0KS5*-Q@@!Q*@^,'!1>^!F;EZ
M5YMHM(J-G5N$E*F];N.==8N7'2(U3"<?=:97/H0,UCJK1:ZD4)\S%\YVE0#<
M;A"3UZ%[S_NM:<TEWA:][L2[/.*-GHE:W$V3;QY;QHJ#-<[+O@KB>OGY#?6G
M-45(&6A(\,-)M5S:O"M/W.5_Q-4&,?QX)E;4O0^SOL_GK_XW)(\OLW;0TYU:
MWN(65Y31F %UN0@ #%P. BZ^C_\_U+?/YF?B@1#> ;CM"G\DV1T/W:4QF!%O
MG_; \M]]^!J^N#OLP=W?89C+Z46;MO<H;?1""CO9@>"<@##5C3E,X;"!N8T)
MQJ0)>D!_MB2'7OH\K_3ZI^2.0ETLVWFOG,\[X!(JH".*-^,UPXUHP)K:IB4"
MWU\Q;/-(OSGO;/1S8$A,YL^S^TX77PJP6CG_O]-6Q,,S@$[J--^#H@67$50=
M45^ S_PSOM]T7>OO-;U/J?.!RL(A*VN//SM:WC5BW_J!QTS4T/39,Q#YZH@J
MO4N2#<3KF,*238MAGIQ;KD^=6KC>'# 5CM"Q<][$P?\TM$D"8!Z$&>FKKILW
M29:U->_7GYD'%,%<<R*'P>!?Q\K JW)A+VFSF+VX"S))FM] <L1;74BAIO,8
M47.=RX.(CK^?G/AG''7WE[; M&-+AD5S\L-(NL]IJ6^<OEES,0WR'E9W[@@7
MD6#8P3ZS: K[S&",+TK$[;?&[P-,#AI$U_B.MO%58"RO S-UW2A=RUH*!Z4_
M!QW;Z1@,"]?0Y70P8[^9.B],.N3E5_)FK1OA08RBGZ?K9 Z*KP")J: L#,2E
M&09T/MV?75Y)Z9UW-V-"W)[P4!784V/3XF2<>I)K!I+7<,M%$+[&]V%6DE8D
M7Z@M(J<I N>MDC-JKAC;N<O+'O/$\9T[_XHAT3J==I:G04Y@7^ -WO)!6@*Y
M3/V+RA JL.XT?K=I$81#Q[2'XD]2!.!FN%\V9X #"2EZ7=[3.6>)DX?;CKPW
M4?].A_ZV=N[E6QPA*L=Q).%BY%@G8],RL.W3\::FM*XQ(+7<U;,T63]=DX=+
MDRXH@#;YD.I6[QG U,Z+WX\MD"6>[D>IVHX8[ K?B/]E>[$DL+I(/B/KR\^L
MU\."0Q+I%_]2^_QQQ(XXX&2C0YT+4\0$B5:1N[)$^J854Z@!H;E8/35MWMI.
M^8+M&5#6&EO]X,* P;T+>#6?"";4CV P"RH: 7+%+;,-\;UNYKOD4#:D8Q^D
MQTDM\6RAC1B>EI;S)Z7K#""8A2CIDWR(X"Y[6:(/O*%73+TMU[+EW@?IZI',
MDE7FA>Z+:1&O9U.CC&0CC!:JJ'8+ 81&-5F.)(A-82-M]UUQ6Y*::)QL[IB4
M:I$RVE)ILB/ GN("1+C14CZP?U\;-]11PNU"CTM/T_9RC284SYE#D6?Y5\_B
M4'07.N=IB8\(\HBZ+:PZ+>:Q5L[?!AQH9YD_ B*R06$E3E<[$!_TWDJ\4?)H
M>TX>$E(E*6X 58GN>67^G)V#)L\*3%P^5LM=,>Q3BL9(-Q)#.J/D*:)+"K]C
M#A,4V.P%2D T:1('5B^]FE.8BYXK:_\$GB),3FO;#0DS*_Q]A3%_O<,:@T]@
M]' Q;\%>_[F^3(I?"?7U[V_[VSQ"LWO*I9Z_2LM 9Y+^G-C ERU(P@2&_@+&
MB1U?*5(*:E,]P#7 =U\!G8,;:6T=3%'XZI6DJ.&A8YCQ9@\C@>R?RTK!R,%7
M!AGP_XV7]P"*ZGO610=!$<E)<I D$B4K44622,Y9R3 .2!Y@R)(S""A(D"@Y
M#CE' <DY,S,$R3/$ 8;A\3OGW7MNU3OGOGO_=>ONJJ[:M6KM7;MZ]>K^OEZ]
MFW3>2=H$1M!*XVO;S/,[<>%=5(VP4(:L[=DRP:A(#'/=]=%\&)/.>GP/*< 4
M/;NQ@I&>!9W%LAO&J\>J?J.+<1DA<*7]6*5LPQ'HYXKC?)YP4RJM=RT[_[T
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M%"S!M7W/T4H*:9KIBUM7[R,.]C_EK;EX/(-9QJH DG>5]0"UU'JVS(25P%L
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M;P&X[;3HD %CC$0:O6*TDX  6U6LN>?]F3>YM3Q)JB1E^&T$H6OR<(* ]>@
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M)V):&>G_U+Z=$E44TLKO[Q16"A\\!)VN\<RL4HR;M/5F6>=\BM^0KQ,:9CS
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M$2* ?FTG?:L8WD&PXW^O'27PLQ#8 '+_5 E+\(OA&+B(:L!Q"GJ?PF+'Z8G
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M8+XC//SW3W6A,\Z'3U*B1Q@K#FI6I@%6B_B?W0;>+1^KIK$PB<:'B_LH1B-
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M+'6%&_?,>:K"(4S#]-&)<[1%G42(/_%"\9P'.5<!VQ8QUQ_O-!WF^?>8G%N
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M$=WM?F:X^H96S)Z7]HR4=YFTY9/)XV&>;SW\]H<#V;^:/OW \ ]\//QXX&E
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MLBR+)W34&0->?4V:0"?G5A-EQNH.TF\A?*ZFB/RN)2=PFV[.$EFT9]=L\K]
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MWB1,PE'P]6-DB%/[1U<2CK+C M Q;&=15%;WD3MKUV^=0&4VXFC*R*D-'@Y
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M'^[O2_P"$O@1Q,S1&/BN5\L%8(*+$W#^OZ;CGX':Z(=TQ?<<C1E>J:S^^K#
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MV9]4YL6%"?=[U0EJK\DQ,@1!=V+6;-P%8-=_"G6L6_&OZ]J"7.Z[)VNJ7A<
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M'](Y7OX@O^F;9#-O(W9VBX ^P<AT+,KTI ?=">N?@"S9?,1=9;W>Z6:GDR$
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M (2J+ZC?!8@B+,DBBD%O-(30GY4.1"8D9A&OWD$EU<33$5&^[X/PIT+;KC
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M[05?HLR7%X!P4PC62"8*3E?IK850Y5@-Y.7QTQ_?E\Y8.\J6--,4 \LGE;7
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M2"NH#0=N/87^>F--MKE]LY;42M:D:)#PI9Y9VIJ$/E2\CU*3I\^E+&N7<W4
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MI8OL[U4/<F9$_7AH=(Y%[8Q)/G()&8?XA.@Z!G7EB5B._P[JSKH&*[%;M)-
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MD3*-) VBPBZN-,9MVJ]-JC)4P;4M?88LZA"O&\%G;BIPYV3,PN>T**AI:0>
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M%@*B ;K_Y<+'Z$G/GG";F@3LH0$HTE=A)+R-Q9B03;OU1KT/DL[N8S^1+M$
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M?;+#_%(Q8LMYF;SI'REW0^VLPN_#2P$O\CHM$50TN-8WC>B\?S#@($,8_^7
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MJA^R#<47U(_V6.E]^BC]D>U>Y_.*YP9[ZR-06Y;8@L12=:MWEC71C5D9/VF
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M4:O6C0O5+%_I ?"/!NMM&$]V'KK\VW\HP7JJ06[R1U=@A^ IT.&5CM*E^\,
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M[4'P:$K@%@(>CNU5^2YNFG[Z;&OM>"D#$KNHD7S'BN':3G'*D)[U3:<,^R
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MR*ROI_ %N\6>8&=)\_G?1HJ.;'6<)J:&%7NO 0OOB7IC>:^W'IH\ &G#EBO
M3'^V4RP1S!15K(;QC89AL'E[O:%<5)]8<E;_([/KOUZ8!M03C.3ODOPZ083[
MVXGIH=&],^KU O8E&<O#=S"A";D/[ F%<[H!HA=7GKUQLV ?W9WA0\YN)X 9
MZI<2%I4)30G;?Y?_Y,@]"KDI*L)RH2ZQ-][:B]Q"<O&X&9X1>N?(!@@K)C9M
MD;%P$6^;XN.]EO>5ZE-M%CD_$4ZAHYC-<_U\8B&2S :8K9?EINLOGWTYD;)N
M6:'WP6LBLUC8;*OO\<2]0U8L;P\*X[Z,[(8QD4H[.R['X>22RGXUJL>L14$,
M7W^N2[?BU$]<M/ ]P>/(_*>?Y<L49AZZ-$;*[6Y!Q3K61&-!_8%WC+3D<6<,
MS[YSE2MX\8[I,'B[?_GM19?+':.I)V.5#28O2V(^%C'HY^]Q8V&-QJ4]QJK+
MJHD4,Z)\CX7(I0DE6]6L4]6O$I)';ND*/4.BN313$YH-^K=UP&;'-3'?A.N\
M>+,IE%(/-'41S-:Q2OFF]:Z@2G7G%R0;:X+QWF\GE@X@N2"7QW^0K%43VT"E
M^A_M#9R;59"LE6R:S8R<O:QOZOH53#0M?TW'SM  WUM@^\B,X_+]4.K4_I-#
M!]\QE&_87*O:/O)G$A;1V^Z.1?>R@LY['/TNQY93>H1F<C3[-6)>?.&4IG0"
MLVO4EBVW?K\@BU%TB7HQI9L"EOB'*S(+\@^;4G>F-Y2<Z_YV<C5;"Y36H7A_
MZW'\I!8C9=XG'1SNH!!B?SPY]+I8.!-=UX1#7>NX KE[7-]Q@6))"B.0;4BE
MRRS3%'^E3Y[CF%E1'=9+.F3<M-=7OL^L#;9BY_L"$2+:K!3'XSP*9X?\),AS
MB7.#Y]J"/MNGVMM/NJRNBT,GRBY_6Y;JO6O4C-6%VE-TZ$04G>"@.:'IA PM
M,IVDW"X^U=%5;GQEM@K2M'MN -X:)QZK\6XLN=.10$C^Y5QD>GSA<0=T1X?_
MKFW_P)XJ 6A(2BFD*'UJ(%54>MH<I&09YFR0=4T;1V+UKC,Q2QZ>K@>^?J8Q
M4Q -S@#5 A.@:M#IK!F94DCDE)+6K?'9TN8HG(PAO]7=<]+]<I#]6Q]4<YP?
M#4J>OMR1T7:,@'G V:WZ9U -9VRZVO12@@IN??M]_U:YV]5O3Y\6B>WQ5S>\
M7K8S.Z+('2F#QJ\B/.5_N.?"NO0U98B@960L1(?HWK,D K$NM5[<:-R?[KC0
MD%G0U,@I92KJ+U_(T[^XM@FVA'Y#,4$L"=$F4ZM$R[[($%S:5!;&UGUZ%/X)
MS\ES_J?^" UPS9U.NBUDB*W[DZ1U')K?*QP<[0>50Q-->BQ&YS;6GP:BMD@Q
MO36<B%9IH<Q$G8.::%$YYK/0PN,8R-_B[OLO20%7,K$F< %H= #VA3!\7Z2X
M"#-O5_RQ,+[X[!A/()4M_;Y97GX>G^N>EV4F=T)4(MGDK>Z1)ZRS225S"UK]
M^P#YC@;P0J< !: <4E-088K".,4;:\0NYZ-O-27_)]2'/3NS^<U)3^YWIV9"
MOG*4.LB\;"%)D1TK;S21CO.'Y*!;'<!&G<,D%TK%ZM+< .Y@8"F*R@)FH!-N
M=!SDMGRB[&I#VT2@AN3XNNQ->[SBJ=?]8HL7&%(Z.]286[P?[ZV;9EJM2-U=
MX,I<*L:AKNL5933):'<<OZ*+V>U48+WY2#1R$W%&*9(%FUK%U)L6FHZV2K64
MYP]D7>77''E\JU12W;TX,@0<!_RTC9<@&MT=7<*BXCHD/+79QZO$#>M)RE77
MD2?3[>P^Z/$E/_VRHG@O)=G1+U@-D$/N7NI"-097G5GPH %X.H2\P@-H@(J6
M5*&XKAX7GR)Y-K[(E?%2]HR)WG%S$877\N.FZ3 -7:J3=*K<?.4! B/3K2*B
M0#+#P1FLK6V-JT@_IR-.F1=R-.HGZ_D]1A/FD%GDA(VTRY1OB:';L=K"-=-4
M)0AD F+ 7.'JXU)("I?',_X,R[&:N%?U;NW2S\^M\[!XY(TYL%+HW+[$<27U
M8FCM2F]X4Y_/:67#0@-6SQ9JJ8M ;S,F2>C<989T$\;TWCQ#Y358_<\,\DWJ
M,)1M MFP$-))6)^QD:>(/BN-"Y*2_>V[1PXZGC^;SE>,\$@C$'ZGG4PUNNAL
M8K<C?<W2:L-D4)7.9C+P@N2K&\I^&.#^1Y(,63I4'W>'?3D7!= I\#P_-_A1
MWU^[0C+]E#.GT2Z3\SCG7-.S4Q+*^WY; Y'$%=/&*:2V(OQ49 Y.T#,01M)M
M6YB/4SB<.TZV&B!;X\&IX 86O.??SG<OZN7CJ.*3@:<H(*]+*+@)8:>GYH2,
M/MNSL'MS9Z0D!L6XQ4,D73N/-O>5CSLZKF\B6'V4*L QMW'W$5B9B$@%W*Y>
MAU395:=3"1_B.#72$U*Z;CY+&=%!RMVPO_L].Z9 ;?#@IR%(;"%S^,94,WRR
MQ?.)Y9<</\J%(6Q?S*H-+!4"PFW'J6=$DH+PP@0M@]GF+R+%3/ZP!HE437;B
M0#<O585@@K_Q,52*HERP:,_.U7VT7ANI,V:CN\3Q)M7NTREMT_LW-VV<:S71
MS,T5V-6BQ1EP> O%,,7*<%;Q-WXM3^K/X0\Z!T$33!+H<E2U>XE/&9:ZJ$XT
M'VX[V%='O R2=8BH./DF+*W0H-;@V1U3G6M?U*ZVR^RIM"D^^#<U_1B[Z*QM
MF*5/ -Z%X.[#FG"L"ZP*9":_"DU<W%_/;_L\<>):EHSJ]Z\2.QC[&$(\OI7-
MD"67)%&Y#N."@D*SK6VM!6_YQ4$%?$Y,'P?4=O]!NKZY\&3GIR3W,:2814-/
MR[)WB7%OB3LTUV+*3_,V+G2K(>)1W62@I+*[O3I.F0DVY?@F20K3?\6XI]H+
MQ@?A&FVS+OON=6YA(T]P\NJ6[5U;),="KG[Z8&+&$]+)"TPZIH# H2>N\[.
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M\6N7GR$LB:])1-4^\*5D7>I*_*8\FTX,.<T*YST;YX08,FU>4C,3[F^!VR6
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M5"Q-$X81Z;QD!P5U3MB?9@4(9,4;#6F27;JJ4:,L1OHC]$M,85/ F[HRUW,
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M)>$HG\O+L%F[*5,F-BV:[5N43C#^\ ALL#:ZI**D,OI95!!60-2J(-K@NY'
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M3*M[[.YG/..'>76L5@1@[Q)#"[UB/D;MWNZJD84TXA,QT7LGA;[T9NES17S
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M%V\40E0W -(^68!\T9HLP<M*YEYS-\?/#;^K8J%^FFI2(V(@HAB3OYU:C*A
MMK3#GY\#GH;VQ0U@D"9-.)N#%C-9C<_R$D?!5DMRK$H2XNP#(XX,J<VC1$]"
M%N[+ YQW#*Y\O4^='3=Z#DA657*C7:JJ!EE_TW4J?H<2HA, R=Y7+:9Z=2O0
M1>7Q37X^77<0$U2P!-(^W/OJ3/SK#M08&FWP@''=.$YE/DOEP_A'Z]"8^C;
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M86$&Y&F+C#^\N-7WM+K;):X5%WSBXJ8F?[1S;_W+SY;L)(!+]@W=6^H''12
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M!!)-*?8X'1&"" WO8R@-D:X;MJ1N%W8EZW<S:,,=[V2@K?W:2POB!+9_:LU
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MV\QK"2LX!)4K9 HEGJF(H0V ?8%KUG:+*[_HC0[ZML0G]*HB*!'D5"E=-P]
M&._:%1B6U=CQ>AB$(O*X5M-/I)Z/[YM=K^,#^X@GDXMSLVV'I9%V,:EDG(I.
MN;NT1L"AL9CZ=&@\GPDBP:+\9]F0P$4AA%EQ;7!,T6FLA>+O25Y%)\'>)^^$
MGOD;^7&"%=G)DP%6I8V()O&Y0B*D+00!C&-VK6??7\KMT7\NJ087M,EW6&3=
M+5S^K@*O"\Q[]Q\XX?@+S7R8_EW1X.GWWE7T+5*RIA$<;6X>(C >/:5)XNUR
M];;IB6.VTSPY;515CO;T<;V#X*Y&6ZRR@PMY_"L)#'ZDG7,XUFFO&66-37V
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M,5I<?Y.%OFY"P(=_B6"K2WM,NPH<U?+V/#%'FFU_D1EY8QPN>Z?[N$ICM0]
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M:. _D# BV[HI_&'P +\2<"$T4H1H1%\U1GX[;I-PHB=79#A^MKF-/L.:%;]
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MZ:>2"&HC[HJ7Q6+-T8GCFZN  ((+AP\>4K7*H"NGH^M&)\9/@:<K/ZDNCM_
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M(-_X8L'B_$/<K1Z)"7-1EEM.3696[^/5 MA)0ID<1 *]KT6^HC&AJ%71RXZ
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M[(K\G&W3QDB']1;H23YQ+\\P[4*!F*D<SK%$'*"7UB])$S*U>J*F3=SPM6&
MB\DMR]4E>-PM.G6WCX+IZY%@&D4LS["8?0+CL17BY"3]:LQNN.Y6U>/^RQ8]
MT=!TH:O2T$IS\TX5/'61&$Y=,$BOP2/9>P"_#O6)&O/=?=11^[Y5S84V+HPM
M1=^<;'Y0O<RDT]Z-#RT]$/6=H85^MLE9= $-:'TT57&A:)!VVR.+)3S"L_L$
M;P0Y>4#[E1WIX@WISS*$/(9DE8;0Z^5@9MVKM&&=H(97(0=]ZZE3\N;IEJM-
MR,L7=S9(".YH/Z?H#NRF> 14WDV\E*GT\[4YNS4*E[2/R.4=6XT3L<UPY0-@
M05E[GTO&\E%V*_9BJ!_X,_9X]X,E[B29H!Q]<2W+:VRO8;W'=6+7+T/LBN#@
MDOW%G;#[4BRAJ\])Q#/BVS2VKX4_2 99!._'7^?BM301PTCR(:=D:WN^3/._
MZU;8;#I:,9NW$VL_:DASN_K.!YBI03THU>;NS/--&V_<A1!VH;,IM:'2%*LL
M::90INC#.=&X_N*BI1JA!GV']A'KD,'=;]0NJW5MJCO>$3]SEHQ>-'N]ER_7
M0&DX/NM04-A8*Y*HU8!_<\.M[C'U*';^=FPF,.[Y+DB*SQ!!];UIN@/+V&B%
M05$4%.$JI#LHKHD"QA5W<ZE:$HRJKEYHDP=1U"5VH.>0DQN2SH?P1=>UF,+@
MT1,/@).M^3N2-5N259>E3N_'*^5%7<[7)XG7/,O/0=J;@4PFKEADU _]<=$D
MG?ME:7[I4 /*%7-\]P'BV1[_(N2 0^Q7:T/@=R5&<EKUIEQ<?$+OLAL-X@6X
M6,])XH%;OR.GXU<ACCJZ33HOBWV]TSLQ"+:I(,C=G&"YH>!I"FGH2+3"Q6+@
MGF1^H:NO:T/.K;PM/:RY?5K.J!;G"3).B<2-?D5R</)4D(A"[9S *=[>*_/E
M_;-40RXCAOH%3T']I1TVDZ7% V1(F;>S=ZC>+=)4WP(MR&'5ZLJLXPMR],5@
M@7*>(</;P1Y615FV\<<@DG1/>Q^D_P HM /NJS13'M0O-K551]4AB$5EW4JU
M'D>;>9M?NX<9*V5&[1<MCBDN/JA9C4F]F:FK7.W/+XA'O>WZ6XK:R^[C3[LI
MLM-(4\V/21F)!P>H1<]O--&XHBXCYN_,$#33;989.*DJK=V)'3[&7]L^<2.9
M^^^T+ FD=0<^RS U?I.C[2><#7+\L)$#9/GY8I5"P!'9U#"UMD[[[THGOY^E
M.=_]R/=\ZX<0&#$6K 9#^71#-3D$MMO;H)BBZ=KB06N1Y+EH1:40GSM@5=A4
MOF\.=PITJYBRA9S GG!*,';R*%R\N[N7NJS[K!$2@?V<NMB ,MNG'!/8997G
M*F)5*AC;F_N=*?NMY\!YI12P[Z(&[9&KG7%(,E@=$^09;$8A2/STR%]ZH?$I
MY;;S#8N_[EZEO:G%WU&S!DRS0C\*BY A4O93MENJ/SJT46[&(1M!?PGDV9*&
MCUW]XO5OEF.0//+L_W7)"FR+RY>9FA[.!9),G>"V]_5:04XV)"^XD4,;)[^L
M(R^)'!LYE>\]KE/&ZYO/!";"V$2\(SAQ\TFB5^(96^[TH[#Y7H2C$.=7(.%^
M+>UF.I!I_\H-'O-S6MF!4&7Q2US!TCGQHCK?/'DNWM1TKY$:HO#%5X< RE6%
MUA$#NI1+<EKN/^2EA7-U)4PV13-'^8EXY#0>J!K?4.:1(?P&DD+P5[UE'Q?&
M(FSZ%?").TN,EQN^.0^O'[(5<KJ(+9>E2PS^=KF>0#NSRW@57Y)1&2-&A6K\
MD3%GK%GMC6[+K"0]/O8# !HJ6E*TXM3_)?:AQ?Y"[P*Y2H)UMK)]HB6R,:3B
M&U*XI7$*DP3L1TV;];L/FPGD+\./M@1].]*<KGI*F<76QU=T][.2,*]R<=>P
M;$E/JP\7J6<G.^MK>*[U+?W7A.U[!UHYT3M'1^E7QS?,20SW]4F?J14<](7E
MJRQE8$8P89X4,SA]@Y3X"\]P'15U0K-KK7%$4[\VF$L^]5Q1N.Z-$#]9WWT
M*E_#:RR-G?#:&/@XJ]'3XIN71371OTTJ=;I;5['8_"?AX00FZ@W0=$HH<3(*
MKRTIFB'F0E;R/:J]\C.53!-+[3QV&V( \,Q%^?2>!/FVJ,,6+O0 ,!7KW"P_
M3E.A(S7M_LT#T&*WDQ,*/C/RT*@<1WRT0=Z/CK9A:%+[P2P9,568%\1LM+^S
MN.F=S,HW4&F>]ZTEJC@H3W .X8XD0!Q#/-L7<^U:RBI&N_]X$Y)[&>7.,H"
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MS6R)&/>W<X #)WD:ZXJ>/Q4MC&O4A.[@@/+!O,6\Z?HF!].695Q8S'5+Y/5
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MU( Q8_>8;)LQ2>=N5Z!<"VJ4\QN'J@]56Z,9"7AMCL.RG82UGNGR@N,+G"@
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M?LAS?@*P.8B:W[H]L)0MF3C][DVK3;-L6'?S$6; CKUH'S'OLH+95("&SY\
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M0Z(4MUF";)EGKQ?_@3%\-K0GMFN\5EFMEIH9+9+U*5ID.>*($J/72,"U'Q]
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M'Q)\H)U#<' G[G&#PW^K'9SSXAE6?Z%/XTE5LI1UG;)^K.+3$D9)J7/#1\J
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MJ ,39=S*7*:H6X?SY<I<&L75YS V!ET<\&'343PRL/S_FP!02P,$%     @
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M, AOEQT.FE)4$OL"$X$8[T>($H01PM.'SZ]&K'F\@X6<FV#X+.DJ_G2*5MW
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MY..7O:6/96:N[!(*ZCR?81B9,KK% R@ON:^<K P]ZH#\^KM87K/G2*PYXJ4
MN4]/ZRG ;D#\GZ4;#)BF?S+0GO^[%P%,C5"K;Z __H+3ZF\C)Y&'+*G4&'B)
M L2]I@"CG'B&TZQC*W)L(-3S"ZUUT\V)?Y.&@_]<>%33$ALG SPS)PZ6941F
M9W7\GR9(WQT/&](7)*[TDQF(K3@(XU;' )2MF\:KR'"F*]S45;[N@_/"P -X
M"_*"*[?8'U/L-51E=%K]-:G9I.IK/+G#*OF3+W5?B_HTW*2Y3F@3=M7Q%$!]
M1C/ E8C!KM@E@6;P @3G_+U1^,&H7GM$_\=\>)Q_Y7E\V_V!D95S<CE*!H,
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M<W<NCLW2CWT;N2>4<6V@X^5GB5-,_5^UO#9*9<?!1<"OT^GBG6]6R:7XFUG
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M,<N+$@I>TMI<[*9L;"$;6J?]8#A3]DED)_1L)5ZEQ][6[DLBRFX\S_S7Q;J
MY#F7WAM(#:CI^U:N P8RYPI!? SDG(^WR"LFYO9UFA$SIK_G&ME:ONY8.BSS
M:TCT6T[,CJS.NAB?Y^I?X#KSL[M /9@,DJK(D]0>1/8>I;3#V?9\SNA3XKQ%
M&WR0?K+](L!R_QE=:6EWO01UCL4" 1$;WE KJZO^CKE-KZ<E)#-L))UR)#NH
M *_M0T63."1!Q@'VN]H!#<Y$X1ZPSXAT(EFV:K=?C4//UXPJFG 0G?R/.A$2
MR4"UI82ZY\H?/]&M3-0"PEU)-"'W/9=,0])*[[Z_,;(U,HJV=<&4*6U18F9
M#EFX"?>Q\&-NL%^'6OVX2,B=E/<V$A-/1=QF!;.U-"963_\-8* PRC"JEF?3
M$,?9=;8FFQ7'&0RVQ?/](H/\1*N^:[9-409<3CRJ236]>[T-R[4/VM@NA3P<
MUY0M,<2GW\)1HBK*EV=4(5J2AIPS3^XW'&B09^H/5F,/=RE,K^4^D5EZ_I!"
MU.(^87[H.O.?L2E:]PVK)Q3[FC5,ZQ()[5L\]=G3 2S)W:VE(B='SQJ(_)I8
M@<7"7&$1!"3N/CL]45LVBB*4U#XAS)2]XR7D/]G2)XHQ?)Z:USU,/)GE^@*<
ME_HOVO2<@H,Z0L&O_36D!6Z-;.Z57^Z^>+H\-<M1]5.\_P.SUI/3-<7_+6].
M_C\SY#]LFY2HUP15NP>]71WI\H0.R<\,:NI985,8/.7I[[4*.M/S"74!I EP
MU\]ZN81QYN*1-^()=NR^;ZTI?/C &$R?[7=%H=LC#^JK&L+XG*O>&0KZ71#
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M-*J=OPY.4B*QTK8[[4&R!IZ'TC$$6U7_Q;#*]?<2KAC*&=JO$O IE!YC?2I
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ML.Q"P3#T5I1R)2;<QP1'264_ZNN_O70A)KQ>[J3VG"<ZW(FP3.PCW;0S*H(
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MV"G,W,1/".'%'-OFC@7#5BCOV?J 0CV'=^B%HBFF*AD=+W>;JG0VM#IQ(*I
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M!]NDA5BGMWJF-X<^[^*;GML<5&O)D',4^/?;CHK>!;.\IX\W'MZ;?_DDJ T
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MH8$YR4=Y&0^)W)V ZA3X^^0:IOV\O27L8M]GS9V?II.@QGCFC3C'Z;VFO')
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M?@GF_*.1VGJ"(TD-^']\M]:8'9TV$!Z?"(1]>T\R/@9\/@7[Y8?_IX*@<BU
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M0*CUP&+5ESJZS/1VC$^SLVE)N,^X=X*#!NE&\_9?WUM.=I/X4QQ=/I$V@PO
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MNT5OP%DY$W8K@Q^.M&D@86:OD_33>RHC$25#L7QK%D,>YV,\+CC +G?<?RS
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MLO5$"E9),CYY6M/&7K9I *^\0ZTRN1A7=14J>#R@]OVJSC NCA.,HR0.^#V
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M.>+C'UP,^6]1+GB66]>8/;]D5?=,T819LX^U1 ,%0VPL.+W+,> C P%$"T
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MHZZNY<&DRN-3-I[6&]N1MQAP7D:-PYYV97IV_'-K,VV3SW4Z767H)\W5D[4
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MI;II/*,JL*$\7PFE;]N-BP-[O/YP!O@[+S@W2W*&\LS/ #IHM1:[_;+3"P'
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M3)G9<<]'?JDH\T+>@V0IQZ78:;\12=!\[$4'A2LN[Z69=#ZRG7[$.Z-7LSS
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MX/P0#;@F<4,#L']?JYO%(#\]\!F?H>R_^[4:Z-(CB? RC)KK']JB%DOX-S2
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M)5+]4R^@!J,0QW=5*=YV-_'U=6&25;TI[F99W7:OI3YE\).3N0J5Z64/SQR
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M>PM'$^[L<-:(?^]6S.W*H^[^1AL01M"',Y")5:Q1A3AQ^)=ZFM$]T7MJ&BO
M'%AFOD:T@KWEH!IQH&]7E5&RJLHR/IB;32MJDFG$LM*4HIK_3.XK\L%+-.!I
M-?AY>+>5QNE=H>OQP(H/C-E-.8\30@=8EY8LXU#7]&B ?K/6P8A,<6!VX>U2
MM;OF(E$G[PAO9Q51PM3&S3.SPUF(_UE ^WSYSW.[0SF5)^1Q-%U!983;2G:!
M,>F3"2+D'.L2D_'^.@?TCV=?K66I*6=TC@)U&KZEW9LY[?3*A?1D,M&=T1:@
MGIH'6N9QHZY+4%]1\?NP\*#\X-AIU0*;-=X%P1M3+#3@%LTT_VR<8L\OLNM^
M)E2P;0Z,UBJ7YASYS@@#IYW_VRG^_\/)!7]8TH6F,YUABO_HH50!)%[1[,,>
M\0>'_OZ8Q&<//EI13CLIF<L\JRBBRZ++>QUG)VNFS_>)PCF:M_9LZ.U1Q\E
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M-"5D +4WLZK@;3LKC,D7O!KJH8_U!*7QH1[=QT+YQ_C9HX#S,/Y9!86MV._
MU;D("%AC"+PB!"/$:.SHFY,,A!+-<:I'" K<@[Q203$V4_S+/_*#VY]G@D=X
MN09;NY-J<Q"M 323/":GIS"K5#2@W6F5Y@H-H+G< ,&307_7H9<@@O8I#A*+
M%O&_2GA(8713IKE)"CB2>C'Z!'5/O"@<#<C(^"RZA2**?H@&#,/1@%86-*#S
M=V60GE#P%@+\^PVZJW:CK2L/1T#;Y$\V__*2LG_N\^(,G'0L<?Y:!X% Z&V!
M_G;\T7!E42DT +2&0F!X()%Q)!IP+]@?#7C9VRKPER(J_]+A7V9$6/RV=6MK
M=5@8,\ZU3M I"G34!X9A9OZWTSMSA+_B)[S&EK[Z2_62O^U0K)EF _'05X,$
M\TP0J><P@HGZ.69R,#3 #R->83G_:H;3.7^SIM%_T^O!-AK M1RX^Q5Z=06O
M_,_L4+2C[!7X#HUF%WAXN"O=^>^7TOKOI@?<7CH.M:8Y(_A\^KMLR[]TY^T%
MZH<_N\YG0_GYL9]F_/U:ROZKN4%E_FYO:?ZFR[E1E$D;SO\(R_\(R_\(R__?
MA$4*#'8N6JB>G$\W'XRH&>&+?F-<_\_H)NWOYS!97170M\!QD/.H,Y4U:I*D
MI-M)+5R@?<5*P<'9_2_<J<#CWR>R'S0\-G_Y&#T((E!DW"%0[S4LB@RI$::^
M*HJ/=P?FR;@Z]D(MW+==JX<7X/VR%1/I[3:IRK&YKV\?DT>30#GV!5:E^,.S
M5+#JU\;J*9 O)!M@!/JE-7[F@80C ;JW)>CVPNGSIQM$.,,=YXP7C8;F*2/"
MV03&KJP"R-Y\Y9_I(+UC=EQJK]-]T: 2_FR,*8*=TS]]Y>NQ_(];+S=3<[-*
MP_(47$W821:W=*2?/8_GWI:1YN##P)D-'Z,U S#!N]!73/6F%'V6+ E#0D+/
MTKTT^Q183X Y,J[Y64I&E<6ED6:=R6Y!_(],Y/K&2RKLR5=D5$Y+PL!$O+%M
M:MF/L44?*#FW,-2.^DC<D=REHVM?IWNH0[Z+,WT[-1YR>,BJG)Q\4;MQ,K_#
M?W/CJ]Q.,:?-05!2+T\&M"QWN9FC4+QE;UU"+A&Z:JKIYZK3B6+"R*'QU&@Z
M0UVBIT#:T$/F0[]X^9/NDWL:KK8?- SV7>*U[,512YK?@R]&+]N8^P3N#0L=
MG97PC[?D\H]7_KXW?.</_2T:ZD93['S1:83KJY!)(SF'[_&^A+NL5L<5.SY.
MY\^8^']1F"LOABLQW^3LJ!D1K1]0Z05$#WUWE,IG/:!%AGNZJ4)OA!%7Q9ZG
M7&64+O/$?EC)XZHDDE$?WU:4HCP0PU?;71AJJ0-TT/TV[KX9X_+^+ETJATB.
M<YSF3X-(#+U2Q&/.7Q^[-:$A4:#Q%[28*\9BG8FM0>?(I?81#?#AI>D'C66H
M#KE]S;BI*&*:$T4E$"HI*ER[<^XR&[>KBOC':$T&,K\9B9CZ]+E%T.3H-AOK
MQ.8OG,L/K3$]9R49G5:*NCYH +0W'CE^5O+TP\$XI-OY:QNB2\>QP2_!3(EL
M[  GEP41]! >HK&,.=;?;/]+2RW_5[=2)<NQ/O8%LN<&2<MRQ(YFY\6+'#"A
MXX4F=7E3ATSP>03C/57S![?6SP\TH9R#G3&U&5LO2]HK[L^C 2*T$WD.W7$%
MZ@^UGH[IU/9_.$_(BI5)MF0?'&<2(N$_SI1W8Z90!NS$H4A>&_$[K7)D->]6
M3<<J!%$-K2P5K+(IDAD&[U^IE[!<):5.-C.XS&UZ'D'6$E?IXBW)?PR3(>RH
M-XVSHI1 4LG\S7KTLW3:6TR4OBQU"[9X2F*$$C0NOBQV26--ELFMH9MC!_LF
M/T,3!!FU=K']CHPG)[0?Q29VGUL/Q2G8#I8@5S2!+UY0A/K<]#X'LWTYK&<[
MN\RW:\C9OM9,BIGSS<,8@)+3VW[Y]:%-KY(78X@O2DWU4K9JOV#/RE[*(5CR
M4^N]0BH+BVXTJYJAFR8UM3>:Q?MR87Z[<5W6BG?>:D5J$B8Y"XAX$6[IN57F
M.F%1OE$QE6%.1!EKS3UOKKO6KN&N)]G&%HT)\/;28+^?AQPSL%5C'_URN^2$
M[TASZTO0\]33\=D2@]ZG1W#GB(T4FC1Q XB$?(&+%T=AF'V,J6H,<SLS&8!0
M(;GNII5"HL VV2_:_NTTKT*XWJ=B?VRG=*_+U4; AUNEQ''VG,&G>4(RO+%C
M^IF_'0WM?^1@*+*U1T641S?3A^<<"X,R@6Z54,)OX#N^.=I?;J@#SSC4U&[R
MJW1:,DR[604V#R<-@I92;_Q_H%Q9UB>>Z.E.2=^,UKVY6KN>XIU9%&E\JL/K
MJ5WQ$]G)<8678YU"&^E+"C&AW)F^0UTN &(-?A"XHZ^XQAMR_$M,TFNB(*NP
M\,W#WUX%8%'4*K^5&&!0]+R04\>KYXD-E2:2E;X_O!'+GE?O<R7;U=?%T8S&
MVO'=N\H15%@//EE"OY KQ+21 1-L$CYU>^60 )5%(;2:5^..66_#F?.?843Y
M5@A$P@NW(H7*C5(K<"HGP;VS?_=>86R#=5TC_R"W%#-=UKJVIA218>%-"4O/
M.N%Y24T%N+.&17[X,-#7HU@[U2# JYY396*SS.&"+[_>LV55H[?(I68P'&-C
M$RUR$,1?0!)JZC,"_8U?6YO#<%9Y$%W,C?(D#!Y\DI@#/O2G*/N_WV0LI-GW
M2635E9EO69=]V.MY"JP4BBQSJ/%=L\%2P*F1EGX#P^J8OOQLZ6!>5>?82+4N
M\WA):<&:*GU+3?K9LX\2=ZA7$_W_=#W#/]'(KZ/"\G>/\)=^];P?H>PV 6%@
M!6TY<$Z7O1.;MC@RH9>.?EK'T#)KM9GW5"_II2[]C?(I64Q<9$<9"XL,YU%1
M=I!^>97#A.N9M F/9A+E8V$@EF*UI_ 9T/)&.7G)^0ZCZ!I;+TVD^1 ]3R*6
M__1LK2P?;4-JN7V.V! K^ %VG':43%!>.'OC\@.<HD&MRLJZY@;5F,3K*-PS
M8.N#^@(/ UU47^*8295A126_V7O5'JSCX=,\=:> B0;- FWM@/KQ.6N15T]C
M)CGVWRK64@[DQ,7HNX1G$;-&W%+4S4WLCHW/@[U(@)[=**F/0AQ-]9;-8B-'
MI@3R\G1W9C4HA-;"WM!MD%W)YKEH]<.3NI]:!KI3I<WS*M)_COO45RCJ+!5O
M=L2[@E<-=L=OJ>&EBWEM+<$1)47TVG/BD*+AO5_U!U]>M7N)]/0D\UJ>SY[V
MN,;1 M5QE[$,(,I6F7/?PGY@T1]72\XKBLV^*AS:_W&72DGL3?+FQG.\SL2V
M61'MT<;:X^Q9D\69RD'>_<BW6^)H@#X#\*Z;B,N&M@*WSKM=[* <6[!%8X9*
MY&8MX+EKQW.<%K$N>RTQSL/[,NUL-ZZN42M2*\&$!;1EVGAS.7K""-X=^-U_
M5+:X=,"QJ2YNGFD9&PRQF22+NR>_JQMW->6L4PYA,N\^*#Q\F.*)4_UZ]!N]
M;@<)3B)=&4N%U,8WLY\6+#$9/>&#D/MF#$Z74FY1BS#"#?E[/V@4$E_=+R#9
M%FW=>647X<MZ<&08Q.4*Y7YSDFS)^E8H_R!_)(ZNBZQ(8+0F(63@I2R0NGW:
M;8W\5ABB^*>Q#8F3,_GUF!.+7*U>^7,B0W/7^(P-?2TUG<M8-*#%=A-J)N+P
M,RR<1]T^QUXI?/.?^OF,PW/+V ;OV/9MTQC)#_Y2X//$P*>4SV"H*!S4"]6Y
M(M)1K(EG*"T;(LNO8=./_*\UY7&^[E'KJ>DP43>W0MCLMX$,1UYA-<F!%@BN
M$6YF7R0((A=3\:)[P,!F.4-!.YKK$6HO4#ID<*11FEA[B_G_M"3Y+WJY'!MZ
MT\+,2IYM %0 ]J"A(?[M[J%P[GBR"FN/4NC*T?J^ 3+#X>OZ9@/XR=")A$5N
M9Y<^RKY,HIM6+1$-^"6[IM="-+XV49T"<9,>$.C\M0.[>$7CV5,O:C4SQF)=
MIEUY[-=<U!YK.SN1;&ZDWJ'P2CK"ZXD%0_0XB8KAL66EF3E*:0E!+_+^3G_!
MKEK6EZA-8>('OGS)9PW,%4^+.+<2/!2[:&8<[?'G!YU6;HI$ORXN;QK@>MV;
M3W?;BDA/U2D^A_+"HH+LS%;O]>?S-X,%W)VBPGCNY$1+RO5,A._X8!7-[XJ3
M1;%M<OB:T<T:\NP.DK,UPKK!3Y^8QBHYTQ5BK,"7_YHZ=:I*GG8.*TSUP8QT
M[W7>YT8;6S]5VE?1B_/P5LS0B=9,G #.FWYZVX,E=K%%CF"3U^4-5K]']RSJ
MK"I9Q:E;/6JH_>XMMX\\XR1;#4EAU$O=)F:H+GGVJ=47.E_\^T%2$<[S*))M
M5PJ#'X/U61$U4N:%0[)2YWD,3,>-3]72A&H/Z 8+O'W:G@71GHS1OP*U%P.*
MHW-L3FS[BZOK!$MHXNGG9?M3ER.645I^X?G0^GCSM<KO:M)2' M5A!5VH3GO
M'&8/;_5 ^6\K[2OI-;0$YN_%R%)GO6/4G1%!="G+UM'1S5;Y]_;N2#/&:9M%
MY.$,/K'D%8JEQWT:9&*[BO LJXF:^MZ1!^GO>RK[)<*4$\?$V*XV7YY PVPP
MC(9*D)D_-W>Z8;\_AUG25HMNH/&=ZLAZP)%\37/PJ/T +)B5^+9XU1Z22&7R
M,7%SX.!#^4W94Y)9W^_2)EIX69H G)<L-K.[ U$.>LY2+P&W/G+?)=9\;#S;
MOA\[WQZ5^1CR[,[M]X1;K^4%R\4PQN(/@QI9FC^Z7TQ,J%O;S(0RTM\_"*=7
M&DQU)2NRSFX;X$GBQ@ O*^+PNB+F[#:GNMPYE>S/=[LQIUH\G/T)W9Q\Y99&
M5'!>]F<<;DT);MWKU(DJ-5/E#LQ9SY FQ8^8DYGU)=;EE*V)B6.UU6?^[GS_
MUPTD?2;_58J\>"9>(J8+6I:;;D=#58V8'B_,1\H!YK]]&\%_HO&X(O57!R&E
M+F<Z$YPSH9?(";5^X6O"B?"\"Q"1^_0;-.#'[]QECI[9)OLB900R<9'9;-B^
M,Q%Q$=U7\U2I *!98W-OOOTI=8%3D81GX:[=>].H5Y':#[\NU3)%7TK+FF7;
MS5J$Z_W:<\I]M&4JT"?WDZE,; \\Z&BK=+"GL)D^L&4\WEW<0_V\JN?=+!=<
M0WQX3>6:[!T:</P(W%Y;IE<3I:)?%.N5K/QZBI]V<LA;?:1)OE36$3L/JM_T
MR+#+Z5,-WB]9 FYOE[Q Z6F71J2D/9-!;0#%SX$#BKF0YZ$]^MO,19L6-_=F
MNWFH>0]6\:70  <S!)M&NQ]MXX0#%W^:'IV2>O_="!_VT?0HG-,B.[PM =!#
M43%O&NSM?BMFFLX\_.C>PN*(%*]ODSDD%#DCUMGA(VO_)RN.-S )/ #)>KLT
MQ1>E2X>YE;T?'!</#!\OL^ND?CA>[2LIIN[^C?,Y_J4)7INRC&QY41*P>5Q?
M?#CELK8V9C3XSHV9<!E3=PM9M&%S36.TJIV[+B($OY<E%6-+Q^2/'!ET$>W/
MM=HLEFNG$HUXR<)>UJ]YDO]0V_6US5/FU8[AMYO($?=R&)@83W^AQ$%'V"+T
M,I)"F!T;@+1)3FQ]DPLL-NG?D/\PI_9R6/S<_P6P[)?IVX+"'J_@/?D:6,*
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M Z0_"%@HD.Q"-'?ZZ0NRG]L7?A5Z&(+O7[G7]$+R9Z_DQ:K.]R8!@->$'@!
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M^U:LCS_7<O-?EZC_=6?J]=E/?^XQ:F7-'%K]PUXJ5*<YG><P+'P2*OGK$JV
M-F+/*[-S43*! T"+45#QAHO0<?93C%[G'TJR_DHT'A7JNQNS$O]?9/]UD8&L
M%OL0!CUY]@[K4N'4&0,D5[,5\A1(4Y:NDN+\PJ<K92\3^7-82,)[*(D)KPZ0
MPU;&Z#>Q,6/)[$I3G9I198A^Q&'YKI/DWM"QM-JWLRU;F-P@4ZYH(DJE6_;+
M80#&JQ5[Z5PYA:ZEGFSO/IQ@7*NNM%(O-AMJ:5.%EM'(*:XQZHME;.O]9"Z?
M I72N^, =YI7?4::%QPO\2> :TCW@+M.8CXY)*<SO]V35HYWU(EPZ?&LDWL2
M5N<7X\NK:<TN8\)OHTQMS#1:F81VSK6]/FOVY72Q&D.<7\(U=NRGT68IB#I:
M34X@^4[29#?+428?G:%(:@12:V>JXS"E%^=R7G[J7+3OP]>BN5\B"MG>-/YD
MG^$5O8SB>#W1&C9&T;*KGYCWS@UQ.4B4I =RV_RE77+'IOI<O.$SE6J,5)[;
MLX(?HD% V[BQ+*_]=9>AUM[[:ZF#A9:"&.94CBL=.-M4^ MG5$DQN)NS=D;?
MK!WJ>58>=J5QKIV2QPR7['_A@%69<'L>GAH)Q-W]?:O[5QJR 0WX(7ZN_A=.
MQUZ.8=K8Q,D/3+\P/\"&)1TDO])NG^.LOW#%TU#QBH:FQ?,BT>;&9-"_^2+D
M/C80O]837<\ 'Z$TM,+OK6;2^R/POW#UMNRG(T<7[[>^[F%/G24/8%YYV/<+
M.8Q_9CS&U'_WA'#\S=SESG+ $MTAZ)*P64GRS\QN?M:,<M\>26%[_<54!P[0
M)KR<=D[B'QOP+TS<C+I"57S\+./_@"1R3.YZI3]E,UZ1B+L:1W]IY6LF%'@_
M^T\9@ ;(4J-LAYI^=UZG_;H\:#\G:GQ9F! ((Y$=\^,L;GYMCZE9,^//Y+WH
M,NL2-:VO:YUP0Z]517M$O:@O>^8<22C]@BE+\,EZ'%#)+4MEEW9FW>7Y 3O
M/RX[DB]7[?4*C)/VI5CM]6=Q@_WO]PVJ2AACY_77Y=N*14DT-Q>.D ;"(^S=
MUN52Z9U'M^_=;,$4XI$:M$0TW_;N:';S'$0ZFH!N/R6#K*3OJUDKTL6[@"JK
MWP4V!HIMB/_<55HI#<WP,M$N/RQ*K"AK=S9?JE(RMU]2B@08I]@UYA9R6EGC
ML8EI(JA;Y4]%['12+)//69I6:#M%[+N0Z2 K^]OW7Z+;5'<* RB$BTU)2.:L
MFRBJJL98+V01][\*SS 29NP1>!.HC[W-:I378P'<'!CR8=2W!:8EJS9<PDLW
M?5(][6^>N^I'RC56<2:_2^4DKSK*736_']BR^F"N@E1>VIR+W.I=-"@=.2,<
MS=F*UT-#<ZOU8;*SFF&+?6]924\-+;F+7>:3J.F0V,#)/K!*212DL#MR1B?=
M,&52HI'3093:.R_874738)3G;1[,SHLH@:G&0Y;6BO6K" YP@A@>NY?.4+,>
M8[J_\*Z>NE^D5$VQJBY% #B0S7S+GOZ>NAR%_#^5J?JWZ%6B]>X2)-<I*O.S
MI5D+7J-$S0(TQE#V8%_3SD7V7N$D=O,U[7&_EED_2UALK>E4I#_SUOGX;"E:
M64H0=4B?NVZJ37UA6D="A/ZD-UY<;"\00:0BH4LNF) 6]7/2ZC /(QZ$6FC1
M9Z\DHMA57W#T9.8^7Z\#6[RP,J70,H^9U.[O-.8@)6"S>>[J__ P(O5=\::(
M^9JGB6)EF*23&^'/3D=C5?NW#D\ LZ81R7@+> )+WLG@)L&:PR>UXIA[W]Z*
M-0HPO$8>T1WP+5!C[$8P@LL4AX+M(4U<MY>'5Y(#J@JE,>=8 <WLS)B+;\$Z
MCR=F7:8].^#4MMYFMJ@FFNHD51E9?H>9KR)GQ?MMQAR5AP[A/+M161:FT2^Z
M8VV/'/%]Y4H/2@+G1Y2)IXKQBWO:>&:CI5JXTS:-\MKI61MXEQ+V!2#IE3Z_
M&G;+E #JDU9"^SK@1,5-APZ-_!G]A5K7CJ:'AY\3"N8B>*0KZT;?2&V+P5JB
M*BA_^-#!V[ZZ23)Z+710VOB8+=73<.N=4MV=JSL[*Y%N;JAL'!*@X7[R)H6@
M(;!"E1JOXC#*,*#UE]G[I>D^_C Z.['@E!G 79$83<I:VK5QRM$-Y21Y;S)*
M]IP0:IA"1AY8(F/9[W&W4OT8P6YCFWZ7N7N(MBN\94(P<QLKB/+O*W@"SY7-
MGHWLH^W%>LD.EX_F59JG3]=F):IV0PRKPWTUG9=J*]R"YCGD3B8BUV7\U6%9
M%(,+7F=&C6.5+ =KGY-/$VTZ!B$<=WCI90 *8@R5<<N[WHQDF_ZWQQ_)4L>K
MM3\2GFYY'7YI]U+#M^_+@+MV&L>T31-G;=,AMG1IHCKL=2E,4%%:-,DE9*/:
M>PO15W%1:G;HV:5C0=/Q/$JQTCOY11Y%P>(@I1WV<0-L6;<B*O<E=6P06/#>
MBM \";VSDMLYLBB4*(71P[-"6T5#N<>M+XS_.&QO_%:8I9",WV".L[Y.>.4/
M,>T;P<O$XD*-JV]/RW5[.F_1_%)U':0@?1]=QQ\[9I2PL&<TXWEG<H"OGS;>
M?Z[=@R_\)_1(\LX\NFIEV:&JE/C&RXT7=3 ;HX::LF=,8JYP=53$]9^=,1B-
M"4K2-[&3U;S]P+IN!B_2*)A_)G*X\N2')<)XVEW< [J(T5R6I/SA2>7I@?)^
M,6U416O6V[8TBL=R>]$%M*:Q-2_Y=/,!?Z)V_'3EG=<DY5+]P0S9:5*V?K$I
M13H5T,:!T([SBD2J$/<[&M0CBMQOGG%*.+T\Z91LGTY.' S=<:<QTUVM^2C*
M>4PX7=-\;]:K&'3=*T225-]F.+V<F^ZS0S>;^$W;O"4XI2T5V)LJ%"-\IV%$
MSJ$DP%6D7.'Z*1Z^[T*$3GD#/]NTST;!\,O::<%[JL(/-5"/6_]FO8NG4I3^
MV7WNW3&UAWN[T-;#4*C!BV!NKB")+)$]#1S @QQ[$2"-I>C89* =;P#Q-CT+
MS,8!NB^7$VC@F8_E"9<)2XO61$59/=R'VSEDI[7BN0(D7W@V'Z1XV7V?N43<
ME6S$2*;836YYB"0S&0#S\V3G: 6^!;15A_;VH$H:=MQG&+Y?/M\X*38!'\R7
M+(5U[G]Y_AX'8#Q]G:&YR62^ZJ?(T!:3C$(^D ]AR*M7]?"W[=L7I](\2(U!
MF/A5K=,0M$I%L&@\H\1+%]J&%EPY3X:PS:LX\1T(RY]*>@@Z7>6V\Z 0H";G
MV[TH*SF;.(=N;M6:<;\UW9I(OTSC V^Z)ERY9)(7QU<!;4L>#O"@X]#Q U?%
M_IW9>5V_(I5;"F:GH4+A3^>=T_;V2J1SZUBBREX6]K3?+GIV\YA?Q'F'M$M'
M1<+S+)58(LK.YT%8*H3<A8\O($+GJE(39<:C 9.+\X45(RNHKZ1=QE<_9DVI
MDJ>@,J40:0:0T&OY(7%:_CJVD(RQ?<M0;90I:3L[B.DFIEEP#=QUI*K \OKU
M(:HFY9:P[KGN^C&S<HH1! ([\&R/P-,>ZE^[S/X^\@JK"=GC8Z3>/T'B &AM
M!C(<(.TJ CI@Q0&ZZMD?0J?Q@VZBA++4"@N%KF<7=RK=TN\>&&0,BTV.G6Y.
MNHJ+_OA$!;\CP,M3>DP#V]7S*1:?^1NSL&$XG54>Q:BZB@S''+/P,F) K"S)
M;CR87!WL^G>S!R[&O(?V@R&5XD0H8NL<(WF/L.\?U@ S/=T7XZB)+QAM'" J
MM+7YY!<;=A3)P;)A::5=29PU6@A$?-SEMJB)71:*K&=\8\BZ\0FCR 9SQ(AF
MVYSR_0+/F[N\^EY_5^&)M##]5\ JS+:R^I-  !F:V)#;PCHQ+L$.TG6J>^ZB
MH#E:*6G!/=E8./5@_NZA<?DR(J3!GA-H3SJ.">N+8;XWN>K6;=);+W*X<'/;
MF.7@*G+3$Y"F3)SVJ[B-TKMKSF7YJ#K\77A,N(^.RK+C@RU]P?89%?]Y6G!]
M4M]L-)"<MF[Q.LFVMHA][_"^Z1MU]GFC8L\XC9^:I:.KU;"]+7;CI5,9^J]&
MC03.$DR'5:6.R\%#%5X5/;FZ8'"\NH>6;_@2KQH:H?9ERY_HD_;(#FMM;:K,
M1;5@=+L#T;WVB29OHCC%3?\<$82!FS@#=-$!8[3,K6/</-K \<:,R]NYLV,B
MO$4TP-WC['R4!1TFA@.0.)QL&^@NCW$S]B;>*NLM%CE^N!Q?%GE9!)+.;/B.
M/NNHTOPAJ)\:9T:94!@;\<*A2^T[8?^/:P-2&["3S=@<0OK>\+&JJYE0>OK?
MX%TP@P^*$<XKQ/9*TT<ZE59WGD*<2 /JJ!H]CK5Z.0T21Y"<*C4GX&=/^)-\
M^L*S+7FXS+Z;+ M\-N55)N?V2HB-S!)Z:$4'.QF?("G"B*@8F(CDCQE3SH87
MWF=]GIR2)V:UJ:H9;;Q5HY:GY&);5*N3,Q#F9@XC&^C2HXHE# 2F'O*$N!LI
M=#P'Y0V<H@P4XU9\R7U/\# GQ5/RXWC"+5TVUHD;8-,L[>$T,4\:,NJE%Y9/
M>M,IQ4&-$E".A& 7">&#O1SDC.SC>%<F$-5UWB>=PLPQQS3%== $.46]Q&$$
M)Y\V<]V>:6YDVM1I54Q^])(6)!INO"$@@QVN6 =?J-W;(_Y)=[]U\(AB;$)@
M.>VF['(8D@'2RUK7<]M'\;;N&Q"^F]BH2S2\/K^@ZWZB-GV\C\D!]XSUU02\
MX;,KB^HS"B^*I.5=(NR9G&Y%3)4S^UQE573"9N+<L-M*MC4J$?+E^^MPMB_R
M@C[+)4/[[%,?S NTUF%5EOZA9A))63/3AH:-'5%!MV$NSLGOTASB,N3(62U,
M+=@>KYX'_[U=)?\,%4X'1S3EY0U:N"4MIA")G+\'6Z>3<)4=[,,PY,:#[;OV
MA38685".[)O#0=XN<GH-U>@HGPQ;TW5:/H$Q&6K[C#BMCEN_OI0*B9F[[QO'
MR=GM&HSGN/*8?PZKIZ.,.LAJ]SA7J= Y]P9YE,)%9+K7'4YTVK%DXPT"15XA
M;2-CSX-][HN70Q!'PB;UX1M-?+O&<#D>.V['_,M8[2+(Q@=?DF>^0FGMYR>%
M<OP#&]?B>C=H=>^!9#A!1%YF:C$R,5*''DD4XRD('""S=P1(:#R+%X6>")"[
M6Y2":=6 5D=]H@IUNV23:?XZ7&1:I;?BNM;=8@4,_XD&,P;Z<COGHBDJC+S[
MKT4K/),Q%+(0VLN;KK?E<*W7]86>"2L/AM;A6=<%PU+>W/DT+V-FPTRXQ8=&
M&0<VB8V\*1O.&^6RK*B:H9H);J$)=[HQ4-OI>:QY"D-YAY;KU T="6,("JW/
MYS!5B02P6BM/CBBQF3363+9BR'I%91JA+=^F,?5[T(C];D3*1IHK_K.(J%47
M:;94/^!(?N'IR%":V?V@ZH/3:KM#PH[I[\^'(52?#Y&(;TQQ'C?3@Z[UT!#F
M%^W?16L:,PA5H1PJ$$8,U.H=R]-.RS^B CU@*:[]WN[DC8CJ189O)H?")?36
MYZG52PEOCPL\#*G P&:'$\*XP;<3%+EH07T36FN1_ .,B'U.\9)(SG*O0J_\
MRJ O+&Y;JYW+5)TTZL4'\R<0YDTE 4/MR#45Q;EDUI"PDA]II"?T\O-=0"2/
MEONS_@W."G')#T?>&@8__!\.-['8/D"FA.OH.V236L1^+QQZ-[8KEKC/_%E8
MFK>G^%KKM.M[4-:TQ!P70[_G3S$?M0.%CSE^#C1N'RMI'-8@W">$C3?--(>O
M;^  2'W'17M[7\&E3TE\Y"+KT+0M\]?:O[X9PL2!HU=2.F*;?+%8>;/!;)F'
MV XL$A)A9_W3@'IW!;9F6+\QD<ZH_VW$EZ;$2W5%<>S80!O"$OQFG,MW'+""
M;F7#QTH.-*I"E1!*WZP%%04]3D@5S0EB"Y@C?32&Y<QM__#=U8=@_-3WB?KR
M:KU:Q\PW L4\J,T/3<(-7\Y$[ZU-]8CYI3)77#NA!2W;33)!A1Z]S)2*2I\N
MS (0;1P[WIC\49?0!-7+=@>_C!LD19@Q+Z2O3BBHWZSTV7,W1<AG04/;HI5/
M,#()_+R#Q.V<A!&M8# =*2BS:$VLL'>X071%^*$J 2)4W@P'>+('&1RZ@0GV
M3G\8J"!K;+5L^!N6H=#'YBHRDNLSCB,Y_X(#S#'VEN=EV7W?[6RR'DV:ZSZR
M)\F$ F4_KHC9YTRUYOCEL@<I<L_Z6XI(K*\FEB]=,G79\#"\I&CX5+J&-RSI
M$1&%+L5L8D5Q@$A\DY,S*FPPN$%@5!,'*"F]&E]913NU [GQXS$_ Z)_HR0-
MK?V[R>.E!K^E?DU#E)B <]Y,F%E9+83ML9Q1H<?K(\@/;QU7.2WSY;VP6*VX
MA,Y-[QLY]H?*VJBU0.[@SDBHL& !:S5'%U]4BWAA:$@#-V)S6A"*W$,&*0<X
M[3N(=8JV&MX-A7<UWH666., /"UIELTE?(&C&.8"R=;6I:1870$\X@*-I4 )
M&^>>GDWX0&VC8[N_& ISWS'C6XY>1U6.%+%+3F[KXDD+8X0//?FX#9N/>TT*
M=:7=<>D&P[-A,6F$H:(C8RC_I?QD%X*@W?#F:N!*M.M$(FR[M6[1!%^A<\8&
MQ-'PI>?&T,S++1?G<.=-XW@Y(H0BR]UH^RK(\!!&?<GQWE9\*GUIU1BWP'.R
M9\I"X6TKS>(* GI7AD$?\WS,K>?4<.OLZ-=/SJ_:\S[7G:YT.FOFI7@L2/R0
M)_C$3T'^(*(1^17BMIEN%[7./DG.[I"7&IKC34&NI:2"H*+.W@N"LA>P_P/\
MV<$'QN@@VAEV_OS'E!=1\UYPOPX*Q[>OQWH-"]<K;'STCN9X-,N+^;H8GC8<
MS&?=)M7C+U7$>]8TXLIF@9B&0\&=? \@Q5+X@M<,&"]M.R4>US8]?!45E,?Q
MKN5\7"DYAYX^6!XIXMJP\KV>OC-VQ%#78)#+DH,ES"CR1$.*Q9]"W/5Y*H>E
M?34OST6O5]$"Q8*=:X!54\A17Y744?>UKJ7)^YM*GD$U&D$(=?E-DZ9N9SGP
MZ&IMDFI5]-$CBC[Y7-UNN;<NG/W\LF"/*UWZ;]Q6J\G*52KZL(^ A413ZMZL
M[7,PK, 5XDA</:?'JLVV&?/B/"XB7]/9Q_'FF[AG2HBT7!6(21"_'VVG8[$Q
M^I,]*CO> 4DWH!!%_4-J=R'-=F@"!R@5X+84)QIM1Q:!+*SO+G$6=M)L!KW\
MADQAR>DU+:QF,!M>;:@*F=DEFVV+=/^IUV(RF//4]OEC]T#CF81D"[.?.JXD
M;Q(/Z@T*<M'<Q0:](^058_K4'T*Y$*VM&$6D)"7:$S2$$5Q2T>@2A&&5^RQ\
M@E;+;\AT^+_6]B'P>0ZJ\JA3*#,TFM'K7C><E;L>X*U#),DG8S2CZ'CZ<8_)
M6FKP2S$1U@_8EU-=<<C8^0DIVL&E/T]L_OQS&>\M#G&O_6UU7]FJJJ$*>Z#B
ML*9EBJMOVQKS%_:>F0]<JC=<O,<*%2MIMWK=]57!PPP%!)<I8XZLC;/WF?S6
M85*M_MENV9_42VO8'S541WY+26+5K*=W?M\/<4A(MZVS^JB_U_?B@7$<]X<^
MUWOU,*F%1].MLO?/2@<;]=!R2XT2*M=G#-VC2L V<;<"XN27A<B5DC4<EAY$
MVP,9,E^J*=\#;*GHO%<OK8O*JFZH3I3;*NTM4EB\XRQ)6?*$NT'4BMREX7DU
M51C]6+Z3-HFQCR>FL-?+IQW+.)([[D;-1+5I!IRI4_S\98=-:%\CO5;33\G5
M%V5TMV*+4F9[)_=HUC!@D$? $ZO7[R12@HGW8\.VFERH;P</'RM?NK:E.90-
M?S_/B/UVF>N8!08/RA";D]CNL%R\1'<O+7GSNE^&I#H1"OD-UD?M)TYIJCD,
M9O&ZTXV,%G)A6-WAKR;H)SF+,QZQ) .>V0UQER!Y9&D-\MF()WHCGTMR'C:3
M;);;8@&'W!&-QQZNROEQ"E&G0'H<P%/B4O+!9A.]BHT=8DO_12*+-QCA\&FC
MB*=)F*J4O+!5D(-"R9Z]X]B6/;,6%OCOQ'5X_;X*. !S<0D.\/K*>J<K&\/_
M["(:-CID)?A1)+FQDL<TP.$,'$"3\2+K%]AI+D47OC1Z?*E[SIY9(:QJTIUV
MQ-.- Y@X!XA4+@6<Z,,O_4@N[]-K'VY@/AWB !.S)@-(+Y-+\&^X=ED<X$6W
MWF5S%.JJ#1UTVFK$UN]*_N9CF_\.JET@L_VY^5GC!>FG_@X-#[PFOZT2^'ZE
MZ!TR8;>J6KWP+X]OGC&^/2<:&&-4JQNJV!A?.2INR%1:^6P6ONHASB&C.!B+
M<J.S+JS6KX<D7X!8EPM[O^L),?P&8Z2HV6H4WQ(U\'T="-2@K@&8KZ#J#(1)
MB62C4@N]G?43Q?L[FS+H9%Z0]GJ4NG\[[6;*@%UC,5"'EM+7P0(NW8;N-"Z3
M\081U0L2E+?D>\=Z$J=D.1/41_(J&_M.QW]<.3S)"6_RGJ3/6_U8UG.SCZP=
M!ARRN_E-L9FY$$FE*%?M;^'T&S9"YK]16G?-P&B_I10']/R\3:_#K3ZQMYH0
M',"./N"!^UF@KW"^,GZY;N1!>L0KEV<6"E).$$;]36O$1KR+,//DNND!26CZ
MT-ZQ]<[<6X?<GSGA2K-5@,6-=RV+VKN@]@?@TKPIW?F604<+)L7K842[YM3&
M"L9WWJHKIQK,^D9-=S'4+]TAZ;!-F_8  KN>%P7&.8D+WK7YBN:3"I6QIW!#
M3W<F02*PCDD74V(;\]7Y6:G@RO9HP4:8G<(!56@%C65T6W_4>D2FAXT>;'3L
M=BI0\\4PEZ]X;G%:WHOA&2!?L!67BRKH<85U1B_(@XC7@*GQ)+@XSXHU9^>6
M>,/[.[3A[W6]>=Z)B2]=2BW8H.1%P^_19%M.DQ "4H'9F<&/XV)HH0Z[=+$X
MP!TQ#HF,4]3H=>5ZC\FY.#[L#R%DF)APKG+)S+8]L5_338E!VE"A6]'.L)1^
MVV'9Y-0=)5(#YF30=33$K1XI-.5061O;SU3_^=?/Y" 08[#> 0X0S.]X6X%I
M$YRJ'K]?SVOIV/'30$MMXS'220WJ^?4?'K'U9VQ!QV627W0G)1<$/-CWK-Y<
MDEM70:!; .?/?E^\%7JW<QL@)KM$-O3R5< >?$V=?FK4!.UV*0F6@+(CA&'_
MKXY</)HB%?]>NTGZ&%%3PT#)3Q/GX#FG>8$Q,6FKPJF<<-NW%C,,8[<'F<E<
M1]/Q&--6<P3NZ"$YGU34,J-CD6:B!R"V8^2%LI>V7DH(N?G[D>R:X5N4ZU1
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MA.?$"2Z]Y8<^)YK.A%84N2JIJNY<J:?YW\T<_U\@1MS4_P)02P,$%     @
MC8)G6' CN^WA*P$ 19,! !(   !I;6<R,#4V.38P.3%?-BYJ<&?LNG=<4\VZ
M-KR0IK1(KQ(1$*1:*"(E-IH(B$HO49 :BB*=0!0$E*H@H"!$0$1J0$JD1GI3
MD*[T*C604$* E#<^>Y^SG_:][[O/.=_O^^=;9/)C)FMFS5WFNJ][UE"_4Z>!
MH]=T]'4 .CHZX [M#Z". 5< ^D.'?GUH%P/MPWB8D9&!@9&%F9GI,!L+&QLK
M"RLK.P?7478.3@Y6UJ-\1SFY>7AY>=E _ )\/ )</+P\OP:AHZ?U86 \PLAX
MA(>=E9WGW[ZHGP'.PX>^,0+T="> 0YQT])QTU!8 # !TC'2_7< _+[I#M#DR
M,1\^PL)*NZ'R*'"(CI[^$ /]KUG3?@VA_0XP<#)RB9VYQ,1M<I?YQ .>LX]?
M9!T6OUS6R'NS#R=QSMX[[ @+'[^ H)#D22GI4S)*RBJJY]4N7+FJK:.KIW_M
MUFU3,W,+2RN'>XY.SBZN;@]]?/W\ P*#PI]$1$8]?1:=F/0R.27UU>NT[)QW
MN>_S/N07?"ROJ*Q"?ZJN:6IN:6UK[^CLZA\8'!H>^?YC=&9V;G[AY^+2\@I^
M<VM[A[!+W-O_)1<=3<[_N/Y6+DZ:7(<8&.@9F'_)17?(_]<-G R,8F>8N"Z9
M,-]]P'WB[./#/)=?9)4U'A$_=Q/':^_=Q\(GH30CB?\EVF^2_=\)%O9?DNP_
M!?N77*, &ST=S7CTG  $(-_*CI8&_O_R/U>*-*W;:A2B0N0S=C8;?46.>/?Q
MV+>IOKSZZO->C-[E"$&)%^TGT+))>,7F#$BK4+.;N2H_YWA(IH##9C0V+JO:
M^M4[(#S%DM-8X^AI;<"TCC@T'2-L5HUL4>GT+ "]XNU*](/GL';3G>#*268[
M<JAF57U)^?"H02!#62'/Y%NLA&_CQLZQK66[D&P2'>Y]>')5I%DX]X7F,Y:\
M3J\=+-\#J*F[7+[3(L^98-DX9#-9O1$].M0:.^*MD'_V"V&7VROZV-M'90DS
M(E1 \1HP/*!\(&]N7%47[1BO_G3XMJ6>^6C0/:<B*N!B105ZOT!VOZ-D!D+I
M21#BXRR7FO:G)*GWJT+I%E>.U-0D/%PSV439A9]\3P4B;Q&UJ<!5*D#[QC"3
M8$<NH/MD@S";:@LRN[OVQ2M4H&.;"F!9H7M[490#'L2_1C_]E\XN?VEQ?6A&
M,=W%;$JE<Y(*-Q"D9R L^X$^$38-:JX/;N&>6*YI*'L_EMMB)TH9C)Y<65**
M#G=13Q=)>IZWGK;:($JZC1MI20#]6+$RJLR=Z):L4.7GJ_+'VR@7ZJ6':0TT
MBL1?[!FP4\77$H[AF!.T!%='(4_@9]X&0%O-GQ=8PN)<#*Q*7U@\U_W:%6D'
MJ;>%1$(<II[L*SS.LYH(8+WT:5"L,EJV\ /6;V]3!N@)?O,F,P36<!-J:A9&
M2$6X8AT'4H:GB@^V^55.4 &6@ZD]T4YR%HP*0&B23]DG_(=.>'^"<5V(PY@E
MY!)F=YH*Q/VI>O^?.@"KB.^93U*!/>X!*E ACUC\"3Y8,PNMG)-G;O9;UBHN
M7JZY=U:E)9&P?MXT7?"SG(Z1[*._*C0QM!/#_-Y&'[=Q^;D?E[4G_982"OK;
MN!U&%IDO$GY[P+GI7NS=Z8UH.V:MXT/*\N#&+=9.;%QD5E$SQMVK0C_E1[.O
M2.C) K@8&54GAK_5-GD!MSJY+"0;$&QA*],V:^LD"*FB8^9JPB@R3-\U\!49
M4<=!"7PX<!B)RZ=7B.C53%$8#AW1F!H%.1FOORX70:A"I&<+X/+D<#CW#(0O
MX. &7N7QS,;1Y;2J0D(]2^^:,T72[#ND6G"Y1VLCU_?./*484J2M]L-Z$E;0
M$"WO7S]17)6G*>B@^28DVWP51:)?GL*R>OW%XQ(1SI ?5&!F)%H9%7O&;?+H
M@._A;92(G2O!0,,QHKZFT;.;ZV%3V)<'E#Z4\U]59Y[WM'G09]38$U6 <<@R
M/CKT5W.8&MYJ&=6*<MI-2REVR!L5HRM1*+DIW2@%\-DSGZS;H @:S_"3N<G\
M%!(8_[[S0(H$3O;#-'_ET*:LCLV'7AW17*4",C1/8581?^>PBZ%<[25:']P,
M@,[JQI"<LS1[7N=D,)L*>;S97"D[/W2I1_)9P/1S)CK/>MB/[#2UEZ_F+8'I
MY.,C7Z@ .Q6XFT ?X- RJ=J YX^J8/<W'%)6K'091MX3/U"98MX5U[P0GYG,
MO#:"@FOTA6K!K7"8\$K-$ZR"PD;![!>:9J[I]8V55I]AFXFNWJOZ69T_5,QA
M,5(Y/SHUTK&08U>OI3=[LR[=>G4(ZR6^(B.=7<\]Q"*=_8A%NL!JN)@I/&=J
MQ5_]:^5++IONA9*?H]$6T_[GF5)&RU0=_6RSZWJGH5C&&>BH\.5!7R\65KSK
M76]YIX.03Q'HEZ#/X]ZGFRHI)TC6WQKX5T1YRX?-UK[.&M[4/-&^5KH7WHNH
MQ;RH#-DK&K(X'WQU>_U>X:UDB%ON^JZZE6PLT0'O<)58Z5@\X0+S*W/9+]K7
M[!V=V>P=%1O#>$G);K$)K:W,24I^Y<]ZYRA8XE+[-CM:)OH?T_XOE.B5&?F[
M9QO\PICI!^?V!RNO6%.!Y^[(#2E*I/0A,H_)149MC_OH&Q+Y&<4#FFY6.=FT
M):8 RJ(X/5(TT>8!?E],V6$V93ARD?^%)[.C1Z2B?]CDNW?*%CU  3M.)IEO
MAO8[\+J1,WBSU\>26_H;A6RM)R*CA-%7SE[+>1X@%Z[UXRU;3$*,%E=E8L#\
M<!;7Y;78Z/@O?J_IDP%XUWM!_[/SBBD_Q)E* A"S_%%P4R6\JU#1A2?/;80M
M&>CB)>BET.+T&Z#4R6KAA!]S35N3Z2VP3PHO/$^@4]3X57 ] Q7XD^8YZ:_C
MC?2ZIDG9%1L45F(0MF++BY"AN*9Z>ER;C#P>=4*2Y<-W\-DWAQYV:A)YZ$;&
M5U6&T]ZHG"W3=XS4;Q9A8(F@Z\1V%QO^#O^JP0(!7M?QSL^*?>+LN^2O&-;W
MK\]^JGKEZ @]2Q^^9ZY)!=CR<#&49Y08*A *(@[?]%5<EZ @<(*Q$[?)+<A"
M]%*O,>5;)15 OD)LE.D2(E D4C,5"(G> A$=(4^@V\;;T ,<HBWA#[6<-/0F
MJIX*O$#^'9R:QY.,R/DD6=Q&:P-KGUAM_\X+E%N446UUE%F$3@K3.;F<S+-Z
MC;+?MJP0?P3IP*F6A._0SY.2>$B88IWZS 3]I0&?>@/LA:_('R#2]6(<Q/O!
MMF8(3*B_9?/@&72$0M=K9]%C/-$*-4*O+H6 WA%S=$:*AC>N#ZWY"NM(7B6D
MGI+ANA#7I==1B!SEPVQM@<@$V>X<<E(#Z&JM S$PJPTS80 '=0CYD\XBFQ3W
MI?85R43(G+4=YA_2853$BWX#D/]&\'7Y6?PKZ,YKN>O^-NBF5!9,5*Y/ ^*F
MX&OH;#S@$</ ;6<KH?]I6]">*4!YGJ8/F.(1^'4O7M:#KU)-5.![3=WHO9-;
M%D_(E=P"&>?0"^[XV(2'5IN_A2"!I)G)J..K457CD%MVOK@$ C=.]XEPJVYK
M QA'!9ZU915^#7P?60Y94BF.2YGS=R04G<3;X!>NC4Y!B<S*^@XA[P)O5J%'
M*,SS?E8(K.V,\%2<%>JQ'170#S?ZV)\S>*O%L.@*(3#C]>W/.>]G:B$!F1?,
MRW0++;ZR>;<'>TG<E+[GFWRM5/QX>*:.[,\QR'?GSRD(P4HO;MN X.9-XDF/
M4_+%)"WWGN\*IB\KR'Z;=. X^!LJP(]PUC0@/!GSQTTR$?T)ROTY@2=$;]H\
M^YX^):LA=IF_!)MS'FO9S+5D* >[)E_YGK#=3P54XLWC"B-@JWXV_:ZP@?7O
M9&W*0#G-;S]!-F9_Q?M1/\36+C.9!,6C4B SMI0V*K#5/H.BL!VG G/)XRZ8
MCY"U@UE#A;%;_0U@(O3F0,FM+V'K?0QEUQH*NEHXMU%O8[H7WKEU4H&Q,BHP
MWVNE?'LB>V O<XJ<1PMCD/N(J58J( 2I6*,"B^N@ R)FSDZ=MKHL<:J49_&/
MJ<"CQ=^L+T<4IEF__2(5^/R0HIQWDI42:DP%Z*"DUWGUWPF*6'7(WD$XA:)(
M[/O#N/@IHGWO8\SV=1\0B1DRITLZX_QY:O_D!68*/1*?D\1(NU.*]@P4Y;KF
M>GL9PI46@7O'P;MXVLK\UY C\52@F0]."UO9#F\1TVJ_YCL3H\5$!?K.?(/@
M:)PU3N25XMX>A,2(V+R[X:<9<V#42PFE+3U,#$7I]X/6^5,$RJ>]R-S'Z&F3
M[R7V_5G2^49$+TU5T[)4( D47+8&_9WZU8D_\ <TSV6$LZ)64T<S4WWSEVM\
MT#B71+<'UN-V:PQ/8L](_3S^Z')FL%#C7U36#;]!#@OE"BB?V7A:@>0@<C>G
M\3_U<G=$EPZE?4MR/7?JR/'&WJ[ V9K3N.[ZHI"B^3E?A*\BN?K9UMC5($@C
M.('"3_PQ;4MO6S:X76MK?',@>U!!26_G?(F"'/KQR^<*H"X]AF01 NKJ']P'
MOHQ#$PX3]6<4HS*/]6MH3QMSP!K$RLJB:>!F9GV9?;SKK4:4%.3,8MH*XD\J
M%7CJ.#ELU^5M4HNNR402N1A[/4Q^KX^<WRE9>0Z#:T72(Y9>+8&)'+]@]?=6
MMR']IW4<=FM%7\^"P '.37[XWN* &/V^V>3HMOV([1NRI8*?%9I/UL40W,BE
M&J<.K@0XP?9.]I,4"^)NSAF%:W\:%DN;]4U@N%;XQ%Z ^Q$/>:"S<#.TA0H<
M>@=-G_&*NK<]!:L%OT:=(2,ATQD04.BQ (4-(_QB9)WJG*&;X;7@#[Z*9:5G
MQJJF%.3*>KO#]T9"SCM"S?)[3SV<L-9>#%: ^=5/92EF+NUW_U?=!Q;^>X]&
M_=%_<@ZNT49]2QLUG 1K_[.VP7_07_QU?A(IE7((LW=ZMU80(HAQ1S'#)?'^
MCY6D%9401U6?5I;E3/9Z%3>""1<6+J4Y-M\_HL9FOIX)&_6!"KJ(2I;QU^A4
MOU^I<HQFC9']]#.V=$7UE/B)!ALB#:D9EHC!<V!N.*0>EQ>IH3J3H:XSS+5K
M77' C6CI'^3]PNRZ$;FZ:I>)*3/^_*&->\8_ZH9OD]5T:&3MZA49@A+Y3>[7
MXFWCDE2;3GEU^([DPXGQ)2UE4B@.T^A%'Q!NTS"D5)AA;#C@-"B_K>][OGA=
MT>^4F#A[4HK,13%CS3AMG"HA H=IVZ C(FS*![<+Y<UOE1HL;TOOZ-$\>==!
M9OKN)XE#U^+K97M#I2B-D,,D2]QN2Y!Q5!WSS%=0"_\PM_5WMZ\N^A6O7SYY
M?F=Q04)44P82 2E5;/(Z#%?#K;^8A1XB/H3B>>->WH>ZK;I<JGT)2KN>E!FR
M--_54(@W&'WH9VV-5BY&J$=AOL[[8\ 85Q KZ3 1,<L>M'BC?T?3X7H%_X,
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M*L%D%F$1=W1FDL(WK).73+]\N-U\ZVUI7YTU);1J;!)CZ+59QL*!'<>M]L9
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M!$PJ#)&D>-M0<F&P1^4=SVTZ(/%ZX8P.J^V:6W:](JYL,!&W?*%'!06G@6,
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MN2[9:@(\)MK_KQ6X,;Z6T$(,F4&.AC>&67J58.M.^ K+FZT/ _AV.7PV4+=
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M3E$FPV_8BJF.6<U1-%)_]O1FT9/3=@E$>EPGOG9F(^)[@JWH%!5XF@/:Z<;
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MHHWMJ-RY=V%ZMXW%0"\_JZOUJ"KHH[X%#!:YY<8</6VQN_N6^3\.???"-:G
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MX5$TN=NN=U7!5G84S2ZLX"#2WGRE*]B]F./67:PN)_69VHI[XDPWT6QG,>>
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M%,JPM##ZI&0J,#KQ:A"OQXM>DEJSKB;\R5H?5M/H\3P2Y;X"K27=)NLQ=*G
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M#9"X'54JNWP/?1UG(Q>\HCBY<[H@+'C4:EZG6.#JIQ[:ID=6/<K7Y62I(EO
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M3Y&Y'$]<\1D4%'X98IOP(VZQS0W%52U>+,F?U:W,\Y?9_5+'A-1O810=YRL
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MK[)MCRV0$:#4#[L0F45((7A_/1+<3(TA=,T_F.%IW;XG [VY&!#MQY/3)C_
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M144%Q$(O@A11JM*1$A1I(KV#$ 7I @+22Y3>D:X@(+T3Z9W0$9!>0N^])M1
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M4W_X[3H+)8^@0T_^DQML7441&;\ .MO%D+861&)Q;[:5L2%\D"SYUOT/+.\
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M:-)LV?.^=^GN7DF>W%K4%WU=T;-)M8>5ZE,-'OSQP<^&+7J33I8]PY^)T\1
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M1E>E*IB@;W+&_9@K'F@+Z#DDUK$:1Y6SQ]+/2X"0#D:_M&70,?YWME!N-N,
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M3W='<M.Q4+[@(G9AO7X_RY"9O<K%#2^_ 4-Q'(#$%>Z##; "H0E3_LS.'P_
M9$?OX#L"U,#D81T0C8Z8B7B1UL")Q(N!\V?[7WE8SX6 "3><LQ\KZJ8C"!32
MJ_>W+Q#N$!7)LPE/]C'51TMCRB2N;NJ]<39K(\FF9/%,QK:[9#ZCLZ^]PC?L
M3M,EW'4].CAAZ%L[M3^-?8S&:+(57+PA&+&+M.KS93@0Q>NV.3$<X'NY_NE
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M/099 ;N.'#JB!U'CB^ 7F,_ -3XX/FG/Q^,+C5?$%VP_PP$UT@$'\.[& ;!
MPT[IFVU@/E3+QN9)YG%I.[8%)0GN-YOOPQ+QX/D'P_#S"/51P>+!6+/C@!'8
MOL*N61CFYTE(_#2".RN9.SFZ;Y<T'[(2/]-W9?0-PP2S^A=W=Q"%"Z'<QT"F
M#9A<C?,SNO?GHDKVAR)!=.MNQVTI/@V"R-6%&$1XB%6.A9M?_%%KO)ZYQNA+
MHT>%7U[X-<=])3^U!5T%-TD!S4"!*92.$.)-KVNET:"A5US)$];LU+$O_=50
M=<M:C(+S?L)+K^CS>SI48BQ0>C9*"CVG-Y5,_#_==;=44E)==Q[1AT/7/ NS
M-BA."_WJES,0!OI*[Q83"*^$DSJ^:+JY4 #KF"U9W1I .#0R7+8NPT@M*!Y[
MFT0M*/CU%W*^VHT;UZ>C9M5JN7Z)/=N\+U=@,P6>XW4;+P(<1H'PE"$P<L19
M':*FHA9[._$ !^ ;R S,?V 7DU,VBP3WW.Q^5MC11DHRX2%7!J>K>0<BF]:I
MR"2)B+XU;4.5ZXER"M> *WGFOZU""B"X-V9T0(M%%?E,,5PW_;*9 3*\5-+O
M/3N8&MR&<0"3E$#CH\\#Z:# !L'J$KSX\'HT(W@_-VJZ#D_OCTF/)8'N]%Z6
MP>4;[5-E,X5.&&KR8H'Y[D[YC<'1V72)G;0ZM8XY2&NA1"^M.5;4JD3VNJ]6
MU0#_R4M&9S/S3N,=)4M;I ;P!GBM>I,!J;P.15M6'.&U;HHM#H#/-[[T20W\
M%^5=O.IA<><B7P3]# '#SP> 5L"3(QQ@#[1/:JV.]02B\;$5)1X7C(#\])R(
MG[__ZQN+B]"4GV>1:1VM\0\$0K&,Q7Z%VX[RC%I5WH*]2_(7NWRBWY,Z&.+E
MX.6 !5L,I;@Q#G )(X0G4=6_'U(/<XM$/H?U@#^X6Z;LK^,K.A0=N56F[>V2
MW]0@ )?P<2ZTFBWC.HK,G"A:M]DY$+_/K-023:GF0I";@SV/'9@ !T)-VQ$5
ME85M"US:#XL3%@T,Q)DI+QISRQC1/BIE\GY H%),E!)E%3MQ.IF=_K) PQ63
M)-VU-5,Q[B;HSA8D=@/?RE(I9G47K570U"68--:6N$\ZQDP^?2!_<\[IRR'=
MZ+0=D%""RQS?Y]41O%C 7";J]N1%+,L-G@K(.]"%AKVG"L]SAR5X/,:4UY'
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M:Z<[_/YFCW-Y_8.$_8<;8>G"PU".^C*QQ:-H'"#:"9F. Q@U9., &26:N^^
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MOBI!Y>$0<O0<28YO_R,*>=!"@KEIW!&ITO.'N@>YQ-9+G9SOG(4#7]ZSK4_
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MX$E(+C$; =T?FH=B4,- 9-[VT>PTV&X-8XR*0D4\+^BA;)V0#9* 8:+S=#?
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MQD .K!23%H@(+*.UOL! ,0.VGNC)AJ8X-0WUF>M32=O&V[@9%>N,/\!V1^(
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MQ9.)=9L:_(C5="C]?GI//75J$&3%&69[X5R/\B2=B\OK)(G /3N+"Z<[3I=
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M7!AA5Z!D1=CV;=22E2W)EBJ8N?5^MWX:SB%ZMF<%[27 +>1-A^X\G[!G&+1
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MMVYDDB<T#O,,#+PEE"(Y9$'-=/;P]MC21C.Y(NQ$S/H%OO_AF4K%5ZACZ-!
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M,#.,_,1O.+Z&UR>MX@JN1R=@GPK[".*Y!*10X 89!</5P6U%,,C%E7CD):"
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MX'7/W=WT7D^<#F5>KDUL=>[$G=!TX[AL*N<M,U1K^^>3XFA.NK<#/2,]CL\
M J8\0]O_] 1MWA-1FPDLJ$P7]BK-E_'/PO9"6+'F1&]V/W1W8@\]7"^>NTI7
MTHQ=7.VX!^1EMVG^WJ,NK[QRNO9Q60WRO_(@B\Q EIK ">TMKMX*>[6O!PX<
M'Z,6RR"QA56]^JF_<9"#+:K3H->4NJ!MAR ]9D8^';)CH1ETS+.US,B<TX@<
MSTT0A2L!RSCF=!5E1AY*7S!@'&M'4K>BN1);:U,BW![(./!)P4R-[G'"ML;;
M7PMY2[2P?9>TMWYG?06QM8:+3<=;*R3J;646%]CM4?8]CQ_AC,R)XZX:5=*U
MY##0MW IR;6X ;56+ JO=/9KV,BOL^-!QM:I#[J=,&^RM'1,=9=QB8OS.5*]
MS]0NRE=J.DBW8_ONW?(26SKZIS[Z0Q5DD3/R(,90!WX".5-VV(8?2?FVR<ZI
MI0+\>3:X2&*PE?0%8Z8 C.DUHP%20P3M,LZ1>J+9,S<X$8=CF+:X;F3%3B6K
MZ]=2]_:&D!>R\&NQKND[IATU^(J#S\(?\T8_^H^X<)?HWS;IL1<=&P^*R%%#
M"!Y';5(<Z.J"%>TUSV0UGI3J3]$?O.>;#FCH3#]S21.%Z%US_;!Q.?#A@T.>
M,((G7ER#4#Z[C23H/!O:]1>U@GHF:=M@)?4NQP^.&!A=5J>_3L_R2N_WEK.=
MDB0EU Q*H\5%;$K6?SN'X7?N!_WIMX#![/JY)CG&>CF\@LZ(R!F U"M$951
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MN2!7^S3_R=V^,3[VDS2YRJ0$"R6>)8<'3V894I4FR[(*5>EX70_;]@/SH[9
M9JO<E6\PJ'/P*92Z6", QT+@J+)P;/_K8 &1R0?MPFU4+?MZ,;G5U?ZM^Z$/
M)2T9>)J9@I?@:]!7A 6D <%S5B/"G?1HTJIEE)Y(.I/U#/!Z[V",LL7)Z4O
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M?-5Z6M\-12@O.TE^TW\GV#1 VWG:)U>!B)2]OOISFI"BB]E,&VA-\PP56<"
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MZ>2J(GM5(^-<(^G\EQ8,O+E=F+B<:'C#T:VU3*[1DF.M$Z2_?^%RW$FH?9E
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M>\+?$_Z_GJ "S6Z&.E5X5U-+!=,-9,R39N9>]!D-I;EP-OY_ %!+ P04
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MG+'EW&I,:1KKMX;;]S^A%.,F#:-)=%/(L%2S,(4%Z37Y_J&UF7Y;_'['6XO
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M(&EK8E3OQKY6S[J;3V>Z;-/HOH& /M&VK?.IZ8@.XHW[Y]V H?(#AX+N1EI
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M:_,C2!I3,H*7H^:Z6\QV4LYT<O^L?8XO9CG]L$N"'GK>X:>4[1H5"%43'$!
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MJ.,;3&<:'MIXF'VM1W8IQ(YV(?&O TL:]E(HEI:BI?D9M<LA R6?B"F?FK.
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MO219L&N="A20<PP*BW?UE"(5'NK+R3<,)3^*2"Z2?E3YLK_;-*,'XGT@*'[
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M\G*%V&83V#Z:$/(3<&YU"*%=_P#M(K2X'W,G'B^D I&EJ%'X##R[=_N6/16
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M;52S8!"E%F11LX=-ROH#? :@JUH@%_OP$K9#]XR&\&-<Z.$?EDY(^3]0L1[
MI)$*%*^0PJVXJ0!:%+9NX^T'AU(&,:LR'DZ4BN_O.'I&LV;SP[7X4G8E00IY
M'X_970.'BU+<#@,\!54@04J ,E(!#(P2VPQ/?0:8S)0L'0-'6D$]; ,+(Q^.
MVSD"3QXM#"+%M[-2@7X[L-LO7:%/_"7N1G/A.^^>&U5Y=H6^&P8.-U(8GPAX
M.Z:H=5GT^YQ)^.\YV;4?,V'1K&*6X-[LGR9T%6LI7$2#/)(AH7_S<@)'U&R5
M1$)MLU-ZJVBD8_W0@ZR7'R\%W64JY8TI:7V<++SI161,]1AL;,TFOA_%0?Q]
MCGGHX6JWC/!WLG#F7L,*\])A[^/$BLKV+]\*.";&/7Y[E'L[:?#42 DA;7QI
M*]+GI*H*#\FHC @G:+2KAXWJLS]ESW%R3:]8/=IGFK7G#,XU]A;]09IGCL<^
M*J#\4'0;J$ I1-E,*.F^.X&CT0SOKZP&__0A2#^L9A_!Z:!L)S+_Y%.+9.T[
M;M8:SH#R@W\WJB4]31HH-+R7Y@J(L[[(W$[N 79$DVWU).W=O:[0OLU<G@QA
MQ(% (H4J.CT/N+(.C_2P5S?_$DU19NCYBE /J(3HCH9_?PVC4INDQW3*GR=3
MMO&PI9P'+8(EB 2=:+.BN/&4;3HTV3V%"FA4 G85K5Q2^0="&*R]:*[8EV5D
MYF<-PDTMU#QM7 ^W[ZTO#XHP_;;G?:X\O_]^P3Q;C]8:K%.DDD2V!\I4^T2W
MS/Z*[)AS5K(-+G6B=#=\/90KY7.=P.G%L [W1T$>.M'/[ALO')8=/G;]=*;]
M[;BX/0E"L?Z#+D7.:4J ?"JCR@EBQGC*?H>^G7LYV=[)JS::WS[HB#SEW11L
M:<JP-AR@>>FKI81'/-!%Z0:>2X^]4A0A?WOUMML+5<T&M]ADB#)$IF$! Y')
MKK#Q>D_T^GQ_%H4M[NLKB]&^<?I5#+V;AM] ;5I<=,>RR5'^ #J7J3+;17B&
MV8A5Y7().9ONHP6K3JO:62=)[D+CA"]Q<9-J'E]XC7RFS[8#T M?T?9]M9-?
M40B6HI.GY;ZD-0]ON4^2/BTE"O4_)-XYJ^UU-^8I.U0\\\K@X/)[J9?)=7E(
M4 3M"C9GS9OTQU,$\I_K2G,PV*#2R)E]G@:\G,L&F5^>/#TZ?IWUC#%6ZZM:
MMD\]UG4D(=.L'L?)I8-X89/HE>0FX1RYMX+_4\2U$Q?9ZV[%J#+7V2]\3\^/
MP.6=V+4J[W1$CY?VB@M<GRD.+Y'6^M+">,OW07B#2[WN+2IP3%R'O Y:^KV>
MF%I]/S%\P>>RJG=E+SE:/>W9PASB]W"^..PY?=A"IS)L-?;<WB:+)7J>Q/50
MZ#:# WPEB^(K0GOA?V#1J *QF4@(>EH!&\<PVEFQ]$QT(,_CJ, A,Z(/KX/6
M8=3BY,-X^RS3(3;WU3%7HWMR"C,97N+W,6Q5;'-PC@JH1-"&>=(@S4R])R+;
M_D&PTZE[ULX$B_/'Z&\'U_%':0JQG!?P5?$!C>QM^&&D5%<1C)6HMOF86.")
M4Y;L0R0I.G%X!(I?U8GK95A=%A]AX3QZ^S:+B:+?7G5O1GQ6PP0.54L%]A,K
MS+F/]Z\G65XV/]L>-W/AHV,[\E[CN!6CZ^XI)(+@7-9)<MS5FT]<\4?W:<GP
M"NO@?5YE# \-?N#_+"'8JIE,RZ9GXCQQ#GIYMHPW,DC:BU?L<G%$JVZ^GWB>
MXTT+(0.!@(L&LP M/I5Q@_M+=)IB5$AJS!=G@%?/X1)A%%M2GWP8KU^=<@AA
M)=5QG' OTD$@[N'1N.?S'&(GGQ^SL7IWFZ'<6<Q7VW#??OH\<C'DM*C2+.G3
M_OV[#=S*9[QFE![UE%?FK$D9XI7840RD4R.B7.[!)&7/\7;.877;UQ?Z%8SC
MWH\H29I=O_Z.]J-IYTP(;RG_MC^LLGT8JS2BTDDY1#S_D S5[:^P2/1^^>B9
M"G_O9'>/%C^?"Z=U<>EQ4DUX.7!.V+EA_U[(3ZGY<NJJ:*V((6LX5/TV4C_#
MODPEUVF]8[,,I&8D&O4G7EKQ.AY'8\YHK39(]?27=OP/+!QMOR P4C17#G_W
M3H"V3Z/(9:,#>>'[1NS/F,TCGT!KF&?QP[+1)G11APH(P(-1B_R8'7'$1,LN
M9/,X>+K$9]@F"YS,7DBS'O  Q0Z;C">V4JK[4W:.+>2^U\<UDF)&.5'?N$ \
MO:@,^-S],=&CR:S[XMKW>+':E(WY[WC8SD5F)B>C)D.)5RF5^I3 'IK9HG%X
ML28I1AZU* RA^!WWRO,P68H&RT1 =QE -IJJK0IE^0ZT+@W[7+I''E-\7J+"
M'V4]R7,LD@C:^9J<,3Y[6$?QZ 8W(O+#MN&0VF:A]G$.^FFW8V$W.0Y%,8PG
MO(*%C'!\[)$.]<H[HALV MJ3D<$Z1-9<I*.T<70C=W!F:*NQI\#!P<DZUW,N
M$8 2:$WZ05.B;(?6CV@35QMG_IB0R%L9GY&1%U=?T5#7[%8<<Z'*_>6#->F
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M4(Y%]-'R!^):1O!JTGZ305_"SH:_4#UX+48.D(H8%HO/@QWR"%G[O),PZ'2
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M!NVQR@DAKH/Z]&;'?56X[043AT>^I*FVM 5,;$^$#QVC:9F<$(]B=FI(*3+
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M0^H\8D+Y+MB$8FIN/W>+JN%6@&_1]+E&"3IM9%GIX(N$LNYX*:L2)' FR($
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M/-G[$-9W2F<N)AWPYG;S5^T1S^H(MNN+[5LS:LV:*-.Y<(;1CG.8XXCI>U7
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M!>V>)QZ:@#C /U58:"G4?F_M0+V.I5WCR4DC7R@J/**!%V(U3!=4)S^"_X
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M*PQ([/F"*"%5G,:*2]I;=>BFAUW*R6AB]*.]YD17^%ZE3["U4VVM),]2RF$
MVJZO84-I[!(6! F@1.H1%H6@](0L9*JW*/$"0UP8HTK&8430IYPP+B,2I\PG
M$75C[?DI<_W>&K9N5%'@=UWHBN=;A=I2HZS(0$CBZ JR\XQK"L1,4:$T(RGS
M)$BW7!).54*HIEIR[>M8]NY:OA^%RA['C2*.I<L#/R04Z^6P($V)X)H2R40<
MQL H!;MWSYRG0=D**)LJ7V)25-"<:2P(9TP1FD::F2(H<A <>L-<:(QU*00E
M(.7%F-O#)XGP% F2A/EQY'(MGH(LT(-$S+VLF-MK&6F=EW\ZTB[W(R*HR['H
M:8RFB0C=I5(?_N.J_I5;[UWHZ3V59(V34(4AB#9^"AL2 6>($RPGG #$*)E&
MD=\[?O #2>=; 3A?U<8&<:B+0M>UUIT3ST?XG3)2[H/[$7W*) K,,S>B9RDY
M<_B?]$'^BC1FAM9N3!(@(^)'T@L27_.X?]FH!GKJKV3OA5Q0*3VB/ S.8S(!
M>A(^":30R@_])%)/^>)P$#KN3>C03 6^%IQX&FO<QJE'1.(#"0OFNXQZD:]Z
MZT'0+]GYY=%.J'Q!?:E)0+&":RHY2;PD(0J^5VG@1DP..8_Z13LW'E+?_%[7
M*,R[D72Y CE>2P\=) )-8D ZS+D$BA8/N<=Z)\SW$_(&SOV(9,Q!Z50B# @/
M-!H)F  REHSXKA(ZY"I*^E=]XB=TB&V>9VE9%1D_X,6'3!__*/G SY#M3P;<
MS,<R"[GY6%;[^MA<^N USV>MH-/"II&_7Q6#1@34Q1NI&/;5-879\S !TL++
MG@!0DVFL4I5R4%FYCE48:.WU3F4=?!/O'X8 =Y0.>$R #"*\B(]([%)%)$]H
M$,DTH6YO2WD,<M=#4HKGRRC@*B22AI(P$4C"HR F(E8B2M)4)E[OU(4A%O2>
M8D$-S^R/)6YML:!:"JH5&G5IC'G,?4YX$@._=KD.TC2)_/3>[R)_[H2OL?16
MJI0"Y<G#;*DI87$ 2I5'L=*H#H563("X.ISPEW'"#T_@R?,\XHHF# XR"8#>
M0?$"*H^#0! M4J!*Y4=2^GVC\I]+F/K 5;'6>8<>ICX-?(W7LR%A*@(M10>*
M<.8%(3/A&$_]#OVY5Z-*6<B$% FAK@]L%%7.6*B$"!;$U(]<E=R_T_;3N/6C
M2<*5ZRF2*(S^C/V0Q"&PVSA1,J0\E=KO;>:[7N6=N(G2]4 F@EY;+]>9#UE%
M0G >D,@-&&%!Y&&M28\DON>F29C& >TM[?;&V:D':"U3KH1"SV_7!WTG2B16
MRO9)*F(W@<5G6O76_-,[AOLX;(0E+-7,<PD'P15+;U'8S BD)\^+78$U2/H;
M,#P@]X,C-\@6L71C2B(_P:"ZU"4)CUWB"N$I%HO4=WL;03M4:KOU5>S39$]!
MR$,:QY+XKH_U(!4G// 3$BC!7"T\'X20WA+K4RS[^3@LC"LN=)K$1"4",0F9
M62 #3#/I^D)Y82A[R\*>X>7D_0'BTT0AC7&2/HA4,DXQ,;KV21PQ4-1!TTE$
MX&H_NG>6^?,K]3-E8->&USY+>1"')/0UENUB/N8DY)CX&7U: J_'7@8K;*N[
MA9I((^?AP^4Z5$_?V)I$VM=)E!*18.6%.(X(YS$C0KAQ$*34C>(^Q),N3=X-
M0118Q^1#E22QJP*B?>X2)KR(Q&&,^=>\-/0E#0/16P-&/QWW'M\.^%2TN776
MK64BB%(E24*-_S\*R-RG)%:ITJ'K<\IZ>V$RT,[CXK\;!8KZ,B9"<<!_KCPB
M9$31 S4-M4ZYJX=*'P\G]#]-U2WE<:"B5(/4@*4APC0F/!(40R&5XB YZZB_
M?+17WOA/!(#6R+QB-TQUXDL21 *30&E!DL"+29HJ2E/)V /H5;>EG1N[VFS#
ME&%/X('9L/WL^*2I'RJ<E1+Z$R6)%U^]DQ88P&*',B&N## UHPX)7@D2WP]#
M[3(E047LZ[X^E6.XSAA2T'NT1S6A0@C"9.!;AR@9)2*)PS2E8>]DR%[D@<+X
MC!L>+WAU?2PWCGP0[B5&:Z:$:<E =?49G-] <Q]04WF].UX/<(72<XGP8>L7
M/))'D\?0A=(CGL)2K%*GA*>^!H:><(57.:[JG6OE SD0KSH 67$_)O,YFZ A
M<8-U)=&)F.N' &0>NO.!;!:36(.T1ETOU,)-F!?UUE7DQ8/#/;GKJC"2D>^1
M$).7,&E27J6"4"VCD%(6R+2W:4%[E4%@\(-Y^' VID08 CHFJ<"L@RPFW'-=
M0A7G4>"Y(@CO/?[ZIV\_&/S?.B;/DX!IYE.2*M#+F. :1,@P(MIW?1E&&L"]
MMP>WQVGTUQB+)80744])W)<4*V^"*(79?7R9**7A2>+WUC;2XQU:9P('7X4B
MBA7AOBG>Q#T2NRDCD><IY4I!W2');']$%:F2((D\!J(*99C_P$-_64J49JZD
M,A2AV[O=&F(;[RFV\>Q'R4@>5/U>6V1C$*5,"%>0T&."L-B3)$G2@,28_]1-
MJ,]I[U+*O/#+X+5J"$\TL41(/9%R!IPS8!AV'FHBTD03 .K IQCVR?N;_[N7
MKC@O18?30H5Q'&$B$DRYG88^B,N >B&54<P\23VOMR:I+6A!9?D$70?GQ+!S
M+O.)TNIC58Y0VIHTAL7NI5T4VE=='9SP"@U9*QM8WN:=T3@OIUJ;Z*>]\0TR
M^-Z5\SU2.2')0*Y3 GI&-ZB(HFU2A<1/L$9?%$G6OU(FO31$#7CVF'A&?8_I
M(!4DB7V,JM6<Q*G"_)8Z];16$9.]%> >O:1[#V"(QF$:I*%'9!I2 K*X1Y)0
M2")X*/V L83Y/<L>M$8-V\<4@BY+B/1Y AIV AJVTH+0(.&)2X,X2GO+C(?"
MC[VZ1Y9"^S1)?!(QA;9Y:#CQ1$!"4&FUUDDJW-[FPQ](Z>J(I)O6$%UK.>U
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M"YV//]:-^SD7OLM])FA I$<5AD0'1$BFB$I"O!$,!4N"=9V+.9U\A&_J7I
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MA5[\[\M"Z04D7"E]0G=5\\Y@'D';:OU6P,FQ"NT%=)P#%@)O].^/!9=L,PH
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MDB]0T$Q%5BVE.3,E=! O!WJ[ ;UE(VBV03IKZ61F$1B-0=:RM2]6D]%<;3=
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ME1*6-7%L[1-5F6Q:('AH6ZEP/D>T4HQK&P50Z;0R"6:F0 0-Q_8RB2D!6^]
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MO!S9ZGAJQZN+G(,*ZL8]?WLL=VUR660KA(7JU(<QF,I]]5WT5?R&KH;ZG T
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M!YA>8 [&F !?[P!8G,&]IH?A)B'Y-83F:).0_#8)R3G?#/K^L(L6^MP]U>7
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MJ&><A/+#XB%_@%E4E&-QE]C/&83!Z"VO*^'_D"KB1B_LZ6@&4]_K<,<R@)&
MJ[ MP4/\RZ5GD2CL)HP?+Z6Q#D?6)5^9)5?94@U#X %X7E,>1[@#_MD :=$(
MS5)H+*?0+&K2JBP$,O1-(.:[9E:#UD-L49.K9#GY8O6T3YR/X!)%#;K00U2C
M,A3IQF7G29.SZDBHP(BDDV?$!X ;>/U>NK."8Z)M.F%I+*9R=M6&;I^+.K?6
M6_9TM%X53R4X;&$P,SAZ\U3]*=J+JE:7*IMP5DB:Z\#FN,BSR?QBR5^.7TW>
MZ0)Z1.9W69P7$\0Y,[G=$C2G2MUD @4I3W#N-J?-!@)OY$.(-0A:2VTEOU97
M6.TT"I7Z_E>RSD&(5-<2L\1KR>/1YFKB#OLV7N2G7R ;("?<_!+[OO4O0V_)
M2A3=^Y9U)ZGM2!<$1E[*RS3(.2[C<N/2#Q.N,0IN+JH1JRXU;?-D@JU._KW@
M%JV<#AR[50_:='7J']G#D9MYN%XCTHW%W'!WH0\V)3\O*XMFNM%'WUL?L=X0
M%%HLPRY4(A9 X^.,KMRF'1IV"H #PD[]J B;"]NP[_K^Y%V3^J]&8/O6]37G
M5F[O31?]R1H$AS&))H$G=MW\D0Z8Y-)J3L#0="GK= V)YQXY8B",3PEK2V]6
M-5(W*K<Y^U(\F*%4 [/%Y1KIA7K0RE#,O' -'K7W7",!)G-*R2\4WZ?=%0\M
MXOAWY+*=Y]I-,6C]A_/H%R.R0IK<62&\ZJ;WR4T5]TO-(=VRX+%;7:X$QDSV
M67UN/239=D'1%LE\CFX=H:5DXW""H4-)78&61!^=4#C$0;L:(]S2C0;Y3AID
M11X8YXHK=3G36T+P8)9ER"Q*[2+0"'JZFTO"?7A T503%DK2(I-\\2&;H1J!
M*V2EK6-H$>1E=TI*DRXKD31\F/-=\QIQ"0TR9FBJ1_(^*=!\D=^,# HL(7]9
M>4&U5 X=%7Z>?G&IB9T@>,FY&G05Q<=RLO!&8A*X<9D2*.AO]8QC0_P!S>;H
ML'LM=%"4OA%TSK\7%OG.2H\.$CNCTW40E\G EKQ>[#5JLT*S#\DX*Z8+VI"*
MYJ?)'D=K4(< ^Y:BI]W2+)C&>8,MH^-,CU O;$$_U><53!!N;#_/)16I)IJ8
M,^3E:! Y;*S=9%/76EP[K;HHO"E:":Y#/[4#]E%4?8.C^;;Z8V=[ Z2Y-T":
MOT@3]Y?%^8(TQKY9*Z<"2+90\ZG6NKVWW.4W!/;>@>;I:TC#MYM>,3U/FGKX
M?_\7_=#?WC]X<K#]9.?_W]_ZU^S\OT@AS[O_$%52[/:W9Q^?ZOGMDX+[B$-O
M<_H^(.S[ME,_V(F]?>C?YWG.VD@'T I\!YO[BZW=9V-,^MO]74[7#:OI-.=T
MXRKQ0AKB2%(U)'M9/27'>T:FY"0;@,Z#Z0]Z<FX55!)"*<2Z<A *LIS(3))6
MN.0L7]#CLF'UH6#+6Z-2,#JU8"<$6H0XE68Q^!>946MQ*I,.3(K$IY[U6A^@
MM[Q^=O):7OWFY/56<FS46^L&'HW&=U7/R*]DUQ)1=O8Y!95_VG^.,>M:IOI#
M7^ 5M@/<EGY1LT-.:R?H?D9H5DI&M6Y)-8,2C8K#"?J>M+5:F"UF37.5(2"'
M7=;59&(6<3^QWL8*'X*5S>#1885R[X?F+-^?@_N<?"*. ;L3' (&Y/2!YYU<
MD\5,"M*.%<&BS"B\H20I.Q^]X7S'J;18$9O%C&YL/[^#K<-/G.#!=Q2K$.)
M\TD^G*> G[FB[XLZSST\COQ"E(=(_=HDGW-$/*/+C#QQ2R8*MN;-.\>$0/]7
MU"/_W8P!)LI/X[]R2M\8+)/Q9%&1V9E7'Y?GD\40V\9T=S4=PWQ:")B;I!,
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M"V!:_<VH"!LQ1;SQ37IC>VNC(&Y2$++T6*N#S5K=L%;WT3:X?PKEJ\=9CCW
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M%>8^I(M)B5<Z'&SG_W/?72Z7"6@K/.' F/FP/Z55XH\%Q+V!#_Q@:_7\=AQ
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M5=YGQ17MSZ/_^D792?C3__4X-4J*&"P1JHU?\@IP2U#>K?H7QNT7*9-5PRP
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M/P)I#I=;92NJ%K K%5-QM4@&F0ZRU ' 2V8V6GA>3KLHN_).Z)6:-UU9<2?
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M>E[Z"Y?[GD)LDIWOYYG_;)6=[11IH]$$B+Y/9,H%8]ZHQ(C<Q<0N5<YFSS@
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MGBXM2^D+8'(+S2!(NJD<K<^$Q:H8UM0H '1A2 [");SBLE%&6Q.%BKZG(M[
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MUM0 U 268.$=?>0/ZLXD;@BR#/7F58:D,4?5):5B<!AAR(WSOP#!@"J73<C
MI^Y2T>U,KE%TS+GF##A6>*=&X.MR4FOM]H=;:O;B(W"PD./G 54*+A4M.SO5
M0-;#]2LM E7A9FH<P#MW*S=JK9S'Y$@($,="<'=+!3G$E )T4[]$0.ECACRF
M]U:9#BAY"9[Z]W4&+F1YHE,1$;&7#B< <EA!0$A/(6.3,JNKJ#^B$>OB'+FJ
M7LV)H=94L1&,A;#O-J$U)/CSG':+^07QMF#LH5Z0L[^,R<G,,& GVQ/V&"]\
MM9YS-+:P!557L%4=$CKD@6_&C2,Y'2E$WM-\KC' ">N/:VUX3IMW?(>=_L"G
MO>#:6S\;1,^R\[)J.'TJ)KD,(O<8%G$+O2\MGN9R:]U2L@F?N\8.VHNG"^T2
MT[)%2>UU-PMNH:A&]WT<SVT+9^L]%YVV+L<MQK6X4YYX*&)7LCZ0.0G[R$&#
MVA6>PE*"GE[7\B.U$0%ZO46"VD*I;B4 P\.#!HR5 T/7S30.,#'V"#>W/V\D
MQ1XCTHJ"8Q.3NIHP=E>8\<+6:@[;$,P@GI_>I+8O"C1DAVIXD8\6.L7Y1;NF
MCW^S=F!^4LRF)'%NP<=?,QLNXN\P$=Q0' @;XNU;Q+C1<Y?-<NE16:Z<,%G,
MQ!5O34%<\";N_MW5?GACE?_%K?(.XLV.Z.V=;Y0(G1YJC6>  M#7J\7Y!7<<
M($T=QW+PH??/H_N9 5Z=%@.24ZM3 '[8_ D\JQ@'K+R^RTJ27VH[E0X,58?&
M0G%[KHU>PEM#HBH!;E%"1:NW?:KP&G_'NCH'A#VF[-C(S8<*X/QCX?B@:)W8
MB"\[ 9*3901LHOT3ACT?*@I?Y"]8(S*N!HR+'R5Y5C/:-0!9M9CO8JO$Y3$G
MVI9QU?(:Y]SHN(GZ;$\KLV/8MV+X-5 LF>^.A:PBYX5]2VV$+7B CMIR1UOG
M6*\.0PAZ0LE(D 0^U6EZKKOZPVI$[9%FEE9#!T @7]DY@D<;\-$W!A_M;L!'
M&_#1%[\3RV7'E=))&A+"'N.JY2C@GJWS1&YU'ZZ]2K6Z:#G+'7>4\Y\[W=QN
MS>?OB!6+_EBL;0'U2+BMDZC[.K_ ;.UN7V?%QW3\I=&%%EZ-&G9SEU@:^(C\
M>BXTM6H=9[ITFBEA>S2)[T7@HN/KO[T^99TU3344WA"6 +KN!L6(DRN6,LO:
M=W_&Q0\H)*;#TZ/_(+G!]P4CB<^0MNQ-A.X T*E\,NYQ?H@)'=T+."]LB&P%
M<?N H#$CY\$WV!/73Q8UEJ^6=@<NY H2=2T-8?],0> MI%%&QV,ZFPN/%JZZ
M$)Q&!H"PK-CY"9KS\CX%DA9$BCL%JF0F^/$8! I(',6AFU:Y*(RA/+NLZK!0
M=*4^=.4EP1%T%:1!I:?SHUSY:")4U[[;GB\W#9Q:D,H9/89CQ4!H2+O]9G6B
M:7,N!Q>:ER(HX;,'H?CU82>BPRC]*.RL-G=&:JOV'C*]REC5H9FZPAW'Y(&C
M4Q"DT@I MA@O(YOH0WJK#M0MW*<F4B#-K8<@'G[F @@M:$JWUI7C(]56K(AJ
MNC?P1W,<4M%MK!+K(-T\R0;@:04^8DJC7@AL,DWJ;%18YP72961VI9X5&#N1
M^@H,_6+J0K+ (I*9I;U31L#:N5W2K@GR]3+L86A#E<=HQ:@^6_R8PC)!D5+S
M>D^<J+E6^-IH'-@' &+K0&CCBA;N%H_ULUZ=T5S@030%#A)5BU+#/G@H#ZG.
MY+]ZJV43:_TI4:XP>LM2+A%05YLX@;D!W1I07;E;$[=;''QU^%I#5S/(Q]6R
M.FJB%@&_IX@7CQMSZA140Q^[TD...I,_V--FS1-IRSLN &*N0C_=J/^K!$LS
M7FK(3*J-9.ZD-(?%C-_XB3ND>QQ2C[F]:E<C\1KPL8@&[+A=1'%?^1;HC%80
M2-62@WFV/*YJ!EDC9?MT1[LQC'+W@F;S"[S"P.^>\,+G67!SC>KLRL!+W(^Z
M'?YT%#!&-!7 HD=M&+IG1D-32E+6$XR@+*6"SDJ.[%-X=+!OHI+6K?,:H+Q:
M&Z$,9K'HKE6.]*X0KN$PNUPR($G6)@;V:XLG:<";K<)^)QD991=M@-T&0+$)
MU7Y]>Z>_O7/HCX5K2Y2/#+O(RIKU/&?9P,C"L*>A? 2^I10MO#E^G\8Y,4]_
MR9P;4Z5GB])B_1WR8D_HMPO2=2?_A[VW;7+;2+8&_PKC[MP-*0)JJR7;LL>Q
M&]&69%MCR]9M2>/8_7(#),$F+!+@ $2W.;_^J3SY4ED 2+7ED=1R\Y-E-@D4
M"E59^7+R'%B2,^6]I$LF5]3T7Z_FNNA6BU*2A>/7&TJZ6[@='7T^B 7DX.-:
MRSH2^I>U&B7Z-0\\@Q'N ]-.)N>C$QASK^K.A9"\G@=K1G1],!:8TQF0%^+H
M.4=N6.!UO!714&OD[M,("\H:;/M9@Q#"^9S!=BQGT'\;V:AYS,;89M*?:=G9
MH"*1XDH+W7^?W"GO3K3/)<'Z1>8<&&Q>=@;WIC[6"D1E9,P+7A2\1CU8>,L=
MVT45]F11^,)F)J*5^"TW\^*KGO03JNHN5Z\.,9^M.*M<=MW4M>A4H+!0 9@,
MR2RA@W2GW/>\Y8CS?V"U_/&ZRC=XS#" ,((_7-$8#'<T :-%_F&U7GC_$ P<
MA@3=T&/P+QH)CR<7LVND%H=FHF\,P* ]YEG-:\;9A_CJ0KK>C&0H(0ZD?!-Y
MJ'MK,/[+QLFC_>MCT7G*QY74W;2_*UI3CS)0-%[:W:XWJ.H)D5<C0BV$MLO9
M\8A(4DA!/;P6V 3$R-N!XY[/,RM('\)-(FT/#L;BM/C3"Y6_2E?^>TE1UFSO
MTCVGTS&2XSX1H_)"5Z$ ZOY9!Z-#_++\6O_X?+T/?^]ZD_56^-Y[-6@?[[G_
MI)_[((O8VL<UD1<3[DQY5A+YLIR0_P/#=<E+!E[;F/@&<*V1SU2/,^O,<@EB
M<G I"1X=6M\H'4[;NFNHO:@GG&=@09\=C.T@RB9HU0HX,![(=WBH;1]@V$DO
M7QQJYOK*KY9U[,+)>\T%(RUJ_#%T;>]_,SX"_/'T&YA6P6K*SV3RD]1<B/J9
M7G!K QF\-"[86..0@USW^1/S8>O%R1!JM^<E>PBGRUKE^Q81GC#XX55+''=W
MHH,^W:'?CKU!>V@BO1.R&1X,C\Q?+,R'-MCK=4'9&YS5JEM/F?V=A0D=L$VO
M0)AOD/T%_PUZ"^+'&:D,9Q:Y2B:C)E^/#IY=L?6US.4>5D<K.H:9J-]P ]2^
MV9%LTJ')3KM1](>$=<?N920H#<^*<!Y<+^47.NFI0\K%(/ E<J$D[_//?*3C
MX9:F/][SL4!H[TW7$-V!5-]2.W<M2X6BQIW\[K7B+F/<Y*3\_A^$88>/6N43
M"-MDS=KOW':<]!B'<T(:=:=E0^C=>G+ZE?;].0#!!:6,ZVY#STJ51++Q5*4M
M:JJ+XKN+' "OV;)<A8BMRH37KUX5+8%R6HD5IW>3'HY^G4G)<9<HGE2.KJS7
M$7XR^27\3S"6,$\/'F7AF'YPGX_I=W/CL/^5NE8E!.!U"\<8J_128KWMJK;8
M,CB <*Q4MT,S\DNB)L:('M['B#[/S'[5%;T#> ?Q2,+AX6@OKN\']+/F$"#8
M8_-<'LQ@\1"LX5I-OAWT_"@??CA2AL^DK=>#OWR9I>VJ_+#!5O^Q-W)$KGUH
MY-KG1^3:!T:N_>7;TDA173J:S;GW=(:WMQOM%VEW\:5 %UI(5&E](F**T]R1
M%E+5918FJ<6 BM912,2,F'FW924"3EPK#9>9KHIU.)1GX=!S_/$Q.LFA.LQ]
MGS3DD\E/G,8J6Q!_[+BP&>QY\$_"@==5;ZKZJHJ7%@BB7I'+V"0,-@&1+[,;
M*1.2OS?UUU$:SOII7#&YKXM#'HT?(Y]7$4\ M1B#*G+6T*!@?5HO1W PGVO?
MG9/:R2PT3KEC];+L"!GTS+3AH-I#KD.35,LU$G,Y.\_ZP2"?'L;']^!Z^JDB
M"E0#*FZ!C&=4$-7.2&WEJ<WF(XBBO?J?6^A26B5PG?;N*H^JJ2YQZ>R"J4/%
M84SG LP18:*IJ;BJZ@ZE0T_8VZ-H';\TG)[^QA BZHM$!XEG;95?M8)(O8BB
M08_353(NY(WQ8PD#'R#2J1GWN0U@81%3ZH TN$W*48=0-Z4HD3B<F_NL/DJ.
MJQ-MY>=R$K,I=;'P(#=-;+Q"*3(L.ODM\_;13($=9TWQSB1JTB;TM$!^=;+<
M*WHO93._QWP:Z?J$QWE5).2N->403BBY'UR"<&U*(:6_,F$N4@)06(E0YE)5
MJRI$&$&@F++2PQO)'=.9/K9JEPO8AQ&W; ['E\JH!JRSKO%'MQD&>::E;$LK
M>LIYX9\3Y01(6+2=Z&+XU4VP-WH;/1R1O'P1@E/AL6@"7,@ZKO5!Y%3-G-2G
M^JLWFR1*RP*[P1)KB-NX<';,M#Y#%*U9G^^$QC#L@CDJ4RDM9=CBLUTJ?,P,
MX=0OK@1=B0U.!X?%A=9S7I!BY@J2^&KJ"NK.]&BBYH90KFN*WE5,)SI>25#Z
M#$.2D^J2I#_;_@S%9-S OK5>8#/^/.M=N=<@X/E!8R5< 7UD]8@ZTR17A=DH
MVJ%V*"/0=Q\&^>[>21E/]NV2+9LQ; MDG%==VZUIW_M'$W=C64Y+]P3TM-5%
MFE/O),L1WM=0D=H]+GED"B*T<WK34T*Q<]F\B#OL7X5GD)Q3O5C<PU_ISI)J
MNDM;8]Y!L3:JAK; JZ!_'.LTW$D;UJ#3"-=!41D1JA;_)FZ%;@*TS%7PMU1!
M%>GV=?ZFX/0'3S,[/A,OXSJR7<9$7N)LV43T/8 H&V$;-N9I' +;32.UYI<K
MD$O5LD'LQVVZB:274_S5<2NCQH-9XIC9*V=)=Q;/PX;F4_>R2)=5U-P!7U28
M9X:2A%6Q!DH_''GYBCFN7BB_*<.SA>B3:%^*"V!D(P?!<$'^L667Z!ESP@CU
M#O6TP9,@M'T[<P*&K^AD\K(#7-$M41,]7).=F#4UJ4D)S@/\!GN>ET947'KP
MZ\AEZ;Y3J/-:*6O!/9*[R"X3'OHR;\H^L5FT>,;CIQ9/KKO,+TLN[FSBV'@*
M29]]69?BUSF8L[]F-EDJOY?QNGH#Y020'(%M>+(IT>4FCQMEX6\RI>LM\(">
M7#<0ED3L8J_I\7TB"1.D,T=O#Y\3W8_<1]/7CI][BMV,7V?;1(&5FJ8VY_ZP
M]I ]]0^%:EIZB&\Y="#<BK"&^''UD)6BUMY#ZP#ATHOW:9K4D8SB1HSV2?BK
M@#B+PK=,=/5;1^!+L\>CSQQ])V_Y.1J+7THYJYMBT;4"<Q-F1PT0DXXPP-RB
M0G'\>JHLF/7>J$LQ91&2MZQ7\W@@T7&@[)1V.+E:=#A'W =M4?Z;>^>W]9;Y
MJ2F^*\'RR+32'$:Z8,N[_(SAK'Z31D)2AB:.D4QG N?S!>V>"N\8P5D.^..:
M<E= Z8^>G%Q&2HPDZ\?7,Z9,G!?3O)'N((J MYV195_4S84UT8>1A_W,_/O#
MUQU/WQMH7/_R*64DOJ0O9?+<[-K32,OW9][*?WBP_YDS\)-,</.K2>@2G0ON
M8%.=U5B_>_+X#+[U/ 0%["YZFJ FS7,[--(H)F><CNWQF6=66@0+<@_X#4XR
M B-55_>H:8M _"12Y)_ 5:9Q;DD:D*F+XH%"%+\]OE0VQ;%GG=+'LV6QEK[!
M+<Z),Q,2'_V"9W%4[(QS+N)Y8,S AO<2+7L]2\':FK,!7==E$8F'2\GK<^LO
M,\L@$X&(T1H&\"82IJ94[.QD\B2>W,D:P#RG=0S/:JP)?J&H<FW*=))-IPWR
MDL7<0=F\B#4U7?U,22 NJ=-\1V01K[27DNC\XOX7=Z9W[SRXBR_;_TWP\_@C
MHG&K5+J#PUFNUT="':+[BCF*L;EE!C((*(;I\JJK^L('_'E]1F;!4UFG=EE5
M86'A+@J4\^.*O\R<:%U<HA;-D#L*Y "=I1PU,IDHIS:!9YLQDZ>TR&!76.H_
MD=F*5,4]]<C8#ZCRV'#.%G77,-)$&OMEG7+W1;-UP&80@3+70KB3-4W2;BVK
M!:VU0JEU +\69Q:_";%KV28JWI!XWDG" A,I??[D&1W!!Q\>?/#%$7QPI,UY
M/Y2OX<AW[>:K770 6):<[4]Z\OLC:V%G299&8:(E;91H9#]*!EE;I)74VBBB
M$,M/ .2R3MKC3;)12F.L?TM^+A=-8LY6+%>TY@#3,90Y55<GNH:VC9U4?0^J
M![;-\+#B,@U+W*)+AL&('GDKGHU- @M+ 9V.Z67WRL\G,B.MYH(+[D4;YXAW
M/?RN+UU/6F;9E*<X,.M<6-$#3Q/V-DU(=$0]X#.PG/1= LZ:<B&\YTS)6<\"
M(GI\NW/:CO"$CB<,&\7.[\P%Y;3JZ)19C\X^SSCQ,ZFA=46#'CV/*P-;,\!<
MOSRY0EYBFI;UM?V^CA( ^]P#P+&+O@+I))%V'N57Z%$J5 5E<*B%$/KUCIAP
MC\K;;:ZU1CQE0DS?FB.H@CTQ1O)?'%?[&;^HF4W%JT8X2\I"M.=6VRWAAN:^
M&2%&72ZWV5.>$(M,5#+<?:?M(R;>W%] 5+T7!+(D1%DV&03 5PTYH%4DN]<T
M)RH3=&)0PZZ",8;?=V4 Y=V(^%M",%"0L:5B%S<5:E&E-\@>K\0>A0&T4\1K
MY--@.CF1"19S=.N&/= /84=?@-=P,6+PI-1Q:W-*WY9U6X9?Y(*;&DDFW;X$
M#FV%,T+1S&$?'I./<8;6 =.)#.<(TL;:"D K_ENKLK]HJ/+U6#1K% #P3.+6
M\+]TM;!:']R__S53[+YX_.S,J$_0S##OA_TQT2],,XMZ3-C(U3:G]G)9>HDK
MU(RPPI,Q&+%B<8PPY(J"^7BT#2\>ZW>4A6$);=,3,(K8>1VV%H+/NMNNV%W0
M;'P^6WKF-Z_G%28DCOA6'VUQ5SIAK)3R:8O,QI0*V)YW6+I&@F=C+7DSM*UM
MKPI161O1PE+.JOCJ]2]T-H;C!X<;.R&*2W#%>@(K2%\A*6#1;;C-/0\GY&Z;
MJK*'\:W3_Y][(C'Z?,=N-KY IX5;M!PO]-FO;+1M;\V//Y0^KH%P"5J7:BT0
M^Y@U2[+,()_?_!M5EET["CNN0[::KAJ=2_(4+\AW,RP,D)$+1W7A,!Y2B8.<
MX#I<NZ30A/L0.?Z*O4Q9\FI'7JC]2?)1&A=*@!4L 3P43DY1&HDV^)36C,^S
M^A&I;&VPBL32!@(/=E-)]15QA/R#E+GPPV7AX&",?[D4+*/J^CBAWN'@>X)@
MJQ!Z;9G/)"7XI%^'%7!1".L,=VTQ1S?_+J,PKD/5LQ7#T[>C"4.V+!=RSPO
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M_=*'##.2JHX]?D7,Y43O1"2DL2UV[]R$D=#3#B8C>\O/\!2T=LJJ*T0&-+A
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M$'B<(_J@_%+.\"WM36 ^:%J+MH8EXM)BVD[[[FG:J>>?OHR:+0O/TYU(>H8
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MPAS^L7T7YEHW+/H72X\^ITSC/?7073IR'*B,UT91H;>).M_\[B,?L!P:P]N
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M%;#JQAK!20RHA4HF']U\]G\+CTHX<1Y^\G"T1W6_H!ONHH;LQYC?1(H75"X
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M#V/3 XLQBK*\+>IS]=8]$7*"PL[B!77)KU8\P?L47<EG/:1")GD,)-REJE%
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M+^' 'F UCT1@)9'-(N#<3T8)RQ">",KJ<W,^&D"Y$]+DNIMN<6C4_48G"],
MU>">?[IDT0QH]6]9:$$+) ]>/&@VQ]Z:IPS=]Y*8?#0,:Y/38D%7)H)>\<NP
MBP^] P@U)!\Q\0WG-""X(,Q/=&GG\:57+JL([#G -L=9HQ[K3U,P]1M63ML6
M4O?SF)]5Z6IY?!Y7)')"(Z"R"I@O/$NV9%\X4&)6N7Q."59KW _NSJH0!J--
M+1)-,DH.GEH]^IN"JSJRJIFM.HP4? 3:S2DC-Q:D=L_W_*-8XZSX"]9K&);#
M];;0?F+87AMCNHV=!\8)JH277,C_:/P5N9$@6:26VG 477& N-<&&./R]1[
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M8V(R+N8WSNI_F%A9N8_MZ3]:T@E(#(D5I?<6>+5\=8_/>UHKP=X7%=)ZFRW
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M^RNKX! &T6U)PUC?)LWS[=Z0OQK+UYLJK(FK98%7CU4K9C2BJGHUSXL2,3R
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M'&_%2BSW_V'OS9;<N(YNX5?!S1<A1<!MDI(LV;JB*-GB.:;%(.50Q']7#12
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M4\?("]R9P-9M<BS?9W%1'*P2FA:14H;?ZX3/<EKJ=@CI\;@R(VPP'.#EFZ]
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M8=UW0( P 23[792X%^M;K._*5)YBQC&&-/K6ZXJ'B\$M!G=Y\X;%V00"[(L
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M+.FDWNHI(B3A3Z)F5+$OP"<#%XM9W'2N^#TW'2^OQ9&H5.^5(%%G8A+OBSF
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M80<ONMCHC$,L_C,4^J["IK['1 GV$I[PCZ-4#Q(@I=3I#/)+SG)=B&WFH6G
M='TJ*7].1)'^Q ^$Y\E<S*L9/OHH)_&0C>-#) IRY+2:"@W\8@5N,DH+/J!J
MT0?I>W^OFC["_M=O7K[Z)C&?L Q$:H9MT:< :VRF1Z[.=W5=&O":A,]2+ET+
M,S%P,*TS5L\KL+'T1_X3[=>"QRB:37\DYX?",WR7"[XO)-"))@PM23'JD#"
M4,Z[Q%\UV99<^U?/M/V3>N2QAC=FLELVZ(]>:\S]2D4#/TZL_%KSOMK*$@G
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MR/AP8NU'9IVO@C<B7-S:5YRR%<; GWSIBDWXS=,O9R.-@6U13Q<*NMPXHV'
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ME:(]9"5%M0,<+YP\,05?TLW<#=_(?>[#NP'!@?"@VUC@L+*2',FQ9\S=X&9
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MK.\?7D%CN*Q<=9T*K8X3YP7@^+A[A)$]0GN"BK>Q60'D)0R+YD1>YF 1A-+
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M,69V2T6D<,5$CGM2Y?<XB3)'(2$^*1$71,Q+O>QBT\.195.AK5G'CH4OG",
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M]10;0>;M)?X_A7\?P]7U75I9X,FTYJ[8**ORD5[E[")E*]Y1(QNTH>!GN&2
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M=>5)FB(3!,T=MECYU,\NRP&'NO>2LE7%@#$)P+C"5IW7IN^" )J#QR:'9-O
MF<14)EXG F[^TGW.Y&I\?VO>9)-;'-0UM<]N-=$?=/+.$4J%:P6MOXPQH+ I
MH_[NVB*3$;_IHRB#%*7$(+7P?58Y1>&$\4M%( G656G[VZY<RV@^&W#+Q$<P
M*9_B5!B5QAOB7*7 0)X13U> !2.\2LU",T>F1DCN_('(Q?>G4\O0<(Y74O!
M?3(6FT"X:\(@+D'X2.Q+GNR^J>^[@U2PJ5JQ5C+$]001&B=SN2>U=_M_SE7\
M>T=IK>-&[HVX("=DV"'>3.!UV+62Z?)N037][/<UCY*=B4K'+Y:AA^(GB-W5
ME#;4QR@K;?Y Q)OT>2#J-BEJA<)C'*+TGW',FU,6Z)(\3N#U/'"[LUW#BU=]
ML_K>ID-MA';JNBD@1F<QG8F+\3L%?N59!MD57L2(,![%<T>545]VHW%H-6W@
M<M4L,R(>UMR;J#(.X)!K9PIQ:T^:H:X4ML!R'@\LY],%EO,[PW+^%VY6P^SU
M<GO^TE9PH5M! 4(LH%S@K9N,5!Z.4:;#$)<7_VW>.<F+H3= ,<FS+_XG]4SN
M)?\E/.-)%]1V84?_$J_R3P55%OY&;3T2:!Q9=WP/% !]_C]_E!5\>O/Y9\^>
M?O[%7S[]Z[-//O_T\V>?Q?LN*KKT/^'V+]POK9DOGCW[BRT:]U3Y)$^?/!D>
M]8^R<@5;S6W;""V<*?.<I[-'BQ&BCR#_$+W$8E./RZ9TZC_83"?CT3O1VBM)
M_:+GRA^5<X.MT5:ZF,YB.C =1LR!U4K9>FTSFZ(K $Z130@=;>N1-GF9WS&_
M5ITT:Q=+6RR-+K2O%*60\))E3=@0"1[2D/!0Y!FHMG,;Y&)0BT'1A9(">4W3
M5/<AKZP QXG=)PP1<X?@U-^6X5/"X1%LJ!%8%)H*1-RHL_>M834*/\QL@9><
M,>D"M5^N%GM<[#&<$G6Z EL@]Z6SG];$MU#69Y[(+(['8M]$8 IZ;:S&!Z =
M/DIR6&5Q)W""X!7OH$HFE$"+[UMLC2[44D% HHAXMNPISA>LI9_"9T@=QM@K
MTS!A;!WQ@?"TA&ZXG$=H'W7M&BQU<*)[:0P+-I8I(6K,F"@$'LU]7\H^+R:[
MF*PWV00AFW0,6&\*#C2$?G38Q786VZ$+O:^;=PR@\J2LA2N%21>9M]2^(FY&
M2$+6QV-=+6:TF!%=J!3W@;LC\FP01D2=-.X@5V> R@DCQ[@7ZK!F]R;'J>.[
M@#"ZYF>*U9)PS3="%^-[U,;G0J1@2$U_4@;XQ/SV>1TSTFPC\5S,:^\SIKFB
M0]1-T1XOYK=>4Z?N.W1@6=F*N=Y:X"69 *RIJ^RN:'IO]_2]UYA!,[WD-[F<
M+WSIQ:&HLL&@"HV.T"@74405;48CWJV[_CR\M<-_^NP=)NW.IT.-&]R5=;U5
M)=O&XW;21?/;]S]_61_]9R*PYFSF#=J);Z**$P%ZOE)#^BZ=D'G)W('G!;(V
MA$#%=$?GBX"5E)1I0/"@V1--I3/]CB"HQD>9EEHR<C8>*:HG+X 8KC,@WHGY
MFBNC$79+F]"^+[9<3,AMJ#%D70NBC=#B35BCHB:3554?N=]_SCLN.O<F6;;!
MO]!+)J 3L3[]QHGK#6%+A7\X&8<UCHVCX,?X4@@II\3?1D0"!+!S_VN0G1.@
M3D7ZNGH!%#SNN&) =B(L)5RZ,:[%1#!R[4:F$\JX*2S-$ $JY4O"@W.DRS.V
M/'(Q-UZIJ^T<A6UH-IV&>V@2-?Q_2=$6:^8B^L-27$-5PBM$PGDYQ&ZU^'.&
MUH@@E.-K]$BPQ3(7RU0_.TD!=877(Z2VP.[Q!1X-"W%,L$:."EQI0N=ZTI,4
M;=OS!+"*9\/W4EL<KC_"-M+O14^]-EX%C%1IE#$Y19R@/APS9[,LAV4Y_+;E
MC,D"@A8RKBP?H+$_5Q;!'\-'B8EU,>?%G*>B:)%S$EF9<*00/<M (C<W1="F
MM2D=D-B)%@K3@J<JI(/!4EH<]P?ZC\Q]#SC%F=8YVXARW_06LQCO8KQ 0OV$
MR**#\(_.&!\Q@TY5"*I L"&M(ZUB,QA^< '$S-R$5QI9+&^Q/'6;5F0(.RIV
MX#FF[E%$G-3D%I-:3 HX$4[-LPUZ^\+&5-74^.<=MT[D&9'"N,]*D6#IO"X6
M-1/;"6<%V9&1MNQ 5VJ*XUW(3B39'BC"S)/(R9::TC:G>L<R,NX41I4EQM,:
ME^$K[28[Y9$OAAM[/G$B3I9@ZELIQ_+P]H"\''D.-!@>[J<^CNX1T3%N^F,O
MK)"B1A*Y<J0W,T).LG9.TN3A&4_I$3G8>'UU@VH@NLB2K5I/&K>SZ#6O0/JM
MU9FNUC(-?DL$KD5"_'C,,QKNW_4@S:$. -U<>V!UIKHSUAM8=$BU[610'?8,
MHV**2JN2-V$A'"%SOPS;_\[#]I\MP_:+!L9OXAR#]Z!&M1<]&+DX=HW0*HO^
M$:XA[*72!CSF>6=<_!'7L+.=#'NO,7QE(>D\MYWPYZF;,ET+.#>,_7M>]GK*
M1SI(Q=3IIT]4-_(5\$;5P5UE;:3G5XHY*>THU5<-XC#P)?MO3'Y:1'/?ZZJ<
M++O3)3D2<K&K-^_D-6P1LS!C./&S02KI9O46U5+Y)!]#/\G?8W0"N'/O#WEE
M1:@CV$*A,WQ7U'U+DL,HHX9_A!-T<39 !.UH>VG?&ZKR02Z>WX/!EJ51J5@#
M.D"._81&SQHR47V10?$)X9J2G0F18N39%M)$%@MG&<>T)Z3'M!+FN_SLE1L3
M)0.PT2U2!@(XTHR!7UVKTX$:.=&'B[ FMIY!*^LZDNY-*"^/=0@["8Q$FMIA
M247:2Z^X:2D':]<82[Z]*V/6DL-$BR+">%Q2FU=%W22'340CZ3,O#D6^6WT#
MH4V*AK\C"!1Q:CLY B$FSXG!W QT='"AP:3HFFCS0/KOC#J2% YL59T8T64*
MRSZ.=O"21U,,FII=G8H3$FW*C(*I2ZC*65"9)T0R(:NJXN03ND;ZNV&.)P*Y
MDYR:LQ+$97< D:&Z4A$PW;H)0-]JI55(JVM50J]6>J^@R^6G??EAK^5INB-"
MNY%HUIA8FHK M(@9S]#@_S6#QPHFHA790MJ_YB@5HY<IFOA*L]8(YV&*VQK?
MB_3<1YK/H"^B1/#DR^AI\(NG7ZZ"V>=NW$<\80DRXSIA0+:I2+*O$*"4V>8=
MAQ+Z9<IRTK(W70U>@O'"(BVNVLRX,3IGJT,G/#+41^X"57"WRAF$'%X^Y[63
M#+IQ"VL@CF8KCG[P09]31A9:4HHD*<<0N8:H>7;JF[;G0T\*$$^#U,+%U<V8
M^#;E+%5;U<2[KXK_]"K-&\+=$%>B'(DSP,]+D"L.GC=<6/N4.Q\Z\<QK*$<V
MXD2C6V&C+/(Q5L\F^XWG<I3&J )=TK<^N\>N>WT^%!26:WD;S.SK(M_7Y%DR
M%M>Q^/T@/H )JHE=G/:B%4@.:07U307>6L;*Z+-([I<(O,+OSB&*;(>TLNI_
M;!.EQT"CT_GT?AHY;N,IT/7BF>SVD$8W-:B[6"=-7(9CVZ;2&N8BC+ 7P5 B
M EB$M[$511\6>_#;4[)CN7,-2#;#.=JD\;;)3D6G:R/];$$;FC&2VYU \R[?
MGY=0>^BQ\%(K] 7R)N*[A0+46,SI:0HU*OP97-N@"$=YFG='CWP[>(Y-\A7$
M[)^N5\^>//MTS6'/=O7L\Q4]HC\!VAL)#1AX%D(5>)K!7U$'O<\MC#9T,E-I
M>S<?4<> <_*ND I@O4?4ED2Z2O#-9/L"'I)=("II#K9 U#VB#NB#L.IY?= +
MBA\8 Z"=9EKDPTH.([D1"W3D-O"@!W;--X(;Y)C. JGD?I4=W[,QBQ3.H3A)
M]$JU(^*F%:=$*8NT']8\-&G,/A.0&-Y@9 .,88*K-$^YQ??F*88E3LHY\@U?
MP8VLSR*RC(L#\3SIBS^>*'TXSDRU%6$%")%AV$\;6D18"!VR9$#W-AGFNN\3
M3BA.X&P)2AM/7JR2)?.*F/JJ9)X4*3T@.Q4MT20*'[G[_RZ)I-*G)2D@/SGI
MXX^(_;G&260BJ'.ZMTQR#>&H<#!@FS;=B?4D&=U9(7:;$)761_(NP8G5X:7S
M!!=FL,NS9P4?VILSMUV3]9S59+>]J-ZPHWK $'4(#'_#D(M&D/"^\6$E16__
M7/B WJ&J+H*(X[!"9B_3:+Z($5O"A_J>B7%U$[I:EH+V"3N1<):[G4E&@:2N
MC+L4T<!E]FQ!5NA">A[B+UF?_[?8O+NE.LW;L+!Z*)&SH'=3'XK; I3[$W3S
MG+NIRED1@;(D[\J"@V#J#_LTEP5:@'U8! G5-/R+F:&%0(NC(PZPB$;PV%>R
M=E8?Q:5#?WLG%QTRYK!&T. 0JI'PM5L*'CX.<1VZV<S^0 4B_FD-D1;Y]4;^
MC1ABD[4'D85Z5TA<$1)8$G(,BRX*3AUHW88;:)CR5WKO7'[2>F0(=S<A[\Y)
MH!O_HQHBE4L860)_ N ]?@]-[! 052:X.OM]K;CMZSI<88A.52XG+#GZD-3&
MULY/"/Q9E72.V18U6((TE[G<,,=/?45GR,Q,4G<?<OJC@?M?07)3BBW\0[$-
M0:L8AMG%>;6M@VE0H4#C4Z[V,=,M64N9;_>JU7J-A>(VH[ZOZM#?%74)V9(N
MJ4WA;/1T6=(BD\\5"]/,XAC'CG$7@IE@+F56'"5:"0N[7 4'F'=<L@KA#IP=
M;:U#F63^\-]QC!=\C.=4$;O*HPX:@W->]40Q0]69PEY&$<M>9&;ECS1#*35)
MO3%6#]&F%2YM5]MHQ,K3F".IA @K;H0B(8JV^A)?CE=RS-[A*O@"1M="?F:%
M 7V,=,K1R-,UF)= (">.2=AZ,'X_<5:^XC7_,GD:? TS)]=CQ3/1">[J8DM)
M/_/K2=*^R1%>.N8\I.O!8]*K/\\_S8'"&7TH_O$*MM$%=_6;X*[^LN"N?A_<
MU;)93FV6=T5;<!'J;X=BN\VK]]\^/_Q]D^+)K T!I]0A,W;3GMA9E5:M8SLD
M<(O1V/L$@,C9"_IG>VG#X!VN;ZC*8,WCZ3UZB0676%!CP6]Y"OFE@19>$_V@
MPUD^YQ$6_=7S#9J)3__ZU[^@2Y%1(A=2C=OS*CD<:N,P]>]CCY=,]!LE1Z>#
MO]"&LWQ/CO[LR9._KD>E4>LTYJ(0C S.I)>M7/[MR]?/GVL<&KZ$!;%I:,Y"
M:6.P+$K#DR+CG0I3Y_)[QM!H6$J"I<>34LT(OH:BP'9SR)E)9IMK$>_L$\W;
MO,K#.]&$$T>;.R>M_&!S.*D$<1H-4@Q&_^Y/4-.6 ',G(  )&YFY@?\FAW/1
M(A<%J$&]<9+;D DF\ LA8W=,2R]!-)[9^%;:]=@1WJS>AH=/?/6#R/)B92;[
MI=EUNV30B]?\;3/HUX=S6VR*< FO=>S^;4^%\BKWR;"(A+16MTN(2TQ*"]U9
M6C# QM \\T8$'5!R*K57V4[4NXKPR;LL+#+J)7!I2ZM6:RM9:<'NQ:$HMTU>
M&7?F>!>0"MA'\ -ZV?E/)(--SOAC!N&=PF8A8T2EY8TOD OQ14Y6SE9OQ3&L
M5R]>O27/$W>+)E)*&I-!['<(;*\+%]GNY-&%++[/%;Z'5)B^JR^F77T4?&]1
M\2&E.Q <B5#=44NL:,EKU2=JU'0-_W2JMT7&/_".<2B:^M3P%-;':WLB5:WL
M"';&%3Z&%)FN\*/X!U8@YZY11>Q1Z4<=P);_"J\5EC.NB,[(N"JB("?RD?!/
M_EQ6Y6UX/'(C\E-;"*[*3LHW8H?A[QZ+[3UA@#Z627H"#:%ETP+QDT(1ZGNZ
MSD-Q$E)T1]U&UT,/ZY"7%@RXE[#-VPT5KZF%5=_E2OA3-*0]D=.SI@H,K4/%
M]"[N=G&WF+H65XN>ZS%OO)8<SP'MLJ))8(A<K63_J)U6"21U\B7<UB8?PG;<
MC\CQ#+M3GKDCK]>P#'$O!FH&2E-2]9X@(_^^>7LC+7NAFX"NQ#1$1'M+^GF+
MA+7=Q\?P)7IOUZA'@.Y]H&HG>\HFT7:=8&=-0&%.X'8M8*\H)(7D80@*D$L*
M>T!=HJ7I4H&I2HCP)6)OB)MFK![/J/J=L4O'^S@UC*L%R!Y[)@W)R783'FW.
MV-AP_KR\([(%?KQX!5C3$HH-P,@"1!/@V@"J,_RL8HTM>@J/@#+DYKQR2DLT
M>H9EJB##7)4(N^''\ ]2G._+/8(?N:&I=H8.2=T7Z"_0>Z-Q$PV5<(^N]XF4
M)FEL$B0O ;MYI41I] KL/7EZPVP\>9H4O@Z"6N*1+J!V3T%BRL;JI56BC?DP
MT.);/0,!#9'&[HM=$A(FG7.$)6Q]$ACJ+6_3J' ]!M"DST8[4E\Z' Z(:VLR
M@;$]\?NEP*RQ"M_ ;GA=A>?!?2M,^H?<>"% H%-^0PN:6XM9)^02(::L(C^!
M0KG,T8T!7"D$U2]C![1Z #,E"#QV;,D *T@V:2( V=:I#H$UI@'H@A-'EO7=
MH6XXD !VD\HUR#OLYBY[:YG=T^KQ^$9=9#T)!C-;#MX\9#5,YET?59M\*Q.X
MM7 C9NUX#LE\MRZ@M8U3N>>JN+K:$+)2=6G7Z7:7[:$&9NX.34R&IKE-Q./A
M!J WFPY]$/,F\]C>;*B_6_>,L+T%MTE2BH]S@'S(8;:2\*,DKWK>-28;=!_G
M.5*%=C>\$=OM"9T*E2K7:?DRVX9_BZ>YR_WWMMF1I&,PSD3_"PE[V;=XI=2!
M0(#B.K:['K7;,?+%Q2>3&3SVH5:*>OH=U-&<P)J@Q'\,Z[JE07TVA!!K[.MF
M;T5' Q,5Q[ MM+6V[05;3G^QNPJ^L^]D9 L1^3H%?M-.PU/W3K4<"R3<<DM-
M3!E:OB4(4O(B,A(:"=_GX()F>E  URE&?[_QEZB!M/ 3Q'RK*G3!E&*(,Q)?
M-$0F/0N\R -3D5'UU&*%L+"ZK"CUW-CI>^/U'5KXS>KOX?,'JH9OPR;.T*IL
MGY%R*$R7W^9&/%QP[K?,&4QH, P]<&H3-V53MDU,-)V2BR---BD'Q*F.;F*,
M/TZ)I^-M5URG#V9N@3KM[,-].Q@,E\\%*\J(F!)NP*UKYS$C5:;M^!Z"@K>D
M#)@Z>D!R@G[G<?Y$AO=0/D]?M?-F_+[#6<\33D 7]UH:$^1NTB7>9M68HG:P
MN*]:UQPAN94V?$[B\(B&@2KYRJJQI05$S166X!E.'K EYND;41#\)(9]F4-(
M]70P<TB=I2J#$G5)L:0*!<O6ZGZ'A^O>+Y;<D2:.6W!M"L<FHW[0QM$YL_/*
MQ!BBHL@LM%K(3MYCA@7['AN)$8489TF;=X]\2.$E0^^Q$R.SH'U(*P6#K1)-
M3NY(W>9YQ1U1/P]%?]8 DR?4$-]0[ZSJ=5;?K.8N]Y$*:6DH6Z$4[IT]M><V
MI%$IKUO;V9:&P62&LZG%F;-FK59R8B@VK"X()Y!Q5?E]Z2@Y6?@ 4<ZDI^%]
M,OC4LTX/G*<L\=K!@9=>3GOTQ/UPM3S;Y-$JMP.1 V1=?+'C$0Y0D<I#:O/\
M'8<.>%#NJ2/!,!=-CEC8^$LAXX^??>3+Z.^T8_^4$2( G6L>^GSVY.D3AB6^
MYEH0];%\L?@Y#=YOL2._H >.'MTLBN&%AKW?A!?%;O<-*:T3#)U_?,X\*E0V
MR65\SP$11-_N^0M"(]!<NOCVPOF YT =L*>L"4DE :1\$59VI+@68457ZVO_
M_1_Y:N'3^YUQG9\ON,[?F4_O?Z&G1*AF)=ZI67-Q-7];A1PSN$;.1ZE=C;[^
MFG+9;0X-&-1E<K#B0(V643FR\UOQE_GBCESV%>0-^=8F@X^E\F?(>%!Z<MN]
M(AY0*>K:+X-[[]@I)W5E*;I'+ &/0#DP%[SP'=KC?'3R0RQ<  1 '#P(21Y2
MN;QJR&W#,=MQ>9B:M!*A';K/*AG;QZ71;'IPZ.'=%DH_V!3 5CG80[&UO$N_
MP]"UF&SR$7C\DRX4E9-6 !S8R'C>7W8D.=R7%MMO'=*)(CK*&H_]40?#  >+
M3X\%(0CH'T]@E_HUU?#?\--\K>>ALS .*L1IL1;TFDC&OHZAW3X[V=7'BXSV
MU,H!9%N6.)*!(N'HW_4=U6-(4%0(%EXJYA79"9)/VN@!U]A1Q%=H@;6P*(T-
M&V2U'.T:G,+FWY&7QKY75M+FBUR=4F:=44,10C_%#8!D:0C"Y0+ Y655A?B2
MPXZ.0"X(L2']+7^ANIU =Q E<K4UHNV.]18!8[TJZ_M\[CRM"#<]\FCP;4'!
M$97/$&)Q!7$8R_\8\AAFP\B-60X8U& #C0YW>PTK<B0"\\D@Z>8#LYO5=]7J
M__15OGKZ.:A&GJYC4/>V/U'U,1RZ;TC"LST6K:[58PTV8U ,Z27%LVHJ1J&?
MEKQN*=6Y0T*!9*(URC2%-0*AT/2ED_ RU#AN2]('N_;O#WUT_)Q"A@NF.RTJ
M62WT+WJB6N&G^H(K,V(%ZM5.W#1?S3IXDKS%LEU]1?]CM3!L+_$M"/B2MA')
MJ+#*!/XD[EEYFHA/>@AUYP0O=J$=!YNY*)U;UYOV.!#4S_Z>WS8]-7&??L8O
MU+[RO-^3W]3?,Y_@\/*I*DD5VGQK5I,VA53D"9G?79'?2T),;ZH0;UQ05E.T
MB6  ?ZPO-<?FK#ICXL>DO>O3=8=F1N&<DB5^1.8\MOF1Z0#@IX+7_A$VCB)#
M1EXH5@WEW7 3Z[YNWB4E=M4PE.MEU4)L'&&?B0Q8MUG3%-(:CF]L>".7WMT0
MQTBV_+@]7S*/QU5M7^_1 D_T@N&5TK*1SMJV/I'!MO"?Y@YBJ@HO)^;_C*S_
MJ;BYK_KM/N_(=Y(0<,3M/WV*KU// /$4[5_9O8!6IC'V7![FZ*O)16L0!F%[
M7H0WU+ZUJ04>!B#6ZK@H+P_NJ60.J*>?K, C)-1UU,\-IDO?20IC5 "P<SCT
M^'K&.ZI)/GORR;-UA(H80I;%[&DNH&Z@*-,C"+5J_:L0A#%'U9-HW@A]/N%?
M/Z,)]1)U]-CB2O<J[I-0,[K+WN45;TDAW*/S\=OZ1)S\,?A-ZOI\GX4H]!P>
M_IL09^0[]]Z>_8SW1N6K[?1;T@W+O2W/!Q+!I<"1CF-9M*SAZ:2GYCS_8.P4
M_G3#I'[A/Y.V(K*^(/H","6\<N;W>]SNP[9S#99:]A)<&<C)%I)-+"1N-/9R
M3DI88Z2+XGL,W "I"O1?)0IIBE:+RJ)Q,L@)A=/%3DB7YCV%&IA$4IMD8105
MU$>5C<V[/*W!395H8W=EF\M*()S<E/'?H@][K!F95(4WTP#?P$;'%,#\$-:Z
MVPL"S*ATPI/N[MDE>S24R]8$T.::\APQH-7C5H#25:3%]6,>@L2MR*)QR"2T
M.G 40I/WU >OYB="'K8)_O)UF5711SR[Y-LIDZ4F9C=*26.\00FFI.N;[!0>
M8GCB%8( ]5K"VL<1EGR4SNEHW\,W3_0N0SSVY,G_L)NE(QL:+Y.@(7V4#7A"
MPD-X_NKUS>I5#,)!DF*;W-._J/.EFWA9[4JM^ZH(;GP<SW"\EV^DNCMX+EK:
M3>T&1WWS/$Z$C"9!-'@4!>BPJU7[C/5XF#"_RO>U,$I+L]H\\$?QB8:/ATO\
MR\>R-TD;CD,S;O_K<6C_3W 0P;78V)S6$=*)$L[_OW*Y:*P)T H@0 JU"?F"
MU;^W"G_JR(\1W$\>[D>[H@G/GG9HONQ//OY23!WQ>2LE_8=K#M)W1ZU!_R:B
M1SS.,GQ GWW,MD;OY$0<U0P?7;TEQ@1 .L5A?9U3GTBY5*4<0]?X;1]>H9MH
M"2;Q[;=OURDUZC%A&G>5?MWZ%1>%;D1]8G^%G4UA16O;^SA'*I6@UD5H?X7Q
MADT_7 &5[Z!-QNN1IDALZAB/.[AW+S..,"?%)8SMC4HF0B>.IC*MZ-&G[&D7
MK:/>=L<EI(S/M$-:64O^YW&=6<N ARX]4+BG,MPY6,5T.>G%<W!&Q-K;1[ZS
M/^_,#4OW<6T['&JTHNV*I2ED*QF*%$.4@1^[]2@WMT<R6BOD 8,XP-=U7?'9
M=L8$U\T]8]WSTKW,,1^O8YET;0!H[II5YCSU3))<ICAC!!UTD+)NE4$[V<2U
MI[WFS(&B#>K2$UX1(V/QOL'C"V\D3;K. OPA$HZAJ^4[9;NBJMWJG[02F*%\
M"T_,ST$>)V[)JH1'+@VC13G#.&C(IN2Y#"@E%9^CF=< F+.>8I;4.(K+8 ,:
M&((],R(O=K(]!)9C?,/Y6?2/VGMB@4QJ<UMLQ2;JX+T87$ 3U*PA$ ("S.8,
M(TYA#$3U @%))'95[R %#&W %LTX[IR%TR( $Z9_%6%#^YY6&>%T:;3:"XW.
M,?L6.P,[\#QUW^$R8(JJ>#9<*'Q'?-X*.,.[ 1CK5WBKC]MA_I#R#%OCGK=L
M"B@,ZSNRCR'ZR@,7M<:2$NDS4$95JA(0JU5 K!O5S%!^2L]BS7E(4^SKAL:0
M+$+2EM0:EV_,>$E>P&4@._VVOJ_NLV:;F*3AN%9*P2PX\EE%W1#\5N=X+US:
M29 _J('HW9G?&B<U[?!1&0PW.;IE_3BP3@FQ6^0(S[8Q0WUC'YC$,DUAS?D=
MMR(CQ7HPO9SO-D?^)MH ^[QB-*0H4JV)($)V)6"7N&$X$KJ^PF,\\C7ZLIJ#
MRJ74=-_\>VUFX@C/6P].G,>5O?];0?Q*#0 .X<.K_CHL$*#$.+E^8W'3ZE\U
M?O?G9\^^>$:+2U()QY+RG*0O6AOW^O;[Y^L%]?-X4#]?+*B?!?7SBX>2E5_W
M:UZ?8:^FYLR?GWWZ9W*.5*^2P.1F]<.A*#F.=6Y*H1DH9P6GBX)-["Z@^E5(
MU:"NRC,7\U!!PM 3]D4KZZ$;\>RS\$D*+EHK2N7 :E"5,,DT<0E_4BJ0MLM/
MW);)WN4K[MA*-(49P>)(11 :Y[=YBWAMS!!$Z0+EMH,@@#45TJYY2"&K&,A(
M\. >#!B$MLSB7G,$86&VE(J_^;=*I4F_'@@"<NJN16W21X.!+PK5P/>"<2^]
MC+7&ZJJH(9K*.T01[@(ZV0 YY\???ZP+D,2I>)]M+^W*A!I)28E'&_'4N!0V
MOA&,LN4J^!EVIO";FOHX25!I%ZOI6[9I2-%,MV9J(/,D\#Y'F%70O@YU+GI2
M="G^B<Q>O]:S'*9FXN'&YAPI01$&)\+A:%IHTPDY+$^/K^5\3AI+Z?ZEY$JM
MDMNS!A:48%)%%:CN; L4#XR?GHY+@PV]Y(2K@RDV^QF;0 $QXIWJ(W=,DH_D
M)(NU]BAU^H@?1X^68<-Y^JIC1CYZS1,S!12"GPBIH&"U:-!56*OV=C[*;_8W
MZU4N+&\T?RJ@F^Y '_C88VF&MRWW(H1EVWRC>.BT29*D$LL@45KWXY%),N@0
MP_*PKZB0C+@-W'Q:"&HSQZRRYA1J<Q9PVJ;'."1/L:4T%AV5KH)/3TJW;OSR
MP@#9@S6+;-$YF93#SE?[LK[%9&SRVL(+"EO3)COE5#(/IRN(^B:7Z6J;'Y*4
MFPL4PT'8B@AN6"P)JG:^4>H93=;C*5M?'>9,WKC"92R"+*LGAO]8?H5N'KFY
M6@:<S-JH+XP)4W1TC1LBCB9[P@BOLBEGFV(T'"JJ%H-QK Q\0<$[IH%":N5Y
M]?_8>[,FN8TD:_2OI-F=OB:9@6PN6EM/'$KJ3_--CV@4-?V,RD160<P$<K!4
MJ?K7W_#C2W@ @:PB*4J:6WCI%LE,)!#P\/#E^#D(B*1,H2UN#*37;RN>^!;
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M8A+@2\/)04,5< Z<I1* .(U8R6KFR6]I:$K_,@0TK-@)O@?E, LY155?LW@
M>F>'6X[S]4]%S 9/Y>U1:_+A9!\ 4*D.G.A=EX=10'8A"*L%'\R)"[1W&107
M<NH!_<GP*-:^E"I+BD#<S],]HDYGG,?>+ PE>^+_3V<"-<'&P4)".I1ZE1F,
MW.FJE,F&OW)'6-K&<:@H/#HQ:A!?^U:@J=2Y!1CZTCR0?U\Y/3L\+.)Q7EF_
MRFQ?I0?SMJA^J_YCS!))"CXF+&176TF-XU^+(8?X*IQHP">$U ",%.'6QX9Y
M-TTL)0,,YE,RG!89/4#>5^Q-E@IA@LQ.BG4?<1/$7"P.)A""@,S\8/.I_ZI8
M/O&Z4C5I2GD/U8Z!&):P19=PZPYZ8U?)57=V-J$;;O"Z.J-4Q,.MB,4T\A#%
M1PQ?63*4IAT>="PG**,$Z+]H3]64L5*J5(5(3;Y3_KJAXRG8:R^94VQPZ IS
M5H(<-[+T9C*:%*%GP= :><^;7[YF'/']F.C+",,[Y/RA#FG?#G7&!"EETG92
MX:$B7))F8]S,KLT%JLBG^\!#T.^G(T\&R"%#KEGC)?>6"O$(5$@++X8K'.EX
M2X%*3-B!8W!BI;ZB<$:) ^;S0@[:NIG_[?[,K*:-MALJBP=D)(V7]XSCI01Y
M5>X7N&9,Y02M%BD,-TN-%6&YB;U:XR(:);"+=/5#VUS*SX8C[,C6&JR8T:W1
M"=JP-PW=UH>1BY!]/Y;(JO2T"+<*U7M4W"<M-88-'D/$QVQV,I%>,4K>8(W!
M!TJE1B3N$MFW\DA5%CG[;6MAUDM86&P9PQ(!+&;'%-=PG<*QC:KDZARQNI$=
M&[?MOHD#Y-/"1DARK#X4I^7GOF1JT8G0D76<2F0^(KD=2RL=L(C3MLZ?I^V]
M0KP^-L3K^0KQ6B%>'TQT?#+'&7*7OG#'JL;I--M8;'YIPZ&W@1B6GA'"I\ U
M<=(%0*L$_VI^*GC^"QDZU\8_?8Y!$YOOV=4E1[4!8[6IRC-^RF<97:OX9S0Y
M#+@L';/RN@SG+24_U&<HKUN9-@EG'1\;U/8[J'AJXIJ9 Y1P2Q<)KQ//FUA#
M/8GE3/3 E'E2=81)GXM//ZKW6\<S0?7[TT$.N,GA0/\BV'^)-F7X,:F]JY*>
M=*-_+=!+NY6IG)ZR+*H>T?*DA(]Q#8+[ '\Q_S:8SYIJ+TR5X%^*[XYZUEMP
M9UQ2 :)4RDY*0"PQ;5H*OP0XI@\*3C74@M >!7.,TZ5SS?1;;P')>Y/[$<JG
M26Y7G/VJH[JPG_KM2&CR^K-:B/JCA&8_[.AZSZ1LR0N]1LOZ=1Q9)M38#S[(
M?B5!]IJZ3L%ULE.$$Z=7FW2M%B7NY?F_3.9BC3H__>H3F >>C?XH*0R7(&<K
M+H2_F95W),R&KY4BI-<DC8T,T#_X?YNH!R93W$MORQ6S>5(RDN(M=&T5)$ \
M235-*%ZJKJS] .,5X-@@ZJI<=E1GCR#QNTU-K].ION_9CW$5W\9I=#7<R-.9
M]9',\U2%L 2H!04\V+0T%<D(_?'/:A-R3D(6'"B-K=Y.G\6OA%WFXG:3U JH
M;@OV"KQ@/X:^!"1S) T?^I(-*\_UQ9*1 ND4_H^8LY2R%=UXV_72^<K>M6C$
M$@*)R8<B""8M^I^X/Z5VXUX/V*2YY<2%&7_]L3D8S1<&LK1$WZ/&()._L^\9
MMJHAQJ-;Q0D9N0!7*&B:3EG(%84>;PRAW[FHI'W'M4((XPHG\AP\@RCW$_F_
M\4?]##-X$TW$;D+2;AY"5EVMF7EH"5BE=25[,&('Z?!8''9=2-24/AUVMR[U
M7F\(-R)O7%Q!A8%CF;XH.TAKHRQV7>HT*UJKSAIT!"U]2 HI#Q )OU");KD(
MH]?$PCAF[S1T/;8[C+!QS^NZ?<NFA!I/18%F[Q%:TSL)5R#,A+6.Y;VA26/
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M^5[PP$2)AAQ%VTX1NRRFHV?&PL-9FP(%(K"048UXN1FP*L4^#"DK1HT%[YB
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M@W(K\9ZD%' R5P6^H.G0WD#H2Y?VC2JN<*_:RAS?(E,?RF^.UTNTH5I)2&E
MM8JTV+.5Y?2G O;W&>E8.HT8PKJ@&X7G!!B3 8S]H.I-*A\5E7(![($(%_&'
MRFE13QAH!'$;QU[EBU2ZWS&O6#\$0[Z$8+%_;AV5UV;-7<'P(OLVN1O0U#1,
M$DBP2E#ER)++K0.!S.:P0R"QJUPE1S(I&T6-V13S30F(>1&TJ\5@.JJ-SO^^
MA8(_9=#[T8NL;[+;P;UF3TI X0)X*A:WBT:0K)2#=]%,<L>'G8?\,T-%0FMV
M3R82U[,%9:'+!GI15;T+GN*9)-Z5LT0XXXX)LT:.784>B<YA1V,>2:WD!%27
M5/GHPZJ^2N>2,KD06[DL!6H[RE@2"5"<+H]8Z5T^+4O<S(^ J9!"$S'&DR>U
MJ"2$GB&,N-/%P1Z==WR %I.\DF,PR2X1<2! !W>VWADT>\L=M:^/>M/ >_:>
M.*/CR0=K-^EJ<49+"U:D7#%N<Q<N^M(AM/=?O2)E Q&OH/HO,E(PB:F,UF5>
M>Q9E0CUN<94B7Q/B 9#I71=6E)J=$87MO;#HX5IU?U6X'F.7%K1GB,1SPQNR
M"A)\V00,EU=IN0\US\7M<-\3M$17(:Q7140I[%SCX<+A"2"MG8^E#><D[]13
MR,S?K^NH)3><!HTFGD4'=3BAPR;8<972II;D=#<)ZFS?=EI2Q8F2H0>(W#/<
M/HUAOZJPW[-M^C!.%#2=E,J#7TFZG*"3OYT=Q M,7TN:*Q,Y.[<%M+YM*D'6
MRL_O#9Z%\''$?" 7(W-X_<Q^Q45@3X85G.J1N,B4!TLEO_J$*XE<J)8RDI;O
MHMN_W\X^Q^;$/BSA:TH7_C?G:[+KF(O\\PS#KBBNCXWB^F)%<:VRX!_ZV&<[
M;;%*?MXGO@I9R"C<.!AYK61:-#OXIHJ&LX, \9J?+.H7> 74]V?"U@EW8,^<
ME7O<@40^4LZ24KLHQ+A2NZ.WBB=>E4Y:LR:?4"2>Z/&%W2JY)?OIPK2O[\N)
M>.Z@R1!:4K%Q2TF<DY6,H]2MY2*"9*LMOI\LX93+SRT=,R_RVF4$8)G\L&[2
M2,#"\\FD.H0/(RN/S,!S"V1KD!P+ +4 ICJ"TUGKBXKY 6N=XM>8<[3B4DA&
MFU$: .>9/KPHNY$;B'YNRNSXP]YCRI84O1+V$?GGK+:7YB-N+(]U&)6,];RZ
M<$P;^X3!T\/>%L1S[\5ZR#V ]^4[G* N5\;#WP!NZTN_<%!&9[/L,S/E/6L7
M+-=Y]9+E5F@<6N=JL\D<O_40KW&8FS$.>*7JEW%7;[D0+3N?>S'V![7<Q>Z8
MR2,3JWOX"6F[M>W;#;@BI.DFC3_JSAW9G%P",5^5!VY;/TZ&B!??NY(@9:$W
M#E! T^T01=&@X<>S;[4-$6LC7[+33PH3-E0?WODTJA@3YJ]D!] !@=D_^OKA
M-A%UN87W9$DXQ6*66](!K;?*2\)<-2.=YCCT43)2%*HGI=C7#7>,L$#V3:<!
M/B02U:(;R7HOFVU(<EJDN.Z23'MQU1Y*DN:-Y*52'*82'\<1OL^=_HH65G<U
M10B4+M(OM@WYW@ET:^FE6&>M[OP$I:>(UK.<I,HC10]7AYHM];Y<RXRIRZN$
M -H&W7K=L0L#FM8A8]JL?G1<4 ]SST8.'!6EGLL[!]^&PSR[H5.-HQ0\G[Z7
MR.>B=!69MY2GWLG-6X#S-KU0H?Q?.>FC"0^/&QW9!?NGL.W& I6:W#S]%U?,
M?_1Q8S]05'=Y*WVK7K5QG+IJPMN[CVL%C)4N8@(#!..C\R,6K?CF"05E7HB[
M77Q3O)^27P"A=K;6NKR>W,Q87-&U4[JTJWYR>6H^83!$$/EE(:D;KCKP3SN!
MI3T=/#LEV]3 9<P=EOO@@>E0\;4^)8O&X.D36M'ME;QBWH3/GGYCY7P[,2MJ
MOM%Y((EG9&4N:=N0!AE5&^GT(^B@7)"F>'>Q04^XW[0PR?T-=W?T#!'H801C
M"7=_%@B",(RJ^[AN).@6)1['9_W O;O:(5<KSC"'G8W5M:7)_^:QY2G6W@HO
M,&P.<@9GUXY$82HD1G:NN1M=9E"O-S%RDVV?&_N$!+=WC[Y(JG[3=F_)C4Z9
M:\$M_=63KSBCU9[ (&+!O!5OPKZ2[4E<>/%9[-< ,\V-^DR?WA9N$K12CS_[
MUJHCI-7LL,XDV*=)?>W?RUO=^M^VX51]P7-*3[_^Z@F.[<R_J[KW]'9-1H'%
MO4NW QU+8/Q+I1[@UFW=,3R7CO:HO:86)3&WPR[LI3*2JD*/';&J3J!,N;4E
M1VLA?2%Y@*ZSQCP3+94AZI PG(@!P^[A1*69B(7C7W(V,%V)2-,8ZRI\/KN'
MC.CIA)L_Q%+U8 A&H:;\V^:3^M/PU.$.4;T;JE,?^U\\C!:2@F:.')2B)?_H
M-^$RX3I>S6^K3/I1OH?B_8H855D]3R3R"-M3[JN!BUT<]X6KW?]RR<F"(A1?
M'X(=>$6YX^P3D8@)MB2TD$MGF]BH''&?,H!ZIEY(5TOL YN%$JJA'CCRG+TI
M@<LIA'Q;GU XI3H<\T^J<$&RV+H+W:]314^_)+W59-X*1GA)PC'=&?]-)R"!
M"D_A3DATEU&#L&L _7+?B9Z9E[I<CC@,HYSQP?DXH9@U)&.//MU42NGIDCLK
M/]]C8\O%E&^_B3S>[!YO^3S)[S<;N\D?3TM?NZA\>)'<^\$23-SH&Y*AR01+
MX4.[D*QWMQK!W93U=20H5JN'W+V4E0UWR4<M'Y1BAB#IB)0NU1VG/<W>]5>
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MV,BP\[&3NJS>QP-W\\2PYO:#>@GM4P,>*/@&>_L8:+UK@Q2QZ0TIY1)$ZOV
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M,H7@DY6*Z^#?01F=R>6^AV;=:7<Z[G]O; P4MJ^GW=YH?)W;?D^EY231/U_
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M73TUJ*=C\)\[=J:F8]IE.A94F9WYTAXYC1RP74DUC)D7!\YHDC-"PR>Y6%+
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M&FJI#EQ!42IVCFHH$JKUFY$<(T+E8-B(CO:)+I%X(GG&\^;6'D#Q,$&LP<Z
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MCXZ#F$G,*O!T^X(UKKH6M-<(QPU2HF,+GX!$=:BB@2A'5XBI<(H,J!!?!J?
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M$O3P&TSX8I<0%28$,A0E_ (6,1/A5]O85 _IW"?!K]*E@;23LZNY5QD=<QW
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MHKJGJB)FE9&QB\JE*(JI%[6VJ(N+J!5+X2;A,PK:6B"H\9?>7<ZP(NJ$EM[
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MZ5^;J0N6:81#O\5$@O2/A70G_FCD#H0(H\ 38CC9";2@YK13B]%68Q8G:?0
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MT %UY6IX'%O%ON\#J?WP.K\8ZSFRZ893?)#;>E#3#8FVH>_/L31[>_DLI?V
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M$;$1Q)1)D1FIXC)AP603\/:Y:OZ$^G?C%?ZRN+R<&DR[$=-(P^&>UNVB<16
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M37NRMB*ZNAK69&J^$5TUQI'".QCWXF+VLZ[:RZFX>8=7?[X4&JW%HV"-RN]
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M;U!UZS[XMQ<1(V)0D5*A&5%E"6H2/)64&1 8*E&<946L6+8A1A0J%FF2$5H
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MN'F'5W^^%!H=S*/0J<JO?Q]L!']BV?[*WO0C<5\D9J8!$;[A).'[[P9P^/9
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MPL#P1_->88KK;&HK VSGHIG_[,XO@?V\:-]AWYHIC&GCI"_WAY^D2?ZGYPB
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MKV8JKD7COL#B.'&W 3VY+E[N*;#<OU;FK)Y$[V$G8$BS2IS@4D3=?/%V$2G
M"F=U )0Y,Y&LZLMST5S 9BR<-:*?'4Q*+?#9<+9P$;2Y,M/Z$AD;GK59#7_"
M-=S:LQN\ U8<*!37PMT_!P%YWM^M,#N@::/K:GX>*2Q'B&]:S"[,/+HPVOTU
M,T:OC-=E7^<_M\.0H\OJTD$_KN=TH>%M'_]X_Y6D"9_ S/0";2FJAY6F/C,S
M6$D%RPMCJF;GE:SPM\NFU@LUQT%I)^S<-N9VWCB0(@!8%08)S_&[+?)WM_PU
MSGKS540WU17\W4\:;W7C+.("Q_G^]'/T-?I1G5>>H<-SJY6A?B7*3*?M3UM&
M.C\7\PC8PYF9M]'GCY_IQ#W^OZMIC>8D<2$DON)\ 83B.F1=U+-:3;$#G'N/
MK/6-?P@<9>TD*GS*230<_F'5X>5GC;B(<$6O7 %)^,A<5?6BA9/>[4 W,T8S
M' A\>F6 H9T)WW0N:B_$= ICF!JUF.(90A\$? E>V^V'6_??6!9];<2L]98W
MW, OET8A(XA^[*COMZ]?>H*+/##@)N$!A('.@5Z6*OK+0T\TAMR=RGDT-ZE@
M648RF@J,4J)PQ#4G-E.J4 8$"Y[N0LY[/\C^L/J.W=[<+M$]Q/!0'"C/_=3
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MXDM##"'C?JX^9PGM\U47^N9=$M=.>)!F*?8LVX=TX\44E%ZWPLXPUH>U#S-
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MLBVSZR)VW2#NZ/K:=3.#I4)(6%QBM>!(N-K%K=]IK J#)\356=K6GA07;]D
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MB\9WA?U]R/%9.&^>Y@0>2_/V> 11./RO\9+\W'M1+XOW\3+:<??]L=:<>(B
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M8#.R=27&OU>U%AI9MZ"H6J:=ASYQN)P9EN\N^I'+F04P='U"TB]^,LK;3%'
MB%I$R_;9UFQQ/M*?77ZQ?3I5/DTJ*<=YZ9W'R2(KP8]0ZHU&:-N_INVX;\L\
MZ._S]S/2S?)53P_39_VN UDY\,C5: I#;5L0 W!J>E%.[<?QHF?#60C&:B=+
MY_HUO!B5,(K]>;"#X<KGP"4@?>'9G/6I#_X=9HZ?;L:).[N_,.=^:0N13.Y?
M-H2O90%=/TQR<9#3"+I,$P/X6T:KG2QX?S*W\T)OCBO[?,_>M#HH\]9T53E>
M48[_86?4/PO5N,S*WR-,\-E"%_['N[\O5.&B+_0*<;?[&K\Q1NQ.1!G/7P\N
M<_;N[V4MS!7:-7;I,P"PZTW-H@?U!ZG3BZ/,GI/68<]\YLB)%'&>(_*-<BA2
M%6&7%0%[LY4]9Y@B5ALD$R:(JY"0\TPB2R)7QN!(EAPY#Z4)\^-,]IB,"E4Y
M; !K%&A7,)UMJK^%T5FPWK6WH'>>G:VOJ:-')U.!"I(4PTC(!'I:XF!G20\R
MY9V@P2LFPY:>YHQ)GBJ%I!4)A%$3Y+0,R&C/>,":)Z'6,X>\'T]C>#L;TH^%
M-9L\[]2AB]ZIW4M5O[W&3/"]3!/*P5<+QI[>"NMWX2TFOYP"-QGT6LW\C'T]
MPSS'H(W'Q0$&#VQ+39(92>'H2VE'\:2%-B?1=;T. U=GHL,,F:F0\>4P,QA%
MM-1$BD!O-.8J%:M7C5J_5*_@DS)KV6*<:54+"OV[I'1L)$P=J;5C&/;>&0#8
M0#S\T!0904A>5-KZ()6B6\$M=T'F95)13S:X-P\Q/\:E<Y1G@MJED$@Y]I Y
M'2['+T6+4:#,!&R4)0EO3K'(:91:>[!@6<[S"19,6V:0"([CZ"AS[@IBPKU.
M,3E*#L)-+O,,7[V--0\(*2;DI-?H]@$<QWNVYI(7#@GC<L4-#.O?2H4 ,YC7
M5A!AMV),[JS2]<Z-V<C.72-[@Y#K2P17"-E,B8.Q5]2@)$0.=5:@,KE,@2&U
M=CPXG03;!4(./MGD*)E.K@"3K-/T&M6<DB(+1*Z6<G1"D1& )2=RSJ,!9=IR
MD(=\F$R=UX$QK=16J-%=%/#YOO+;T+69ROHM/"FWH-M[S.&1<KD=)11@G#/-
M,4:D'&HIIV%9PS9 3<YI4,1IMW6H11T.L/0UPCY'[.ADD&: (2YJ*@'WB1;R
M,6;]&#$A@\!TUO>5RDC=K+37;>ENYUSNV:7D<NVPWI+O#U*AW0N.P+X 6L\:
M4IVHL\E8UG)KULH/WG%\CMH9>?O1N+E W=RE_-,/;RHI[UKUO:V@AE4JWAS%
M<&V232D-^,.;_@1U7@<) *T_?9VY8<9MH=>;N6+>Q]'%("Z<>[_&BT+ 7YB4
MS]JA/6G^/@)CY/_ CY/F9^OMM&_>1]M^L<OB(W_+A]?0_G+/LECC@J-BEML'
M;5S2\>;*#+UH9)+>\>^9NFA!S=N+3I>/O7/MB6LJ,6U5%%@]!/I;'&4^I'SN
MO9T!.??U7)\C^=VR[@8T>ZV#S6@XN/Q^U;T%HWZR6GFJ&PTR&4>&U\RJE+U+
M_3S8[TM_UGRNF5_XBJH0J\[8A1\*9*'D:.<VC5PY+%SA3"Q4()_A,?#Q>HNS
M-[>; KIO#]E)\YW[OD^!/&O' 5V4JJD+3I/Y86D^^]\X\,OE0Q;5*G<?\IF\
M^._S\^<F\*(*RPJ)5K-*HG6Y3H;5#M<%_<5FZ7U<@,$5Z=PK&=SSY.V<\#H?
MT>RM71P E&^NSCW.S\^IM2XNLVMS_9@><!9%5'-F7JE<-[[\$T@KO!6Y3#*Q
M^DD6KP5/W^4Z95\/:$3CDHVYD88YBPZ);=%*>N$M_=Q,;2Y)7E<E-)O^N0NX
MVGS:3*2R<=4?D8]6O@3=<%!(=-LA+'JXQ%\VVXG(,/8+M6HX C'^-&P3+/CE
M*K^\.NQS/@FWC/=L/L0(NPG )U\3_$H;\C)H0V2E#7DDVI 7:/)D.QNF/\/4
M?]O!%';V7LO;5O+7JOV]<'7__4KAMZ(S??RC.8^@-HU78']-K8?]Y[^FH(#E
M<NUK49<_E]N6ZO:*OG12:#HN<@#(<-)'ML-&W]<[79S#PK3,=KU\%RC=XT((
M?](7><\19C-*CD];;9K=OIS5TV:S8VM?GURIOZ\482V-ZL\N9GZ+]OP\AK9G
MM;L8MZ/Q_,%]MY<GI%DYS2];,'N57EQG,ZPQW9_%0;CI1<="_?6"ULB;I?$[
M6K&.>W6'G&R+USQJH%L5\2S>*U$$O5(J\+>K%/79<+B8575?2M0&"\Y*".AA
M^"*L8UQQ(Y"A0N0C=8^<# 2E@*4(3CC)M@)3-)8I&N:14+D2L(@.&4$U2BD0
MDCSG3/&UPY(^U/>?V<<W.S+Y)<%G65>"!?Y+^D><S.O;_W,T'82_Q%FN8C%S
M83"OY);(BNFCR,@*1=JQ,$H4GHMY7/"\.%)L<L'D&:OR"GRMA<^#+&?VCF4E
MHWPB;)O)V Z[WL]\TK2I*< .F#X=3&9U&!;A-"?%_BU!_>6NU--U]74J%R4_
M+TNT<6_HSPR88A:-/%A$W>$%'6-C R8$82HR]Q&C2#/B\JD@<U)9(OU68,$N
M@EY"^3(Q^2_CC[-1^27U:LK'T6QY?[#C\,L8?IY_7 S3V[P /L+V!S,U6RS]
M*O@\7F#.D2V'X^-.NMMR*#5A>Y(X M9^N1=$?LG"WWLENK,(D-T[NN"+%8EM
MAVTA3R=X]<7?OUYZ(8_M8$QSJBF+ 8G$<XQKS%5#4B:#U8'X&+RWV[2Q]U@-
MJQ!?6/K7CL,NIN.X. ]#=/5 C-Y4T.B(3L/*MGYU=5O8SM^#1IA3J\8E:\"F
MU [:XB]>$: Y"N>#K]'XHN0CS;[:A-&O9"T,1ZNP79@/EZTJU>+*0T=7/K<<
MVQ<P!DU[S8.SM:IGQOV:.V=G?&:,1B,9090RD2F:!4BD$\AQPZ4R.CJR+9':
M8RN81$0+G:N9)N1L)+DPFY8:A-CQK0/Z'VT[+C;C#VV7\2 ':GZ$1_YE %KY
M-TT$:;S(FNYX&K]9<TNL^:8VC>PK_5#=!+:YUT6C12!YY]VK#"F#=ABW=-^E
M:&6U6GW[R);X5G/FG6^'N?FHC,%7^OS-G^5"A%:&L'\DP7CS@8_6O0T'&LA&
M[U!8R'_O=RD_]RKN#EOB=5 H@O:!N+$269HBBD8)#V(= ]\JT;.3N/=U)'Z.
M-DM\^&7X:YP%+_\E^[FO7P$/8?OEJX_%^KLV;&'STUGPXZ+&99.R]'PN[JBS
M-HYS=@?HN'T\Q,P=TEWI%UCFQ\WJH9S/9BGG!Z\\==0SH,Z#SOL#BN^*ZC*:
M=M#&[OM7*\#]OV;I^J4)\W&<#7P>XE=V.AF]GGE0\UAFARJ8X?ER!&MS-(4U
MW?X1P^O%NCV%E3N[H63.7G3Q51=!FX<-;3ZGQ7/3/_N;>1N@$0LO\.>V:QWL
M@9/+5_-GK%P(5X9UN&#TE.IOLY/X^FOH*;GI$G+3]_B4[?H,NFL;Z*G:]1GT
M5.S:"GG*'[\1Y!1SO/+?C3>L??^??YJ,KQ*^V2E"WK*=];]_&H^FPX!FX)+*
M?U>#2R:R[,\N7O4G&/F#:^1V@S&Z![FK .X*%[[>TW'%U>=0=[(<KCB%F(0[
M=/BP';SU><P.W0.YR-\6:^2K75T<0\U/*B\F.1"C#<U\QSJ&V;^/5G7M&?]H
M8@?WEXVO#%B_"C$[BB&K"Z8NF/TLF/\['97(3# !^EBA-SV1]<\E_JQ/>GV7
ME>L2C-5KZ\UWI5)A0[ZO*VVO*^TY=KBNO>LCI%>"G@HO8/.+Z^*XQ*HW[X87
MT^52HW6I[7>I/0UI.^+%^/!:P:&6WF_#T77+CAUXV3UIU>I>QJR'?B=_*&/V
M:0OE-6Z^JKG? K!NA]9["[L\@AWLY?6XBO.35CYJAY][AZMXUPX_XP[?6KR?
M_D;U?+MW@]52]*6'/H-[A!RA^X>RW"81YL-9YE&<]*%CGV-7*'"[5R]4Y*HE
M4WM\;8^7K3EDGTOTRS&*^#/J?NWR2^AR%?+:Y6??Y1TMG8?/;G]84^>I].]^
MML[\B.8.9LV5;3Z:$=TA3>FWTP^GS<=Q"7S.U"9NTG0YTKF0$-U&K'8>F:=D
MXUSQV.'HF&7ANK[^[SU/[7'L$GM/U_,I.*EY1)I0CKC4F14["&0-T2E089+9
MRA;AAJ?(*<Z5L1GB.!%DL9*94UMC1^!Q(6YFB[Q;^A"NR).ZELJ2K5%9LAM2
M]R@[T?QZ1O2G*O#[7<Y/0LXKK%58VP76&";,QEP514B *)X<,DD8Q(V+D7%F
MM"*;L&:X\))[CP#X<HD>@Y$60J!H@_3*DR3Y%MG_@\ :P2>&7%\%X*D*?(6U
M"FL5UNX$:R1(8DW(I2) 4>,D@7DGHD=1&\NQ,P%;OPEKQ&1Z$AJ0"?"#:R:1
ME@1^F.#A:<E'1AX'UNB)8176GH&<5UBKL+8+K+DDL9:19'(.#0:E &W-RPCF
M*+>:6XR%WZJ^19EA@@$ RJ1!K_-.(D>H0#+DZCH)QQ"WJF\= M9*'COZ=QR/
MLFAK2NCK"FD[N"[G81K5=9G)2,_/X[CP-[RW%W%<O94O9>W4_6&MQ)+6CH1
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M1')90;2": 71"J(/!Z(J@B)*.4'>N(1XE!HYY@.*F++(I2&%F&4=1'WP+&$
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MIYLK:\]RR12>Y/69.G&P8';5V1X\\KXU<_)5U<D<V?MSOL>$=HZA4KDTPX(
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MER .U<Z\M+.)+\VT.[F"!V1./==;64>6.1*6.6%@C,Z173I'BL(XC"6B/ 7
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MRWS?WJ:U;VACD3A8+KOJ.$F SD/A\^2KJI-UL>[WF,SN@20OB+!,(YU3#*#
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MN9(""6D8+DB6XOSP=.Z.@?\QY]]="AR"\>#Y52&,>G<$P@B$FX$09ZEDSB?
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MS+"L0%)2V4:FL-PBFDN>8H<U:/^/HM_WTOUWZ$J/=;8C;L4M/07<4BIE1*<
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M<?0";[V $H7%669S1)D!%3_W'K%"Y2AC1&*7IQQG*\%GK,@=9Q3N21G<([A
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M34KIS[/Q?FB#ID6[*WYW6TW7=C8X0*MI>=X&^V],T&E:;;>\!B#&J*.H #"
M8=8!%:A !2I0$6-$C''752TL/*2C5WCQ\8=TO-T^I',K6HC'<VJQ?B"$J $J
M0H@8YB<- ;R4N?JH>#P'C^=4>&+<-.,U8?.@%5@-<81JNI(#%:A !2I0S46M
MB>T,@7V=AW@H5':M5/9''^)Q+MQN!1[BD=X\H>VG'^$YESTR)O]F__>GV"-?
M\8H)XY88:/!:H$*#QS _J<$_5YVM##9&&(_Q0(-'^CK Z@Y6HUD'5* "%:A
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MN8&+"+4:GW7%Q@BO RYW:'B6YR(%N?JHFV69TTZ3ZDJ.05YSM?[*XH9MPUN
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M"WG2^'X=\.E<([<MRX8N7L'U JA !2I0@6HN:DUL>R/M>6C%8*V\VX*5&ZA
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M0^^NB2KO^'U3Y?J_WR,?SXY/,7T IB]8)>8GW%6XJ^ "E^DS#N[J5I^T%4%
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M"8H-1H=6C_;&V([Y5.(97&)V)O7;NN4/I>)"<2RU.U2T'$!,_M5\3M'T1/.
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MK<7ES+)_2,RY(-R!Q]X%*L4A4*+Q:_UL% T4-W" "';(,_+SP^M:E0I0I$&
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M;@++&.:]N8,:,<FSV'0[^"*@R(LN)+((_*+U<I*L%@Z&NI4<62Y=K4<.!WZ
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MR,5[ZG*J]U =Y!?7&PZ,S"+,^1E\#.10,_*&2J"?;P2..P=F2E2?CG$Y#,^
M6-02R [UE>A)0E+E?9TTX^4)\OKBVG>N'^3O8#9(!9>#A7=9]OY1!=]*JK<J
M9T^^LUG*8I_E<OJ:GRXNHI'P3ZB1,"^'0*&X=9#)T-NF*@",VI@Y1S"ENZ!F
M&(DPZS(;99AMC.@I,10V\'(23.PJ6B$"S"G\HQ$F<=GGI";9U$9JZ0FQLPM:
MI?,T*Z3+OL%<$?([1P4]&9[PJCN^A$BT5.1<^3A*4KC-)&VS!.VUQ01M\\,7
M2U&>=N\NS=XH3SMJ#/*62=XBR1LNDW7SH*A:<>\EV58SB*7G6_V7\=?@V*-.
MD"&,#MR?,"AXBX">@X*<ME@KJB(:?[8-U!=>NIPDV)6H:O[1"R*4M"9S$ 47
MH )%%/^X][8PT/ ^@4.7,7T;>P<;.4NLV*R0.LAX:Q@!B>07"P]K&N#-',]1
M!)3CP#_7?"1H(15#@986]W4O,Y5[, CVBSY"[%F5GL>^.3;N9$ZT[O%/,0"2
MCX#@$+ZI^='?%S87O)YTPSZ!CXO$6[']\FU,1VG"Z+ FQ'(>AH9GSZW#PXDG
M+L^-*10/X$/^K4Y]N6D?#0%)P"9M$P4@^^\6U?RM3E>Q/-\>/D1='5);4Y8F
MV5\?<%HZ2>*H#05I%LR\4.:&<-WH,L:*@];DNHZCWZTW4\*"[:UZ1S.\:.#V
M> Y\ZI]O/Z=HV5,!A&.$]^E20!Q-)$P"D5W@&?@&>R%!]+T6J9CW=+H\ZQ8[
M9)R)6AO.*[QEDE7/.JN\J*@7TO13 /_)8KC#V6DSB<:S94"?V>::S*<!S<M!
MW2*L;]>(_E_B)/1?8%Y9S$%*5JI_ 6^$#H%\"'C\9&P0L@86"=DP+!<L=C(U
M\G1B$Y'W)ISI$Q -M(D P9MW*2MJ$=[I-S /A9Q40_O#KOC-KL;)_-+;ILR]
MP7R$:YB-NQB.:(85N[WV@A A_9B_KZLFJ^YB'[H43HR$=\KB^%FW>(K,H5<6
M;PC2N/ U6M9<K<^%O"GX',![@%V)Y _1&4LCX7,PQ3S?+1$]6@:(<S0#A?2Z
MF@TPD@L_%]Q[]KD_6ICE"=$W$0CC;*NG#.5JNO0B(>:"&CNG 0B9DR2O':L2
M/#N^43QLJ:06L5=4QU*MG0S&]3B*/<>S"G(&2,PPR#)@0<G,<\D$&J&2G U\
M5WFRF>6;[$261]>2.T6="9@Q;>"$0\/AT*4*3:[U9=&&#\^)/+/756FC0/."
M+TR-'N63^E;K^K<]CPV :X.82:QI<"E.1\[>5>1?'E]%5-*2"9M76/4:R U^
M_(5KUC$3RE30P7%5:>:PZKSJ-/(!F#A: 7,?G7E9M*D-)^G4+M=A>8!%-1ZY
MP\Q2NYQ7Q)>,=GC'V2CX8?5$$\LU&])T@Z%ODSDOVL823F F9- UJX$B&[%R
MICP6_MB %$$)5311)8ZC66-E A7HC=8P:* :\S*JCU;349S.QF[U"LDHO/LS
MO78>;@P)5,K2\Z%!(!O/V*SP)!V[:H.K:2D $57,R:AT'L@;T*#X5%@/T=H-
M#+P$[3H[(M.D(6!3D.TI9/-(IL)&?DZ$D:; 3=\--WLE_')@"!A0H8R?N3*&
M!4@(Y+O0SPFSO+NHN9.%+>_L6V&S$!A_X/(Z.F\^(_*>J)8.0SNG$9T'1T,(
MZ=08IY+>B;"A;\Q3YX7;,4%]2[(FCD;P:1%$$8=?#&T6S[;"Y%7D-[-XQ9/9
M'/''BL5A*6JM5%S'(')>?VZZ6W_.'7"J0F_4[ "I^O(O 1QFR6RYY>$;G7%$
MB2+(,4+'7ZQ'AG#\DR1X!@UP I]I$GFAD<AL090HJI:!<XSP()9D;^QN N7-
M\%" C=EEQ.KXF>TZ3U-%Y4P4G;F)9N$&#R.&K]-Q9W$W2IZ[R?5340X-B[?R
MKC@<CMU=9XMCL0\YIQI]5I15%1(:$=4+1V,Z25X+(<X,4PH/OWAGD7LYZ15F
M<Z?31 >*SE&@;9\H-AG3ETR[OO0><DZ''L6JA:L^Q&%XS;61 417:P,CO^+0
MB!B;@UK#.QJBYA" U]Z(5IB!J.H)K1#.[Q-CJ<Z$<6>/&^YL%A6:)W.!)9G>
M)Q1+YHPCG[N/.V%T[@:H:/6@/=$?6?,.\Y/:<O"(78[ENZMQ*OLA][N<.L0@
M=<%[5>EOG6\G9?\^/TX3=G]L<S"%3M?NYT<B*6KX#,[N77/\%$PT/SS^D+/E
M%R'N'62(8\_TDO)_;R)Y_NE773?,?G&>NBPN:X<MZ784Q,D;2?Y[#+E3C%XX
M9/0ZB(*,WB+<SPV<[Q%#IN>WUB?O;W%R$<*%?.>M:#=[!NOEC'5#\G[4]<BZ
M(JPO@IU9MW$X8K\@%!\X!TX* '$0LP+H.W-;LA^%U*D*(0Y _I5CT2HDG_X\
MZ;M$+PK*O>Y:M"Y/RG'H7+;(>T/TH:K[3%V5X41<TS@,?+8W&0S[MGN,D49R
MQ+'=M^17\:_3N")SO.W8$J-9L YYH%BA%^N5"7)=#:1>XW7:]))=+)=95(AV
MYF:PQ5^Q<F21R;+J;0Z*1D_F\V!&']?>[,ADU%UC,*-'4B1HV=;;=>32J,M'
MS BY\2MT'GFA!KPV?)N1U*Q:S7;L^] FO8_3S O_;["^B/UCP\$Y02(HX@F-
M- D0)4CU-'@IB ]],\30#%F2,+WT,D]X [HMCT83X]P]Z>LX%6Y*%L@U2]5Z
MK;(@>=L. +H5*FUN,N/43XZ]':A88>D\568TFWO+!7,5[VFNM*Y+$:VN.-;G
MR ]2-IG4O_HZ@Z8'YM>6*DC8)0E6ZTVF81:?-I^'EP'3NR2\3\NYU)W]BHTY
M?1\Y,KV!#-5NEI;*%-5,2U$=\= "ET:8@4[\84FHK"^[R9)<OOB%AN%_1O%+
M] @O3QQ1G]EPCM5.A,R"1,_^CE2)),N+(%CS QEGJ$02<\]52Z1RXU#WG[SD
M[Y07G,_]0V3& <8QY+QW1'OWZ/4#1:DW,A&[4<'=9L1UZ+"[&=*#P[O.D?,(
M<B>'R,&E#7HN8= H+:0-\5_*S23E@E\H%DND_O@9Q-(%E;_?PRU_K,K<1EA+
M._C%1D0.FHA1JU:$C?NWO0H%8"\Y49Z8*.ET(NN$01=9=T+I)J=9G*QC7EZ/
M0>5?H&:3;+N;.0ND1QR''S%F1 ?.+(0&&2PUK?7'I?*W>>D2$_CA'U1 GN%4
M1+.-&:<B^H 98@%^T,CWZF"TP7 !KZ"*:S=5N"+_$J'[XC6>45QE-%9L#9CR
M<^(\1<%R"KU)OL2V5/P@=H)&5)@*3H:=O=2#E&.J<3SA1/0$C>RF_<!]@WME
M02?S.\JJ3W?=<#E)!LI',XYB:;UV>6<^Q ;3QH^(BI37&1_^,NR4["Y; _MA
M/*+B#K>&H3@61RP7\WA )V$HS&DYJD-BE)>"^+#+D'W_CDI?1:T*,=/9$#1U
MKFN])=7!B##%38MDT<.?W91A8J&-D[F :=F1Y1\HQE>"XHQ81#B6C1=BDF_'
M0X^'4\*[)G!KR(OH]DR*^HGLF)78$CT3V!@KNR>CD]F0(B.;!3@U16_[FJ'J
MD&@]$NSR]">A"',F.SG[+;!>IN3VR#@J@;?QS OOEW#$=BI9PL@01L=R(1$3
M@RYN07=C5Y?FYBD-_,!+MBC"3.8<,JL#FJ/',X(X6IJCB]\4#X7T)IT1ZQRH
MM*W\9N8U$1_H.D[P]6=>[/1\>P%"SB).MM-.,3FR$R(J+_(T->LK59T\(Z#X
M+>7-".HGQUYIMA,S \C" ;W&^3\H;S9_Y5 ;9AA[ @EX<PRVGN92X(<([YWP
M[I4)FX\ <^251UT@-'(#^!U'W]-&XLK%X'K&0AN3]<W-4AO,1K(!!8]5AL+)
MJPS78'DVCW;S;)@D*$1 E4+#W!D2,+"3Q">D?469^WUR&,3\E]-A<+=FC^!1
M>6BXRR8'1[2KQ1EE+6RY;,Y,+),Y6MNOP_BE,VJ7JOF,>4)HPF=4'09K<A$(
MH1XVV3).@JP;0I>0J!C&@R3H+&O5%"^%T[*$(;L*<!S"G\Q/]TPUK_!]G,%_
M R]\H(M-Z&4@!:LJ3\))W-447NA:KZHR(FO9.]P*LON\T),LLV+9:NYR:J2)
MJ# E>KRHZI3DO>85P61$@ET[O,L)*=CKV^T&V^_[)%EX4?!/MGL+29;C"&X<
MFLJ=#:)3$('( P-6!V[7DUOO>U1,\63F9+U_)EW*$9!\" Z/^?$,WO0- Z]G
MD;YHSD_HDD8I[!Q^QF$@$I,SX:SKHK=H78D8Z4)G4NE^@_U]KZ1OZ-21BF)Y
M*L*.LW#B[.]D!JDYX(! L\(<!*PW%S5FQE&TP=,0S4E=2^1P6H03&_K@2^OC
M..% [K?[))Y1ZJ?72;S*[ZLXZ78!":)D#E1A5VED3X:?L(R5"Q>LZ"I:RLT0
M#I5KWN&I\%94/E-I8G*D>IKFIMQ*D+(R'?LV A=E?42=DGLOF21,,O(90&;'
MY=*KUHRP6@]&.G+R H#3F=7  I.[!8ORJBMKX/092=M5._BM#E?XQ1)5CIMH
M\A+!F);!.H_DZ:J+JC[(C'7"ZFW+;G"/BGXLJYPV6)6;-&>1$\=*EHH\R>F?
M'H>%';J[DFG54EKE<YQ-EY3G>O%0G\E\3IGM/8D7B;<R K$RSLY SCU;L6YD
MN=E8= 3'*^N)K%A7=C>N'7:E<I.= ?4S3EY&3LD.B.C!#6"+'3X+6LSTDV3)
M@6P);T.VO0<",O!MS=-XI_!\A\B$VSA:"(R]:0%ASU&4@@7."HA-5>PY2>9Y
M:D[ ?JK(Y?E"4XQO@ GYNJ;H:IO&^)6&9]TR!.K] % (.3,\FE*P@\'A^'4!
MHKLD!<M]T-7IKV!I%%MS_*9:,.;K%>M%M?5Z=H"=<31P 0\,F\RY!UJX9/[9
M)PAGCF_ QT3R07WSLUB(&>/<[T85H!T\P8,9<UYE.4AW(67'9UMVB3'3X<&[
M)[2Z"E#K;=9*D=4G8NI(T]2=;PL->YFZ*D^<R<+,59[(WHHR6V.Y",8)VB$B
M'6G]H<N-)Z&QJ"Z>8/>X>6(9:62\2"B?&988^>4A_\::214KJG_RO@:K33?-
M2M"PKCMU'F\10841LJKGW<%_O73)4*]0TH(MT5%7%Q1)R&)G*:=I5RDWP(38
M)W+PO B]H#7TL1=0H<IFWUF T-57;Q5$'/:91EXHX(1O!')<M[710H:T?D9$
M]<3.)=F7[<5SQ'LQ9DJPAGRN91^GSF 1)?*(%78%&KE:A_&6TD<0NQ'+N%R4
M6\"5B B*^6W=O0)IB?BJQY"-?3_ OD$/U446]Q5*;Z(U:.>WF!+_H[%R=9SH
MB#"RY$?W1>NZ<U40PX-%%,R#&?IR/T?Q$RIQ#".-=T/>"#ZMUUH8^W_;B&S=
M:9QOH7LO@#?ZPEL'\$J5VW >T/Z>!IE\$WB0_0,O 8P-V+0=:P*_O[D8E:ML
M^IY7N3D,\2F&PT#K_[<V=87]A<:!,]:QTPI&@YL3/7+.P)YR=,FH4X>7Z8'K
M52N:((I;^I-(5;:$!B#Q)?)/X"Y(NQA8R@N%LE+06C?.M'^09'<P?O(L'H$!
M5/Q"1P-B^V@_>TX4BKWZRKVF#W!97\WG].C[&;L=E: C:6E1O G.XLZ7.WA*
M;,2D).]0+[,K!TYPY(0/_;>]$/J[C@&?ON@"_>$S">3$/E#70$[20#)]B:?+
M>)/"2*8O\/?V.G@V4 DC1T%2MID/[S[\=+*\A95L02=$]D)X-P3[<>,-M\ES
M)5"7XCT#WC/)>\9YGT-_UHPJRKO,4?GQ&AK/9LG&"[LJ,Y(B>R4E35>(,$J3
MI<?=D3LK);35#.G9M6]U'?B> 051>.Q>X4;&79XP9G_P<O]_I!%-O!"WO[\*
MH@ W*5KEA>&ATQDG:/,7H4!=VC6<J;I6V"P VVF\>H4NK&X_[9"^#N89I1&&
MR1@YI:?ZD3SGQ,D:J-L]"$QR)/9AX6(51 E2=7.SFN1(WW(?WKW_B2W(8&,%
M1+2(AC[0?SD.%7*DC>H$JFX8F,JV]4%G&&81AG:AF65&T740/6:K["I)XN0B
M3D#_QE%<A]["2+Y22>XD87V1O#/R*W9G[0RPPVTX/$;98==U@S?'Q+'?6(80
M"D@F <QW+D >&;)O9]33V_&P2;5V(G^9 ]RJ0L,UT7(DSCD3#11O"EJQ D7=
M[D5\RBNI7Q<-04#U,4 RWE'$IX[U^-0ICT_5PU-%@WP%>RH8</(+>% M@<+K
MI89C+?XE6R=_O1@?:TH=W]Y<3Q[N;L8#&U\1PR\BEP%=Q&CT#8-YG$2!YRZ$
M<!QE@1^$&]2><E#=JZ]H3:4^SY[%@GT"H>'*2S!:.94Y<5W#Y?0(3'TH.L"O
M'(Q,O57#P8?D@+3,5:[-NZP?T/]TEH9FPO0H")!P"[NL<6Z]<,:2P/C<L@?@
M-S2"(]@ 2SGE<_Q+O E]<D[9HIU)CFV*=1=88C.A7H="(A>LN##0L%XKI,M@
M"TEY3D8LMS&L,_I:[I/X.8 ]<;[]#)?53:2*68ZQXJ\):&_<4,Q?);M"T>X-
M]@;:X?=:]<R\1X<!*/:G8:\TR)S!B;%W,%;,>ZH?AUCN" ?*T-SS>GM[N.Z1
M?T&3S NB:>(QT80YEPT'%#\NXR0[PTP8H@WOMS(3RL2NAL.Q8@4*OE8,<1\0
M_PV+I^;C(F)@/,TN_=YU%#JWVXMTDLE<R[*'N9.X!@S$1C;"2(ECTR<59N9D
M3G1L :8J*!0%/'V@@6K,>CSQ"=CU)56!A^+6>)$3$7$T(YGM RU3V]AP]F>B
M#8;JJ)1U_.*___A[:^[N,FB:?#XP-Q;S"_$=-X)1HS//$F^1.CM"3H_!:E"A
MM;>%%B$F[6?"\A;&]LWT%EC4HD[:+J2C*+(&AYXUC^6)\=6OB](24\7:#_<>
MJI/\HB!>2A:5;+K*%3&]AMI;V+Q!';U_.\:^8E:P9B+$<,U9%X[W+*A[2=,%
M> #6W[<P!^'Q[)\TW[70!*E(%-=9?G+!\DX]"LV(CA@DG7"O=XMM.,.\KK I
M"$^B.].*ZG!0IA6#TU!G6IDKYMV95AY*BWN*^X-7F.T:U>KME"Q5EU-_!74M
M<%T:IUS!>C$>M&\\ACR2G6F[G[$\!_/]B=W.RR1U]J0TY:-HN0+<*((#&<ES
M8-NKVZ27B2M8&S>KE9<@"%SY/*EI<A/@BIE"<%*%@4B/358>%O6\R>BJLVE(
MA1F3I- +>G=X-R3 ?AS%()MD55E-5=YOD3I1Y FC?WH<[I3CU=?+65V53H@[
M*F#*%5A.IU$74R%=#[WA>&2GDX@?<7N5\$X'?7>8GYR*ZX+?$;PGZ[?$/O</
ME 'WWWL)\ =+E'K,")J>;PN_& +)$C0)(TKT_D:H9Q1_[O$UT2.L])V J:@\
M,BM--RO^G9E7I@));"<@6M\LB,0HAT.T\0SD97(WA56Q*_J<, 4VBT'81X]P
M$%&2IQ:["29.L88N"P*_AN^.%4VT&.*4E='E.;J,Y$GP41'Y[8P9N65O:9I2
MJF(R&-Z1S&W?RN))E]T2_9EA4T ?N2J69(TO;=V^);[$>\7)C[30(=;#B*@^
M1GA\/&'%K\!ZYDD>ML%M'>;"0/HTZACCJO\PG[:[\;^HETQ?XFZ98_82Z!VQ
M<]0[-B+8&R;:.RB5E;"**_$<1LAP8JXI32\V20)\'U\8+.$59'*J!,F.B"!\
M6FP5L#KI IB9TYZMWSSVF%G]_[$)$G0$L,"'-,7 'TM6<?)&=4MDORPED??,
M@L&L@V4YG)9*L[F?=^S,!G,+@GL7PYYF@D%2W(CGSH1T]/ KS$@.>!!P(]X"
M;P!#@"*<F%WS<+<AJ[. $W$%ZM)ER,7WE \;=.!L2='_\ R_\AHU#I.$.N:R
MC%?QYOCKUTPNT(CP47R34U5:ZC?<$C5OJ1J)Y?+&*I)7AO$^B&H"UW%RO<$,
M>AG#V+GTM1;+K.*8$[UVP9SUIR)[;9>ZML>Z>!,*<>PJAEWV@L@*A/>CXD1/
MEN.J@GEJI1W#)98 )#)$1!UHE>&L%CU\YUOV^$7HI6FG:"5>^8G1L1ZH)*ZP
MZ%C<Y3TI 00<)V#M'<:LQ(3(.KQWUZ$6Q8-\;MUY!F3HW-3[6@8F:MR+HD+U
MT(W/>V1ZB]9GKYX2J_-1Y6O4T)Y1H(@C*2=BV%_)C-DM->!Q4-Z;*,V";)/!
MI/R%>F&V9#4_F./(@# \!0E8]D145\@S[XR\^1__\H</'][]Z>[F+^S3^S]]
MSZN.<*?;J<Z!>"5*6)\HUG4VW2@Y]OC=142#98\D[X&^[,OBLD?!\KOOR8+-
M!$."L:>9EM0*[K2V!='.%3I?Y\&72&F,FD-(<%&5A)E.IK&4OB@<@CSH"L$*
MIK&;7'9M6",BRZ6PD3%KN!H<.Z)%9-H;'.#W^/-PL^"'-MV%6J_YV' 2$S7'
MF-89(E(%?(N?V6)L^(R69M;_T>II^3'F]2-G-(DZ^LQVCD=&F0C2+IV!IOD2
M;]$WPT\A"5!GRBH#S-*4!L]4E&%3P-)&[F)%G82<? XF;5>W,\R6V&LY.X*L
MA@ON1(@RS):^Y6IX<P'JCX 81;3^<7;A)<D67H0N95PN).S^?I4##_.=> ]V
MP\&L\KF7MN2RQH!=SK2 JD.6T5%>::[0MRO(%<*E(*SXHIS+/ZG/ ]\87(7U
MV&MA0/+%/+)*.#@&Z>KHU2C2\QQ6F4VJD(P=X0QTK5VNX3[>1%D"VG P8^_(
M$*K):X/#LC)B>&Z.XN%,[%Z%;5$SJWEVGP8[NQB 1-F$KN(D"_XI7EE$D,*#
M!@V>]PE=!9M5JH7N=8/(5GWB>^O+G@AZ@O) P<!=H*#E.=B/.>/,O]&[^YYC
M,<JYP'-?]CER&30)G:Z]P!>'9K?P.D$KSU5V%%1GA(<B5 ]G!%<ESI8TD9X9
MDMD47S"F_RK*@FRKV?/V0"&.59 8X0*"VJ@$ >.T>"MH2?TRN.=NGLP5I#P:
MUA.F?*>=T 'R]!@\/7+$>HU^G['D5EC7EUCC7[CQW=P7I8% =]ZJ&VY)13C4
MB"!E9R FIIDKF'3K.+0<T1*A41AV!]LN#PB#DYHUH.5=B"W).\EM,[:CE,QS
MJ%Q8#9RYL:C9X+!@DOGR8-^0QH"CXV>:&,&^04*#'6FH#=*!3VL_ Q)S4TSF
M<;)<%\=9G$?S4)?#:9\1%488<+4%+8[R]9T%9FHI:N2Y)57OP'Y(J$G.U*N2
M<X1HQ@7"3JHOFF9L-XZ@-^Z4-<EC&?"H#:#0,9EK^ :=I#<DG$-%N)+6S+-3
M+%NB\=1/)3=N)(/M<A/-,/C]F6*MOVYJ4X/YO0]5R0'SQ?PD8*K$-FR;S1Q7
M(@SC%PP?O^V8+::A:TB23G*N\*86&LQ65B/'-_#8+2E(Y97:;:I$I@9?V%).
M.>CL'+CZN@X2B=75:_W,?"0N2V;V,6?Z=I%UX&C./9K]K</.QBN:9L'L LWL
MR;:36BQI\5#L3;:,V?YW%>-IA)6"-8WZ"(5M'Q[V93QC;@X0_NZ3.(*/,ZI9
M!,T$FT$W).^'%#OJTRIJF_]B%@G*#>&V>B8<^&)XPH)FX,?4,7KLB:L([ICT
M.='38:=8[4+R)"J7"%CNH#>>Q''V3^/+E!,^+;;:+)?GC#=F^YS,/Z<\B7'R
MA&6@,!9;"E_7<5*!%'-L_ASV>!;/SSYCN"'+692]8MBU$OHP.W<'.R:'COF&
MIJ5PRLJYV6#4+,]BB[7)H?KDY 'J')LKS-/)[%IVO'09TE2&P]#)7*;V=C7#
M"<)Y%=EXKI)Y+9OAC/$D#7"2%U55>#)7^=@GPLINE&GEVO1CT]#TC+2A7C*\
MK7,:8+)Y>B-4#ELUK1M4N+1MH)PV9 8XQ 8]ZJMJ]:FLQ$'%J6=HXPE#^Y?L
MT&>M6+6I<=[$:*C_ECS0-?"]Q&&[JO.B3Z&Z=$5HUCCR,?NL.^:92HZ>.;1I
M6N<PW&&N<$AIL'RB+^8+RWL[>?;U0+PCY\!1FD%)D-/X:W"L+%(6SD5^18(.
MP-! K>%J[>4&$5'XX<7"+G28:'E\'6T]9;XRWA'A/:DK4^2'%,"TU;5I_^RW
M/0/%?*Y<..-8.+'@%Q4&3!"R'X5YM:+) OC\F,0OV1)?+R\Z5E<4D9>2).$T
MB2!Z(KR4A)+VP- 8WGJ?18.$WK&1OHH&02*#'6TA4-#)D/=3FP0<JTW(&XDY
M.Q2(&],L5Z1GE;!M59^>OL339;Q)01"X"R*:48I^=.W;ZV".7Z)#W0R6R4M,
M,D&;1*)+)H=D^B]SWBU90[]VC2/V9T#L;N1<TB2R*Q;A4_A%=$>P/S<!H_9G
MH(@!_OYGMM[PX2>VOE:9R^V8<9JRK%H0%A@T#LB]S%-+[S&]*#XX FAG8^?6
M7 :Z,=.[(E$<<1<NJ)F\-[N;VA[78C-KMFODMM %:A3<74^)Z.5$F2UZX@]:
M7_L%"$HKJL$7%Z#X!1R)$@&NCQ5.YW,L(?],B5Y!SLOH3AFY$?N!]\GJ*K).
M76'-FI^%TDS,*K!P,F.]%#>#U;U^2=-9$JQYYN7Y)H7S.DT9$.=D?H_8K^(\
M@@-<2!63N8:4IWG4T7L.TL7ML8%E.\>?-C"48Y[$T%B59(;*M]9&Q^8QS:6>
M5,/R\W(7_%J,D808J.:@$.-P9E<9L_)9G<R)'!(KMYWB-_JHF"PA9<E)$2%1
M#VR0L^H,<WTXTUJT@I[XW"H/OBAJ,HU%E83_G[VW;6X<1])%_XIBSHE[9R.J
M9[IJ=G9V[CG[0;;+U=YU63ZVW!US]D,'+4(2IRE20U*NTOSZB\0+"9( "(HO
M@$1';.QT60"(3 ")1+X\.7_S@A!>)[=Q K')10K9#7H].4N9?07@Q-AW9C!<
M*4$M__(/6!K^ -\^5^*E]\ C<P<0@>:5:$TA!GQXD'%.]DN$GX<A(JD'D"Z4
M0@A3\-8AJ8*/.,N'G!5CGA$YXA'/::*0F,G@]!3&M5L !3QT0>:BQK1; I=(
M!G)YTA(SX @S+W \0_R7&/3S-R1Z'IE'1?&S6+.SZTU=FD(IK)F47Q?^O2#(
M"-D6/^_+G<:\,VQRK)SLI& ;S7VJ3J7$2'$R8Q:0J15BIU"_+P1]!/EXW@)N
M0M]5'XK/,Q_( 2JR4[!?_-]T"A2!HYC$^,4@QN92F#_49/7J*7?XI\G.$CX^
M>MV(L9E3J7O5?O\,+8V(2 0W48*V* +(1OJP?XD21!'=?HI#F,@7+XC RK.(
M"K5NG@18<]^(_L<'E"W62^][-]V!?WNVP5^=_3XD.,7P>+6I^+G"*FX'O+[[
M8/(,^# 3^,EF./M"^$KPGS_,7A%NBP5\#F?\8>:M\8* ?6G0TUCX>%@H83\E
MTBMR6_1ML<A"#KU\G&7$KY6!7^L5OC6L;!Z(X*H3KP@)S4O!SZ@#[[_'PC(>
MB%*9[TY&+<G>)B'-Z>PN*@H6C0BK5,$O[89O4@$J'0^FOP\B:JBRGX<'DR6;
ML!++R)^X!R]<HF37 <6K(F%JD8VKXDLD:7",&WU8BME&K(4)"U^8P2?&.&'#
M4JH-]=4M[(<9HDKMJQ<.J<CF<8U!NL*:$=9.%VLQVO )A6 X(QBVM339KG4F
M&I$)!D?1X4A+D#=(\W*?@O0WZG2"_^JWPD'I0S.LQ/W&/4_DOXF?Y#@X;M9
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MF\4'>$CVQZ$/HEC/I1=7=[F(BPT_=T("$!#]W[NH-ZQG/O3L]WSP?P%WK 4
MYR&(E($SAV=.DF B,%^\@?%7:28Q_>PU_B%8>>$R";RP<VXX(V7%!IUE9-2!
M,\#[("0L[SH^V(R.YO[\2^;O,O<'G?QC$J\0\E.HPD9"@A<<-9M&./A8GV9
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M_(OU(^1@LDNFZV[D'YH)7R*&=5H? ;]!Q*^-LC''XT&YZG1!/Z::?_R#@A'
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M4EY%Y/3ZKG$+/GF7I@?DW^"W<;2AQ-&TEP?TC?QT,@X?H8>./J/#Y\5=Z1?
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M#I0F:(N)S8OE8JFQ6&,9HK*;*YK;ES1/B-1]H$H/6Q.E*JAJ:I^,QDARO+_
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M,*\')'DF-C2U[HQ_1ILJ.+L\<%?9T(F54*-O.X2F7?;0:>YQHPZ.O"F>T"8
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M_ZG!09,L(_QNG\LFD8NL#!U[#"_C%Z9&$C54>E?V/+03ZYJ#"5SA%YH'^7-
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M=<LA8FUT^U9#V5^O!X]&$P*R5Y =,DS!3\@+,UHCEKQ+5!+=O*L3JRT()'4
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MDX%T7[9I\53N&>D8DS#N],!!I<B[= -/3YRKR+M^[1D7RS69L/O+98(,2:U
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MOV7* *E#K<5E2YV*]@ 6[8"R\9I $6Y0M*(,8S$X4#GSB+D6I1XIBWEFVH5
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MUPLOP>W8R7 "$N5]D6RXQ=^A4KJMI!M.Z4'05*:TC-9-_T, K#AJB;2TC /
MX;PCK#BCI+2&$'A7,&W=>.;2L%^XE2DMTJBQ X. JUP\0J)+^@?X]X<!5SE/
M8X=+-UMKC*,1@%MLY$4_X?_WJS8Y.O=1S=/TL*-,?4F!CY_3+-B)&WZQ%G"2
MJ>9WEGG3!3\6:W'7/:$0K,'7<9JEM2LY;<AW[3CH^04*Y=M"V#A/0?K;;8(
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M-Q;^*Z?V?;.WY"2;.OFJ9'D\ZZ_&EH^MR52>4K0(2<Q2I,.+/,JO/]W@G01
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MG8%&+)I_%@4&X@$O, +(@>2DJEI,?OZ6,-+;./XZ\D!JZ#^O[/':$)NOZCZ
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M99><F63JBV#Z@L1C[5NR(K= S]+77I()0ZYW]-S4\;]XR9ZR">0+>^]M'7X
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MKPI564//( Y]S\72F[0:&*8FL$Q8/8,G-EL]1=X1OK(J.!G?3,49J?V ".V
MK4$3(Z_6./@1&!\(0D')QK/*@_!Y/D:'3->&9KH0#!86,*+F&',Y4<QC$14
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M,<;S%F/?"<BA^O 5,VQBU/6;A*6*B0@^:&UXHM!AV? PB]R#)D>[R,=T]#M
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MG,\*OF0MVN[":$L\M#N6$"E"&^M+II45S4RR=4=9+G+Q8]N'O\A:6LFD^$6
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M&"78T/<ZHKVJMQNL$&268/06\UVL-4^6Q%@3Y>!*@BN[ZS0[9_0)?I+3C!4
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M7]0F@Y^[HW41^RI[*R.CLF@WEL8Z?Z>I%A_19:=[@8'?:*W2:?4LKN;^4$.
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MKW65J%J?;;L!K_GTS,L\O8\7]G.1P"@+E4<72PT/T6V3)74<O2N2$^\U#KW
M_IL96^,O>V-?^&9H*:PTX9<U,):[O39Z_)6J,A!ZK^J5RO/C1*WK7;VUIT].
M7T1O__[KNXO_&[U[__KM^XMW_W@;??CI_/W8.WL N3*\4G<3I*>W+ #_%._\
M*FO@L<GHDEPLLSI:YZJ(TC)I5_!AM%1U-->ZB-IUJAJ=1DT957J1ZZ2)FJ6.
M7I>KM2IN_L>_?X;U_/:LCLI"'\.Q/&ZNX?(;^.V5KFH-,RN33U&]SK,FTHL%
M7 [WFM_X]X!+H_^MBE95-]$W<?3TR=/GD2I2^HE*_]G6#8ZHCN#N]-E*5Y>Z
MBLI%<)/KK%E&?[GXS,<ORN">;:$C'%WW,'I:EEY)5J3P@%<O3UZ^A/WL5OA)
M^*IQ)-GBQJS;*U@,T,"-JIJA4^366NY[BU;YW<)MNTWAAO7TY+D,2N;_Y"S-
MX$6IFU=9D6?X.F&"FV;];]^?VJ7UUI1O?_KDR7]T;OBEVWU$ -S?_O_05NNR
MUF8N#W<DQP;@=BAJ_ &]OW&?_FZ)[VU->=T/*YG&EN&_@!Z-UOPRS/G^@&()
MQ!/('Y5>J2+1]'&&\E/7(!9".> $$DF>)>P9D$,H<72QA*M!?0W_7,TSD%$W
M])P&SF'2Q"#$&@6"!(71JFRR*Q"$$1S+NBSJZ'I91BOU24='()94I2/]><W2
MK>$O9I$U]2.<8I7-P3[ 2^$'ON2"L:VK\BI#U1K5;;)TST"9IO_5XKC*ZP(^
M76;KJ%SC;=LB:S)859&4E8;;S'4#JQ+1FS03#1:J?_=FZ:WUQC4\B5ZK-1VD
MWW"2NEK545O#/V&%[(O"A4CU @X[??X15@2F')V>PMCR\GKO)/'(=C](8?ST
MZQ#&;^'%9'P8'UX@;S^L242SB/ZHJZL,A/ '$EDH6TGXT4O+-<JVN8XNX>B@
M*#R_5E4*8@)6I;)"(@8Q-/\G&9(L"/-L!8O/LC'5=0*2$JY%F985D\1X0(GQ
M[.N0&.<I?)/5L/JD;% COM&YOJ0_AV3(H[^L[43)R-X^?7;R[-FS!]C<YL:[
MDRW/3[[YW9OX2,T>8Q<_[*8]V9WO@<$K-MZNLSQ'Z:UD:"" K:_N#;>L3NB:
MX*.H7BJX>JFN-,:YEV4EQG2JT52$A0>+.0/KLZ\_Z+&53G0&U[+&B/%*4B)&
MA9"96T:U;B)\#IN?^"%,),U8=X 5*[\^RHHD;]&@CB.PNJ.B;%C+D'D>1U=@
M$-.7^C.<_ PL8+P5"(.%SIH6]!D9Y#7>=782O0.9DO)#XOYB^#.GD(4_^P8]
M!/Q:)3Q&\B7,AV9M1/?1.UG!7O5B)&Q5\^156J[!*U$K#7_C9Y5>:Y6S5:^\
M_00CJ=I<PS)>MK#&N.WYR6OT:V#U:[@4'D,^0ND]IXZR1N:3:KU"CRNK%>CU
MH3>^4C<PY*I"38Y^#-C]^$]TAU;S[!*]%E3UZW5^0]^7JZS&)<5?P$4E.&.Y
MIF_@;<'\<<<5R4W@3^#-X ?T6LT7L)D+]')X4? 3$" 8LPK'7L".JFL,*N%-
MUO!&UU6&'AQ<E*BJZJRO?4R-+E,IP:H8U\1NX;N>AK$7'=I#9E[!'3P?K(15
M AF6@#=JU!O>D]YZY\;\6#C"X('!QL"?SD&RXGO&*^$[X_S!=J5/JRC)%9P,
M^#>_"?86NR^!O&!9H$E]W:OZFA^F^EJO2]@L%"L&N?NZ7(%T;;2N=ZK) G&P
MQI/1B"R%\<)T4)1%/ZGKFN7X#R6*%91C*=N++(Y07L!1@6EE31VMRVO44ITS
M"Q*B!)V&8K"LM#]_D@;NS@KLWJQ>THWMKR+%(K.!F8DD/[Z28P?/U/F"OH;%
MN<K*ML[= %.G7^YX#B<7Z4N.Y_.OPT7Z2&F8\RN5Y70&,)?"VF[RC[YV!7.8
M_M'[=C7G+-_'I:IVJU<^NGB52TB*1C A[F\H8%4N8F-%HO"?H[6:ZJ[R2,HK
M7:')U:[QGL].XQ<O7J+Q!O,TVA1N28<6W(^%9P/KS^N,?E5%N5K7_"],CX@9
MJ%.TN<$HQR>"MD ##Y,F.?P; _YEVQC;C]*[BS8'[6+<H%3N)IX0!_&OEVB!
MLA&XACWE>5=H'>.L8$1M3H; \"3\B!_9K3R9N<9[@!?35LE2U?W,L")W@E('
M]#GHO4NR;,&3:"D7!#9]HF>Q,5!12M&_C9?0+.$>/+S:_&ADC/16> S>&-%U
MY''B,WF%^.\:,^(J^5>;5;V1LWW1%I0@V>(I;+BK2TPWH0<>"&J\%3O#SL,-
M=]1)]&-;818H'IL<>H'\X"-XL?!+'  X@ZW*S7=L^(!Y4G,P=C:0J%+1!]@!
M69*M<3CX-N&G]8+GKIR-9?UJN*5YN_RN[!S0[OD3SL[=A%ZYNTFC/M.>Q004
M.2MSD,$<X_.VH$R8<W7]+;2HRA6[5]Z6"_:[VWTR(O"TQ#=>\B#<@V?.Q5)I
MJJT'6EAI-;+^MZLT$MII5K$\>06BK5T55CB3G._@?GJPP"<GW\('@]H Y,%N
M$(-[@J!;5@Y8>:F/Y_"*/QVK!8C-5RJ_5C?UH2 P]V0]_8W[N';7[HV8L>6Z
MN]3^*_B65RBU)=Q"Z@M^_JY @!C&\5AZ_+SF^,X1Z%O.B]'6-:GV&:L;>*J^
M+%%PN?"EDU>>"D:YZ"?=W+!>EZD^$8NK)\-$ 7:,&0X#4OANT%J NXC+BK@!
MC,:VA=R)9:7564X0E[P<Y5KC_:M/FNR !@XMV#9&@4]NPA2'^AY,<YA4TS9Z
M@S_[2&XK)@K@ST(\ L+7* M7K.B4((Z631@\%T6$Q[RY,5@<#Q/))XS,RYI2
M#SW4Y */.7CF#?V:@9;^38=R%7A8@[P*G-+:+"$^9"$1]U(D#OQ9DKDH]Y=_
M',_98.*;F'0_&'ABT*%E.S9Q8_G*U.F!D5HLLIS#\^Q'G42]5VM<*O.XLN ;
M23*H'I@O9@+J(/IO)&U6)>T*-C](6I! 8.7C*\"_4Q,+]R4D/$K&@.];&7R3
MD^3]P;+@1?<A*5M8<#+N:T;/H@] ,7P49/P@2FW!ZL,^\(!3S\%[MXZE_ISH
M=8,3E86HM',^4#;RKK+7/GWJ@%T@UJ=PX<.'"U]\3>%"L3JF".'7KOH/,T+X
M%UV@%-TU=&),P1J;7>SM+NYA(PH.I/>8"^  <HRH'4T^.^#%5@$*!NYYT2FM
M0+7R4V-)JTE,Q\9QO)_8B@T/CX$?^;/R0SME>,OP9N@/F?".=S\?L]#+YS%V
M@1P10I6$Z7^+8Y@$Q^0SC!RM?1<DB,TH).;XKQ9FB!'3>E10E$5.$"1$%)4W
M6G<K)>)(O(A!Y#_,KJ;<?A4M6H)$\7?)&3CUFDH:JG7)X+6:OTK/\-?F9^A5
M9&F&!W#PIX2KZ18*U&"T/C_2,[S1T6+FFZ]8C5%CA07,-*?!,V:'O1/R); <
M@J2*/V-&G74QR@9N-K9XW8C(.0C4+WP/PP&8U'V.,JNI,!YB45!-[KF$8N5S
M$=P&^Q[V&4?V?2^Q$$=R'*Q'GHY?_>*'^&.#P.)EQH .K/U1-HLR\C1%^!_)
MKRC@(P[<3)8^&UTQ-:;EHH7*\GKK7^-FR6!(QG=EK!VYK@9R-H3;XMQ0HMJ:
MT''F;NBQ;?ED7T^9Y)I3>+'1AU@)Z3S^D4G0RK\OB^._TX,S6*WN)(.(HANP
M7=V-BT23M>OJIVV"_15N_([*'KT['!!8=_])7_#6&:KIANBN,B^6?=QM5ATK
MI.R2VY'-=5*NO/P/S0ND#SK6M96/_QU45PS2WKNI9W7!SR],'/(7?=GF_ -;
MZ70"Q_+X>>R.-T8M&WD[FU[P0F!'4O\VA3?OUU1)#M)4>6L,Y ]H<^^7A<([
M'+/%<T*X;><CH [/1/)T?BT!-4_F<,[V_++2))[8V>E<90\:@;SQ'(, @H,(
M+]6<Z!]55D5_XSS"/U3>:I-@2"7@:$6IC652,-=/R8Q+5A..9 %IC ],A,0(
M8* D,N+\X"96>KMGQEC969,&11B'$Q;P,4%$ I0)F$>^SI])6+;28J_A%01(
ME#6P2W!5TG<$9J3IP)HEN:IKMI)L]-BW'4BK;[#[MC?[["_%-B"Y;>#<6M%$
MG67C6X'XKTV&H*2^UKJ28.KX[O WQ^GOVQR3:+Y/T9P>I&A^TU8VD;,''N1;
M3\[:3>_;.2"*.%M"=R11W %E#1;5#*95T#DU@OQ6J1U+>3N*R*41B/"HCG'F
M\B5HCE&)>1'=:(65YY,LQC']83%$C\&6,TH7-,&))CC1;N!$AV%Z&5'N64H]
M4;Y 0<VR?#*=[M-TT@=I.KWUTCZ\9<ZB]Z 4%V! &)/J#8R\9.3++LTJ$\45
MQ(4##L]O'&ZZ@Y-&E1Y=5UCI1>%$XPG+M0Q6QWC/BI$I5R.%I=$11U#EV6C0
M(/]:51990I?#":QAY[K+N;K3Q]MA L"LMF_H-.6EII NA9G7ZH9*&C(N"*
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MYER9>NPQA<6P*. R+[(<*^R%5\RKFLE@@Z@JP-A,LN'19<,A" ?+VN 5M?=
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M]7;<,#D[$KGVK#Z3;T1?BAQP<,1 P"\QUMR &&:#T/-T<HTY(0RVSVN.K0^
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M+\ N0%E?L:PG<&U;)4MD6Z1P]@A!<E7R"^,8YX5[LR9&/=B?L1/A#E&7V>R
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M_J%4IQ.4:H)2';(A>0B6Y,4&V"O)9]>:ARE_\;,Q3S(,>G)?,&0=^-#.08.
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M$^HRR:CD@ I_I?*Y;BLR< V<S+*-H%C@1J4X?G-+$-Y$LV(: 1%_RC_+>=3
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M1S_2=_OD27:/Y '*.-3,IS CMNY//%W0UJ9LEE6]?MYM-K9.36//[[H'KUF
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M[*G] /L1MQJ54-!FO.+1D BA64[@2#!+<4L1RH11R*1?UO S)^ZTWR,54,M
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M!_G4+GG1PYL)_)#W6%>8VFTGO/?)<N:V)>L7B3N/S) A[%C38>5G;IDN$.D
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M'KTN?^+K<C*Y[\+D_O5^+>Y/-["'A.[]KTO<SS<4=[JX4B:G<PF]$J7E=@\
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M2]\E9YBE8FDKW?GF#-W_03)O7R6W@>IZ))V#F(<Q@LQT'1C17FB,-71Q=T%
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MP_$7D4,]$*,685VR[1!H)I1*UU+$ETI@NK;!)L T@9!]VI2920.4ZN>?NR2
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M&J[@O&2WU^U7\?S3)"18*5T!-@_S_.;)E='7P8W;+4*'>G-(UMFM13DGH8M
M&EOH>E"M;I@]N;(:(X%@ZUJ"ZHV7FMN^DY9K NQBO_S,@9%9N3NR'&JK*\7)
M4%NV3,2-LC^KU+5%%K/Q98VC ('Y#16]PW06-&EL^ (=-5SW#U9?_)G8$JH0
M>;)J8>70,U>V54KU",*BNWV6 2%Z'JX'X(&8?KEU%"U4!1&B;O/C9*Z\>J]"
M,/4 %FZIY5+K<:/74B$O>HNGL@[GLKY],AFE0%&9<+=('"HNX;GD;PB[M_V(
M*_6)FZ-7Y%&6 ULSU6ZK,;F8]NEB^O:874QOL'#0 018I.0,E?&):5^L_UJJ
M 6 R@H6.&^)A9[L_9])E\C9?P7;*7.P"4[:M$)#'A%]*GC1-0 (3</\S#0/7
M ZN:3GS'F3^NU$E,VX4%5/"XI\SA)>)DH)M! &E%T6Q=L).):A?9SPR\V"F/
M4+3P7WP<$0#3$=\OI=Z#8S[C?Z,$>MS'+\J40F#W"@YZ%8;H;(DV00HN='.-
M!R!RK@T!^9QUBWH*-.WIQ5T;,<U<UU=ST@N+S<8(C%;*UP"<=PX]DQ,X:BJ6
M2)Z*SN-9,![EP1I;!I+)&DF:FVTB'2;%"@0799U-YWZOY_ZHN33]N?]!7=]W
M$J<_S3YQTX6= X8/YD63>+%P. XP$Y'CT)9 :Z00Y0N=8ZU%C='ZVEM%%!?&
M9P+_Y*HTJ3XMEZ?P1E@;CQUKUK818C4/^0ZI 'QKW)G&4<4,=FHZFOL]FD=-
M//D<]L3I0J7O$D_\<:\17G\H/:#"V_ZY@V0)(%=J"LX30G+X2PRFJRC7<%E9
MQ@M04EM;RUVTXU3PDN)[[U4CY72+0A[8"#K$%A0+LB[Q#RX%(G@8[MZ@P$98
M=":_L2>;&IAYNK8ZYMF,45V"@)(5HP3G&^_$&B@%L\,4]MJC/.Q>_GJ/PO(D
M#M2^*+/L]*^5*MXE_R JJ@84BR9YC<1':Q*FSV$0+2' 7(@EN4@;IUEQ*1B:
M-L^&@K6@VUR*^&"\AZ:/T[6+K - CD"WI.3T!E<&==(F*MZ[$HE'S>[X%F/Z
MO+W^2RO<X/?.>-3X+JVD2[$7LI)J<V5QI0NCI2"JRQP2+SCY*IW1LX0#T7@S
M(F13>X_.7^7U""F%WL@!M7V8>YJTJLRG0[3?0W34!(T@[%'PB_?\C2\,AG?'
M?1ZGR!1/WQ7E=:ZS2UU[FYMA#3%)1\K#&4UX&635&R=>P8O,C!3(W&:?^""5
MEL@68YS)F^_,DGY)LJC7W8N<RX*.?=Q?DKX;2*2,WL0UST\WJA9,UD0T>*<B
MXJB9!E^'^<BP5[BNQO>2]WK?E34D'7NHE/A"B_,_JO +)]&FUEE;O\.Z0@8+
M,W\2LL=4$GNNJ<P?$Q6AK8+U6DEGOZS*=N/ABG#?ZGQ)24P=8A=F5+\5;W];
MD0J)M3KU65(P7/ C<&YZ97PZU/L]U$=-'O@]8;Y.+P@UB-298 #?KY-?JB)?
MN>P+AJ6=*MM%:Z/;F@G#64..GV&)&,^6\B6OQ5,8>PWHK)?]$A9A''& (TP:
MY51$RASQLF=)!9LQ;FY5>QO8__;LR;/D1,WZ!3)JA%\W*Y @ESR"P7%;@49/
M!RFIX9"7IJH;J5I88\[P/,Q #3),51WFGIXG)XO94$D)^I9B"(TL28Z5'3 *
M(RH,"YX(8A#:.RBJJ)(HJBF;\*D)]_?9SYB/34RXOPGW]YDWG_AN23=! ,FE
MU+T'X9/.PM )FB!#($$4T*"#&OS[4LJILJ3T#A',]@O($1& QN3,*A?\^6)7
M$#CJ3R2A!Q(M(Q"@3;KT!<D(&#[GK\]!2*]AL'68^6I+G'589;"7,!W9K&.]
M#J2G9%2R26OK$J^=@]TQ$=&M0;8R*I/LE97+BR[$@9)&<(_PN_A&S3>LJE>V
M.R,+%# <,' &GKCIW"]Z-ICV8(?!"?]\C<:,CS@_R#1YR8ON1R9 3;Y3VEQ5
M=CM11?+ES%Y#K$^(AWY@AA2A[.H6<V2-9B)56S9\%%,:S(3OZS!HL%,B:M-A
MD:!H!&RPP$<^MM14/\!:,+0NP[WF0(@#(G7P44/#\6.83(3]F@A'3:L0E+=#
M_Q#E.-^KA="!RGB_'^%>@H(;P3'RNSRHSE'WJK>I.&%5VG EF0H4AZ-HO@!L
M[J. +E#8Q28@8KW0'-Q$!5\JM5A> _J%O> L5=F9Y6M*,30Z3WY2=:;^Q04(
MDQ]5]0XC>"V(HR=/'S_!"_62B;ASE_@3C=]/UM*5>BLW-')7*T'"L_!R<Q.3
MU8I %J86"4(N^"%5H._X>E4B;8MW)J.4S=F:$=ME: 0PVKI5+,W8;."N*2D4
M8[LJ<E6ELGCP;>$XJ#WM0NVK*=A2ZW6;-TH(=#CJ:'M\=NN,GGP]LQX8(GM@
M)FA)*;#)LZFITG:-;F3$4./<VM3.H,HJ2)0VU1'%FPQPA%=OAZ[-MOBP.\YK
M\6G/+<"T?T[B92-C;]NRT;U76 ]XQP^'2T7^;TNBY:KT:MXGEDZY"0N0$:05
MW@Z9,NRZWNH\(TW+4Q>!T0HJ"=C&F7:T3$ND3#X-UB0.QP^UB2E\J"1B&6SA
M^_ +Z<HWV<E^V>.B(KN/77;P3/#I;FG=(?:/X;EUP8:@1!QZ& 97]7EX@N&'
M-6('-9V RM1(GU6@GQ-Q%\OD%7P(BV%A_U[8\T1<YHL9";#?F&1\3-0.O@_#
M(%@63 **L/"P[[##!8U=XSOL69%)L8*X]I4T23$CS<JC0*H$M.1&3I3'5=91
M/Z(X+>[)#LCC@^Z8'72IG16GJ<!]K\#]JS]<A?L72!)(^L=8??O-3DKXISA4
MNMOG,^O=G>*!-2979TF4UDQN5B?=KTLK S:K2J%I[3GZXR?E0JV?!1Z;R;3Y
M2-/FX=E=XYSWXJ [ EJ-*''@_ODUA%]8+C=6$B:GP%Y/SEW#D+^8DQ-#5@[J
M[(C1S29RE_RN2W>WM%:V*5!;0R\Y6^&L[__][,U9LM09VO-,@$B) F$!02RU
MX]W>@7<R*%Z8<$6EH,90QZ<KL-ZE9#^@*J[?IRORO8+Z_*^V9#1R4M^ (;]&
MBY"-="LLX!>LP9O:&?O\GJ0W=C[HJ%RB+]L:BI80QKDBPDR*A"AEG E0.2+"
M25;M55;=-3[XBY%5N%$/14+- _94FV?!1'J893$' Y\K@G7<#7 ^?]Z(Z.!S
MCDYAG1J6"J]Q"N%/K\',KDS*Y5CAJ?YOJ%HKN1,82<:_A!^?8U#C>X4J/Y_L
MZ33O]33?-5#YBSK-'F][*.<:#FX_MUFCQ[I(XW WW]OB1O?,9'..I! _""9I
M<38!E1W!:]J%1^K;"A;,>\$-)FZ.G&F##0<QENGP[_7PWS4$^4LY_-^7!W25
MTV&A'E'BL'?51_[I73S1$]ANSV"[1Q/8[K.#[:;[8/?[X*[1ZU_*?? <JT@<
MS'V \5_3*36(_A@E=*[$N6JUQ" *[0$2I"DZ]7$L.@T73(^WN R*8WFZ&A.Z
MB5#G<Y@(JK_A^F]<E:RY>^)Y]$101\OFO:BP[%=&X6F#P?W.7Q/]WA 8$ZM8
M;6, U&$Y/I]H&,SE4ADI1 3J+((M&D-6]$97G$LW!K++6H)4G 2L'P[YB8VV
M%6%<904(33K:U@M3"P/;[!S&M,=!I:JJB-UPSEO"TPH0M%5=+]M</(D"]=2"
MS$"WI:@=HI#T.()]GQP$$L:_P5)1=5G12&0H1.Y4V1R*H4H:BQX\TQHO;9Z%
M0%2T<-YC:@</D*<8-]")$#7Q;VA3S<9[C!G;1FH-;'*M&$1"MI)&FDO_NUQ^
MB]X3SL P:V)#%F=O6ZCLMS8SS*.]J<J%<D42R &J\U+@GP6Z.QEFNEQ2L1-<
ME KK9IGBJLRIG,*Z1,=PTU8;T[09HFW-U9:!M(6L8AO73EEH_%_O\S'%,B>6
MR1F7<2&V:QF"Y9;+JO:RMM @D&JP.+JK?-XB,4 VY-J>GJW%!.0 \>83+#B>
M 2-0J]V^2?4T3[9-$%*I&C=4/*8I9;]0Y14$E2WT[[\[IG\XB0@*V51&0,#P
M&[1GVY2/$&IXF*"W1 122X63N#:.+6FS6[<G8WBORL]=XW*_&.6'PT,&(67$
M+7$PBA"S@A$IIA3$$K'D$"'//NQ(3:5QMY?&57==&G</>^2""Q\(#RI5\.9[
M:!G^H:NDT>5;"70P"G2*)U/ ULFF7<!A<;F<Q+/MX[P4MI4\3=2VG&H=D&[@
MKGUI@Z[/@XNH2M2.?2<M:*UU,Q")AF?37!$E-6K"I#(;+NR*VJRDJB)^? %*
MR/6,PZP+SBFQ BFL2L;EJ6U!!_L$9</[!Y:=5^NH-&[H9,8D( %\O;&\Y0\?
M8T84=O7AU_"ODT>N#JV;J(NTF45K%E%KC=RH<T)Q6X!QE)Z/N3/H >_Q=-UF
M_8S-$:X)D@:8LF++ 8?L%\V"UG.G]<E/0MB#$;O:_I!3KUBOM!"!E#>E/$$[
M*TKOFHU]0"#TM:_KF&.5.>@]<CV,X-$)F?OP<7;Z.% 7X\7 #>5W=4<AM+HD
MZZY2>O;)@S_9YYH2+AT<TX*6X*IL.)$)"PF. F^#KP74[&&J%:<^LV&(PV:-
M'#?P=!'L\R)8',%%\**M+/>'SPEHKLL$Q0LQYZ<M6;0W6E51P)R2%N:VA/$"
M!'Q1A*AR;HX#8 T89(T.3.*FO-0DI9Q%74!7K=L>JY5'-X_[BR0!JL;R&$BQ
M5<R?X#PC KR2NYO$)Z65;G/C8 X"\Y;']TI4 \_?">Q80LLIG<TDO4?GOCI>
M9/4CGV/A;=KN<]L3LZX#ZF0>*YQ_]@(T"=C8:#%=EZ=4HLA)%A_XH%04F'BJ
MD"I9031-VO#$(VS(/SZTC"2"X!.X%TYQ_8-JWIV1;QGL-7$LN(R6N@P(H5.-
M220QV[SP,=D]$R19$&]#N9P$U;X%57H$@NHM9V[5[5JJ@'04DA/0T&ACNRO=
M.X:ZR<3%+<]8O16K,_H")*B::5%RZ&(_>4\Y0+JZQ!(\V+DR-YEX/V"G5I>@
M*?PN/Z,'!,N38/XDW^BNQN_)#;;#I"X6XX=3'KC*4+)1UG?H::5?CJ@!"C0+
MIB AWRJF&NEQO=D5(@OU9^S9[\)(X-4$Z@TW[C,FT3LD:9+0N::;)1:)\N ;
M'VAX/GIP!T<8&[U/+XYW(WW" 39'<( Y]L$^9L>-T]NWHN/NH,4ND*>7=8IP
M7^,'3=$*RMA5[TE.Y-Y;A)P 8=LE_8V=O\1*6C56@QCH5,^S2XY?5D;8R*%$
M:G&RV\LTM'2\23-LDLR[7P!S9,O#'RLAK,2YQN1 4-R8&4+L>2>Q.N,]Z70M
M*-+-W3X*G]T;'&U=0_]?DM2Z?Y?=;,P^G7NEKY]UNM5 [ XR(+L(-G]_A_<-
MQMX.AG<G/,UGWRN>JGK"T]P+GF920T;5D&/00UB8L392E/;.!OG(U*7>_X<R
M&*[< =GHM K\/?GKQ$CX&(%\GGSDO7.GE#>68_7^[L3Y0<[+"I825,/[G!:*
M:PSL7,>STX#L1]T5_2J6-X=W'SK/*>S!T0Y5][;[/G8TTF5JKF';U8"CU[GZ
M8&0(^-! T[7W^SKT&!3@"R,'Z/+=<&RWTI<E,3*CEZ(S<1Q"P9"/"DJP_$B.
MC "PQAL*V3\B?UPOU#V\T3P[%/HW"(K7?],WS,B\&TG5<*[:@(W6%Z\Y(1R.
MHW-S?Y R=(Z=R()A,JPJ43%;243@1(^;.DS(L#2U7S_X]F+>X1\,^>L4UHID
M?% $:@HJ'#?JO;:!J4ZSJYXSAL<\XG5&I_.<0'WL>>[-35 ?+YP<\9C:8CW$
M/_3!:^EI=1NS[O'&X,IVPWA@=]9E9VT=UM%]T0;I:.3S$7#C6W0*M]5-\MHE
M[/H2P6<XFZ>/3\SLY,GL+-#AOD I\+:7A13$0Y:VP"G3,JNV69$%:1.@W-5A
M:8)H[HET,2P%7?K,)ER]-&]KKD=E?:]#&PJ1A8)BS'H<0VI17FE>;^.I(S.I
M_]8'0-).ZW_#%F3"6G2XSC!&N#4:#*/XG',\"TUY[NGCF2VON(E+9-FYD2WZ
M6UL$O-JJ R*%%[:-W>RP\S]YX_O5&R32\YGNW1,R0>8^"C+WS>';.$?A?GM>
M9H>3+H"BYA4Z=5 ^OL:#V:)2FI%,>/CM-T_9H<OU8SSI95CX#0G7HIIO$U1U
MK^?NKHO%?SGG3NB,#NKPC= R1HD4GJ-10"K62GT14)T*PO5Z5:Z[-;'^U<+$
M+,4P_:DL3AVMIL.7L"8QR-LX'>?]\J;==6'X+^D\6R#N01UI 6,ZC,"')6)/
M9^D#SM)$0KBWLX3;\V".T<]@?+)."O8]?$*WC4GAEGM5I&?(3V0KI,-9JS;B
M\)Y;<'9M_;+3:=OO:3L"XL+C0& \=U3T!W/B! E-2):@UADFWF97H'M6H&(6
ME^IR,"4"/68;.(Z<1QZ4,20H$CF":TSR3;FB#I>8X9B)6?J0!\T(G6+^)-=+
MXP;J@,4];"OH"9<QLX^[A]"1/U(JCO)Z",@CE>5"( B"]E*UP:4\K92A=(7(
MV0LJ<U;*!T;2*[ H.J&7*Y=30D 6(CCOY*P.Y3)(-9MTQBZU0C4MY1G10DWB
M;;_B;>(ZW(]T>^%S%;ZW8=;J<'0+QON[?A$ TOV()[]+*^!R+R@/Q-=OV4Z
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M&B."F:)NF=X)/9*#QQ;K>5M1 V]LK/K8Z+#H8YP>0UM/=H'+@?"!)4_5T]5
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M44R8H]Y%BW$H;/B=*4@A8%\;)5>R"FN'X#72F:4!JO%9U'XX9RTBRMW> -4
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M6G'R?AGW_9AX(^,:\1"19M5JPCF6W)^8'S0Q101.J"BS!!%@2#,+2O?IL41
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MT'665;V_K<>J<+B&;5U'INO>DEOUAMSJEY*6B+A"-T\&I1_"9861/679[L"
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M#9'JMEOH#4>J@UTJ5GO_V\&N^7O6_P=02P,$%     @ C8)G6!O)$=E' P
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MW?MU*]* H@'%#^?8/4+_@\7B0$#]IL]1+B%CPW-(*VK[LY/86EBLPC>:DS7
M>ESQ]V@=NT>0;WV(CZPQ5;Z&IQ=/% #W6,ZW]%PT8?_A-LW9JQ;;Z>[L/HP8
M>K3@^$:.+>(>_U+9]/AKQY760VA.Q'ZW-)I*O*K05YHY\M+7 JQM;X 6E[XO
M(+\@D))/())&FV=8T"=<S?C<!88XV*;O+'C]T\%V^+:#_P-02P,$%     @
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M'3SB4;](+E8%3 7^UA0M@??>F,HY75I?H4S[^#K_X-FT[_\1X!]02P,$%
M  @ C8)G6*>:*/D)!@  ]B    \   !O;F-T+65X,S)?,BYH=&WM6E%/VT@0
M?N^OV&O5"J38B1,(8.>04$I/Z'2E GJZAWM9>]?Q7NU=GW=-DE-__'V[CD,"
MH>)Z+;0%!"3VSLY\,YZ9G9EDE)DB/WQ&1AFG#*]D9(3)^>'Q']Z@[_='W>82
M!-T%Q2A6;$ZTF>?\Y^<%K29"AH361OTDBE)5ADH3E90Q(2<AV2]GT7/'EHG+
M=M-BU3.J#'O^KI!1(:27<3')3!C@,E8S3XM_+(=858Q7'NZ SZAL6:1*&DO"
MPZ!7FJB!T3",W%I*"Y'/PPM1<$W>\BDY4P65+6&LC%$%: V?&8_F8B+#G*?&
MRK#;6S'33!CNZ9(F/"PK[DTK6D8KLON0_4EQD#45S&1A*HR7@))+*^35BV#8
MBT9=N_=PU"WQ!_LX.WU-%2MKX>LZ)BI75?BBYWZBVS6>-L\G5CG[$B8XGF4B
M%H8T7K8TQ-<V00+IO/I&;# ^/KLX>7,R/KHX.7W[6(WPKJYTC:1!C"+G/#%"
M27+0&Q*5$I-Q<DZKF$JNO=-9SN?D*#%VI=_K/5JOV3JO8]T82I,MNDVH9&0K
MWK9V:0T8#'9['3+.: G<9#BP:Q<VDY-@OT/>2T!EY-Q0 XECQ?CV/1KS01/M
MFG(.E) ,M.'0'P[W7D;WI.]=7>?_:7\B"2[DPB>FPF0NI(ZDK&E.SK@]K@E6
MWJBJ($'/^]6ZR:E,X#,2!!<9!Q!>&Y'H#CF1B4^V[/Y7+V;]7I!$8U645,Z;
M2Q9MDU153D#)*Z$8X; L(Z]YPHL87C@(.HC;_J!#J":IR+&VA 2_K2MA!-2R
MWGP\2S(J)QR^611":PL?OY:2P6<)@'% 74/3J+,$ \ =<B; IV+D%Y_\+J2-
M8B=\G F>DC="4ID(*'J:IB(!PD7*6>C5(;AG1(HWY4J."O;)>__<'_O7@@U\
M*5.E#:SR<U-:!^O4;2OFY(-44QAIPL-OSW_O-5Y72L<%3 LI'/B#P>!EQ(0N
M<SH/TYS/UO7]J];V\;7L'86G#:U,Y#3SH$.APYAJG@O);]C@"N1"U ,%]<#?
MV=D[" Z"G=V@-QP<[%TI+:1%[CG=/Z'N\\/ ;XVZ8LV&?=#K76?X,.D*^:9-
M2FF=YW,DKZ+,;4Y8YHF*_UV+BA?8H-?/.WL0(OT$NUML>QEH5UEEF5$6T18<
M#'8BFVN6OF8+\/LIPY\"Z@<(J/YW$E!"XE0NJ(L2NT*!AN&N"Y VVJBH$&X0
MK6U@=>PRS7.";3C)<4!BH42DZ8[;E2X/3C!DPK&VIS:HZKR)2X42@#85ZOJA
MZC_&>#,T1N6](>+LV"1:C#@L%COQ '1+[L%Y5 VG$S/.HJ5C^7"MQ0;X4$Y+
MS4/-2PIK+^/-M?D-;S=[ 8"JE7XI--KN7)AYV.Y?$(&*K?OQ[L#?WWEI+=<U
M[!::G:$?#-=H\*:Z+K6=[5BK3H'>BRM./X3NOV=O; Z!F\ N;466T'SQ9.$6
MMXV%^O?M//]AUK/!FAL46XZ^&E#^;@D *A?L(52^0\*ZS0!=W=U0B&\RR)/K
M?"'7^;X<Y)9VK-7["TDA3Q[WY''M".U=A2PD2CC;#;?;_I2?X-4>S@]2LMQ/
MS?@:A00+R6^T2C*RYR8V.X]R./A#/57;": /X!.%$G,QUT($N])=:!)S>SNM
M*RETAO8 909'0V 4H4G2%.ZK_<*=QF%H",!9*M-R=Q,_.R+$]E)IOM[ []^Q
M:6\&;86;+:Y) 9;8MCN) G=;#C,2S]&3I+SBJ#BP8M6!(@!B\5P?]DTSCNL*
M30_CX&2M90<*-+43]&N3QP[X3E#/Y%P[+2S;"9?H>?(5!%:O'/AK.K'BB:X1
M4HUTGQP1#9< 2(5R7=AQJP,$9:;0'H\-#@*!=M+13CV<0JOSQ(S:1P?2LE*7
MP@Y;H>**4LX\4X%.+K:CDT7O%\]OT%P]^06#N\QC*R+0[ %EFI*ZQ!T+DVOC
MWSYM<!TT@RI.!]N!U(5<'SBT'PY?E;TW/Q_>V)C#(Q[C!\??=+[:_TPU/[X_
M]UZ?CL__#'H'!WN(^H$??/RX\?/R;%FWE0BSIE;S7-"&-)_2N7:%V:AKO[5P
M^&S4==]W^!=02P,$%     @ C8)G6$K6^[;;%P  GJT   X   !O;F-T+65X
M,U\Q+FAT;>U=;7/;MK+^?GX%;GM/)YFA'=MQTAPY-S..XS2^D]H=VWWY"I&0
MA(9O!4#+NK_^[BX $I0H64Z=R&IX>MI$$@D"BWW?!\O7$Y.E;_[%7D\$3^!/
M]MI(DXHWIW_L/-_=?_W,?H+?G[D+7@^+9,:TF:7B?[[+N!K+?,!X98K_DEE9
M*,-S<U3R))'Y>,!>E;='W]&HB;SQ-[E?=TQ1#O9V7\C\*)/YSD3(\<0,]N'C
ML+C=T?+_<(1AH1*A=N ;&.=UZ8<8%;G!2\1@?Z\T1W8:=L C^FW$,YG.!M<R
M$YJ=BRF[+#*>^PN'A3%%!M<:<6MV>"K'^4#AX_$A>+]_3ERDA1I\OT?_.YI.
MI!$[NN2Q&)1*[$P5+X_FIK+RZ?#HJ4S,9#"29B>&*T6.CSS]X\/9V[-K1@3'
M =Z\?E9^V=6F8K2PV"^UO!^^WW^Y=Q2N[!EP W'% R]Q_P#N#589PP2$VLRF
M7IY>71]?G[Y[/51O3DXOK\_>GYW 9W;QGIV=GUQ<_G)Q>7Q]=G&.OU^\I_^>
MGUR?7IX??V37'TXOCW\Y_?7Z[.0JPLMW ^K]P^GVY)=*Z0JT"#,%NQ*QD47.
M#@Y?L&+$S$2PGT0N%$_92:% W7#Z^2.?^I^O##<"/[P3*9]R)9XN(QVM5^8)
M/';P<O?ERQ__/3_]!Z)FEZQ]'5I>Y#'L8P[4NIX T4I1&1EKX*@\WHT89W%
MPT*->0Y/2QC/$R9NI3:@@%D%!%*?17CV!+_^X?O;@[W]^"BXRWZ5'#V-6%+
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M1&I@Z)+G\8P-A9D*D</OA6[-B"^=I/(TBYN)]2S>:0 O?KV\_K =/(XJ-*E
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MV?N.SG?<8N>QC]V_J23^Q[KC(YKKCY(/90J>YF:[3=D<N\/,N(:.-5B0WAP
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MT B!&X^0 E]5#?2HW2_'9(<]:G<1M?OZV;!(9F_^]?K9Q&3IF_\'4$L#!!0
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M?=?7;/$O"4<J#N=,G*;BG#,(VGIV&*G"WXDBU 3J7NJS'#- XN#^\E$!+*V
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MX[QAAJC6G//6X0J*VN/#:U4TE0428!2WSPBJ1%D7:MVN1Y"EA5*9UZ2C%KC
M\ZQQ [4-88V-U8U#<Z%;&0B EPX0^0%=1@*O<DUM<-*%_%7X$,:AGR"17W!0
MJJ"X 9.4A$3<A.$-[&BAA=LHXJB.??T@T$KB+@"W%!*F9_8&/&Y.)\>G+TY/
ML].)2&;\I3@5)UQ\G?!D^M6+-)^]R"=?G\QFLP$!D7_QJD)&SUNYGK-_PJY9
M#_,J]JHA@:2]#FT>$TQY[XR\M^ND]$:HBI#GC (UE8%.TL(!@U:;DKR7[>+&
MDH\\>S_$<%Y R=<P5EHTF>CP?-'N#P(?5(;2.5LIZMVB<%L7ZR(G*IV(],T
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M !(              ( !     &EM9S(P-38Y-C Y,5\P+FIP9U!+ 0(4 Q0
M   ( (V"9U@,U8-FA:0" -(S P 2              "  993 @!I;6<R,#4V
M.38P.3%?,2YJ<&=02P$"% ,4    " "-@F=8!?Y;K.LL 0#B10$ $@
M        @ %+^ 0 :6UG,C U-CDV,#DQ7S(N:G!G4$L! A0#%     @ C8)G
M6-]$^4% Q@  >O,  !(              ( !9B4& &EM9S(P-38Y-C Y,5\S
M+FIP9U!+ 0(4 Q0    ( (V"9UANW@-?UJX  &C/   2              "
M =;K!@!I;6<R,#4V.38P.3%?-"YJ<&=02P$"% ,4    " "-@F=8YA;R.#NQ
M  #VW@  $@              @ '<F@< :6UG,C U-CDV,#DQ7S4N:G!G4$L!
M A0#%     @ C8)G6' CN^WA*P$ 19,! !(              ( !1TP( &EM
M9S(P-38Y-C Y,5\V+FIP9U!+ 0(4 Q0    ( (V"9UBE[XH'?*D   /A   2
M              "  5AX"0!I;6<R,#4V.38P.3%?-RYJ<&=02P$"% ,4
M" "-@F=8Y^ FJF_= P",!R< $0              @ $$(@H ;VYC="TR,#(S
M,3(S,2YH=&U02P$"% ,4    " "-@F=8A54AYDDT 0 JH1$ $0
M    @ &B_PT ;VYC="TR,#(S,3(S,2YX<V102P$"% ,4    " "-@F=8'%O:
MWY@-   P:0  $               @ $:- \ ;VYC="UE>#$P7S$T+FAT;5!+
M 0(4 Q0    ( (V"9UB1;0^6HE<  &J_ @ 0              "  >!!#P!O
M;F-T+65X,3!?,34N:'1M4$L! A0#%     @ C8)G6$(3=0:!70  =[$" !
M             ( !L)D/ &]N8W0M97@Q,%\Q-BYH=&U02P$"% ,4    " "-
M@F=8,!;CU9U1  #]<P( $               @ %?]P\ ;VYC="UE>#$P7S$W
M+FAT;5!+ 0(4 Q0    ( (V"9UC8]OA_\@D  -9:   0              "
M 2I)$ !O;F-T+65X,3!?-6(N:'1M4$L! A0#%     @ C8)G6!O)$=E' P
MN1$   \              ( !2E,0 &]N8W0M97@R,U\Q+FAT;5!+ 0(4 Q0
M   ( (V"9U@J6B%&,@@  /1    /              "  ;Y6$ !O;F-T+65X
M,S%?,2YH=&U02P$"% ,4    " "-@F=8H-\ILB$(  "40   #P
M    @ $=7Q  ;VYC="UE>#,Q7S(N:'1M4$L! A0#%     @ C8)G6#Q8YBOR
M!0  #R    \              ( !:V<0 &]N8W0M97@S,E\Q+FAT;5!+ 0(4
M Q0    ( (V"9UBGFBCY"08  /8@   /              "  8IM$ !O;F-T
M+65X,S)?,BYH=&U02P$"% ,4    " "-@F=82M;[MML7  ">K0  #@
M        @ ' <Q  ;VYC="UE>#-?,2YH=&U02P$"% ,4    " "-@F=84275
ML:(0   <AP  #@              @ ''BQ  ;VYC="UE>#1?."YH=&U02P$"
M% ,4    " "-@F=8+]0#9^L1  "\<P  #P              @ &5G!  ;VYC
B="UE>#DW7S$N:'1M4$L%!@     7 !< F@4  *VN$     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>onct-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:onct="http://www.oncternal.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="onct-20231231.xsd" xlink:type="simple"/>
    <context id="C_8ae3137a-dca4-44e8-9e74-9a641eabeef4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4a9ea6d5-a2b4-44b7-a30b-0362d9e0d9d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onct:RepricedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_e9b3636c-d8fd-4fc6-949c-e35056896198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="C_a7fcd6fe-26a1-4370-be58-59d9b95517db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5b521705-9521-4715-a360-b03c0afb492c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ec9bb144-86a5-4e9b-906e-419e8387d5a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_390cdc10-d67e-4245-b090-a0003a2a440e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ac63083b-0e54-4d72-845f-1395615d3acc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eaf7c44c-5611-4b86-8805-7a0f392d4123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3ed66ec3-01b3-42a3-840a-a1a07973fcfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_befd2887-568e-464a-9888-a3946d8ca800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_22537a93-b320-44dd-a549-708fcd3422dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2fc5f62a-291e-46d8-9a20-5a29e0475095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_66241dba-1f12-43c0-83cc-7d8e203311cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="C_239353fd-6f89-4cb6-b125-6d9371f0edeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_721f94da-46a0-4238-a04c-81022ac3098d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_f8ac1f25-733f-4759-8f62-55c4db818235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_22cf68f2-c77f-4eed-9ca5-da8ef5c46854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_be17b684-ca82-4e8f-9152-2a66d621a493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d3b5002b-9469-4aba-b020-3e3c596b6535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_10b44321-be1f-47e8-a18e-447594cad864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7969de4f-8469-45fc-82de-c6f6103bd889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c7417c2f-59d7-47f2-b82f-869b45d68de1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c6b88d8c-42b2-44bd-afc8-e948c76c63df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_18a29548-1851-4d54-88f2-fd40d4620a4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_54d18d54-d3a4-492f-b13b-e21ffaa85ccf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_25540dfb-13c9-4cf9-b450-dba094402df1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_cdc3f0e1-0d49-4984-a42d-fbfadb17116b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7f9b6b80-f252-4916-a2f7-309b047bf50e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c0da6fd-d05b-4a5b-92ed-45a0294999a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_c9b0328c-d0e2-4383-b5a2-733916d1b3cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f4a3a9c0-78f1-4226-a01b-c86a4a08a0b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="C_98e40839-86be-43a6-9e04-8e2e7abd9e58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bf19402d-8314-4a7e-802d-f56c3da68afb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f23d092f-edc0-4d76-893a-ca1ffe860492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_098930be-5884-474e-975f-9a2650ccb706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a20da3ab-11b5-4858-a9c2-a02c8c66bf0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_08168037-6b24-4204-95ca-d790554ec7eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_97f0b34a-98a0-4cbd-85a6-33dc53e598fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cfcce48d-55f4-42fa-bc8b-242ea98fde12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f14623dc-d310-4e54-b789-c60026ee8444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9a46d83e-f6dd-44d4-909e-9d8f3ea263ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_008b4d81-ffe3-4ba2-bbc8-a66325c8241c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-25</instant>
        </period>
    </context>
    <context id="C_3fb8e0da-acaa-47c5-a6c1-2e4c104b6914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fd81aada-e08c-4c52-98c2-314c93335b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_30d36d96-6cac-47d1-9709-bc013ca4bfac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d80acc3e-af09-4afd-b5cf-5196b734c37c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2b0d5398-0c7c-48f9-837d-be8269901856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ee21224-3ff5-40c8-8d3b-f3bc87c0f528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b28e1922-05f1-4509-a2c3-99e3ae9adb2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_64618a52-3613-4a92-9d8a-011deabe6e3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f73bd1b2-ebe8-43b0-9837-980ac35e9116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_885b6bbf-2f96-47f6-8d8a-193adfbcc27b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a4cb10c4-5548-41a5-bded-833419a5f7c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_39371a89-6f01-47df-bc36-a1e47990e15b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_88e26592-4d13-462a-9b53-e67a374ae51e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onct:RepricedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_467dc9e5-7495-40f7-ab23-9880e9cfc171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c3f1feeb-4862-4bb4-888b-eed88eeb8df2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b56bb628-693a-44de-82e4-d1feaf30ec85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3f9e4329-2631-4545-b375-e1684aab746d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bf9fff34-6f4a-4470-8d7d-50c7f427439f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_76233f9f-1322-4238-beea-ec554143cbd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ef53d5cd-37dc-49c8-870b-ecc190d62e21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_83e4c228-480e-409e-8176-6d50e59820db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_46c60dff-cac9-4018-8575-385d2a411a84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0ec0d6a2-b31e-4889-b743-4923e7241cd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fb81806a-0e46-4915-b3ab-4166af11612d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f742e918-e6dc-4348-81a6-2801923bd3ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9bd0a19a-3bcb-4dee-819e-826450508497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dd4a10dd-2b20-4eb7-a455-5be36a531fe8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1fbc6ca3-a3dc-4149-94d7-cb8b93ecb98d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_ff6125a7-fb79-405a-8961-0ede053bee4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_80c0e7a1-8307-44d0-921c-0a9be8697b02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_caa34144-abe4-4bd3-99a2-59f166c310aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f27580a4-262d-49d1-b2c6-fb20b05f065f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cf6a6ea3-bfb5-4119-956f-554febc07729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_94005552-abb1-417c-87b6-43d4fedeb7de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3649747f-9c0d-4482-8bdd-75153c2821e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_62fa3949-0347-4273-b069-49f2fd0e5194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_060e4155-636b-4f25-aae8-2486660150ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2eeadccf-0f17-4175-823b-dbcd8f8dac1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_406903e5-8180-4559-aaf2-4760656464dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_441dc867-c190-4ac7-8f43-7108e23f4032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_84d1bde4-f42c-44ac-a1d9-1e1ecae3e8c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_88c0a536-1858-45ff-bae1-c4b868dccb47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d4d11d3c-bc06-418b-a44d-1f7e43dc53ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_188444b1-f178-47d3-9b2d-59943870aebd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8e7e0a37-b10a-43a8-b067-4e1f34e10da0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c896d669-13f7-473c-89c3-89994dcf773a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aaaac3ff-7e7c-4e08-9dcf-37c2593ea85b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_26ab1cc2-d243-44c9-9db3-5cbed36397d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4d53eba-2e84-48f2-b931-0b43041273df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6d3b13ce-5124-4fca-9299-dd3bdf5074c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_07c0adf7-ec21-415e-8412-b371f3a6a24a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a773db65-a5e7-4e4b-84c4-30dbe6ad792f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_3a6930d4-f451-44ee-affa-37ae8d65ee2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e4bde5a8-ae87-4557-801d-ca9157cf9106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_23c75ad6-c16c-4b5c-a758-b8db79ffc925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fddd24a2-50cf-4852-b216-6ce6bed4bb65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_ed194973-5fdd-4e52-855b-ebf609d37cc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_86f3153e-89c6-4d7e-ae5d-a42564364970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f464bcb9-103c-40d4-8bd9-b4581370d91a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_199ad02d-9d2d-4836-8616-89dc61afce31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4d7bbaa5-7054-4572-8d82-9320f96f8511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cfadbdac-a035-479c-8d33-fb8090124ed6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_494fe420-acc3-40f1-a076-42280b1684de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc68c081-7397-41f0-9a80-0bb2d48bf304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_56a6188c-3033-46da-a539-5db40eb23bba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_adabef98-d9b7-4120-a5c5-cb803bd266ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed1bd376-c8fc-43e3-8746-8f969b50e374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_534fa586-63e2-4243-8afa-2b2e6ad52e2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:InducementPlanAndTwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_97e3e97f-b9c5-4887-aa84-bb0855f10787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_6d9980d5-e3a0-4b27-8681-b22f63c165b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b4b57fdc-9184-48da-aa31-8dfde603a140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_075d13c8-bda5-4ad2-bc71-30df6eefa0e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fa85d7fe-bbad-46f8-a7b1-37cddaed1e71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_806fe93c-57b0-45eb-9528-ffd11fc44374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="C_559906c9-0c59-49e6-96f8-3366e04dca58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e681e21e-1bbb-4c53-855b-c79b986ff160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_f873de6c-929f-4ec4-8634-115ea3443d28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_124609d2-2d46-4cef-af3e-ff9ad6a610d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_c7403617-2bd9-4378-8e28-1026eb094276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d67c732-6cc2-4ca8-b0fb-1ec761145cf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_24db6605-9fb8-4748-a200-1daa7520b56f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="C_a954e431-fdf8-4bae-8667-e303c67e3782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb2712dc-866f-414f-a8f2-3c9dde12d934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a3d6b78d-a32d-49a2-80f4-722dd0cb10ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cd959724-6c14-44e2-acc1-de40c1c6b60a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_57f4bb0b-624b-482c-99f5-8c8960913a1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_612bfa44-754f-486e-bf9e-c145316436ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ebd6887c-a70a-4f63-862c-61c7842c1226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4c46c1db-0184-4718-8ed6-39821e77c4c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1324e5fb-9834-45ea-8fde-84ef2eed74cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ee2b049-c3a9-4492-adeb-159a901587f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cbe31993-74d8-4712-92b5-682ceee9fb09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_945c64cc-8fd5-4390-8555-ead6c7c1f64a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d70503fc-4a1c-4d6b-9214-610f9b23fc86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="C_42761111-9f62-4a8d-88a7-53d404e3f90e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8bff7594-8784-4e75-992e-1abf18d3a26a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b99fc277-6a5f-4381-b86d-98c34d084f57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e420a3e6-0b0a-450b-a468-f2a3164e557e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>onct:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_646342b7-ae99-43b7-a311-6b6c2f42d92f">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_172e3ea9-bc50-4cd3-913c-fef462d45e07">0001260990</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_a711c1cd-0219-4139-9d92-02c1d6d4ffd3">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      id="F_c51b8fcc-6943-4e4a-ba2d-2e171034ab9b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      id="F_6a5f452d-b332-4939-a1c1-8e54f1e5256f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_eaf7c44c-5611-4b86-8805-7a0f392d4123"
      id="F_ee1e1737-1e34-4355-a0d8-679b3a702be0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      id="F_0942af95-94b2-4cac-8c0c-f1444938ea88">http://fasb.org/us-gaap/2023#Assets</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      id="F_cdb93c50-11db-48e2-b68f-a8c32248923f">http://fasb.org/us-gaap/2023#Assets</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_25540dfb-13c9-4cf9-b450-dba094402df1"
      id="F_cb4bed05-8324-4d04-8ccd-d2135d259695">2023-07-31</us-gaap:LeaseExpirationDate1>
    <dei:DocumentType
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_41b9a9ec-b88f-44c3-9fb3-b65751c279ca">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_a393c71b-c780-466b-aa22-562f4be83d8b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_dc4ce151-87df-4fb1-8858-4537721a6d38">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_d06894c1-eab9-415e-a806-568145c4a049">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_30a34b15-c21d-4ca5-bc4d-d9676116b495">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_f031e6e7-6520-4998-8801-cf16536fd134">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_1f672d56-b489-4549-9bce-e024e498264c">000-50549</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_0178f3c6-b85b-49a9-b733-98138601d7a0">Oncternal Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_3286542e-2b27-471d-b23e-dcb5c731bbf4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_42c15c9d-8bd9-4933-b649-e25905c13390">62-1715807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_1aa9dd67-7fc6-4c4c-b45c-73890e917d0b">12230 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_fa08278a-926f-4260-a5f2-4195e96545fd">Suite 230</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_7441fb1b-fbf5-4e99-86cc-f9df3c927415">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_193288df-47bc-45bf-a3b4-109deacdba9d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_58426588-ff28-49e2-8280-ad35c451db40">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_c4c3fe6c-bf41-40d2-835e-a771e47da62c">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_6c8239ae-d7f9-4145-95ef-a04c58950923">434-1113</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_0a1a6fbe-3439-491c-819a-fe4df2b88a84">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_2c6bfe5c-e8bf-4915-9f50-aaf83b82b8f4">ONCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_b53479a9-2899-40ef-adcc-e3278c8abfab">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_b30a8ac3-9874-4923-8f56-1a582819b48e">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_cbbe51e5-fc2c-408a-857c-fe6ba9d88464">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_18adb29f-0f52-4378-bd01-b98bbaaed017">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_0f10f27e-21e0-4c63-be95-43148893c541">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_4a1f0d5d-7651-49d4-aa6c-3598c7f6e7ec">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_9cf32ad8-056e-4f89-b4bf-e9add4f7ff87">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_1eb2da4f-21ac-4be1-adca-b1cc0b1fa836">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_026aeb9c-ce78-4dff-8243-8da34868e158">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_b5830e9a-435a-4a66-afe5-047f1f116441">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_1d01cd12-d7f5-4053-b5e3-dbe465f00606">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_97e3e97f-b9c5-4887-aa84-bb0855f10787"
      decimals="-5"
      id="F_76cc460a-4806-4117-9578-96782853fda8"
      unitRef="U_USD">18800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_66241dba-1f12-43c0-83cc-7d8e203311cb"
      decimals="INF"
      id="F_78d85ebe-6040-4608-adb2-39114b968b12"
      unitRef="U_shares">2959645</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_ef92521e-a655-4801-bb68-c3e1533d7552">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#x2019;s 2024 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#x2019;s fiscal year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_da03a402-644c-4b72-b1aa-e5544cc3dca8">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_8dcf1647-373f-49c1-b298-d46d8897c705">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_7d05e64d-6b13-4871-bdb6-c32b9d0be886"
      unitRef="U_USD">6697000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_a59b23a0-1f2d-486d-b457-3f3439cf17a4"
      unitRef="U_USD">37142000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_c8a6697d-c2f7-4b70-ae51-9cffe44259b1"
      unitRef="U_USD">27558000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_e86252c0-5ec5-48ec-98e8-c27cded898fc"
      unitRef="U_USD">26582000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_4e0a29b4-60cb-4e8b-85ed-8d4592abf0d6"
      unitRef="U_USD">1804000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_78af9f81-9fac-442c-81ae-a5951b8d5c30"
      unitRef="U_USD">3566000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_31965d95-0113-49f3-83c0-466468f5231c"
      unitRef="U_USD">36059000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_c887f52a-4825-4e50-939f-b668ea87fd99"
      unitRef="U_USD">67290000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_f32958c1-c193-4963-b50f-5f2c980182d6"
      unitRef="U_USD">258000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_f341cb38-35ec-49d8-92e4-e087abbdfeab"
      unitRef="U_USD">87000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_b9107ac4-027b-45bd-babb-0094be8d0bba"
      unitRef="U_USD">412000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_4b3a649c-0ed9-4484-93a7-c704e5a9299c"
      unitRef="U_USD">1274000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_fe1db68b-dcff-44c2-a23f-502010594d18"
      unitRef="U_USD">36729000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_48914609-387b-4fc1-bfd7-ab8bb030325c"
      unitRef="U_USD">68651000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_8a4c2748-6c4d-4a76-ac79-8da8dcf1e759"
      unitRef="U_USD">1148000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_84db9ae4-b12f-40e9-b46b-11fa7cfc440a"
      unitRef="U_USD">2917000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_979ae2a2-ccc5-42cc-971d-5bbc87ce8103"
      unitRef="U_USD">3877000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_6ce8ced8-5fda-4924-a003-ed4b1923a088"
      unitRef="U_USD">4678000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_4458b57a-bb62-41ef-adf0-c199cd54eac9"
      unitRef="U_USD">173000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_003338e8-bbdb-4aaa-bad9-3d254b049029"
      unitRef="U_USD">87000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_1bb9fbb1-3976-4054-b21a-be58cceb0b66"
      unitRef="U_USD">5198000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_3e1da1e1-427a-47e0-af8f-4bba73e94af0"
      unitRef="U_USD">7682000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_e9fbd97d-a8ea-4fae-8466-3aacdb2aa58a"
      unitRef="U_USD">1334000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_3b5450af-20b1-4752-acbb-78d538593315"
      unitRef="U_USD">0</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_cf3fb3f8-4a2e-4a13-a4d0-b60e625cb254"
      unitRef="U_USD">145000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_77411462-e7aa-4583-91f4-cbeb8dde1c98"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_8bc6c65f-f03e-4193-99c0-5559b0660c12"
      unitRef="U_USD">6677000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_ecb3566f-593e-45ad-8a4f-a89a6af5780a"
      unitRef="U_USD">7682000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="INF"
      id="F_a7d4cbe2-2bdf-42fc-b8eb-9e1511ba467b"
      unitRef="U_USDollarShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="INF"
      id="F_ea5aba8e-1be2-4eb7-9098-2921d56a0e56"
      unitRef="U_USDollarShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="INF"
      id="F_9e3fd3dc-5da4-4a70-a6a9-3d4dd0cd5e94"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="INF"
      id="F_8cf08ae3-1b4b-4fc5-8251-d2a2177f3de6"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="INF"
      id="F_629bc0a9-f086-4dc1-8f4c-1321b988bcc6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="INF"
      id="F_7525ef1e-e39a-49dc-9d29-38866e3fe1ae"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="INF"
      id="F_885115c8-2bf7-47e5-80b2-483ea8c8ba60"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="INF"
      id="F_bc9af3e8-81d9-4a1f-b29f-a312bf24f4fe"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_a70709f7-6038-43e1-aae2-7a00c5f54ace"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_75f60bd2-c81a-4268-b8a4-875d57edc282"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="INF"
      id="F_c3cdd683-ff47-43fb-8610-aff515210255"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="INF"
      id="F_60a4e10d-b86f-4b33-ab0d-c21ce974f168"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="INF"
      id="F_eca027be-c8af-495a-9854-9320e165faae"
      unitRef="U_shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="INF"
      id="F_1b1bc9f9-1722-42de-aeff-647cf4b0f304"
      unitRef="U_shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_95b89420-de2f-4568-bd45-73cfaca6e88c"
      unitRef="U_shares">2948000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_3f7f65e5-e0df-4e50-9fe4-a90546f76fe4"
      unitRef="U_shares">2948000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_edb007c4-9009-4b07-9be9-befe9ca6fb3b"
      unitRef="U_shares">2874000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_7c8d5ae0-869e-4f63-b218-4b57a4efded2"
      unitRef="U_shares">2874000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_ee933cbc-b95d-4505-9523-ee8d589ef804"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_daa650d6-aef3-4386-b86b-ffa3568c43e6"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_d44122d7-d11b-4d6f-92cb-0482fe6a3bbf"
      unitRef="U_USD">227825000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_44b64fff-1011-4edf-9cc9-b87d8566b5e5"
      unitRef="U_USD">219257000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_c809ec37-7e79-4f57-9dea-72777cdeb179"
      unitRef="U_USD">3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_3dfc5a86-f0fa-4a8d-8610-9769f58df0c9"
      unitRef="U_USD">9000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_5ba1ab22-d522-4a65-84c8-8697714e6bfd"
      unitRef="U_USD">-197779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_4ffd2c99-c9b7-49f5-bcb2-1f884ddf8a24"
      unitRef="U_USD">-158300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_68a3ce19-3990-44d1-8f9d-fe9b5cdeccbe"
      unitRef="U_USD">30052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_7ebad1fd-5752-4f91-a022-e6f1f420db6c"
      unitRef="U_USD">60969000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_8fad6f91-48d7-4cab-befb-6c699b875622"
      unitRef="U_USD">36729000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_eb112e88-d154-420a-8745-b9f356d3cbf9"
      unitRef="U_USD">68651000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_545bfd90-7ab1-4031-9271-88d166669256"
      unitRef="U_USD">785000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_14e883a6-d555-474e-9449-61fd805996f3"
      unitRef="U_USD">1490000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_faf32110-ad7e-43b5-b636-eb9dde63dad2"
      unitRef="U_USD">29753000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_411438ef-cdfd-4897-b363-699e5cec6635"
      unitRef="U_USD">32980000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_8ca16fce-d20c-45b2-afb4-9b6a00d7e19a"
      unitRef="U_USD">12746000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_2f24750f-2992-4c0e-adf3-d291d91f1cfc"
      unitRef="U_USD">13457000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_3dd1d7ba-3e8c-4862-95a6-802a1b2576f7"
      unitRef="U_USD">42499000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_a8cf893f-b320-4406-bdc7-1ed8101b4fb7"
      unitRef="U_USD">46437000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_da8be38b-64e0-412d-afbd-01861c3ca6ca"
      unitRef="U_USD">-41714000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_57b273b6-5289-4c2c-b9cb-78e9a0c0d2f4"
      unitRef="U_USD">-44947000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_b15f2fa0-39c5-4662-9694-91778a30e3c4"
      unitRef="U_USD">2235000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_02a0c224-ff29-4833-855e-3cceaf3553c5"
      unitRef="U_USD">777000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_7380cc02-1572-415f-b2f6-58e46cf76ebf"
      unitRef="U_USD">-39479000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_2ff6e934-2cee-4eb8-bb94-24916f24f4bf"
      unitRef="U_USD">-44170000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_c973cf0f-0466-4128-98c9-07c659835e10"
      unitRef="U_USD">-6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_a1c632da-a128-49f5-932a-81d93a5e5038"
      unitRef="U_USD">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_ab0bbe16-7363-4f87-bd77-9362c9505d8d"
      unitRef="U_USD">-39485000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_a446a116-3864-4984-b970-ef84d5860fb9"
      unitRef="U_USD">-44161000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="2"
      id="F_7faf2d43-be14-4bb1-8871-6d81a64482b6"
      unitRef="U_USDollarShare">-13.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="2"
      id="F_201d1c4f-a503-4168-816c-83e6b1f7c679"
      unitRef="U_USDollarShare">-13.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="2"
      id="F_98f1cc88-5b6c-407a-9189-f5f4e967afda"
      unitRef="U_USDollarShare">-16.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="2"
      id="F_30158169-2d1a-47ea-b038-f0be182dcd6b"
      unitRef="U_USDollarShare">-16.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_9ce3999f-73fb-48e3-83b9-679e56e57f2a"
      unitRef="U_shares">2940000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_8bd17dea-9eaf-4d9d-90a7-804248542ef0"
      unitRef="U_shares">2940000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_e14fa655-a680-4197-be5a-a945c7868a5a"
      unitRef="U_shares">2630000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_ad634c8a-c86a-426a-a014-83416ca45001"
      unitRef="U_shares">2630000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_d6956472-c16e-494e-ba5a-2129fea85ad2"
      unitRef="U_USD">-39479000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_8559b416-0c57-4006-a4b2-bbe78ae0467d"
      unitRef="U_USD">-44170000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_549c6f3c-8365-4463-9190-6d6c15bcb264"
      unitRef="U_USD">7500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_baef4213-61ef-4165-9e5c-4b953cf503ca"
      unitRef="U_USD">7431000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_851594e4-86ad-4e11-9878-02cf155e0543"
      unitRef="U_USD">1633000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_642a576c-9279-48cf-8fe4-4ffe6083d60e"
      unitRef="U_USD">75000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <onct:NoncashLeaseExpense
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_35d9c405-0d35-4c4a-8124-ccdd21219dc4"
      unitRef="U_USD">174000</onct:NoncashLeaseExpense>
    <onct:NoncashLeaseExpense
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_8f4b7c29-4e35-4afc-a779-91d74bc2a80c"
      unitRef="U_USD">179000</onct:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_01d162b5-77c0-4953-ae7d-64c43f0efdb5"
      unitRef="U_USD">-2624000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_7a2144f9-6461-4c1d-b7a4-d45985f1e735"
      unitRef="U_USD">2095000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_f3201021-28be-44c0-bed3-171acdde2f7b"
      unitRef="U_USD">-1769000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_05f71a8c-40bb-47a6-bb44-053570352b18"
      unitRef="U_USD">958000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_3d6d0acd-1dd6-48e5-987a-2d7ac55cdd1a"
      unitRef="U_USD">-801000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_d9b35030-7035-4bef-b06a-0a82c7ef1638"
      unitRef="U_USD">1247000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_2d4577f5-4aae-4993-9813-15be7d2bde26"
      unitRef="U_USD">1334000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_ff53fa80-a3f6-47ef-a96c-ad4110e20342"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_8d536f3d-1485-4fd8-b6ec-578db7b2a7c9"
      unitRef="U_USD">-114000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_38dc56d3-45d4-4e16-9094-046a1c03a899"
      unitRef="U_USD">-179000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_62c7281c-d149-40d2-9d0a-b7146b23692c"
      unitRef="U_USD">-32164000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_13954250-b35c-44cc-81a8-27d3176158d5"
      unitRef="U_USD">-36704000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_128153ec-c1d5-4806-bbc5-04a427e16806"
      unitRef="U_USD">64349000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_50edae7d-fb22-4f20-8fdb-b11c27bf9855"
      unitRef="U_USD">26498000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_f58c7f01-fe45-40ce-b505-6aa6bbd3203f"
      unitRef="U_USD">65000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_41a45fc6-91c6-4ed0-a6cd-128b4a415ffc"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_9b266694-75d1-4e59-8ab2-f73caf06d369"
      unitRef="U_USD">651000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_4ec2e686-e4f0-4a05-bf5a-bbf0a825531d"
      unitRef="U_USD">-26498000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_4df20756-6ef7-4ebf-adc0-1dac1c4d5b78"
      unitRef="U_USD">1224000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_8f083bc8-71a3-4149-9438-448f6567d2d1"
      unitRef="U_USD">9582000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_72898f4c-404b-4439-af62-0d855541b428"
      unitRef="U_USD">156000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_efa59dd0-2612-45d7-9671-5f28131a282f"
      unitRef="U_USD">3000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_e1865bba-4faa-457d-a3e1-adc9e3b10c7e"
      unitRef="U_USD">1068000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_74c41bf4-e556-43fa-ad03-206ea8424445"
      unitRef="U_USD">9579000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_3cd8ee6f-1d1c-46f3-b2ae-91a1d418a8d3"
      unitRef="U_USD">-30445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_ae6d4b63-a6fd-430c-a5f9-7a1da756e17d"
      unitRef="U_USD">-53623000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_703a878a-7ae1-4cc3-bb41-a3aa91057d66"
      unitRef="U_USD">37142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd"
      decimals="-3"
      id="F_789defe3-510e-4aa2-b3e5-dc63db9ee5df"
      unitRef="U_USD">90765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_5f81ebeb-1957-4496-adac-328e65ed1483"
      unitRef="U_USD">6697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_1902cfcd-1854-4bf0-a0ea-e9386ebc0932"
      unitRef="U_USD">37142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_c3695b07-a8a4-4a4d-afec-dd34e60f009a"
      unitRef="U_USD">345000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_b223f3f2-45fa-4ea4-aa4a-5258c82ef0df"
      unitRef="U_USD">191000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b28e1922-05f1-4509-a2c3-99e3ae9adb2f"
      decimals="INF"
      id="F_278bbafa-78fe-426e-841e-83e2d81f4ff7"
      unitRef="U_shares">2471000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b28e1922-05f1-4509-a2c3-99e3ae9adb2f"
      decimals="-3"
      id="F_9fbef201-9e5f-4338-aaf8-4f43017f1ba3"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a954e431-fdf8-4bae-8667-e303c67e3782"
      decimals="-3"
      id="F_26158b6f-1249-4203-b3ff-43e9d93358cd"
      unitRef="U_USD">202248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_098930be-5884-474e-975f-9a2650ccb706"
      decimals="-3"
      id="F_3cfd7676-a20b-40c3-b58f-9463f4268b9b"
      unitRef="U_USD">-114130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd"
      decimals="-3"
      id="F_214ec329-df50-4820-8ef5-a2fb5c3e5da7"
      unitRef="U_USD">88120000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_c017e56b-170f-4dc3-b36e-25ea2fda7fa5"
      unitRef="U_USD">375000</us-gaap:PaymentsOfStockIssuanceCosts>
    <onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares
      contextRef="C_cfadbdac-a035-479c-8d33-fb8090124ed6"
      decimals="INF"
      id="F_8bf82836-c3c2-41a4-bb21-76b7f134c873"
      unitRef="U_shares">403000</onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares>
    <onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
      contextRef="C_cfadbdac-a035-479c-8d33-fb8090124ed6"
      decimals="-3"
      id="F_82ccf4a8-ba0f-482a-9b9a-3aa0da4f6c08"
      unitRef="U_USD">1000</onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts>
    <onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
      contextRef="C_d80acc3e-af09-4afd-b5cf-5196b734c37c"
      decimals="-3"
      id="F_7c1f3e58-629c-4249-86de-2b05457a4d35"
      unitRef="U_USD">9581000</onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts>
    <onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_e6b42eb2-2963-4619-b18b-2ef70c204566"
      unitRef="U_USD">9582000</onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_d80acc3e-af09-4afd-b5cf-5196b734c37c"
      decimals="-3"
      id="F_79344d83-a309-4623-921f-351fb8ce39c6"
      unitRef="U_USD">-3000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_86f96b0a-8fb9-4620-a973-775319c0c347"
      unitRef="U_USD">-3000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d80acc3e-af09-4afd-b5cf-5196b734c37c"
      decimals="-3"
      id="F_124bb71e-93d1-4817-953e-13e99f0a627f"
      unitRef="U_USD">7431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_458f17ed-1617-47b7-a984-28a4a6e111df"
      unitRef="U_USD">7431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_2fc5f62a-291e-46d8-9a20-5a29e0475095"
      decimals="-3"
      id="F_5604f27c-3e64-491c-b62c-73523b420443"
      unitRef="U_USD">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_3f95ebb5-7111-49d1-871d-27e6346b481e"
      unitRef="U_USD">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_bf9fff34-6f4a-4470-8d7d-50c7f427439f"
      decimals="-3"
      id="F_93e33bbc-33a3-45b2-946e-b8e7b7773720"
      unitRef="U_USD">-44170000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_dcf922ce-aa3a-4010-b45e-bb65d7cf9d47"
      unitRef="U_USD">-44170000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f73bd1b2-ebe8-43b0-9837-980ac35e9116"
      decimals="INF"
      id="F_822fa259-8ca0-4ed4-9448-0fad234eea08"
      unitRef="U_shares">2874000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f73bd1b2-ebe8-43b0-9837-980ac35e9116"
      decimals="-3"
      id="F_6e3ff626-f6ac-42b2-8304-3305137bc4a3"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bb2712dc-866f-414f-a8f2-3c9dde12d934"
      decimals="-3"
      id="F_dd3d8b58-5783-4d85-ba18-4bd1fe88afb2"
      unitRef="U_USD">219257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d4d11d3c-bc06-418b-a44d-1f7e43dc53ca"
      decimals="-3"
      id="F_8052cbf1-74d7-4968-9285-4d60b9fc8c9c"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8e7e0a37-b10a-43a8-b067-4e1f34e10da0"
      decimals="-3"
      id="F_b7f47c6e-b33f-475e-b83f-b42bc5986db8"
      unitRef="U_USD">-158300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_b6bb20a4-0138-4ef9-9d58-f90ceacef909"
      unitRef="U_USD">60969000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_09685ad2-c995-4000-9604-cbf142680c26"
      unitRef="U_USD">38000</us-gaap:PaymentsOfStockIssuanceCosts>
    <onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares
      contextRef="C_86f3153e-89c6-4d7e-ae5d-a42564364970"
      decimals="INF"
      id="F_8efb8a4c-a2e1-4025-b052-6f68ff0d579d"
      unitRef="U_shares">55000</onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares>
    <onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
      contextRef="C_f27580a4-262d-49d1-b2c6-fb20b05f065f"
      decimals="-3"
      id="F_d2d526e7-ab4a-41e0-bce1-1e961bd74fda"
      unitRef="U_USD">1224000</onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts>
    <onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_25b819b3-6fd5-4540-abca-f682b3988aab"
      unitRef="U_USD">1224000</onct:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_86f3153e-89c6-4d7e-ae5d-a42564364970"
      decimals="INF"
      id="F_15937d6e-428d-48ef-ada6-9d4361a3bb2f"
      unitRef="U_shares">30000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_86f3153e-89c6-4d7e-ae5d-a42564364970"
      decimals="INF"
      id="F_5df447ce-aa17-487e-9755-626748572de6"
      unitRef="U_shares">-11000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_f27580a4-262d-49d1-b2c6-fb20b05f065f"
      decimals="-3"
      id="F_69e6840b-4cb4-4e10-82b9-5049e5b7645e"
      unitRef="U_USD">-156000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_7c9ab630-b81e-4178-b6f4-cac762e274c9"
      unitRef="U_USD">-156000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f27580a4-262d-49d1-b2c6-fb20b05f065f"
      decimals="-3"
      id="F_c3ade514-9342-4d6a-a235-7440a9020edb"
      unitRef="U_USD">7500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_3b244eaf-6f5b-4214-b382-b791951b9084"
      unitRef="U_USD">7500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_2eeadccf-0f17-4175-823b-dbcd8f8dac1a"
      decimals="-3"
      id="F_5dd3adfd-81ed-4372-8bdf-485e6eedfd86"
      unitRef="U_USD">-6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_b1410ce7-fb70-4f5e-a903-9dd55a46ab27"
      unitRef="U_USD">-6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_4d7bbaa5-7054-4572-8d82-9320f96f8511"
      decimals="-3"
      id="F_c1c44ded-9813-4eb2-8c9f-ea2b59b0f4d1"
      unitRef="U_USD">-39479000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_3ecb19b1-f04f-4a3e-b477-669554c0cfbc"
      unitRef="U_USD">-39479000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_83e4c228-480e-409e-8176-6d50e59820db"
      decimals="INF"
      id="F_a55535e2-7be7-44f9-bcd5-11c937e97753"
      unitRef="U_shares">2948000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_83e4c228-480e-409e-8176-6d50e59820db"
      decimals="-3"
      id="F_098a75bf-2e45-492a-bbc4-fd763f8576e2"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_62fa3949-0347-4273-b069-49f2fd0e5194"
      decimals="-3"
      id="F_062d2721-202d-4842-9bb6-939f2e4f34cb"
      unitRef="U_USD">227825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a3d6b78d-a32d-49a2-80f4-722dd0cb10ca"
      decimals="-3"
      id="F_3651eee4-837e-43d2-9f4a-ae2b46375cbe"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_30d36d96-6cac-47d1-9709-bc013ca4bfac"
      decimals="-3"
      id="F_549c4ac7-8a96-4715-bce5-3c3bd3924bce"
      unitRef="U_USD">-197779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_749ef4a1-3aab-4438-90b6-0b187a7bbbda"
      unitRef="U_USD">30052000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_f25df9fe-384d-460b-9058-c2876b21c07a">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Description of Business, Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Oncternal Therapeutics, Inc. (the &#x201c;Company,&#x201d; &#x201c;Oncternal,&#x201d; or the &#x201c;combined company&#x201d;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#x2019;s clinical pipeline includes ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers and ONCT-808, a CAR T (chimeric antigen receptor T-cells) product candidate that targets ROR1, and zilovertamab, a humanized monoclonal antibody that binds to ROR1. Oncternal&#x2019;s program activities previously included ONCT-216, an investigational small molecule designed to inhibit the E26 Transformation Specific (&#x201c;ETS&#x201d;) family of oncoproteins.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash, cash equivalents, and short-term investments, no debt and an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. From its inception, the Company has incurred recurring operating losses and negative cash flows from operations. The Company has concluded that the balance of cash, cash equivalents and short-term investments will not be sufficient to fund its planned expenditures and meet its obligations for the twelve months following the financial statement issuance date without raising additional funding or making changes to its operating plans or programs to reduce expenses. As a result, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for twelve months following the issuance date of these consolidated financial statements. The consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;          &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of its pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had capacity to issue up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock under its at-the-market (&#x201c;ATM&#x201d;) equity offering program. Through December 31, 2023, the Company has sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;457,342&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the ATM program. There can be no assurance that the Company will be able to sell any additional shares of its common stock under the ATM program and no assurance regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM program may be at prices that result in additional dilution to existing stockholders of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nasdaq Listing and Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 4, 2023, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) indicating that because the closing bid price for the Company&#x2019;s common stock had closed below $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#x201c;Minimum Bid Requirement&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 8, 2024, the Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1-for-20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reverse stock split of its issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company regained compliance with the Nasdaq listing rules. Each of the Company&#x2019;s shareholders received one new share of common stock for every 20 shares such shareholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#x2019;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock was not adjusted as a result of the Reverse Stock Split. The Reverse Split also affected the Company&#x2019;s outstanding common stock options and warrants, and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data, common stock options and warrants included in these consolidated financial statements, including the exercise price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of accruals for research and development costs. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist of Level 1 financial instruments in the fair value hierarchy (see Note 6 &#x2013; Fair Value) and include cash in readily available checking accounts, money market accounts and commercial paper.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments consist of U.S. treasury notes and bills, certificates of deposit, commercial paper and U.S. government sponsored enterprise securities with maturities of less than one year from the balance sheet date and are debt securities considered to be Level 1 and Level 2 financial instruments in the fair value hierarchy (see Note 6 &#x2013; Fair Value).  The Company determines the appropriate classification of marketable securities at the time of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;purchase and reevaluates such designation at each balance sheet date.  The Company has classified all of its marketable securities at December 31, 2023 and 2022 as &#x201c;available-for-sale&#x201d; pursuant to ASC 320 Investments &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The Company records available-for-sale securities at fair value as determined by prices for identical or similar securities, with the unrealized gains and losses included as a separate component of other accumulated comprehensive income (loss).  In accordance with policy, the Company does not invest in or hold equity securities in its investment portfolio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company adjusts the cost of available-for-sale debt securities for amortization of premiums or accretion of discounts to maturity.  The Company includes interest and dividends on securities classified as available-for-sale in interest income.  Such amortization and accretion are included in interest income.  The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Realized gains or losses on available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company records unrealized gains and losses on available-for-sale marketable securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders&#x2019; equity on the balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in short-term investments in the accompanying consolidated balance sheets. The Company&#x2019;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which the Company determines the accrued interest will not be collected.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates short-term investments for other-than-temporary impairment at the balance sheet date.  Factors considered in determining whether a loss is other-than temporary include how significant the decline in value is as a percentage of the original cost, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company&#x2019;s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized loss positions until their amortized cost basis has been recovered.  As of December 31, 2023 and 2022, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment charges on short-term investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company obtains the fair value of its available-for-sale marketable securities from a professional pricing service. The fair values of available-for-sale marketable securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank. The service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service or mathematical calculations. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, credit spreads, current market and contractual prices for the underlying instruments or debt, as well as other relevant economic measures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred compensation represents the accrual of retention bonuses for certain executives and certain other members of senior management.  The retention bonuses were entered into in connection with the waiver of annual cash performance bonuses of such personnel for the year ended December 31, 2023 and a temporary reduction of the chief executive officer&#x2019;s salary from April 2023 through December 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, which include clinical trial accruals, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as an exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;develop its own assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, and accrued compensation. The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has short-term investments that are measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented (see Note 6).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company generates revenue from certain grant awards or a research subaward (the &#x201c;Grant Awards&#x201d;) (see Note 5), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment in the United States.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:52.33%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;737,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Statements (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net loss. This update is effective for the Company and was adopted on January 1, 2023, which did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting &#x2013; Improvements to Reportable Segment Disclosures (Topic 280), which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. Topic 280 includes amendments which a) introduce a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker&#x202f;(CODM), b) extend &#x202f;certain annual disclosures to interim periods, c) clarify single reportable segment entities must apply ASC 280 in its entirety, d) permit more than one measure of segment profit or loss to be reported under certain conditions, and e) require disclosure of the title and position of the CODM.  This update is effective for all public entities beginning after December 15, 2023. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Tax &#x2013; Improvements to Income Tax Disclosures, which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. The standard requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This update is effective for all public entities beginning after December 15, 2024. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_17e5a266-615a-49f1-acd4-f6cc8ce53745">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <onct:GoingConcernPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_f6f77880-d7ff-4592-ae58-76cb85597d20">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash, cash equivalents, and short-term investments, no debt and an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. From its inception, the Company has incurred recurring operating losses and negative cash flows from operations. The Company has concluded that the balance of cash, cash equivalents and short-term investments will not be sufficient to fund its planned expenditures and meet its obligations for the twelve months following the financial statement issuance date without raising additional funding or making changes to its operating plans or programs to reduce expenses. As a result, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for twelve months following the issuance date of these consolidated financial statements. The consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;          &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of its pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had capacity to issue up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock under its at-the-market (&#x201c;ATM&#x201d;) equity offering program. Through December 31, 2023, the Company has sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;457,342&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the ATM program. There can be no assurance that the Company will be able to sell any additional shares of its common stock under the ATM program and no assurance regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM program may be at prices that result in additional dilution to existing stockholders of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&lt;/span&gt;&lt;/p&gt;</onct:GoingConcernPolicyTextBlock>
    <onct:CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-5"
      id="F_e81be9e1-d179-43d6-9298-0403c77d7ed3"
      unitRef="U_USD">34300000</onct:CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-5"
      id="F_9e9f7a0b-1ec3-4d61-b268-a3f6d796977a"
      unitRef="U_USD">-197800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb"
      decimals="-5"
      id="F_58baebb7-bbf2-4d97-9e9b-4e923dada47d"
      unitRef="U_shares">38800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_cbe31993-74d8-4712-92b5-682ceee9fb09"
      decimals="INF"
      id="F_f1b7cf3d-04f6-4ebb-bacd-94071ed7a151"
      unitRef="U_shares">457342</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_cbe31993-74d8-4712-92b5-682ceee9fb09"
      decimals="-5"
      id="F_7a612739-1e93-43aa-8dbc-fea090f49bcb"
      unitRef="U_USD">10800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <onct:NasdaqListingAndReverseStockSplitPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_f9649b97-c14c-471a-adc0-636951129ed4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nasdaq Listing and Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 4, 2023, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) indicating that because the closing bid price for the Company&#x2019;s common stock had closed below $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#x201c;Minimum Bid Requirement&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 8, 2024, the Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1-for-20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reverse stock split of its issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company regained compliance with the Nasdaq listing rules. Each of the Company&#x2019;s shareholders received one new share of common stock for every 20 shares such shareholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#x2019;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock was not adjusted as a result of the Reverse Stock Split. The Reverse Split also affected the Company&#x2019;s outstanding common stock options and warrants, and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data, common stock options and warrants included in these consolidated financial statements, including the exercise price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/p&gt;</onct:NasdaqListingAndReverseStockSplitPolicyTextBlock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_24db6605-9fb8-4748-a200-1daa7520b56f"
      decimals="2"
      id="F_ff39426b-1160-4699-b635-ca1a79d95b0c"
      unitRef="U_USDollarShare">1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_dd4a10dd-2b20-4eb7-a455-5be36a531fe8"
      id="F_6befb006-e366-4d35-9f39-6fdddfadc6d6">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:UseOfEstimates
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_716a8897-3fa4-4611-85c4-2319e022cd25">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of accruals for research and development costs. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_4c7eb4e5-7dab-4018-8e6e-e0c257789246">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist of Level 1 financial instruments in the fair value hierarchy (see Note 6 &#x2013; Fair Value) and include cash in readily available checking accounts, money market accounts and commercial paper.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_c7d24eda-dfa0-4ab3-9e7b-3fa28ca1d9bf">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments consist of U.S. treasury notes and bills, certificates of deposit, commercial paper and U.S. government sponsored enterprise securities with maturities of less than one year from the balance sheet date and are debt securities considered to be Level 1 and Level 2 financial instruments in the fair value hierarchy (see Note 6 &#x2013; Fair Value).  The Company determines the appropriate classification of marketable securities at the time of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;purchase and reevaluates such designation at each balance sheet date.  The Company has classified all of its marketable securities at December 31, 2023 and 2022 as &#x201c;available-for-sale&#x201d; pursuant to ASC 320 Investments &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The Company records available-for-sale securities at fair value as determined by prices for identical or similar securities, with the unrealized gains and losses included as a separate component of other accumulated comprehensive income (loss).  In accordance with policy, the Company does not invest in or hold equity securities in its investment portfolio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company adjusts the cost of available-for-sale debt securities for amortization of premiums or accretion of discounts to maturity.  The Company includes interest and dividends on securities classified as available-for-sale in interest income.  Such amortization and accretion are included in interest income.  The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Realized gains or losses on available-for-sale securities are determined using the specific identification method and net realized gains and losses are included in interest income. The Company records unrealized gains and losses on available-for-sale marketable securities as a component of other comprehensive loss within the statements of comprehensive loss and as a separate component of stockholders&#x2019; equity on the balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in short-term investments in the accompanying consolidated balance sheets. The Company&#x2019;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which the Company determines the accrued interest will not be collected.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates short-term investments for other-than-temporary impairment at the balance sheet date.  Factors considered in determining whether a loss is other-than temporary include how significant the decline in value is as a percentage of the original cost, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company&#x2019;s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold any investments in unrealized loss positions until their amortized cost basis has been recovered.  As of December 31, 2023 and 2022, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment charges on short-term investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company obtains the fair value of its available-for-sale marketable securities from a professional pricing service. The fair values of available-for-sale marketable securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from the custodian bank. The service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service or mathematical calculations. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, credit spreads, current market and contractual prices for the underlying instruments or debt, as well as other relevant economic measures.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="INF"
      id="F_1180fe21-ceef-46d2-9798-ae6e0686b9d8"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="INF"
      id="F_f012fb60-3672-4f3b-a305-8a6d187542ae"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_474fe9a4-5689-4ff2-9961-c6e26de7820a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred compensation represents the accrual of retention bonuses for certain executives and certain other members of senior management.  The retention bonuses were entered into in connection with the waiver of annual cash performance bonuses of such personnel for the year ended December 31, 2023 and a temporary reduction of the chief executive officer&#x2019;s salary from April 2023 through December 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <onct:ConcentrationRiskCreditRiskPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_bf91c41a-e1d7-49d9-aed3-606bdee0a988">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/span&gt;&lt;/p&gt;</onct:ConcentrationRiskCreditRiskPolicyTextBlock>
    <onct:PatentCostsPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_9dcf2787-6f39-4ae0-a09c-421008e89bf4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;</onct:PatentCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_115fb645-b971-4515-8fbd-3696f1ae9e81">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, which include clinical trial accruals, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_ae1ed852-f00d-4ece-a2bf-b6ed4c80efb1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as an exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. These tiers are based on the source of the inputs and are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;develop its own assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable, accrued expenses, and accrued compensation. The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has short-term investments that are measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented (see Note 6).&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_36ab95ef-3e2b-4b93-b8c8-157ac7b81ae8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company generates revenue from certain grant awards or a research subaward (the &#x201c;Grant Awards&#x201d;) (see Note 5), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_073b6acc-fcd6-4181-b4d1-b919d5bb8d25">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_e930ad23-b5de-4128-aa3b-404d1fbe3f5b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_36c1b999-5311-47ae-babb-58ee7edc3142">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="INF"
      id="F_b1bbf1e5-9952-41d4-978e-48446f4373f9"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_3e6690c1-7b30-4eb1-93d1-0cc2c1f405cb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:52.33%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;737,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_a4832dc7-e5eb-4619-9e05-53167578e779">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:52.33%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;737,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f23d092f-edc0-4d76-893a-ca1ffe860492"
      decimals="0"
      id="F_16927502-aa83-4c25-a8af-cc7f64e65a57"
      unitRef="U_shares">170521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f742e918-e6dc-4348-81a6-2801923bd3ec"
      decimals="0"
      id="F_c86e5240-4a83-4e88-8ee2-753aab403833"
      unitRef="U_shares">170521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ebd6887c-a70a-4f63-862c-61c7842c1226"
      decimals="0"
      id="F_f6de7473-fbe8-4eeb-92df-fdcc49a7e22e"
      unitRef="U_shares">548073</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a7fcd6fe-26a1-4370-be58-59d9b95517db"
      decimals="0"
      id="F_7317b883-af5b-4ca6-982b-d15c65f6cfe6"
      unitRef="U_shares">425785</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      decimals="0"
      id="F_7dad2efc-1529-450d-9878-6defde821ca2"
      unitRef="U_shares">18557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5b521705-9521-4715-a360-b03c0afb492c"
      decimals="0"
      id="F_81cf4598-0565-41d3-81d9-d6a7c8bcbf1a"
      unitRef="U_shares">50454</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="0"
      id="F_ae9d5a26-85dc-440c-b797-7211f0988d93"
      unitRef="U_shares">737151</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="0"
      id="F_a3b1d5a0-574d-44a5-a047-e4a7c1b2be91"
      unitRef="U_shares">646760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_993cedb7-618c-4e32-8413-99aadd3bba36">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Statements (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net loss. This update is effective for the Company and was adopted on January 1, 2023, which did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting &#x2013; Improvements to Reportable Segment Disclosures (Topic 280), which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. Topic 280 includes amendments which a) introduce a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker&#x202f;(CODM), b) extend &#x202f;certain annual disclosures to interim periods, c) clarify single reportable segment entities must apply ASC 280 in its entirety, d) permit more than one measure of segment profit or loss to be reported under certain conditions, and e) require disclosure of the title and position of the CODM.  This update is effective for all public entities beginning after December 15, 2023. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Tax &#x2013; Improvements to Income Tax Disclosures, which intends to improve financial reporting primarily through enhanced disclosures about significant segment expenses. The standard requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This update is effective for all public entities beginning after December 15, 2024. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_6bb4c7c9-50df-4e61-bc2c-c5f18ccf28ed">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Balance Sheet Details&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid and other consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.681%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.605%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.681%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.605%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Related party receivable (see Note 4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Grant and other receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.991%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.959%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.415999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.915%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legal fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <onct:ScheduleOfAccountsPrepaidAndOtherTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_e803ee86-030c-4c42-9262-fb24f04f659c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid and other consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.681%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.605%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.681%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.605%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Related party receivable (see Note 4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Grant and other receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</onct:ScheduleOfAccountsPrepaidAndOtherTableTextBlock>
    <onct:PrepaidResearchAndDevelopmentExpense
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_30bbed3e-eff4-4dcf-b145-6674072d7a02"
      unitRef="U_USD">312000</onct:PrepaidResearchAndDevelopmentExpense>
    <onct:PrepaidResearchAndDevelopmentExpense
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_975348be-23f9-4cbd-8628-d8ebe3c4dffa"
      unitRef="U_USD">0</onct:PrepaidResearchAndDevelopmentExpense>
    <onct:PrepaidClinicalTrialsExpense
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_fb211e2a-3442-4b3c-97cf-2aa00c022cb6"
      unitRef="U_USD">294000</onct:PrepaidClinicalTrialsExpense>
    <onct:PrepaidClinicalTrialsExpense
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_54ee9359-3bbc-4c17-af85-ee8771ea46e3"
      unitRef="U_USD">2616000</onct:PrepaidClinicalTrialsExpense>
    <us-gaap:PrepaidInsurance
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_ac1a39b1-716a-4237-8ab5-d925272f9b2e"
      unitRef="U_USD">478000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_e80aec49-02ee-4045-a60c-7202d7d45890"
      unitRef="U_USD">669000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_fda8f267-8fa7-4d29-aaeb-38c6d20b3fa4"
      unitRef="U_USD">88000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_072d2b41-2b1b-4879-8399-b3f6856508c7"
      unitRef="U_USD">103000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="C_64618a52-3613-4a92-9d8a-011deabe6e3d"
      decimals="-3"
      id="F_74019477-af8e-4816-9f7f-50c5b89064e6"
      unitRef="U_USD">139000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_c7417c2f-59d7-47f2-b82f-869b45d68de1"
      decimals="-3"
      id="F_77319c26-fc69-4dbb-8609-3385fbddba41"
      unitRef="U_USD">0</us-gaap:AccountsReceivableNet>
    <onct:OtherReceivablesNetCurrentIncludingGrant
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_b5b98335-7d95-49dd-a69a-30fc8b881a96"
      unitRef="U_USD">493000</onct:OtherReceivablesNetCurrentIncludingGrant>
    <onct:OtherReceivablesNetCurrentIncludingGrant
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_e05e34fd-7ed2-4840-af19-cee4a6c5fe57"
      unitRef="U_USD">178000</onct:OtherReceivablesNetCurrentIncludingGrant>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_6bf13fe1-194c-4084-8d1e-b81a929c04de"
      unitRef="U_USD">1804000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_2f517a29-200b-40c6-9727-4ab04ca82303"
      unitRef="U_USD">3566000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_3ae633e0-2675-4708-a8e7-fcb6861efc99">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.991%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.959%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.415999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.915%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Legal fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_45c82ae7-924a-4a6b-b9f5-d71200b9d92c"
      unitRef="U_USD">146000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_3359a919-b985-4f8d-90b9-d3a1d07a8382"
      unitRef="U_USD">972000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedClinicalTrials
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_e6799252-65b1-498a-8853-aba20d29be0c"
      unitRef="U_USD">2018000</onct:AccruedClinicalTrials>
    <onct:AccruedClinicalTrials
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_732d8c34-3376-4382-8b92-e88cbbea18c3"
      unitRef="U_USD">868000</onct:AccruedClinicalTrials>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_ba46fed7-5e70-43ab-9d78-f1e4ebf82dc7"
      unitRef="U_USD">134000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_15cd343f-47df-4ad7-a6ac-4e8b9b86bdbf"
      unitRef="U_USD">138000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_fed1302a-5d6a-4494-ad34-8dbaf5706787"
      unitRef="U_USD">1579000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_9d9da905-4c03-4db6-8549-d4c54556a7bb"
      unitRef="U_USD">2691000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_7904746f-4239-4ef1-b7fb-1d37eb9e19a6"
      unitRef="U_USD">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_4e29fe43-eb13-4196-ac5a-db6ed9fe1974"
      unitRef="U_USD">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_9be47a57-8421-4e0f-b5b6-012f720205d4"
      unitRef="U_USD">3877000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_b0f7247a-f828-47a9-9742-fc3197be2c3c"
      unitRef="U_USD">4678000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_99451c80-980f-44ec-9f18-7486a32b2fdc">&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests in available-for-sale marketable securities consisting of money market funds, commercial paper, certificates of deposit, U.S. Treasury securities and U.S. government sponsored enterprise securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Available-for-sale marketable securities with original maturities of more than three months from the date of purchase as of December 31, 2023 have been classified as short-term investments and are measured at a fair value on a recurring basis, and were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.606%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.743%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.862%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.461%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;"&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Available-for-sale marketable securities with original maturities of more than three months from the date of purchase as of December 31, 2022 have been classified as short-term investments and are measured at a fair value on a recurring basis, and were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.606%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.743%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.862%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.461%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_ee1e1737-1e34-4355-a0d8-679b3a702be0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined there were no other-than-temporary declines in the value of any available-for-sale securities as of December 31, 2023. All the Company&#x2019;s available-for-sale marketable securities mature within one year. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; allowance for credit losses as of December 31, 2023 and 2022. During the years ended December 31, 2023, and 2022, the Company recognized an unrealized loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and an unrealized gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, in the accompanying consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0942af95-94b2-4cac-8c0c-f1444938ea88;"&gt;&lt;span style="-sec-ix-hidden:F_cdb93c50-11db-48e2-b68f-a8c32248923f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued interest receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on available-for-sale securities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; at December 31, 2023 and 2022, respectively. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t written off any accrued interest receivable in any of the periods presented in these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_61d78e6c-756c-49d0-a6ec-673f0a69495a">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.606%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.743%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.862%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.461%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;"&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.606%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.743%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.862%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.461%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_ee1e1737-1e34-4355-a0d8-679b3a702be0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <onct:MaturitySecuritiesDebtMaturitiesPeriod1
      contextRef="C_adabef98-d9b7-4120-a5c5-cb803bd266ce"
      id="F_4045e83e-e145-4916-ac12-279bb44f5b92">P1Y</onct:MaturitySecuritiesDebtMaturitiesPeriod1>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c6b88d8c-42b2-44bd-afc8-e948c76c63df"
      decimals="-3"
      id="F_e541fabc-9ad4-468f-a9e1-f50a02452091"
      unitRef="U_USD">23840000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_cf6a6ea3-bfb5-4119-956f-554febc07729"
      decimals="-3"
      id="F_75155b16-1128-4907-844d-ce38e4dd946f"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_cf6a6ea3-bfb5-4119-956f-554febc07729"
      decimals="-3"
      id="F_e05d370f-619a-42c6-908e-3f288b4a7368"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c6b88d8c-42b2-44bd-afc8-e948c76c63df"
      decimals="-3"
      id="F_cd7e463e-d600-4f47-97b1-c1a28857e7fd"
      unitRef="U_USD">23844000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <onct:MaturitySecuritiesDebtMaturitiesPeriod1
      contextRef="C_3fb8e0da-acaa-47c5-a6c1-2e4c104b6914"
      id="F_0465659e-7512-49b9-97f9-d4e12304f84c">P1Y</onct:MaturitySecuritiesDebtMaturitiesPeriod1>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c7403617-2bd9-4378-8e28-1026eb094276"
      decimals="-3"
      id="F_ada8cdee-9e0a-443a-91af-94a88043f8f3"
      unitRef="U_USD">2738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_80c0e7a1-8307-44d0-921c-0a9be8697b02"
      decimals="-3"
      id="F_ff29fa2b-4360-4f7f-a955-3e5e0c789684"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_80c0e7a1-8307-44d0-921c-0a9be8697b02"
      decimals="-3"
      id="F_cf905912-97a3-492f-9a6d-e3e9fddb1a3b"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c7403617-2bd9-4378-8e28-1026eb094276"
      decimals="-3"
      id="F_0e864e2e-d460-4183-8e64-86dc6acdccf8"
      unitRef="U_USD">2737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <onct:MaturitySecuritiesDebtMaturitiesPeriod1
      contextRef="C_dc68c081-7397-41f0-9a80-0bb2d48bf304"
      id="F_27080be1-9d5a-4144-b1f5-b12dc4215d5a">P1Y</onct:MaturitySecuritiesDebtMaturitiesPeriod1>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2ee21224-3ff5-40c8-8d3b-f3bc87c0f528"
      decimals="-3"
      id="F_f9efce03-a2f8-4534-8faa-bbb0d8109eee"
      unitRef="U_USD">977000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_ac63083b-0e54-4d72-845f-1395615d3acc"
      decimals="-3"
      id="F_9bd301a8-1215-494d-a3d1-6123c5567c07"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_ac63083b-0e54-4d72-845f-1395615d3acc"
      decimals="-3"
      id="F_946ddb81-2e5d-4902-ab30-e8226d08ba7f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2ee21224-3ff5-40c8-8d3b-f3bc87c0f528"
      decimals="-3"
      id="F_598d00b9-c88f-47c1-ba06-252fa3153808"
      unitRef="U_USD">977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8bff7594-8784-4e75-992e-1abf18d3a26a"
      decimals="-3"
      id="F_5c5b46b9-7b6b-4df3-9675-a3fe5bf08235"
      unitRef="U_USD">27555000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_18a29548-1851-4d54-88f2-fd40d4620a4f"
      decimals="-3"
      id="F_c20fc62e-9316-4141-843f-ef42a6536dff"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_18a29548-1851-4d54-88f2-fd40d4620a4f"
      decimals="-3"
      id="F_16169e00-39b1-4ed1-b097-9f8bb51ede0b"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8bff7594-8784-4e75-992e-1abf18d3a26a"
      decimals="-3"
      id="F_07aa9719-7467-4112-aa29-4f035892b445"
      unitRef="U_USD">27558000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <onct:MaturitySecuritiesDebtMaturitiesPeriod1
      contextRef="C_7969de4f-8469-45fc-82de-c6f6103bd889"
      id="F_72dd7453-9f8b-4766-86d6-a2174e794661">P1Y</onct:MaturitySecuritiesDebtMaturitiesPeriod1>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3a6930d4-f451-44ee-affa-37ae8d65ee2b"
      decimals="-3"
      id="F_c914e28a-a5e7-41cc-8a0a-0df97418664e"
      unitRef="U_USD">21681000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_075d13c8-bda5-4ad2-bc71-30df6eefa0e7"
      decimals="-3"
      id="F_afba6d6d-4395-4505-87de-7877f051fb7a"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_075d13c8-bda5-4ad2-bc71-30df6eefa0e7"
      decimals="-3"
      id="F_45cd6caf-d580-44b0-8019-01a3057b38f1"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3a6930d4-f451-44ee-affa-37ae8d65ee2b"
      decimals="-3"
      id="F_ed6febc3-c0e7-433b-b5f6-3a1e0c962a49"
      unitRef="U_USD">21688000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <onct:MaturitySecuritiesDebtMaturitiesPeriod1
      contextRef="C_f873de6c-929f-4ec4-8634-115ea3443d28"
      id="F_6690a836-45c9-4beb-921d-ec0a497dc2e0">P1Y</onct:MaturitySecuritiesDebtMaturitiesPeriod1>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c3f1feeb-4862-4bb4-888b-eed88eeb8df2"
      decimals="-3"
      id="F_6c24961b-3c0f-427d-8e95-6103c564245b"
      unitRef="U_USD">2936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_eaf7c44c-5611-4b86-8805-7a0f392d4123"
      decimals="-3"
      id="F_d047d197-df26-4f47-b9d6-c2ba6a57762f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c3f1feeb-4862-4bb4-888b-eed88eeb8df2"
      decimals="-3"
      id="F_9d0e5a5d-1ca4-4dda-82f0-eb7c7ef5edca"
      unitRef="U_USD">2936000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <onct:MaturitySecuritiesDebtMaturitiesPeriod1
      contextRef="C_467dc9e5-7495-40f7-ab23-9880e9cfc171"
      id="F_966c1dad-a698-4861-93ec-c9d488f3fae2">P1Y</onct:MaturitySecuritiesDebtMaturitiesPeriod1>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_10b44321-be1f-47e8-a18e-447594cad864"
      decimals="-3"
      id="F_26a2ed1c-d163-4278-ae73-dc97cd2d8c57"
      unitRef="U_USD">1956000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_9bd0a19a-3bcb-4dee-819e-826450508497"
      decimals="-3"
      id="F_db24a623-6f6f-4492-b8e8-175f779c8b78"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_9bd0a19a-3bcb-4dee-819e-826450508497"
      decimals="-3"
      id="F_8602ceab-25fc-4d72-a93c-15eb007ea4ca"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_10b44321-be1f-47e8-a18e-447594cad864"
      decimals="-3"
      id="F_2de642ee-cadd-4590-9293-6342a9d2a9db"
      unitRef="U_USD">1958000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_08168037-6b24-4204-95ca-d790554ec7eb"
      decimals="-3"
      id="F_f0677993-412c-459b-b497-ff92b4ecf87a"
      unitRef="U_USD">26573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_42761111-9f62-4a8d-88a7-53d404e3f90e"
      decimals="-3"
      id="F_4f072160-f111-410b-986f-1665af963529"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_42761111-9f62-4a8d-88a7-53d404e3f90e"
      decimals="-3"
      id="F_5e6c8a38-445f-45f5-93ed-657a976314ad"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_08168037-6b24-4204-95ca-d790554ec7eb"
      decimals="-3"
      id="F_f06a1eaf-3168-4735-b1a4-bf4a03451dc2"
      unitRef="U_USD">26582000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_7068e389-dbb1-4fd2-b1a1-ecfa2021de8c"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_cdd6c390-783a-4b20-9651-873f983629d7"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="0"
      id="F_cc767e40-5bbf-457f-8683-0aeb4f624bc7"
      unitRef="U_USD">-6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="0"
      id="F_f42ed21b-75da-4d7e-9a7e-81d245dc957c"
      unitRef="U_USD">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="0"
      id="F_6c12d718-8ad4-493a-86d2-827850cdfd33"
      unitRef="U_USD">15000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="0"
      id="F_c83a075d-266c-47a1-8e61-3d622e0c356d"
      unitRef="U_USD">116000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_e18033b5-fd88-4312-bc4d-8fa0f5989ede"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_7df48caa-f383-42b2-854b-3f3be5a58b4a"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_e7f6012f-4a2b-43ef-bc84-d15fdab40767">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments, Contingencies and Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rent expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2022. From May 2019 through April 2022, the Company leased office space in San Diego, California. In April 2022, the Company entered into a sublease agreement for office space in San Diego, California which expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_cb4bed05-8324-4d04-8ccd-d2135d259695;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;July 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;San Diego Lease&#x201d;). In May 2023, the Company entered into a lease agreement for the same office space which expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Base rent under such lease is approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; annually and the monthly rent expense will be recognized on a straight-line basis over the effective term of the lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. As of December 31, 2023, the Company has recognized a net operating lease right-of-use asset and a lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that matures in September 2025, which has a weighted average remaining lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. As of December 31, 2022, the Company&#x2019;s lease had a weighted average remaining lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:32.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#x201c;SPH USA&#x201d;) entered into a Materials Supply and Services Agreement (&#x201c;SPH USA Services Agreement&#x201d;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During 2023, the Company sold $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of materials to SPH USA which was recorded as an offset to ONCT-216 operating expenses. As of December 31, 2023 and 2022, the Company had amounts receivable of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, from SPH USA related to license agreement. SPH USA is the Company&#x2019;s largest stockholder and an affiliate of one of the Company&#x2019;s directors.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <onct:RentExpense
      contextRef="C_cfcce48d-55f4-42fa-bc8b-242ea98fde12"
      decimals="-5"
      id="F_6570b602-1aa5-4a2c-8347-494ba1c76a77"
      unitRef="U_USD">200000</onct:RentExpense>
    <onct:RentExpense
      contextRef="C_c9b0328c-d0e2-4383-b5a2-733916d1b3cc"
      decimals="-5"
      id="F_b535d4bf-ecd5-4e7e-953b-e41ec2d72f70"
      unitRef="U_USD">200000</onct:RentExpense>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_721f94da-46a0-4238-a04c-81022ac3098d"
      id="F_22190ddd-b8a9-433a-aaed-da0a553dec77">2025-09-30</us-gaap:LeaseExpirationDate1>
    <onct:AnnualBaseRent
      contextRef="C_721f94da-46a0-4238-a04c-81022ac3098d"
      decimals="-3"
      id="F_a66e31a7-0cc9-473b-8169-3fa0b6ef8d12"
      unitRef="U_USD">145000000</onct:AnnualBaseRent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc"
      decimals="3"
      id="F_25131c30-3517-495a-9ea3-1ee475b6317d"
      unitRef="U_pure">0.10</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc"
      decimals="-5"
      id="F_ef47170b-7e43-4e4b-b4d2-e1ac771b21ca"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b4e5b3ac-7dad-4e1d-9356-4eac6750fcfc"
      id="F_2cc521f2-cd99-4113-8e8c-145f9d1ba67b">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_7f9b6b80-f252-4916-a2f7-309b047bf50e"
      id="F_d278b212-3836-497c-96e4-5e7a60858114">P0Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_23ed6bf0-0aa0-4aeb-9fc5-9a2cec46ff28">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:32.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_018827ca-da6b-43af-b1d7-73b87365ac18"
      unitRef="U_USD">196000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_00c768d8-295e-4c01-aede-6f2fb12eb85d"
      unitRef="U_USD">150000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_bea46202-99bf-4b7b-8def-6c1adb7a8241"
      unitRef="U_USD">346000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_e1c359a6-9a66-40cb-935f-9c23494074bc"
      unitRef="U_USD">28000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_69098570-f09c-4392-8631-ed5334358e0f"
      unitRef="U_USD">318000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_90e60ae7-644b-4f9a-8cbb-402617daa988"
      unitRef="U_USD">173000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_523ed84a-ecf3-49e2-b778-48e7497e2024"
      unitRef="U_USD">145000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_caa34144-abe4-4bd3-99a2-59f166c310aa"
      decimals="-5"
      id="F_79624140-1fbd-47f8-82c1-3e6fb3218185"
      unitRef="U_USD">500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:AccountsReceivableNet
      contextRef="C_a20da3ab-11b5-4858-a9c2-a02c8c66bf0b"
      decimals="-5"
      id="F_20fee4c9-31a1-41ab-a362-c1ce801f86ef"
      unitRef="U_USD">100000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_22cf68f2-c77f-4eed-9ca5-da8ef5c46854"
      decimals="-3"
      id="F_c89a11db-473b-47e6-88ed-72e8bff2a818"
      unitRef="U_USD">0</us-gaap:AccountsReceivableNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_d6a016a9-acb0-43c6-91a8-d847c7c52c3a">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License, Collaboration, Grants, Research Subaward and CVR Agreements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;University of Tennessee Research Foundation (&#x201c;UTRF&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2015, and as amended and restated in March 2022 and August 2022, the Company and UTRF entered into a license agreement (the &#x201c;DAARI License Agreement&#x201d;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader technologies owned or controlled by UTRF, including all improvements thereto, which is now known as the dual action androgen receptor inhibitor, or DAARI program. Under the DAARI License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the DAARI program to advance one or more lead compounds into clinical development.  The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expenses under this agreement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for each of the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Agreements with the Regents of the University of California (the &#x201c;Regents&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2016, and as amended and restated in August 2018, and as amended thereafter through January 2024, the Company entered into a license agreement (as amended and restated, the &#x201c;Regents License Agreement&#x201d;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was paid and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,355&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were issued, (ii) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain annual patent costs, (iv) certain development and regulatory milestones aggregating from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: (i) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in license maintenance fees as research and development expense for each of the years ended December 31, 2023 and 2022, and (ii) approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in patent costs as general and administrative expense for each of the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; anniversary of the first commercial sale of a licensed product. The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. The Company may terminate the agreement at any time upon at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2022, the Company entered into a Research Agreement (the &#x201c;Research Agreement&#x201d;) with the Regents for further research on a ROR1 therapeutic development program. Under this &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; agreement that expires on December 31, 2025, the Regents will receive payments aggregating $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, with quarterly payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in 2023, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,813&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in 2024 and 2025. The Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in research and development expense under this agreement in each of the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) Award&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2017, and as amended and restated in December 2020, CIRM awarded an $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million grant to researchers at UC San Diego to advance the Company&#x2019;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. This study is known as CIRM-0001, or Cirmtuzumab and Ibrutinib for Relapsed Lymphoma or Leukemia (the &#x201c;CIRLL study&#x201d;). The Company: (i) conducted this study in collaboration with UC San Diego, (ii) received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in development milestones under research subaward agreements during the award project period from October 1, 2017 through March 31, 2022, (iii) was committed to and met certain co-funding requirements, and (iv) was required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. As of December 31, 2023, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The National Institutes of Health (&#x201c;NIH&#x201d;) Grant Awards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The NIH has awarded the Company three research and development grants for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to support preclinical activities for the Company&#x2019;s ONCT-534 and ONCT-216 programs, including $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payable to subawardees. Under the terms of the grant awards, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and the Company is required to provide periodic progress performance reports. During the years ended December 31, 2023 and 2022, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, in award payments from the NIH. During the years ended December 31, 2023 and 2022, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, in NIH grant revenue and had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in unbilled receivables as of December 31, 2023 and 2022, respectively, which has been included in prepaid and other assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;SPH USA, a Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License and Development Agreement (&#x201c;LDA&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2018, and as amended in August 2020, the Company entered into the LDA with SPH USA for: (i) the territory of the People&#x2019;s Republic of China, Hong Kong, Macau, and Taiwan (&#x201c;Greater China&#x201d;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#x2019;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country/region-by-country/region or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) either party in the event the other party declares insolvency or bankruptcy. There has been no significant activity under this agreement for the years ended December 31, 2023 and 2022. See Note 4.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent Value Rights Agreement (&#x201c;CVR Agreement&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the GTx merger agreement entered into in June 2019 (the &#x201c;Merger&#x201d;), the Company, a representative of holders of the CVRs, and Computershare, Inc. as rights agent entered into the CVR Agreement. Pursuant to the CVR Agreement, the Company&#x2019;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#x2019;s common stock held immediately prior to the Merger.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i) 50% of certain net proceeds received by the Company during the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-year period after the closing of the Merger (the &#x201c;CVR Term&#x201d;) from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10-year period); and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of net sales of products by Parent or its affiliates during the CVR Term incorporating the DAARI technology. As of December 31, 2023, no transactions or net sales relating to the DAARI technology had occurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c896d669-13f7-473c-89c3-89994dcf773a"
      decimals="-5"
      id="F_3ba877d4-5f38-41b1-a62d-1e9b3cb06102"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_aaaac3ff-7e7c-4e08-9dcf-37c2593ea85b"
      decimals="-5"
      id="F_7cbbb665-43f2-45f7-8240-9e0624694f6e"
      unitRef="U_USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:UpfrontLicenseFeesPaid
      contextRef="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0"
      decimals="-5"
      id="F_ee61fd26-321d-4096-85d2-c4b9878f83f1"
      unitRef="U_USD">500000</onct:UpfrontLicenseFeesPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0"
      decimals="0"
      id="F_8405d5c8-315d-46d2-aaa3-ec6ad1c3c2eb"
      unitRef="U_shares">5355</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:AnnualLicenseMaintenanceFees
      contextRef="C_e681e21e-1bbb-4c53-855b-c79b986ff160"
      decimals="0"
      id="F_9ad505bb-749a-43f4-a00f-356d96c8a39f"
      unitRef="U_USD">25000</onct:AnnualLicenseMaintenanceFees>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_124609d2-2d46-4cef-af3e-ff9ad6a610d3"
      decimals="-5"
      id="F_4ff05691-5a04-4c29-a45a-ee477507c3be"
      unitRef="U_USD">20100000</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_3c0da6fd-d05b-4a5b-92ed-45a0294999a0"
      decimals="-5"
      id="F_77dab53a-2fe1-4f15-9df0-2bbfcc4974fe"
      unitRef="U_USD">24500000</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels
      contextRef="C_78fbddc3-8585-4a21-8c6a-c75b2439e2c0"
      decimals="-5"
      id="F_594b9f87-ef4f-40d2-a5d7-a722c13a718d"
      unitRef="U_USD">75000000</onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels>
    <onct:AdvanceLicensedAssets
      contextRef="C_124609d2-2d46-4cef-af3e-ff9ad6a610d3"
      decimals="-5"
      id="F_5f924d9b-2160-48df-9c73-b09978be075d"
      unitRef="U_USD">1000000</onct:AdvanceLicensedAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2"
      decimals="0"
      id="F_5a41bfc9-28c8-420d-8a83-228b51785b64"
      unitRef="U_USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_84d1bde4-f42c-44ac-a1d9-1e1ecae3e8c8"
      decimals="0"
      id="F_784839bd-aca2-4264-8f63-f3d531aef142"
      unitRef="U_USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2"
      decimals="-5"
      id="F_c0858667-8ee3-46f3-99cf-4cc1c297bedc"
      unitRef="U_USD">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_84d1bde4-f42c-44ac-a1d9-1e1ecae3e8c8"
      decimals="-5"
      id="F_22c4f78b-9cdc-4116-b99a-41d290ec784d"
      unitRef="U_USD">100000</us-gaap:GeneralAndAdministrativeExpense>
    <onct:NumberOfDaysInWrittenNoticeOfTermination
      contextRef="C_c22afd86-4dfb-4abe-8cba-0aa47ab6b6a2"
      id="F_ca9cdd63-418c-47e2-b925-76e400ec25e6">P60D</onct:NumberOfDaysInWrittenNoticeOfTermination>
    <onct:ResearchAgreementTerm
      contextRef="C_cd959724-6c14-44e2-acc1-de40c1c6b60a"
      id="F_989f22dd-f0f9-402a-bbde-021ff40d4fa8">P4Y</onct:ResearchAgreementTerm>
    <onct:ResearchAgreementResearchFundingAmountReceivable
      contextRef="C_cd959724-6c14-44e2-acc1-de40c1c6b60a"
      decimals="-5"
      id="F_a76dad2b-18e9-4ee9-94d9-af0da4d0df8b"
      unitRef="U_USD">1600000</onct:ResearchAgreementResearchFundingAmountReceivable>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_cd959724-6c14-44e2-acc1-de40c1c6b60a"
      decimals="0"
      id="F_1ec82cba-3e99-4b1b-a740-a1a70fa6138f"
      unitRef="U_USD">125000</onct:ResearchAgreementResearchFundingAmountPayable>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_fddd24a2-50cf-4852-b216-6ce6bed4bb65"
      decimals="0"
      id="F_61f2ce6f-9e40-4dd8-8c31-c6d290de1fd6"
      unitRef="U_USD">131250</onct:ResearchAgreementResearchFundingAmountPayable>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_1fbc6ca3-a3dc-4149-94d7-cb8b93ecb98d"
      decimals="0"
      id="F_e31636cd-27bf-4137-b5ea-443b78127e62"
      unitRef="U_USD">137813</onct:ResearchAgreementResearchFundingAmountPayable>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_23c75ad6-c16c-4b5c-a758-b8db79ffc925"
      decimals="0"
      id="F_e9a9867b-0f7c-4251-a93e-a15c92b35335"
      unitRef="U_USD">137813</onct:ResearchAgreementResearchFundingAmountPayable>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_0ec0d6a2-b31e-4889-b743-4923e7241cd7"
      decimals="-5"
      id="F_fd27afb9-bad5-44a7-945f-24fd75cf4e9d"
      unitRef="U_USD">500000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_a4cb10c4-5548-41a5-bded-833419a5f7c4"
      decimals="-5"
      id="F_b91d5524-3183-4e4f-9790-3e1600eaebdd"
      unitRef="U_USD">500000</us-gaap:OtherResearchAndDevelopmentExpense>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_a773db65-a5e7-4e4b-84c4-30dbe6ad792f"
      decimals="-5"
      id="F_d7213ba5-85ae-4ac3-ab92-a241b904028b"
      unitRef="U_USD">18300000</onct:ResearchAndDevelopmentGrants>
    <onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod
      contextRef="C_a773db65-a5e7-4e4b-84c4-30dbe6ad792f"
      decimals="-5"
      id="F_7928a878-1c1e-4dfc-8d46-0075981c91e7"
      unitRef="U_USD">14500000</onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_39371a89-6f01-47df-bc36-a1e47990e15b"
      decimals="-5"
      id="F_6ab0c3c5-43e2-440d-897b-e27ec1e5d0c9"
      unitRef="U_USD">4000000</onct:ResearchAndDevelopmentGrants>
    <onct:AccruedClinicalTrials1
      contextRef="C_b99fc277-6a5f-4381-b86d-98c34d084f57"
      decimals="-5"
      id="F_d251f730-56fe-4f45-86cb-ecb52dc736d7"
      unitRef="U_USD">1000000</onct:AccruedClinicalTrials1>
    <us-gaap:Revenues
      contextRef="C_39371a89-6f01-47df-bc36-a1e47990e15b"
      decimals="-5"
      id="F_930ccb91-4d1c-4d82-9511-56f8acd67728"
      unitRef="U_USD">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_56a6188c-3033-46da-a539-5db40eb23bba"
      decimals="-5"
      id="F_8bfdf15f-2468-422a-bea0-d239d097a1f0"
      unitRef="U_USD">1200000</us-gaap:Revenues>
    <onct:AwardPaymentsReceived
      contextRef="C_39371a89-6f01-47df-bc36-a1e47990e15b"
      decimals="-5"
      id="F_fd2bfc5b-59b4-4b06-aa67-cd63c8a515af"
      unitRef="U_USD">800000</onct:AwardPaymentsReceived>
    <onct:AwardPaymentsReceived
      contextRef="C_56a6188c-3033-46da-a539-5db40eb23bba"
      decimals="-5"
      id="F_22ece729-f553-417d-9b15-9688b4db8f53"
      unitRef="U_USD">1100000</onct:AwardPaymentsReceived>
    <us-gaap:UnbilledContractsReceivable
      contextRef="C_b99fc277-6a5f-4381-b86d-98c34d084f57"
      decimals="-5"
      id="F_fd2b3fb5-f429-43a4-9648-42bc8d338776"
      unitRef="U_USD">500000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="C_2b0d5398-0c7c-48f9-837d-be8269901856"
      decimals="-5"
      id="F_00aef100-15ae-47b8-a55b-29afd871b8bb"
      unitRef="U_USD">100000</us-gaap:UnbilledContractsReceivable>
    <onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR
      contextRef="C_806fe93c-57b0-45eb-9528-ffd11fc44374"
      id="F_ab347495-9255-4d8c-b6d1-fd065db5b637">P15Y</onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR>
    <onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement
      contextRef="C_806fe93c-57b0-45eb-9528-ffd11fc44374"
      id="F_009ad011-025c-4732-831b-9683b67a16c0">P10Y</onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement>
    <onct:PercentageOfNetSales
      contextRef="C_806fe93c-57b0-45eb-9528-ffd11fc44374"
      decimals="2"
      id="F_842823ed-5f42-44e9-a4fc-448d1cedccad"
      unitRef="U_pure">0.05</onct:PercentageOfNetSales>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_332e9631-2235-4cc5-a4b5-b4946798eb1d">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and December 31, 2022, the following fair value hierarchy tables presents the Company&#x2019;s financial assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Valuation of short-term investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies its money market funds, treasury notes and treasury bills as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices for identical assets in active markets without any valuation adjustment.  The Company classifies its commercial paper and U.S. government sponsored enterprise securities as Level 2 assets under the fair value hierarchy, as these assets have been valued using information obtained through a third-party pricing service at each balance sheet date, using observable market inputs that may include trade information, broker or dealer quotes, bids, offers, or a combination of these data sources. The Company does not hold any short-term investments classified as Level 3, which are securities valued using unobservable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The Company did not transfer any investment securities between the classification levels during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_b0a1c8d7-e3b6-49a6-a2fe-e975c8c0ed4e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and December 31, 2022, the following fair value hierarchy tables presents the Company&#x2019;s financial assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;Short term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial Paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government Agency&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_494fe420-acc3-40f1-a076-42280b1684de"
      decimals="-3"
      id="F_cfdb684e-8124-468a-bed5-a918fd259f9e"
      unitRef="U_USD">23844000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_945c64cc-8fd5-4390-8555-ead6c7c1f64a"
      decimals="-3"
      id="F_3013ae30-5563-44fb-9f59-49bee3439871"
      unitRef="U_USD">10912000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_199ad02d-9d2d-4836-8616-89dc61afce31"
      decimals="-3"
      id="F_1d61a9d6-a18a-41fd-b5ec-e89a40b9d0ac"
      unitRef="U_USD">12932000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_239353fd-6f89-4cb6-b125-6d9371f0edeb"
      decimals="-3"
      id="F_bf6086e1-4cc8-405b-9c6e-464a84a005c8"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_9a46d83e-f6dd-44d4-909e-9d8f3ea263ed"
      decimals="-3"
      id="F_f88b1dd2-bc28-4f4f-9830-8c4b331e53d8"
      unitRef="U_USD">2737000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_54d18d54-d3a4-492f-b13b-e21ffaa85ccf"
      decimals="-3"
      id="F_31714ad1-940a-4370-833c-3186d1c56778"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_ff6125a7-fb79-405a-8961-0ede053bee4e"
      decimals="-3"
      id="F_fafd1a63-5ae9-4816-a6c9-0240e5f5a36a"
      unitRef="U_USD">2737000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_46c60dff-cac9-4018-8575-385d2a411a84"
      decimals="-3"
      id="F_cbb8d1fa-e1f6-40b6-afb8-d6513d7de6a3"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_26ab1cc2-d243-44c9-9db3-5cbed36397d9"
      decimals="-3"
      id="F_ccf6eddf-bcad-4765-89b4-b53823f8fe48"
      unitRef="U_USD">977000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_188444b1-f178-47d3-9b2d-59943870aebd"
      decimals="-3"
      id="F_86a15084-6ae7-415c-aa6b-dba77d171f35"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f4a3a9c0-78f1-4226-a01b-c86a4a08a0b1"
      decimals="-3"
      id="F_b2ea3e3f-1048-44c7-8485-8aaea0239c3b"
      unitRef="U_USD">977000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_ec9bb144-86a5-4e9b-906e-419e8387d5a5"
      decimals="-3"
      id="F_59f51588-3641-4233-a504-49d9a9b09b5e"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_559906c9-0c59-49e6-96f8-3366e04dca58"
      decimals="-3"
      id="F_cedfc8b6-0778-4f35-b1be-b1c9d164c593"
      unitRef="U_USD">27558000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_e4d53eba-2e84-48f2-b931-0b43041273df"
      decimals="-3"
      id="F_abc18e1a-2836-420a-b6e5-d565175bff85"
      unitRef="U_USD">10912000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b4b57fdc-9184-48da-aa31-8dfde603a140"
      decimals="-3"
      id="F_52e79be1-bce2-47d7-8c3d-726f1648b03c"
      unitRef="U_USD">16646000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_cdc3f0e1-0d49-4984-a42d-fbfadb17116b"
      decimals="-3"
      id="F_7e18e241-c9bf-4e68-b3cd-e023e4691e31"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_22537a93-b320-44dd-a549-708fcd3422dc"
      decimals="-3"
      id="F_ba3d0d51-3061-4b95-a3aa-45b44aa5a049"
      unitRef="U_USD">21688000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f14623dc-d310-4e54-b789-c60026ee8444"
      decimals="-3"
      id="F_81a4c810-1a7d-40b4-8f08-fd3c90c4b441"
      unitRef="U_USD">21688000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3ed66ec3-01b3-42a3-840a-a1a07973fcfa"
      decimals="-3"
      id="F_c143f897-0b70-4859-bf83-af78dae07f72"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8d67c732-6cc2-4ca8-b0fb-1ec761145cf2"
      decimals="-3"
      id="F_98d2512f-0ec8-4e6f-89d6-9913f7b53663"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_e4bde5a8-ae87-4557-801d-ca9157cf9106"
      decimals="-3"
      id="F_74fa843f-3412-44d7-a0f0-80ef0f3e98fc"
      unitRef="U_USD">2936000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_fd81aada-e08c-4c52-98c2-314c93335b95"
      decimals="-3"
      id="F_61ebf69a-622e-4f27-b585-eb679db8292c"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_57f4bb0b-624b-482c-99f5-8c8960913a1f"
      decimals="-3"
      id="F_f21092a9-c684-4702-b03e-8fa41f7e2466"
      unitRef="U_USD">2936000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_6d3b13ce-5124-4fca-9299-dd3bdf5074c5"
      decimals="-3"
      id="F_7b7db6fb-53c4-4e77-b4ec-d445149e0f68"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_612bfa44-754f-486e-bf9e-c145316436ad"
      decimals="-3"
      id="F_125b79eb-fecd-41b3-a88e-7aeb95a45f95"
      unitRef="U_USD">1958000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_07c0adf7-ec21-415e-8412-b371f3a6a24a"
      decimals="-3"
      id="F_aa8e258e-4129-48c0-ae98-54e01f326cd9"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_6d9980d5-e3a0-4b27-8681-b22f63c165b1"
      decimals="-3"
      id="F_bd28928b-677d-4041-be0b-ee3046536694"
      unitRef="U_USD">1958000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_4c46c1db-0184-4718-8ed6-39821e77c4c8"
      decimals="-3"
      id="F_743d83f5-7820-45b8-8d7e-9e56ea205197"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_406903e5-8180-4559-aaf2-4760656464dd"
      decimals="-3"
      id="F_424da17d-2056-4c05-afd6-b9cffc903a4c"
      unitRef="U_USD">26582000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_fa85d7fe-bbad-46f8-a7b1-37cddaed1e71"
      decimals="-3"
      id="F_a9dc32bf-1717-4ed3-b654-b6b6bee765b4"
      unitRef="U_USD">21688000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f8ac1f25-733f-4759-8f62-55c4db818235"
      decimals="-3"
      id="F_e1d17455-febf-44d3-92b5-f0024d5eb716"
      unitRef="U_USD">4894000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b56bb628-693a-44de-82e4-d1feaf30ec85"
      decimals="-3"
      id="F_6c6c47f5-1234-4444-bd22-4a4c923c2784"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_6cd5911d-be86-41ec-88f6-e25dc80a8471">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ATM Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2021, the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC, pursuant to which the Company is able to offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company has no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. During the years ended December 31, 2023 and 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,274&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;402,068&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.032%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.51%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.241%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.032%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.427%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares Underlying Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance Outstanding - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;772.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance Outstanding - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issued / Exercised / Forfeited / Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance Outstanding - December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, all warrants met the criteria for classification in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contemporaneous with the Merger closing: (i) Oncternal&#x2019;s 2015 Equity Incentive Plan, as amended (&#x201c;2015 Plan&#x201d;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#x201c;2019 Plan&#x201d;) under which the sum of: (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,708&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, and (b) an annual increase on the first day of each calendar year beginning January 1, 2020, and ending on and including January 1, 2029, equal to the lesser of (A) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as is determined by the Board, are reserved for issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2015, Oncternal adopted the 2015 Plan which provided for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the options issued under the 2015 Plan expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant and vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan was terminated as to new grant awards in June 2019.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the stock options issued under the 2019 Plan expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant and vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period. Certain stock option grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#x201c;Inducement Plan&#x201d;). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#x201c;inducement exception&#x201d; provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of non-statutory stock options to certain new hires who satisfy the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#x2019;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of the 2019 Plan. As amended in May 2021 and December 2021, the Company has reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares for the issuance of common stock under the Inducement Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.19%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.382000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;279,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant date fair value per share of option grants for the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The intrinsic value is calculated as the difference between the fair value of the Company&#x2019;s common stock at December 31, 2023 of the option exercise and the exercise price of that stock option. There were no stock options exercised during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, the Company repriced certain stock options held by employees and consultants. The repricing action was taken by the Company's board of directors to align the stock options with current market conditions and to retain key employees. The board of directors determined that the original exercise prices of the stock options were no longer reflective of the current market value of the Company's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the repricing, the exercise prices of the stock options were adjusted to reflect the fair value of the Company's common stock as of October 2, 2023. The vesting schedules and other terms of the stock options were unchanged. The repricing was implemented through an amendment to the existing stock option agreements, which was approved by the board of directors. The repriced stock options are subject to terms such that any exercises prior to a premium end date shall use the original exercise price prior to the repricing amendment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the repriced stock options was determined using the Black-Scholes option-pricing model.  The incremental fair value of vested stock options resulted in a one-time charge to stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.  The incremental fair value of unvested options of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will be recognized over the remaining vesting period of the stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Unit Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock unit awards (&#x201c;RSUs&#x201d;) are rights to receive shares of the Company&#x2019;s common stock upon satisfaction of specific vesting conditions. The Company began issuing RSUs in the first quarter of 2022. The RSUs generally vest over an 18 month to two-year period. RSUs activity under the 2019 Plan is summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.860000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/ Repurchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Units expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant date fair value per share of RSU grants for the years ended December 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The total fair value of shares vested during the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The total fair value of shares vested during the year ended December 31, 2022 was nominal.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.227%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.546%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.588%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.607999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The expected volatility assumption is based on a blend of volatilities of the Company&#x2019;s share price and a peer group of similar companies whose share prices are publicly available. The volatility of the Company&#x2019;s shares price was measured using the closing share price beginning June 10, 2019, the date of the closing of the Merger, through the current period.  The peer group was developed based on companies in the life sciences industry with comparable characteristics to the Company including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected term. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected term represents the period of time that options are expected to be outstanding. Due to limited historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs represent rights to receive shares of common stock contingent upon satisfaction of specific vesting conditions. The stock-based compensation expense for these awards was determined using the closing price on the grant date applied to the total number of shares that were anticipated to fully vest.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the unrecognized compensation cost related to non-vested stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the unrecognized compensation cost related to non-vested restricted stock units was nominal, which is expected to be recognized in the first quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.232%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock unit awards unvested and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock available for issuance under Inducement Plan and 2019 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;832,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;708,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_060e4155-636b-4f25-aae8-2486660150ed"
      decimals="-5"
      id="F_8ce0d8c6-d14e-4d6f-9fc9-7be23eba89c0"
      unitRef="U_USD">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb"
      decimals="0"
      id="F_2c1686e3-bf15-4fd2-af82-ea2a1a83c4ce"
      unitRef="U_shares">55274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_3ee2b049-c3a9-4492-adeb-159a901587f6"
      decimals="0"
      id="F_f8ff019e-9bba-44e2-b7ee-24edb63f781e"
      unitRef="U_shares">402068</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_9d10a61e-4ad9-4991-b985-d783a8eb5fdb"
      decimals="-5"
      id="F_8bf321de-08a2-463a-bd17-4ffce5a33c8a"
      unitRef="U_USD">1200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_3ee2b049-c3a9-4492-adeb-159a901587f6"
      decimals="-5"
      id="F_486f9aca-1a1e-4d48-8851-7c1f3cd40dd5"
      unitRef="U_USD">9600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <onct:ScheduleOfWarrantActivityTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_c7af57c4-9e5e-40f2-9276-f8c413e02387">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.032%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.51%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.241%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.032%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.427%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares Underlying Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance Outstanding - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;772.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance Outstanding - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issued / Exercised / Forfeited / Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance Outstanding - December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</onct:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd"
      decimals="-3"
      id="F_1541201d-e5b9-465c-8f2e-6933bfcd4090"
      unitRef="U_shares">211746000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ecb1ed7c-4185-403a-a988-00ae5ff973fd"
      decimals="2"
      id="F_d2c06f53-2d88-4e62-a955-8692365bde50"
      unitRef="U_USDollarShare">210</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm
      contextRef="C_76233f9f-1322-4238-beea-ec554143cbd5"
      id="F_687a3271-7371-4101-b375-73612af0782e">P3Y3M21D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <onct:WarrantsExpired
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_3dc57936-02d1-48c9-8288-e249685a524c"
      unitRef="U_shares">41225000</onct:WarrantsExpired>
    <onct:WarrantExpiredPricePerShare
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="2"
      id="F_6bd343a1-3602-4124-b951-1020dfedb2c3"
      unitRef="U_USDollarShare">772.8</onct:WarrantExpiredPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_84d25b4f-f0cd-47f5-8700-cac7ff91321f"
      unitRef="U_shares">170521000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="2"
      id="F_c7956ee1-292a-4ba1-8032-ac752013b388"
      unitRef="U_USDollarShare">74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      id="F_9235ab10-b46f-4850-80b5-d8cc7724a687">P2Y11M8D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <onct:WarrantsExpired
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_fb44762d-334a-4e3e-b5c9-1494a9ce2abd"
      unitRef="U_shares">0</onct:WarrantsExpired>
    <onct:WarrantsIssued
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_e08a74cf-81df-44d7-b11b-b4e660cd6fa1"
      unitRef="U_shares">0</onct:WarrantsIssued>
    <onct:ExerciseOfWarrants
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_cdabef1c-c521-4cd1-975e-77b0b2620eff"
      unitRef="U_shares">0</onct:ExerciseOfWarrants>
    <onct:WarrantsCancelled
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_a59d1cbd-7851-4db0-95eb-ba5e30c581d2"
      unitRef="U_shares">0</onct:WarrantsCancelled>
    <onct:WarrantExpiredPricePerShare
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="0"
      id="F_d2b885c8-8ee9-4709-9f7f-727f4e571da7"
      unitRef="U_USDollarShare">0</onct:WarrantExpiredPricePerShare>
    <onct:WarrantsIssuedPricePerShare
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="0"
      id="F_440a23a5-74de-4cab-81dd-e0ed1c5db81c"
      unitRef="U_USDollarShare">0</onct:WarrantsIssuedPricePerShare>
    <onct:WarrantExercisedPricePerShare
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="0"
      id="F_0d1a442c-ee9a-4485-a6ae-cb2f171abec4"
      unitRef="U_USDollarShare">0</onct:WarrantExercisedPricePerShare>
    <onct:WarrantForfeitedPricePerShare
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="0"
      id="F_90590764-4bd1-45a5-ab26-cd93a28254e5"
      unitRef="U_USDollarShare">0</onct:WarrantForfeitedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_309c3ed9-dcdd-4941-8eea-ff902e1e6b61"
      unitRef="U_shares">170521000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="2"
      id="F_887fb373-395f-46d6-ae0a-74cfcfbb57cc"
      unitRef="U_USDollarShare">74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_0e495459-7f14-4693-b1c0-7bcec095aa14">P1Y11M8D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_ed194973-5fdd-4e52-855b-ebf609d37cc3"
      decimals="0"
      id="F_4318e631-a871-4386-bc8b-f5ef34cf3c48"
      unitRef="U_shares">97708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="2"
      id="F_76a4fc84-9dc2-451c-a512-2a986151133f"
      unitRef="U_pure">0.05</onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_e9b3636c-d8fd-4fc6-949c-e35056896198"
      id="F_f64a06d5-d031-40c9-98e7-832f191cfbdb">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_e9b3636c-d8fd-4fc6-949c-e35056896198"
      id="F_32b31c9c-0551-4d74-acde-b15b613d49bc">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_d70503fc-4a1c-4d6b-9214-610f9b23fc86"
      id="F_f52b58cc-4caa-4a8d-aa69-5402c9880a7b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_d70503fc-4a1c-4d6b-9214-610f9b23fc86"
      id="F_58668e0f-cd23-47b2-be0c-fd43bdb506a6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_008b4d81-ffe3-4ba2-bbc8-a66325c8241c"
      decimals="0"
      id="F_697d1f2a-ffcd-45ee-a8fc-e097da89db53"
      unitRef="U_shares">140000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_417360e1-10ba-44a1-979c-ee0ee91f3669">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.19%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.382000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;279,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1"
      decimals="-3"
      id="F_ac7d8d1b-bafa-4d7c-bfba-825d96638219"
      unitRef="U_shares">425766000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e0cf2d5a-4f32-4b64-9d5a-ca3f53cef7f1"
      decimals="2"
      id="F_78b5ba93-140b-4fb5-ac29-f244a363f7e6"
      unitRef="U_USDollarShare">83.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493"
      decimals="-3"
      id="F_a40e0690-ad81-492d-81eb-5de7093d3870"
      unitRef="U_shares">173794000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493"
      decimals="2"
      id="F_e266e909-2a3e-4334-9fe4-a73aed5b7fbb"
      unitRef="U_USDollarShare">16.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493"
      decimals="-3"
      id="F_258e998a-2c05-413e-bf32-a23c3534f893"
      unitRef="U_shares">51487000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493"
      decimals="2"
      id="F_6ef2a86a-7f02-4948-b27f-95c04821d61f"
      unitRef="U_USDollarShare">69.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="-3"
      id="F_2f6b9363-979e-4821-b8cd-8905f6e836c3"
      unitRef="U_shares">548073000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="2"
      id="F_077d2a23-d81d-4c75-ac01-fa40f4b2b6e4"
      unitRef="U_USDollarShare">56.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <onct:WeightedAverageContractualTermOutstanding
      contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493"
      id="F_560c38ba-1690-4b71-a9a5-c1d8d0972ba8">P7Y4M24D</onct:WeightedAverageContractualTermOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="-3"
      id="F_945a268e-3315-4eac-bcd1-287682347f51"
      unitRef="U_USD">155648000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="-3"
      id="F_e994319a-e460-40d6-8181-e359ac9839a3"
      unitRef="U_shares">548073000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="2"
      id="F_5f160fe2-00ad-44ee-b5ef-7c4e8243c1a1"
      unitRef="U_USDollarShare">56.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493"
      id="F_d37145b4-44ad-4fee-aa3a-2bd12658fffd">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="-3"
      id="F_ad38d88a-5b55-4fa3-9048-b10bfbf7bbd5"
      unitRef="U_USD">155648000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="-3"
      id="F_47cf1ecb-d737-4ad1-9692-c157f0e95064"
      unitRef="U_shares">279184000</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="2"
      id="F_50d0a78c-731d-414c-931d-6631bea4060f"
      unitRef="U_USDollarShare">74.09</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm
      contextRef="C_be17b684-ca82-4e8f-9152-2a66d621a493"
      id="F_cca59f2a-2602-4a43-a36b-025c9b5bd296">P7Y1M6D</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue
      contextRef="C_3b9c7d26-f3c5-4c2d-be2b-f82857ca3601"
      decimals="-3"
      id="F_9ae45988-77ba-430a-92d4-7fe08d2a6502"
      unitRef="U_USD">68418000</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ef53d5cd-37dc-49c8-870b-ecc190d62e21"
      decimals="2"
      id="F_8ae67051-776c-43ad-8596-3db901091d01"
      unitRef="U_USDollarShare">13.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d3b5002b-9469-4aba-b020-3e3c596b6535"
      decimals="2"
      id="F_628d7156-a0a4-4640-82d0-a41fa5bf57ad"
      unitRef="U_USDollarShare">25.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88e26592-4d13-462a-9b53-e67a374ae51e"
      decimals="-5"
      id="F_83cdc66d-fd2c-46b0-90b0-f1f130fa5d45"
      unitRef="U_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_4a9ea6d5-a2b4-44b7-a30b-0362d9e0d9d8"
      decimals="-5"
      id="F_fe703cc4-0a3e-4b3c-b816-3dca24a5399a"
      unitRef="U_USD">400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_f52c1f48-c71b-4df6-9137-78e858370537">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.860000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/ Repurchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Units expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant date fair value per share of RSU grants for the years ended December 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The total fair value of shares vested during the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The total fair value of shares vested during the year ended December 31, 2022 was nominal.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e420a3e6-0b0a-450b-a468-f2a3164e557e"
      decimals="-3"
      id="F_f22b70ae-b134-46cc-a61e-75c4d95f230f"
      unitRef="U_shares">50438000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e420a3e6-0b0a-450b-a468-f2a3164e557e"
      decimals="2"
      id="F_13b53c95-277c-4216-aa63-8b389ba0d610"
      unitRef="U_USDollarShare">32.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      decimals="-3"
      id="F_77682716-4c19-404d-a81f-4ef1003657c4"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      decimals="-3"
      id="F_e0a8e5b6-e095-457e-8c73-74682548fedf"
      unitRef="U_shares">30537000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      decimals="2"
      id="F_6508ee45-c543-463d-8abf-034109ce6c2e"
      unitRef="U_USDollarShare">35.56</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      decimals="-3"
      id="F_bb69bca6-44a5-49ca-b29a-de107282b3d6"
      unitRef="U_shares">1344000</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedOrRepurchasedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      decimals="2"
      id="F_f46f77c2-07d8-4805-8e55-1ddf18fa1188"
      unitRef="U_USDollarShare">32.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0"
      decimals="-3"
      id="F_2b5f3e2f-0ee3-4bde-b69b-af92913bb75a"
      unitRef="U_shares">18557000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      id="F_1f24b7ac-9d89-4caa-bdec-7f2148d25afc">P0Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0"
      decimals="2"
      id="F_fffce008-2466-4ae4-a48e-4b70982eddaa"
      unitRef="U_USDollarShare">28.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0"
      decimals="-3"
      id="F_ce8fa99a-eaea-49c0-8a1f-81b8bbc44766"
      unitRef="U_shares">18557000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      id="F_4dbcb504-d9e5-4338-aef1-49604f1d5a71">P0Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_3649747f-9c0d-4482-8bdd-75153c2821e0"
      decimals="2"
      id="F_80cf08cd-65fb-4d2c-a504-4963b28447eb"
      unitRef="U_USDollarShare">28.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fb81806a-0e46-4915-b3ab-4166af11612d"
      decimals="0"
      id="F_89f15d3b-b920-4432-b288-ad498267bdbf"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5b521705-9521-4715-a360-b03c0afb492c"
      decimals="2"
      id="F_599a2c6b-d542-4c8d-9dcf-f3f1cb644440"
      unitRef="U_USDollarShare">33.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-5"
      id="F_9be51a5f-03de-49c7-878a-bc71db98e4e9"
      unitRef="U_USD">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_9d7b939d-0f4e-4a68-a51f-b84378007d5e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.227%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.546%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.588%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.607999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="3"
      id="F_c0b8d427-ddc3-4687-9b82-a5f67f0102f2"
      unitRef="U_pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="3"
      id="F_ebf857e6-1317-474f-98df-7cc51884c88c"
      unitRef="U_pure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="3"
      id="F_aca15514-6ac8-4304-9a85-58c30f176092"
      unitRef="U_pure">1.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="3"
      id="F_07683edd-7ddc-4130-90bc-e1c6c005f98a"
      unitRef="U_pure">1.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_4a2e01f3-5d4b-4c76-9074-dd35f1c346d1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      id="F_425c4eb1-cad8-4c43-87f7-cc1ac0bca3a3">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_1fa6aa1f-64dc-493e-827a-b9b4ceb03324">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_97f0b34a-98a0-4cbd-85a6-33dc53e598fe"
      decimals="-3"
      id="F_dd080b49-c060-45b8-9cfa-9998a8b93ddd"
      unitRef="U_USD">4064000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bf19402d-8314-4a7e-802d-f56c3da68afb"
      decimals="-3"
      id="F_af581ba4-f835-491b-99d6-fb8a7f9aafd7"
      unitRef="U_USD">4055000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_441dc867-c190-4ac7-8f43-7108e23f4032"
      decimals="-3"
      id="F_43ac928c-f167-4367-b066-ec2aae91b7ed"
      unitRef="U_USD">3436000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8ae3137a-dca4-44e8-9e74-9a641eabeef4"
      decimals="-3"
      id="F_b4cf5325-5fe6-4852-9302-31dc0866ff8d"
      unitRef="U_USD">3376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_dcf4633c-d151-418c-9ae1-0fdae7cb9d78"
      unitRef="U_USD">7500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_8d2f0c76-4389-43a5-9b3d-b9a85461dabf"
      unitRef="U_USD">7431000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-5"
      id="F_77720134-86a4-4872-ae8e-1dbcccd0f0d4"
      unitRef="U_USD">7700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_9da5f2a0-f3c1-4f69-bc30-0d730c5c1b47">P1Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_fd7bdb9c-2591-4d99-96b4-ba321d2ce381">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.232%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;548,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;425,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock unit awards unvested and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock available for issuance under Inducement Plan and 2019 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;832,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;708,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <onct:CommonStockWarrantsReservedForFutureIssuance
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="0"
      id="F_6543f7ee-1655-4b72-821e-60a790d513a9"
      unitRef="U_shares">170521</onct:CommonStockWarrantsReservedForFutureIssuance>
    <onct:CommonStockWarrantsReservedForFutureIssuance
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="0"
      id="F_9c3281de-281d-4456-8edd-ecceac98c0a0"
      unitRef="U_shares">170521</onct:CommonStockWarrantsReservedForFutureIssuance>
    <onct:CommonStockOptionsOutstandingForFutureIssuance
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="0"
      id="F_6befe4cd-0acc-46d4-bb22-60f6b45117dc"
      unitRef="U_shares">548073</onct:CommonStockOptionsOutstandingForFutureIssuance>
    <onct:CommonStockOptionsOutstandingForFutureIssuance
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="0"
      id="F_fc5b56da-3c83-4a83-ad13-626aaa175cb7"
      unitRef="U_shares">425785</onct:CommonStockOptionsOutstandingForFutureIssuance>
    <onct:RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="0"
      id="F_1fdaafbb-c953-49d9-92b3-e10af597d343"
      unitRef="U_shares">18557</onct:RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance>
    <onct:RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="0"
      id="F_0e58e234-a057-4d71-b67a-c3db4e91c6de"
      unitRef="U_shares">50454</onct:RestrictedStockUnitAwardsUnvestedAndOutstandingForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_534fa586-63e2-4243-8afa-2b2e6ad52e2b"
      decimals="0"
      id="F_1ac81b03-f817-4187-abc1-e1c6f0264323"
      unitRef="U_shares">94909</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_885b6bbf-2f96-47f6-8d8a-193adfbcc27b"
      decimals="0"
      id="F_d22a1c1f-8ac8-4fe2-9d15-2a97386c1d26"
      unitRef="U_shares">61500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="0"
      id="F_1851d572-0779-4593-9d6a-19d488a0dd03"
      unitRef="U_shares">832060</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="0"
      id="F_dc3475a8-e206-4e2a-9aba-a877370ef8fc"
      unitRef="U_shares">708260</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_6abdad20-2ef3-4f64-b670-ab0f6f7a99ba">&lt;div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.848%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company's deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of the Company's deferred tax assets, management considers all available evidence, both positive and negative.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#x201c;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#x201d; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2023. Accordingly, a valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million has been recorded to offset this deferred tax asset. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At December 31, 2023, the Company had federal and state net operating loss (NOL) carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Of the federal and state net operating losses at December 31, 2023, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne, respectively, do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, unless previously utilized. At December 31, 2023, the Company also had federal and state research and development credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The federal research and development credit carryforwards will begin expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unless previously utilized. The state research and development credits do not expire.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Utilization of the net operating losses and credits may be subject to substantial annual limitations due to federal and state ownership change limitations provided by the Internal Revenue Code Section 382 and 383 and similar state provisions. Such annual limitations could result in the expiration of the net operating losses and credits before their utilization. The Company has not performed a Section 382 analysis to determine whether ownership changes will impact the use of net operating loss carryforwards and credits carryforwards and limit their ability to offset future taxable income. For financial statement purposes, the Company has included the federal and state net operating losses and credits in the schedule of deferred tax assets offset with a full valuation allowance. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by historical ownership changes will not impact the Company&#x2019;s effective tax rate in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;be recognized. At December 31, 2023 and 2022, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#x2019;s 2014 through 2023 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized interest or penalties in its consolidated statements of operations since inception.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_2414d7d9-4a09-48f8-80b0-ffac8b7694c0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.848%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_52a24472-c1f8-4850-a68b-44e87ecbbfa3"
      unitRef="U_USD">-8290000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_e55d9e19-c4f3-43f9-b291-da551dd511a4"
      unitRef="U_USD">-9276000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_0e59ba9b-8342-4f36-b192-a27b54a99816"
      unitRef="U_USD">-58000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_719574d3-08c7-478a-bee6-d7f4b5e155ff"
      unitRef="U_USD">-2820000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <onct:IncomeTaxReconciliationPermanentItems
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_068f9eda-a3ba-4aa1-868a-9d5d235a3e72"
      unitRef="U_USD">8000</onct:IncomeTaxReconciliationPermanentItems>
    <onct:IncomeTaxReconciliationPermanentItems
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_9dccba76-eba1-4c0b-bc7c-5a7739328578"
      unitRef="U_USD">3000</onct:IncomeTaxReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_8e8667b4-0567-4714-9417-178acc68fe41"
      unitRef="U_USD">1172000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_1b0fa47b-ce5d-486e-9386-08fb1f6263f3"
      unitRef="U_USD">831000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_3329f2ea-bed4-409b-a4b2-20053c2f1767"
      unitRef="U_USD">2910000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_ae512e01-fd90-4367-afe0-d1c4aa5da298"
      unitRef="U_USD">4747000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_c94e5e1a-c2c6-40a0-8f25-c7cb7cc46fd1"
      unitRef="U_USD">1222000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_f9991e7f-4d42-4c17-9fd2-c3153c2c0d22"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_5077501e-e48d-479f-9842-f6ab244e48c6"
      unitRef="U_USD">196000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_59d80508-2332-4edc-88f2-473ee109f328"
      unitRef="U_USD">-48000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_2d0bfc6f-900f-410c-80b1-9921ca7d92a6"
      unitRef="U_USD">8660000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_05652010-ed31-48df-8dc3-80f6acb54fdb"
      unitRef="U_USD">16057000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-3"
      id="F_c70af50b-401e-466a-b5c8-e78c682e3367"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-3"
      id="F_16ed4218-0dd3-434d-8a3a-95c6ee23d3f8"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_ae23d3bc-b615-4ced-a4f7-e000f0d78c27">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_25ee5eae-1729-4f73-a461-c48d55d9dda4"
      unitRef="U_USD">29997000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_92676d63-698a-447b-88d8-65fbf948ef99"
      unitRef="U_USD">27889000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_a8384f59-78f4-4c7e-b32a-1d66107bbb75"
      unitRef="U_USD">10958000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_c90c0b9e-18b6-40fb-8ef2-b554eb6a1d74"
      unitRef="U_USD">7804000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_f2584bf9-7852-4700-bf74-04e3b38a3d00"
      unitRef="U_USD">676000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_26bb63e4-78e1-4857-b57c-75050361826f"
      unitRef="U_USD">860000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_05dc122f-d051-4612-b4cf-f7552016344c"
      unitRef="U_USD">22501000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_b2d6acb5-084e-4d5a-9032-74678254445b"
      unitRef="U_USD">19153000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_d7a4611a-7650-40a3-9b8c-3b0edc3b99e3"
      unitRef="U_USD">2406000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_edcce877-01fb-41d3-8ce6-709afd02086a"
      unitRef="U_USD">2188000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_29f0a94f-5377-405e-9a38-05203456765a"
      unitRef="U_USD">90000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_9bc10fe4-aefe-45cd-89a2-616f17ea8fe0"
      unitRef="U_USD">29000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_da039d66-d1fe-4bc8-bd39-22ade80056d0"
      unitRef="U_USD">66628000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_d004e3bc-ee5c-4685-85ed-83da5b7b2704"
      unitRef="U_USD">57923000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_fbffa3e9-9129-470a-aadb-b368e4f5c0a2"
      unitRef="U_USD">66561000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_a23da573-b5a2-4bbd-9512-eb548241078b"
      unitRef="U_USD">57899000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_e2d3c37f-8828-405e-939d-298460e0bfa3"
      unitRef="U_USD">67000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_eaa631b6-291e-4d3b-8456-f87a2b92611d"
      unitRef="U_USD">24000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <onct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_f9d8eaf6-97dc-4afc-a084-daf25fc70c6b"
      unitRef="U_USD">67000</onct:DeferredTaxLiabilitiesRightOfUseAsset>
    <onct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_ec7ecc39-aa22-4443-ad52-ff2888660257"
      unitRef="U_USD">24000</onct:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-3"
      id="F_1da45e83-faa7-4c3d-aea4-8a4b31f48ad0"
      unitRef="U_USD">67000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="-3"
      id="F_c86d825c-351a-496c-8b16-48a8e02c05b8"
      unitRef="U_USD">24000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_3f9e4329-2631-4545-b375-e1684aab746d"
      decimals="-3"
      id="F_5fd077d9-23c1-4939-afa9-73180e96407d"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_94005552-abb1-417c-87b6-43d4fedeb7de"
      decimals="-3"
      id="F_48049a75-089b-43a4-9bb5-1a04557872bd"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="-5"
      id="F_77f095ce-dd40-488a-b21c-70383951dd50"
      unitRef="U_USD">66600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="-5"
      id="F_7860986d-3624-4391-b901-e9dce3680d3c"
      unitRef="U_USD">8700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_f464bcb9-103c-40d4-8bd9-b4581370d91a"
      decimals="-5"
      id="F_9dd73acc-1b23-42e5-90ec-d2d9921f849a"
      unitRef="U_USD">16100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4"
      decimals="-5"
      id="F_4f7565b0-6cac-4360-ae3b-7bd191807f4c"
      unitRef="U_USD">119500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_390cdc10-d67e-4245-b090-a0003a2a440e"
      decimals="-5"
      id="F_bf9fcce5-193a-4397-9b3f-780d8177ae50"
      unitRef="U_USD">70400000</us-gaap:OperatingLossCarryforwards>
    <onct:OperatingLossCarryforwardsNonExpirePortion
      contextRef="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4"
      decimals="-5"
      id="F_d9899e2c-7926-40b9-862e-8000e53c0482"
      unitRef="U_USD">93200000</onct:OperatingLossCarryforwardsNonExpirePortion>
    <onct:OperatingLossCarryforwardsNonExpirePortion
      contextRef="C_390cdc10-d67e-4245-b090-a0003a2a440e"
      decimals="-6"
      id="F_7f42900e-c4d4-44fe-a9bc-9a5914463927"
      unitRef="U_USD">0</onct:OperatingLossCarryforwardsNonExpirePortion>
    <onct:OperatingLossCarryforwardsExpirationYear
      contextRef="C_1324e5fb-9834-45ea-8fde-84ef2eed74cf"
      id="F_3a8071e4-0eef-45a3-9072-46ce8a5b4193">2033</onct:OperatingLossCarryforwardsExpirationYear>
    <onct:OperatingLossCarryforwardsExpirationYear
      contextRef="C_befd2887-568e-464a-9888-a3946d8ca800"
      id="F_c2bd9fbe-4461-43c7-8b7d-1ddda71485b2">2029</onct:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_2dac6146-c3a3-43ba-8af2-8b4ece776bd4"
      decimals="-5"
      id="F_991c43ba-1aa8-4ca9-b02d-98652aa27963"
      unitRef="U_USD">4300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_390cdc10-d67e-4245-b090-a0003a2a440e"
      decimals="-5"
      id="F_d3dab805-3bba-47d9-a77f-c1e739380855"
      unitRef="U_USD">2900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear
      contextRef="C_1324e5fb-9834-45ea-8fde-84ef2eed74cf"
      id="F_a1c019b1-1d2e-43ff-9262-0b3b1af8b91b">2034</onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_186f5f62-cf61-4bb2-96bc-ba6c3544943d"
      decimals="INF"
      id="F_03017f21-2a27-4116-8091-6dc46511aa98"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_98e40839-86be-43a6-9e04-8e2e7abd9e58"
      decimals="INF"
      id="F_d5e64b24-fd61-4077-a5a2-88cfefb0d445"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      decimals="INF"
      id="F_9b4cc966-422b-4257-8806-1e30fde1c3eb"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374"
      id="F_1fbe8857-5707-4f0e-8238-d54d3cf9a57e">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374"
      id="F_1fd1fd70-ad09-4bb5-8101-ee400bfd2a68">false</ecd:NonRule10b51ArrAdoptedFlag>
    <onct:NonRule10B51ArrModifiedFlag
      contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374"
      id="F_5aeb53ab-a747-4b00-a55d-053de4b6b89a">false</onct:NonRule10B51ArrModifiedFlag>
    <onct:Rule10B51ArrModifiedFlag
      contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374"
      id="F_d6060915-2128-4778-b891-a452bd901176">false</onct:Rule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374"
      id="F_110a205b-da8b-4565-8de6-86227479b2fe">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_ed1bd376-c8fc-43e3-8746-8f969b50e374"
      id="F_73366469-403b-4c0b-91ea-805dc0a1b51a">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="C_88c0a536-1858-45ff-bae1-c4b868dccb47"
      id="F_906ea54f-8bf3-4589-8552-6cc127b629f1">243</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
